286	single	common schizophrenia drugs	Which drugs are commonly used to treat the different stages of schizophrenia?	clueweb12-0209wb-15-25751	2	<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <head> <title>Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia — NEJM</title> <meta name="description" content="Original Article from The New England Journal of Medicine — Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia" /> <meta name="pageType" content="Article" /> <meta name="evt-pageType" content="Article" /> <meta content="10.1056/NEJMoa051688" name="evt-doiPage" /> <meta content="2005-09-22" name="evt-dt" /> <meta content="6Months-1990" name="evt-ageContent" /> <meta content="full" name="evt-artView" /> </head> <body class="article"> <rel link="canonical" href="http://www.nejm.org/doi/full/10.1056/NEJMoa051688" /> <meta http-equiv="content-type" content="text/html;charset=utf-8" /> <meta name="sessionEvt-individual" content="" /> <meta name="sessionEvt-idGUID" content="" /> <meta name="sessionEvt-freeCntry" content="" /> <meta name="sessionEvt-instId" content="" /> <meta name="sessionEvt-audSegment" content="" /> <meta name="sessionEvt-prodCode" content="" /> <meta name="sessionEvt-nejmSource" content="" /> <meta name="sessionEvt-offers" content="" /> <link rel="stylesheet" href="http://cdn.nejm.org/css/styles.css" media="all" type="text/css" /> <link href="/templates/jsp/_style2/_mms/_nejm/css/toolLayer.css" rel="stylesheet" type="text/css" /> <link rel="stylesheet" href="http://cdn.nejm.org/css/smoothness/jquery-ui-1.7.2.custom.css" media="all" type="text/css" /> <link rel="stylesheet" href="http://cdn.nejm.org/css/jquery.jcarousel.css" media="all" type="text/css" /> <link rel="stylesheet" href="http://cdn.nejm.org/css/jquery.cluetip.css" media="all" type="text/css" /> <link rel="stylesheet" href="http://assets.resultspage.com/autosuggest/autosuggest.css" media="screen" type="text/css" /> <script type="text/javascript" src="http://cdn.nejm.org/js/jquery.min.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/siteEditor.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/jquery.cookie.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/jquery.bbq.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/mmsEventMappings.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/mmsEvents.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/script.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/mmsFilterBanks.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/mmsMenus.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/mmsClassData.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/mmsAds.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/mmsCarousels.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/mmsUtilities.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/mmsTabPanel.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/mmsViews.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/mmsBoxy.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/jquery.form.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/swfobject.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/jquery.dimensions.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/jquery.cluetip.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/jquery.highlight.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/jquery.jcarousel.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/jquery-ui-1.7.2.custom.min.js"></script> <script type="text/javascript" src="http://cdn.nejm.org/js/mmsLayers.js"></script> <script type="text/javascript" src="/templates/jsp/_style2/_mms/_nejm/js/mmsAddThis.js"></script> <!--[if IE]><script language="javascript" type="text/javascript" src="http://cdn.nejm.org/js/lib/excanvas.min.js"></script><![endif]--> <!--[if lte IE 6]><script type="text/javascript" src="http://cdn.nejm.org/js/DD_belatedPNG.js"></script><![endif]--> <script type="text/javascript" src="http://cdn.nejm.org/js/ntpagetag.js"></script>&quot;&gt; <noscript> <img src="http://pt000185.unica.com/ntpagetag.gif?site=nejm&amp;js=0" height="1" width="1" border="0" hspace="0" vspace="0" alt=" " /> </noscript> <script type="text/javascript"> var CM8Server = "web.checkm8.com"; var CM8Cat = "mms.nej.articles"; var CM8Profile = "pharma=no&articlecat=research"; var servicesURL="http://imc.nejm.org/ExamService/ExamService.asmx";</script> <script type="text/javascript" language="JavaScript" src="http://web.checkm8.com/adam/cm8adam_1_ajax.js"></script> <!--[if lte IE 6]><div class="ie6and7" id="ie6"><![endif]--> <!--[if IE 7]><div class="ie6and7" id="ie7"><![endif]--> <!--[if IE 8]><div id="ie8"><![endif]--> <div id="topAdBar"> <div class="bannerAd"> <div class="inner"> <div id="CM8ShowAd1329516014311" title="Topbanner" class="Topbanner CM8"> <noscript> <a href="http://web.checkm8.com/adam/ep/click/mms.nej.articles/Topbanner"><img src="http://web.checkm8.com/adam/noscript?cat=mms.nej.articles&amp;page=1329516014311&amp;format=Topbanner" border="0" alt="Advertisement" /></a> </noscript> </div> </div> </div> </div> <div align="center" style="margin-top:30px;"> <!-- placeholder id=null, description=N-ad-global-top --> </div> <script type="text/javascript"> $(document).ready(function() { $("#lnkSignOut").click(function(){ $.cookie("redirectUri",null, {path: '/', domain: '.nejm.org'}); }); })</script> <div id="authInfo"> <!-- placeholder id=null, description=N-ad-global-top-left --> <!-- topLeftAniv --> <div class="topLeftAniv"> <a href="/action/clickThrough?id=2865&amp;url=http%3A%2F%2Fnejm200.nejm.org&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476" target="_blank"><img src="/sda/2865/nejm200-join-anim.gif" width="277" height="57" border="0" alt="Join the 200th Anniversary Celebration" title="Join the 200th Anniversary Celebration" /></a> </div> <!-- /topLeftAniv --> <ul> <li class="status">Welcome Guest</li> <li class="renewSubscribe"> <a href="/action/cdfProxy?action=renew&amp;promo=ONFLNRA2" class="renew"> Renew</a>, <a href="/action/cdfProxy?action=subscribe&amp;promo=ONFLNSA3" class="subscribe"> Subscribe</a> or <a href="/action/cdfProxy?action=register&amp;promo=ONFLNAR3" class="createAccount"> Create Account</a> </li> <li class="signin"> <a href="/action/showLogin?uri=http%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688" class="viewType-Layer viewClass-WideLayer event-signin-header"> <else> </else> Sign In </a> </li> </ul> </div> <div id="header" class="withAd"> <h1><a href="/">The New England Journal of Medicine</a></h1> <!-- placeholder id=null, description=N-ad-header-1 --> <div class="ad"> <a href="/action/clickThrough?id=2922&amp;url=%2Faction%2FcdfProxy%3Faction%3Dsubscribe%26url%3Dhttp%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa051688%26promo%3DONFQNDS1%26prc%3DONFQNDS1%26cpc%3DSMAAALLA1211A&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476"><img src="/sda/2922/DefaultSubscribe_200th_280x83.jpg" /></a> </div> </div> <div id="topNav"> <ul> <li><a href="/">Home</a></li> <li class="menu dropDownTrigger-articles"><a href="/medical-article-index">Articles</a></li> <li class="menu dropDownTrigger-issueArchive"><a href="/medical-index">Issues</a></li> <li class="menu dropDownTrigger-topics"><a href="/medical-specialties">Specialties &amp; Topics</a></li> <li class="menu authors dropDownTrigger-authors"><a href="/action/cdfProxy?action=authorCenter">For Authors</a></li> <li class="menu cmeButton lastChild"><a href="/continuing-medical-education">CME</a></li> </ul> <form action="/search?pageType=search" class="search" method="get"> <fieldset> <input id="sli_search_1" class="text" type="text" name="q" value="Keyword, Title, Author, or Citation" size="15" maxlength="180" autocomplete="off" /> <input class="searchSubmit" type="image" value="Search" src="http://cdn.nejm.org/img/searchButton.gif" /> <input type="hidden" name="asug" value="" /> <a href="/medical-search" class="more advSearch">Advanced&nbsp;Search</a> </fieldset> </form> </div> <div id="main"> <div id="content"> <a name="articleTop" rel="10.1056/NEJMoa051688"></a> <div class="articleCorrection"> <span class="moreLink"><a href="/doi/full/10.1056/NEJMx100054" class="tab-article-correctionHasBeenPublished">A Correction Has Been Published</a></span> </div> <p class="articleType">Original Article</p> <h1>Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia</h1> <p class="authors">Jeffrey A. Lieberman, M.D., T. Scott Stroup, M.D., M.P.H., Joseph P. McEvoy, M.D., Marvin S. Swartz, M.D., Robert A. Rosenheck, M.D., Diana O. Perkins, M.D., M.P.H., Richard S.E. Keefe, Ph.D., Sonia M. Davis, Dr.P.H., Clarence E. Davis, Ph.D., Barry D. Lebowitz, Ph.D., Joanne Severe, M.S., and John K. Hsiao, M.D. for <span class="NLM_on-behalf-of">the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators</span></p> <p class="citationLine"><span class="citation">N Engl J Med 2005; 353:1209-1223</span><a href="/toc/nejm/353/12/">September 22, 2005</a></p> <!--DiscussionPollOpenDateReplacer--> <dl class="articleTabs tabPanel"> <dt class="active abstract" id="abstractTab"> Abstract </dt> <dd id="abstract"> <div class="left section"> <div class="section"> </div> <div class="section"> <h3 id="abstractBackground">Background</h3> <p>The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study.</p> <p class="fullTextLink"><a rel="gotofulltext" href="#Background">Full Text of Background...</a></p> </div> <div class="section"> </div> <div class="section"> <h3 id="abstractMethods">Methods</h3> <p>A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and randomly assigned to receive olanzapine (7.5 to 30 mg per day), perphenazine (8 to 32 mg per day), quetiapine (200 to 800 mg per day), or risperidone (1.5 to 6.0 mg per day) for up to 18 months. Ziprasidone (40 to 160 mg per day) was included after its approval by the Food and Drug Administration. The primary aim was to delineate differences in the overall effectiveness of these five treatments.</p> <p class="fullTextLink"><a rel="gotofulltext" href="#Methods">Full Text of Methods...</a></p> </div> <div class="section"> </div> <div class="section"> <h3 id="abstractResults">Results</h3> <p>Overall, 74 percent of patients discontinued the study medication before 18 months (1061 of the 1432 patients who received at least one dose): 64 percent of those assigned to olanzapine, 75 percent of those assigned to perphenazine, 82 percent of those assigned to quetiapine, 74 percent of those assigned to risperidone, and 79 percent of those assigned to ziprasidone. The time to the discontinuation of treatment for any cause was significantly longer in the olanzapine group than in the quetiapine (P&lt;0.001) or risperidone (P=0.002) group, but not in the perphenazine (P=0.021) or ziprasidone (P=0.028) group. The times to discontinuation because of intolerable side effects were similar among the groups, but the rates differed (P=0.04); olanzapine was associated with more discontinuation for weight gain or metabolic effects, and perphenazine was associated with more discontinuation for extrapyramidal effects.</p> <p class="fullTextLink"><a rel="gotofulltext" href="#Results">Full Text of Results...</a></p> </div> <div class="section"> </div> <div class="section"> <h3 id="abstractConclusions">Conclusions</h3> <p>The majority of patients in each group discontinued their assigned treatment owing to inefficacy or intolerable side effects or for other reasons. Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone. Olanzapine was associated with greater weight gain and increases in measures of glucose and lipid metabolism.</p> <p class="fullTextLink"><a rel="gotofulltext" href="#Discussion">Full Text of Discussion...</a></p> </div> <div class="section"> </div> <p class="fullTextLink"><a rel="gotofulltext" href="#Top">Read the Full Article...</a></p> </div> <div class="right section"> <div class="articleMedia"> <h3 class="title">Media in This Article</h3> <div class="mediaRefs"> <div class="mediaRef"> <span class="fig"><span class="figureTitle">Figure 1</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=f01"><img src="/na102/home/ACS/publisher/mms/journals/content/nejm/2005/nejm_2005.353.issue-12/nejmoa051688/production/images/small/nejmoa051688_f1.gif" alt="" /></a><span class="figureCaption">Enrollment and Outcomes.</span></span> </div> <div class="mediaRef"> <span class="fig"><span class="figureTitle">Figure 2</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=f02"><img src="/na102/home/ACS/publisher/mms/journals/content/nejm/2005/nejm_2005.353.issue-12/nejmoa051688/production/images/small/nejmoa051688_f2.gif" alt="" /></a><span class="figureCaption">Outcome Measures of Effectiveness.</span></span> </div> </div> </div> <div class="articleActivity"> <h3 class="title">Article Activity</h3> <p><a href="#citedby" class="articleActivity-citedby more">1192 articles have cited this article</a></p> </div> </div> </dd> <dt class="article" id="articleTab"> Article </dt> <dd id="article"> <div class="section"> <p>Antipsychotic drugs have become the cornerstone of treatment for schizophrenia. The first-generation “conventional” antipsychotic drugs are high-affinity antagonists of dopamine D2 receptors that are most effective against psychotic symptoms but have high rates of neurologic side effects, such as extrapyramidal signs and tardive dyskinesia.<span class="ref"><a href="#ref1" class="showRefLayer" rel="#refLayer">1</a></span> The introduction of second-generation, or “atypical,” antipsychotic drugs promised enhanced efficacy and safety.<span class="ref"><a href="#ref2" class="showRefLayer" rel="#refLayer">2</a></span> The atypical agents differ pharmacologically from previous antipsychotic agents in their lower affinity for dopamine D2 receptors and greater affinities for other neuroreceptors, including those for serotonin (5-hydroxytryptamine<sub>1A</sub>, <sub>2A</sub>, <sub>2C</sub>, <sub>3</sub>, <sub>6</sub>, and <sub>7</sub>) and norepinephrine (α<sub>1</sub> and α<sub>2</sub>).<span class="ref"><a href="#ref1" class="showRefLayer" rel="#refLayer">1</a></span> </p> <p>Although studies indicated that the atypical drugs are similar to the conventional drugs in reducing psychotic symptoms and produce few neurologic effects, the evidence of their superior efficacy has been neither consistent nor robust,<span class="ref"><a href="#ref3" class="showRefLayer" rel="#refLayer">3-8</a></span> with the exception of clozapine, which repeatedly has been effective in patients whose condition is refractory to treatment with other types of agents but has severe side effects that limit its use.<span class="ref"><a href="#ref9" class="showRefLayer" rel="#refLayer">9-11</a></span> The newer agents appear more efficacious than conventional drugs in reducing negative symptoms (e.g., lack of emotion, interest, and expression), possibly owing to the absence of extrapyramidal symptoms<span class="ref"><a href="#ref12" class="showRefLayer" rel="#refLayer">12</a></span> or other secondary causes of negative symptoms (e.g., depression) rather than to direct therapeutic effects.<span class="ref"><a href="#ref13" class="showRefLayer" rel="#refLayer">13</a></span> The results of studies of the effects of treatment on cognitive impairment and mood symptoms have been inconclusive.<span class="ref"><a href="#ref14" class="showRefLayer" rel="#refLayer">14,15</a></span> The ability of atypical agents to prevent relapse and their effects on social and vocational functioning, quality of life, long-term outcome, and the caregivers' burden have been incompletely explored.<span class="ref"><a href="#ref8" class="showRefLayer" rel="#refLayer">8,12,16</a></span> </p> <p>The safety advantages of the atypical drugs have been questioned because of their propensity to induce weight gain<span class="ref"><a href="#ref17" class="showRefLayer" rel="#refLayer">17</a></span> and alter glucose and lipid metabolism.<span class="ref"><a href="#ref18" class="showRefLayer" rel="#refLayer">18,19</a></span> Nevertheless, these medications are widely used and have a 90 percent market share in the United States,<span class="ref"><a href="#ref20" class="showRefLayer" rel="#refLayer">20,21</a></span> resulting in burgeoning costs. In the wake of this trend, questions have been raised about the clinical advantages and cost effectiveness of the atypical drugs. We report the primary outcomes of a double-blind, active-control clinical trial sponsored by the National Institute of Mental Health (NIMH) that was designed to compare the effectiveness of atypical and conventional antipsychotic drugs.<span class="ref"><a href="#ref22" class="showRefLayer" rel="#refLayer">22,23</a></span> </p> </div> <div class="section"> <h3 id="articleMethods">Methods</h3> <div class="subSection"> <h3 id="articleStudy Setting and Design">Study Setting and Design</h3> <p>The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study was initiated by the NIMH to compare the effectiveness of antipsychotic drugs. Its rationale, design, and methods have been described previously.<span class="ref"><a href="#ref24" class="showRefLayer" rel="#refLayer">24-28</a></span> The protocol was made available to the public for comment, and a committee of scientific experts, health care administrators, and consumer advocates critiqued the study under the auspices of the NIMH. The study was conducted between January 2001 and December 2004 at 57 clinical sites in the United States (16 university clinics, 10 state mental health agencies, 7 Veterans Affairs medical centers, 6 private nonprofit agencies, 4 private-practice sites, and 14 mixed-system sites). Patients were initially randomly assigned to receive olanzapine, perphenazine, quetiapine, or risperidone under double-blind conditions and followed for up to 18 months or until treatment was discontinued for any reason (phase 1). (Ziprasidone was approved for use by the Food and Drug Administration [FDA] after the study began and was added to the study in January 2002 in the form of an identical-appearing capsule containing 40 mg.) Patients whose assigned treatment was discontinued could receive other treatments in phases 2 and 3.<span class="ref"><a href="#ref24" class="showRefLayer" rel="#refLayer">24</a></span> The present report is limited to phase 1 results.</p> </div> <div class="subSection"> <h3 id="articleParticipants">Participants</h3> <p>Eligible patients were 18 to 65 years of age; had received a diagnosis of schizophrenia, as determined on the basis of the Structured Clinical Interview of the <em>Diagnostic and Statistical Manual of Mental Disorders,</em> fourth edition; and were able to take oral antipsychotic medication, as determined by the study doctor. Patients were excluded if they had received a diagnosis of schizoaffective disorder, mental retardation, or other cognitive disorders; had a history of serious adverse reactions to the proposed treatments; had had only one schizophrenic episode; had a history of treatment resistance, defined by the persistence of severe symptoms despite adequate trials of one of the proposed treatments or prior treatment with clozapine; were pregnant or breast-feeding; or had a serious and unstable medical condition.</p> <p>The study was approved by the institutional review board at each site, and written informed consent was obtained from the patients or their legal guardians.</p> </div> <div class="subSection"> <h3 id="articleInterventions">Interventions</h3> <p>Identical-appearing capsules contained olanzapine (Zyprexa, Eli Lilly) (7.5 mg), quetiapine (Seroquel, AstraZeneca) (200 mg), risperidone (Risperdal, Janssen Pharmaceutica) (1.5 mg), perphenazine (Trilafon, Schering-Plough, at the time of the study) (8 mg), or (after January 2002) ziprasidone (Geodon, Pfizer) (40 mg). The packaging was done by Quintiles. The dose of medications was flexible, ranging from one to four capsules daily, and was based on the study doctor's judgment. Overlap in the administration of the antipsychotic agents that patients received before study entry was permitted for the first four weeks after randomization to allow a gradual transition to study medication. Concomitant medications were permitted throughout the trial, except for additional antipsychotic agents. Patients had monthly visits with study doctors.</p> <p>Because of product labeling, quetiapine and ziprasidone are given twice daily and olanzapine, perphenazine, and risperidone once daily. To protect blinding, half the patients randomly assigned to perphenazine, olanzapine, and risperidone were assigned to twice-daily dosing and half to once-daily dosing. To minimize initial side effects, patients assigned to quetiapine began treatment by receiving one 100-mg capsule on days 1 and 2, one twice daily on day 3, and one for the first dose of day 4. All patients assigned to twice-daily dosing received five identical-appearing capsules to begin treatment. Patients with current tardive dyskinesia could enroll, but the randomization scheme prevented their assignment to treatment with perphenazine.</p> </div> <div class="subSection"> <h3 id="articleObjectives and Outcomes">Objectives and Outcomes</h3> <p>We hypothesized that there would be significant differences in the overall effectiveness of olanzapine, perphenazine, quetiapine, risperidone, and ziprasidone in treating schizophrenia that reflected variations in efficacy and tolerability. The primary outcome measure was the discontinuation of treatment for any cause, a discrete outcome selected because stopping or changing medication is a frequent occurrence and major problem in the treatment of schizophrenia. In addition, this measure integrates patients' and clinicians' judgments of efficacy, safety, and tolerability into a global measure of effectiveness that reflects their evaluation of therapeutic benefits in relation to undesirable effects. The key secondary outcomes were the specific reasons for the discontinuation of treatment (e.g., inefficacy or intolerability owing to side effects such as weight gain, extrapyramidal signs, or sedation as judged by the study doctor). Additional secondary efficacy outcomes included scores on the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impressions (CGI) Scale. PANSS scores can range from 30 to 210, with higher scores indicating more severe psychopathology. Scores for the CGI Scale can range from 1 to 7, with higher scores indicating greater severity of illness. Secondary safety and tolerability outcomes, which were evaluated at months 1, 3, 6, 9, 12, 15, and 18, included the incidence of serious adverse events, the incidence of adverse events during treatment, the incidence of neurologic side effects, and changes in weight, electrocardiographic findings, and laboratory analytes.</p> </div> <div class="subSection"> <h3 id="articleStatistical Analysis">Statistical Analysis</h3> <p>Randomized patients who received at least one dose of study medication made up the intention-to-treat population. Two hundred thirty-one patients with tardive dyskinesia were excluded from random assignment to perphenazine. Ziprasidone was added to the trial after approximately 40 percent of the patients had been enrolled. Consequently, comparisons involving the perphenazine group were limited to patients without tardive dyskinesia, and comparisons involving the ziprasidone group were limited to the cohort of patients who underwent randomization after ziprasidone was added (the ziprasidone cohort). In general, the trial had a statistical power of 85 percent to identify an absolute difference of 12 percent in the rates of discontinuation between two atypical agents; however, it had a statistical power of 76 percent for comparisons involving perphenazine and of 58 percent for comparisons involving ziprasidone.</p> <p>We used Kaplan–Meier survival curves to estimate the time to the discontinuation of treatment. Treatment groups were compared with use of Cox proportional-hazards regression models<span class="ref"><a href="#ref29" class="showRefLayer" rel="#refLayer">29</a></span> stratified according to site, with adjustment for whether the patient had had an exacerbation of schizophrenia in the preceding three months and tardive dyskinesia status (for models excluding perphenazine). Sites with 15 or fewer patients were grouped according to the sites' health care systems.</p> <p>The overall difference among the olanzapine, quetiapine, risperidone, and perphenazine groups was evaluated with the use of a test with 3 degrees of freedom (df). If the difference was significant at a P value of less than 0.05, the three atypical-drug groups were compared with each other by means of step-down or closed testing, with a P value of less than 0.05 considered to indicate statistical significance. Each group was then compared with the perphenazine group by means of a Hochberg adjustment for multiple comparisons.<span class="ref"><a href="#ref30" class="showRefLayer" rel="#refLayer">30</a></span> The smallest resulting P value was compared with a value of 0.017 (0.05 &divide; 3). The ziprasidone group was directly compared with the other three atypical-drug groups and the perphenazine group within the ziprasidone cohort by means of a Hochberg adjustment for four pairwise comparisons. The smallest resulting P value was compared with a value of 0.013 (0.05 &divide; 4).</p> <p>Successful treatment time was defined as the number of months of treatment during phase 1 in which patients had a CGI Scale score of at least 3 (mildly ill) or a score of 4 (moderately ill) with an improvement of at least two points from baseline. Treatment groups were compared with use of proportional-hazards regression.</p> <p>A sensitivity analysis of the Cox model for the discontinuation of treatment for any cause evaluated the effects of potentially important baseline covariates and their interaction with the treatment group.</p> <p>The PANSS total scores and CGI Scale scores over time were compared among the groups with the use of a mixed model including the same fixed covariates as for the time to discontinuation, plus baseline value, time, the interaction between treatment and time, and the interaction between baseline value and time. Time was classified into months (1, 3, 6, 9, 12, 15, and 18). The results of assessments made at the end of phase 1 were assigned to the next interval. The correlation of the repeated measures within each patient was modeled with the use of a random subject intercept and an unstructured covariance matrix.</p> <p>The study was funded by the NIMH. The pharmaceutical companies whose drugs were included in the study donated drug supplies, and each provided advice on the dose of its own drug; they were otherwise not involved in the design of the study, analyses, or interpretation of results. The manuscript was written solely by the listed authors.</p> </div> </div> <div class="section"> </div> <div class="section"> <h3 id="articleResults">Results</h3> <div class="subSection"> <h3 id="articleCharacteristics and Disposition of Patients">Characteristics and Disposition of Patients</h3> <p> <a class="viewType-Layer viewClass-ImageViewerLayer" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=t01">Table 1</a><span class="table"><span class="figureTitle">Table 1</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=t01"><img src="/na102/home/ACS/publisher/mms/journals/content/nejm/2005/nejm_2005.353.issue-12/nejmoa051688/production/images/small/nejmoa051688_t1.gif" alt="" /></a><span class="figureCaption">Baseline Demographic and Clinical Characteristics of Randomized Patients.</span></span> shows the baseline demographic and clinical characteristics of the patients. <a class="viewType-Layer viewClass-ImageViewerLayer" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=f01">Figure 1</a><span class="fig"><span class="figureTitle">Figure 1</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=f01"><img src="/na102/home/ACS/publisher/mms/journals/content/nejm/2005/nejm_2005.353.issue-12/nejmoa051688/production/images/small/nejmoa051688_f1.gif" alt="" /></a><span class="figureCaption">Enrollment and Outcomes.</span></span> depicts the enrollment, randomization, and follow-up of study patients; 1493 patients were enrolled in the study and randomly assigned to treatment. All data from one site (33 patients) were excluded before analysis, owing to concern about the integrity of data from that site before the end of the study and before unblinding. The mean modal doses were 20.1 mg per day for olanzapine, 20.8 mg per day for perphenazine, 543.4 mg per day for quetiapine, 3.9 mg per day for risperidone, and 112.8 mg per day for ziprasidone (<a class="viewType-Layer viewClass-ImageViewerLayer" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=t02">Table 2</a><span class="table"><span class="figureTitle">Table 2</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=t02"><img src="/na102/home/ACS/publisher/mms/journals/content/nejm/2005/nejm_2005.353.issue-12/nejmoa051688/production/images/small/nejmoa051688_t2.gif" alt="" /></a><span class="figureCaption">Outcome Measures of Effectiveness in the Intention-to-Treat Population.</span></span>). Seventy-four percent of patients in the intention-to-treat analysis (1061 of 1432) discontinued their assigned treatment in phase 1 before 18 months (median, 6).</p> </div> <div class="subSection"> <h3 id="articleDiscontinuation of Treatment">Discontinuation of Treatment</h3> <p>The time to the discontinuation of treatment for any cause was longer in the olanzapine group than in the quetiapine group (hazard ratio, 0.63; P&lt;0.001), the risperidone group (hazard ratio, 0.75; P=0.002), or the perphenazine group (hazard ratio, 0.78; P=0.021) (<a class="viewType-Layer viewClass-ImageViewerLayer" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=t02">Table 2</a>). However, the difference between the olanzapine group and the perphenazine group was not significant after adjustment for multiple comparisons (required P value, ≤0.017). Within the cohort of 889 patients who underwent randomization after ziprasidone was added to the trial, those receiving olanzapine had a longer interval before discontinuing treatment for any cause than did those in the ziprasidone group (hazard ratio, 0.76; P=0.028). However, this difference was not significant after adjustment for multiple comparisons (required P value, ≤0.013).</p> <p>The time to the discontinuation of treatment for lack of efficacy was longer in the olanzapine group than in the perphenazine group (hazard ratio, 0.47; P&lt;0.001), the quetiapine group (hazard ratio, 0.41; P&lt;0.001), the risperidone group (hazard ratio, 0.45; P&lt;0.001), or the ziprasidone group (hazard ratio, 0.59; P=0.026), but the difference between the olanzapine and ziprasidone groups was not significant after adjustment for multiple comparisons (required P value, ≤0.013) (<a class="viewType-Layer viewClass-ImageViewerLayer" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=t02">Table 2</a>). There were no significant differences between groups in time until discontinuation owing to intolerable side effects (P=0.054). The time until discontinuation owing to the patient's decision (i.e., the patient independently chose to stop treatment) was similar to that for discontinuation for any cause (<a class="viewType-Layer viewClass-ImageViewerLayer" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=t02">Table 2</a>).</p> <p>The duration of successful treatment was significantly longer in the olanzapine group than in the quetiapine group (hazard ratio, 0.53; P&lt;0.001), the risperidone group (hazard ratio, 0.69; P=0.002), or the perphenazine group (hazard ratio, 0.73; P=0.013) and was significantly longer in the risperidone group than in the quetiapine group (hazard ratio, 0.77; P=0.021).</p> </div> <div class="subSection"> <h3 id="articleAdjustment of Outcomes for Covariates">Adjustment of Outcomes for Covariates</h3> <p>An exploratory analysis identified the following predictors of an earlier time to discontinuation: higher baseline PANSS score (P=0.001), younger age (P&lt;0.001), longer duration since the first use of antipsychotic medication (P=0.057), and the antipsychotic drug taken before study entry (P=0.001). Baseline antipsychotic agents were grouped into six categories (<a class="viewType-Layer viewClass-ImageViewerLayer" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=t01">Table 1</a>). Patients receiving olanzapine or risperidone before enrollment stayed in phase 1 of the trial longer than those taking no antipsychotic agents, those taking combination treatments, or those receiving a single antipsychotic agent excluding olanzapine, quetiapine, or risperidone; pairwise hazard ratios ranged from 0.68 (P&lt;0.001) to 0.80 (P&lt;0.02). No interactions with treatment group were significant at a P value of less than 0.10. After adjustment for these predictors of discontinuation, the results of treatment-group comparisons were similar to the primary results.</p> </div> <div class="subSection"> <h3 id="articleEfficacy Measures">Efficacy Measures</h3> <p>Total PANSS scores improved over time in all groups (<a class="viewType-Layer viewClass-ImageViewerLayer" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=f02">Figure 2</a><span class="fig"><span class="figureTitle">Figure 2</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=f02"><img src="/na102/home/ACS/publisher/mms/journals/content/nejm/2005/nejm_2005.353.issue-12/nejmoa051688/production/images/small/nejmoa051688_f2.gif" alt="" /></a><span class="figureCaption">Outcome Measures of Effectiveness.</span></span>). The mixed model revealed significant variation in treatment effects over time (P=0.002). Improvement was initially greatest in the olanzapine group, but its advantage diminished over time. The pattern of change in the scores for the CGI Scale was similar to that for the PANSS scores (P=0.004 for the interaction between treatment and time).</p> </div> <div class="subSection"> <h3 id="articleAdverse Events">Adverse Events</h3> <p>The rates of adverse events and side effects are listed in <a class="viewType-Layer viewClass-ImageViewerLayer" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=t03">Table 3</a><span class="table"><span class="figureTitle">Table 3</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=t03"><img src="/na102/home/ACS/publisher/mms/journals/content/nejm/2005/nejm_2005.353.issue-12/nejmoa051688/production/images/small/nejmoa051688_t3.gif" alt="" /></a><span class="figureCaption">Outcome Measures of Safety among Randomized Patients.</span></span>. Fewer patients in the olanzapine group than in the other four groups were hospitalized for an exacerbation of schizophrenia (11 percent vs. 15 to 20 percent, P&lt;0.001). After adjustment for the different durations of treatment, the olanzapine group had a risk ratio for hospitalization of 0.17 per person-year of treatment, as compared with risk ratios of 0.30 to 0.44 in the other groups.</p> <p>The rates of treatment discontinuation due to intolerable side effects differed between treatments (P=0.04). Risperidone had the lowest rate (10 percent), and olanzapine had the highest rate (18 percent). Moreover, more patients discontinued olanzapine owing to weight gain or metabolic effects (9 percent vs. 1 percent to 4 percent with the other four drugs, P&lt;0.001) and more patients discontinued perphenazine owing to extrapyramidal effects (8 percent vs. 2 percent to 4 percent, P=0.002).</p> <p>Patients in the olanzapine and quetiapine groups had lower rates of insomnia (16 and 18 percent, respectively) than did patients in the other groups (24 percent in the risperidone group, 25 percent in the perphenazine group, and 30 percent in the ziprasidone group). Quetiapine was associated with a higher rate of anticholinergic effects than were the other drugs (31 percent vs. 20 to 25 percent, P&lt;0.001).</p> <div class="subSection"> <h3 id="articleNeurologic Side Effects">Neurologic Side Effects</h3> <p>There were no significant differences among the groups in the incidence of extrapyramidal side effects, akathisia, or movement disorders as reflected by rating-scale measures of severity.</p> </div> <div class="subSection"> <h3 id="articleWeight Gain and Metabolic Changes">Weight Gain and Metabolic Changes</h3> <p>Patients in the olanzapine group gained more weight than patients in any other group, with an average weight gain of 2 lb (0.9 kg) per month. A larger proportion of patients in the olanzapine group than in the other groups gained 7 percent or more of their baseline body weight (30 percent vs. 7 to 16 percent, P&lt;0.001).</p> <p>Olanzapine had effects consistent with the potential development of the metabolic syndrome and was associated with greater increases in glycosylated hemoglobin, total cholesterol, and triglycerides after randomization than the other study drugs, even after adjustment for the duration of treatment. Ziprasidone was the only study drug associated with improvement in each of these metabolic variables. Only risperidone was associated with a substantial increase in prolactin levels.</p> </div> <div class="subSection"> <h3 id="articleOther Potential Adverse Events">Other Potential Adverse Events</h3> <p>There were no substantially different effects of the medications on the corrected QT interval on electrocardiography, and torsades de pointes did not develop in any patients. There were no significant differences among the groups in the incidence of new cataracts. There were no significant differences among the groups in the rates of suicide attempts or suicidal ideation reported as serious adverse events.</p> </div> </div> <div class="subSection"> <h3 id="articleConcomitant Medications">Concomitant Medications</h3> <p>There were few substantial differences among the groups in the rates or types of medications added during the study. Patients in the olanzapine and risperidone groups were the least likely to have anxiolytic agents added (9 and 10 percent, respectively, vs. 14 to 15 percent). Fewer patients receiving quetiapine were prescribed anticholinergic drugs (3 percent vs. 8 to 10 percent).</p> </div> </div> <div class="section"> </div> <div class="section"> <h3 id="articleDiscussion">Discussion</h3> <p>All second-generation antipsychotic drugs were included in phase 1 of this study except aripiprazole (which was approved by the FDA in November 2002) and clozapine, which was included in phase 2 for patients who discontinued phase 1 of treatment owing to lack of efficacy of the assigned drug. Although haloperidol is the first-generation agent most commonly used for comparison, we chose to use perphenazine because of its lower potency and moderate side-effect profile.<span class="ref"><a href="#ref31" class="showRefLayer" rel="#refLayer">31</a></span> </p> <p>Only a minority of patients in each group took their assigned drug for the duration of phase 1 (rates of discontinuation ranged from 64 to 82 percent). This outcome indicates that antipsychotic drugs, though effective, have substantial limitations in their effectiveness in patients with chronic schizophrenia. Although the rates of discontinuation may have been increased by the fact that patients were participating in a blinded, controlled trial, the rates are generally consistent with those previously observed.<span class="ref"><a href="#ref5" class="showRefLayer" rel="#refLayer">5</a></span> Within this limited range of effectiveness, the olanzapine group had the lowest rate of discontinuation, which might lead one to consider olanzapine the most effective of the medications studied. Its apparent superior efficacy is also indicated by the greater reduction in psychopathology, longer duration of successful treatment, and lower rate of hospitalizations for an exacerbation of schizophrenia. The results for the other second-generation antipsychotic agents and the representative conventional drug, perphenazine, were similar in most respects. It is important to note that the differences between olanzapine and perphenazine were moderate. Although there were no significant differences in the time until discontinuation owing to intolerable side effects, there were differences in rates. Moreover, olanzapine was associated with greater increases in weight and indexes of glucose and lipid metabolism than the other treatments.</p> <p>Dose could have been a factor in the performance of the various agents studied. The dose ranges approved by the FDA for quetiapine and ziprasidone may be below their optimal therapeutic doses, and the recommended doses of risperidone (6 mg per day or less), intended to limit extrapyramidal symptoms, may not encompass its full therapeutic range.<span class="ref"><a href="#ref32" class="showRefLayer" rel="#refLayer">32,33</a></span> However, the dose ranges we used were based on information from the manufacturer of each medication plus knowledge of clinical practice patterns. Moreover, the average prescribed doses of these drugs in the United States for patients with schizophrenia during the period in which the study was conducted (14 mg of olanzapine per day, 3.8 mg of risperidone per day, 388 mg of quetiapine per day, and 125 mg of ziprasidone per day) were generally similar to the ones we used.<span class="ref"><a href="#ref34" class="showRefLayer" rel="#refLayer">34</a></span> The fact that a higher proportion of patients assigned to quetiapine and ziprasidone received the maximal dose allowed in the study suggests that these agents are either less effective or require higher doses (<a class="viewType-Layer viewClass-ImageViewerLayer" href="/action/showImage?doi=10.1056%2FNEJMoa051688&amp;iid=t02">Table 2</a>). The dose range of perphenazine was chosen to minimize the potential for extrapyramidal symptoms that may have biased previous comparisons of first- and second-generation drugs.<span class="ref"><a href="#ref4" class="showRefLayer" rel="#refLayer">4,7,31</a></span> </p> <p>The use of low-dose perphenazine appears to have diminished the frequency of extrapyramidal side effects in patients who received the first-generation drug. In contrast to previous studies,<span class="ref"><a href="#ref35" class="showRefLayer" rel="#refLayer">35</a></span> the proportion of patients with extrapyramidal symptoms did not differ significantly among those who received first-generation and second-generation drugs in our study. Despite this finding, more patients discontinued perphenazine than other medications owing to extrapyramidal effects.</p> <p>As in other studies, we found that risperidone was associated with hyperprolactinemia and olanzapine was associated with substantial weight gain in addition to adverse changes in glucose and lipid metabolism — all features of the metabolic syndrome. Concerns about potential prolongation of the corrected QT interval with ziprasidone and of cataracts with quetiapine were not realized in this study.</p> <p>We used broad inclusion and minimal exclusion criteria and allowed the enrollment of patients with coexisting conditions and those who were taking other medications. The study was conducted in a variety of clinical settings in which people with schizophrenia are treated. These “real-world” features of the study, which were intended to make the results widely applicable, may account for the differences in results between this and previous studies comparing first- and second-generation antipsychotic agents.</p> <p>In summary, patients with chronic schizophrenia in this study discontinued their antipsychotic study medications at a high rate, indicating substantial limitations in the effectiveness of the drugs. Within this limited range of effectiveness, olanzapine appeared to be more effective than the other drugs studied, and there were no significant differences in effectiveness between the conventional drug perphenazine and the other second-generation drugs. There were no significant differences among the drugs in the time until discontinuation of treatment owing to intolerable side effects. However, olanzapine was associated with greater weight gain and increases in glycosylated hemoglobin, cholesterol, and triglycerides, changes that may have serious implications with respect to medical comorbidity such as the development of the metabolic syndrome. How clinicians, patients, families, and policymakers evaluate the trade-offs between efficacy and side effects, as well as drug prices, will determine future patterns of use.</p> </div> <div class="section"> </div> <p>Supported by a grant (N01 MH90001) from the NIMH and by the Foundation of Hope of Raleigh, N.C. AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Forest Pharmaceuticals, Janssen Pharmaceutica, Eli Lilly, Otsuka Pharmaceutical, Pfizer, Zenith Goldline Pharmaceuticals, Schering-Plough, and Novartis provided medications for the studies.</p> <p>Dr. Lieberman reports having received research funding from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutica, and Pfizer and consulting and educational fees from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Novartis, Pfizer, and Solvay. Dr. Stroup reports having received research funding from Eli Lilly and consulting fees from Janssen Pharmaceutica, GlaxoSmithKline, and Bristol-Myers Squibb. Dr. McEvoy reports having received research funding from AstraZeneca, Forest Research Institute, Eli Lilly, Janssen Pharmaceutica, and Pfizer; consulting or advisory-board fees from Pfizer and Bristol-Myers Squibb; and lecture fees from Janssen Pharmaceutica and Bristol-Myers Squibb. Dr. Swartz reports having received research funding from Eli Lilly and consulting and educational fees from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, and Pfizer. Dr. Rosenheck reports having received research funding from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, and Eli Lilly and consulting fees from Bristol-Myers Squibb, Eli Lilly, and Janssen Pharmaceutica. Dr. Perkins reports having received research funding from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Otsuka Pharmaceutical, Eli Lilly, Janssen Pharmaceutica, and Pfizer and consulting and educational fees from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Janssen Pharmaceuticals, and Pfizer. Dr. Keefe reports having received research funding from AstraZeneca, Eli Lilly, and Janssen Pharmaceutica; consulting or advisory-board fees from Forest Pharmaceuticals, Eli Lilly, Janssen Pharmaceutica, Pfizer, and Bristol-Myers Squibb; and lecture fees from Eli Lilly and Janssen Pharmaceutica. Dr. Sonia Davis is an employee of Quintiles. Dr. Clarence Davis reports having received consulting fees from Eli Lilly and Quintiles. Dr. Lebowitz is a former employee and Ms. Severe and Dr. Hsiao are current employees of the NIMH.</p> <p>This article (10.1056/NEJMoa051688) was updated on September 8, 2010, at NEJM.org.</p> <p>We are indebted to the 1493 participants in the CATIE study; to the late Mahmoud A. Parsa, M.D., of the Department of Psychiatry, Case Western Reserve University, Cleveland; to Grayson S. Norquist, M.D., M.S.P.H., previously director of the Division of Services and Intervention Research, NIMH, and currently chairman of the Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson; to Ingrid Rojas-Eloi, B.S., project manager of the CATIE study, and Tiffany Harris, staff assistant, Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill; to Allison Andors, Ph.D., director of Grants Development at the Research Foundation for Mental Hygiene, New York State Psychiatric Institute; and to the Quintiles CATIE project team.</p> <div class="section"> <div class="sourceInfo"> <h3>Source Information</h3> <p>From the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York (J.A.L.); the Department of Psychiatry, School of Medicine (T.S.S., D.O.P.), and the Department of Biostatistics, School of Public Health (S.M.D., C.E.D.), University of North Carolina at Chapel Hill, Chapel Hill; Quintiles, Research Triangle Park, N.C. (S.M.D.); the Department of Biological Psychiatry, John Umstead Hospital, Butner, N.C. (J.P.M.); the Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, N.C. (J.P.M., M.S.S., R.S.E.K.); the Department of Psychiatry, Yale University School of Medicine, New Haven, Conn. (R.A.R.); and the Division of Services and Intervention Research, National Institute of Mental Health, National Institutes of Health, Bethesda, Md. (B.D.L., J.S., J.K.H.).</p> <p>Address reprint requests to Dr. Lieberman at the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, or at <a class="email" href="mailto:jlieberman@columbia.edu">jlieberman@columbia.edu</a>.</p> <p>The CATIE investigators are listed in the Appendix.</p> </div> </div> <h3 id="articleAppendix">Appendix</h3> <p>The CATIE Study Investigators Group includes the following: L. Adler, Clinical Insights, Glen Burnie, Md.; M. Bari, Synergy Clinical Research, Chula Vista, Calif.; I. Belz, Tri-County/Mental Health and Mental Retardation Services, Conroe, Tex.; R. Bland, Southern Illinois University School of Medicine, Springfield; T. Blocher, Mental Health and Mental Retardation Authority of Harris County, Houston; B. Bolyard, Cox North Hospital, Springfield, Mo.; A. Buffenstein, Queen's Medical Center, Honolulu; J. Burruss, Baylor College of Medicine, Houston; M. Byerly, University of Texas Southwestern Medical Center at Dallas, Dallas; J. Canive, Albuquerque Veterans Affairs Medical Center, Albuquerque, N.M.; S. Caroff, Behavioral Health Service, Philadelphia; C. Casat, Behavioral Health Center, Charlotte, N.C.; E. Chavez-Rice, El Paso Community Mental Health and Mental Retardation Center, El Paso, Tex.; J. Csernansky, Washington University School of Medicine, St. Louis; P. Delgado, University Hospitals of Cleveland, Cleveland; R. Douyon, Veterans Affairs Medical Center, Miami; C. D'Souza, Connecticut Mental Health Center, New Haven; I. Glick, Stanford University School of Medicine, Stanford, Calif.; D. Goff, Massachusetts General Hospital, Boston; S. Gratz, Eastern Pennsylvania Psychiatric Institute, Philadelphia; G.T. Grossberg, Saint Louis University School of Medicine–Wohl Institute, St. Louis; M. Hale, New Britain General Hospital, New Britain, Conn.; M. Hamner, Medical University of South Carolina and Veterans Affairs Medical Center, Charleston; R. Jaffe, Belmont Center for Comprehensive Treatment, Philadelphia; D. Jeste, University of California, San Diego, Veterans Affairs Medical Center, San Diego; A. Kablinger, Louisiana State University Health Sciences Center, Shreveport; A. Khan, Psychiatric Research Institute, Wichita, Kans.; S. Lamberti, University of Rochester Medical Center, Rochester, N.Y.; M.T. Levy, Staten Island University Hospital, Staten Island, N.Y.; J.A. Lieberman, University of North Carolina School of Medicine, Chapel Hill; G. Maguire, University of California Irvine, Orange; T. Manschreck, Corrigan Mental Health Center, Fall River, Mass.; J. McEvoy, Duke University Medical Center, Durham, N.C.; M. McGee, Appalachian Psychiatric Healthcare System, Athens, Ohio; H. Meltzer, Vanderbilt University Medical Center, Nashville; A. Miller, University of Texas Health Science Center at San Antonio, San Antonio; D.D. Miller, University of Iowa, Iowa City; H. Nasrallah, University of Cincinnati Medical Center, Cincinnati; C. Nemeroff, Emory University School of Medicine, Atlanta; S. Olson, University of Minnesota Medical School, Minneapolis; G.F. Oxenkrug, St. Elizabeth's Medical Center, Boston; J. Patel, University of Massachusetts Health Care, Worcester; F. Reimherr, University of Utah Medical Center, Salt Lake City; S. Riggio, Mount Sinai Medical Center–Bronx Veterans Affairs Medical Center, Bronx, N.Y.; S. Risch, University of California, San Francisco, San Francisco; B. Saltz, Mental Health Advocates, Boca Raton, Fla.; T. Simpatico, Northwestern University, Chicago; G. Simpson, University of Southern California Medical Center, Los Angeles; M. Smith, Harbor–UCLA Medical Center, Torrance, Calif.; R. Sommi, University of Missouri, Kansas City; R.M. Steinbook, University of Miami School of Medicine, Miami; M. Stevens, Valley Mental Health, Salt Lake City; A. Tapp, Veterans Affairs Puget Sound Health Care System, Tacoma, Wash.; R. Torres, University of Mississippi, Jackson; P. Weiden, SUNY Downstate Medical Center, Brooklyn, N.Y.; J. Wolberg, Mount Sinai Medical Center, New York.</p> </dd> <dt class="references" id="referencesTab"> References </dt> <dd id="references"> <div class="section"> <h3>References</h3> <ol class="striped"> <a name="ref1"></a> <li id="refItem1"><p class="number">1</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Miyamoto S </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Duncan GE </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Marx CE </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Lieberman JA </contrib>. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. <span class="NLM_source">Mol Psychiatry</span> 2005;10:79-104<br /><a href="/servlet/linkout?suffix=r001&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1038%2Fsj.mp.4001556" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r001&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000225888300007" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r001&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=15289815" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref2"></a> <li id="refItem2"><p class="number">2</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Kane J </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Honigfeld G </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Singer J </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Meltzer H </contrib>. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. <span class="NLM_source">Arch Gen Psychiatry</span> 1988;45:789-796<br /><a href="/servlet/linkout?suffix=r002&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1001%2Farchpsyc.1988.01800330013001" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r002&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=A1988P938300001" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r002&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=3046553" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref3"></a> <li id="refItem3"><p class="number">3</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Leucht S </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Pitschel-Walz G </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Abraham D </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Kissling W </contrib>. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. <span class="NLM_source">Schizophr Res</span> 1999;35:51-68<br /><a href="/servlet/linkout?suffix=r003&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1016%2FS0920-9964%2898%2900105-4" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r003&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000077932100006" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r003&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=9988841" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref4"></a> <li id="refItem4"><p class="number">4</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Geddes J </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Freemantle N </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Harrison P </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Bebbington P </contrib>. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. <span class="NLM_source">BMJ</span> 2000;321:1371-1376<br /><a href="/servlet/linkout?suffix=r004&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1136%2Fbmj.321.7273.1371" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r004&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000165720100023" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r004&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=11099280" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref5"></a> <li id="refItem5"><p class="number">5</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Wahlbeck K </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Tuunainen A </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Ahokas A </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Leucht S </contrib>. Dropout rates in randomised antipsychotic drug trials. <span class="NLM_source">Psychopharmacology (Berl)</span> 2001;155:230-233<br /><a href="/servlet/linkout?suffix=r005&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1007%2Fs002130100711" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r005&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000169275000002" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r005&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=11432684" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref6"></a> <li id="refItem6"><p class="number">6</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Davis JM </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Chen N </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Glick ID </contrib>. A meta-analysis of the efficacy of second-generation antipsychotics. <span class="NLM_source">Arch Gen Psychiatry</span> 2003;60:553-564<br /><a href="/servlet/linkout?suffix=r006&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1001%2Farchpsyc.60.6.553" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r006&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000183424900002" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r006&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=12796218" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref7"></a> <li id="refItem7"><p class="number">7</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Leucht S </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Wahlbeck K </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Hamann J </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Kissling W </contrib>. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. <span class="NLM_source">Lancet</span> 2003;361:1581-1589<br /><a href="/servlet/linkout?suffix=r007&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1016%2FS0140-6736%2803%2913306-5" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r007&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000182746300006" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r007&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=12747876" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref8"></a> <li id="refItem8"><p class="number">8</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Leucht S </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Barnes TRE </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Kissling W </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Engel RR </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Correll C </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Kane JM </contrib>. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. <span class="NLM_source">Am J Psychiatry</span> 2003;160:1209-1222<br /><a href="/servlet/linkout?suffix=r008&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1176%2Fappi.ajp.160.7.1209" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r008&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000183957200002" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r008&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=12832232" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref9"></a> <li id="refItem9"><p class="number">9</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Wahlbeck K </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Cheine M </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Essali A </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Adams C </contrib>. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. <span class="NLM_source">Am J Psychiatry</span> 1999;156:990-999<br /><a href="/servlet/linkout?suffix=r009&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000081187200003" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r009&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=10401441" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref10"></a> <li id="refItem10"><p class="number">10</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Chakos M </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Lieberman J </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Hoffman E </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Bradford D </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Sheitman B </contrib>. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. <span class="NLM_source">Am J Psychiatry</span> 2001;158:518-526<br /><a href="/servlet/linkout?suffix=r010&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1176%2Fappi.ajp.158.4.518" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r010&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000167931900002" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r010&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=11282684" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref11"></a> <li id="refItem11"><p class="number">11</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Tuunainen A </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Wahlbeck K </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Gilbody S </contrib>. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. <span class="NLM_source">Schizophr Res</span> 2002;56:1-10<br /><a href="/servlet/linkout?suffix=r011&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1016%2FS0920-9964%2801%2900212-2" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r011&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000176481400001" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r011&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=12084413" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref12"></a> <li id="refItem12"><p class="number">12</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Rosenheck R </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Perlick D </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Bingham S </contrib>, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. <span class="NLM_source">JAMA</span> 2003;290:2693-2702<br /><a href="/servlet/linkout?suffix=r012&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1001%2Fjama.290.20.2693" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r012&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000186788100021" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r012&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=14645311" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref13"></a> <li id="refItem13"><p class="number">13</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Tollefson GD </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Sanger TM </contrib>. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. <span class="NLM_source">Am J Psychiatry</span> 1997;154:466-474<br /><a href="/servlet/linkout?suffix=r013&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=A1997WQ18300005" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r013&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=9090332" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref14"></a> <li id="refItem14"><p class="number">14</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Keefe RS </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Silva SG </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Perkins DO </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Lieberman JA </contrib>. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. <span class="NLM_source">Schizophr Bull</span> 1999;25:201-222<br /><a href="/servlet/linkout?suffix=r014&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000080718700004" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r014&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=10416727" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref15"></a> <li id="refItem15"><p class="number">15</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Tollefson GD </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Sanger TM </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Lu Y </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Thieme ME </contrib>. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. <span class="NLM_source">Arch Gen Psychiatry</span> 1998;55:250-258[Erratum, Arch Gen Psychiatry 1998;55:1052.]<br /><a href="/servlet/linkout?suffix=r015&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1001%2Farchpsyc.55.3.250" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r015&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000072412500006" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r015&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=9510219" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref16"></a> <li id="refItem16"><p class="number">16</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Csernansky JG </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Mahmoud R </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Brenner R </contrib>. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. <span class="NLM_source">N Engl J Med</span> 2002;346:16-22[Erratum, N Engl J Med 2002;346:1424.]<br /><a href="/servlet/linkout?suffix=r016&amp;dbid=20&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1056%2FNEJMoa002028" onclick="newWindow(this.href);return false">Full Text</a> | <a href="/servlet/linkout?suffix=r016&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000173033600003" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r016&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=11777998" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref17"></a> <li id="refItem17"><p class="number">17</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Allison DB </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Mentore JL </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Heo M </contrib>, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. <span class="NLM_source">Am J Psychiatry</span> 1999;156:1686-1696<br /><a href="/servlet/linkout?suffix=r017&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000083446100004" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r017&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=10553730" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref18"></a> <li id="refItem18"><p class="number">18</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Henderson DC </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Cagliero E </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Copeland PM </contrib>, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. <span class="NLM_source">Arch Gen Psychiatry</span> 2005;62:19-28<br /><a href="/servlet/linkout?suffix=r018&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1001%2Farchpsyc.62.1.19" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r018&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000226250300003" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r018&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=15630069" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref19"></a> <li id="refItem19"><p class="number">19</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Koro CE </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Fedder DO </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> L'Italien GJ </contrib>, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. <span class="NLM_source">Arch Gen Psychiatry</span> 2002;59:1021-1026<br /><a href="/servlet/linkout?suffix=r019&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1001%2Farchpsyc.59.11.1021" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r019&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000179174700007" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r019&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=12418935" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref20"></a> <li id="refItem20"><p class="number">20</p><p class="content">Atypical antipsychotics — generating evidence to inform policy and practice. London: IMS Health, 2002. (Accessed August 26, 2005, at http://research.imshealth.com/research/research_schizophrenia.htm.)<br /></p></li> <a name="ref21"></a> <li id="refItem21"><p class="number">21</p><p class="content">Harrington C, Gregorian R, Gemmen E, et al. Access and utilization of new antidepressant and antipsychotic medications. Falls Church, Va.: Lewin Group, 2000. (Accessed August 26, 2005, at http://aspe.hhs.gov/search/health/reports/Psychmedaccess/index.htm#TOC.)<br /></p></li> <a name="ref22"></a> <li id="refItem22"><p class="number">22</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Tunis SR </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Stryer DB </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Clancy CM </contrib>. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. <span class="NLM_source">JAMA</span> 2003;290:1624-1632<br /><a href="/servlet/linkout?suffix=r022&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1001%2Fjama.290.12.1624" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r022&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000185461300028" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r022&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=14506122" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref23"></a> <li id="refItem23"><p class="number">23</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Lebowitz BD </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Vitiello B </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Norquist GS </contrib>. Approaches to multisite clinical trials: the National Institute of Mental Health perspective. <span class="NLM_source">Schizophr Bull</span> 2003;29:7-13<br /><a href="/servlet/linkout?suffix=r023&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000184166500002" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r023&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=12908657" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref24"></a> <li id="refItem24"><p class="number">24</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Stroup TS </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> McEvoy JP </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Swartz MS </contrib>, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. <span class="NLM_source">Schizophr Bull</span> 2003;29:15-31<br /><a href="/servlet/linkout?suffix=r024&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000184166500003" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r024&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=12908658" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref25"></a> <li id="refItem25"><p class="number">25</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Swartz MS </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Perkins DO </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Stroup TS </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> McEvoy JP </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Nieri JM </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Haak DC </contrib>. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. <span class="NLM_source">Schizophr Bull</span> 2003;29:33-43<br /><a href="/servlet/linkout?suffix=r025&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000184166500004" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r025&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=12908659" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref26"></a> <li id="refItem26"><p class="number">26</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Keefe RS </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Mohs RC </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Bilder RM </contrib>, et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. <span class="NLM_source">Schizophr Bull</span> 2003;29:45-55<br /><a href="/servlet/linkout?suffix=r026&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000184166500005" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r026&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=12908660" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref27"></a> <li id="refItem27"><p class="number">27</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Rosenheck R </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Doyle J </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Leslie D </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Fontana A </contrib>. Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. <span class="NLM_source">Schizophr Bull</span> 2003;29:81-93<br /><a href="/servlet/linkout?suffix=r027&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000184166500008" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r027&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=12908663" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref28"></a> <li id="refItem28"><p class="number">28</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Davis SM </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Koch GG </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Davis CE </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> LaVange LM </contrib>. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. <span class="NLM_source">Schizophr Bull</span> 2003;29:73-80<br /><a href="/servlet/linkout?suffix=r028&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000184166500007" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r028&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=12908662" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref29"></a> <li id="refItem29"><p class="number">29</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Cox DR </contrib>. Regression models and life-tables. <span class="NLM_source">J R Stat Soc [B]</span> 1972;34:187-220<br /></p></li> <a name="ref30"></a> <li id="refItem30"><p class="number">30</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Hochberg Y </contrib>. A sharper Bonferroni procedure for multiple tests of significance. <span class="NLM_source">Biometrika</span> 1988;75:800-802<br /><a href="/servlet/linkout?suffix=r030&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1093%2Fbiomet%2F75.4.800" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r030&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=A1988R296800023" onclick="newWindow(this.href);return false">Web of Science</a></p></li> <a name="ref31"></a> <li id="refItem31"><p class="number">31</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Rosenheck RA </contrib>. Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. <span class="NLM_source">Psychiatr Serv</span> 2005;56:85-92<br /><a href="/servlet/linkout?suffix=r031&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1176%2Fappi.ps.56.1.85" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r031&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000226217200015" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r031&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=15637198" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref32"></a> <li id="refItem32"><p class="number">32</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Citrome L </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Volavka J </contrib>. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. <span class="NLM_source">Harv Rev Psychiatry</span> 2002;10:280-291<br /><a href="/servlet/linkout?suffix=r032&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1080%2F10673220216279" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r032&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000178233100003" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r032&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=12202454" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref33"></a> <li id="refItem33"><p class="number">33</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Davis JM </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Chen N </contrib>. Dose response and dose equivalence of antipsychotics. <span class="NLM_source">J Clin Psychopharmacol</span> 2004;24:192-208<br /><a href="/servlet/linkout?suffix=r033&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1097%2F01.jcp.0000117422.05703.ae" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r033&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000220310400012" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r033&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=15206667" onclick="newWindow(this.href);return false">Medline</a></p></li> <a name="ref34"></a> <li id="refItem34"><p class="number">34</p><p class="content">Intercontinental Medical Systems National Disease and Therapeutic Index. Plymouth Meeting, Pa.: IMS Health, January 2001-December 2004.<br /></p></li> <a name="ref35"></a> <li id="refItem35"><p class="number">35</p><p class="content"> <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Lehman AF </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Lieberman JA </contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author"> Dixon LB </contrib>, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. <span class="NLM_source">Am J Psychiatry</span> 2004;161:Suppl:1-56<br /><a href="/servlet/linkout?suffix=r035&amp;dbid=16&amp;doi=10.1056%2FNEJMoa051688&amp;key=10.1176%2Fappi.ajp.161.1.1" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="/servlet/linkout?suffix=r035&amp;dbid=128&amp;doi=10.1056%2FNEJMoa051688&amp;key=000221354600001" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="/servlet/linkout?suffix=r035&amp;dbid=8&amp;doi=10.1056%2FNEJMoa051688&amp;key=15000267" onclick="newWindow(this.href);return false">Medline</a></p></li> </ol> </div> </dd> <dt class="citedby" id="citedbyTab"> Citing Articles <span>(1192) </span> </dt> <dd id="citedby"> <div class="section"> <h3>Citing Articles</h3> <ol class="striped"> <li><p class="number">1</p><p class="content">Antonio Ciudad, Luis San, Miguel Bernardo, Jos&eacute; M. Olivares, Pepa Polavieja, Amparo Valladares, Inmaculada Gilaberte. (2012) Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>36</b>:2, 245-250<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2011.10.014" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">2</p><p class="content">Mark Viron, Travis Baggett, Michele Hill, Oliver Freudenreich. (2012) Schizophrenia for Primary Care Providers: How to Contribute to the Care of a Vulnerable Patient Population. <i><span class="NLM_source">The American Journal of Medicine</span></i> <b>125</b>:3, 223-230<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.amjmed.2011.05.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">3</p><p class="content">M. Harrow, T. H. Jobe, R. N. Faull. (2012) Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. <i><span class="NLM_source">Psychological Medicine</span></i>1-11<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S0033291712000220" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">4</p><p class="content">Adib Essali, Ghassan Ali, Adib Essali. 2012. Antipsychotic drug treatment for elderly people with late-onset schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD004162.pub2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">5</p><p class="content">J. Ventura, S. P. Reise, R. S. E. Keefe, I. M. Hurford, R. C. Wood, R. M. Bilder. (2012) The Cognitive Assessment Interview (CAI): Reliability and Validity of a Brief Interview-Based Measure of Cognition. <i><span class="NLM_source">Schizophrenia Bulletin</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbs001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">6</p><p class="content">E. C.-C. Lai, C.-H. Chang, Y.-H. Kao Yang, S.-J. Lin, C.-Y. Lin. (2012) Effectiveness of Sulpiride in Adult Patients With Schizophrenia. <i><span class="NLM_source">Schizophrenia Bulletin</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbs002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">7</p><p class="content">Haya Ascher-Svanum, Nicolas M. Furiak, Anthony H. Lawson, Timothy M. Klein, Lee J. Smolen, Robert R. Conley, Steven D. Culler. (2012) Cost-effectiveness of several atypical anti-psychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. <i><span class="NLM_source">Journal of Medical Economics</span></i>1-47<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3111/13696998.2012.662923" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">8</p><p class="content">Robert M. Savage, Jacqueline M. Dillon, Jacinda C. Hammel, Tonia C. Lewis, Natasha C. Johnson, Lafon M. Barlow, Molly M. Brooms, Patricia M. Moore, Henry E. Parker, Kanini Z. Rodney. (2012) The Alabama Coalition for a Healthier Black Belt: A Proof of Concept Project. <i><span class="NLM_source">Community Mental Health Journal</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s10597-012-9488-z" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">9</p><p class="content">Jamie D. Croxtall. (2012) Aripiprazole. <i><span class="NLM_source">CNS Drugs</span></i> <b>26</b>:2, 155-183<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/11208400-000000000-00000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">10</p><p class="content">D. Ben-Zeev, G. J. McHugo, H. Xie, K. Dobbins, M. A. Young. (2012) Comparing Retrospective Reports to Real-Time/Real-Place Mobile Assessments in Individuals With Schizophrenia and a Nonclinical Comparison Group. <i><span class="NLM_source">Schizophrenia Bulletin</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbr171" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">11</p><p class="content">Jonathan Rabinowitz, Stephen Z. Levine, George Garibaldi, Dragana Bugarski-Kirola, Carmen Galani Berardo, Shitij Kapur. (2012) Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. <i><span class="NLM_source">Schizophrenia Research</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2012.01.015" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">12</p><p class="content">Stephen Z. Levine, Jonathan Rabinowitz, Douglas Faries, Anthony H. Lawson, Haya Ascher-Svanum. (2012) Treatment response trajectories and antipsychotic medications: Examination of up to18months of treatment in the CATIE chronic schizophrenia trial. <i><span class="NLM_source">Schizophrenia Research</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2012.01.014" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">13</p><p class="content">A. Carlo Altamura, Donatella Moliterno, Silvia Paletta, Massimiliano Buoli, Bernardo DellʼOsso, Massimo C. Mauri, Silvio R. Bareggi. (2012) Effect of Quetiapine and Norquetiapine on Anxiety and Depression in Major Psychoses Using a Pharmacokinetic Approach. <i><span class="NLM_source">Clinical Drug Investigation</span></i>1<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/11597330-000000000-00000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">14</p><p class="content">Lisa Wood, Jason Price, Anthony Morrision, Gillian Haddock. (2012) Exploring service users perceptions of recovery from psychosis: A Q-methodological approach. <i><span class="NLM_source">Psychology and Psychotherapy: Theory, Research and Practice</span></i>no-no<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.2044-8341.2011.02059.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">15</p><p class="content">Kristi M. Ninnemann. (2012) Variability in the Efficacy of Psychopharmaceuticals: Contributions from Pharmacogenomics, Ethnopsychopharmacology, and Psychological and Psychiatric Anthropologies. <i><span class="NLM_source">Culture, Medicine, and Psychiatry</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11013-011-9242-y" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">16</p><p class="content">C.-J. Kuo, S.-Y. Yang, Y.-T. Liao, W. J. Chen, W.-C. Lee, W.-Y. Shau, Y.-T. Chang, S.-Y. Tsai, C.-C. Chen. (2012) Second-Generation Antipsychotic Medications and Risk of Pneumonia in Schizophrenia. <i><span class="NLM_source">Schizophrenia Bulletin</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbr202" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">17</p><p class="content">Pascale Chrisphonte, Robert B. Ostroff, Robert A. Rosenheck. (2012) Perphenazine Suspension: A New, Old Treatment, Side Effects and Continuous Use. <i><span class="NLM_source">Psychiatric Quarterly</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11126-011-9203-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">18</p><p class="content">Lawrence David Scahill. 2012. Adrenergic Agents in Child and Adolescent Psychiatry. , 341-364. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9781119958338.ch14" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">19</p><p class="content">K. Piontek, S.-U. Kutscher, A. K&ouml;nig, N. Leygraf. (2012) Pr&auml;deliktische Behandlungswege schizophrener Patienten der forensischen Psychiatrie. <i><span class="NLM_source">Der Nervenarzt</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00115-011-3409-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">20</p><p class="content">B Almoguera, R Riveiro-Alvarez, J Lopez-Castroman, P Dorado, C Vaquero-Lorenzo, J Fernandez-Piqueras, A Llerena, F Abad-Santos, E Baca-Garc&iacute;a, R Dal-R&eacute;, C Ayuso. (2012) Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. <i><span class="NLM_source">The Pharmacogenomics Journal</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/tpj.2011.57" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">21</p><p class="content">Pichai Ittasakul, Kaja R. Johnson, Shefali Srivastava, Meredith E. Childers, John O. Brooks, Jennifer C. Hoblyn, Terence A. Ketter. (2012) Effectiveness of quetiapine plus lamotrigine maintenance therapy in challenging bipolar disorder patients. <i><span class="NLM_source">Journal of Affective Disorders</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jad.2011.12.024" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">22</p><p class="content">Kathleen L. Benson. 2012. Schizophrenia and Its Associated Sleep Disorders. , 705-713. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/B978-1-4377-1703-7.10057-X" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">23</p><p class="content">J. P. Lindenmayer, Frank Tedeschi, Anna Yusim, Anzalee Khan, Saurabh Kaushik, Robert C. Smith, Mohan Parakadavil. (2012) Ziprasidone's Effect on Metabolic Markers in Patients with Diabetes and Chronic Schizophrenia. <i><span class="NLM_source">Clinical Schizophrenia &amp; Related Psychoses</span></i> <b>5</b>:4, 185-192<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3371/CSRP.5.4.2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">24</p><p class="content">Michael Makhinson. (2012) Biases in the Evaluation of Psychiatric Clinical Evidence. <i><span class="NLM_source">The Journal of Nervous and Mental Disease</span></i> <b>200</b>:1, 76-82<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/NMD.0b013e31823e62cd" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">25</p><p class="content">Michela Nos&egrave;, Maria Angela Mazzi, Eleonora Esposito, Marco Bianchini, Paola Petrosemolo, Giovanni Ostuzzi, Michele Tansella, Corrado Barbui. (2012) Adverse effects of antipsychotic drugs: survey of doctors’ versus patients’ perspective. <i><span class="NLM_source">Social Psychiatry and Psychiatric Epidemiology</span></i> <b>47</b>:1, 157-164<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00127-010-0320-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">26</p><p class="content">A.C. Silva, M.H. Amaral, E. Gonz&aacute;lez-Mira, D. Santos, D. Ferreira. (2012) Solid Lipid Nanoparticles (SLN) - based hydrogels as potential carriers for oral transmucosal delivery of Risperidone: preparation and characterization studies. <i><span class="NLM_source">Colloids and Surfaces B: Biointerfaces</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.colsurfb.2012.01.014" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">27</p><p class="content">Gary E. Duncan, Beverly H. Koller, Sheryl S. Moy. (2012) Effects of the selective kainate receptor antagonist ACET on altered sensorimotor gating in a genetic model of reduced NMDA receptor function. <i><span class="NLM_source">Brain Research</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.brainres.2012.01.009" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">28</p><p class="content">Natalie C. Edwards, Erik Muser, Dilesh Doshi, John Fastenau. (2012) The threshold rate of oral atypical antipsychotic adherence at which paliperidone palmitate is cost saving. <i><span class="NLM_source">Journal of Medical Economics</span></i>1<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3111%2F13696998.2012.667465" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">29</p><p class="content">Steven R. Erickson, Jolene R. Bostwick, Sally K. Guthrie. 2011. Psychological Symptoms Associated with Cardiovascular Drugs; Cardiac Symptoms from Psychiatric Drugs; Drug Interactions. , 194-210. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9780470975138.ch15" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">30</p><p class="content">Lawrence Maayan, Christoph U. Correll. (2011) Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents. <i><span class="NLM_source">Journal of Child and Adolescent Psychopharmacology</span></i>111213120153001<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1089/cap.2011.0015" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">31</p><p class="content">Unax Lertxundi, Saioa Domingo Echaburu, Rafael Hernandez Palacios. (2011) The use of antipsychotics in a medium–long stay psychiatric hospital from 1998 to 2010. <i><span class="NLM_source">International Journal of Psychiatry in Clinical Practice</span></i>1-5<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/13651501.2011.633172" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">32</p><p class="content">Max Marshall, Ruth Crowther, William Hurt Sledge, John Rathbone, Karla Soares-Weiser, Max Marshall. 2011. Day hospital versus admission for acute psychiatric disorders. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD004026.pub2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">33</p><p class="content">Somayeh Jafari, Francesca Fernandez-Enright, Xu-Feng Huang. (2011) Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects. <i><span class="NLM_source">Journal of Neurochemistry</span></i>no-no<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1471-4159.2011.07590.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">34</p><p class="content">S. Farooq, Z. Nazar, M. Irfan, J. Akhter, E. Gul, U. Irfan, F. Naeem. (2011) Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS). <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>199</b>:6, 467-472<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.bp.110.085340" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">35</p><p class="content">Eliseo Iniesta, Marta Lucas, Juana Ruiz, Mar&iacute;a Portela, Patricia Romero-Rodenas, M. Teresa Tolosa, M. Carmen D&iacute;az, Miguel &Aacute;ngel Mart&iacute;n, Karen Nieto, M. Dolores Mart&iacute;nez, Joaqu&iacute;n Lloret, &Agrave;ngels Mayordomo, Mar Domato, David Fraguas. (2011) Elegibilidad de pacientes con esquizofrenia ingresados en una unidad de hospitalizaci&oacute;n psiqui&aacute;trica para participar en ensayos cl&iacute;nicos. <i><span class="NLM_source">Revista de Psiquiatr&iacute;a y Salud Mental</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.rpsm.2011.10.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">36</p><p class="content">Rudi Hwang, Arun K. Tiwari, Clement C. Zai, Daniel Felsky, Eli Remington, Tessa Wallace, Ryan P. Tong, Renan P. Souza, Gabriel Oh, Steven G. Potkin, Jeffrey A. Lieberman, Herbert Y. Meltzer, James L. Kennedy. (2011) Dopamine D4 and D5 Receptor Gene Variant Effects on Clozapine Response in Schizophrenia: Replication and Exploration. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2011.11.018" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">37</p><p class="content">S. Bouloudnine, J.-M. Azorin, F. Petitjean, P. Parry-Pousse, F. Sciorato, O. Blin, E. Fakra. (2011) Analyse de discours de patients schizophr&egrave;nes et perception des effets ind&eacute;sirables de diff&eacute;rents antipsychotiques atypiques. &Eacute;tude TALK. <i><span class="NLM_source">L'Enc&eacute;phale</span></i> <b>37</b>, S143-S150<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0013-7006(11)70042-2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">38</p><p class="content">Emmanuel Stip, Simon Zhornitsky, Hoda Moteshafi, Genevi&egrave;ve L&eacute;tourneau, Irena Stikarovska, St&eacute;phane Potvin, Val&eacute;rie Tourjman. (2011) Ziprasidone for Psychotic Disorders: A Meta-Analysis and Systematic Review of the Relationship Between Pharmacokinetics, Pharmacodynamics, and Clinical Profile. <i><span class="NLM_source">Clinical Therapeutics</span></i> <b>33</b>:12, 1853-1867<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.clinthera.2011.10.027" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">39</p><p class="content">Miquel Bernardo, Eduard Vieta, Jer&oacute;nimo Saiz Ruiz, Fernando Rico-Villademoros, Cecilio &Aacute;lamo, Julio Bobes. (2011) Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry. <i><span class="NLM_source">Revista de Psiquiatr&iacute;a y Salud Mental (English Edition)</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.rpsmen.2011.07.001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">40</p><p class="content">Eduard Vieta, Nuria Cruz. (2011) Head to head comparisons as an alternative to placebo-controlled trials. <i><span class="NLM_source">European Neuropsychopharmacology</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2011.11.011" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">41</p><p class="content">Renrong Wu, David E. Kemp, Martha Sajatovic, Jingping Zhao, Joseph R. Calabrese, Keming Gao. (2011) Communication of Potential Benefits and Harm to Patients and Payers in Psychiatry: A Review and Commentary. <i><span class="NLM_source">Clinical Therapeutics</span></i> <b>33</b>:12, B62-B76<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.clinthera.2011.11.013" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">42</p><p class="content">T Kishimoto, V Agarwal, T Kishi, S Leucht, J M Kane, C U Correll. (2011) Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. <i><span class="NLM_source">Molecular Psychiatry</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/mp.2011.143" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">43</p><p class="content">Hans-J&uuml;rgen M&ouml;ller. (2011) How close is evidence to truth in evidence-based treatment of mental disorders?. <i><span class="NLM_source">European Archives of Psychiatry and Clinical Neuroscience</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00406-011-0273-8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">44</p><p class="content">A K Malhotra, J-P Zhang, T Lencz. (2011) Pharmacogenetics in psychiatry: translating research into clinical practice. <i><span class="NLM_source">Molecular Psychiatry</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/mp.2011.146" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">45</p><p class="content">Jelveh Lameh, Krista McFarland, Jorgen Ohlsson, Fredrik Ek, Fabrice Piu, Ethan S. Burstein, Ali Tabatabaei, Roger Olsson, Stefania Risso Bradley, Douglas W. Bonhaus. (2011) Discovery of potential antipsychotic agents possessing pro-cognitive properties. <i><span class="NLM_source">Naunyn-Schmiedeberg's Archives of Pharmacology</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00210-011-0702-2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">46</p><p class="content">Christopher N. Graham, Josephine A. Mauskopf, Anthony H. Lawson, Haya Ascher-Svanum, David Bruhn. (2011) Updating and Confirming an Industry-Sponsored Pharmacoeconomic Model: Comparing Two Antipsychotics in the Treatment of Schizophrenia. <i><span class="NLM_source">Value in Health</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jval.2011.08.1741" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">47</p><p class="content">David A Mrazek. (2011) Pharmacogenomic testing to guide treatment using antipsychotic medications. <i><span class="NLM_source">Clinical Investigation</span></i> <b>1</b>:11, 1513-1521<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.4155/cli.11.144" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">48</p><p class="content">Rei Kitajima, Seiya Miyamoto, Tomomi Tenjin, Kazuaki Ojima, Shin Ogino, Nobumi Miyake, Keisuke Fujiwara, Yasuyuki Funamoto, Jun Arai, Sachiko Tsukahara, Yukie Ito, Masanori Tadokoro, Kiriko Anai, Yasuhiro Kaneda, Noboru Yamaguchi. (2011) Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2011.11.008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">49</p><p class="content">James L. Roerig, Kristine J. Steffen, James E. Mitchell. (2011) Atypical Antipsychotic-Induced Weight Gain. <i><span class="NLM_source">CNS Drugs</span></i>1<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/11596300-000000000-00000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">50</p><p class="content">Neal R. Swerdlow. (2011) &iquest;Estamos estudiando y tratando correctamente la esquizofrenia?. <i><span class="NLM_source">Psiquiatr&iacute;a Biol&oacute;gica</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psiq.2011.10.010" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">51</p><p class="content">S. Leucht, S. Heres, J. M. Davis. (2011) &Uuml;berlegungen zur Wirksamkeit von Psychopharmaka. <i><span class="NLM_source">Der Nervenarzt</span></i> <b>82</b>:11, 1425-1430<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00115-011-3349-9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">52</p><p class="content">Mar&iacute;a Fe Bravo-Ortiz, Jos&eacute; Ram&oacute;n Guti&eacute;rrez-Casares, Alexander Rodr&iacute;guez-Morales, Mario Alberto Pe&ntilde;a Garc&iacute;a, Rebeca Hidalgo-Borrajo. (2011) Influence of type of treatment on the well-being of Spanish patients with schizophrenia and their caregivers. <i><span class="NLM_source">International Journal of Psychiatry in Clinical Practice</span></i> <b>15</b>:4, 286-295<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/13651501.2011.608469" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">53</p><p class="content">Joseph Jankovic, Kathleen Clarence-Smith. (2011) Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>11</b>:11, 1509-1523<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/ern.11.149" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">54</p><p class="content">Benoit Allenet, Sophie Schmidlin, C&eacute;line Genty, Jean-Luc Bosson. (2011) Antipsychotic drugs and risk of pulmonary embolism. <i><span class="NLM_source">Pharmacoepidemiology and Drug Safety</span></i>n/a-n/a<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/pds.2210" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">55</p><p class="content">Daniel E. Adkins, Amit N. Khachane, Joseph L. McClay, Karolina &Aring;berg, Jozsef Buksz&aacute;r, Patrick F. Sullivan, Edwin J.C.G. van den Oord. (2011) SNP-based analysis of neuroactive ligand–receptor interaction pathways implicates PGE2 as a novel mediator of antipsychotic treatment response: Data from the CATIE study. <i><span class="NLM_source">Schizophrenia Research</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2011.11.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">56</p><p class="content">Shaunna L. Clark, Daniel E. Adkins, Edwin J.C.G. van den Oord. (2011) Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>132</b>:2-3, 114-120<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2011.07.031" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">57</p><p class="content">Zoran Vukadinovic, Ivana Rosenzweig. (2011) Abnormalities in thalamic neurophysiology in schizophrenia: Could psychosis be a result of potassium channel dysfunction?. <i><span class="NLM_source">Neuroscience &amp; Biobehavioral Reviews</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.neubiorev.2011.11.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">58</p><p class="content">Miguel Fribourg, Jos&eacute;&nbsp;L. Moreno, Terrell Holloway, Davide Provasi, Lia Baki, Rahul Mahajan, Gyu Park, Scott&nbsp;K. Adney, Candice Hatcher, Jos&eacute;&nbsp;M. Eltit, Jeffrey&nbsp;D. Ruta, Laura Albizu, Zheng Li, Adrienne Umali, Jihyun Shim, Alexandre Fabiato, Alexander&nbsp;D. MacKerell, Vladimir Brezina, Stuart&nbsp;C. Sealfon, Marta Filizola, Javier Gonz&aacute;lez-Maeso, Diomedes&nbsp;E. Logothetis. (2011) Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs. <i><span class="NLM_source">Cell</span></i> <b>147</b>:5, 1011-1023<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.cell.2011.09.055" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">59</p><p class="content">Lamiae Grimaldi-Bensouda, Frederic Rouillon, Bernard Astruc, Michel Rossignol, Jacques Benichou, Bruno Falissard, Frederic Limosin, Beatrice Beaufils, Guillaume Vaiva, Helene Verdoux, Yola Moride, Alban Fabre, Florence Thibaut, Lucien Abenhaim. (2011) Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). <i><span class="NLM_source">Schizophrenia Research</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2011.10.022" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">60</p><p class="content">Euitae Kim, Joon Hwan Jang, Hye-Yoon Park, Geumsook Shim, Jae Yeon Hwang, Sung Nyun Kim, Jun Soo Kwon. (2011) Pharmacotherapy and clinical characteristics of ultra-high-risk for psychosis according to conversion status: a naturalistic observational study. <i><span class="NLM_source">Early Intervention in Psychiatry</span></i>no-no<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1751-7893.2011.00295.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">61</p><p class="content">J. L. Roffman, D. G. Brohawn, A. Z. Nitenson, E. A. Macklin, J. W. Smoller, D. C. Goff. (2011) Genetic Variation Throughout the Folate Metabolic Pathway Influences Negative Symptom Severity in Schizophrenia. <i><span class="NLM_source">Schizophrenia Bulletin</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbr150" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">62</p><p class="content">Marc De Hert, Johan Detraux, Ruud van Winkel, Weiping Yu, Christoph U. Correll. (2011) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i><span class="NLM_source">Nature Reviews Endocrinology</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/nrendo.2011.156" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">63</p><p class="content">Leslie Citrome. (2011) A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. <i><span class="NLM_source">Expert Opinion on Pharmacotherapy</span></i>1-29<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14656566.2011.626769" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">64</p><p class="content">Jennifer Kern Sliwa, Cynthia A. Bossie, Yi-Wen Ma, Larry Alphs. (2011) Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>132</b>:1, 28-34<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2011.06.016" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">65</p><p class="content">T. Kendall. (2011) The rise and fall of the atypical antipsychotics. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>199</b>:4, 266-268<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.bp.110.083766" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">66</p><p class="content">V. Frighi, M. T. Stephenson, A. Morovat, I. E. Jolley, M. Trivella, C. A. Dudley, E. Anand, S. J. White, C. V. Hammond, R. A. Hockney, B. Barrow, R. Shakir, G. M. Goodwin. (2011) Safety of antipsychotics in people with intellectual disability. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>199</b>:4, 289-295<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.bp.110.085670" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">67</p><p class="content">Y. J. Lee, J. H. Jeong. (2011) A systematic review of metformin to limit weight-gain with atypical antipsychotics. <i><span class="NLM_source">Journal of Clinical Pharmacy and Therapeutics</span></i> <b>36</b>:5, 537-545<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2710.2011.01255.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">68</p><p class="content">G. Foussias, S. Mann, K.K. Zakzanis, R. van Reekum, O. Agid, G. Remington. (2011) Prediction of longitudinal functional outcomes in schizophrenia: The impact of baseline motivational deficits. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>132</b>:1, 24-27<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2011.06.026" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">69</p><p class="content">P.J. Elton, R. Watkin. (2011) Reliance on credibility to prioritise interventions can lead to sub-optimal management strategies. <i><span class="NLM_source">Medical Hypotheses</span></i> <b>77</b>:4, 541-543<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.mehy.2011.06.026" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">70</p><p class="content">Benjamin U. Nwosu, Bruce Meltzer, Louise Maranda, Carol Ciccarelli, Daniel Reynolds, Laura Curtis, Jean King, Jean A. Frazier, Mary M. Lee. (2011) A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics. <i><span class="NLM_source">Journal of Pediatric Endocrinology and Metabolism</span></i> <b>24</b>:9-10, 619-626<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1515/JPEM.2011.300" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">71</p><p class="content">Ren&eacute; E. Nielsen. (2011) Treatment of psychosis during pregnancy - a case report and a mini-review. <i><span class="NLM_source">Acta Neuropsychiatrica</span></i> <b>23</b>:5, 210-214<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1601-5215.2011.00590.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">72</p><p class="content">Erin J. Wamsley, Matthew A. Tucker, Ann K. Shinn, Kim E. Ono, Sophia K. McKinley, Alice V. Ely, Donald C. Goff, Robert Stickgold, Dara S. Manoach. (2011) Reduced Sleep Spindles and Spindle Coherence in Schizophrenia: Mechanisms of Impaired Memory Consolidation?. <i><span class="NLM_source">Biological Psychiatry</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.biopsych.2011.08.008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">73</p><p class="content">Louis S. Matza, Glenn A. Phillips, Dennis A. Revicki, Haya Ascher-Svanum, Dawn Kaiser, Virginia Stauffer, Jodi M. Shorr, Bruce J. Kinon. (2011) Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation. <i><span class="NLM_source">Psychiatry Research</span></i> <b>189</b>:3, 463-468<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psychres.2011.05.030" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">74</p><p class="content">G. C. Smith, M. H. Vickers, P. R. Shepherd. (2011) Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. <i><span class="NLM_source">Archives Of Physiology And Biochemistry</span></i> <b>117</b>:4, 241-249<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/13813455.2011.576681" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">75</p><p class="content">S. Leucht, J. M. Davis. (2011) Are all antipsychotic drugs the same?. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>199</b>:4, 269-271<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.bp.111.095323" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">76</p><p class="content">R. R. Girgis, M. R. Phillips, X. Li, K. Li, H. Jiang, C. Wu, N. Duan, Y. Niu, J. A. Lieberman. (2011) Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>199</b>:4, 281-288<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.bp.110.081471" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">77</p><p class="content">Katrina Weston-Green, Xu-Feng Huang, Jiamei Lian, Chao Deng. (2011) Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. <i><span class="NLM_source">European Neuropsychopharmacology</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2011.09.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">78</p><p class="content">Robert I. Berkowitz, Anthony N. Fabricatore. (2011) Obesity, Psychiatric Status, and Psychiatric Medications. <i><span class="NLM_source">Psychiatric Clinics of North America</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psc.2011.08.007" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">79</p><p class="content">Emma Elizabeth McGinty, Gail L. Daumit. (2011) Epidemiology of Obesity. <i><span class="NLM_source">Psychiatric Annals</span></i> <b>41</b>:10, 484-488<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3928/00485713-20110921-07" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">80</p><p class="content">Cristina Cuerda, Jessica Merchan-Naranjo, Cristina Velasco, Alberto Gutierrez, Marta Leiva, Maria J. de Castro, Mara Parellada, Marisa Gir&aacute;ldez, Irene Bret&oacute;n, Miguel Camblor, Pilar Garc&iacute;a-Peris, Elena Dul&iacute;n, Inmaculada Sanz, Manuel Desco, Celso Arango. (2011) Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics. <i><span class="NLM_source">Clinical Nutrition</span></i> <b>30</b>:5, 616-623<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.clnu.2011.03.007" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">81</p><p class="content">Stephanie V Phan, Tiffany-Jade M Kreys. (2011) Adjunct Mirtazapine for Negative Symptoms of Schizophrenia. <i><span class="NLM_source">Pharmacotherapy</span></i> <b>31</b>:10, 1017-1030<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1592/phco.31.10.1017" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">82</p><p class="content">Leslie Citrome, Jan Volavka. (2011) Pharmacological Management of Acute and Persistent Aggression in Forensic Psychiatry Settings. <i><span class="NLM_source">CNS Drugs</span></i>1<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/11596930-000000000-00000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">83</p><p class="content">Rohan Ganguli. (2011) Comorbidities of Obesity in Serious Mental Illness. <i><span class="NLM_source">Psychiatric Annals</span></i> <b>41</b>:10, 469-472<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3928/00485713-20110921-04" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">84</p><p class="content">Stephen Z. Levine, Jonathan Rabinowitz, Haya Ascher-Svanum, Douglas E. Faries, Anthony H. Lawson. (2011) Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study. <i><span class="NLM_source">Schizophrenia Research</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2011.09.018" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">85</p><p class="content">Joseph Ventura, Kenneth L. Subotnik, Lisa H. Guzik, Gerhard S. Hellemann, Michael J. Gitlin, Rachel C. Wood, Keith H. Nuechterlein. (2011) Remission and recovery during the first outpatient year of the early course of schizophrenia. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>132</b>:1, 18-23<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2011.06.025" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">86</p><p class="content">Peter F. Buckley. (2011) Bromization. <i><span class="NLM_source">The Journal of Nervous and Mental Disease</span></i> <b>199</b>:10, 736-737<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/NMD.0b013e31822fc639" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">87</p><p class="content">Bita Moghaddam, Daniel Javitt. (2011) From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment. <i><span class="NLM_source">Neuropsychopharmacology</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/npp.2011.181" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">88</p><p class="content">Avril Pereira, Anthony Sugiharto-Winarno, Betty Zhang, Peter Malcolm, George Fink, Suresh Sundram. (2011) Clozapine induction of ERK1/2 cell signalling via the EGF receptor in mouse prefrontal cortex and striatum is distinct from other antipsychotic drugs. <i><span class="NLM_source">The International Journal of Neuropsychopharmacology</span></i>1-12<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S1461145711001404" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">89</p><p class="content">Lior Greenbaum, Robert C. Smith, Mordechai Lorberboym, Anna Alkelai, Polina Zozulinsky, Tzuri Lifshytz, Yoav Kohn, Ruth Djaldetti, Bernard Lerer. (2011) Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients. <i><span class="NLM_source">Psychopharmacology</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-011-2499-6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">90</p><p class="content">Joseph Stoklosa, Dost &Ouml;ng&uuml;r. (2011) Rational Antipsychotic Choice: Weighing the Risk of Tardive Dyskinesia and Metabolic Syndrome. <i><span class="NLM_source">Harvard Review of Psychiatry</span></i> <b>19</b>:5, 271-276<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/10673229.2011.614100" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">91</p><p class="content">A. P. Morrison, P. Hutton, M. Wardle, H. Spencer, S. Barratt, A. Brabban, P. Callcott, T. Christodoulides, R. Dudley, P. French, V. Lumley, S. J. Tai, D. Turkington. (2011) Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial. <i><span class="NLM_source">Psychological Medicine</span></i>1-8<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S0033291711001899" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">92</p><p class="content">S. Bahn, E. Schwarz. (2011) Serumbiomarker f&uuml;r psychiatrische Erkrankungen. <i><span class="NLM_source">Der Nervenarzt</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00115-011-3346-z" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">93</p><p class="content">Kathryn Kelly Erickson-Ridout, Junjia Zhu, Philip Lazarus. (2011) Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. <i><span class="NLM_source">Pharmacogenetics and Genomics</span></i> <b>21</b>:9, 539-551<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/FPC.0b013e328348c76b" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">94</p><p class="content">Miquel Bernardo, Eduard Vieta, Jer&oacute;nimo Saiz Ruiz, Fernando Rico-Villademoros, Cecilio &Aacute;lamo, Julio Bobes. (2011) Recomendaciones para el cambio de antipsic&oacute;ticos. Posicionamiento de la Sociedad Espa&ntilde;ola de Psiquiatr&iacute;a y Sociedad Espa&ntilde;ola de Psiquiatr&iacute;a Biol&oacute;gica. <i><span class="NLM_source">Revista de Psiquiatr&iacute;a y Salud Mental</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.rpsm.2011.07.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">95</p><p class="content">R. S. E. Keefe, S. Vinogradov, A. Medalia, S. M. Silverstein, M. D. Bell, D. Dickinson, J. Ventura, S. R. Marder, T. S. Stroup. (2011) Report From the Working Group Conference on Multisite Trial Design for Cognitive Remediation in Schizophrenia. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>37</b>:5, 1057-1065<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbq010" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">96</p><p class="content">Christian R. Dolder, Jonathan Mckinsey. (2011) Antipsychotic Polypharmacy Among Patients Admitted to a Geriatric Psychiatry Unit. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>17</b>:5, 368-374<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.pra.0000405368.20538.cd" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">97</p><p class="content">Bj&oslash;rn H Ebdrup, Hans Rasmussen, J&oslash;rn Arnt, Birte Glenth&oslash;j. (2011) Serotonin 2A receptor antagonists for treatment of schizophrenia. <i><span class="NLM_source">Expert Opinion on Investigational Drugs</span></i> <b>20</b>:9, 1211-1223<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/13543784.2011.601738" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">98</p><p class="content">Stephanie Sisley, Darleen Sandoval. (2011) Hypothalamic control of energy and glucose metabolism. <i><span class="NLM_source">Reviews in Endocrine and Metabolic Disorders</span></i> <b>12</b>:3, 219-233<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11154-011-9189-x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">99</p><p class="content">A. J. M. Brnabic, K. Kelin, H. Ascher-Svanum, W. Montgomery, Z. Kadziola, J. Karagianis. (2011) Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study. <i><span class="NLM_source">International Journal of Clinical Practice</span></i> <b>65</b>:9, 945-953<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1742-1241.2011.02743.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">100</p><p class="content">Ruzanna ZamZam, Cheah Yee Chuan, Salina Abdul Aziz, Badiah Yahya, Sharifah Suziah Syed Mokhtar, Chee Kok Yong, Norsiatul Azma binti Muhammad Dain. (2011) National mental health registry for schizophrenia in Malaysia: A preliminary assessment on service utilization. <i><span class="NLM_source">Asia-Pacific Psychiatry</span></i> <b>3</b>:3, 151-156<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1758-5872.2011.00107.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">101</p><p class="content">Daniel J. Lodge, Anthony A. Grace. (2011) Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. <i><span class="NLM_source">Trends in Pharmacological Sciences</span></i> <b>32</b>:9, 507-513<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.tips.2011.05.001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">102</p><p class="content">V.M. Linck, M.M. Bessa, A.P. Herrmann, M.M. Iwu, C.O. Okunji, E. Elisabetsky. (2011) 5-HT2A/C receptors mediate the antipsychotic-like effects of alstonine. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2011.08.022" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">103</p><p class="content">Laurent Azoulay, Hui Yin, Christel Renoux, Samy Suissa. (2011) The use of atypical antipsychotics and the risk of breast cancer. <i><span class="NLM_source">Breast Cancer Research and Treatment</span></i> <b>129</b>:2, 541-548<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s10549-011-1506-2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">104</p><p class="content">J. Volavka, L. Citrome. (2011) Pathways to Aggression in Schizophrenia Affect Results of Treatment. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>37</b>:5, 921-929<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbr041" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">105</p><p class="content">Alberto Parabiaghi, Barbara D'Avanzo, Mauro Tettamanti, Angelo Barbato. (2011) The GiSAS study: Rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia. <i><span class="NLM_source">Contemporary Clinical Trials</span></i> <b>32</b>:5, 675-684<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.cct.2011.04.008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">106</p><p class="content">Julie Kreyenbuhl, Eric P. Slade, Deborah R. Medoff, Clayton H. Brown, Benjamin Ehrenreich, Joseph Afful, Lisa B. Dixon. (2011) Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>131</b>:1-3, 127-132<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2011.04.028" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">107</p><p class="content">Silje Skrede, Johan Fern&oslash;, Mar&iacute;a Jes&uacute;s V&aacute;zquez, Sveinung Fj&aelig;r, Tina Pavlin, Niclas Lunder, Antonio Vidal-Puig, Carlos Di&eacute;guez, Rolf Kristian Berge, Miguel L&oacute;pez, Vidar Martin Steen. (2011) Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. <i><span class="NLM_source">The International Journal of Neuropsychopharmacology</span></i>1-17<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S1461145711001271" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">108</p><p class="content">Shaun R. Stauffer. (2011) Progress toward Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 (mGlu <sub>5</sub> ). <i><span class="NLM_source">ACS Chemical Neuroscience</span></i> <b>2</b>:8, 450-470<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1021/cn2000519" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">109</p><p class="content">Richard I. G. Holt, Robert C. Peveler. 2011. Metabolic Syndrome and Mental Illness. , 177-193. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9781444347319.ch11" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">110</p><p class="content">David Misdrahi, Marion Petit, Olivier Blanc, Franck Bayle, Pierre-Michel Llorca. (2011) The influence of therapeutic alliance and insight on medication adherence in schizophrenia. <i><span class="NLM_source">Nordic Journal of Psychiatry</span></i>1-6<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/08039488.2011.598556" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">111</p><p class="content">Magdolna Tardy, Stefan Leucht, Andrey Potapov, Werner Kissling, Rolf Engel, Maximilian Huhn, Katja Komossa, Magdolna Tardy. 2011. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD009268" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">112</p><p class="content">L Greenbaum, A Alkelai, P Zozulinsky, Y Kohn, B Lerer. (2011) Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. <i><span class="NLM_source">The Pharmacogenomics Journal</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/tpj.2011.32" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">113</p><p class="content">Chris M. Kozma, Terra Slaton, Riad Dirani, John Fastenau, Srihari Gopal, David Hough. (2011) Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE). <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>27</b>:8, 1603-1611<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/03007995.2011.595000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">114</p><p class="content">Vered Baloush-Kleinman, Stephen Z. Levine, David Roe, Dan Shnitt, Abraham Weizman, Michael Poyurovsky. (2011) Adherence to antipsychotic drug treatment in early-episode schizophrenia: A six-month naturalistic follow-up study. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>130</b>:1-3, 176-181<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2011.04.030" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">115</p><p class="content">Clemente Garcia-Rizo, Emilio Fernandez-Egea, Cristina Oliveira, Azucena Justicia, Eduard Parellada, Miguel Bernardo, Brian Kirkpatrick. (2011) Prolactin concentrations in newly diagnosed, antipsychotic-na&iuml;ve patients with nonaffective psychosis. <i><span class="NLM_source">Schizophrenia Research</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2011.07.025" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">116</p><p class="content">Sidney H. Kennedy. (2011) Improving the clinical effectiveness of antidepressant treatment. <i><span class="NLM_source">Journal of Affective Disorders</span></i> <b>132</b>, S1-S2<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jad.2011.03.044" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">117</p><p class="content">Mark J. Niciu, Benjamin Kelmendi, Gerard Sanacora. (2011) Overview of glutamatergic neurotransmission in the nervous system. <i><span class="NLM_source">Pharmacology Biochemistry and Behavior</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pbb.2011.08.008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">118</p><p class="content">Tom Stargardt, Paraskevi Mavrogiorgou, Christian A. Gericke, Georg Juckel. (2011) Effectiveness and costs of flupentixol compared to other first- and second-generation antipsychotics in the treatment of schizophrenia. <i><span class="NLM_source">Psychopharmacology</span></i> <b>216</b>:4, 579-587<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-011-2256-x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">119</p><p class="content">James J. Gugger. (2011) Antipsychotic Pharmacotherapy and Orthostatic Hypotension. <i><span class="NLM_source">CNS Drugs</span></i> <b>25</b>:8, 659-671<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/11591710-000000000-00000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">120</p><p class="content">Karin E. Kerfoot, Robert A. Rosenheck, Ismene L. Petrakis, Marvin S. Swartz, Richard S.E. Keefe, Joseph P. McEvoy, T. Scott Stroup. (2011) Substance use and schizophrenia: Adverse correlates in the CATIE study sample. <i><span class="NLM_source">Schizophrenia Research</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2011.07.032" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">121</p><p class="content">Camilo de la Fuente-Sandoval, Pablo Le&oacute;n-Ortiz, Rafael Favila, Sylvana Stephano, David Mamo, Jes&uacute;s Ram&iacute;rez-Berm&uacute;dez, Ariel Graff-Guerrero. (2011) Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>36</b>:9, 1781-1791<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/npp.2011.65" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">122</p><p class="content">Xiaofeng Guo, Jinguo Zhai, Qinling Wei, Elizabeth W. Twamley, Hua Jin, Maosheng Fang, Maorong Hu, Jingping Zhao. (2011) Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: A naturalistic 12-month follow-up study. <i><span class="NLM_source">Neuroscience Letters</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.neulet.2011.08.027" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">123</p><p class="content">Ana Paula Werneck, Jaime Cecilio Hallak, Eduardo Nakano, Helio Elkis. (2011) Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. <i><span class="NLM_source">Psychiatry Research</span></i> <b>188</b>:3, 315-319<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psychres.2011.04.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">124</p><p class="content">Scott Patten, Sophie Grigoriadis, Serge Beaulieu. (2011) Clinical effectiveness, construct and assessment. <i><span class="NLM_source">Journal of Affective Disorders</span></i> <b>132</b>, S3-S8<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jad.2011.03.045" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">125</p><p class="content">Neal R. Swerdlow. (2011) Are we studying and treating schizophrenia correctly?. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>130</b>:1-3, 1-10<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2011.05.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">126</p><p class="content">Zoran Vukadinovic. (2011) Sleep abnormalities in schizophrenia may suggest impaired trans-thalamic cortico-cortical communication: towards a dynamic model of the illness. <i><span class="NLM_source">European Journal of Neuroscience</span></i>no-no<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1460-9568.2011.07822.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">127</p><p class="content">Stephen Z. Levine, Jonathan Rabinowitz, Dimitris Rizopoulos. (2011) Recommendations to improve the Positive and Negative Syndrome Scale (PANSS) based on item response theory. <i><span class="NLM_source">Psychiatry Research</span></i> <b>188</b>:3, 446-452<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psychres.2011.03.014" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">128</p><p class="content">Wolfgang Gaebel, Mathias Riesbeck, Thomas Wobrock. (2011) Schizophrenia guidelines across the world: A selective review and comparison. <i><span class="NLM_source">International Review of Psychiatry</span></i> <b>23</b>:4, 379-387<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/09540261.2011.606801" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">129</p><p class="content">Maithri Prabhakar, William G Haynes, William H Coryell, Elizabeth A Chrischilles, Del D Miller, Stephan Arndt, Vicki L Ellingrod, Lois Warren, Jess G Fiedorowicz. (2011) Factors Associated with the Prescribing of Olanzapine, Quetiapine, and Risperidone in Patients with Bipolar and Related Affective Disorders. <i><span class="NLM_source">Pharmacotherapy</span></i> <b>31</b>:8, 806-812<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1592/phco.31.8.806" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">130</p><p class="content">Xiaofeng Guo, Maosheng Fang, Jinguo Zhai, Bo Wang, Chuanyue Wang, Bin Hu, Xueli Sun, Luxian Lv, Zheng Lu, Cui Ma, Tiansheng Guo, Shiping Xie, Elizabeth W. Twamley, Hua Jin, Jingping Zhao. (2011) Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study. <i><span class="NLM_source">Psychopharmacology</span></i> <b>216</b>:4, 475-484<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-011-2242-3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">131</p><p class="content">G L Daumit, A T Dalcin, G J Jerome, D R Young, J Charleston, R M Crum, C Anthony, J H Hayes, P B McCarron, E Khaykin, L J Appel. (2011) A behavioral weight-loss intervention for persons with serious mental illness in psychiatric rehabilitation centers. <i><span class="NLM_source">International Journal of Obesity</span></i> <b>35</b>:8, 1114-1123<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/ijo.2010.224" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">132</p><p class="content">Philip Prah, Irene Petersen, Irwin Nazareth, Kate Walters, David Osborn. (2011) National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom. <i><span class="NLM_source">Pharmacoepidemiology and Drug Safety</span></i>n/a-n/a<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/pds.2213" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">133</p><p class="content">Claudia Ress, Alexander Tschoner, Susanne Kaser, Christoph F. Ebenbichler. (2011) Psychopharmaka und Diabetes. <i><span class="NLM_source">Wiener Medizinische Wochenschrift</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s10354-011-0004-9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">134</p><p class="content">Xin Wang, Gregory R. Sliwoski, Edgar A. Buttner. (2011) The Relevance of <i>Caenorhabditis elegans</i> Genetics for Understanding Human Psychiatric&nbsp;Disease. <i><span class="NLM_source">Harvard Review of Psychiatry</span></i> <b>19</b>:4, 210-218<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/10673229.2011.599185" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">135</p><p class="content">W. Wolfgang Fleischhacker, Srihari Gopal, Rosanne Lane, Cristiana Gassmann-Mayer, Pilar Lim, David Hough, Bart Remmerie, Marielle Eerdekens. (2011) A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. <i><span class="NLM_source">The International Journal of Neuropsychopharmacology</span></i>1-12<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S1461145711001076" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">136</p><p class="content">Frank B. Yoon, Garrett M. Fitzmaurice, Stuart R. Lipsitz, Nicholas J. Horton, Nan M. Laird, Sharon-Lise T. Normand. (2011) Alternative methods for testing treatment effects on the basis of multiple outcomes: Simulation and case study. <i><span class="NLM_source">Statistics in Medicine</span></i> <b>30</b>:16, 1917-1932<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/sim.4262" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">137</p><p class="content">A. James O'Malley, R. G. Frank, S.-L. T. Normand. (2011) Estimating cost-offsets of new medications: Use of new antipsychotics and mental health costs for schizophrenia. <i><span class="NLM_source">Statistics in Medicine</span></i> <b>30</b>:16, 1971-1988<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/sim.4245" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">138</p><p class="content">Eva Lindstr&ouml;m, Jonas Eberhard, Bj&ouml;rn M. Fors, Karina Hansen, Christophe Sapin. (2011) A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. <i><span class="NLM_source">Nordic Journal of Psychiatry</span></i>1-11<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/08039488.2011.590603" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">139</p><p class="content">Enric Alvarez, Victor Perez, Marianne Dragheim, Henrik Loft, Francesc Artigas. (2011) A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. <i><span class="NLM_source">The International Journal of Neuropsychopharmacology</span></i>1-12<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S1461145711001027" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">140</p><p class="content">S Ono, Y Suzuki, N Fukui, T Sugai, J Watanabe, N Tsuneyama, T Someya. (2011) Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine. <i><span class="NLM_source">The Pharmacogenomics Journal</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/tpj.2011.28" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">141</p><p class="content">Goran Jassim, Silje Skrede, Mar&iacute;a Jes&uacute;s V&aacute;zquez, Hege Wergedal, Audun O. Vik-Mo, Niclas Lunder, Carlos Di&eacute;guez, Antonio Vidal-Puig, Rolf K. Berge, Miguel L&oacute;pez, Vidar M. Steen, Johan Fern&oslash;. (2011) Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. <i><span class="NLM_source">Psychopharmacology</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-011-2397-y" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">142</p><p class="content">David E. Kemp, Onur N. Karayal, Joseph R. Calabrese, Gary S. Sachs, Elizabeth Pappadopulos, Kathleen S. Ice, Cynthia O. Siu, Eduard Vieta. (2011) Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: Long-term changes in weight and metabolic profiles. <i><span class="NLM_source">European Neuropsychopharmacology</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2011.06.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">143</p><p class="content">Amy K Lee, Jeffrey R Bishop. (2011) Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications. <i><span class="NLM_source">Pharmacogenomics</span></i> <b>12</b>:7, 999-1016<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/pgs.11.45" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">144</p><p class="content">Maurizio Pompili, Gianluca Serafini, Marco Innamorati, Elisa Ambrosi, Ludovica Telesforo, Paola Venturini, Gloria Giordano, Michele Battuello, David Lester, Paolo Girardi. (2011) Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>11</b>:7, 989-1006<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/ern.11.82" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">145</p><p class="content">Jelle Vehof, Arne J. Risselada, Asmar F. Y. Hadithy, Huibert Burger, Harold Snieder, Bob Wilffert, Johan Arends, Lex Wunderink, Henrikus Knegtering, Durk Wiersma, Dan Cohen, Hans Mulder, Richard Bruggeman. (2011) Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. <i><span class="NLM_source">Psychopharmacology</span></i> <b>216</b>:2, 257-265<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-011-2211-x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">146</p><p class="content">Silvio Caccia. (2011) Pharmacokinetics and metabolism update for some recent antipsychotics. <i><span class="NLM_source">Expert Opinion on Drug Metabolism &amp; Toxicology</span></i> <b>7</b>:7, 829-846<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/17425255.2011.575061" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">147</p><p class="content">H. Ascher-Svanum, X. Peng, W. Montgomery, D.E. Faries, A.H. Lawson, M.M. Witte, D. Novick, N. Jemiai, E. Perrin, D.P. McDonnell. (2011) Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia. <i><span class="NLM_source">European Psychiatry</span></i> <b>26</b>:5, 313-319<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.eurpsy.2010.03.015" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">148</p><p class="content">Basant K Puri. (2011) Brain tissue changes and antipsychotic medication. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>11</b>:7, 943-946<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/ern.11.87" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">149</p><p class="content">Michael Saraga, Friedrich Stiefel. (2011) Psychiatry and the scientific fallacy. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>124</b>:1, 70-72<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2011.01708.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">150</p><p class="content">Joop van Gerven, Adam Cohen. (2011) Vanishing clinical psychopharmacology. <i><span class="NLM_source">British Journal of Clinical Pharmacology</span></i> <b>72</b>:1, 1-5<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2125.2011.04021.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">151</p><p class="content">Anirban Basu, Anupam B. Jena, Tomas J. Philipson. (2011) The impact of comparative effectiveness research on health and health care spending. <i><span class="NLM_source">Journal of Health Economics</span></i> <b>30</b>:4, 695-706<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jhealeco.2011.05.012" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">152</p><p class="content">Jeffrey McCombs, Sara Zolfaghari, Vaidynathan Ganapathy. (2011) Impact of Drug Treatment History on Comparative Effectiveness Research in Schizophrenia. <i><span class="NLM_source">Value in Health</span></i> <b>14</b>:5, 679-686<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jval.2011.02.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">153</p><p class="content">Ralitza Gueorguieva, Robert Rosenheck, Haiqun Lin. (2011) Joint modelling of longitudinal outcome and interval-censored competing risk dropout in a schizophrenia clinical trial. <i><span class="NLM_source">Journal of the Royal Statistical Society: Series A (Statistics in Society)</span></i>no-no<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1467-985X.2011.00719.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">154</p><p class="content">Erin Schwenger, Jane Dumontet, Mary H.H. Ensom. (2011) Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?. <i><span class="NLM_source">Clinical Pharmacokinetics</span></i> <b>50</b>:7, 415-428<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/11587240-000000000-00000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">155</p><p class="content">H. Uchida, T. Suzuki, H. Takeuchi, T. Arenovich, D. C. Mamo. (2011) Low Dose vs Standard Dose of Antipsychotics for Relapse Prevention in Schizophrenia: Meta-analysis. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>37</b>:4, 788-799<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbp149" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">156</p><p class="content">Leslie Citrome, Richard I.G. Holt, Daniel J. Walker, Vicki Poole Hoffmann. (2011) Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder. <i><span class="NLM_source">Clinical Drug Investigation</span></i> <b>31</b>:7, 455-482<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/11589060-000000000-00000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">157</p><p class="content">Ei Sejima, Atsushi Yamauchi, Tsuyoshi Nishioku, Mitsuhisa Koga, Kengo Nakagama, Shinya Dohgu, Kojiro Futagami, Yasufumi Kataoka. (2011) A Role for Hypothalamic AMP-Activated Protein Kinase in the Mediation of Hyperphagia and Weight Gain Induced by Chronic Treatment with Olanzapine in Female Rats. <i><span class="NLM_source">Cellular and Molecular Neurobiology</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s10571-011-9663-8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">158</p><p class="content">Mohammad-Reza Noori-Daloii, Majid Mojarrad, Ali Rashidi-nezhad, Majid Kheirollahi, Ali Shahbazi, Mehdi Khaksari, Asghar Korzebor, Ali Goodarzi, Maryam Ebrahimi, Ali Reza Noori-Daloii. (2011) Use of siRNA in knocking down of dopamine receptors, a possible therapeutic option in neuropsychiatric disorders. <i><span class="NLM_source">Molecular Biology Reports</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11033-011-0947-3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">159</p><p class="content">R.A. Kroken, L.S. Mellesdal, T. Wentzel-Larsen, H.A. J&oslash;rgensen, E. Johnsen. (2011) Time-dependent effect analysis of antipsychotic treatment in a naturalistic cohort study of patients with schizophrenia. <i><span class="NLM_source">European Psychiatry</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.eurpsy.2011.04.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">160</p><p class="content">Sanjiv Kumra, Manzar Ashtari, Jinghui Wu, Donaya Hongwanishkul, Tonya White, Kelly Cervellione, John Cottone, Philip R. Szeszko. (2011) Gray matter volume deficits are associated with motor and attentional impairments in adolescents with schizophrenia. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>35</b>:4, 939-943<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2011.01.001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">161</p><p class="content">Yong Chen, Becky A. Briesacher. (2011) Use of instrumental variable in prescription drug research with observational data: a systematic review. <i><span class="NLM_source">Journal of Clinical Epidemiology</span></i> <b>64</b>:6, 687-700<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jclinepi.2010.09.006" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">162</p><p class="content">Mehmet Sungur, Haldun Soyg&uuml;r, Perihan G&uuml;ner, Besti &Uuml;st&uuml;n, İlkten &Ccedil;etin, Ian R. Falloon. (2011) Identifying an optimal treatment for schizophrenia: A 2-year randomized controlled trial comparing integrated care to a high-quality routine treatment. <i><span class="NLM_source">International Journal of Psychiatry in Clinical Practice</span></i> <b>15</b>:2, 118-127<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/13651501.2011.554987" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">163</p><p class="content">Susan Varghese, Subimal Banerjee. (2011) Psychotic disorders in learning disabilities- outcome of an audit across community teams. <i><span class="NLM_source">British Journal of Learning Disabilities</span></i> <b>39</b>:2, 148-153<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1468-3156.2010.00641.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">164</p><p class="content">Elisabeth K. Degenhardt, Hassan H. Jamal, Susan Tormey, Michael Case. (2011) Early Weight Gain as a Predictor of Substantial Weight Gain With Olanzapine/Fluoxetine Combination. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>31</b>:3, 337-340<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e3182196e64" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">165</p><p class="content">K L Bigos, R R Bies, B G Pollock, J J Lowy, F Zhang, D R Weinberger. (2011) Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>16</b>:6, 620-625<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/mp.2011.38" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">166</p><p class="content">Jan-Henry Stenberg, Viatcheslav Terevnikov, Marina Joffe, Jari Tiihonen, Evgueni Tchoukhine, Mark Burkin, Grigori Joffe. (2011) More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>35</b>:4, 1080-1086<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2011.03.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">167</p><p class="content">Chun-Hsin Chen, Tsang-Yaw Lin, Tzu-Ting Chen, Vincent Chin-Hung Chen, Ni-Chi Lin, Wen-Chuan Shao, Mong-Liang Lu. (2011) A prospective study of glucose homeostasis in quetiapine-treated schizophrenic patients by using the intravenous glucose tolerance test. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>35</b>:4, 965-969<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2011.01.015" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">168</p><p class="content">Afshin Shirani, Sergio Paradiso, Mark Eric Dyken. (2011) The impact of atypical antipsychotic use on obstructive sleep apnea: A pilot study and literature review. <i><span class="NLM_source">Sleep Medicine</span></i> <b>12</b>:6, 591-597<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.sleep.2010.12.013" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">169</p><p class="content">Shermin Imran, Soumitra Shankar Datta, Elaine Vincent, Jade Whitfield, Andrew F. Clark. (2011) Antipsychotic Prescribing: Old Wine in New Bottles?. <i><span class="NLM_source">Child and Adolescent Mental Health</span></i>no-no<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1475-3588.2011.00610.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">170</p><p class="content">A. McArdle, J. O. Larkin, F. N. Awan, P. H. McCormick, B. J. Mehigan. (2011) Large-bowel obstruction secondary to urinary retention. <i><span class="NLM_source">Colorectal Disease</span></i> <b>13</b>:6, e160-e161<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1463-1318.2011.02553.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">171</p><p class="content">Katherine Seto, Jane Dumontet, Mary H H Ensom. (2011) Risperidone in Schizophrenia: Is There a Role for Therapeutic Drug Monitoring?. <i><span class="NLM_source">Therapeutic Drug Monitoring</span></i> <b>33</b>:3, 275-283<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/FTD.0b013e3182126d83" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">172</p><p class="content">Corrado Barbui, Simone Accordini, Michela Nos&egrave;, Scott Stroup, Marianna Purgato, Francesca Girlanda, Eleonora Esposito, Antonio Veronese, Michele Tansella, Andrea Cipriani. (2011) Aripiprazole Versus Haloperidol in Combination With Clozapine for Treatment-Resistant Schizophrenia in Routine Clinical Care. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>31</b>:3, 266-273<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e318219cba3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">173</p><p class="content">Martijn J. Kikkert, Maarten W.J. Koeter, Jack J.M. Dekker, Lorenzo Burti, Debbie Robson, Bernd Puschner, Aart H. Schene. (2011) The predictive validity of subjective adherence measures in patients with schizophrenia. <i><span class="NLM_source">International Journal of Methods in Psychiatric Research</span></i> <b>20</b>:2, 73-81<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/mpr.335" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">174</p><p class="content">Tanya Park, Kim Usher, Kim Foster. (2011) Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics. <i><span class="NLM_source">International Journal of Mental Health Nursing</span></i>no-no<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1447-0349.2011.00747.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">175</p><p class="content">H. LEE, I. KANE, S. M. SEREIKA, R. Y. CHO, C. J. JOLLEY. (2011) Medication-taking behaviours in young adults with schizophrenia: a pilot study. <i><span class="NLM_source">Journal of Psychiatric and Mental Health Nursing</span></i> <b>18</b>:5, 418-424<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2850.2011.01689.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">176</p><p class="content">Helena Chmura Kraemer, Ellen Frank, David J. Kupfer. (2011) How to assess the clinical impact of treatments on patients, rather than the statistical impact of treatments on measures. <i><span class="NLM_source">International Journal of Methods in Psychiatric Research</span></i> <b>20</b>:2, 63-72<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/mpr.340" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">177</p><p class="content">Adrian P. Mundt, Marion C. Aichberger, Sardor Fakhriddinov, Maria Fayzirahmanova, Renate Grohmann, Andreas Heinz, Sebastian Ivens, Shakhnoza Magzumova, Norman Sartorius, Andreas Str&ouml;hle. (2011) Prescription patterns of patients diagnosed with schizophrenia in mental hospitals in Tashkent/Uzbekistan and in four German cities. <i><span class="NLM_source">Pharmacoepidemiology and Drug Safety</span></i>n/a-n/a<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/pds.2166" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">178</p><p class="content">Ikwunga Wonodi, Hirekatur V. Gopinath, Judy Liu, Helene Adami, L. Elliot Hong, Robert Allen-Emerson, Robert P. McMahon, Gunvant K. Thaker. (2011) Dipyridamole monotherapy in schizophrenia. <i><span class="NLM_source">Psychopharmacology</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-011-2315-3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">179</p><p class="content">Keith Gaynor, Barbara Dooley, Elizabeth Lawlor, Richard Lawoyin, Eadbhard O'Callaghan. (2011) Group cognitive behavioural therapy as a treatment for negative symptoms in first-episode psychosis. <i><span class="NLM_source">Early Intervention in Psychiatry</span></i> <b>5</b>:2, 168-173<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1751-7893.2011.00270.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">180</p><p class="content">Leslie Citrome. (2011) Drug safety evaluation of ziprasidone. <i><span class="NLM_source">Expert Opinion on Drug Safety</span></i> <b>10</b>:3, 437-448<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14740338.2011.560114" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">181</p><p class="content">Maria J Arranz, Janet C Munro. (2011) Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia. <i><span class="NLM_source">Expert Review of Clinical Pharmacology</span></i> <b>4</b>:3, 389-405<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/ecp.11.16" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">182</p><p class="content">Eric Hermes, Henry Nasrallah, Vicki Davis, Jonathan Meyer, Joseph McEvoy, Donald Goff, Sonia Davis, T. Scott Stroup, Marvin Swartz, Jeffrey Lieberman, Robert Rosenheck. (2011) The association between weight change and symptom reduction in the CATIE schizophrenia trial. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>128</b>:1-3, 166-170<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2011.01.022" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">183</p><p class="content">Sonia M. Davis. (2011) Time to All-Cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study. <i><span class="NLM_source">Statistics in Biopharmaceutical Research</span></i> <b>3</b>:2, 253-265<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1198/sbr.2011.10013" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">184</p><p class="content">Robert H. Yolken, E. Fuller Torrey, Jeffrey A. Lieberman, Shuojia Yang, Faith B. Dickerson. (2011) Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>128</b>:1-3, 61-65<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2011.01.020" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">185</p><p class="content">Paul Howard, Robert Twycross, John Shuster, Mary Mihalyo, Andrew Wilcock. (2011) Antipsychotics. <i><span class="NLM_source">Journal of Pain and Symptom Management</span></i> <b>41</b>:5, 956-965<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jpainsymman.2011.03.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">186</p><p class="content">Rune Andersen, Birgitte Fagerlund, Hans Rasmussen, Bjorn H. Ebdrup, Bodil Aggernaes, Anders Gade, Bob Oranje, Birte Glenthoj. (2011) Cognitive effects of six months of treatment with quetiapine in antipsychotic-na&iuml;ve first-episode schizophrenia. <i><span class="NLM_source">Psychiatry Research</span></i> <b>187</b>:1-2, 49-54<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psychres.2010.10.013" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">187</p><p class="content">Jimmi Nielsen. (2011) The safety of atypical antipsychotics: does QTc provide all the answers?. <i><span class="NLM_source">Expert Opinion on Drug Safety</span></i> <b>10</b>:3, 341-344<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14740338.2011.576665" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">188</p><p class="content">Susana Majadas, Jose Olivares, Jaime Galan, Teresa Diez. (2011) Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia. <i><span class="NLM_source">Comprehensive Psychiatry</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.comppsych.2011.03.009" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">189</p><p class="content">Erik G. J&ouml;nsson, Peter Saetre, Maria Vares, Pontus Str&aring;lin, Sten Levander, Eva Lindstr&ouml;m. (2011) Use of antipsychotics — An analysis of lifetime treatment in 66 patients with psychoses. <i><span class="NLM_source">Psychiatry Research</span></i> <b>187</b>:1-2, 80-88<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psychres.2010.10.027" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">190</p><p class="content">Carlo Cianchetti, Maria Giuseppina Ledda. (2011) Effectiveness and safety of antipsychotics in early onset psychoses: A long-term comparison. <i><span class="NLM_source">Psychiatry Research</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psychres.2011.03.020" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">191</p><p class="content">B. NELSON, A. R. YUNG, P. D. McGORRY, D. SPILIOTACOPOULOS, S. M. FRANCEY. (2011) Letter to the Editor: The need for drug-naive research in first-episode psychosis: a response to Moncrieff &amp; Leo (2010). <i><span class="NLM_source">Psychological Medicine</span></i> <b>41</b>:05, 1117-1118<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S0033291711000262" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">192</p><p class="content">Thomas W. Meeks, John W. Culberson, Monica S. Horton. (2011) Medications in Long-Term Care: When Less is More. <i><span class="NLM_source">Clinics in Geriatric Medicine</span></i> <b>27</b>:2, 171-191<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.cger.2011.01.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">193</p><p class="content">2011. References. , 209-234. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9781118093368.refs" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">194</p><p class="content">Philip S. Wang, Alan M. Brookhart, Christine Ulbricht, Sebastian Schneeweiss. 2011. The Pharmacoepidemiology of Psychiatric Medications. , 155-165. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9780470976739.ch10" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">195</p><p class="content">Masayoshi Kawai, Kenji J. Tsuchiya, Nori Takei. 2011. Recent Epidemiological Studies of Psychiatric Disorders in Japan. , 559-577. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9780470976739.ch30" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">196</p><p class="content">Jouko Miettunen, Jaana Suvisaari, Jari Haukka, Matti Isohanni. 2011. Use of Register Data for Psychiatric Epidemiology in the Nordic Countries. , 117-131. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9780470976739.ch8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">197</p><p class="content">John R. Geddes. 2011. Experimental Epidemiology. , 243-261. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9780470976739.ch15" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">198</p><p class="content">Vivek H. Phutane, Cenk Tek, Lydia Chwastiak, Joseph C Ratliff, Banu Ozyuksel, Scott W. Woods, Vinod H. Srihari. (2011) Cardiovascular risk in a first-episode psychosis sample: A ‘critical period’ for prevention?. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>127</b>:1-3, 257-261<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2010.12.008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">199</p><p class="content">Georgios Paslakis, Maria Gilles, Florian Lederbogen, Claudia Schilling, Barbara Scharnholz, Michael Deuschle. (2011) The effect of a 4-week treatment with reboxetine on metabolic parameters of depressed inpatients. <i><span class="NLM_source">European Archives of Psychiatry and Clinical Neuroscience</span></i> <b>261</b>:3, 173-177<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00406-010-0164-4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">200</p><p class="content">Javier Quintero, Eduardo Barbudo, Juan D. Molina, Carlos Mur, Antonio Ceverino, Eloy Garcia-Resa, Javier Correas Lauffer. (2011) The Effectiveness of the Combination Therapy of Amisulpride and Quetiapine for Managing Treatment-Resistant Schizophrenia. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>31</b>:2, 240-242<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e318210347c" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">201</p><p class="content">Wulf R&ouml;ssler. 2011. Management, Rehabilitation, Stigma. , 217-246. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9780470978672.ch8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">202</p><p class="content">Nicolas M. Furiak, Haya Ascher-Svanum, Robert W. Klein, Lee J. Smolen, Anthony H. Lawson, William Montgomery, Robert R. Conley. (2011) Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>27</b>:4, 713-730<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/03007995.2011.554533" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">203</p><p class="content">Jonathan E. Sherin, Stephen R. Marder. 2011. Pharmacological Treatment. , 161-183. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9780470978672.ch6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">204</p><p class="content">S Suratman, K Leach, PM Sexton, CC Felder, RE Loiacono, A Christopoulos. (2011) Impact of species variability and ‘probe-dependence’ on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. <i><span class="NLM_source">British Journal of Pharmacology</span></i> <b>162</b>:7, 1659-1670<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1476-5381.2010.01184.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">205</p><p class="content">Sandhya Mehta, Hua Chen, Michael Johnson, Rajender R. Aparasu. (2011) Risk of Serious Cardiac Events in Older Adults Using Antipsychotic Agents. <i><span class="NLM_source">The American Journal of Geriatric Pharmacotherapy</span></i> <b>9</b>:2, 120-132<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.amjopharm.2011.03.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">206</p><p class="content">Meike Kasten, Norbert Br&uuml;ggemann, Inke R. K&ouml;nig, Katja Doerry, Susanne Steinlechner, Liv Wenzel, Katja Lohmann, Christine Klein, Rebekka Lencer. (2011) Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility. <i><span class="NLM_source">Psychopharmacology</span></i> <b>214</b>:3, 729-736<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-010-2079-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">207</p><p class="content">Gary Remington, Ofer Agid, George Foussias. (2011) Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>11</b>:4, 589-607<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/ern.10.191" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">208</p><p class="content"> (2011) Erratum. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>27</b>:4, 835-836<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/03007995.2011.558077" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">209</p><p class="content">Troy A. Moore. (2011) Schizophrenia Treatment Guidelinesin the United States. <i><span class="NLM_source">Clinical Schizophrenia &amp; Related Psychoses</span></i> <b>5</b>:1, 40-49<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3371/CSRP.5.1.6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">210</p><p class="content">Chieh-Hsin Lin, Hsien-Yuan Lane, Guochuan E. Tsai. (2011) Glutamate signaling in the pathophysiology and therapy of schizophrenia. <i><span class="NLM_source">Pharmacology Biochemistry and Behavior</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pbb.2011.03.023" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">211</p><p class="content">Paolo Pinton, Chiara Pavan, Barbara Zavan. (2011) PKC-β activation and pharmacologically induced weight gain during antipsychotic treatment. <i><span class="NLM_source">Pharmacogenomics</span></i> <b>12</b>:4, 453-455<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/pgs.11.25" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">212</p><p class="content">Martien Wampers, Linda Hanssens, Ruud van Winkel, Adrian Heald, Julien Collette, Joseph Peuskens, Jean Yves Reginster, Andre Scheen, Marc De Hert. (2011) Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study. <i><span class="NLM_source">European Neuropsychopharmacology</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2011.03.010" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">213</p><p class="content">Timothy L Ramsey, Herbert Y Meltzer, Guy N Brock, Bharat Mehrotra, Karu Jayathilake, William V Bobo, Mark D Brennan. (2011) Evidence for a <i>SULT4A1</i> haplotype correlating with baseline psychopathology and atypical antipsychotic response. <i><span class="NLM_source">Pharmacogenomics</span></i> <b>12</b>:4, 471-480<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/pgs.10.205" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">214</p><p class="content">Tore Haslemo, Helge Refsum, Espen Molden. (2011) The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine. <i><span class="NLM_source">British Journal of Clinical Pharmacology</span></i> <b>71</b>:4, 611-615<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2125.2010.03880.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">215</p><p class="content">Richard Whittington, James McGuire, Tilman Steinert, Beverley Quinn. 2011. Understanding and Managing Violence in Mental Health Services. , 79-96. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9781119991175.ch5" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">216</p><p class="content">Detlef Degner, Michael A. Nitsche, Frank Bias, Eckart R&uuml;ther, Udo Reulbach. (2011) EEG alterations during treatment with olanzapine. <i><span class="NLM_source">European Archives of Psychiatry and Clinical Neuroscience</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00406-011-0208-4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">217</p><p class="content">C. Abbott, M. Ju&aacute;rez<img src="/entityImage/?code=204E&amp;eTag=1cqp96h" alt="" class="entityD" />, T. White, R.L. Gollub, G.D. Pearlson, J. Bustillo, J. Lauriello, B. Ho, H.J. Bockholt, V.P. Clark, V. Magnotta, V.D. Calhoun. (2011) Antipsychotic dose and diminished neural modulation: A multi-site fMRI study. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>35</b>:2, 473-482<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2010.12.001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">218</p><p class="content">Julia Haj-Ibrahim, Rajiv Tandon. (2011) Practicing evidence-based psychiatry- 2. Interpreting integrative literature: Systematic reviews and meta-analyses. <i><span class="NLM_source">Asian Journal of Psychiatry</span></i> <b>4</b>:1, 80-85<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.ajp.2011.02.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">219</p><p class="content">Shahza M. Somerville, Adrienne C. Lahti, Robert R. Conley, Rosalinda C. Roberts. (2011) Mitochondria in the striatum of subjects with schizophrenia: Relationship to treatment response. <i><span class="NLM_source">Synapse</span></i> <b>65</b>:3, 215-224<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/syn.20838" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">220</p><p class="content">Brian L. Crabtree, John Montgomery. (2011) Iloperidone for the Management of Adults with Schizophrenia. <i><span class="NLM_source">Clinical Therapeutics</span></i> <b>33</b>:3, 330-345<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.clinthera.2011.03.006" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">221</p><p class="content">K. Ross, D. Freeman, G. Dunn, P. Garety. (2011) A Randomized Experimental Investigation of Reasoning Training for People With Delusions. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>37</b>:2, 324-333<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbn165" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">222</p><p class="content">D E Adkins, K &Aring;berg, J L McClay, J Buksz&aacute;r, Z Zhao, P Jia, T S Stroup, D Perkins, J P McEvoy, J A Lieberman, P F Sullivan, E J C G van den Oord. (2011) Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>16</b>:3, 321-332<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/mp.2010.14" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">223</p><p class="content">Stefan Leucht, Stephan Heres, Werner Kissling, John M. Davis. (2011) Evidence-based pharmacotherapy of schizophrenia. <i><span class="NLM_source">The International Journal of Neuropsychopharmacology</span></i> <b>14</b>:02, 269-284<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S1461145710001380" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">224</p><p class="content">Katrina Weston-Green, Xu-Feng Huang, Chao Deng. (2011) Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. <i><span class="NLM_source">Behavioural Brain Research</span></i> <b>217</b>:2, 337-346<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.bbr.2010.10.039" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">225</p><p class="content">G. Papageorgiou, F. Ca&ntilde;as, M. Zink, A. Rossi. (2011) Country differences in patient characteristics and treatment in schizophrenia: data from a physician-based survey in Europe. <i><span class="NLM_source">European Psychiatry</span></i> <b>26</b>:1, 17-28<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0924-9338(11)71710-2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">226</p><p class="content">K. P. Grootens, N. M. J. van Veelen, J. Peuskens, B. G. C. Sabbe, E. Thys, J. K. Buitelaar, R. J. Verkes, R. S. Kahn. (2011) Ziprasidone Vs Olanzapine in Recent-Onset Schizophrenia and Schizoaffective Disorder: Results of an 8-Week Double-Blind Randomized Controlled Trial. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>37</b>:2, 352-361<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbp037" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">227</p><p class="content">J.-M. Montes. (2011) Use of ziprasidone in patients with schizophrenia in four European countries. <i><span class="NLM_source">European Psychiatry</span></i> <b>26</b>:1, 29-37<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0924-9338(11)71711-4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">228</p><p class="content">Claudio Mencacci, Giancarlo Cerveri. (2011) Paliperidone ER: efficacia nella gestione in acuto e nel mantenimento per la schizofrenia?. <i><span class="NLM_source">Quaderni Italiani di Psichiatria</span></i> <b>30</b>:1, 33-42<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.quip.2010.11.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">229</p><p class="content">I. Sibitz, A. Unger, A. Woppmann, T. Zidek, M. Amering. (2011) Stigma Resistance in Patients With Schizophrenia. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>37</b>:2, 316-323<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbp048" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">230</p><p class="content">T. A. Ketter, L. Citrome, P. W. Wang, J. L. Culver, S. Srivastava. (2011) Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>123</b>:3, 175-189<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2010.01645.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">231</p><p class="content">Stephen Z. Levine, Ido Lurie, Robert Kohn, Itzhak Levav. (2011) Trajectories of the course of schizophrenia: From progressive deterioration to amelioration over three decades. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>126</b>:1-3, 184-191<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2010.10.026" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">232</p><p class="content">Rohan Ganguli, Martin Strassnig. (2011) Prevention of Metabolic Syndrome in Serious Mental Illness. <i><span class="NLM_source">Psychiatric Clinics of North America</span></i> <b>34</b>:1, 109-125<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psc.2010.11.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">233</p><p class="content">Samir Kumar Praharaj, Amlan Kusum Jana, Nishant Goyal, Vinod Kumar Sinha. (2011) Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. <i><span class="NLM_source">British Journal of Clinical Pharmacology</span></i> <b>71</b>:3, 377-382<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2125.2010.03783.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">234</p><p class="content">Robert R. Althoff, G. Scott Waterman. (2011) Commentary: Psychiatric Training for Physicians: A Call to Modernize. <i><span class="NLM_source">Academic Medicine</span></i> <b>86</b>:3, 285-287<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/ACM.0b013e3182082ec7" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">235</p><p class="content">C.U. Correll, F. Ca&ntilde;as, I. Larmo, P. Levy, J.-M. Montes, A. Fagiolini, G. Papageorgiou, A. Rossi, R. Sturlason, M. Zink. (2011) Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups. <i><span class="NLM_source">European Psychiatry</span></i> <b>26</b>:1, 3-16<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0924-9338(11)71709-6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">236</p><p class="content">Chun-Hui Liao, Chen-Shu Chang, Wan-Ching Wei, Shih-Ni Chang, Chien-Chang Liao, Hsien-Yuan Lane, Fung-Chang Sung. (2011) Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: A population-based study. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>126</b>:1-3, 110-116<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2010.12.007" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">237</p><p class="content">I-Ching Lai, Mao-Liang Chen, Ying-Chieh Wang, Jen-Yeu Chen, Ding-Lieh Liao, Ya-Mei Bai, Chao-Cheng Lin, Tzu-Ting Chen, Ying-Jay Liou. (2011) Analysis of genetic variations in the human melatonin receptor (MTNR1A, MTNR1B) genes and antipsychotics-induced tardive dyskinesia in schizophrenia. <i><span class="NLM_source">World Journal of Biological Psychiatry</span></i> <b>12</b>:2, 143-148<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/15622975.2010.496870" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">238</p><p class="content">H.N. Boyda, R.M. Procyshyn, L. Tse, D. Wong, C.C. Pang, W.G. Honer, A.M. Barr. (2011) Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. <i><span class="NLM_source">Neuropharmacology</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.neuropharm.2011.02.019" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">239</p><p class="content">Bart A. Ellenbroek. (2011) Psychopharmacological treatment of schizophrenia: What do we have, and what could we get?. <i><span class="NLM_source">Neuropharmacology</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.neuropharm.2011.03.013" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">240</p><p class="content">C A Jones, D J G Watson, KCF Fone. (2011) Animal models of schizophrenia. <i><span class="NLM_source">British Journal of Pharmacology</span></i>no-no<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1476-5381.2011.01386.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">241</p><p class="content">Edwin Lee, Lai-Yin Chow, Chi-Ming Leung. (2011) Metabolic profile of first and second generation antipsychotics among Chinese patients. <i><span class="NLM_source">Psychiatry Research</span></i> <b>185</b>:3, 456-458<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psychres.2010.04.050" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">242</p><p class="content">Marija Vučić Peitl, Vjekoslav Peitl, Eduard Pavlović. (2011) Sexual self-perception in schizophrenic and depressive patients. <i><span class="NLM_source">Nordic Journal of Psychiatry</span></i>1-5<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/08039488.2010.545144" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">243</p><p class="content">Marina Economou, Alexandra Palli, Lily Peppou, Michael Madianos. (2011) Recovery from Schizophrenia: A Four-year Study of an Inner City Cohort. <i><span class="NLM_source">Community Mental Health Journal</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s10597-011-9390-0" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">244</p><p class="content">Hisham M. Ibrahim, Carol A. Tamminga. (2011) Schizophrenia: Treatment Targets Beyond Monoamine Systems. <i><span class="NLM_source">Annual Review of Pharmacology and Toxicology</span></i> <b>51</b>:1, 189-209<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1146/annurev.pharmtox.010909.105851" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">245</p><p class="content">M. Olfson, T. Gerhard, C. Huang, J. A. Lieberman, W. V. Bobo, S. Crystal. (2011) Comparative Effectiveness of Second-Generation Antipsychotic Medications in Early-Onset Schizophrenia. <i><span class="NLM_source">Schizophrenia Bulletin</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbq172" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">246</p><p class="content">Joseph L McClay, Daniel E Adkins, Karolina &Aring;berg, Jozsef Buksz&aacute;r, Amit N Khachane, Richard S E Keefe, Diana O Perkins, Joseph P McEvoy, T Scott Stroup, Robert E Vann, Patrick M Beardsley, Jeffrey A Lieberman, Patrick F Sullivan, Edwin J C G van den Oord. (2011) Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>36</b>:3, 616-626<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/npp.2010.193" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">247</p><p class="content">David J. Greenblatt, Jerold S. Harmatz, Richard I. Shader. (2011) Psychotropic Drug Prescribing in the United States. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>31</b>:1, 1-3<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e318209cf05" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">248</p><p class="content">Prem N Yadav, Atheir I Abbas, Martilias S Farrell, Vincent Setola, Noah Sciaky, Xi-Ping Huang, Wesley K Kroeze, LaTasha K Crawford, David A Piel, Michael J Keiser, John J Irwin, Brian K Shoichet, Evan S Deneris, Jay Gingrich, Sheryl G Beck, Bryan L Roth. (2011) The Presynaptic Component of the Serotonergic System is Required for Clozapine's Efficacy. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>36</b>:3, 638-651<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/npp.2010.195" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">249</p><p class="content">Robert Bod&eacute;n, Leif Lindstr&ouml;m, Pentti Rautaharju, Johan Sundstr&ouml;m. (2011) Electrocardiographic signs of autonomic imbalance in medicated patients with first-episode schizophrenia spectrum disorders – relations to first treatment discontinuation and five-year remission status. <i><span class="NLM_source">European Psychiatry</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.eurpsy.2010.12.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">250</p><p class="content">Davide Amato, Sridhar Natesan, Leonid Yavich, Shitij Kapur, Christian P. M&uuml;ller. (2011) Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment. <i><span class="NLM_source">The International Journal of Neuropsychopharmacology</span></i>1-13<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S1461145711000010" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">251</p><p class="content">Stanley N. Caroff, Irene Hurford, Janice Lybrand, E. Cabrina Campbell. (2011) Movement Disorders Induced by Antipsychotic Drugs: Implications of the CATIE Schizophrenia Trial. <i><span class="NLM_source">Neurologic Clinics</span></i> <b>29</b>:1, 127-148<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.ncl.2010.10.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">252</p><p class="content">Christoph U. Correll, Todd Lencz, Anil K. Malhotra. (2011) Antipsychotic drugs and obesity. <i><span class="NLM_source">Trends in Molecular Medicine</span></i> <b>17</b>:2, 97-107<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.molmed.2010.10.010" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">253</p><p class="content">N Fleeman, Y Dundar, R Dickson, A Jorgensen, S Pushpakom, C McLeod, M Pirmohamed, T Walley. (2011) Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. <i><span class="NLM_source">The Pharmacogenomics Journal</span></i> <b>11</b>:1, 1-14<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/tpj.2010.73" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">254</p><p class="content">Merc&egrave; Masana, Anal&iacute;a Bortolozzi, Francesc Artigas. (2011) Selective enhacement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia. <i><span class="NLM_source">The International Journal of Neuropsychopharmacology</span></i> <b>14</b>:01, 53-68<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S1461145710000908" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">255</p><p class="content">M R Kuzman, V Medved, N Bozina, J Grubišin, N Jovanovic, J Sertic. (2011) Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. <i><span class="NLM_source">The Pharmacogenomics Journal</span></i> <b>11</b>:1, 35-44<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/tpj.2010.7" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">256</p><p class="content">Hong Liu-Seifert, Olawale O. Osuntokun, Peter D. Feldman. (2011) Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia. <i><span class="NLM_source">Comprehensive Psychiatry</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.comppsych.2010.12.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">257</p><p class="content">Michael T. Compton, Mary E. Kelley, Robert Brett Lloyd, Tamela McClam, Claire E. Ramsay, Patrick J. Haggard, Sara Augustin. (2011) Predictors of the Discharge Dosage of an Atypical Antipsychotic Agent Among Hospitalized, Treatment-Naive, First-Episode Psychosis Patients in Naturalistic, Public-Sector Settings. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>31</b>:1, 10-15<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e3182042154" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">258</p><p class="content">L. Charlot, S. Abend, P. Ravin, K. Mastis, A. Hunt, C. Deutsch. (2011) Non-psychiatric health problems among psychiatric inpatients with intellectual disabilities. <i><span class="NLM_source">Journal of Intellectual Disability Research</span></i> <b>55</b>:2, 199-209<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2788.2010.01294.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">259</p><p class="content">John Teilmann Larsen, Maria Fagerquist, Mette Holdrup, Bjarne Christensen, Catarina Sigalin, Peter M. Nilsson. (2011) Metabolic syndrome and psychiatrists' choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden. <i><span class="NLM_source">Nordic Journal of Psychiatry</span></i> <b>65</b>:1, 40-46<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/08039488.2010.486443" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">260</p><p class="content">Yukihiro Ohno. (2011) Therapeutic Role of 5-HT1A Receptors in The Treatment of Schizophrenia and Parkinson's Disease. <i><span class="NLM_source">CNS Neuroscience &amp; Therapeutics</span></i> <b>17</b>:1, 58-65<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1755-5949.2010.00211.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">261</p><p class="content">HY Meltzer, BW Massey. (2011) The role of serotonin receptors in the action of atypical antipsychotic drugs. <i><span class="NLM_source">Current Opinion in Pharmacology</span></i> <b>11</b>:1, 59-67<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.coph.2011.02.007" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">262</p><p class="content">2011. References. , 199-205. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9780470977507.refs" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">263</p><p class="content">Tim Lambert, Jos&eacute; M Olivares, Joseph Peuskens, Cherilyn DeSouza, Chris M Kozma, Patrick Otten, Concetta Crivera, An Jacobs, Wayne Macfadden, Lian Mao, Stephen C Rodriguez, Riad Dirani, Kasem S Akhras. (2011) Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. <i><span class="NLM_source">Annals of General Psychiatry</span></i> <b>10</b>:1, 10<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1186/1744-859X-10-10" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">264</p><p class="content">Guillermo Gonzalez-Burgos, Kenneth N. Fish, David A. Lewis. (2011) GABA Neuron Alterations, Cortical Circuit Dysfunction and Cognitive Deficits in Schizophrenia. <i><span class="NLM_source">Neural Plasticity</span></i> <b>2011</b>, 1-24<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1155/2011/723184" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">265</p><p class="content">Viviane M. Linck, Ana P. Herrmann, &Acirc;ngelo L. Piato, Bernardo C. Detanico, Micheli Figueir&oacute;, Jorge Fl&oacute;rio, Maurice M. Iwu, Christopher O. Okunji, Mirna B. Leal, Elaine Elisabetsky. (2011) Alstonine as an Antipsychotic: Effects on Brain Amines and Metabolic Changes. <i><span class="NLM_source">Evidence-Based Complementary and Alternative Medicine</span></i> <b>2011</b>, 1-7<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/ecam/nep002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">266</p><p class="content">N. G. Cascella, D. Kryszak, B. Bhatti, P. Gregory, D. L. Kelly, J. P. Mc Evoy, A. Fasano, W. W. Eaton. (2011) Prevalence of Celiac Disease and Gluten Sensitivity in the United States Clinical Antipsychotic Trials of Intervention Effectiveness Study Population. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>37</b>:1, 94-100<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbp055" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">267</p><p class="content">B Levitan. (2011) A Concise Display of Multiple End Points for Benefit–Risk Assessment. <i><span class="NLM_source">Clinical Pharmacology &amp; Therapeutics</span></i> <b>89</b>:1, 56-59<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/clpt.2010.251" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">268</p><p class="content">Jack Tsai, T. Scott Stroup, Robert A. Rosenheck. (2011) Housing arrangements among a national sample of adults with chronic schizophrenia living in the United States: a descriptive study. <i><span class="NLM_source">Journal of Community Psychology</span></i> <b>39</b>:1, 76-88<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/jcop.20418" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">269</p><p class="content">Hakuei Yamashita, Hiroo Yoda, Noriomi Kuroki, Michiko Kuwabara, Yuji Odagaki, Tetsushi Kazawa, Ryoichi Toyoshima, Taeko Maruki. (2011) Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine. <i><span class="NLM_source">Psychopharmacology</span></i> <b>213</b>:1, 1-9<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-010-2002-9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">270</p><p class="content">Magdolna Tardy, Stefan Leucht, Andrey Potapov, Rolf Engel, Markus Dold, Werner Kissling, Magdolna Tardy. 2011. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002%2F14651858.CD009396" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">271</p><p class="content">Robin Steinberg-Epstein, Teri Book, Sharon B. Wigal. (2011) Controversies Surrounding Pediatric Psychopharmacology. <i><span class="NLM_source">Advances in Pediatrics</span></i> <b>58</b>:1, 153-179<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.yapd.2011.03.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">272</p><p class="content">I. Sibitz, M. Amering, A. Unger, M.E. Seyringer, A. Bachmann, B. Schrank, T. Benesch, B. Schulze, A. Woppmann. (2011) The impact of the social network, stigma and empowerment on the quality of life in patients with schizophrenia. <i><span class="NLM_source">European Psychiatry</span></i> <b>26</b>:1, 28-33<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.eurpsy.2010.08.010" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">273</p><p class="content">Roberto Roiz-Santi&aacute;&ntilde;ez, Roc&iacute;o P&eacute;rez-Iglesias, Victor Ortiz-Garc&iacute;a de la Foz, Diana Tordesillas-Guti&eacute;rrez, Ignacio Mata, Enrique Marco de Lucas, Angel Pazos, Rafael Tabar&eacute;s-Seisdedos, Jos&eacute; Luis V&aacute;zquez-Barquero, Benedicto Crespo-Facorro. (2011) Straight gyrus morphology in first-episode schizophrenia-spectrum patients. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>35</b>:1, 84-90<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2010.09.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">274</p><p class="content">Helen Barnes. (2011) Does mental illness have a place alongside social and recovery models of mental health in service users' lived experiences? Issues and implications for mental health education. <i><span class="NLM_source">The Journal of Mental Health Training, Education and Practice</span></i> <b>6</b>:2, 65-75<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1108/17556221111168913" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">275</p><p class="content">Dominic Hodgkin, Joanna Volpe-Vartanian, Elizabeth L. Merrick, Constance M. Horgan, Andrew A. Nierenberg, Richard G. Frank, Sue Lee. (2011) Customization in prescribing for bipolar disorder. <i><span class="NLM_source">Health Economics</span></i>n/a-n/a<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/hec.1737" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">276</p><p class="content">G. J. Lyon, A. Abi-Dargham, H. Moore, J. A. Lieberman, J. A. Javitch, D. Sulzer. (2011) Presynaptic Regulation of Dopamine Transmission in Schizophrenia. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>37</b>:1, 108-117<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbp010" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">277</p><p class="content">Shannon Hughes, David Cohen. (2011) Can Online Consumers Contribute to Drug Knowledge? A Mixed-Methods Comparison of Consumer-Generated and Professionally Controlled Psychotropic Medication Information on the Internet. <i><span class="NLM_source">Journal of Medical Internet Research</span></i> <b>13</b>:3, <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2196/jmir.1716" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">278</p><p class="content">M.C. Diaz, N. Morales, J. Ruiz, K. Nieto, E. Iniesta, M.A. Mart&iacute;n, D. Fraguas. (2011) P03-199 - Eligibility of the patients admitted to psychiatric inpatient units for participation in catie clinical trial. <i><span class="NLM_source">European Psychiatry</span></i> <b>26</b>, 1368<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0924-9338(11)73073-5" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">279</p><p class="content">Daniel Tarsy, Codrin Lungu, Ross J. Baldessarini. 2011. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. , 601-616. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/B978-0-444-52014-2.00043-4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">280</p><p class="content">J L McClay, D E Adkins, K &Aring;berg, S Stroup, D O Perkins, V I Vladimirov, J A Lieberman, P F Sullivan, E J C G van den Oord. (2011) Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>16</b>:1, 76-85<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/mp.2009.89" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">281</p><p class="content">Marek Krzystanek, Irena Krupka-Matuszczyk. (2011) An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. <i><span class="NLM_source">Human Psychopharmacology: Clinical and Experimental</span></i> <b>26</b>:1, 81-85<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/hup.1173" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">282</p><p class="content">Gabriele Masi, Francesca Liboni. (2011) Management of Schizophrenia in Children and Adolescents. <i><span class="NLM_source">Drugs</span></i> <b>71</b>:2, 179-208<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/11585350-000000000-00000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">283</p><p class="content">Kathleen L. Benson, Irwin Feinberg. 2011. Schizophrenia. , 1501-1511. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/B978-1-4160-6645-3.00131-6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">284</p><p class="content">Albert Bolstad, Ole A Andreassen, Jan I R&oslash;ssberg, Ingrid Agartz, Ingrid Melle, Lars Tanum. (2011) Previous hospital admissions and disease severity predict the use of antipsychotic combination treatment in patients with schizophrenia. <i><span class="NLM_source">BMC Psychiatry</span></i> <b>11</b>:1, 126<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1186/1471-244X-11-126" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">285</p><p class="content">Shin Ogino, Seiya Miyamoto, Tomomi Tenjin, Rei Kitajima, Kazuaki Ojima, Nobumi Miyake, Yasuyuki Funamoto, Jun Arai, Sachiko Tsukahara, Yukie Ito, Masanori Tadokoro, Kiriko Anai, Shinobu Tatsunami, Hiroshi Kubota, Yasuhiro Kaneda, Noboru Yamaguchi. (2011) Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>35</b>:1, 78-83<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2010.08.030" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">286</p><p class="content">Stanley Fahn, Joseph Jankovic, Mark Hallett. 2011. The tardive syndromes. , 415-446. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/B978-1-4377-2369-4.00019-6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">287</p><p class="content">Eirik Kjelby, Hugo A Jorgensen, Rune A Kroken, Else-Marie Loberg, Erik Johnsen. (2011) Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial.. <i><span class="NLM_source">BMC Psychiatry</span></i> <b>11</b>:1, 145<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1186/1471-244X-11-145" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">288</p><p class="content">Hong Liu-Seifert, Haya Ascher-Svanum, Olawale Osuntokun, Kai Jen, Juan Gomez. (2011) Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics. <i><span class="NLM_source">BMC Psychiatry</span></i> <b>11</b>:1, 87<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1186/1471-244X-11-87" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">289</p><p class="content">E. Cabrina Campbell, Melissa DeJesus, Barry K. Herman, Brian J. Cuffel, Kafi N. Sanders, William Dodge, Vasant Dhopesh, Stanley N. Caroff. (2011) A pilot study of antipsychotic prescribing decisions for acutely-Ill hospitalized patients. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>35</b>:1, 246-251<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2010.11.018" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">290</p><p class="content">Kuan-Yu Chu, Nan-Ping Yang, Pesus Chou, Lin-Yang Chi, Hsien-Jane Chiu. (2011) The Relationship Between Body Mass Index, the Use of Second-Generation Antipsychotics, and Dental Caries among Hospitalized Patients with Schizophrenia. <i><span class="NLM_source">The International Journal of Psychiatry in Medicine</span></i> <b>41</b>:4, 343-353<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2190/PM.41.4.d" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">291</p><p class="content">Gebra B Cuyun Carter, Denai R Milton, Haya Ascher-Svanum, Douglas E Faries. (2011) Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study. <i><span class="NLM_source">BMC Psychiatry</span></i> <b>11</b>:1, 143<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1186/1471-244X-11-143" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">292</p><p class="content">Peter N. van Harten, Diederik E. Tenback. 2011. Tardive Dyskinesia: Clinical Presentation and Treatment. , 187-210. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/B978-0-12-381328-2.00008-0" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">293</p><p class="content">M. De Hert, H. Hudyana, L. Dockx, C. Bernagie, K. Sweers, J. Tack, S. Leucht, J. Peuskens. (2011) Second-generation antipsychotics and constipation: A review of the literature. <i><span class="NLM_source">European Psychiatry</span></i> <b>26</b>:1, 34-44<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.eurpsy.2010.03.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">294</p><p class="content">Simon Gibbon, Edward Silva, Rupinder Kaler, Inti Qurashi, Mrigendra Das, Jon Patrick, Manjit Gahir, Douglas Gray, Lakshmanan Ramachandran, Anthony Maden. (2011) Risperidone Long-acting Injection (RLAI) – real world outcomes from the United Kingdom high-secure hospitals. <i><span class="NLM_source">The British Journal of Forensic Practice</span></i> <b>13</b>:4, 264-269<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1108/14636641111190024" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">295</p><p class="content">Haya Ascher-Svanum, Michael D. Stensland, Xiaomei Peng, Douglas E. Faries, Virginia L. Stauffer, Olawale O. Osuntokun, John M. Kane. (2011) Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>27</b>:1, 115-122<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/03007995.2010.537594" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">296</p><p class="content">Charles E. Dean. (2011) Psychopharmacology: A house divided. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>35</b>:1, 1-10<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2010.08.028" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">297</p><p class="content">Lior Greenbaum, Anna Alkelai, Amihai Rigbi, Yoav Kohn, Bernard Lerer. (2010) Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia. <i><span class="NLM_source">Movement Disorders</span></i> <b>25</b>:16, 2809-2817<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/mds.23377" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">298</p><p class="content">Thomas R. E. Barnes, Stephen R. Marder. 2010. Principles of Pharmacological Treatment in Schizophrenia. , 515-524. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9781444327298.ch24" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">299</p><p class="content">John W. Newcomer, Stefan Leucht. 2010. Metabolic Adverse Effects Associated with Antipsychotic Medications. , 577-597. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9781444327298.ch28" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">300</p><p class="content">Andreas Meyer-Lindenberg, Edward T. Bullmore. 2010. Functional Brain Imaging in Schizophrenia. , 353-371. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9781444327298.ch17" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">301</p><p class="content">John L. Waddington, Colm M. P. O'Tuathaigh, Gary J. Remington. 2010. Pharmacology and Neuroscience of Antipsychotic Drugs. , 483-514. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9781444327298.ch23" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">302</p><p class="content">Stephan Leucht, Christoph U. Correll, John M. Kane. 2010. Approaches to Treatment-Resistant Patients. , 540-560. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9781444327298.ch26" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">303</p><p class="content">Chris Hollis, Judith Rapoport. 2010. Child and Adolescent Schizophrenia. , 24-46. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9781444327298.ch3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">304</p><p class="content">John R. Geddes, T. Scott Stroup, Jeffrey A. Lieberman. 2010. Comparative Efficacy and Effectiveness in the Drug Treatment of Schizophrenia. , 525-539. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9781444327298.ch25" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">305</p><p class="content">R. E. Becker, N. H. Greig. (2010) Lost in Translation: Neuropsychiatric Drug Development. <i><span class="NLM_source">Science Translational Medicine</span></i> <b>2</b>:61, 61rv6-61rv6<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1126/scitranslmed.3000446" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">306</p><p class="content">Adrian Preda, Lawrence Faziola, Adrian Preda. 2010. Asenapine versus other atypical antipsychotics for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD008902" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">307</p><p class="content">Brandon A. Gaudiano, James D. Herbert, Steven C. Hayes. (2010) Is It the Symptom or the Relation to It? Investigating Potential Mediators of Change in Acceptance and Commitment Therapy for Psychosis. <i><span class="NLM_source">Behavior Therapy</span></i> <b>41</b>:4, 543-554<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.beth.2010.03.001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">308</p><p class="content">F. Manoudi, F. Asri, S. Boutabia, I. Haida, I. Tazi. (2010) Personnalit&eacute; schizotypique en milieu universitaire &agrave; Marrakech (Maroc). <i><span class="NLM_source">L'Enc&eacute;phale</span></i> <b>36</b>:6, 478-483<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.encep.2010.03.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">309</p><p class="content">John March, Helena C Kraemer, Madhukar Trivedi, John Csernansky, John Davis, Terence A Ketter, Ira D Glick. (2010) What Have We Learned about Trial Design From NIMH-Funded Pragmatic Trials?. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>35</b>:13, 2491-2501<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/npp.2010.115" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">310</p><p class="content">James E. Frampton. (2010) Olanzapine Long-Acting Injection. <i><span class="NLM_source">Drugs</span></i> <b>70</b>:17, 2289-2313<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/11204930-000000000-00000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">311</p><p class="content">Coleman Gross, Christine M. Blasey, Robert L. Roe, Joseph K. Belanoff. (2010) Mifepristone Reduces Weight Gain and Improves Metabolic Abnormalities Associated With Risperidone Treatment in Normal Men. <i><span class="NLM_source">Obesity</span></i> <b>18</b>:12, 2295-2300<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/oby.2010.51" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">312</p><p class="content">Peter P. Zandi, Jennifer T. Judy. (2010) The Promise and Reality of Pharmacogenetics in Psychiatry. <i><span class="NLM_source">Clinics in Laboratory Medicine</span></i> <b>30</b>:4, 931-974<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.cll.2010.07.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">313</p><p class="content">Arun K. Tiwari, Jarlath B. Rodgers, Michelle Sicard, Clement C. Zai, Olga Likhodi, Natalie Freeman, Herbert Y. Meltzer, Jeffrey A. Lieberman, James L. Kennedy, Daniel J. M&uuml;ller. (2010) Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>34</b>:8, 1484-1490<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2010.08.009" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">314</p><p class="content">, Greg Greenberg, Robert A. Rosenheck, Steven K. Erickson, Rani A. Desai, Elina A. Stefanovics, Marvin Swartz, Richard S. E. Keefe, Joe McEvoy, T. Scott Stroup. (2010) Criminal Justice System Involvement Among People with Schizophrenia. <i><span class="NLM_source">Community Mental Health Journal</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s10597-010-9362-9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">315</p><p class="content">J J Crowley, D E Adkins, A L Pratt, C R Quackenbush, E J van den Oord, S S Moy, K C Wilhelmsen, T B Cooper, M A Bogue, H L McLeod, P F Sullivan. (2010) Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice. <i><span class="NLM_source">The Pharmacogenomics Journal</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/tpj.2010.82" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">316</p><p class="content">Thomas R. Insel. (2010) Rethinking schizophrenia. <i><span class="NLM_source">Nature</span></i> <b>468</b>:7321, 187-193<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/nature09552" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">317</p><p class="content">Alison Abbott. (2010) Schizophrenia: The drug deadlock. <i><span class="NLM_source">Nature</span></i> <b>468</b>:7321, 158-159<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/468158a" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">318</p><p class="content">W. J. Casstevens. (2010) Social Work Education on Mental Health: Postmodern Discourse and the Medical Model. <i><span class="NLM_source">Journal of Teaching in Social Work</span></i> <b>30</b>:4, 385-398<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/08841233.2010.515920" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">319</p><p class="content">Richard J. Beninger, Tyson W. Baker, Matthew M. Florczynski, Tomek J. Banasikowski. (2010) Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients. <i><span class="NLM_source">Neurotoxicity Research</span></i> <b>18</b>:3-4, 229-243<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s12640-010-9178-y" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">320</p><p class="content">Ravi Anand, Yona Geffen, Daniel Vasile, Irina Dan. (2010) An Open-Label Tolerability Study of BL-1020 Antipsychotic. <i><span class="NLM_source">Clinical Neuropharmacology</span></i> <b>33</b>:6, 297-302<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/WNF.0b013e3181f8d501" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">321</p><p class="content">Thomas J Raedler. (2010) Cardiovascular aspects of antipsychotics. <i><span class="NLM_source">Current Opinion in Psychiatry</span></i> <b>23</b>:6, 574-581<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YCO.0b013e32833f46c9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">322</p><p class="content">Esther M. van der Zwaal, Mieneke C.M. Luijendijk, Simon S. Evers, Susanne E. la Fleur, Roger A.H. Adan. (2010) Olanzapine affects locomotor activity and meal size in male rats. <i><span class="NLM_source">Pharmacology Biochemistry and Behavior</span></i> <b>97</b>:1, 130-137<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pbb.2010.05.009" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">323</p><p class="content">M. JONES, D. ROBSON, S. WHITFIELD, R. GRAY. (2010) Does psychopharmacology training enhance the knowledge of mental health nurses who prescribe?. <i><span class="NLM_source">Journal of Psychiatric and Mental Health Nursing</span></i> <b>17</b>:9, 804-812<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2850.2010.01583.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">324</p><p class="content">H. Moore. (2010) The Role of Rodent Models in The Discovery of New Treatments for Schizophrenia: Updating Our Strategy. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>36</b>:6, 1066-1072<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbq106" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">325</p><p class="content">Steffen Moritz, Francesca Vitzthum, Sarah Randjbar, Ruth Veckenstedt, Todd S Woodward. (2010) Detecting and defusing cognitive traps: metacognitive intervention in schizophrenia. <i><span class="NLM_source">Current Opinion in Psychiatry</span></i> <b>23</b>:6, 561-569<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YCO.0b013e32833d16a8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">326</p><p class="content">Silvio Garattini. (2010) Evaluation of Benefit-Risk. <i><span class="NLM_source">PharmacoEconomics</span></i> <b>28</b>:11, 981-986<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/11537590-000000000-00000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">327</p><p class="content">Ganesan Venkatasubramanian, Seetharamaiah Chittiprol, Narendran Neelakantachar, Taranath K. Shetty, Bangalore N. Gangadhar. (2010) A Longitudinal Study on the Impact of Antipsychotic Treatment on Serum Leptin in Schizophrenia. <i><span class="NLM_source">Clinical Neuropharmacology</span></i> <b>33</b>:6, 288-292<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/WNF.0b013e3181fa2a6f" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">328</p><p class="content">Chen-Lin Chang, Dong-Sheng Tzeng, For-Wey Lung. (2010) Treatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injection. <i><span class="NLM_source">Psychiatry Research</span></i> <b>180</b>:1, 16-19<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psychres.2009.11.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">329</p><p class="content">Takahira Yamauchi, Kouko Tatsumi, Manabu Makinodan, Sohei Kimoto, Michihiro Toritsuka, Hiroaki Okuda, Toshifumi Kishimoto, Akio Wanaka. (2010) Olanzapine increases cell mitotic activity and oligodendrocyte-lineage cells in the hypothalamus. <i><span class="NLM_source">Neurochemistry International</span></i> <b>57</b>:5, 565-571<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.neuint.2010.07.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">330</p><p class="content">Lars B. Heemstra, Barrie C. Finnin, Joseph A. Nicolazzo. (2010) The buccal mucosa as an alternative route for the systemic delivery of risperidone. <i><span class="NLM_source">Journal of Pharmaceutical Sciences</span></i> <b>99</b>:11, 4584-4592<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/jps.22175" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">331</p><p class="content">Michelle N Sicard, Clement C Zai, Arun K Tiwari, Renan P Souza, Herbert Y Meltzer, Jeffrey A Lieberman, James L Kennedy, Daniel J M&uuml;ller. (2010) Polymorphisms of the <i>HTR2C</i> gene and antipsychotic-induced weight gain: an update and meta-analysis. <i><span class="NLM_source">Pharmacogenomics</span></i> <b>11</b>:11, 1561-1571<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/pgs.10.123" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">332</p><p class="content">Joyce C. West, Donald S. Rae, Haiden A. Huskamp, Maritza Rubio-Stipec, Darrel A. Regier. (2010) Medicaid medication access problems and increased psychiatric hospital and emergency care. <i><span class="NLM_source">General Hospital Psychiatry</span></i> <b>32</b>:6, 615-622<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.genhosppsych.2010.07.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">333</p><p class="content">Jason M. Uslaner, Sean M. Smith, Sarah L. Huszar, Rashida Pachmerhiwala, Richard M. Hinchliffe, Joshua D. Vardigan, Shannon J. Nguyen, Nathan O. Surles, Lihang Yao, James C. Barrow, Victor N. Uebele, John J. Renger, Janet Clark, Pete H. Hutson. (2010) T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats. <i><span class="NLM_source">Neuropharmacology</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.neuropharm.2010.11.015" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">334</p><p class="content">C. Combes, F. Feral. (2010) Observance m&eacute;dicamenteuse et lieu de contr&ocirc;le de la sant&eacute; dans la schizophr&eacute;nie. <i><span class="NLM_source">L'Enc&eacute;phale</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.encep.2010.08.007" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">335</p><p class="content">Parthipan Sivaraman, Ranganath D Rattehalli, Mahesh B Jayaram, Parthipan Sivaraman. 2010. Levomepromazine for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD007779.pub2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">336</p><p class="content">Selvizhi Subramanian, Christine Rummel-Kluge, Heike Hunger, Franziska Schmid, Sandra Schwarz, Werner Kissling, Stefan Leucht, Katja Komossa, Selvizhi Subramanian. 2010. Zotepine versus other atypical antipsychotics for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD006628.pub3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">337</p><p class="content">K &Aring;berg, D E Adkins, Y Liu, J L McClay, J Buksz&aacute;r, P Jia, Z Zhao, D Perkins, T S Stroup, J A Lieberman, P F Sullivan, E J C G van den Oord. (2010) Genome-wide association study of antipsychotic-induced QTc interval prolongation. <i><span class="NLM_source">The Pharmacogenomics Journal</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/tpj.2010.76" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">338</p><p class="content">Alexandre P. Muller, Ana H. Tort, Juss&acirc;nia Gnoatto, Julia D. Moreira, Elsa R. Vinad&eacute;, Marcos L. Perry, Diogo O. Souza, Diogo R. Lara, Luis V. Portela. (2010) Metabolic and behavioral effects of chronic olanzapine treatment and cafeteria diet in rats. <i><span class="NLM_source">Behavioural Pharmacology</span></i> <b>21</b>:7, 668-675<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/FBP.0b013e32833e7f2a" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">339</p><p class="content">L. V. Kessing, A. F. Thomsen, U. B. Mogensen, P. K. Andersen. (2010) Treatment with antipsychotics and the risk of diabetes in clinical practice. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>197</b>:4, 266-271<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.bp.109.076935" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">340</p><p class="content">C Pavan, V Vindigni, L Michelotto, A Rimessi, G Abatangelo, R Cortivo, P Pinton, B Zavan. (2010) Weight gain related to treatment with atypical antipsychotics is due to activation of PKC-β. <i><span class="NLM_source">The Pharmacogenomics Journal</span></i> <b>10</b>:5, 408-417<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/tpj.2009.67" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">341</p><p class="content">Haya Ascher-Svanum, Allen W. Nyhuis, Virginia Stauffer, Bruce J. Kinon, Douglas E. Faries, Glenn A. Phillips, Kory Schuh, A. George Awad, Richard Keefe, Dieter Naber. (2010) Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>26</b>:10, 2403-2410<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/03007995.2010.515900" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">342</p><p class="content">Chris J. Bushe, Mauricio Tohen. 2010. Bipolar Disorder and Safety Monitoring for Clinicians: A Review of the Evidence and the Implications. , 367-383. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9780470661277.ch28" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">343</p><p class="content">Scott G Williams, Nima A Alinejad, Jeannie A Williams, David F Cruess. (2010) Statistically Significant Increase in Weight Caused by Low-Dose Quetiapine. <i><span class="NLM_source">Pharmacotherapy</span></i> <b>30</b>:10, 1011-1015<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1592/phco.30.10.1011" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">344</p><p class="content">Terence A. Ketter, John O. Brooks, Jennifer C. Hoblyn, Anne A. Holland, Jennifer Y. Nam, Jenifer L. Culver, Wendy K. Marsh, Julie C. Bonner. (2010) Long-term effectiveness of quetiapine in bipolar disorder in a clinical setting. <i><span class="NLM_source">Journal of Psychiatric Research</span></i> <b>44</b>:14, 921-929<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jpsychires.2010.02.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">345</p><p class="content">Chi-Un Pae, Manmohandeep Singh Sohi, Ho-Jun Seo, Alessandro Serretti, Ashwin A. Patkar, David C. Steffens, Prakash S. Masand. (2010) Quetiapine XR: Current status for the treatment of major depressive disorder. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>34</b>:7, 1165-1173<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2010.03.023" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">346</p><p class="content">Ching-Hua Lin, Chao-Chan Kuo, Li-Shiu Chou, Yeng-Hung Chen, Cheng-Chung Chen, Kuo-Hao Huang, Hsien-Yuan Lane. (2010) A Randomized, Double-Blind Comparison of Risperidone Versus Low-Dose Risperidone Plus Low-Dose Haloperidol in Treating Schizophrenia. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>30</b>:5, 518-525<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e3181f28dff" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">347</p><p class="content">David Meltzer, Anirban Basu, Rena Conti. (2010) The Economics of Comparative Effectiveness Studies. <i><span class="NLM_source">PharmacoEconomics</span></i> <b>28</b>:10, 843-853<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/11539400-000000000-00000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">348</p><p class="content">Nam Young Lee, Se Hyun Kim, Belong Cho, Yeon Ji Lee, Jae Seung Chang, Ung Gu Kang, Yong Sik Kim, Yong Min Ahn. (2010) Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea's general population. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>34</b>:7, 1243-1249<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2010.06.029" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">349</p><p class="content">C. Demily, V.-A. Chouinard, G. Chouinard. (2010) Reconna&icirc;tre les sympt&ocirc;mes psychiatriques iatrog&egrave;nes li&eacute;s aux antipsychotiques. <i><span class="NLM_source">L'Enc&eacute;phale</span></i> <b>36</b>:5, 417-424<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.encep.2010.01.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">350</p><p class="content">Pornpoj Pramyothin, Lalita Khaodhiar. (2010) Metabolic syndrome with the atypical antipsychotics. <i><span class="NLM_source">Current Opinion in Endocrinology, Diabetes and Obesity</span></i> <b>17</b>:5, 460-466<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/MED.0b013e32833de61c" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">351</p><p class="content">Safiya Abouzaid, Eric Jutkowitz, Kathy A. Foley, Laura T. Pizzi, Edward Kim, Jay Bates. (2010) Economic Impact of Prior Authorization Policies for Atypical Antipsychotics in the Treatment of Schizophrenia. <i><span class="NLM_source">Population Health Management</span></i> <b>13</b>:5, 247-254<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1089/pop.2009.0063" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">352</p><p class="content">Rafael Gafoor, Sabine Landau, Tom K.J. Craig, Thomas Elanjithara, Paddy Power, Philip McGuire. (2010) Esquire Trial. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>30</b>:5, 600-606<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e3181f198da" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">353</p><p class="content">Ahsan Y. Khan, Matthew Macaluso, Robert J. Mchale, Megan M. Dahmen, Kathrine Girrens, Faryal Ali. (2010) The Adjunctive Use of Metformin to Treat or Prevent Atypical Antipsychotic-Induced Weight Gain: A Review. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>16</b>:5, 289-296<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.pra.0000388624.91039.a3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">354</p><p class="content">Marja Hensen, Bart Heeg, Mickael L&ouml;thgren, Ben van Hout. (2010) Cost Effectiveness of Long-Acting Risperidone in Sweden. <i><span class="NLM_source">Applied Health Economics and Health Policy</span></i> <b>8</b>:5, 327-341<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/11536180-000000000-00000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">355</p><p class="content">Rajiv Tandon, Henry A. Nasrallah, Matcheri S. Keshavan. (2010) Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>122</b>:1-3, 1-23<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2010.05.025" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">356</p><p class="content">Shanaya Rathod, Peter Phiri, David Kingdon. (2010) Cognitive Behavioral Therapy for Schizophrenia. <i><span class="NLM_source">Psychiatric Clinics of North America</span></i> <b>33</b>:3, 527-536<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psc.2010.04.009" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">357</p><p class="content">V. Jordanova, N.P. Maric, V. Alikaj, M. Bajs, T. Cavic, D. Iosub, A. Mihai, A. Szalontay, N. Sartorius. (2010) Prescribing practices in psychiatric hospitals in Eastern Europe. <i><span class="NLM_source">European Psychiatry</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.eurpsy.2010.05.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">358</p><p class="content">E. Habermeyer, R. Wolff, M. Gillner, R. Strohm, S. Kutscher. (2010) Patienten mit schizophrenen St&ouml;rungen im psychiatrischen Ma&szlig;regelvollzug. <i><span class="NLM_source">Der Nervenarzt</span></i> <b>81</b>:9, 1117-1124<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00115-009-2913-z" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">359</p><p class="content">Shirin Ali, Karen Klahr Miller, Oliver Freudenreich. (2010) Management of Psychosis Associated With a Prolactinoma: Case Report and Review of the Literature. <i><span class="NLM_source">Psychosomatics</span></i> <b>51</b>:5, 370-376<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0033-3182(10)70718-0" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">360</p><p class="content">W. Wolfgang Fleischhacker, Martti E. Heikkinen, Jean-Pierre Oli&eacute;, Wally Landsberg, Patricia Dewaele, Robert D. McQuade, Jean-Yves Loze, Delphine Hennicken, Wendy Kerselaers. (2010) Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. <i><span class="NLM_source">The International Journal of Neuropsychopharmacology</span></i> <b>13</b>:08, 1115-1125<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S1461145710000490" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">361</p><p class="content">Henry A Nasrallah, Srihari Gopal, Cristiana Gassmann-Mayer, Jorge A Quiroz, Pilar Lim, Mari&euml;lle Eerdekens, Eric Yuen, David Hough. (2010) A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>35</b>:10, 2072-2082<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/npp.2010.79" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">362</p><p class="content">2010. References. , 165-193. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9780470666630.refs" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">363</p><p class="content">D J M&uuml;ller, C C Zai, M Sicard, E Remington, R P Souza, A K Tiwari, R Hwang, O Likhodi, S Shaikh, N Freeman, T Arenovich, A Heinz, H Y Meltzer, J A Lieberman, J L Kennedy. (2010) Systematic analysis of dopamine receptor genes (DRD1–DRD5) in antipsychotic-induced weight gain. <i><span class="NLM_source">The Pharmacogenomics Journal</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/tpj.2010.65" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">364</p><p class="content">Laura C. Amann, Michael J. Gandal, Robert Lin, Yuling Liang, Steven J. Siegel. (2010) In Vitro–In Vivo Correlations of Scalable PLGA-Risperidone Implants for the Treatment of Schizophrenia. <i><span class="NLM_source">Pharmaceutical Research</span></i> <b>27</b>:8, 1730-1737<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11095-010-0152-4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">365</p><p class="content">Stephen Z. Levine, Jonathan Rabinowitz, Michael Case, Haya Ascher-Svanum. (2010) Treatment Response Trajectories and Their Antecedents in Recent-Onset Psychosis. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>30</b>:4, 446-449<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e3181e68e80" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">366</p><p class="content">A. Carlo Altamura, Ira D. Glick. (2010) Designing outcome studies to determine efficacy and safety of antipsychotics for ‘real world’ treatment of schizophrenia. <i><span class="NLM_source">The International Journal of Neuropsychopharmacology</span></i> <b>13</b>:07, 971-973<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S1461145709991271" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">367</p><p class="content">Roger S. McIntyre, Lael Cragin, Sonja Sorensen, Huseyin Naci, Tim Baker, Jean-Pascal Roussy. (2010) Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. <i><span class="NLM_source">Journal of Evaluation in Clinical Practice</span></i> <b>16</b>:4, 744-755<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2753.2009.01189.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">368</p><p class="content">Viacheslav Terevnikov, Jan-Henry Stenberg, Marina Joffe, Jari Tiihonen, Mark Burkin, Evgueni Tchoukhine, Grigori Joffe. (2010) More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. <i><span class="NLM_source">Human Psychopharmacology: Clinical and Experimental</span></i> <b>25</b>:6, 431-438<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/hup.1137" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">369</p><p class="content">Robert J. Fountaine, Ann E. Taylor, James P. Mancuso, Frank L. Greenway, Lauri O. Byerley, Steven R. Smith, Marlene M. Most, David A. Fryburg. (2010) Increased Food Intake and Energy Expenditure Following Administration of Olanzapine to Healthy Men. <i><span class="NLM_source">Obesity</span></i> <b>18</b>:8, 1646-1651<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/oby.2010.6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">370</p><p class="content">Georges Brousse, Alexandre Meary, Olivier Blanc, Christophe Lan&ccedil;on, Pierre Michel Llorca, Marion Leboyer. (2010) Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia. <i><span class="NLM_source">Psychiatry Research</span></i> <b>179</b>:1, 12-18<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psychres.2009.03.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">371</p><p class="content">Stephen M. Stahl, Ashok Malla, John W. Newcomer, Steven G. Potkin, Peter J. Weiden, Philip D. Harvey, Antony Loebel, Eric Watsky, Cynthia O. Siu, Steve Romano. (2010) A Post Hoc Analysis of Negative Symptoms and Psychosocial Function in Patients With Schizophrenia. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>30</b>:4, 425-430<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e3181e69042" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">372</p><p class="content">Cecilia Adrianz&eacute;n, Cesar Arango-D&aacute;vila, Danilo Mart&iacute;nez Araujo, Ignacio Ru&iacute;z, Richard J. Walton, Martin Dossenbach, Jamie Karagianis. (2010) Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3-year observational study. <i><span class="NLM_source">Human Psychopharmacology: Clinical and Experimental</span></i> <b>25</b>:6, 439-447<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/hup.1143" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">373</p><p class="content">Stanley Sacks, Karen McKendrick, JoAnn Y. Sacks, Charles M. Cleland. (2010) Modified Therapeutic Community for Co-Occurring Disorders: Single Investigator Meta Analysis. <i><span class="NLM_source">Substance Abuse</span></i> <b>31</b>:3, 146-161<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/08897077.2010.495662" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">374</p><p class="content">Christopher P Alderman, Dasha Loutchkina, Anita C Abarno. (2010) Psychotropic drug safety issues: continuing vigilance is needed. <i><span class="NLM_source">Expert Review of Clinical Pharmacology</span></i> <b>3</b>:4, 427-432<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/ecp.10.12" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">375</p><p class="content">Jaewon Yang, Won-Myong Bahk, Hyun-Sang Cho, Yang-Whan Jeon, Duk-In Jon, Hee-Yeon Jung, Chan-Hyung Kim, Hee-Cheol Kim, Yong-Ku Kim, Young-Hoon Kim, Jun-Soo Kwon, Sang-Yeol Lee, Seung-Hwan Lee, Jung-Seo Yi, Bo-Hyun Yoon, Seung-Hyun Kim. (2010) Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia. <i><span class="NLM_source">Clinical Neuropharmacology</span></i> <b>33</b>:4, 169-175<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/WNF.0b013e3181dcda50" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">376</p><p class="content">A. S. Young, N. Niv, A. N. Cohen, C. Kessler, K. McNagny. (2010) The Appropriateness of Routine Medication Treatment for Schizophrenia. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>36</b>:4, 732-739<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbn138" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">377</p><p class="content">Stephen Z. Levine, Stefan Leucht. (2010) Elaboration on the Early-Onset Hypothesis of Antipsychotic Drug Action: Treatment Response Trajectories. <i><span class="NLM_source">Biological Psychiatry</span></i> <b>68</b>:1, 86-92<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.biopsych.2010.01.012" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">378</p><p class="content">J. P. Koning, D. E. Tenback, J. van Os, A. Aleman, R. S. Kahn, P. N. van Harten. (2010) Dyskinesia and Parkinsonism in Antipsychotic-Naive Patients With Schizophrenia, First-Degree Relatives and Healthy Controls: A Meta-analysis. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>36</b>:4, 723-731<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbn146" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">379</p><p class="content">Robert C. Smith, Jean-Pierre Lindenmayer, Qiaoyan Hu, Erin Kelly, Thomas F. Viviano, James Cornwell, Sumathi Vaidhyanathaswamy, Santica Marcovina, John M. Davis. (2010) Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: A randomized five month study. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>120</b>:1-3, 204-209<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2010.04.001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">380</p><p class="content">A. Pope, C. Adams, C. Paton, T. Weaver, T. R. E. Barnes. (2010) Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>197</b>:1, 67-72<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.bp.109.070961" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">381</p><p class="content">Lawrence Maayan, Christoph U Correll. (2010) Management of antipsychotic-related weight gain. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>10</b>:7, 1175-1200<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/ern.10.85" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">382</p><p class="content">Galen E. B. Wright, Dana J. H. Niehaus, Britt I. Dr&ouml;gem&ouml;ller, Liezl Koen, Andrea Gaedigk, Louise Warnich. (2010) Elucidation of CYP2D6 Genetic Diversity in a Unique African Population: Implications for the Future Application of Pharmacogenetics in the Xhosa Population. <i><span class="NLM_source">Annals of Human Genetics</span></i> <b>74</b>:4, 340-350<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1469-1809.2010.00585.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">383</p><p class="content">Colin A. Ross. (2010) DSM‐5 and the ‘Psychosis Risk Syndrome’: Eight reasons to reject it. <i><span class="NLM_source">Psychosis</span></i> <b>2</b>:2, 107-110<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/17522431003763323" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">384</p><p class="content">Brooke H. Miller, Claes Wahlestedt. (2010) MicroRNA dysregulation in psychiatric disease. <i><span class="NLM_source">Brain Research</span></i> <b>1338</b>, 89-99<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.brainres.2010.03.035" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">385</p><p class="content">Elaine Morrato, Daniel Hartung. (2010) Lipid profile screening in second-generation antipsychotic users: the gap between policy and practice. <i><span class="NLM_source">Clinical Lipidology</span></i> <b>5</b>:3, 299-303<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/clp.10.29" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">386</p><p class="content">R Hwang, C Zai, A Tiwari, D J M&uuml;ller, M J Arranz, A G Morris, P J McKenna, J Munro, S G Potkin, J A Lieberman, H Y Meltzer, J L Kennedy. (2010) Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. <i><span class="NLM_source">The Pharmacogenomics Journal</span></i> <b>10</b>:3, 200-218<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/tpj.2009.65" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">387</p><p class="content">Sun H. Kim, Lilla Nikolics, Fahim Abbasi, Cindy Lamendola, James Link, Gerald M. Reaven, Steven Lindley. (2010) Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents. <i><span class="NLM_source">Journal of Psychiatric Research</span></i> <b>44</b>:8, 493-498<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jpsychires.2009.11.007" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">388</p><p class="content">N. A. Crossley, M. Constante, P. McGuire, P. Power. (2010) Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>196</b>:6, 434-439<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.bp.109.066217" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">389</p><p class="content">H G Shertzer, E L Kendig, H A Nasrallah, E Johansson, M B Genter. (2010) Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole. <i><span class="NLM_source">International Journal of Obesity</span></i> <b>34</b>:6, 970-979<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/ijo.2009.291" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">390</p><p class="content">C.U. Correll. (2010) From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. <i><span class="NLM_source">European Psychiatry</span></i> <b>25</b>, S12-S21<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0924-9338(10)71701-6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">391</p><p class="content">Robert L. Findling, Jacqueline L. Johnson, Jon McClellan, Jean A. Frazier, Benedetto Vitiello, Robert M. Hamer, Jeffrey A. Lieberman, Louise Ritz, Nora K. McNamara, Jacqui Lingler, Stefanie Hlastala, Leslie Pierson, Madeline Puglia, Ann E. Maloney, Emily Michael Kaufman, Nancy Noyes, Linmarie Sikich. (2010) Double-Blind Maintenance Safety and Effectiveness Findings From the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study. <i><span class="NLM_source">Journal of the American Academy of Child &amp; Adolescent Psychiatry</span></i> <b>49</b>:6, 583-594<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jaac.2010.03.013" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">392</p><p class="content">C. BESENIUS, D. CLARK-CARTER, P. NOLAN. (2010) Health professionals' attitudes to depot injection antipsychotic medication: a systematic review. <i><span class="NLM_source">Journal of Psychiatric and Mental Health Nursing</span></i> <b>17</b>:5, 452-462<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2850.2010.01550.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">393</p><p class="content">Kalman Applbaum. (2010) Shadow science: Zyprexa, Eli Lilly and the globalization of pharmaceutical damage control. <i><span class="NLM_source">BioSocieties</span></i> <b>5</b>:2, 236-255<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1057/biosoc.2010.5" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">394</p><p class="content">Anne-Marie Wijnveld, Marie Crowe. (2010) Walking a fine line: managing the tensions associated with medication non-adherence in an acute inpatient psychiatric setting. <i><span class="NLM_source">Journal of Clinical Nursing</span></i> <b>19</b>:9-10, 1378-1386<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2702.2009.03029.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">395</p><p class="content">Wolfgang Gaebel, Mathias Riesbeck, Martina von Wilmsdorff, Tom Burns, Eske M. Derks, Ren&eacute; S. Kahn, Wulf R&ouml;ssler, W. Wolfgang Fleischhacker. (2010) Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>20</b>:5, 310-316<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2010.02.001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">396</p><p class="content">Roza Ghotbi, Buster Mannheimer, Eleni Aklillu, Akira Suda, Leif Bertilsson, Erik Eliasson, Urban &Ouml;sby. (2010) Carriers of the UGT1A4 142T&gt;G gene variant are predisposed to reduced olanzapine exposure—an impact similar to male gender or smoking in schizophrenic patients. <i><span class="NLM_source">European Journal of Clinical Pharmacology</span></i> <b>66</b>:5, 465-474<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00228-009-0783-8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">397</p><p class="content">Carla M. Canuso, Augusto Grinspan, Amir Kalali, Chandrasekharrao Venkata Damaraju, Ursula Merriman, Larry Alphs, Awad George Awad. (2010) Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>25</b>:3, 155-164<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YIC.0b013e3283372977" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">398</p><p class="content">Amy M. Bauer, Ken Fielke, John Brayley, Mesfin Araya, Atalay Alem, Bernard L. Frankel, Gregory L. Fricchione. (2010) Tackling the Global Mental Health Challenge: A Psychosomatic Medicine/Consultation–Liaison Psychiatry Perspective. <i><span class="NLM_source">Psychosomatics</span></i> <b>51</b>:3, 185-193<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0033-3182(10)70684-8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">399</p><p class="content">Carol D. Clayton, Jeffrey Veach, Wayne Macfadden, John Haskins, John P. Docherty, Jean-Pierre Lindenmayer. (2010) Assessment of Clinician Awareness of Nonadherence Using a New Structured Rating Scale. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>16</b>:3, 164-169<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.pra.0000375712.85454.c6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">400</p><p class="content">Edward J. Brnardic, Mark E. Fraley, Robert M. Garbaccio, Mark E. Layton, John M. Sanders, Chris Culberson, Marlene A. Jacobson, Brian C. Magliaro, Pete H. Hutson, Julie A. O’Brien, Sarah L. Huszar, Jason M. Uslaner, Kerry L. Fillgrove, Cuyue Tang, Yuhsin Kuo, Sylvie M. Sur, George D. Hartman. (2010) 3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts. <i><span class="NLM_source">Bioorganic &amp; Medicinal Chemistry Letters</span></i> <b>20</b>:10, 3129-3133<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.bmcl.2010.03.089" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">401</p><p class="content">T. Treuer, F. Martenyi, M. Saylan, Y. Dyachkova. (2010) Factors associated with achieving minimally symptomatic status by patients with schizophrenia: results from the 3-year intercontinental schizophrenia outpatients health outcomes study. <i><span class="NLM_source">International Journal of Clinical Practice</span></i> <b>64</b>:6, 697-706<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1742-1241.2009.02331.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">402</p><p class="content">Jan-Henry Stenberg, Viatcheslav Terevnikov, Marina Joffe, Jari Tiihonen, Evgueni Tchoukhine, Mark Burkin, Grigori Joffe. (2010) Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. <i><span class="NLM_source">The International Journal of Neuropsychopharmacology</span></i> <b>13</b>:04, 433<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S1461145709990897" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">403</p><p class="content">Joel F. Farley. (2010) Medicaid Prescription Cost Containment and Schizophrenia. <i><span class="NLM_source">Medical Care</span></i> <b>48</b>:5, 440-447<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/MLR.0b013e3181d502bd" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">404</p><p class="content">Jamie Karagianis, Angela Hill. (2010) Schizophrenia in a worldwide perspective: explaining similarities and differences. <i><span class="NLM_source">Future Neurology</span></i> <b>5</b>:3, 345-348<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/fnl.10.11" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">405</p><p class="content">Herbert Y. Meltzer, William V. Bobo, Myung A. Lee, Philip Cola, Karuna Jayathilake. (2010) A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. <i><span class="NLM_source">Psychiatry Research</span></i> <b>177</b>:3, 286-293<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psychres.2010.02.018" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">406</p><p class="content">Sebastian Walther, Helge Horn, Nadja Razavi, Philipp Koschorke, Alexander Wopfner, Thomas J. M&uuml;ller, Werner Strik. (2010) Higher Motor Activity in Schizophrenia Patients Treated With Olanzapine Versus Risperidone. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>30</b>:2, 181-184<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e3181d2ef6f" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">407</p><p class="content">Marilyn A. Davies, Yvette Conley, Kathryn Puskar. (2010) Incorporating Evidence From Pharmacologic and Pharmacogenetic Studies of Atypical Antipsychotic Drugs Into Advanced Psychiatric Nursing Practice. <i><span class="NLM_source">Perspectives in Psychiatric Care</span></i> <b>46</b>:2, 98-107<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1744-6163.2010.00245.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">408</p><p class="content">Stefan Klingberg. (2010) Evidenzbasierte Einzelpsychotherapie bei schizophrenen Psychosen1. <i><span class="NLM_source">Zeitschrift f&uuml;r Psychiatrie, Psychologie und Psychotherapie</span></i> <b>58</b>:2, 95-102<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1024/1661-4747/a000013" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">409</p><p class="content">Ulla A. Botha, Liezl Koen, John A. Joska, John S. Parker, Neil Horn, Linda M. Hering, Piet P. Oosthuizen. (2010) The revolving door phenomenon in psychiatry: comparing low-frequency and high-frequency users of psychiatric inpatient services in a developing country. <i><span class="NLM_source">Social Psychiatry and Psychiatric Epidemiology</span></i> <b>45</b>:4, 461-468<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00127-009-0085-6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">410</p><p class="content">C. W. Ritchie, S. Harrigan, M. Mastwyk, S. Macfarlane, N. Cheesman, D. Ames. (2010) Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3&frac12; years duration. <i><span class="NLM_source">International Journal of Geriatric Psychiatry</span></i> <b>25</b>:4, 411-418<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/gps.2354" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">411</p><p class="content">Swapna Verma, Mythily Subramaniam, Edimansyah Abdin, Kang Sim, Alex Su, Nelson Lee, Siow Ann Chong. (2010) Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: A 6-month open-label trial in Asian patients. <i><span class="NLM_source">Human Psychopharmacology: Clinical and Experimental</span></i> <b>25</b>:3, 230-235<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/hup.1104" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">412</p><p class="content">Roger S. McIntyre, Miriam Cohen, Jun Zhao, Larry Alphs, Thomas A. Macek, John Panagides. (2010) Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial. <i><span class="NLM_source">Journal of Affective Disorders</span></i> <b>122</b>:1-2, 27-38<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jad.2009.12.028" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">413</p><p class="content">Roland Vauth, Rolf-Dieter Stieglitz. (2010) Compliance-Aufbau im Fokus der Schizophreniebehandlung. <i><span class="NLM_source">Zeitschrift f&uuml;r Psychiatrie, Psychologie und Psychotherapie</span></i> <b>58</b>:2, 119-125<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1024/1661-4747/a000016" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">414</p><p class="content">Hans-Georg Eichler, Brigitte Bloechl-Daum, Eric Abadie, David Barnett, Franz K&ouml;nig, Steven Pearson. (2010) Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. <i><span class="NLM_source">Nature Reviews Drug Discovery</span></i> <b>9</b>:4, 277-291<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/nrd3079" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">415</p><p class="content">Matthew James Girgenti, Laura K. Nisenbaum, Franklin Bymaster, Rosemarie Terwilliger, Ronald S Duman, Samuel Sathyanesan Newton. (2010) Antipsychotic-induced gene regulation in multiple brain regions. <i><span class="NLM_source">Journal of Neurochemistry</span></i> <b>113</b>:1, 175-187<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1471-4159.2010.06585.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">416</p><p class="content">Keith Lloyd, Muhammud A. Latif, Steve Simpson, Keshar L. Shrestha. (2010) Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. <i><span class="NLM_source">Human Psychopharmacology: Clinical and Experimental</span></i> <b>25</b>:3, 243-252<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/hup.1108" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">417</p><p class="content">Arun K. Tiwari, Clement C. Zai, Herbert Y. Meltzer, Jeffrey A. Lieberman, Daniel J. M&uuml;ller, James L. Kennedy. (2010) Association study of polymorphisms in Insulin Induced Gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. <i><span class="NLM_source">Human Psychopharmacology: Clinical and Experimental</span></i> <b>25</b>:3, 253-259<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/hup.1111" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">418</p><p class="content">H. Akil, S. Brenner, E. Kandel, K. S. Kendler, M. C. King, E. Scolnick, J. D. Watson, H. Y. Zoghbi. (2010) The Future of Psychiatric Research: Genomes and Neural Circuits. <i><span class="NLM_source">Science</span></i> <b>327</b>:5973, 1580-1581<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1126/science.1188654" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">419</p><p class="content">Jung-Ying Tzeng<img src="/na102/home/ACS/publisher/mms/journals/entities/2217.gif" alt="" class="entityA" align="bottom" />, Wenbin Lu<img src="/na102/home/ACS/publisher/mms/journals/entities/2217.gif" alt="" class="entityA" align="bottom" />, Mark W. Farmen, Youfang Liu, Patrick F. Sullivan. (2010) Haplotype-Based Pharmacogenetic Analysis for Longitudinal Quantitative Traits in the Presence of Dropout. <i><span class="NLM_source">Journal of Biopharmaceutical Statistics</span></i> <b>20</b>:2, 334-350<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/10543400903572787" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">420</p><p class="content">Katja Komossa, Christine Rummel-Kluge, Heike Hunger, Franziska Schmid, Sandra Schwarz, Lorna Duggan, Werner Kissling, Stefan Leucht, Katja Komossa. 2010. Olanzapine versus other atypical antipsychotics for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD006654.pub2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">421</p><p class="content">2010. The Impending Crisis in CNS Drug Development. , 1-13. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9781444318579.ch1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">422</p><p class="content">G. S. Ungvari, S. N. Caroff, J. Gerevich. (2010) The Catatonia Conundrum: Evidence of Psychomotor Phenomena as a Symptom Dimension in Psychotic Disorders. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>36</b>:2, 231-238<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbp105" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">423</p><p class="content">Daniel M Blumberger, Paul B Fitzgerald, Benoit H Mulsant, Zafiris J Daskalakis. (2010) Repetitive transcranial magnetic stimulation for refractory symptoms in schizophrenia. <i><span class="NLM_source">Current Opinion in Psychiatry</span></i> <b>23</b>:2, 85-90<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YCO.0b013e3283366657" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">424</p><p class="content">Subhrojyoti Bhowmick, Avijit Hazra, Malati Ghosh. (2010) Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. <i><span class="NLM_source">Australian and New Zealand Journal of Psychiatry</span></i> <b>44</b>:3, 237-242<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/00048670903487134" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">425</p><p class="content">V. Jude Forbes. (2010) Unawareness as a Barrier to Treatment in Patients with Schizophrenia. <i><span class="NLM_source">Journal of Psychosocial Nursing and Mental Health Services</span></i> <b>48</b>:3, 30-36<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3928/02793695-20100202-01" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">426</p><p class="content">G. Foussias, G. Remington. (2010) Negative Symptoms in Schizophrenia: Avolition and Occam's Razor. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>36</b>:2, 359-369<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbn094" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">427</p><p class="content">Lawrence A. Maayan, Julia Vakhrusheva. (2010) Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. <i><span class="NLM_source">Human Psychopharmacology: Clinical and Experimental</span></i> <b>25</b>:2, 133-138<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/hup.1097" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">428</p><p class="content">Maria Isaac, Armin Koch. (2010) The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia11The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the EMEA or one of its committees or working parties or the BfArM.. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>20</b>:3, 139-145<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2009.12.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">429</p><p class="content">Jeffrey J. Miceli, Thomas G. Tensfeldt, Thomas Shiovitz, Richard J. Anziano, Cedric O'Gorman, Rachel H. Harrigan. (2010) Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: A randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. <i><span class="NLM_source">Clinical Therapeutics</span></i> <b>32</b>:3, 472-491<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.clinthera.2010.03.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">430</p><p class="content">B Mackenzie, RP Souza, O Likhodi, AK Tiwari, CC Zai, J Sturgess, DJ M&uuml;ller. (2010) Pharmacogenetics of antipsychotic treatment response and side effects. <i><span class="NLM_source">Therapy</span></i> <b>7</b>:2, 191-198<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/thy.10.3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">431</p><p class="content">J. Peuskens, J.M. Olivares, J. Pecenak, I. Tuma, H. bij de Weg, L. Eriksson, S. Resseler, K. Akhras, A. Jacobs. (2010) Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>26</b>:3, 501-509<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/03007990903488670" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">432</p><p class="content">RIG Holt, RC Peveler. (2010) Diabetes and cardiovascular risk in severe mental illness: a missed opportunity and challenge for the future. <i><span class="NLM_source">Practical Diabetes International</span></i> <b>27</b>:2, 79-84ii<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/pdi.1451" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">433</p><p class="content">Peter P. Zandi, Jennifer T. Judy. (2010) The Promise and Reality of Pharmacogenetics in Psychiatry. <i><span class="NLM_source">Psychiatric Clinics of North America</span></i> <b>33</b>:1, 181-224<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psc.2009.12.001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">434</p><p class="content">Mehrul Hasnain, W. Victor R. Vieweg, Sonja K. Fredrickson. (2010) Metformin for Atypical Antipsychotic-Induced Weight Gain and Glucose Metabolism Dysregulation. <i><span class="NLM_source">CNS Drugs</span></i> <b>24</b>:3, 193-206<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/11530130-000000000-00000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">435</p><p class="content">Y. E. Savoy, M. A. Ashton, M. W. Miller, F. M. Nedza, D. K. Spracklin, M. H. Hawthorn, H. Rollema, F. F. Matos, E. Hajos-Korcsok. (2010) Differential Effects of Various Typical and Atypical Antipsychotics on Plasma Glucose and Insulin Levels in the Mouse: Evidence for the Involvement of Sympathetic Regulation. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>36</b>:2, 410-418<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbn104" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">436</p><p class="content">Stanley V. Catts, Brian I. O'Toole, Vaughan J. Carr, Terry Lewin, Amanda Neil, Meredith G. Harris, Aaron D.J. Frost, Belinda R. Crissman, Kathy Eadie, Russell W. Evans. (2010) Appraising evidence for intervention effectiveness in early psychosis: conceptual framework and review of evaluation approaches. <i><span class="NLM_source">Australian and New Zealand Journal of Psychiatry</span></i> <b>44</b>:3, 195-219<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/00048670903487167" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">437</p><p class="content">Andrew Thompson, Christian Lavedan, Simona Volpi. (2010) Absence of weight gain association with the HTR2C −759C/T polymorphism in patients with schizophrenia treated with iloperidone. <i><span class="NLM_source">Psychiatry Research</span></i> <b>175</b>:3, 271-273<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psychres.2009.03.020" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">438</p><p class="content">Carla M. Canuso, Cynthia A. Bossie, Joan Amatniek, Ibrahim Turkoz, Gahan Pandina, Barbara Cornblatt. (2010) Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia. <i><span class="NLM_source">Early Intervention in Psychiatry</span></i> <b>4</b>:1, 64-78<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1751-7893.2010.00165.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">439</p><p class="content">Andrew M. Kuller, Brian D. Ott, Robert M. Goisman, Laurel D. Wainwright, Rebecca J. Rabin. (2010) Cognitive Behavioral Therapy and Schizophrenia: A Survey of Clinical Practices and Views on Efficacy in the United States and United Kingdom. <i><span class="NLM_source">Community Mental Health Journal</span></i> <b>46</b>:1, 2-9<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s10597-009-9223-6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">440</p><p class="content">Nancy C. Andreasen, Marcus Pressler, Peg Nopoulos, Del Miller, Beng-Choon Ho. (2010) Antipsychotic Dose Equivalents and Dose-Years: A Standardized Method for Comparing Exposure to Different Drugs. <i><span class="NLM_source">Biological Psychiatry</span></i> <b>67</b>:3, 255-262<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.biopsych.2009.08.040" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">441</p><p class="content">Ludovic Samalin, Olivier Blanc, Pierre-Michel Llorca. (2010) Optimizing treatment of schizophrenia to minimize relapse. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>10</b>:2, 147-150<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/ern.09.147" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">442</p><p class="content">T. E. Tungaraza, S. Gupta, J. Jones, R. Poole, G. Slegg. (2010) Polypharmacy and high-dose antipsychotic regimes in the community. <i><span class="NLM_source">The Psychiatrist</span></i> <b>34</b>:2, 44-46<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/pb.bp.108.020776" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">443</p><p class="content">I. Tarricone, B. Ferrari Gozzi, A. Serretti, D. Grieco, D. Berardi. (2010) Weight gain in antipsychotic-naive patients: a review and meta-analysis. <i><span class="NLM_source">Psychological Medicine</span></i> <b>40</b>:02, 187<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S0033291709990407" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">444</p><p class="content">Jeffrey J Miceli, Thomas G Tensfeldt, Thomas Shiovitz, Richard Anziano, Cedric O'Gorman, Rachel H Harrigan. (2010) Effects of Oral Ziprasidone and Oral Haloperidol on QTc Interval in Patients with Schizophrenia or Schizoaffective Disorder. <i><span class="NLM_source">Pharmacotherapy</span></i> <b>30</b>:2, 127-135<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1592/phco.30.2.127" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">445</p><p class="content">Stefan Weinmann, Volkmar Aderhold. (2010) Antipsychotic medication, mortality and neurodegeneration: The need for more selective use and lower doses. <i><span class="NLM_source">Psychosis</span></i> <b>2</b>:1, 50-69<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/17522430903501999" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">446</p><p class="content">M. Poyurovsky. (2010) Acute antipsychotic-induced akathisia revisited. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>196</b>:2, 89-91<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.bp.109.070540" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">447</p><p class="content">Michael S. Ritsner. (2010) Pregnenolone, Dehydroepiandrosterone, and Schizophrenia: Alterations and Clinical Trials. <i><span class="NLM_source">CNS Neuroscience &amp; Therapeutics</span></i> <b>16</b>:1, 32-44<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1755-5949.2009.00118.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">448</p><p class="content">Karolina &Aring;berg, Daniel E. Adkins, J&oacute;zsef Buksz&aacute;r, Bradley T. Webb, Stanley N. Caroff, Del D. Miller, Jonathan Sebat, Scott Stroup, Ayman H. Fanous, Vladimir I. Vladimirov, Joseph L. McClay, Jeffrey A. Lieberman, Patrick F. Sullivan, Edwin J.C.G. van den Oord. (2010) Genomewide Association Study of Movement-Related Adverse Antipsychotic Effects. <i><span class="NLM_source">Biological Psychiatry</span></i> <b>67</b>:3, 279-282<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.biopsych.2009.08.036" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">449</p><p class="content">Hans-J&uuml;rgen M&ouml;ller, Wolfgang Maier. (2010) Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. <i><span class="NLM_source">European Archives of Psychiatry and Clinical Neuroscience</span></i> <b>260</b>:1, 25-39<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00406-009-0070-9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">450</p><p class="content">Hans-J&uuml;rgen M&ouml;ller, Karl Broich. (2010) Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. <i><span class="NLM_source">European Archives of Psychiatry and Clinical Neuroscience</span></i> <b>260</b>:1, 3-16<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00406-009-0071-8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">451</p><p class="content">Robert C Young, Herbert C Schulberg, Ariel G Gildengers, Martha Sajatovic, Benoit H Mulsant, Laszlo Gyulai, John Beyer, Lauren Marangell, Mark Kunik, Thomas Ten Have, Martha L Bruce, Ruben Gur, Patricia Marino, Jovier D Evans, Charles F Reynolds III, George S Alexopoulos. (2010) Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BD. <i><span class="NLM_source">Bipolar Disorders</span></i> <b>12</b>:1, 56-67<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1399-5618.2009.00779.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">452</p><p class="content">Shelly F. Greenfield. 2010. Tertiary Prevention. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9780470479216.corpsy0983" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">453</p><p class="content">Lisa J. Cohen. 2010. Psychotic Disorders. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9780470479216.corpsy0759" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">454</p><p class="content">Jeffrey M. Brown, Jie Jack Li, Michael W. Sinz. 2010. Antipsychotic Agents. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/0471266949.bmc103.pub2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">455</p><p class="content">Katja Komossa, Christine Rummel-Kluge, Heike Hunger, Franziska Schmid, Sandra Schwarz, Werner Kissling, Stefan Leucht, Katja Komossa. 2010. Zotepine versus other atypical antipsychotics for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD006628.pub2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">456</p><p class="content">Abraham M Nussbaum, T S Stroup, Abraham M Nussbaum. 2010. Paliperidone palmitate for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD008296" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">457</p><p class="content">Ranganath D Rattehalli, Mahesh B Jayaram, Michael Smith, Ranganath D Rattehalli. 2010. Risperidone versus placebo for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD006918.pub2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">458</p><p class="content">Bruce J Kinon, Lei Chen, Haya Ascher-Svanum, Virginia L Stauffer, Sara Kollack-Walker, Wei Zhou, Shitij Kapur, John M Kane. (2010) Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>35</b>:2, 581-590<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/npp.2009.164" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">459</p><p class="content">Joel F. Farley. (2010) Containing Cost Despite the Cost. <i><span class="NLM_source">Medical Care</span></i> <b>48</b>:1, 1-3<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/MLR.0b013e3181caad9a" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">460</p><p class="content">Emmanuel Stip, Val&eacute;rie Tourjman. (2010) Aripiprazole in schizophrenia and schizoaffective disorder: A review. <i><span class="NLM_source">Clinical Therapeutics</span></i> <b>32</b>, S3-S20<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.clinthera.2010.01.021" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">461</p><p class="content">Bruno Millet, Jean-Marie Vanelle, Joseph Benyaya. 2010. Troubles schizophr&eacute;niques. , 148-155. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/B978-2-294-01922-7.00023-X" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">462</p><p class="content">R. W. Buchanan, J. Kreyenbuhl, D. L. Kelly, J. M. Noel, D. L. Boggs, B. A. Fischer, S. Himelhoch, B. Fang, E. Peterson, P. R. Aquino, W. Keller. (2010) The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>36</b>:1, 71-93<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbp116" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">463</p><p class="content">Suzanne M. Hardeman, Meera Narasimhan. (2010) Adherence According to Mary Poppins: Strategies to Make the Medicine Go Down. <i><span class="NLM_source">Perspectives in Psychiatric Care</span></i> <b>46</b>:1, 3-13<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1744-6163.2009.00233.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">464</p><p class="content">Akira Yoshimi, Yukihiro Noda, Branko Aleksic, Koji Senzaki, Mitsuki Ohashi, Shinnosuke Yamada, Kiyofumi Yamada, Norio Ozaki. (2010) A survey of antipsychotic polypharmacy in outpatients at Nagoya University Hospital. <i><span class="NLM_source">Clinical Neuropsychopharmacology and Therapeutics</span></i> <b>1</b>, 43-49<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.5234/cnpt.1.43" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">465</p><p class="content">J. Kreyenbuhl, R. W. Buchanan, F. B. Dickerson, L. B. Dixon. (2010) The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>36</b>:1, 94-103<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbp130" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">466</p><p class="content">Chris Hawley, Martin Turner, Muhammud A Latif, Vivienne Curtis, Packeruther T Saleem, Kristina Wilton. (2010) Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. <i><span class="NLM_source">Human Psychopharmacology: Clinical and Experimental</span></i> <b>25</b>:1, 37-46<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/hup.1085" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">467</p><p class="content">Dara S. Manoach, Katharine N. Thakkar, Eva Stroynowski, Alice Ely, Sophia K. McKinley, Erin Wamsley, Ina Djonlagic, Mark G. Vangel, Donald C. Goff, Robert Stickgold. (2010) Reduced overnight consolidation of procedural learning in chronic medicated schizophrenia is related to specific sleep stages. <i><span class="NLM_source">Journal of Psychiatric Research</span></i> <b>44</b>:2, 112-120<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jpsychires.2009.06.011" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">468</p><p class="content">Alexandra Schosser. (2010) Research Highlights. <i><span class="NLM_source">Personalized Medicine</span></i> <b>7</b>:1, 15-18<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/pme.09.72" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">469</p><p class="content">Jocelyne Moisan, Jean-Pierre Gr&eacute;goire. (2010) Patterns of discontinuation of atypical antipsychotics in the province of Qu&eacute;bec: A retrospective prescription claims database analysis. <i><span class="NLM_source">Clinical Therapeutics</span></i> <b>32</b>, S21-S31<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.clinthera.2010.01.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">470</p><p class="content">Sami Yamin, Krishna Vaddadi. (2010) Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine. <i><span class="NLM_source">International Review of Psychiatry</span></i> <b>22</b>:2, 138-147<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/09540261.2010.482558" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">471</p><p class="content">Michael Makhinson. (2010) Biases in Medication Prescribing: The Case of Second-Generation Antipsychotics. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>16</b>:1, 15-21<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.pra.0000367774.11260.e4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">472</p><p class="content">F. Artigas. (2010) The prefrontal cortex: a target for antipsychotic drugs. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>121</b>:1, 11-21<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2009.01455.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">473</p><p class="content">H.-P. Volz, F. Reischies, M. Riedel. (2010) Kognitive St&ouml;rungen bei schizophrenen Patienten. <i><span class="NLM_source">Der Nervenarzt</span></i> <b>81</b>:1, 39-54<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00115-009-2819-9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">474</p><p class="content">B Riley, D Thiselton, B S Maher, T Bigdeli, B Wormley, G O McMichael, A H Fanous, V Vladimirov, F A O'Neill, D Walsh, K S Kendler. (2010) Replication of association between schizophrenia and ZNF804A in the Irish Case–Control Study of Schizophrenia sample. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>15</b>:1, 29-37<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/mp.2009.109" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">475</p><p class="content">A. Tschoner, C. Ebenbichler. (2010) Medikamente und Diabetes. <i><span class="NLM_source">Der Diabetologe</span></i> <b>6</b>:1, 37-43<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11428-009-0439-4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">476</p><p class="content">David Fraguas, Mara Parellada, Dolores Moreno, Celso Arango. (2010) Quetiapine treatment in adolescents: a 6-month naturalistic study. <i><span class="NLM_source">Revista de Psiquiatr&iacute;a y Salud Mental (English Edition)</span></i> <b>3</b>:3, 106-110<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S2173-5050(10)70018-2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">477</p><p class="content">Anand Mattai, Alex Chavez, Deanna Greenstein, Liv Clasen, Jennifer Bakalar, Reva Stidd, Judith Rapoport, Nitin Gogtay. (2010) Effects of clozapine and olanzapine on cortical thickness in childhood-onset schizophrenia. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>116</b>:1, 44-48<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2009.10.018" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">478</p><p class="content">F. S. Collins. (2010) Opportunities for Research and NIH. <i><span class="NLM_source">Science</span></i> <b>327</b>:5961, 36-37<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1126/science.1185055" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">479</p><p class="content">V&iacute;ctor P&eacute;rez, Juan Carlos Pascual, Joaquim Soler, Thais Tiana, Anna Cort&eacute;s, Montserrat Baiget, Ana Mart&iacute;n-Blanco, Enrique &Aacute;lvarez. (2010) Psychotherapygenetic: Do Genes Influence Psychotherapy Adherence?. <i><span class="NLM_source">Revista de Psiquiatr&iacute;a y Salud Mental (English Edition)</span></i> <b>3</b>:2, 68-71<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S2173-5050(10)70012-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">480</p><p class="content">Jung-Sun Lee, Seockhoon Chung, Joon-Noh Lee, Jun Soo Kwon, Do Hoon Kim, Chul Eung Kim, Kang Seob Oh, Yang-Whan Jeon, Min-Soo Lee, Myung Ho Lim, Hye-Ryein Chang, Chang Yoon Kim. (2010) Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics. <i><span class="NLM_source">Psychiatry Investigation</span></i> <b>7</b>:3, 189<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.4306/pi.2010.7.3.189" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">481</p><p class="content">Gavin P Reynolds, Shona L. Kirk. (2010) Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms. <i><span class="NLM_source">Pharmacology &amp; Therapeutics</span></i> <b>125</b>:1, 169-179<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pharmthera.2009.10.010" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">482</p><p class="content">Harith S. Swadi, Brian J. Craig, Nabeel Z. Pirwani, Valerie C. Black, Jill C. Buchan, Candace M. Bobier. (2010) A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>25</b>:1, 1-6<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YIC.0b013e3283320511" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">483</p><p class="content">Bruno Millet, Jean-Marie Vanelle, Joseph Benyaya. 2010. Antipsychotiques. , 25-38. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/B978-2-294-01922-7.00005-8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">484</p><p class="content">Gary Remington, George Foussias, Ofer Agid. (2010) Progress in Defining Optimal Treatment Outcome in Schizophrenia. <i><span class="NLM_source">CNS Drugs</span></i> <b>24</b>:1, 9-20<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/11530250-000000000-00000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">485</p><p class="content">Ai TAMAJI, Akira SAKAI, Motoko SATO, Yukiko IKEMA, Kiyohide MATSUZAKI, Hideaki TABUSE, Yukihiro NODA. (2010) Development of Clinical Pharmacy Services to Improve Drug Adherence in Psychiatric Hospital Patients. <i><span class="NLM_source">YAKUGAKU ZASSHI</span></i> <b>130</b>:11, 1565-1572<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1248/yakushi.130.1565" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">486</p><p class="content">Marie-No&euml;lle Vacheron-Trystram, Fran&ccedil;oise Cornic, Rapha&euml;l Gourevitch. 2010. Prise en charge des &eacute;tats dangereux des pathologies mentales graves. , 97-152. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/B978-2-294-71205-0.50005-X" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">487</p><p class="content">David B. Allison, Antony D. Loebel, Ilise Lombardo, Steven J. Romano, Cynthia O. Siu. (2009) Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: Effect modification or regression to the mean?. <i><span class="NLM_source">Psychiatry Research</span></i> <b>170</b>:2-3, 172-176<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psychres.2008.10.007" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">488</p><p class="content">Mark Helfand, Sergio A. Aguilar-Gaxiola, Harry P. Selker. (2009) Comparative Effectiveness Research: An Approach to Avoiding &acirc;Overgeneralized Medicine&acirc;. <i><span class="NLM_source">Clinical and Translational Science</span></i> <b>2</b>:6, 444-445<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1752-8062.2009.00158.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">489</p><p class="content">James Bowes Kirkbride, Linda Scoriels. (2009) Review of the 6th symposium for the search for the causes of schizophrenia, Sao Paulo, Brazil, 3–6 February 2009. <i><span class="NLM_source">European Archives of Psychiatry and Clinical Neuroscience</span></i> <b>259</b>:8, 505-509<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00406-009-0025-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">490</p><p class="content">J.P. Lindenmayer, Isabella Kanellopoulou. (2009) Schizophrenia with Impulsive and Aggressive Behaviors. <i><span class="NLM_source">Psychiatric Clinics of North America</span></i> <b>32</b>:4, 885-902<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psc.2009.08.006" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">491</p><p class="content">Jae Kennedy, Yu Yu Tien, Lawrence J. Cohen, David Alexander Sclar, Darren Liu, Elizabeth G. Blodgett, Josh Engle. (2009) The association between class of antipsychotic and rates of hospitalization: Results of a retrospective analysis of data from the 2005 medicare current beneficiary survey. <i><span class="NLM_source">Clinical Therapeutics</span></i> <b>31</b>:12, 2931-2939<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.clinthera.2009.12.017" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">492</p><p class="content">Lieuwe Appel, Yona Geffen, Kerstin Heurling, Catarina Eriksson, Gunnar Antoni, Shitij Kapur. (2009) BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>19</b>:12, 841-850<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2009.07.009" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">493</p><p class="content">Palmiero Monteleone, Vassilis Martiadis, Mario Maj. (2009) Management of Schizophrenia with Obesity, Metabolic, and Endocrinological Disorders. <i><span class="NLM_source">Psychiatric Clinics of North America</span></i> <b>32</b>:4, 775-794<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psc.2009.08.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">494</p><p class="content">Stephen B Woolley, Alex A Cardoni, John W Goethe. (2009) Last-Observation-Carried-Forward Imputation Method in Clinical Efficacy Trials: Review of 352 Antidepressant Studies. <i><span class="NLM_source">Pharmacotherapy</span></i> <b>29</b>:12, 1408-1416<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1592/phco.29.12.1408" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">495</p><p class="content">Arman Danielyan, Henry A. Nasrallah. (2009) Neurological Disorders in Schizophrenia. <i><span class="NLM_source">Psychiatric Clinics of North America</span></i> <b>32</b>:4, 719-757<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psc.2009.08.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">496</p><p class="content">Robert Bod&eacute;n, Arvo Haenni, Leif Lindstr&ouml;m, Johan Sundstr&ouml;m. (2009) Biochemical risk factors for development of obesity in first-episode schizophrenia. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>115</b>:2-3, 141-145<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2009.09.024" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">497</p><p class="content">Robyn Flaum Cruz. (2009) Validity of the Movement Psychodiagnostic Inventory: A Pilot Study. <i><span class="NLM_source">American Journal of Dance Therapy</span></i> <b>31</b>:2, 122-135<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s10465-009-9072-4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">498</p><p class="content">Mauricio Tohen, Jennifer Sniadecki, Virginia K. Sutton, Elisabeth K. Degenhardt, Jamie L. Karagianis, Doron Sagman, Jennie G. Jacobson. (2009) Number Needed to Treat or Harm Analyses of Olanzapine for Maintenance Treatment of Bipolar Disorder. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>29</b>:6, 520-528<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e3181bfe128" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">499</p><p class="content">Chao-Cheng Lin, Ya-Mei Bai, Ying-Chieh Wang, Tzu-Ting Chen, I-Ching Lai, Jen-Yeu Chen, Shiow-Yi Chen, Susan S.F. Gau, Ying-Jay Liou. (2009) Improved Body Weight and Metabolic Outcomes in Overweight or Obese Psychiatric Patients Switched to Amisulpride From Other Atypical Antipsychotics. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>29</b>:6, 529-536<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e3181bf613e" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">500</p><p class="content">J Christopher Perry, Michael Bond. (2009) The Sequence of Recovery in Long-Term Dynamic Psychotherapy. <i><span class="NLM_source">The Journal of Nervous and Mental Disease</span></i> <b>197</b>:12, 930-937<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/NMD.0b013e3181c29a0f" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">501</p><p class="content">C. J. Bushe, A. J. Bradley, S. Doshi, J. Karagianis. (2009) Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies. <i><span class="NLM_source">International Journal of Clinical Practice</span></i> <b>63</b>:12, 1743-1761<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1742-1241.2009.02224.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">502</p><p class="content">Andrew J Cutler. (2009) Iloperidone: a new option for the treatment of schizophrenia. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>9</b>:12, 1727-1741<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/ern.09.119" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">503</p><p class="content">Leslie Citrome, Christopher Reist, Liisa Palmer, Leslie B. Montejano, Gregory Lenhart, Brian Cuffel, James Harnett, Kafi N. Sanders. (2009) Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>115</b>:2-3, 115-120<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2009.09.023" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">504</p><p class="content">Somaia Mohamed, Robert Rosenheck, Ilan Harpaz-Rotem, Douglas Leslie, Michael J. Sernyak. (2009) Duration of Pharmacotherapy with Long-Acting Injectable Risperidone in the Treatment of Schizophrenia. <i><span class="NLM_source">Psychiatric Quarterly</span></i> <b>80</b>:4, 241-249<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11126-009-9111-9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">505</p><p class="content">P&aring;l Gjerden, Lars Sl&oslash;rdal, J&oslash;rgen G. Bramness. (2009) Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. <i><span class="NLM_source">European Journal of Clinical Pharmacology</span></i> <b>65</b>:12, 1229-1235<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00228-009-0696-6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">506</p><p class="content">Jonathan M. Meyer, Joseph P. McEvoy, Vicki G. Davis, Donald C. Goff, Henry A. Nasrallah, Sonia M. Davis, John K. Hsiao, Marvin S. Swartz, T. Scott Stroup, Jeffrey A. Lieberman. (2009) Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. <i><span class="NLM_source">Biological Psychiatry</span></i> <b>66</b>:11, 1013-1022<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.biopsych.2009.06.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">507</p><p class="content">Greg C. Smith, Mark H. Vickers, Emmanuelle Cognard, Peter R. Shepherd. (2009) Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: Implications for glucose metabolism and food choice behaviour. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>115</b>:1, 30-40<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2009.07.011" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">508</p><p class="content">Benoit Labonte, Francis Rodriguez Bambico, Gabriella Gobbi. (2009) Potentiation of excitatory serotonergic responses by MK-801 in the medial prefrontal cortex. <i><span class="NLM_source">Naunyn-Schmiedeberg's Archives of Pharmacology</span></i> <b>380</b>:5, 383-397<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00210-009-0446-4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">509</p><p class="content">Hugh M. Marston, Jared W. Young, Frederic D. C. Martin, Kevin A. Serpa, Christopher L. Moore, Erik H. F. Wong, Lisa Gold, Leonard T. Meltzer, Marc R. Azar, Mark A. Geyer, Mohammed Shahid. (2009) Asenapine effects in animal models of psychosis and cognitive function. <i><span class="NLM_source">Psychopharmacology</span></i> <b>206</b>:4, 699-714<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-009-1570-z" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">510</p><p class="content">Mark Vanelli, Alex Pedan, Nan Liu, Jennifer Hoar, Denise Messier, Keith Kiarsis. (2009) The role of patient inexperience in medication discontinuation: A retrospective analysis of medication nonpersistence in seven chronic illnesses. <i><span class="NLM_source">Clinical Therapeutics</span></i> <b>31</b>:11, 2628-2652<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.clinthera.2009.11.028" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">511</p><p class="content">M. X. Patel, M. Taylor, A. S. David. (2009) Antipsychotic long-acting injections: mind the gap. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>195</b>:52, S1-S4<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.195.52.s1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">512</p><p class="content">Herbert Y. Meltzer, Argyris Dritselis, Uma Yasothan, Peter Kirkpatrick. (2009) Asenapine. <i><span class="NLM_source">Nature Reviews Drug Discovery</span></i> <b>8</b>:11, 843-844<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/nrd3027" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">513</p><p class="content">S. Moritz, R. Veckenstedt, S. Randjbar, B. Hottenrott, T. S. Woodward, F. V. v. Eckstaedt, C. Schmidt, L. Jelinek, T. M. Lincoln. (2009) Decision making under uncertainty and mood induction: further evidence for liberal acceptance in schizophrenia. <i><span class="NLM_source">Psychological Medicine</span></i> <b>39</b>:11, 1821<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S0033291709005923" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">514</p><p class="content">Hans-J&uuml;rgen M&ouml;ller. (2009) Is evidence sufficient for evidence-based medicine?. <i><span class="NLM_source">European Archives of Psychiatry and Clinical Neuroscience</span></i> <b>259</b>:S2, 167-172<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00406-009-0048-7" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">515</p><p class="content">Kuan-Pin Su, Hui-Chih Chang, Shih-Jen Tsai, Feng-Chang Yen, Chao-Hsiun Tang. (2009) Relapse and Long-Acting Injectable Risperidone: A 1-Year Mirror Image Study with a National Claims Database in Taiwan. <i><span class="NLM_source">Value in Health</span></i> <b>12</b>, S118-S121<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1524-4733.2009.00643.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">516</p><p class="content">M. Moscarelli. (2009) Passive and Active Schizophrenia: Toward a New Descriptive Micropsychopathology. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>35</b>:6, 1183-1196<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbn057" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">517</p><p class="content">David L. Penn, Richard S.E. Keefe, Sonia M. Davis, Piper S. Meyer, Diana O. Perkins, Diane Losardo, Jeffrey A. Lieberman. (2009) The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>115</b>:1, 17-23<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2009.08.016" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">518</p><p class="content">P. M. Haddad, M. Taylor, O. S. Niaz. (2009) First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>195</b>:52, S20-S28<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.195.52.s20" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">519</p><p class="content">Chad A. Noggle, Raymond S. Dean. (2009) Atypical and typical antipsychotics in the schools. <i><span class="NLM_source">Psychology in the Schools</span></i> <b>46</b>:9, 869-884<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/pits.20427" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">520</p><p class="content">D. Taylor. (2009) Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>195</b>:52, S13-S19<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.195.52.s13" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">521</p><p class="content">David D. Dore, Amal N. Trivedi, Vincent Mor, Joseph H. Friedman, Kate L. Lapane. (2009) Atypical antipsychotic use and risk of fracture in persons with Parkinsonism. <i><span class="NLM_source">Movement Disorders</span></i> <b>24</b>:13, 1941-1948<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/mds.22679" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">522</p><p class="content">Ichiro M Omori, Jijun Wang, Bernardo Soares, Mark Fenton, Ichiro M Omori. 2009. Sulpiride versus other antipsychotics for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD008126" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">523</p><p class="content">Steven G. Potkin, Peter J. Weiden, Antony D. Loebel, Lewis E. Warrington, Eric J. Watsky, Cynthia O. Siu. (2009) Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. <i><span class="NLM_source">The International Journal of Neuropsychopharmacology</span></i> <b>12</b>:09, 1233<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S1461145709000352" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">524</p><p class="content">Alessandro Rossi, Anna Bagal&agrave;, Vincenzo Del Curatolo, Francesco Scapati, Micaela Maria Bernareggi, Maria Grazia Giustra, . (2009) Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. <i><span class="NLM_source">Human Psychopharmacology: Clinical and Experimental</span></i> <b>24</b>:7, 574-583<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/hup.1067" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">525</p><p class="content">Michelle Y. Deng, Gr&aacute;inne M. McAlonan, Charlton Cheung, Cindy P. Y. Chiu, Chi W. Law, Vinci Cheung, Pak C. Sham, Eric Y. H. Chen, Siew E. Chua. (2009) A naturalistic study of grey matter volume increase after early treatment in anti-psychotic na&iuml;ve, newly diagnosed schizophrenia. <i><span class="NLM_source">Psychopharmacology</span></i> <b>206</b>:3, 437-446<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-009-1619-z" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">526</p><p class="content">Coleman Gross, Christine M. Blasey, Robert L. Roe, Kate Allen, Thaddeus S. Block, Joseph K. Belanoff. (2009) Mifepristone treatment of olanzapine-induced weight gain in healthy men. <i><span class="NLM_source">Advances in Therapy</span></i> <b>26</b>:10, 959-969<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s12325-009-0070-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">527</p><p class="content">S. Leucht, W. Kissling, J. M. Davis. (2009) Second-generation antipsychotics for schizophrenia: can we resolve the conflict?. <i><span class="NLM_source">Psychological Medicine</span></i> <b>39</b>:10, 1591<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S0033291709005455" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">528</p><p class="content">Silvio Garattini, Vittorio Bertele’. (2009) Ethics in clinical research. <i><span class="NLM_source">Journal of Hepatology</span></i> <b>51</b>:4, 792-797<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jhep.2009.07.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">529</p><p class="content">Sh&ocirc;n Lewis. (2009) Second-generation antipsychotics: a therapeutic downturn?. <i><span class="NLM_source">Psychological Medicine</span></i> <b>39</b>:10, 1603<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S0033291709990882" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">530</p><p class="content">Larry Davidson, Robert E. Drake, Timothy Schmutte, Thomas Dinzeo, Raquel Andres-Hyman. (2009) Oil and Water or Oil and Vinegar? Evidence-Based Medicine Meets Recovery. <i><span class="NLM_source">Community Mental Health Journal</span></i> <b>45</b>:5, 323-332<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s10597-009-9228-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">531</p><p class="content">Ana Alkelai, Lior Greenbaum, Amihai Rigbi, Kyra Kanyas, Bernard Lerer. (2009) Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. <i><span class="NLM_source">Psychopharmacology</span></i> <b>206</b>:3, 491-499<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-009-1627-z" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">532</p><p class="content">Kayvon Salimi, L. Fredrik Jarskog, Jeffrey A. Lieberman. (2009) Antipsychotic Drugs for First-Episode Schizophrenia. <i><span class="NLM_source">CNS Drugs</span></i> <b>23</b>:10, 837-855<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/11314280-000000000-00000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">533</p><p class="content">Raffaella Molteni, Francesca Calabrese, Giorgio Racagni, Fabio Fumagalli, Marco Andrea Riva. (2009) Antipsychotic drug actions on gene modulation and signaling mechanisms. <i><span class="NLM_source">Pharmacology &amp; Therapeutics</span></i> <b>124</b>:1, 74-85<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pharmthera.2009.06.001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">534</p><p class="content">Samuel I. Miles. 2009. Psychopharmacology. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9780470061589.fsa305" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">535</p><p class="content">D. Sailer, T. Ninke, F. Brettner. (2009) Erstmanifestation eines Diabetes mellitus nach Clozapin-Einnahme. <i><span class="NLM_source">Intensivmedizin und Notfallmedizin</span></i> <b>46</b>:6, 447-449<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00390-008-0024-x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">536</p><p class="content">Avril Pereira, George Fink, Suresh Sundram. (2009) Clozapine-Induced ERK1 and ERK2 Signaling in Prefrontal Cortex Is Mediated by the EGF Receptor. <i><span class="NLM_source">Journal of Molecular Neuroscience</span></i> <b>39</b>:1-2, 185-198<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s12031-009-9188-5" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">537</p><p class="content">J. Parks, A. Radke, G. Parker, M.-E. Foti, R. Eilers, M. Diamond, D. Svendsen, R. Tandon. (2009) Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>35</b>:5, 931-936<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbn019" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">538</p><p class="content">Siegfried Kasper, Elena Akimova, Martin Fink, Rupert Lanzenberger. 2009. Maintenance pharmacotherapy in schizophrenia. , 174-184. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/9781420080063.015" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">539</p><p class="content">&Aacute;gnes M&eacute;sz&aacute;ros, P&aacute;l Czobor, S&aacute;ra B&aacute;lint, Sarolta Koml&oacute;si, Vikt&oacute;ria Simon, Istv&aacute;n Bitter. (2009) Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. <i><span class="NLM_source">The International Journal of Neuropsychopharmacology</span></i> <b>12</b>:08, 1137<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S1461145709990198" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">540</p><p class="content">S. Gentile. (2009) Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. <i><span class="NLM_source">Obesity Reviews</span></i> <b>10</b>:5, 527-542<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1467-789X.2009.00589.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">541</p><p class="content">Marianne Ulcickas Yood, Gerald deLorenze, Charles P. Quesenberry, Susan A. Oliveria, Ai-Lin Tsai, Vincent J. Willey, Robert McQuade, John Newcomer, Gilbert L'Italien. (2009) The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study. <i><span class="NLM_source">Pharmacoepidemiology and Drug Safety</span></i> <b>18</b>:9, 791-799<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/pds.1781" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">542</p><p class="content">J. Naudin, D. Dassa, M. Cermolacce. (2009) La compliance aux antipsychotiques d’action prolong&eacute;e&nbsp;: d’un probl&egrave;me d’image &agrave; une question d’indication. <i><span class="NLM_source">L'Enc&eacute;phale</span></i> <b>35</b>:4, 315-320<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.encep.2008.09.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">543</p><p class="content">Stefan Leucht, Caroline Corves, Werner Kissling, John M Davis. 2009. An update of meta-analyses on second-generation antipsychotic drugs for schizophrenia. , 164-173. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/9781420080063.014" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">544</p><p class="content">Antonio R. Sa, Ana G. Hounie, Aline S. Sampaio, Jony Arrais, Euripedes C. Miguel, Helio Elkis. (2009) Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. <i><span class="NLM_source">Comprehensive Psychiatry</span></i> <b>50</b>:5, 437-442<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.comppsych.2008.11.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">545</p><p class="content">Martin Knapp, Denise Razzouk. 2009. Economic evaluation and schizophrenia. , 347-361. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/9781420080063.028" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">546</p><p class="content">Felicity Ng, Oommen K Mammen, Ingeborg Wilting, Gary S Sachs, I Nicol Ferrier, Frederick Cassidy, Serge Beaulieu, Lakshmi N Yatham, Michael Berk. (2009) The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. <i><span class="NLM_source">Bipolar Disorders</span></i> <b>11</b>:6, 559-595<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1399-5618.2009.00737.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">547</p><p class="content">Robert R Conley. 2009. Evaluation and medication therapy for treatment resistance in schizophrenia. , 185-200. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/9781420080063.016" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">548</p><p class="content">M. De Hert, J.M. Dekker, D. Wood, K.G. Kahl, R.I.G. Holt, H.-J. M&ouml;ller. (2009) Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). <i><span class="NLM_source">European Psychiatry</span></i> <b>24</b>:6, 412-424<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.eurpsy.2009.01.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">549</p><p class="content">Jamie Karagianis, Richard Williams, Lori Davis, Ric Procyshyn, Neerav Monga, James Hanley, Ranjith Chandrasena, Aruna Thakur, Ruth Dickson. (2009) Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>25</b>:9, 2121-2132<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/03007990903102966" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">550</p><p class="content">Juliane Weber, Paul L. McCormack. (2009) Asenapine. <i><span class="NLM_source">CNS Drugs</span></i> <b>23</b>:9, 781-792<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/11200860-000000000-00000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">551</p><p class="content">J. M. Olivares, J. Peuskens, J. Pecenak, S. Resseler, A. Jacobs, K. S. Akhras. (2009) Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>25</b>:9, 2197-2206<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/03007990903149306" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">552</p><p class="content">Stefan Weinmann, John Read, Volkmar Aderhold. (2009) Influence of antipsychotics on mortality in schizophrenia: Systematic review. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>113</b>:1, 1-11<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2009.05.018" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">553</p><p class="content">Narayana Manjunatha, Sahoo Saddichha. (2009) Clinical Antipsychotic Trials of Intervention Effectiveness Study. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>29</b>:4, 410-411<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e3181acea2e" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">554</p><p class="content">Anthony P. Morrison. (2009) Cognitive behaviour therapy for first episode psychosis: Good for nothing or fit for purpose?. <i><span class="NLM_source">Psychosis</span></i> <b>1</b>:2, 103-112<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/17522430903026393" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">555</p><p class="content">Stephanie Aldebot, Amy G. Weisman de Mamani. (2009) Denial and Acceptance Coping Styles and Medication Adherence in Schizophrenia. <i><span class="NLM_source">The Journal of Nervous and Mental Disease</span></i> <b>197</b>:8, 580-584<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/NMD.0b013e3181b05fbe" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">556</p><p class="content">Diego Novick, Josep Maria Haro, Elena Perrin, David Suarez, Jo&atilde;o Marques Texeira. (2009) Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>19</b>:8, 542-550<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2009.03.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">557</p><p class="content">Kotaro Hatta, Koji Sato, Hiroshi Hamakawa, Hiroshi Takebayashi, Naoto Kimura, Shinichiro Ochi, Yasuhiko Sudo, Nozomu Asukai, Hiroyuki Nakamura, Chie Usui, Toshitaka Kawabata, Toyoaki Hirata, Yutaka Sawa. (2009) Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>113</b>:1, 49-55<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2009.05.030" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">558</p><p class="content">Leslie Citrome. (2009) Using oral ziprasidone effectively: the food effect and dose-response. <i><span class="NLM_source">Advances in Therapy</span></i> <b>26</b>:8, 739-748<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s12325-009-0055-0" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">559</p><p class="content">Joshua Kantrowitz, Leslie Citrome, Daniel Javitt. (2009) GABAB Receptors, Schizophrenia and Sleep Dysfunction. <i><span class="NLM_source">CNS Drugs</span></i> <b>23</b>:8, 681-691<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200923080-00005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">560</p><p class="content">Emilio Sacchetti, Alessandro Galluzzo, Paolo Valsecchi, Fabio Romeo, Barbara Gorini, Lewis Warrington. (2009) Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>113</b>:1, 112-121<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2009.05.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">561</p><p class="content">Jari Tiihonen, Jouko L&ouml;nnqvist, Kristian Wahlbeck, Timo Klaukka, Leo Niskanen, Antti Tanskanen, Jari Haukka. (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). <i><span class="NLM_source">The Lancet</span></i> <b>374</b>:9690, 620-627<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0140-6736(09)60742-X" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">562</p><p class="content">T. Wobrock, J. K&ouml;hler, P. Klein, P. Falkai. (2009) Achieving symptomatic remission in out-patients with schizophrenia - a naturalistic study with quetiapine. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>120</b>:2, 120-128<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2009.01379.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">563</p><p class="content">C Lavedan, L Licamele, S Volpi, J Hamilton, C Heaton, K Mack, R Lannan, A Thompson, C D Wolfgang, M H Polymeropoulos. (2009) Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>14</b>:8, 804-819<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/mp.2008.56" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">564</p><p class="content">Robert A. Rosenheck, Vicki G. Davis, Sonia M. Davis, Scott Stroup, Joseph McEvoy, Marvin Swartz, Jeffrey Lieberman. (2009) Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>113</b>:1, 12-18<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2009.06.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">565</p><p class="content">Trina Webb, Rajiv Tandon. (2009) Antipsychotic treatment of first-episode or early-onset schizophrenia. <i><span class="NLM_source">Current Psychiatry Reports</span></i> <b>11</b>:4, 261-263<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11920-009-0050-9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">566</p><p class="content">J. Karagianis, L. Grossman, J. Landry, V.A. Reed, L. de Haan, G.A. Maguire, V.P. Hoffmann, R. Milev. (2009) A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS Study. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>113</b>:1, 41-48<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2009.05.024" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">567</p><p class="content">Ying-Ching Lai, Ming-Chyi Huang, Chun-Hsin Chen, Chang-Jer Tsai, Chun-Hung Pan, Chih-Chiang Chiu. (2009) Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders. <i><span class="NLM_source">Psychiatry and Clinical Neurosciences</span></i> <b>63</b>:4, 440-448<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1440-1819.2009.01977.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">568</p><p class="content">J. Moncrieff, D. Cohen, J. P. Mason. (2009) The subjective experience of taking antipsychotic medication: a content analysis of Internet data. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>120</b>:2, 102-111<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2009.01356.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">569</p><p class="content">Wentao Feng, Abdus S. Wahed. (2009) Sample size for two-stage studies with maintenance therapy. <i><span class="NLM_source">Statistics in Medicine</span></i> <b>28</b>:15, 2028-2041<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/sim.3593" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">570</p><p class="content">Isuru Herath Mudiyanselage, Jagannathan Alagarsamy, Sandhya Kachhap, Mahesh B Jayaram, Jagannathan Alagarsamy. 2009. Olanzapine depot for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD007947" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">571</p><p class="content">Anna C Need, Richard SE Keefe, Dongliang Ge, Iris Grossman, Sam Dickson, Joseph P McEvoy, David B Goldstein. (2009) Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. <i><span class="NLM_source">European Journal of Human Genetics</span></i> <b>17</b>:7, 946-957<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/ejhg.2008.264" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">572</p><p class="content">Erica J. Duncan, Sandra L. Woolson, Robert M. Hamer, Boadie W. Dunlop. (2009) Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>24</b>:4, 204-213<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YIC.0b013e32832d6c18" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">573</p><p class="content">Gerald M. Reaven, Jeffrey A. Lieberman, Gopalan Sethuraman, Helena Kraemer, John M. Davis, Christine Blasey, Ming T. Tsuang, Alan F. Schatzberg. (2009) In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. <i><span class="NLM_source">Journal of Psychiatric Research</span></i> <b>43</b>:11, 997-1002<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jpsychires.2009.01.010" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">574</p><p class="content">Leslie Citrome, Joshua T Kantrowitz. (2009) Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>9</b>:7, 1045-1058<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/ern.09.54" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">575</p><p class="content">Hao-Yang Tan, Joseph H. Callicott, Daniel R. Weinberger. (2009) Prefrontal cognitive systems in schizophrenia : Towards human genetic brain mechanisms. <i><span class="NLM_source">Cognitive Neuropsychiatry</span></i> <b>14</b>:4-5, 277-298<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/13546800903091665" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">576</p><p class="content">J. Rabinowitz, S. Z. Levine, O. Barkai, O. Davidov. (2009) Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>35</b>:4, 775-788<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbn005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">577</p><p class="content">Celso Arango, Olalla Robles, Mara Parellada, David Fraguas, Ana Ruiz-Sancho, Oscar Medina, Arantzazu Zabala, Igor Bomb&iacute;n, Dolores Moreno. (2009) Olanzapine compared to quetiapine in adolescents with a first psychotic episode. <i><span class="NLM_source">European Child &amp; Adolescent Psychiatry</span></i> <b>18</b>:7, 418-428<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00787-009-0749-5" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">578</p><p class="content">Andrew P. Yu, Pavel Atanasov, Rym Ben-Hamadi, Howard Birnbaum, Michael D. Stensland, Glenn Philips. (2009) Resource Utilization and Costs of Schizophrenia Patients Treated with Olanzapine versus Quetiapine in a Medicaid Population. <i><span class="NLM_source">Value in Health</span></i> <b>12</b>:5, 708-715<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1524-4733.2008.00498.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">579</p><p class="content">Rakesh Karmacharya, Gregory R Sliwoski, Miriam Y Lundy, Raymond F Suckow, Bruce M Cohen, Edgar A Buttner. (2009) Clozapine Interaction with Phosphatidyl Inositol 3-Kinase (PI3K)/Insulin-Signaling Pathway in Caenorhabditis elegans. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>34</b>:8, 1968-1978<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/npp.2009.35" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">580</p><p class="content">J. Xia, C. Adams, N. Bhagat, V. Bhagat, P. Bhoopathi, H. El-Sayeh, V. Pinfold, Y. Takriti. (2009) Losing participants before the trial ends erodes credibility of findings. <i><span class="NLM_source">Psychiatric Bulletin</span></i> <b>33</b>:7, 254-257<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/pb.bp.108.021949" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">581</p><p class="content">Chang Yoon Kim, Seockhoon Chung, Joon-Noh Lee, Jun Soo Kwon, Do Hoon Kim, Chul Eung Kim, Bumseok Jeong, Yang-Whan Jeon, Min-Soo Lee, Tae-Youn Jun, Hee-Yeon Jung. (2009) A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>24</b>:4, 181-188<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YIC.0b013e32832c25d7" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">582</p><p class="content">Richard I. G. Holt, Robert C. Peveler. (2009) Obesity, serious mental illness and antipsychotic drugs. <i><span class="NLM_source">Diabetes, Obesity and Metabolism</span></i> <b>11</b>:7, 665-679<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1463-1326.2009.01038.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">583</p><p class="content">Rosalinda C. Roberts, Joy K. Roche, Robert R. Conley, Adrienne C. Lahti. (2009) Dopaminergic synapses in the caudate of subjects with schizophrenia: Relationship to treatment response. <i><span class="NLM_source">Synapse</span></i> <b>63</b>:6, 520-530<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/syn.20623" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">584</p><p class="content">Lisa J Miller. (2009) Management of Atypical Antipsychotic Drug–Induced Weight Gain: Focus on Metformin. <i><span class="NLM_source">Pharmacotherapy</span></i> <b>29</b>:6, 725-735<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1592/phco.29.6.725" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">585</p><p class="content">Kalman Applbaum. (2009) Getting to Yes: Corporate Power and the Creation of a Psychopharmaceutical Blockbuster. <i><span class="NLM_source">Culture, Medicine, and Psychiatry</span></i> <b>33</b>:2, 185-215<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11013-009-9129-3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">586</p><p class="content">Gary Remington. (2009) From mice to men: What can animal models tell us about the relationship between mental health and physical activity?. <i><span class="NLM_source">Mental Health and Physical Activity</span></i> <b>2</b>:1, 10-15<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.mhpa.2009.01.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">587</p><p class="content">Dieter Naber, Martin Lambert. (2009) The CATIE and CUtLASS Studies in Schizophrenia. <i><span class="NLM_source">CNS Drugs</span></i> <b>PAP</b>, <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200923080-00002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">588</p><p class="content">William Coryell. (2009) Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice. <i><span class="NLM_source">Bipolar Disorders</span></i> <b>11</b>, 77-83<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1399-5618.2009.00712.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">589</p><p class="content">M. JONES, J. WHITE, R. GRAY. (2009) Partial agonists and schizophrenia: theoretical developments for the development of mental health nursing. <i><span class="NLM_source">Journal of Psychiatric and Mental Health Nursing</span></i> <b>16</b>:5, 409-415<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2850.2009.01373.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">590</p><p class="content">Anthony H. Barnett, Helen L. Millar, Jean-Yves Loze, Gilbert J. l’Italien, Marc Baardewijk, Martin Knapp. (2009) UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). <i><span class="NLM_source">European Archives of Psychiatry and Clinical Neuroscience</span></i> <b>259</b>:4, 239-247<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00406-008-0863-2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">591</p><p class="content">Russell L. Margolis. (2009) Neuropsychiatric disorders: The choice of antipsychotics in schizophrenia. <i><span class="NLM_source">Nature Reviews Neurology</span></i> <b>5</b>:6, 308-310<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/nrneurol.2009.68" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">592</p><p class="content">Thomas S. Marshall, Jeffery S. McCombs, Dana Stafkey-Mailey. (2009) Impact of Patient Selection Criteria and Treatment History on Comparisons of Alternative Therapies: A Case Study of Atypical Antipsychotics. <i><span class="NLM_source">Value in Health</span></i> <b>12</b>:4, 473-480<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1524-4733.2008.00458.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">593</p><p class="content">C C Zai, A K Tiwari, V Basile, V De Luca, D J M&uuml;ller, N King, A N Voineskos, G Remington, H Y Meltzer, J A Lieberman, S G Potkin, J L Kennedy. (2009) Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. <i><span class="NLM_source">The Pharmacogenomics Journal</span></i> <b>9</b>:3, 168-174<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/tpj.2009.2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">594</p><p class="content">Jordi Alonso, Tim Croudace, Jacqueline Brown, Isabelle Gasquet, Martin R.J. Knapp, David Su&aacute;rez, Diego Novick. (2009) Health-Related Quality of Life (HRQL) and Continuous Antipsychotic Treatment: 3-year Results from the Schizophrenia Health Outcomes (SOHO) Study. <i><span class="NLM_source">Value in Health</span></i> <b>12</b>:4, 536-543<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1524-4733.2008.00495.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">595</p><p class="content">J.M. Olivares, A. Rodriguez-Morales, J. Diels, M. Povey, A. Jacobs, Z. Zhao, A. Lam. (2009) Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). <i><span class="NLM_source">European Psychiatry</span></i> <b>24</b>:5, 287-296<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.eurpsy.2008.12.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">596</p><p class="content">J. Palazzolo. (2009) Observance m&eacute;dicamenteuse et rechutes dans la schizophr&eacute;nie&nbsp;: des neuroleptiques classiques aux APAP. <i><span class="NLM_source">Annales M&eacute;dico-psychologiques, revue psychiatrique</span></i> <b>167</b>:4, 308-317<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.amp.2009.03.009" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">597</p><p class="content">Darleen A. Sandoval, Silvana Obici, Randy J. Seeley. (2009) Targeting the CNS to treat type 2 diabetes. <i><span class="NLM_source">Nature Reviews Drug Discovery</span></i> <b>8</b>:5, 386-398<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/nrd2874" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">598</p><p class="content">Steven M. Grauer, Radka Graf, Rachel Navarra, Amy Sung, Sheree F. Logue, Gary Stack, Christine Huselton, Zhi Liu, Thomas A. Comery, Karen L. Marquis, Sharon Rosenzweig-Lipson. (2009) WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics. <i><span class="NLM_source">Psychopharmacology</span></i> <b>204</b>:1, 37-48<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-008-1433-z" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">599</p><p class="content">Chadi A. Calarge, Vicki L. Ellingrod, Laura Acion, Del D. Miller, Jessica Moline, Michael J. Tansey, Janet A. Schlechte. (2009) Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. <i><span class="NLM_source">Pharmacogenetics and Genomics</span></i> <b>19</b>:5, 373-382<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/FPC.0b013e328329a60f" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">600</p><p class="content">M. Weber, M. Breier, D. Ko, N. Thangaraj, D. E. Marzan, N. R. Swerdlow. (2009) Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. <i><span class="NLM_source">Psychopharmacology</span></i> <b>203</b>:4, 723-735<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-008-1419-x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">601</p><p class="content">Rajeev Kumar, Perminder S Sachdev. (2009) Akathisia and second-generation antipsychotic drugs. <i><span class="NLM_source">Current Opinion in Psychiatry</span></i> <b>22</b>:3, 293-299<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YCO.0b013e32832a16da" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">602</p><p class="content">Hongyu Zhao, Zongru Guo. (2009) Medicinal chemistry strategies in follow-on drug discovery. <i><span class="NLM_source">Drug Discovery Today</span></i> <b>14</b>:9-10, 516-522<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.drudis.2009.02.008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">603</p><p class="content">Sirijit Suttajit, Manit Srisurapanont, Benchalak Maneeton, Narong Maneeton, Siritree Suttajit, Sirijit Suttajit. 2009. Quetiapine versus typical antipsychotic medications for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD007815" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">604</p><p class="content">Katja Komossa, Christine Rummel-Kluge, Heike Hunger, Sandra Schwarz, Franziska Schmid, Ruth Lewis, Werner Kissling, Stefan Leucht, Katja Komossa. 2009. Sertindole versus other atypical antipsychotics for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD006752.pub2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">605</p><p class="content">Friederike Vogel, Reinhard Gansm&uuml;ller, Thomas Leiblein, Otto Dietmaier, Hans Wassmuth, Gerhard Gr&uuml;nder, Christoph Hiemke. (2009) The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. <i><span class="NLM_source">European Psychiatry</span></i> <b>24</b>:3, 143-148<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.eurpsy.2008.09.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">606</p><p class="content">David B. Allison, John W. Newcomer, Andrea L. Dunn, James A. Blumenthal, Anthony N. Fabricatore, Gail L. Daumit, Mark B. Cope, William T. Riley, Betty Vreeland, Joseph R. Hibbeln, Jonathan E. Alpert. (2009) Obesity Among Those with Mental Disorders. <i><span class="NLM_source">American Journal of Preventive Medicine</span></i> <b>36</b>:4, 341-350<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.amepre.2008.11.020" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">607</p><p class="content">C. E. Dean, P. D. Thuras. (2009) Mortality and tardive dyskinesia: long-term study using the US National Death Index. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>194</b>:4, 360-364<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.bp.108.049395" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">608</p><p class="content">Mehmet Ozbilen, Clive E. Adams. (2009) Systematic Overview of Cochrane Reviews for Anticholinergic Effects of Antipsychotic Drugs. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>29</b>:2, 141-146<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e31819a91f1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">609</p><p class="content">J. Peuskens, B. Gillain, D. De Graeve, B. Van Vleymen, A. Albert. (2009) Belgian Schizophrenia Outcome Survey – Results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. <i><span class="NLM_source">European Psychiatry</span></i> <b>24</b>:3, 154-163<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.eurpsy.2008.11.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">610</p><p class="content">S Leucht, D Arbter, R R Engel, W Kissling, J M Davis. (2009) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>14</b>:4, 429-447<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.mp.4002136" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">611</p><p class="content">Thomas R. Insel. (2009) Disruptive insights in psychiatry: transforming a clinical discipline. <i><span class="NLM_source">Journal of Clinical Investigation</span></i> <b>119</b>:4, 700-705<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1172/JCI38832" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">612</p><p class="content">James L. Roerig, Kristine J. Steffen, James E. Mitchell, Ross D. Crosby, Blake A. Gosnell. (2009) An Exploration of the Effect of Modafinil on Olanzapine Associated Weight Gain in Normal Human Subjects. <i><span class="NLM_source">Biological Psychiatry</span></i> <b>65</b>:7, 607-613<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.biopsych.2008.10.037" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">613</p><p class="content">Cristina Rodr&iacute;guez-Antona, David Gurwitz, Jose de Leon, Adri&aacute;n Llerena, Julia Kirchheiner, Emma Guti&eacute;rrez de Mesa, Dolores Ibarreta. (2009) <i>CYP2D6</i> genotyping for psychiatric patients treated with risperidone: considerations for cost–effectiveness studies. <i><span class="NLM_source">Pharmacogenomics</span></i> <b>10</b>:4, 685-699<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/pgs.09.15" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">614</p><p class="content">David A. Lewis, Robert A. Sweet. (2009) Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. <i><span class="NLM_source">Journal of Clinical Investigation</span></i> <b>119</b>:4, 706-716<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1172/JCI37335" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">615</p><p class="content">A. W. MacDonald, S. C. Schulz. (2009) What We Know: Findings That Every Theory of Schizophrenia Should Explain. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>35</b>:3, 493-508<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbp017" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">616</p><p class="content">Ya-Mei Bai, Jen-Yeu Chen, Tzu-Ting Chen, Chih-Yuan Lin, Pesus Chou, Tung-Ping Su, Chao-Cheng Lin. (2009) Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>108</b>:1-3, 122-126<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2008.10.023" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">617</p><p class="content">Grigori Joffe, Viatcheslav Terevnikov, Marina Joffe, Jan-Henry Stenberg, Mark Burkin, Jari Tiihonen. (2009) Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: A double-blind, randomized, placebo-controlled trial. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>108</b>:1-3, 245-251<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2008.12.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">618</p><p class="content">Diego Novick, Josep Maria Haro, David Suarez, Eduard Vieta, Dieter Naber. (2009) Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>108</b>:1-3, 223-230<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2008.11.007" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">619</p><p class="content">Terence V. McCann, Eileen Clark, Sai Lu. (2009) Subjective side effects of antipsychotics and medication adherence in people with schizophrenia. <i><span class="NLM_source">Journal of Advanced Nursing</span></i> <b>65</b>:3, 534-543<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2648.2008.04906.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">620</p><p class="content">Gerhard Gr&uuml;nder, Hanns Hippius, Arvid Carlsson. (2009) The 'atypicality' of antipsychotics: a concept re-examined and re-defined. <i><span class="NLM_source">Nature Reviews Drug Discovery</span></i> <b>8</b>:3, 197-202<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/nrd2806" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">621</p><p class="content">Mihael H. Polymeropoulos, Louis Licamele, Simona Volpi, Kendra Mack, Shruti N. Mitkus, Eugene D. Carstea, Lise Getoor, Andrew Thompson, Christian Lavedan. (2009) Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>108</b>:1-3, 134-142<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2008.11.025" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">622</p><p class="content"> (2009) Misplaced epistemological certainty and pharmaco-centrism in mental health nursing. <i><span class="NLM_source">Journal of Psychiatric and Mental Health Nursing</span></i> <b>16</b>:2, 199-205<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2850.2008.01362.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">623</p><p class="content">Antonio Ciudad, Enric &Aacute;lvarez, Julio Bobes, Luis San, Pepa Polavieja, Inmaculada Gilaberte. (2009) Remission in schizophrenia: Results from a 1-year follow-up observational study. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>108</b>:1-3, 214-222<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2008.12.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">624</p><p class="content">S Le Hellard, F M Theisen, M Haberhausen, M B Raeder, J Fern&oslash;, S Gebhardt, A Hinney, H Remschmidt, J C Krieg, C Mehler-Wex, M M N&ouml;then, J Hebebrand, V M Steen. (2009) Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>14</b>:3, 308-317<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.mp.4002133" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">625</p><p class="content">Andrew P. Yu, Rym Ben-Hamadi, Howard G. Birnbaum, Pavel Atanasov, Michael D. Stensland, Glenn Philips. (2009) Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>25</b>:3, 755-764<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/03007990802683579" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">626</p><p class="content">S. Mohamed, R. Rosenheck, J. McEvoy, M. Swartz, S. Stroup, J. A. Lieberman. (2009) Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>35</b>:2, 336-346<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbn067" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">627</p><p class="content">C. U. Correll, C. Rummel-Kluge, C. Corves, J. M. Kane, S. Leucht. (2009) Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>35</b>:2, 443-457<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbn018" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">628</p><p class="content">Ming Li, Wei He, Alexa Mead. (2009) An investigation of the behavioral mechanisms of antipsychotic action using a drug–drug conditioning paradigm. <i><span class="NLM_source">Behavioural Pharmacology</span></i> <b>20</b>:2, 184-194<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/FBP.0b013e32832a8f66" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">629</p><p class="content">Kang Sim, Hsin Chuan Su, Senta Fujii, Shu-yu Yang, Mian-Yoon Chong, Tianmei Si, Yan Ling He, Eun Kee Chung, Yiong Huak Chan, Naotaka Shinfuku, Chay Hoon Tan, Gabor Ungvari, Ross J. Baldessarini. (2009) Low doses of antipsychotic drugs for hospitalized schizophrenia patients in East Asia: 2004 vs. 2001. <i><span class="NLM_source">The International Journal of Neuropsychopharmacology</span></i> <b>12</b>:01, 117<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S1461145708009280" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">630</p><p class="content">S. Leucht, J. M. Davis, R. R. Engel, W. Kissling, J. M. Kane. (2009) Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>119</b>, 7-14<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2008.01308.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">631</p><p class="content">M. Smith, R. Porter. (2009) Antipsychotics and risk of diabetes in schizophrenia. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>194</b>:2, 186-187<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.194.2.186a" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">632</p><p class="content">Kok Yoon Chee. (2009) Outcome study of first-episode schizophrenia in a developing country: quality of life and antipsychotics. <i><span class="NLM_source">Social Psychiatry and Psychiatric Epidemiology</span></i> <b>44</b>:2, 143-150<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00127-008-0415-0" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">633</p><p class="content">P. E. Bebbington, M. Angermeyer, J.-M. Azorin, S. Marwaha, F. Marteau, M. Toumi. (2009) Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>119</b>, 22-28<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2008.01310.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">634</p><p class="content">Y. von Hausswolff-Juhlin, M. Bjartveit, E. Lindstr&ouml;m, P. Jones. (2009) Schizophrenia and physical health problems. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>119</b>, 15-21<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2008.01309.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">635</p><p class="content">R. Kerwin. (2009) Connecting patient needs with treatment management. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>119</b>, 33-39<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2008.01312.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">636</p><p class="content">John O. Brooks, Hye-Sang Chang, Olya Krasnykh. (2009) Metabolic risks in older adults receiving second-generation antipsychotic medication. <i><span class="NLM_source">Current Psychiatry Reports</span></i> <b>11</b>:1, 33-40<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11920-009-0006-0" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">637</p><p class="content">S. Dollfus. (2009) Les antipsychotiques lors d’un premier &eacute;pisode psychotique. <i><span class="NLM_source">Annales M&eacute;dico-psychologiques, revue psychiatrique</span></i> <b>167</b>:1, 86-92<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.amp.2008.11.015" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">638</p><p class="content">Arzu Gunes, Kristina I. Melkersson, Maria Gabriella Scordo, Marja-Liisa Dahl. (2009) Association Between HTR2C and HTR2A Polymorphisms and Metabolic Abnormalities in Patients Treated With Olanzapine or Clozapine. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>29</b>:1, 65-68<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e31819302c3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">639</p><p class="content">Siow-Ann Chong, Jenny A.M. Tay, Mythily Subramaniam, Elaine Pek, David Machin. (2009) Mortality Rates Among Patients With Schizophrenia and Tardive Dyskinesia. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>29</b>:1, 5-8<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e3181929f94" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">640</p><p class="content">S. Leucht, J. van Os. (2009) Preface: Treatment optimization in schizophrenia through active patient management - proceedings from two European consensus meetings. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>119</b>, 5-6<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2008.01307.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">641</p><p class="content">Stein Opjordsmoen, Ingrid Melle, Svein Friis, Ulrik Haahr, Jan O. Johannessen, Tor K. Larsen, Bj&oslash;rn R. Rund, Erik Simonsen, Per Vaglum, Thomas H. McGlashan. (2009) Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics. <i><span class="NLM_source">Early Intervention in Psychiatry</span></i> <b>3</b>:1, 58-65<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1751-7893.2008.00103.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">642</p><p class="content">Ra&uacute;l de la Flor, Lee A. Dawson. (2009) Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412). <i><span class="NLM_source">Neuropharmacology</span></i> <b>56</b>:2, 342-349<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.neuropharm.2008.09.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">643</p><p class="content">Sagar V Parikh. (2009) Antidepressants are not all created equal. <i><span class="NLM_source">The Lancet</span></i> <b>373</b>:9665, 700-701<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0140-6736(09)60047-7" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">644</p><p class="content">John R. Bola, Klaus Lehtinen, Johan Cullberg, Luc Ciompi. (2009) Psychosocial treatment, antipsychotic postponement, and low‐dose medication strategies in first‐episode psychosis: A review of the literature. <i><span class="NLM_source">Psychosis</span></i> <b>1</b>:1, 4-18<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/17522430802610008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">645</p><p class="content">Schneeweiss, Sebastian, Avorn, Jerry, . (2009) Antipsychotic Agents and Sudden Cardiac Death — How Should We Manage the Risk?. <i><span class="NLM_source">New England Journal of Medicine</span></i> <b>360</b>:3, 294-296<br /><a class="ref nowrap" href="/doi/full/10.1056/NEJMe0809417">Full Text</a> <!-- ${xml_link: 10.1056%2FNEJMe0809417} --></p></li> <li><p class="number">646</p><p class="content">Cherrie Galletly. (2009) Recent advances in treating cognitive impairment in schizophrenia. <i><span class="NLM_source">Psychopharmacology</span></i> <b>202</b>:1-3, 259-273<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-008-1302-9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">647</p><p class="content">Henry Silver, Yael Chertkow, Orly Weinreb, Lena Danovich, Moussa Youdim. (2009) Multifunctional pharmacotherapy: What can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?. <i><span class="NLM_source">Neurotherapeutics</span></i> <b>6</b>:1, 86-93<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.nurt.2008.10.034" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">648</p><p class="content">Pierre Thomas, K&ouml;ksal Alptekin, Mihai Gheorghe, Mauro Mauri, Jos&eacute; Manuel Olivares, Michael Riedel. (2009) Management of Patients Presenting with Acute Psychotic Episodes of Schizophrenia. <i><span class="NLM_source">CNS Drugs</span></i> <b>23</b>:3, 193-212<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200923030-00002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">649</p><p class="content">Josep Maria Haro, Diego Novick, David Suarez, Mercedes Roca. (2009) Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. <i><span class="NLM_source">Journal of Psychiatric Research</span></i> <b>43</b>:3, 265-273<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jpsychires.2008.06.001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">650</p><p class="content">Peter Tyrer, Tim Kendall. (2009) The spurious advance of antipsychotic drug therapy. <i><span class="NLM_source">The Lancet</span></i> <b>373</b>:9657, 4-5<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0140-6736(08)61765-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">651</p><p class="content">Robert A Rosenheck, Sonia Davis, Nancy Covell, Susan Essock, Marvin Swartz, Scott Stroup, Joseph McEvoy, Jeffrey Lieberman. (2009) Does switching to a new antipsychotic improve outcomes?. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>107</b>:1, 22-29<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2008.09.031" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">652</p><p class="content">Joanna M. Wierońska, Andrzej Pilc. (2009) Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. <i><span class="NLM_source">Neurochemistry International</span></i> <b>55</b>:1-3, 85-97<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.neuint.2009.02.019" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">653</p><p class="content">Joaqu&iacute;n Mould-Quevedo, Iris Contreras-Hern&aacute;ndez, W&aacute;scar Verduzco, Juan Manuel Mej&iacute;a-Arangur&eacute;, Juan Gardu&ntilde;o-Espinosa. (2009) Cost-effectiveness simulation analysis of schizophrenia at the Instituto Mexicano del Seguro Social. Assessment of typical and atypical antipsychotics. <i><span class="NLM_source">Revista de Psiquiatr&iacute;a y Salud Mental (English Edition)</span></i> <b>2</b>:3, 108-118<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S2173-5050(09)70041-X" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">654</p><p class="content">R.S. Ehrlichman, M.J. Gandal, C.R. Maxwell, M.T. Lazarewicz, L.H. Finkel, D. Contreras, B.I. Turetsky, S.J. Siegel. (2009) N-methyl-d-aspartic acid receptor antagonist–induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. <i><span class="NLM_source">Neuroscience</span></i> <b>158</b>:2, 705-712<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.neuroscience.2008.10.031" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">655</p><p class="content">Stefan Leucht, Caroline Corves, Dieter Arbter, Rolf R Engel, Chunbo Li, John M Davis. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. <i><span class="NLM_source">The Lancet</span></i> <b>373</b>:9657, 31-41<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0140-6736(08)61764-X" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">656</p><p class="content">Sylvain Grignon, Claire-Anne Gr&eacute;goire, Myriam Durand, Marie Mury, Dominique &Eacute;lie, Jean Marc Chianetta. (2009) Age-dependent discrepancies between computerized and paper cognitive testing in patients with schizophrenia. <i><span class="NLM_source">Social Psychiatry and Psychiatric Epidemiology</span></i> <b>44</b>:1, 73-77<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00127-008-0406-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">657</p><p class="content">Diana Rofail, Rebecca Heelis, Kevin Gournay. (2009) Results of a thematic analysis to explore the experiences of patients with schizophrenia taking antipsychotic medication. <i><span class="NLM_source">Clinical Therapeutics</span></i> <b>31</b>, 1488-1496<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.clinthera.2009.07.001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">658</p><p class="content">Ronald Pies. (2009) Psychotropic Drug Prescriberʼs Survival Guide: Ethical Mental Health Treatment in the Age of Big Pharma. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>15</b>:1, 79-80<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.pra.0000344924.59027.5e" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">659</p><p class="content">Jos&eacute; Manuel Bertol&iacute;n Guill&eacute;n, Enrique Soler Company. (2009) Use of antipsychotics during pregnancy and breastfeeding. <i><span class="NLM_source">Revista de Psiquiatr&iacute;a y Salud Mental (English Edition)</span></i> <b>2</b>:3, 138-145<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S2173-5050(09)70045-7" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">660</p><p class="content">T. Scott Stroup, Jeffrey A. Lieberman, Joseph P. McEvoy, Sonia M. Davis, Marvin S. Swartz, Richard S.E. Keefe, Alexander L. Miller, Robert A. Rosenheck, John K. Hsiao. (2009) Results of phase 3 of the CATIE schizophrenia trial. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>107</b>:1, 1-12<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2008.10.011" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">661</p><p class="content">Steven J. Edwards, Christopher J. Smith. (2009) Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: A mixed treatment comparison of randomized controlled trials. <i><span class="NLM_source">Clinical Therapeutics</span></i> <b>31</b>, 1345-1359<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.clinthera.2009.07.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">662</p><p class="content">Kang Sim, Hsin Chuan Su, Senta Fujii, Shu-yu Yang, Mian-Yoon Chong, Gabor Ungvari, Tianmei Si, Yan Ling He, Eun Kee Chung, Yiong Huak Chan, Naotaka Shinfuku, Ee Heok Kua, Chay Hoon Tan, Norman Sartorius. (2009) High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. <i><span class="NLM_source">British Journal of Clinical Pharmacology</span></i> <b>67</b>:1, 110-117<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2125.2008.03304.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">663</p><p class="content">John A. Baker, Len Bowers, John A. Owiti. (2009) Wards features associated with high rates of medication refusal by patients: a large multi-centred survey. <i><span class="NLM_source">General Hospital Psychiatry</span></i> <b>31</b>:1, 80-89<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.genhosppsych.2008.09.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">664</p><p class="content">Elizabeth T. Kinter, Annette Schmeding, Ina Rudolph, Susan dosReis, John F. P. Bridges. (2009) Identifying patient-relevant endpoints among individuals with schizophrenia: An application of patient-centered health technology assessment. <i><span class="NLM_source">International Journal of Technology Assessment in Health Care</span></i> <b>25</b>:01, 35<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S0266462309090059" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">665</p><p class="content">Rose J. Julius, Mark A. Novitsky, William R. Dubin. (2009) Medication Adherence: A Review of the Literature and Implications for Clinical Practice. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>15</b>:1, 34-44<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.pra.0000344917.43780.77" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">666</p><p class="content">Parthipan Sivaraman, Aloka Mitra, Mahesh B Jayaram, Parthipan Sivaraman. 2009. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002%2F14651858.CD007779" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">667</p><p class="content">Huei-Ting Tsai, Stanley N. Caroff, Del D. Miller, Joseph McEvoy, Jeffrey A. Lieberman, Kari E. North, T. Scott Stroup, Patrick F. Sullivan. (2009) A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. <i><span class="NLM_source">American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</span></i> <b>9999B</b>, n/a-n/a<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/ajmg.b.30981" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">668</p><p class="content">A. Charpentier, M. Goudemand, P. Thomas. (2009) L’alliance th&eacute;rapeutique, un enjeu dans la schizophr&eacute;nie. <i><span class="NLM_source">L Enc&eacute;phale</span></i> <b>35</b>:1, 80<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016%2Fj.encep.2007.12.009" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">669</p><p class="content">L. Citrome. (2009) Olanzapine pamoate: a stick in time?. <i><span class="NLM_source">International Journal of Clinical Practice</span></i> <b>63</b>:1, 140-150<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1742-1241.2008.01900.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">670</p><p class="content">Rima Kaddurah-Daouk, K Ranga Rama Krishnan. (2009) Metabolomics: A Global Biochemical Approach to the Study of Central Nervous System Diseases. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>34</b>:1, 173-186<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/npp.2008.174" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">671</p><p class="content">Samuel Dagogo-Jack. (2009) The role of antipsychotic agents in the development of diabetes mellitus. <i><span class="NLM_source">Nature Clinical Practice Endocrinology &amp;#38; Metabolism</span></i> <b>5</b>:1, 22-23<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/ncpendmet1001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">672</p><p class="content">Philip S Wang, Robert Heinssen, Molly Oliveri, Ann Wagner, Wayne Goodman. (2009) Bridging Bench and Practice: Translational Research for Schizophrenia and Other Psychotic Disorders. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>34</b>:1, 204-212<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/npp.2008.170" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">673</p><p class="content">Yona Geffen, Abraham Nudelman, Irit Gil-Ad, Ada Rephaeli, Mei Huang, Kinneret Savitsky, Leah Klapper, Ilan Winkler, Herbert Y. Meltzer, Abraham Weizman. (2009) BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>19</b>:1, 1-13<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2008.07.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">674</p><p class="content">David M. Marks, Thanaseelan J, Chi-Un Pae. (2009) Innovations in Clinical Research Design and Conduct in Psychiatry: Shifting to Pragmatic Approaches. <i><span class="NLM_source">Psychiatry Investigation</span></i> <b>6</b>:1, 1<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.4306/pi.2009.6.1.1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">675</p><p class="content">Samuel Keith. (2009) Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost–effectiveness. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>9</b>:1, 9-31<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/14737175.9.1.9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">676</p><p class="content">Edwin J.C.G. van den Oord, Daniel E. Adkins, Joseph McClay, Jeffrey Lieberman, Patrick F. Sullivan. (2009) A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>107</b>:1, 13-21<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2008.09.009" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">677</p><p class="content">J. M. Meyer, S. M. Stahl. (2009) The metabolic syndrome and schizophrenia. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>119</b>:1, 4-14<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2008.01317.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">678</p><p class="content">Lydia A. Chwastiak, Robert A. Rosenheck, Joseph P. McEvoy, T. Scott Stroup, Marvin S. Swartz, Sonia M. Davis, Jeffrey A. Lieberman. (2009) The impact of obesity on health care costs among persons with schizophrenia. <i><span class="NLM_source">General Hospital Psychiatry</span></i> <b>31</b>:1, 1-7<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.genhosppsych.2008.09.012" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">679</p><p class="content">David Healy. 2009. Les effets ind&eacute;sirables des antipsychotiques et leur gestion. , 29-48. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/B978-2-8101-0116-0.50003-2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">680</p><p class="content">P THOMAS, V SRIVASTAVA, A SINGH, P MATHUR, V NIMGAONKAR, B LERER, B THELMA, S DESHPANDE. (2008) Correlates of response to Olanzapine in a North Indian Schizophrenia sample<img src="/entityImage/?code=2606&amp;eTag=1cqp96h" alt="" class="entityD" />. <i><span class="NLM_source">Psychiatry Research</span></i> <b>161</b>:3, 275-283<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psychres.2007.09.010" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">681</p><p class="content">B. Garnier. (2008) Quid des schizophr&eacute;nies r&eacute;sistantes ?<img src="/entityImage/?code=2606&amp;eTag=1cqp96h" alt="" class="entityD" />. <i><span class="NLM_source">L'Enc&eacute;phale</span></i> <b>34</b>, S223-S225<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0013-7006(08)75518-0" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">682</p><p class="content">Padavala Ajay Babu, Dondapati Jesse Smiles, Mangamoori Laxmi Narasu, Kolli Srinivas. (2008) Identification of Novel CDK2 Inhibitors by QSAR and Virtual Screening Procedures. <i><span class="NLM_source">QSAR &amp; Combinatorial Science</span></i> <b>27</b>:11-12, 1362-1373<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/qsar.200860041" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">683</p><p class="content">Jos&eacute; de Leon, Maria J. Arranz, Gualberto Rua&ntilde;o. (2008) Pharmacogenetic Testing in Psychiatry: A Review of Features and Clinical Realities. <i><span class="NLM_source">Clinics in Laboratory Medicine</span></i> <b>28</b>:4, 599-617<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.cll.2008.05.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">684</p><p class="content">Terence V. McCann, Cecil Deans, Eileen Clark, Sai Lu. (2008) A comparative study of antipsychotic medication taking in people with schizophrenia. <i><span class="NLM_source">International Journal of Mental Health Nursing</span></i> <b>17</b>:6, 428-438<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1447-0349.2008.00561.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">685</p><p class="content">J. Volavka. (2008) ITAREPS relapse prevention in schizophrenia. <i><span class="NLM_source">International Journal of Clinical Practice</span></i> <b>62</b>:12, 1824-1825<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1742-1241.2008.01928.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">686</p><p class="content">Bart Heeg, Erik Buskens, Marc Botteman, Sue Caleo, Mike Ingham, Joep Damen, Frank de Charro, Ben van Hout. (2008) The Cost-Effectiveness of Atypicals in the UK. <i><span class="NLM_source">Value in Health</span></i> <b>11</b>:7, 1007-1021<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1524-4733.2008.00344.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">687</p><p class="content">Bronwyn Ramey-Hartung, Rifaat S. El-Mallakh, Kristen K. Reynolds. (2008) Pharmacogenetic Testing in Schizophrenia and Posttraumatic Stress Disorder. <i><span class="NLM_source">Clinics in Laboratory Medicine</span></i> <b>28</b>:4, 627-643<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.cll.2008.08.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">688</p><p class="content">Philip D Harvey, Jean M Endicott, Antony D Loebel. (2008) The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment. <i><span class="NLM_source">Bipolar Disorders</span></i> <b>10</b>:8, 900-906<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1399-5618.2008.00634.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">689</p><p class="content">Atheir Abbas, Bryan L Roth. (2008) Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. <i><span class="NLM_source">Expert Opinion on Pharmacotherapy</span></i> <b>9</b>:18, 3251-3259<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14656560802532707" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">690</p><p class="content"> (2008) Generika in der Psychiatrie; Tiroler Psychologiepreis geht an Schulpsychologen Dr. Hans Henzinger; Ein breites Spektrum f&uuml;r die individuelle Therapie; Konsequente Fr&uuml;htherapie mit Interferon beta-1b verbessert Langzeitprognose bei multipler Sklerose. <i><span class="NLM_source">Psychopraxis</span></i> <b>11</b>:6, 40-42<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00739-008-0097-0" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">691</p><p class="content">Jose Giner, Elena Ib&aacute;&ntilde;ez, Dolores Franco, Renato D. Alarc&oacute;n. (2008) Subjectivity in the Perception and Measurement of Quality of Life: Conceptualization and Development of the Seville Questionnaire. <i><span class="NLM_source">Psychiatric Quarterly</span></i> <b>79</b>:4, 321-330<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11126-008-9086-y" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">692</p><p class="content">Natalie C. Edwards, Jacqueline Pesa, Dennis M. Meletiche, Luella Engelhart, Ann K. Thompson, Jay Sherr, Riad Dirani. (2008) One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia*. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>24</b>:12, 3341-3355<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/03007990802490512" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">693</p><p class="content">Ya Mei Bai, Tzu Ting Chen, Wen Kuo Lin, Wen-Ho Chang, Chih Hung Hung, Jen-Yeu Chen. (2008) Reply to Comments by Dr Peng et al for &quot;Pharmacokinetics Study for Hyperprolactinemia Among Schizophrenics Switched from Risperidone to Risperidone Long-Acting Injection&quot;. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>28</b>:6, 727-728<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e31818de734" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">694</p><p class="content">A. JONES. (2008) What are the nursing implications when using paliperidone prolonged release for people with schizophrenia. <i><span class="NLM_source">Journal of Psychiatric and Mental Health Nursing</span></i> <b>15</b>:10, 792-799<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2850.2008.01299.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">695</p><p class="content">Thomas J. Raedler, Kim Hinkelmann, Klaus Wiedemann. (2008) Variability of the In Vivo Metabolism of Clozapine. <i><span class="NLM_source">Clinical Neuropharmacology</span></i> <b>31</b>:6, 347-352<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/WNF.0b013e31815cba61" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">696</p><p class="content">Lisa A. Mistler, Robert E. Drake. (2008) Shared Decision Making in Antipsychotic Management. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>14</b>:6, 333-344<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.pra.0000341889.97759.54" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">697</p><p class="content">Andrew Davies, Kawitha Vardeva, Jean-Yves Loze, Gilbert J. L’Italien, Karin Sennfalt, Marc van Baardewijk. (2008) Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK*. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>24</b>:11, 3275-3285<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/03007990802507547" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">698</p><p class="content">Pierre-Michel Llorca. (2008) Partial compliance in schizophrenia and the impact on patient outcomes. <i><span class="NLM_source">Psychiatry Research</span></i> <b>161</b>:2, 235-247<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psychres.2007.07.012" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">699</p><p class="content">Tomiki Sumiyoshi. (2008) Possible dose–side effect relationship of antipsychotic drugs: relevance to cognitive function in schizophrenia. <i><span class="NLM_source">Expert Review of Clinical Pharmacology</span></i> <b>1</b>:6, 791-802<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/17512433.1.6.791" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">700</p><p class="content">Nicholas M Wallingford, Puspha Sinnayah, Frank P Bymaster, Kishore M Gadde, Ranga K Krishnan, Anthony A McKinney, Ronald P Landbloom, Gary D Tollefson, Michael A Cowley. (2008) Zonisamide Prevents Olanzapine-Associated Hyperphagia, Weight Gain, and Elevated Blood Glucose in Rats. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>33</b>:12, 2922-2933<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/npp.2008.9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">701</p><p class="content">Chay-Hoon Tan, Naotaka Shinfuku, Kang Sim. (2008) Psychotropic prescription practices in east Asia: looking back and peering ahead. <i><span class="NLM_source">Current Opinion in Psychiatry</span></i> <b>21</b>:6, 645-650<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YCO.0b013e32830e6dc4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">702</p><p class="content">Terence A. Ketter, John O. Brooks, Jennifer C. Hoblyn, Laurel M. Champion, Jennifer Y. Nam, Jenifer L. Culver, Wendy K. Marsh, Julie C. Bonner. (2008) Effectiveness of lamotrigine in bipolar disorder in a clinical setting. <i><span class="NLM_source">Journal of Psychiatric Research</span></i> <b>43</b>:1, 13-23<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jpsychires.2008.02.007" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">703</p><p class="content">Donard S Dwyer, Kathrine Weeks, Eric J Aamodt. (2008) Drug discovery based on genetic and metabolic findings in schizophrenia. <i><span class="NLM_source">Expert Review of Clinical Pharmacology</span></i> <b>1</b>:6, 773-789<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/17512433.1.6.773" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">704</p><p class="content">Antonio Metastasio, Sabine Bahn. (2008) Utility of biomarkers to improve the diagnosis and treatment of schizophrenia. <i><span class="NLM_source">Future Neurology</span></i> <b>3</b>:6, 619-622<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/14796708.3.6.619" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">705</p><p class="content">Sujatha Narayan, Bin Tang, Steven R. Head, Timothy J. Gilmartin, J. Gregor Sutcliffe, Brian Dean, Elizabeth A. Thomas. (2008) Molecular profiles of schizophrenia in the CNS at different stages of illness. <i><span class="NLM_source">Brain Research</span></i> <b>1239</b>, 235-248<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.brainres.2008.08.023" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">706</p><p class="content">P ORIOT, J FEYS, S MERTENSDEWILMARS, A MISSON, L AYACHE, O FAGNART, D GRUSON, A LUTS, J JAMART, M HERMANS. (2008) Insulin sensitivity, adjusted β-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: A nine-month prospective study. <i><span class="NLM_source">Diabetes &amp; Metabolism</span></i> <b>34</b>:5, 490-496<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.diabet.2008.03.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">707</p><p class="content">Robin Emsley, Joris Berwaerts, Mari&euml;lle Eerdekens, Michelle Kramer, Rosanne Lane, Pilar Lim, David Hough, Joseph Palumbo. (2008) Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>23</b>:6, 343-356<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YIC.0b013e328314e1f3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">708</p><p class="content">Joshua T Kantrowitz, Leslie Citrome. (2008) Olanzapine: review of safety 2008. <i><span class="NLM_source">Expert Opinion on Drug Safety</span></i> <b>7</b>:6, 761-769<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14740330802423234" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">709</p><p class="content">Anand K. Pandurangi, Alican Dalkilic. (2008) Polypharmacy With Second-Generation Antipsychotics: A Review of Evidence. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>14</b>:6, 345-367<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.pra.0000341890.05383.45" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">710</p><p class="content">Rodrigo D. Paz, Sonia Tardito, Marco Atzori, Kuei Y. Tseng. (2008) Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychopharmacology. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>18</b>:11, 773-786<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2008.06.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">711</p><p class="content">Hans-J&uuml;rgen M&ouml;ller, Michael Riedel, Markus J&auml;ger, Florian Wickelmaier, Wolfgang Maier, Kai-Uwe K&uuml;hn, Gerhard Buchkremer, Isabella Heuser, Joachim Klosterk&ouml;tter, Markus Gastpar, Dieter F. Braus, Ralf Schl&ouml;sser, Frank Schneider, Christian Ohmann, Mathias Riesbeck, Wolfgang Gaebel. (2008) Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. <i><span class="NLM_source">The International Journal of Neuropsychopharmacology</span></i> <b>11</b>:07, <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1017/S1461145708008791" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">712</p><p class="content">Mary F. Brunette, Christopher O’Keefe, Suzanna Zimmet, Joanne Wojcik, Ree Dawson, Elizabeth Brownell, Alan I. Green. (2008) Clozapine, Olanzapine, or Typical Antipsychotics for Alcohol Use Disorder in Patients With Schizophrenia. <i><span class="NLM_source">Journal of Dual Diagnosis</span></i> <b>4</b>:4, 344-354<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/15504260802313816" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">713</p><p class="content">James J. Crowley, Richard S.E. Keefe, Diana O. Perkins, T. Scott Stroup, Jeffrey A. Lieberman, Patrick F. Sullivan. (2008) The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. <i><span class="NLM_source">American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</span></i> <b>147B</b>:7, 1298-1300<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/ajmg.b.30727" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">714</p><p class="content">Jehan Marino, Joshua Caballero. (2008) Paliperidone Extended-Release for the Treatment of Schizophrenia. <i><span class="NLM_source">Pharmacotherapy</span></i> <b>28</b>:10, 1283-1298<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1592/phco.28.10.1283" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">715</p><p class="content">&amp;NA;. (2008) There are important differences between atypical antipsychotics in the relative risk of adverse effects. <i><span class="NLM_source">Drugs &amp; Therapy Perspectives</span></i> <b>24</b>:10, 19-22<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00042310-200824100-00006" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">716</p><p class="content">Davide Amato, Maria Antonietta Stasi, Franco Borsini, Paolo Nencini. (2008) Haloperidol both prevents and reverses quinpirole-induced nonregulatory water intake, a putative animal model of psychogenic polydipsia. <i><span class="NLM_source">Psychopharmacology</span></i> <b>200</b>:2, 157-165<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-008-1229-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">717</p><p class="content">Roland W. Freudenmann, Peter Lepping. (2008) Second-Generation Antipsychotics in Primary and Secondary Delusional Parasitosis. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>28</b>:5, 500-508<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e318185e774" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">718</p><p class="content">Isabelle Gasquet, Josep Maria Haro, St&eacute;phanie Tcherny-Lessenot, Florence Chartier, Jean-Pierre L&eacute;pine. (2008) Remission in the outpatient care of schizophrenia: 3-Year results from the Schizophrenia Outpatients Health Outcomes (SOHO) Study in France. <i><span class="NLM_source">European Psychiatry</span></i> <b>23</b>:7, 491-496<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.eurpsy.2008.03.012" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">719</p><p class="content">R R Girgis, J A Javitch, J A Lieberman. (2008) Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>13</b>:10, 918-929<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/mp.2008.40" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">720</p><p class="content">Marilyn Ader, W. Timothy Garvey, Lawrence S. Phillips, Charles B. Nemeroff, Georges Gharabawi, Ramy Mahmoud, Andrew Greenspan, Sally A. Berry, Dominique L. Musselman, Jacqueline Morein, Young Zhu, Lian Mao, Richard N. Bergman. (2008) Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. <i><span class="NLM_source">Journal of Psychiatric Research</span></i> <b>42</b>:13, 1076-1085<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jpsychires.2008.01.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">721</p><p class="content">Iris Grossman, Patrick F. Sullivan, Nicole Walley, Youfang Liu, Jeffrey R. Dawson, Curtis Gumbs, Andrea Gaedigk, J Steven Leeder, Joseph P. McEvoy, Michael E. Weale, David B. Goldstein. (2008) Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. <i><span class="NLM_source">Genetics in Medicine</span></i> <b>10</b>:10, 720-729<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/GIM.0b013e3181863239" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">722</p><p class="content">Kenneth W. Perry, Julie F. Falcone, Matthew J. Fell, John W. Ryder, Hong Yu, Patrick L. Love, Jason Katner, Kimberly D. Gordon, Mark R. Wade, Teresa Man, George G. Nomikos, Lee A. Phebus, Annick J. Cauvin, Kirk W. Johnson, Carrie K. Jones, Beth J. Hoffmann, George E. Sandusky, Magnus W. Walter, Warren J. Porter, Lijuan Yang, Kalpana M. Merchant, Harlan E. Shannon, Kjell A. Svensson. (2008) Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. <i><span class="NLM_source">Neuropharmacology</span></i> <b>55</b>:5, 743-754<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.neuropharm.2008.06.016" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">723</p><p class="content">T. V. MCCANN, G. BOARDMAN, E. CLARK, S. LU. (2008) Risk profiles for non-adherence to antipsychotic medications. <i><span class="NLM_source">Journal of Psychiatric and Mental Health Nursing</span></i> <b>15</b>:8, 622-629<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2850.2008.01277.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">724</p><p class="content">Melissa P. DelBello, Mark Versavel, Kathleen Ice, David Keller, Jeffrey Miceli. (2008) Tolerability of Oral Ziprasidone in Children and Adolescents with Bipolar Mania, Schizophrenia, or Schizoaffective Disorder. <i><span class="NLM_source">Journal of Child and Adolescent Psychopharmacology</span></i> <b>18</b>:5, 491-499<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1089/cap.2008.008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">725</p><p class="content">Romain Beitinger, Jingxia Lin, Werner Kissling, Stefan Leucht. (2008) Comparative remission rates of schizophrenic patients using various remission criteria. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>32</b>:7, 1643-1651<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2008.06.008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">726</p><p class="content">D. D. Miller, S. N. Caroff, S. M. Davis, R. A. Rosenheck, J. P. McEvoy, B. L. Saltz, S. Riggio, M. H. Chakos, M. S. Swartz, R. S. E. Keefe, T. S. Stroup, J. A. Lieberman, . (2008) Extrapyramidal side-effects of antipsychotics in a randomised trial. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>193</b>:4, 279-288<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.bp.108.050088" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">727</p><p class="content">Daniel E. Casey, Earl E. Sands, Jens Heisterberg, Hwa-Ming Yang. (2008) Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. <i><span class="NLM_source">Psychopharmacology</span></i> <b>200</b>:3, 317-331<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-008-1207-7" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">728</p><p class="content">Bruce J. Kinon, Haya Ascher-Svanum, David H. Adams, Lei Chen. (2008) The Temporal Relationship Between Symptom Change and Treatment Discontinuation in a Pooled Analysis of 4 Schizophrenia Trials. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>28</b>:5, 544-549<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e318185e74a" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">729</p><p class="content">Lauren Charlot, Curtis K. Deutsch, Aranya Albert, Anne Hunt, Daniel F. Connor, William J. McIlvane. (2008) Mood and Anxiety Symptoms in Psychiatric Inpatients with Autism Spectrum Disorder and Depression. <i><span class="NLM_source">Journal of Mental Health Research in Intellectual Disabilities</span></i> <b>1</b>:4, 238-253<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/19315860802313947" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">730</p><p class="content">Bradley Todd Webb, Patrick F. Sullivan, Tara Skelly, Edwin J.C.G. van den Oord. (2008) Model-based gene selection shows engrailed 1 is associated with antipsychotic response. <i><span class="NLM_source">Pharmacogenetics and Genomics</span></i> <b>18</b>:9, 751-759<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/FPC.0b013e32830162bc" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">731</p><p class="content">John Tiller, David Ames, Henry Brodaty, Gerard Byrne, Sudarshan Chawla, Graeme Halliday, John Snowdon, Graham Hepworth, Peter McArdle, Isaac Schweitzer. (2008) Antipsychotic use in the elderly: What doctors say they do, and what they do. <i><span class="NLM_source">Australasian Journal on Ageing</span></i> <b>27</b>:3, 134-142<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1741-6612.2008.00308.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">732</p><p class="content">Edward P. Monnelly, Joseph S. LoCastro, David Gagnon, Melissa Young, Louis D. Fiore. (2008) Quetiapine Versus Trazodone in Reducing Rehospitalization for Alcohol Dependence: A Large Data-Base Study. <i><span class="NLM_source">Journal of Addiction Medicine</span></i> <b>2</b>:3, 128-134<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/ADM.0b013e318165cb56" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">733</p><p class="content">Ofer Agid, Shitij Kapur, Gary Remington. (2008) Emerging drugs for schizophrenia. <i><span class="NLM_source">Expert Opinion on Emerging Drugs</span></i> <b>13</b>:3, 479-495<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14728214.13.3.479" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">734</p><p class="content">BK Thelma, Vibhuti Srivastava, Arun Kumar Tiwari. (2008) Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. <i><span class="NLM_source">Pharmacogenomics</span></i> <b>9</b>:9, 1285-1306<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/14622416.9.9.1285" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">735</p><p class="content">Gregor E Berger, Stephen J Wood, R Mark Wellard, Tina M Proffitt, Mirabel McConchie, G Paul Amminger, Graeme D Jackson, Dennis Velakoulis, Christos Pantelis, Patrick D McGorry. (2008) Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>33</b>:10, 2467-2473<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.npp.1301628" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">736</p><p class="content">Antonio Vita, Paola Corsini, Silvia Bonomi, Bruno M. Cesana, Emilio Sacchetti. (2008) Factors affecting antipsychotic drug discontinuation in the treatment of schizophrenia: Evidence from a naturalistic, retrospective, 18-month follow-up study. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>104</b>:1-3, 302-304<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2008.02.010" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">737</p><p class="content">Shinsuke Matsuzaki, Masaya Tohyama. (2008) Regulation of pituitary adenylyl cyclase-activating polypeptide (PACAP, ADCYAP1: adenylyl cyclase-activating polypeptide 1) in the treatment of schizophrenia. <i><span class="NLM_source">Expert Opinion on Therapeutic Targets</span></i> <b>12</b>:9, 1097-1108<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14728222.12.9.1097" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">738</p><p class="content">Hendrik S. Temmingh, Piet P. Oosthuizen. (2008) Pathways to care and treatment delays in first and multi episode psychosis. <i><span class="NLM_source">Social Psychiatry and Psychiatric Epidemiology</span></i> <b>43</b>:9, 727-735<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00127-008-0358-5" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">739</p><p class="content">REBECCA BITTER, TAMMIE LEE DEMLER, LEWIS OPLER. (2008) Safety Evaluation of the Concomitant Use of Clozapine and Benzodiazepines: A Retrospective, Cross-Sectional Chart Review. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>14</b>:5, 265-270<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.pra.0000336753.11943.7c" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">740</p><p class="content">BRIAN J. MILLER. (2008) A Review of Second-Generation Antipsychotic Discontinuation in First-Episode Psychosis. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>14</b>:5, 289-300<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.pra.0000336756.65308.83" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">741</p><p class="content">M. J. Arranz, S. Kapur. (2008) Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use?. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>34</b>:6, 1130-1144<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbn114" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">742</p><p class="content">J. Rabinowitz, O. Davidov. (2008) A Composite Approach That Includes Dropout Rates When Analyzing Efficacy Data in Clinical Trials of Antipsychotic Medications. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>34</b>:6, 1145-1150<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbm107" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">743</p><p class="content">Sanjiv Kumra, Harvey Kranzler, Ginny Gerbino-Rosen, Hana M. Kester, Courtney DeThomas, Kathyrn Cullen, James Regan, John M. Kane. (2008) Clozapine Versus “High-Dose” Olanzapine in Refractory Early-Onset Schizophrenia: An Open-Label Extension Study. <i><span class="NLM_source">Journal of Child and Adolescent Psychopharmacology</span></i> <b>18</b>:4, 307-316<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1089/cap.2007.0089" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">744</p><p class="content">Edgardo Carrizo, Virginia Fern&aacute;ndez, Jes&uacute;s Quintero, Lissette Connell, Zulay Rodr&iacute;guez, M&ocirc;nica Mosquera, Arnaldo Acosta, Trino Baptista. (2008) Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>103</b>:1-3, 83-93<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2008.03.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">745</p><p class="content">Vibhuti Srivastava, Smita N Deshpande, Vishwajit L Nimgaonkar, Bernard Lerer, BK Thelma. (2008) Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes. <i><span class="NLM_source">Pharmacogenomics</span></i> <b>9</b>:8, 1055-1068<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/14622416.9.8.1055" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">746</p><p class="content">Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, Shinichiro Nakajima, Kensuke Nomura, Hiroyoshi Takeuchi, Akira Tanabe, Gohei Yagi, Haruo Kashima. (2008) Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. <i><span class="NLM_source">Human Psychopharmacology: Clinical and Experimental</span></i> <b>23</b>:6, 455-463<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/hup.959" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">747</p><p class="content">Jonathan B. Jensen, Sanjiv Kumra, Willa Leitten, Joel Oberstar, Afshan Anjum, Tonya White, Jeffrey Wozniak, Susanne S. Lee, S. Charles Schulz. (2008) A Comparative Pilot Study of Second-Generation Antipsychotics in Children and Adolescents with Schizophrenia-Spectrum Disorders. <i><span class="NLM_source">Journal of Child and Adolescent Psychopharmacology</span></i> <b>18</b>:4, 317-326<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1089/cap.2007.0123" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">748</p><p class="content">T. Wobrock, M. Soyka. (2008) Pharmacotherapy of schizophrenia with comorbid substance use disorder — Reviewing the evidence and clinical recommendations. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>32</b>:6, 1375-1385<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2008.02.008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">749</p><p class="content">J. Volavka, L. Citrome. (2008) Heterogeneity of violence in schizophrenia and implications for long-term treatment. <i><span class="NLM_source">International Journal of Clinical Practice</span></i> <b>62</b>:8, 1237-1245<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1742-1241.2008.01797.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">750</p><p class="content">Reinhard Schnabel, Heiko Friedel, Andreas Erfurth, Matthias Angermayer, Johannes Clouth, Florian Eichmann. (2008) Predisposing factors for early retirement in patients with Schizophrenia in Germany. <i><span class="NLM_source">The European Journal of Health Economics</span></i> <b>9</b>:3, 265-274<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s10198-007-0074-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">751</p><p class="content">Siegfried Kasper. (2008) Do we need another atypical antipsychotic?. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>18</b>, S146-S152<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2008.04.006" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">752</p><p class="content">David Taylor, Linda Hanssens, Jean-Yves Loze, Miranda Pans, Gilbert L'Italien, Ronald N. Marcus. (2008) Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care. <i><span class="NLM_source">European Psychiatry</span></i> <b>23</b>:5, 336-343<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.eurpsy.2008.03.006" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">753</p><p class="content">William M. Glazer, Mathew J. Byerly. (2008) Tactics and technologies to manage nonadherence in patients with schizophrenia. <i><span class="NLM_source">Current Psychiatry Reports</span></i> <b>10</b>:4, 359-369<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11920-008-0057-7" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">754</p><p class="content">Kazuhide Tanaka, Shigeru Morinobu, Mai Ichimura, Akihiro Asakawa, Akio Inui, Hiroshi Hosoda, Kenji Kangawa, Shigeto Yamawaki. (2008) Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>32</b>:6, 1527-1532<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2008.05.013" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">755</p><p class="content">Hans-J&uuml;rgen M&ouml;ller. (2008) Do effectiveness (“real world”) studies on antipsychotics tell us the real truth?. <i><span class="NLM_source">European Archives of Psychiatry and Clinical Neuroscience</span></i> <b>258</b>:5, 257-270<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00406-008-0812-0" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">756</p><p class="content">Bruce J. Kinon, Jan Volavka, Virginia Stauffer, Sara E. Edwards, Hong Liu-Seifert, Lei Chen, David H. Adams, Jean-Pierre Lindenmayer, Joseph P. McEvoy, Peter F. Buckley, Jeffrey A. Lieberman, Herbert Y. Meltzer, Daniel R. Wilson, Leslie Citrome. (2008) Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>28</b>:4, 392-400<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e31817e63a5" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">757</p><p class="content">Jonathan M. Meyer, Vicki G. Davis, Joseph P. McEvoy, Donald C. Goff, Henry A. Nasrallah, Sonia M. Davis, Gail L. Daumit, John Hsiao, Marvin S. Swartz, T. Scott Stroup, Jeffrey A. Lieberman. (2008) Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>103</b>:1-3, 104-109<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2008.04.023" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">758</p><p class="content">David S. Janowsky, L. Jarrett Barnhill, Abdul S. Khalid, John M. Davis. (2008) Antipsychotic Withdrawal-Induced Relapse Predicts Future Relapses in Institutionalized Adults With Severe Intellectual Disability. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>28</b>:4, 401-405<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e31817e63b9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">759</p><p class="content">William T Carpenter, James I Koenig. (2008) The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>33</b>:9, 2061-2079<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.npp.1301639" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">760</p><p class="content">Neal R. Swerdlow, Martin Weber, Ying Qu, Gregory A. Light, David L. Braff. (2008) Realistic expectations of prepulse inhibition in translational models for schizophrenia research. <i><span class="NLM_source">Psychopharmacology</span></i> <b>199</b>:3, 331-388<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-008-1072-4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">761</p><p class="content">Josefina Castro-Fornieles, Mara Parellada, C&eacute;sar A. Soutullo, Immaculada Baeza, Ana Gonzalez-Pinto, Montserrat Graell, Beatriz Paya, Dolores Moreno, Elena de la Serna, Celso Arango. (2008) Antipsychotic Treatment in Child and Adolescent First-Episode Psychosis: A Longitudinal Naturalistic Approach. <i><span class="NLM_source">Journal of Child and Adolescent Psychopharmacology</span></i> <b>18</b>:4, 327-336<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1089/cap.2007.0138" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">762</p><p class="content">Peter Falkai. (2008) Limitations of current therapies: Why do patients switch therapies?. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>18</b>, S135-S139<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2008.04.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">763</p><p class="content">E&oacute;in Killackey, Patrick D. Mcgorry. (2008) Interventions in the Early Stages of Psychosis. <i><span class="NLM_source">Psychiatric Annals</span></i> <b>38</b>:8, 521-526<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3928/00485713-20080801-07" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">764</p><p class="content">C. Leucht, M. Kitzmantel, L. Chua, J. Kane, S. Leucht. (2008) Haloperidol versus chlorpromazine for treatment of schizophrenia. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>34</b>:5, 813-815<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbn087" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">765</p><p class="content">Jari Haukka, Jari Tiihonen, Tommi H&auml;rk&auml;nen, Jouko L&ouml;nnqvist. (2008) Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. <i><span class="NLM_source">Pharmacoepidemiology and Drug Safety</span></i> <b>17</b>:7, 686-696<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/pds.1579" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">766</p><p class="content">Joann Y. Sacks, Karen McKendrick, Zachary Hamilton, Charles M. Cleland, Frank S. Pearson, Steven Banks. (2008) Treatment outcomes for female offenders: Relationship to number of Axis I diagnoses. <i><span class="NLM_source">Behavioral Sciences &amp; the Law</span></i> <b>26</b>:4, 413-434<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/bsl.828" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">767</p><p class="content">Richard R. Owen, Teresa Hudson, Carol Thrush, Purushottam Thapa, Tracey Armitage, Reid D. Landes. (2008) The Effectiveness of Guideline Implementation Strategies on Improving Antipsychotic Medication Management for Schizophrenia. <i><span class="NLM_source">Medical Care</span></i> <b>46</b>:7, 686-691<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/MLR.0b013e3181653d43" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">768</p><p class="content">Norman L. Keltner, David E. Vance. (2008) Biological Perspectives&amp;#x2028;Incarcerated Care and Quetiapine Abuse. <i><span class="NLM_source">Perspectives in Psychiatric Care</span></i> <b>44</b>:3, 202-206<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1744-6163.2008.00175.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">769</p><p class="content">CAROLINE BONHAM, CHRISTOPHER ABBOTT. (2008) Are Second Generation Antipsychotics a Distinct Class?. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>14</b>:4, 225-231<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.pra.0000327312.04153.da" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">770</p><p class="content">Stig Ejdrup Andersen, Majka Johansson, Charlotte Manniche. (2008) The Prescribing Pattern of a New Antipsychotic: A Descriptive Study of Aripiprazole for Psychiatric In-Patients. <i><span class="NLM_source">Basic &amp; Clinical Pharmacology &amp; Toxicology</span></i> <b>103</b>:1, 75-81<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1742-7843.2008.00233.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">771</p><p class="content">Fabiana B. Kohlrausch, Clarissa S. Gama, Maria In&ecirc;s Lobato, Paulo Belmonte-de-Abreu, Sidia M. Callegari-Jacques, Alejandro Gesteira, Francisco Barros, &Aacute;ngel Carracedo, Mara H. Hutz. (2008) Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European–Brazilian schizophrenics. <i><span class="NLM_source">Pharmacogenetics and Genomics</span></i> <b>18</b>:7, 599-609<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/FPC.0b013e328301a763" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">772</p><p class="content">Justin R. Springer, Gordon L. Paul. (2008) Predicting Time-to-Independent-Release from Current Level of Functioning for Psychiatric Inpatients: A “Survivor” Analysis. <i><span class="NLM_source">The Journal of Behavioral Health Services &amp; Research</span></i> <b>35</b>:3, 315-333<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11414-007-9096-9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">773</p><p class="content">Carla M. Canuso, Eriene A. Youssef, Cynthia A. Bossie, Ibrahim Turkoz, Andreas Schreiner, George M. Simpson. (2008) Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>23</b>:4, 209-215<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YIC.0b013e3282fce651" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">774</p><p class="content">K. Jack Ishak, Ye Tan, Jennifer Glass, Doanh Luong, J. Jaime Caro. (2008) Risk of discontinuation of risperidone after exposure to potentially interacting drugs: A nested case-control study in patients with schizophrenia. <i><span class="NLM_source">Clinical Therapeutics</span></i> <b>30</b>:7, 1251-1263<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0149-2918(08)80049-5" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">775</p><p class="content">Alessandro Rossi, Antonio Vita, Paola Tiradritti, Fabio Romeo. (2008) Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>23</b>:4, 216-222<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YIC.0b013e3282f94905" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">776</p><p class="content">J. W. Swanson, M. S. Swartz, R. A. Van Dorn, J. Volavka, J. Monahan, T. S. Stroup, J. P. McEvoy, H. R. Wagner, E. B. Elbogen, J. A. Lieberman. (2008) Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>193</b>:1, 37-43<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.bp.107.042630" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">777</p><p class="content">Leslie Citrome, Joshua Kantrowitz. (2008) Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>8</b>:7, 1079-1091<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/14737175.8.7.1079" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">778</p><p class="content">Y. Hara, V.M. Pickel. (2008) Preferential relocation of the N-methyl-d-aspartate receptor NR1 subunit in nucleus accumbens neurons that contain dopamine D1 receptors in rats showing an apomorphine-induced sensorimotor gating deficit. <i><span class="NLM_source">Neuroscience</span></i> <b>154</b>:3, 965-977<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.neuroscience.2008.04.009" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">779</p><p class="content">Eric M. Snyder, Melanie R. Murphy. (2008) Schizophrenia therapy: beyond atypical antipsychotics. <i><span class="NLM_source">Nature Reviews Drug Discovery</span></i> <b>7</b>:6, 471-472<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/nrd2571" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">780</p><p class="content">Julia Sacher, Nilufar Mossaheb, Christoph Spindelegger, Nikolas Klein, Thomas Geiss-Granadia, Robert Sauermann, Edith Lackner, Christian Joukhadar, Markus M&uuml;ller, Siegfried Kasper. (2008) Effects of Olanzapine and Ziprasidone on Glucose Tolerance in Healthy Volunteers. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>33</b>:7, 1633-1641<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.npp.1301541" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">781</p><p class="content">Kathleen L. Benson. (2008) Sleep in Schizophrenia. <i><span class="NLM_source">Sleep Medicine Clinics</span></i> <b>3</b>:2, 251-260<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jsmc.2008.01.001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">782</p><p class="content">Peter J. Weiden. (2008) Antipsychotic-induced movement disorders – forgotten but not gone. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>117</b>:6, 401-402<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2008.01206.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">783</p><p class="content">L. Citrome. (2008) Compelling or irrelevant? Using number needed to treat can help decide. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>117</b>:6, 412-419<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2008.01194.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">784</p><p class="content">Praveen Dayalu, Kelvin L Chou. (2008) Antipsychotic-induced extrapyramidal symptoms and their management. <i><span class="NLM_source">Expert Opinion on Pharmacotherapy</span></i> <b>9</b>:9, 1451-1462<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14656566.9.9.1451" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">785</p><p class="content">J. Scott. (2008) Cognitive-behavioural therapy for severe mental disorders: back to the future?. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>192</b>:6, 401-403<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.bp.108.053876" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">786</p><p class="content">T. Christodoulides, R. Dudley, S. Brown, D. Turkington, Aaron T. Beck. (2008) Cognitive behaviour therapy in patients with schizophrenia who are not prescribed antipsychotic medication: A case series. <i><span class="NLM_source">Psychology and Psychotherapy: Theory, Research and Practice</span></i> <b>81</b>:2, 199-207<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1348/147608308X278295" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">787</p><p class="content">P. A. Garety, D. G. Fowler, D. Freeman, P. Bebbington, G. Dunn, E. Kuipers. (2008) Cognitive-behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial. <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>192</b>:6, 412-423<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.bp.107.043570" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">788</p><p class="content">P F Sullivan, D Lin, J-Y Tzeng, E van den Oord, D Perkins, T S Stroup, M Wagner, S Lee, F A Wright, F Zou, W Liu, A M Downing, J Lieberman, S L Close. (2008) Genomewide association for schizophrenia in the CATIE study: results of stage 1. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>13</b>:6, 570-584<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/mp.2008.25" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">789</p><p class="content">David Suarez, Josep Maria Haro. (2008) Overview of the findings from the European SOHO study. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>8</b>:6, 873-880<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/14737175.8.6.873" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">790</p><p class="content">R C Smith, R H Segman, T Golcer-Dubner, V Pavlov, B Lerer. (2008) Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. <i><span class="NLM_source">The Pharmacogenomics Journal</span></i> <b>8</b>:3, 228-236<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.tpj.6500474" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">791</p><p class="content">R. E. Nordquist, M. Delenclos, T. M. Ballard, H. Savignac, M. Pauly-Evers, L. Ozmen, W. Spooren. (2008) Cognitive performance in neurokinin 3 receptor knockout mice. <i><span class="NLM_source">Psychopharmacology</span></i> <b>198</b>:2, 211-220<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-008-1119-6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">792</p><p class="content">Jamie Karagianis, Vicki Poole Hoffmann, Belen Arranz, Tam&aacute;s Treuer, Gerald A. Maguire, Lieuwe de Haan, Bharat Chawla. (2008) Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. <i><span class="NLM_source">Human Psychopharmacology: Clinical and Experimental</span></i> <b>23</b>:4, 275-281<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/hup.933" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">793</p><p class="content">David A Baker, Aric Madayag, Lars V Kristiansen, James H Meador-Woodruff, Vahram Haroutunian, Ilangovan Raju. (2008) Contribution of Cystine–Glutamate Antiporters to the Psychotomimetic Effects of Phencyclidine. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>33</b>:7, 1760-1772<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.npp.1301532" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">794</p><p class="content">Christoph U Correll, Eva M Schenk. (2008) Tardive dyskinesia and new antipsychotics. <i><span class="NLM_source">Current Opinion in Internal Medicine</span></i> <b>7</b>:3, 295-300<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/MCI.0b013e328303e7a6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">795</p><p class="content">Ree Dawson, Philip W. Lavori. (2008) Sequential causal inference: Application to randomized trials of adaptive treatment strategies. <i><span class="NLM_source">Statistics in Medicine</span></i> <b>27</b>:10, 1626-1645<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/sim.3039" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">796</p><p class="content">S. Saddichha, N. Manjunatha, S. Ameen, S. Akhtar. (2008) Diabetes and schizophrenia – effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>117</b>:5, 342-347<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2008.01158.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">797</p><p class="content">Arzu Gunes, Marja-Liisa Dahl, Edoardo Spina, Maria Gabriella Scordo. (2008) Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. <i><span class="NLM_source">European Journal of Clinical Pharmacology</span></i> <b>64</b>:5, 477-482<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00228-007-0450-x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">798</p><p class="content">P R Bakker, P N van Harten, J van Os. (2008) Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>13</b>:5, 544-556<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.mp.4002142" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">799</p><p class="content">M. JONES, R. GREY. (2008) Time to wake up and smell the coffee: antipsychotic medication and schizophrenia. <i><span class="NLM_source">Journal of Psychiatric and Mental Health Nursing</span></i> <b>15</b>:4, 344-348<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2850.2007.01217.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">800</p><p class="content">L. Citrome. (2008) Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia. <i><span class="NLM_source">International Journal of Clinical Practice</span></i> <b>62</b>:5, 837-840<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1742-1241.2008.01758.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">801</p><p class="content">Nathan A Caffo. (2008) Curidium Medica, plc. <i><span class="NLM_source">Personalized Medicine</span></i> <b>5</b>:3, 219-223<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/17410541.5.3.219" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">802</p><p class="content">Victor Perez, Fernando Ca&ntilde;as, Monica Tafalla. (2008) A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>23</b>:3, 138-149<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YIC.0b013e3282f47c44" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">803</p><p class="content">Pierre Thomas. (2008) Psychosocial and economic issues related to physical health in psychiatric illness. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>18</b>, S115-S120<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2008.02.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">804</p><p class="content">Lei Chen, Jeffrey S. McCombs, Jinhee Park. (2008) Duration of Antipsychotic Drug Therapy in Real-World Practice: A Comparison with CATIE Trial Results. <i><span class="NLM_source">Value in Health</span></i> <b>11</b>:3, 487-496<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1524-4733.2007.00262.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">805</p><p class="content">Douglas E. Faries, Haya Ascher-Svanum, Allen W. Nyhuis, Bruce J. Kinon. (2008) Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>24</b>:5, 1399-1405<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/030079908X297385" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">806</p><p class="content">Edoardo Spina, Rocco Zoccali. (2008) Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia. <i><span class="NLM_source">Expert Opinion on Drug Metabolism &amp; Toxicology</span></i> <b>4</b>:5, 629-638<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/17425255.4.5.629" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">807</p><p class="content">Levent Atik, Ayten Erdogan, Elif Karaahmet, Ozge Saraclı, Nuray Atasoy, Mehmet Ali Kurcer, Ibrahim Balcioglu. (2008) Antipsychotic prescriptions in a university hospital outpatient population in Turkey: A retrospective database analysis, 2005–2006. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>32</b>:4, 968-974<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2007.12.031" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">808</p><p class="content">Hui-Dong Wang, Ariel Y Deutch. (2008) Dopamine Depletion of the Prefrontal Cortex Induces Dendritic Spine Loss: Reversal by Atypical Antipsychotic Drug Treatment. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>33</b>:6, 1276-1286<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.npp.1301521" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">809</p><p class="content">Abraham M Nussbaum, T S Stroup, Abraham M Nussbaum. 2008. Oral paliperidone for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD006369.pub2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">810</p><p class="content">David Fraguas Herr&aacute;ez, Paula Laita de Roda, Guillermo Gonz&aacute;lez Balmaseda, Eugenia Gonz&aacute;lez Laynez, Beatriz Gamo Bravo, David Pascual Hern&aacute;ndez, Mara Parellada Redondo, Dolores Moreno Pardillo, Carolina Franco Porras, Cloe Llorente Sarabia, Steven A. Kushner, Celso Arango L&oacute;pez. (2008) Factores relacionados con la duraci&oacute;n del intervalo QT corregido en pacientes tratados con antipsic&oacute;ticos. <i><span class="NLM_source">Medicina Cl&iacute;nica</span></i> <b>130</b>:12, 446-449<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1157/13118106" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">811</p><p class="content">Steven G. Potkin. (2008) Introduction. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>28</b>:Suppl. 1, S1-S3<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e318168f758" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">812</p><p class="content">Bharat Chawla, Heather Luxton-Andrew. (2008) Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial. <i><span class="NLM_source">Human Psychopharmacology: Clinical and Experimental</span></i> <b>23</b>:3, 211-216<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/hup.921" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">813</p><p class="content">Peter J Weiden, John W Newcomer, Antony D Loebel, Ruoyong Yang, Harold E Lebovitz. (2008) Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with Ziprasidone. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>33</b>:5, 985-994<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.npp.1301482" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">814</p><p class="content">Peter J. Weiden, Andrew J. Cutler, Mihael H. Polymeropoulos, Curt D. Wolfgang. (2008) Safety Profile of Iloperidone. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>28</b>:Suppl. 1, S12-S19<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e3181694f5a" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">815</p><p class="content">Qayyim Said, Elane M. Gutterman, Myoung S. Kim, Sean D. Firth, Richard Whitehead, Diana Brixner. (2008) Somnolence effects of antipsychotic medications and the risk of unintentional injury. <i><span class="NLM_source">Pharmacoepidemiology and Drug Safety</span></i> <b>17</b>:4, 354-364<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/pds.1559" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">816</p><p class="content">Andrew J. Cutler, Amir H. Kalali, Peter J. Weiden, Jennifer Hamilton, Curt D. Wolfgang. (2008) Four-Week, Double-Blind, Placebo- and Ziprasidone-Controlled Trial of Iloperidone in Patients With Acute Exacerbations of Schizophrenia. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>28</b>:Suppl. 1, S20-S28<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e318169d4ce" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">817</p><p class="content">Karen A. Graham, Hyunsoon Cho, Kimberly A. Brownley, Joyce B. Harp. (2008) Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>101</b>:1-3, 287-294<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2007.12.476" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">818</p><p class="content">Robin Emsley, Rossella Medori, Liezl Koen, Petrus Paulus Oosthuizen, Dana J.H. Niehaus, Jonathan Rabinowitz. (2008) Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset Psychosis. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>28</b>:2, 210-213<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e318167269d" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">819</p><p class="content">Jonathan M. Meyer, Vicki G. Davis, Donald C. Goff, Joseph P. McEvoy, Henry A. Nasrallah, Sonia M. Davis, Robert A. Rosenheck, Gail L. Daumit, John Hsiao, Marvin S. Swartz, T. Scott Stroup, Jeffrey A. Lieberman. (2008) Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>101</b>:1-3, 273-286<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2007.12.487" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">820</p><p class="content">D. Dickinson, J. M. Gold, F. B. Dickerson, D. Medoff, L. B. Dixon. (2008) Evidence of Exacerbated Cognitive Deficits in Schizophrenia Patients With Comorbid Diabetes. <i><span class="NLM_source">Psychosomatics</span></i> <b>49</b>:2, 123-131<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1176/appi.psy.49.2.123" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">821</p><p class="content">Octavian R. Adam, Joseph Jankovic. (2008) Symptomatic treatment of Huntington disease. <i><span class="NLM_source">Neurotherapeutics</span></i> <b>5</b>:2, 181-197<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.nurt.2008.01.008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">822</p><p class="content">Sandra G. Resnick, Robert A. Rosenheck, Jose M. Canive, Cyril Souza, T. Scott Stroup, Joseph McEvoy, Sonia Davis, Richard SE Keefe, Marvin Swartz, Jeffrey Lieberman. (2008) Employment Outcomes in a Randomized Trial of Second-Generation Antipsychotics and Perphenazine in the Treatment of Individuals with Schizophrenia. <i><span class="NLM_source">The Journal of Behavioral Health Services &amp; Research</span></i> <b>35</b>:2, 215-225<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11414-007-9101-3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">823</p><p class="content">Steven G. Potkin, Robert E. Litman, Rosarelis Torres, Curt D. Wolfgang. (2008) Efficacy of Iloperidone in the Treatment of Schizophrenia. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>28</b>:Suppl. 1, S4-S11<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e3181692787" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">824</p><p class="content">John M. Kane, John Lauriello, Eugene Laska, Michael Di Marino, Curt D. Wolfgang. (2008) Long-Term Efficacy and Safety of Iloperidone. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>28</b>:Suppl. 1, S29-S35<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e318169cca7" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">825</p><p class="content">John M Davis, Nancy Chen, Ira D Glick. (2008) Issues that May Determine the Outcome of Antipsychotic Trials: Industry Sponsorship and Extrapyramidal Side Effect. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>33</b>:5, 971-975<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.npp.1301493" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">826</p><p class="content">Ryosuke Arakawa, Hiroshi Ito, Akihiro Takano, Hidehiko Takahashi, Takuya Morimoto, Takeshi Sassa, Katsuya Ohta, Motoichiro Kato, Yoshiro Okubo, Tetsuya Suhara. (2008) Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. <i><span class="NLM_source">Psychopharmacology</span></i> <b>197</b>:2, 229-235<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-007-1029-z" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">827</p><p class="content">Daniel B. Campbell, Leslie A. Lange, Tara Skelly, Jeffrey Lieberman, Pat Levitt, Patrick F. Sullivan. (2008) Association of RGS2 and RGS5 variants with schizophrenia symptom severity. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>101</b>:1-3, 67-75<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2008.01.006" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">828</p><p class="content">Ronette L. Kolotkin, Patricia K. Corey-Lisle, Ross D. Crosby, Jodi M. Swanson, Anne V. Tuomari, Gilbert J. L'Italien, James E. Mitchell. (2008) Impact of Obesity on Health-related Quality of Life in Schizophrenia and Bipolar Disorder. <i><span class="NLM_source">Obesity</span></i> <b>16</b>:4, 749-754<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/oby.2007.133" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">829</p><p class="content">Dilip V Jeste, Dan Blazer, Daniel Casey, Thomas Meeks, Carl Salzman, Lon Schneider, Pierre Tariot, Kristine Yaffe. (2008) ACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>33</b>:5, 957-970<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.npp.1301492" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">830</p><p class="content">Arnold W. Mech. (2008) High-Dose Ziprasidone Monotherapy in Bipolar I Disorder Patients With Depressed or Mixed Episodes. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>28</b>:2, 240-241<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e31816745de" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">831</p><p class="content">Susan Muhlbauer. (2008) Caregiver Perceptions and Needs Regarding Symptom Attenuation in Severe and Persistent Mental Illness. <i><span class="NLM_source">Perspectives In Psychiatric Care</span></i> <b>44</b>:2, 99-109<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1744-6163.2008.00159.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">832</p><p class="content">Istvan Bitter, Tamas Treuer, Yulia Dyachkova, Ferenc Martenyi, Margaret McBride, Gabor S. Ungvari. (2008) Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>18</b>:3, 170-180<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2007.08.001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">833</p><p class="content">Christoph U Correll, Eva M Schenk. (2008) Tardive dyskinesia and new antipsychotics. <i><span class="NLM_source">Current Opinion in Psychiatry</span></i> <b>21</b>:2, 151-156<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YCO.0b013e3282f53132" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">834</p><p class="content">Ian R. Carroll, Kimberly M. Kaplan, Sean C. Mackey. (2008) Mexiletine Therapy for Chronic Pain: Survival Analysis Identifies Factors Predicting Clinical Success. <i><span class="NLM_source">Journal of Pain and Symptom Management</span></i> <b>35</b>:3, 321-326<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jpainsymman.2007.04.022" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">835</p><p class="content">Elda Jano, Michael Johnson, Hua Chen, Rajender R. Aparasu. (2008) Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996–2004. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>24</b>:3, 709-716<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/030079908X260989" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">836</p><p class="content">Sanjiv Kumra, Harvey Kranzler, Ginny Gerbino-Rosen, Hana M. Kester, Courtney DeThomas, Vivian Kafantaris, Christoph U. Correll, John M. Kane. (2008) Clozapine and “High-Dose” Olanzapine in Refractory Early-Onset Schizophrenia: A 12-Week Randomized and Double-Blind Comparison. <i><span class="NLM_source">Biological Psychiatry</span></i> <b>63</b>:5, 524-529<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.biopsych.2007.04.043" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">837</p><p class="content">Juliana I. Ekong. (2008) The Role of a Behavioral Health Medical Director in Medicaid Managed Care. <i><span class="NLM_source">Psychiatric Quarterly</span></i> <b>79</b>:1, 33-42<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11126-007-9065-8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">838</p><p class="content">Ren&eacute; S Kahn, W Wolfgang Fleischhacker, Han Boter, Michael Davidson, Yvonne Vergouwe, Ireneus PM Keet, Mihai D Gheorghe, Janusz K Rybakowski, Silvana Galderisi, Jan Libiger, Martina Hummer, Sonia Dollfus, Juan J L&oacute;pez-Ibor, Luchezar G Hranov, Wolfgang Gaebel, Joseph Peuskens, Nils Lindefors, Anita Riecher-R&ouml;ssler, Diederick E Grobbee. (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. <i><span class="NLM_source">The Lancet</span></i> <b>371</b>:9618, 1085-1097<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0140-6736(08)60486-9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">839</p><p class="content">Claire Advokat, Benjamin D. Hill, Joseph E. Comaty. (2008) ‘Real World’ Comparison of First- and Second-Generation Antipsychotics in Regard to Length of Inpatient Hospitalization and Number of Re-hospitalizations. <i><span class="NLM_source">Psychiatric Quarterly</span></i> <b>79</b>:1, 55-64<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11126-007-9061-z" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">840</p><p class="content">Robert A Rosenheck. (2008) Pharmacotherapy of first-episode schizophrenia. <i><span class="NLM_source">The Lancet</span></i> <b>371</b>:9618, 1048-1049<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0140-6736(08)60463-8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">841</p><p class="content">Lakshmi P Voruganti, Laura K Baker, A George Awad. (2008) New generation antipsychotic drugs and compliance behaviour. <i><span class="NLM_source">Current Opinion in Psychiatry</span></i> <b>21</b>:2, 133-139<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YCO.0b013e3282f52851" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">842</p><p class="content">R.E. Nordquist, C. Risterucci, J.L. Moreau, M. von Kienlin, B. K&uuml;nnecke, M. Maco, C. Freichel, C. Riemer, W. Spooren. (2008) Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. <i><span class="NLM_source">Neuropharmacology</span></i> <b>54</b>:2, 405-416<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.neuropharm.2007.10.010" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">843</p><p class="content">G.D. Cooper, J.A. Harrold, J.C.G. Halford, A.J. Goudie. (2008) Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: Implications for animal models of antipsychotic-induced weight gain. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>32</b>:2, 428-436<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2007.09.012" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">844</p><p class="content">Rima Kaddurah-Daouk, Bruce S. Kristal, Richard M. Weinshilboum. (2008) Metabolomics: A Global Biochemical Approach to Drug Response and Disease. <i><span class="NLM_source">Annual Review of Pharmacology and Toxicology</span></i> <b>48</b>:1, 653-683<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1146/annurev.pharmtox.48.113006.094715" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">845</p><p class="content">I. Gaisler-Salomon, L. Diamant, C. Rubin, I. Weiner. (2008) Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered. <i><span class="NLM_source">Psychopharmacology</span></i> <b>196</b>:2, 255-267<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-007-0960-3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">846</p><p class="content">Peter N. van Harten, Hans W. Hoek, Glenn E. Matroos, Jim van Os. (2008) Evidence that lithium protects against tardive dyskinesia: The Cura&ccedil;ao Extrapyramidal Syndromes study VI. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>18</b>:2, 152-155<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2007.07.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">847</p><p class="content">Martha Sajatovic, Nicoleta Coconcea, Rosalinda V. Ignacio, Frederic C. Blow, Robert W. Hays, Kristin A. Cassidy, William J. Meyer. (2008) Adjunct extended-release valproate semisodium in late life schizophrenia. <i><span class="NLM_source">International Journal of Geriatric Psychiatry</span></i> <b>23</b>:2, 142-147<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/gps.1854" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">848</p><p class="content">Mary Ann Boyd. (2008) The Clinical Antipsychotic Trials of Intervention Effectiveness: What Did We Learn?. <i><span class="NLM_source">Archives of Psychiatric Nursing</span></i> <b>22</b>:1, 56-58<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.apnu.2007.10.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">849</p><p class="content">Nitin Gogtay, Judith Rapoport. (2008) Clozapine use in children and adolescents. <i><span class="NLM_source">Expert Opinion on Pharmacotherapy</span></i> <b>9</b>:3, 459-465<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14656566.9.3.459" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">850</p><p class="content">Nael Kilzieh, Jeffrey A. Todd-Stenberg, Annette Kennedy, Amanda E. Wood, Andre M. Tapp. (2008) Time to Discontinuation and Self-Discontinuation of Olanzapine and Risperidone in Patients With Schizophrenia in a Naturalistic Outpatient Setting. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>28</b>:1, 74-77<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/jcp.0b013e3181602cf3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">851</p><p class="content">Nobutomo Yamamoto, Tatsuro Oda, Toshiya Inada. (2008) Three cases of schizophrenia for which olanzapine was effective after early acute phase. <i><span class="NLM_source">Psychiatry and Clinical Neurosciences</span></i> <b>62</b>:1, 93-97<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1440-1819.2007.01780.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">852</p><p class="content">Yu-Tao Xiang, Yong-Zhen Weng, Chi-Ming Leung, Wai-Kwong Tang, Gabor S. Ungvari. (2008) Subjective quality of life in outpatients with schizophrenia in Hong Kong and Beijing: relationship to socio-demographic and clinical factors. <i><span class="NLM_source">Quality of Life Research</span></i> <b>17</b>:1, 27-36<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11136-007-9285-2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">853</p><p class="content">Kristin L. Bigos, Marci L. Chew, Robert R. Bies. (2008) Pharmacokinetics in geriatric psychiatry. <i><span class="NLM_source">Current Psychiatry Reports</span></i> <b>10</b>:1, 30-36<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11920-008-0007-4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">854</p><p class="content">Jill A. Fowler, Tawny L. Bettinger, Tami R. Argo. (2008) Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia. <i><span class="NLM_source">Clinical Therapeutics</span></i> <b>30</b>:2, 231-248<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.clinthera.2008.02.011" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">855</p><p class="content">Silvio Garattini, Vittorio Bertele’. (2008) Do we learn the right things from clinical trials?. <i><span class="NLM_source">European Journal of Clinical Pharmacology</span></i> <b>64</b>:2, 115-125<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00228-007-0411-4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">856</p><p class="content">James L. Roerig, Kristine J. Steffen, James E. Mitchell, Ross D. Crosby, Blake A. Gosnell. (2008) A Comparison of the Effects of Olanzapine and Risperidone Versus Placebo on Ghrelin Plasma Levels. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>28</b>:1, 21-26<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/jcp.0b013e3181613325" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">857</p><p class="content">Delia Bishara, David Taylor. (2008) Upcoming Agents for the Treatment of Schizophrenia. <i><span class="NLM_source">Drugs</span></i> <b>68</b>:16, 2269-2292<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/0003495-200868160-00002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">858</p><p class="content">Peter M. Haddad, Serdar M. Dursun. (2008) Neurological complications of psychiatric drugs: clinical features and management. <i><span class="NLM_source">Human Psychopharmacology: Clinical and Experimental</span></i> <b>23</b>:S1, S15-S26<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/hup.918" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">859</p><p class="content">Peter M. Haddad, Serdar M. Dursun. (2008) Improving drug safety and tolerability in psychiatric clinical practice. <i><span class="NLM_source">Human Psychopharmacology: Clinical and Experimental</span></i> <b>23</b>:S1, S1-S2<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/hup.919" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">860</p><p class="content">Athar Yawar. (2008) Time and humanity on psychiatric wards. <i><span class="NLM_source">The Lancet</span></i> <b>371</b>:9609, 285-286<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0140-6736(08)60146-4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">861</p><p class="content">Julio Bobes, Jer&oacute;nimo S&aacute;iz Ruiz, Jos&eacute; Manuel Montes, Jos&eacute; Mostaza, Fernando Rico-Villademoros, Eduard Vieta. (2008) Spanish Consensus on Physical Health of Patients With Bipolar Disorder. <i><span class="NLM_source">Revista de Psiquiatr&iacute;a y Salud Mental (English Edition)</span></i> <b>1</b>:1, 26-37<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S2173-5050(08)70056-6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">862</p><p class="content">Sanil Rege. (2008) Antipsychotic induced weight gain in schizophrenia:mechanisms and management. <i><span class="NLM_source">Australian and New Zealand Journal of Psychiatry</span></i> <b>42</b>:5, 369-381<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/00048670801961123" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">863</p><p class="content">Anilkumar Pillai. (2008) Brain-Derived Neurotropic Factor/TrkB Signaling in the Pathogenesis and Novel Pharmacotherapy of Schizophrenia. <i><span class="NLM_source">Neurosignals</span></i> <b>16</b>:2-3, 183-193<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1159/000111562" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">864</p><p class="content">Anna Sparshatt, Sarah Jones, David Taylor. (2008) Quetiapine. <i><span class="NLM_source">CNS Drugs</span></i> <b>22</b>:1, 49-68<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200822010-00004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">865</p><p class="content">Antonio Ciudad, Josep Mar&iacute;a Haro, Jordi Alonso, Manuel Bouso&ntilde;o, David Su&aacute;rez, Diego Novick, Inmaculada Gilaberte. (2008) The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain. <i><span class="NLM_source">European Psychiatry</span></i> <b>23</b>:1, 1-7<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.eurpsy.2007.09.008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">866</p><p class="content">Bart M S Heeg, Joep Damen, Erik Buskens, Sue Caleo, Frank de Charro, Ben A van Hout. (2008) Modelling Approaches. <i><span class="NLM_source">PharmacoEconomics</span></i> <b>26</b>:8, 633-648<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00019053-200826080-00002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">867</p><p class="content">Martin Knapp, Frank Windmeijer, Jacqueline Brown, Stathis Kontodimas, Spyridon Tzivelekis, Josep Maria Haro, Mark Ratcliffe, Jihyung Hong, Diego Novick. (2008) Cost-Utility Analysis of Treatment with Olanzapine Compared with Other Antipsychotic Treatments in Patients with Schizophrenia in the Pan-European SOHO Study. <i><span class="NLM_source">PharmacoEconomics</span></i> <b>26</b>:4, 341-358<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00019053-200826040-00006" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">868</p><p class="content">Judith A Siuciak. (2008) The Role of Phosphodiesterases in Schizophrenia. <i><span class="NLM_source">CNS Drugs</span></i> <b>22</b>:12, 983-993<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/0023210-200822120-00002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">869</p><p class="content">M. JONES, A. JONES. (2008) Choice as an intervention to promote well-being: the role of the nurse prescriber. <i><span class="NLM_source">Journal of Psychiatric and Mental Health Nursing</span></i> <b>15</b>:1, 75-81<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2850.2007.01151.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">870</p><p class="content">Daniel B. Campbell, Philip J. Ebert, Tara Skelly, T. Scott Stroup, Jeffrey Lieberman, Pat Levitt, Patrick F. Sullivan. (2008) Ethnic Stratification of the Association of RGS4 Variants with Antipsychotic Treatment Response in Schizophrenia. <i><span class="NLM_source">Biological Psychiatry</span></i> <b>63</b>:1, 32-41<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.biopsych.2007.04.018" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">871</p><p class="content">Adam M. Mirot, Edward G. Tessier, Michael J. Germain, Lewis M. Cohen. 2008. , 795. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016%2FB978-141605484-9.50075-7" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">872</p><p class="content">Jos&eacute; M Olivares, Alfonso Rodriguez-Martinez, Jos&eacute; A Bur&oacute;n, David Alonso-Escolano, Alexander Rodriguez-Morales. (2008) Cost-Effectiveness Analysis of Switching Antipsychotic Medication to Long-Acting Injectable Risperidone in Patients with Schizophrenia. <i><span class="NLM_source">Applied Health Economics and Health Policy</span></i> <b>6</b>:1, 41-53<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00148365-200806010-00004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">873</p><p class="content">H A Nasrallah. (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>13</b>:1, 27-35<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.mp.4002066" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">874</p><p class="content">Mario &Aacute;lvarez-Jim&eacute;nez, C&eacute;sar Gonz&aacute;lez-Blanch, Benedicto Crespo-Facorro, Sarah Hetrick, Jose Manuel Rodr&iacute;guez-S&aacute;nchez, Rocio P&eacute;rez-Iglesias, Jose&nbsp;Luis V&aacute;zquez-Barquero. (2008) Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders. <i><span class="NLM_source">CNS Drugs</span></i> <b>22</b>:7, 547-562<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200822070-00002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">875</p><p class="content">Alan I. Green, Douglas L. Noordsy, Mary F. Brunette, Christopher O'Keefe. (2008) Substance abuse and schizophrenia: Pharmacotherapeutic intervention. <i><span class="NLM_source">Journal of Substance Abuse Treatment</span></i> <b>34</b>:1, 61-71<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jsat.2007.01.008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">876</p><p class="content">Lawrence James Albers, Alessandro Musenga, Maria Augusta Raggi. (2008) Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?. <i><span class="NLM_source">Expert Opinion on Investigational Drugs</span></i> <b>17</b>:1, 61-75<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/13543784.17.1.61" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">877</p><p class="content">David Fraguas, Cloe Llorente, Marta Rapado-Castro, Mara Parellada, Dolores Moreno, Ana Ruiz-Sancho, &Oacute;scar Medina, Mar &Aacute;lvarez-Segura, Mar&iacute;a J. de Castro, Celso Arango. (2008) Attitude Toward Antipsychotic Medication as a Predictor of Antipsychotic Treatment Discontinuation in First-Episode Early-Onset Psychosis. <i><span class="NLM_source">Revista de Psiquiatr&iacute;a y Salud Mental (English Edition)</span></i> <b>1</b>:1, 10-17<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S2173-5050(08)70054-2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">878</p><p class="content">Hakuei Yamashita, Hiroo Yoda, Taeko Maruki, Ryoichi Toyoshima. (2008) Telmisartan, an angiotensin II type-1 receptor blocker, improved insulin resistance in a schizophrenic patient treated with olanzapine: A case report. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>32</b>:1, 308-310<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2007.08.022" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">879</p><p class="content">Leslie Citrome. (2008) Quetiapine. <i><span class="NLM_source">CNS Drugs</span></i> <b>22</b>:1, 69-72<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200822010-00005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">880</p><p class="content">David Mamo, Shitij Kapur, Matcheri Keshavan, Marc Laruelle, Cindy C Taylor, Prajakti A Kothare, Penny Barsoum, David McDonnell. (2008) D2 Receptor Occupancy of Olanzapine Pamoate Depot Using Positron Emission Tomography: An Open-label Study in Patients with Schizophrenia. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>33</b>:2, 298-304<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.npp.1301409" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">881</p><p class="content">Masako Nishikawa. (2008) Competing Risks Model in the Analysis of Survival Data. <i><span class="NLM_source">Japanese Journal of Biometrics</span></i> <b>29</b>:2, 141-170<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.5691/jjb.29.141" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">882</p><p class="content">Trino Baptista, Yamily ElFakih, Euderruh Uzc&aacute;tegui, Ignacio Sandia, Eduardo T&aacute;lamo, Enma Araujo de Baptista, Serge Beaulieu. (2008) Pharmacological Management of Atypical Antipsychotic-Induced Weight Gain. <i><span class="NLM_source">CNS Drugs</span></i> <b>22</b>:6, 477-495<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200822060-00003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">883</p><p class="content">Guy Chouinard, Virginie-Anne Chouinard. (2008) Atypical Antipsychotics: CATIE Study, Drug-Induced Movement Disorder and Resulting Iatrogenic Psychiatric-Like Symptoms, Supersensitivity Rebound Psychosis and Withdrawal Discontinuation Syndromes. <i><span class="NLM_source">Psychotherapy and Psychosomatics</span></i> <b>77</b>:2, 69-77<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1159/000112883" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">884</p><p class="content">Luca Pani, Jos&eacute; M Villagr&aacute;n, Vassilis P Kontaxakis, K&ouml;ksal Alptekin. (2008) Practical Issues with Amisulpride in&nbsp;the Management of Patients with Schizophrenia. <i><span class="NLM_source">Clinical Drug Investigation</span></i> <b>28</b>:8, 465-477<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00044011-200828080-00001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">885</p><p class="content">Igal Gutnik, Abraham Weizman. (2008) Ziprasidone: clinical properties and therapeutic promise. <i><span class="NLM_source">Future Neurology</span></i> <b>3</b>:1, 19-27<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/14796708.3.1.19" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">886</p><p class="content"> (2008) Genotipado de pacientes psiqui&aacute;tricos mediante micromatrices de oligonucle&oacute;tidos. <i><span class="NLM_source">Psiquiatr&iacute;a Biol&oacute;gica</span></i> <b>15</b>:1, 7-10<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S1134-5934(08)71114-X" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">887</p><p class="content">M. Obradovic, A. Mrhar, M. Kos. (2007) Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. <i><span class="NLM_source">International Journal of Clinical Practice</span></i> <b>61</b>:12, 1979-1988<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1742-1241.2007.01431.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">888</p><p class="content">Stephen R. Marder, Michelle Kramer, Lisa Ford, Els Eerdekens, Pilar Lim, Mari&euml;lle Eerdekens, Adam Lowy. (2007) Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study. <i><span class="NLM_source">Biological Psychiatry</span></i> <b>62</b>:12, 1363-1370<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.biopsych.2007.01.017" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">889</p><p class="content">Zafiris J. Daskalakis, Paul B. Fitzgerald, Bruce K. Christensen. (2007) The role of cortical inhibition in the pathophysiology and treatment of schizophrenia. <i><span class="NLM_source">Brain Research Reviews</span></i> <b>56</b>:2, 427-442<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.brainresrev.2007.09.006" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">890</p><p class="content">D. Taylor, J. Atkinson, C. Fischetti, A. Sparshatt, S. Jones. (2007) A prospective 6-month analysis of the naturalistic use of aripiprazole – factors predicting favourable outcome. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>116</b>:6, 461-466<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2007.01102.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">891</p><p class="content">F PETITJEAN. (2007) Acceptabilit&eacute; au long cours des antipsychotiques. <i><span class="NLM_source">L'Enc&eacute;phale</span></i> <b>33</b>, 84-87<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0013-7006(07)78675-X" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">892</p><p class="content">C RAIGNOUX, T DUSOUCHET, P BRET, E QUEUILLE, M BISCAY, J CARON, M BRET. (2007) La risp&eacute;ridone injectable &agrave; lib&eacute;ration prolong&eacute;e&nbsp;: enqu&ecirc;te d’utilisation dans trois &eacute;tablissements d’Aquitaine. <i><span class="NLM_source">L'Enc&eacute;phale</span></i> <b>33</b>:6, 973-981<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.encep.2006.07.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">893</p><p class="content">D SARAVANE. (2007) Observance et prise en charge somatique des patients en sant&eacute; mentale. <i><span class="NLM_source">L'Enc&eacute;phale</span></i> <b>33</b>, 63-66<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0013-7006(07)78669-4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">894</p><p class="content">L. Citrome. (2007) Olanzapine: interpreting the label change. <i><span class="NLM_source">International Journal of Clinical Practice</span></i> <b>61</b>:12, 1960-1962<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1742-1241.2007.01631.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">895</p><p class="content">L SCHMITT, L CAILHOL. (2007) Discussion. <i><span class="NLM_source">L'Enc&eacute;phale</span></i> <b>33</b>, 81-83<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0013-7006(07)78674-8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">896</p><p class="content">I. Gasquet. (2007) Utilisation des antipsychotiques. <i><span class="NLM_source">L'Enc&eacute;phale</span></i> <b>33</b>, 153-156<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0013-7006(07)78692-X" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">897</p><p class="content">B BONIN. (2007) Le syndrome m&eacute;tabolique : clinique, facteurs de risque, prise en charge. <i><span class="NLM_source">L'Enc&eacute;phale</span></i> <b>33</b>, 23-26<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0013-7006(07)78655-4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">898</p><p class="content">Andrea Fagiolini, K. N. Roy Chengappa. (2007) Weight gain and metabolic issues of medicines used for bipolar disorder. <i><span class="NLM_source">Current Psychiatry Reports</span></i> <b>9</b>:6, 521-528<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11920-007-0071-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">899</p><p class="content">Michael E. Thase. (2007) STEP-BD and bipolar depression: What have we learned?. <i><span class="NLM_source">Current Psychiatry Reports</span></i> <b>9</b>:6, 497-503<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11920-007-0068-9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">900</p><p class="content">P LLORCA. (2007) Discussion. <i><span class="NLM_source">L'Enc&eacute;phale</span></i> <b>33</b>, 56-57<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0013-7006(07)78666-9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">901</p><p class="content">Cengiz Akkaya, Asli Sarandol, Sengul Cangur, Selcuk Kirli. (2007) Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting. <i><span class="NLM_source">Human Psychopharmacology: Clinical and Experimental</span></i> <b>22</b>:8, 515-528<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/hup.882" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">902</p><p class="content">A. C. Leon. (2007) Implications of Clinical Trial Design on Sample Size Requirements. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>34</b>:4, 664-669<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbn035" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">903</p><p class="content">Dan Zimbroff, Lewis Warrington, Antony Loebel, Ruoyong Yang, Cynthia Siu. (2007) Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>22</b>:6, 363-370<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YIC.0b013e32816f7779" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">904</p><p class="content">Leslie Citrome, Constance B. Shope, Karen A. Nolan, Pal Czobor, Jan Volavka. (2007) Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>22</b>:6, 356-362<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YIC.0b013e3281c61baf" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">905</p><p class="content">Eleni Aklillu, Werner Kalow, Laszlo Endrenyi, Patricia Harper, Jun Miura, Vural Ozdemir. (2007) CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. <i><span class="NLM_source">Pharmacogenetics and Genomics</span></i> <b>17</b>:11, 989-993<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/FPC.0b013e3282f01aa3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">906</p><p class="content">Arif Khan, Kelly Schwartz, Nick Redding, Russell L Kolts, Walter A Brown. (2007) Psychiatric Diagnosis and Clinical Trial Completion Rates: Analysis of the FDA SBA Reports. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>32</b>:11, 2422-2430<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.npp.1301361" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">907</p><p class="content">Gavin P. Reynolds. (2007) The impact of pharmacogenetics on the development and use of antipsychotic drugs. <i><span class="NLM_source">Drug Discovery Today</span></i> <b>12</b>:21-22, 953-959<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.drudis.2007.07.018" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">908</p><p class="content">Jonathan C Pfeifer, Robert A Kowatch, Melissa P DelBello. (2007) The use of antipsychotics in children and adolescents with bipolar disorders. <i><span class="NLM_source">Expert Opinion on Pharmacotherapy</span></i> <b>8</b>:16, 2673-2687<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14656566.8.16.2673" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">909</p><p class="content">Jessica Broadway, Jacobo Mintzer. (2007) The many faces of psychosis in the elderly. <i><span class="NLM_source">Current Opinion in Psychiatry</span></i> <b>20</b>:6, 551-558<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YCO.0b013e3282f0f09d" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">910</p><p class="content">Y. Chertkow, O. Weinreb, M. B. H Youdim, H. Silver. (2007) Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment. <i><span class="NLM_source">Journal of Neural Transmission</span></i> <b>114</b>:11, 1443-1454<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00702-007-0753-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">911</p><p class="content">Avi Valevski, Mark Olfson, Abraham Weizman, Roni Shiloh. (2007) Risk of readmission in compulsorily and voluntarily admitted patients. <i><span class="NLM_source">Social Psychiatry and Psychiatric Epidemiology</span></i> <b>42</b>:11, 916-922<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00127-007-0243-7" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">912</p><p class="content">Ingrid Sibitz, Michaela Amering, Ralf G&ouml;ssler, Annemarie Unger, Heinz Katschnig. (2007) Patients’ perspectives on what works in psychoeducational groups for schizophrenia. <i><span class="NLM_source">Social Psychiatry and Psychiatric Epidemiology</span></i> <b>42</b>:11, 909-915<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00127-007-0245-5" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">913</p><p class="content">Lara C. Assis, Giselli Scaini, Priscila B. Di-Pietro, Adalberto A. Castro, Clarissa M. Comim, Emilio L. Streck, Jo&atilde;o Quevedo. (2007) Effect of Antipsychotics on Creatine Kinase Activity in Rat Brain. <i><span class="NLM_source">Basic &amp; Clinical Pharmacology &amp; Toxicology</span></i> <b>101</b>:5, 315-319<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1742-7835.2007.00128.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">914</p><p class="content">Baojin Zhu, Pandurang M Kulkarni, Michael D. Stensland, Haya Ascher-Svanum. (2007) Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder*. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>23</b>:11, 2805-2814<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/030079907X233322" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">915</p><p class="content">Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, Kensuke Nomura, Hiroyoshi Takeuchi, Masayuki Tomita, Kenichi Tsunoda, Shintaro Nio, Ryoske Den, Hiroshi Manki, Akira Tanabe, Gohei Yagi, Haruo Kashima. (2007) How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?—A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. <i><span class="NLM_source">Psychopharmacology</span></i> <b>195</b>:2, 285-295<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-007-0872-2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">916</p><p class="content">Anton J.M. Loonen, Herman M. van Praag. (2007) Measuring Movement Disorders in Antipsychotic Drug Trials. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>27</b>:5, 423-430<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/jcp.0b013e31814f1105" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">917</p><p class="content">Jamie Karagianis, Michael Rosenbluth, Mauricio Tohen, Haya Ascher-Svanum, Tamas Treuer, Mauricio Silva de Lima, Leslie Citrome. (2007) Reviewing CATIE for clinicians:balancing benefit and risk using evidence-based medicine tools. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>23</b>:10, 2551-2557<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/030079907X233269" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">918</p><p class="content">Shawn X. Sun, Gordon G. Liu, Dale B. Christensen, Alex Z. Fu. (2007) Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>23</b>:10, 2305-2312<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/030079907X226050" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">919</p><p class="content">Yael Ratner, Anatoly Gibel, Vladimir Yorkov, Michael S. Ritsner. (2007) Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: A 12-month, open-label, flexible-dose, naturalistic observational trial. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>31</b>:7, 1401-1409<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2007.06.008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">920</p><p class="content">Heather Dlugosz, Henry A Nasrallah. (2007) Paliperidone: a new extended-release oral atypical antipsychotic. <i><span class="NLM_source">Expert Opinion on Pharmacotherapy</span></i> <b>8</b>:14, 2307-2313<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14656566.8.14.2307" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">921</p><p class="content">Robert J. Valuck, Elaine H. Morrato, Sheri Dodd, Gary Oderda, Dean G. Haxby, Richard Allen. (2007) How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs*. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>23</b>:10, 2567-2576<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/030079907X233214" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">922</p><p class="content">R Kaddurah-Daouk, J McEvoy, R A Baillie, D Lee, J K Yao, P M Doraiswamy, K R R Krishnan. (2007) Metabolomic mapping of atypical antipsychotic effects in schizophrenia. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>12</b>:10, 934-945<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.mp.4002000" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">923</p><p class="content">J. De Almeida, G. Mengod. (2007) Quantitative analysis of glutamatergic and GABAergic neurons expressing 5-HT2A receptors in human and monkey prefrontal cortex. <i><span class="NLM_source">Journal of Neurochemistry</span></i> <b>103</b>:2, 475-486<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1471-4159.2007.04768.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">924</p><p class="content">Robert Kerwin, Bruno Millet, Erik Herman, Csaba M. Banki, Henrik Lublin, Miranda Pans, Linda Hanssens, Gilbert L'Italien, Robert D. McQuade, Jean-No&euml;l Beuzen. (2007) A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. <i><span class="NLM_source">European Psychiatry</span></i> <b>22</b>:7, 433-443<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.eurpsy.2007.03.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">925</p><p class="content">J A Gray, B L Roth. (2007) The pipeline and future of drug development in schizophrenia. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>12</b>:10, 904-922<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.mp.4002062" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">926</p><p class="content">J&uuml;rgen Wolf, Firmin Janssen, Henrik Lublin, Raimo KR Salokangas, Herv&eacute; Allain, Enrico Smeraldi, Miguel Bernardo, Helen Millar, Miranda Pans, Christine Adelbrecht, Jim Laughton, Christian Werner, Wolfgang Maier. (2007) A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>23</b>:10, 2313-2323<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/030079907X225448" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">927</p><p class="content">David Cohen. (2007) Chapter 9.. <i><span class="NLM_source">Journal of College Student Psychotherapy</span></i> <b>21</b>:3-4, 199-224<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1300/J035v21n03_09" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">928</p><p class="content">Gunvant K Thaker. (2007) Schizophrenia endophenotypes as treatment targets. <i><span class="NLM_source">Expert Opinion on Therapeutic Targets</span></i> <b>11</b>:9, 1189-1206<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14728222.11.9.1189" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">929</p><p class="content">Helio Elkis. (2007) Treatment-Resistant Schizophrenia. <i><span class="NLM_source">Psychiatric Clinics of North America</span></i> <b>30</b>:3, 511-533<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psc.2007.04.001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">930</p><p class="content">A. Carlo Altamura, William V. Bobo, Herbert Y. Meltzer. (2007) Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>22</b>:5, 249-267<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YIC.0b013e3280de2c7f" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">931</p><p class="content">Yves Lecrubier, Richard Perry, Gary Milligan, Oscar Leeuwenkamp, Robert Morlock. (2007) Physician observations and perceptions of positive and negative symptoms of schizophrenia: A multinational, cross-sectional survey. <i><span class="NLM_source">European Psychiatry</span></i> <b>22</b>:6, 371-379<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.eurpsy.2007.03.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">932</p><p class="content">Deanna L. Kelly, Douglas L. Boggs, Robert R. Conley. (2007) Reaching for Wellness in Schizophrenia. <i><span class="NLM_source">Psychiatric Clinics of North America</span></i> <b>30</b>:3, 453-479<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psc.2007.04.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">933</p><p class="content">Leslie Citrome. (2007) Show Me the Evidence: Using Number Needed to Treat. <i><span class="NLM_source">Southern Medical Journal</span></i> <b>100</b>:9, 881-884<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/SMJ.0b013e3180f63246" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">934</p><p class="content">M. Jones, J. Bennett, B. Lucas, D. Miller, R. Gray. (2007) Mental health nurse supplementary prescribing: experiences of mental health nurses, psychiatrists and patients. <i><span class="NLM_source">Journal of Advanced Nursing</span></i> <b>59</b>:5, 488-496<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2648.2007.04332.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">935</p><p class="content">Stephan Heres, Florian Simon Schmitz, Stefan Leucht, Frank-Gerald Pajonk. (2007) The attitude of patients towards antipsychotic depot treatment. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>22</b>:5, 275-282<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YIC.0b013e3280c28424" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">936</p><p class="content">H.-J. M&ouml;ller, W. Maier. (2007) Probleme der „evidence-based medicine“ in der Psychopharmakotherapie: Problematik der Evidenzgraduierung und der Evidenzbasierung komplexer klinischer Entscheidungsprozesse. <i><span class="NLM_source">Der Nervenarzt</span></i> <b>78</b>:9, 1014-1027<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00115-007-2291-3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">937</p><p class="content">Joanna Teuton, Christopher Dowrick, Richard P. Bentall. (2007) How healers manage the pluralistic healing context: The perspective of indigenous, religious and allopathic healers in relation to psychosis in Uganda. <i><span class="NLM_source">Social Science &amp; Medicine</span></i> <b>65</b>:6, 1260-1273<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.socscimed.2007.03.055" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">938</p><p class="content">Jonathan M. Meyer. (2007) Evidence-based Psychiatry: Outcomes and Decisions. <i><span class="NLM_source">Southern Medical Journal</span></i> <b>100</b>:9, 861-862<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/SMJ.0b013e31806218a6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">939</p><p class="content">Troy A. Moore, Nancy H. Covell, Susan M. Essock, Alexander L. Miller. (2007) Real-World Antipsychotic Treatment Practices. <i><span class="NLM_source">Psychiatric Clinics of North America</span></i> <b>30</b>:3, 401-416<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psc.2007.04.008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">940</p><p class="content">Daniel R Weinberger. (2007) Schizophrenia drug says goodbye to dopamine. <i><span class="NLM_source">Nature Medicine</span></i> <b>13</b>:9, 1018-1019<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/nm0907-1018" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">941</p><p class="content">Ravinder Singh, Paul Zimmet, Jonathan Shaw. (2007) Mental health, antipsychotics and hyperglycaemia. <i><span class="NLM_source">Diabetes and Metabolic Syndrome: Clinical Research and Reviews</span></i> <b>1</b>:3, 209-224<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.dsx.2007.05.001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">942</p><p class="content">S. L. Ruedrich, T. P. Swales, C. Rossvanes, L. Diana, V. Arkadiev, K. Lim. (2007) Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities. <i><span class="NLM_source">Journal of Intellectual Disability Research</span></i> <b>0</b>:0, 070808045409002-???<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2788.2007.00981.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">943</p><p class="content">Rajiv Tandon. (2007) Antipsychotic treatment of schizophrenia: Two steps forward, one step back. <i><span class="NLM_source">Current Psychiatry Reports</span></i> <b>9</b>:4, 263-264<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11920-007-0029-3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">944</p><p class="content">A. Tschoner, J. Engl, M. Laimer, S. Kaser, M. Rettenbacher, W. W. Fleischhacker, J. R. Patsch, C. F. Ebenbichler. (2007) Metabolic side effects of antipsychotic medication. <i><span class="NLM_source">International Journal of Clinical Practice</span></i> <b>61</b>:8, 1356-1370<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1742-1241.2007.01416.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">945</p><p class="content">Xiaoduo Fan, David C. Henderson, Elaine Chiang, Leah B. Namey Briggs, Oliver Freudenreich, A. Eden Evins, Corinne Cather, Donald C. Goff. (2007) Sexual functioning, psychopathology and quality of life in patients with schizophrenia. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>94</b>:1-3, 119-127<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2007.04.033" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">946</p><p class="content">Xavier Pi-Sunyer, Louis Aronne, George Bray. (2007) Weight Gain Induced by Psychotropic Drugs. <i><span class="NLM_source">Obesity Management</span></i> <b>3</b>:4, 165-169<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1089/obe.2007.0045" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">947</p><p class="content">Antonio Vita. (2007) Violence and schizophrenia: Commentary. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>94</b>:1-3, 377-378<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2007.05.010" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">948</p><p class="content">Peter F. Buckley, Philip D. Harvey, Christopher R. Bowie, Antony Loebel. (2007) The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. <i><span class="NLM_source">Schizophrenia Research</span></i> <b>94</b>:1-3, 99-106<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.schres.2006.12.032" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">949</p><p class="content">M J Arranz, J de Leon. (2007) Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>12</b>:8, 707-747<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.mp.4002009" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">950</p><p class="content">Marc De Hert, Martien Wampers, Ruud van Winkel, Jozef Peuskens. (2007) Anticholinergic use in hospitalised schizophrenic patients in Belgium. <i><span class="NLM_source">Psychiatry Research</span></i> <b>152</b>:2-3, 165-172<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psychres.2006.07.012" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">951</p><p class="content">Joo Cheol Shim, Byeong Moo Choe, Jung Gee Kim, Young Myo Jae, Ho Chan Kim, Sung Gon Kim, Min Kyung Oh, Deanna L. Kelly, Robert R. Conley. (2007) Discontinuation of Risperidone, Olanzapine, and Haloperidol in First-Episode Psychosis. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>27</b>:4, 400-401<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.jcp.0000264991.01277.26" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">952</p><p class="content">Robert J. Constantine. (2007) Reducing variation in the pharmacologic treatment of schizophrenia: Defining acceptable standards of treatment. <i><span class="NLM_source">Current Psychiatry Reports</span></i> <b>9</b>:4, 319-324<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11920-007-0039-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">953</p><p class="content">Matcheri S. Keshavan, Ali Amirsadri. (2007) Early intervention in schizophrenia: Current and future perspectives. <i><span class="NLM_source">Current Psychiatry Reports</span></i> <b>9</b>:4, 325-328<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11920-007-0040-8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">954</p><p class="content">Martin Dossenbach, Tam??s Treuer, Ludmila Kryzhanovskaya, Mete Saylan, Svetlana Dominguez, Xiaohong Huang. (2007) Olanzapine Versus Chlorpromazine in the Treatment of Schizophrenia. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>27</b>:4, 329-337<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e3180ca83b1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">955</p><p class="content">Adriana Foster, Manzoor Usman, Edna Stirewalt, Peter Buckley. (2007) Schizophrenia: From brain morphology to psychopathology. <i><span class="NLM_source">Current Psychiatry Reports</span></i> <b>9</b>:4, 337-342<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11920-007-0042-6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">956</p><p class="content">Kyung Sue Hong, Taesung Park. (2007) Searching susceptibility genes for antipsychotic-induced weight gain: is the <i>5-HT2C</i> receptor gene a promising candidate?. <i><span class="NLM_source">Personalized Medicine</span></i> <b>4</b>:3, 357-361<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/17410541.4.3.357" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">957</p><p class="content">JON McCLELLAN, LINMARIE SIKICH, ROBERT L. FINDLING, JEAN A. FRAZIER, BENEDETTO VITIELLO, STEFANIE A. HLASTALA, EMILY WILLIAMS, DENISSE AMBLER, TYEHIMBA HUNT-HARRISON, ANN E. MALONEY, LOUISE RITZ, ROBERT ANDERSON, ROBERT M. HAMER, JEFFREY A. LIEBERMAN. (2007) Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods. <i><span class="NLM_source">Journal of the American Academy of Child &amp; Adolescent Psychiatry</span></i> <b>46</b>:8, 969-978<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/CHI.0b013e3180691779" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">958</p><p class="content">Charles U. Nnadi, Anil K. Malhotra. (2007) Individualizing antipsychotic drug therapy in schizophrenia: The promise of pharmacogenetics. <i><span class="NLM_source">Current Psychiatry Reports</span></i> <b>9</b>:4, 313-318<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11920-007-0038-2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">959</p><p class="content">Hong Liu-Seifert, John P. Houston, David H. Adams, Bruce J. Kinon. (2007) Association of Acute Symptoms and Compliance Attitude in Noncompliant Patients With Schizophrenia. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>27</b>:4, 392-394<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.jcp.0000264986.32733.df" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">960</p><p class="content">Roger S McIntyre, Hanna O Woldeyohannes, Batya S Yasgur, Joanna K Soczynska, Andrew Miranda, Jakub Z Konarski. (2007) Maintenance treatment in bipolar disorder: a focus on aripiprazole. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>7</b>:8, 919-925<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/14737175.7.8.919" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">961</p><p class="content">Catarina Correia, Astrid M Vicente. (2007) Pharmacogenetics of risperidone response and induced side effects. <i><span class="NLM_source">Personalized Medicine</span></i> <b>4</b>:3, 271-293<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/17410541.4.3.271" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">962</p><p class="content">JEAN A. FRAZIER, JON McCLELLAN, ROBERT L. FINDLING, BENEDETTO VITIELLO, ROBERT ANDERSON, BENJAMIN ZABLOTSKY, EMILY WILLIAMS, NORA K. McNAMARA, JOSEPH A. JACKSON, LOUISE RITZ, STEFANIE A. HLASTALA, LESLIE PIERSON, JENNIFER A. VARLEY, MADELINE PUGLIA, ANN E. MALONEY, DENISSE AMBLER, TYEHIMBA HUNT-HARRISON, ROBERT M. HAMER, NANCY NOYES, JEFFREY A. LIEBERMAN, LINMARIE SIKICH. (2007) Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Demographic and Clinical Characteristics. <i><span class="NLM_source">Journal of the American Academy of Child &amp; Adolescent Psychiatry</span></i> <b>46</b>:8, 979-988<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/chi.0b013e31807083fd" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">963</p><p class="content">Yukari Tadokoro, Tomohiro Oshima, Kousuke Kanemoto. (2007) Interictal Psychoses in Comparison with Schizophrenia?A Prospective Study. <i><span class="NLM_source">Epilepsia</span></i> <b>0</b>:0, 070730094150003-???<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1528-1167.2007.01230.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">964</p><p class="content">Katja Komossa, Christine Rummel-Kluge, Heike Hunger, Franziska Schmidt, Sandra Schwarz, Paranthaman Seth S Bhoopathi, Stefan Leucht, Katja Komossa. 2007. Ziprasidone versus other atypical antipsychotics for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD006627" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">965</p><p class="content">Edward Kim, Richard Levy, Andrei Pikalov. (2007) Personalized treatment with atypical antipsychotic medications. <i><span class="NLM_source">Advances in Therapy</span></i> <b>24</b>:4, 721-740<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/BF02849966" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">966</p><p class="content">Gary Sullivan, Markus Bienroth, Martin Jones, Helen Millar, Lawrence Ratna, David Taylor. (2007) Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>23</b>:7, 1733-1744<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/030079907X210633" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">967</p><p class="content">O. S. Niaz, P. M. Haddad. (2007) Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>116</b>:1, 36-46<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2006.00980.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">968</p><p class="content">Thomas J. Raedler, Jens Reimer, Klaus Wiedemann. (2007) Dose-dependent constipation with higher doses of quetiapine: a case series. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>22</b>:4, 244-246<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YIC.0b013e32805b71a3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">969</p><p class="content">James W Michelsen, Jonathan M Meyer. (2007) Cardiovascular effects of antipsychotics. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>7</b>:7, 829-839<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/14737175.7.7.829" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">970</p><p class="content">Judith A Siuciak, Christine A Strick. (2007) Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia. <i><span class="NLM_source">Expert Opinion on Drug Discovery</span></i> <b>2</b>:7, 1001-1009<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/17460441.2.7.1001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">971</p><p class="content">David J. Hellerstein, Goretti Almeida, Michael J. Devlin, Nathaniel Mendelsohn, Stacia Helfand, Dianna Dragatsi, Raquel Miranda, Julie R. Kelso, Lucia Capitelli. (2007) Assessing Obesity and Other Related Health Problems of Mentally Ill Hispanic Patients in an Urban Outpatient Setting. <i><span class="NLM_source">Psychiatric Quarterly</span></i> <b>78</b>:3, 171-181<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11126-007-9038-y" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">972</p><p class="content">A.J. Scheen, M.A. De Hert. (2007) Abnormal glucose metabolism in&nbsp;patients treated with antipsychotics. <i><span class="NLM_source">Diabetes &amp; Metabolism</span></i> <b>33</b>:3, 169-175<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.diabet.2007.01.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">973</p><p class="content">William M. Greenberg, Leslie Citrome. (2007) Ziprasidone for Schizophrenia and Bipolar Disorder: A Review of the Clinical Trials. <i><span class="NLM_source">CNS Drug Reviews</span></i> <b>13</b>:2, 137-177<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1527-3458.2007.00008.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">974</p><p class="content">Roger S McIntyre, Joanna K Soczynska, Hanna O Woldeyohannes, Mohammad Alsuwaidan, Jakub Z Konarski. (2007) A preclinical and clinical rationale for quetiapine in mood syndromes. <i><span class="NLM_source">Expert Opinion on Pharmacotherapy</span></i> <b>8</b>:9, 1211-1219<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14656566.8.9.1211" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">975</p><p class="content">T Lencz, T V Morgan, M Athanasiou, B Dain, C R Reed, J M Kane, R Kucherlapati, A K Malhotra. (2007) Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>12</b>:6, 572-580<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.mp.4001983" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">976</p><p class="content">Michael K&ouml;lch, Kathlen Schnoor, J&ouml;rg M. Fegert. (2007) The EU-regulation on medicinal products for paediatric use. <i><span class="NLM_source">European Child &amp; Adolescent Psychiatry</span></i> <b>16</b>:4, 229-235<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00787-006-0594-8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">977</p><p class="content">Ipsit Vahia, Azziza O Bankole, Pia Reyes, Shilpa Diwan, Nikhil Palekar, Mamta Sapra, Paul Ramirez, Carl I Cohen. (2007) Schizophrenia in later life. <i><span class="NLM_source">Aging Health</span></i> <b>3</b>:3, 383-396<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/1745509X.3.3.383" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">978</p><p class="content">Charles M. Beasley, Virginia L. Stauffer, Hong Liu-Seifert, Cindy C. Taylor, Eduardo Dunayevich, John M. Davis. (2007) All-Cause Treatment Discontinuation in Schizophrenia During Treatment With Olanzapine Relative to Other Antipsychotics. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>27</b>:3, 252-258<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e3180582426" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">979</p><p class="content">M.-A. Crocq. (2007) Neuroplasticit&eacute; de la schizophr&eacute;nie. <i><span class="NLM_source">L'Enc&eacute;phale</span></i> <b>33</b>:3, S402-S407<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0013-7006(07)74591-8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">980</p><p class="content">Alberto Ambesi-Impiombato, Fabio Panariello, Carmela Dell'aversano, Carmine Tomasetti, Giovanni Muscettola, Andrea de Bartolomeis. (2007) Differential expression ofHomer 1 gene by acute and chronic administration of antipsychotics and dopamine transporter inhibitors in the rat forebrain. <i><span class="NLM_source">Synapse</span></i> <b>61</b>:6, 429-439<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/syn.20385" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">981</p><p class="content">Paul J. Rosenfield. (2007) Poison or Cure: Meanings of Medication in Schizophrenia. <i><span class="NLM_source">The Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry</span></i> <b>35</b>:2, 189-201<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1521/jaap.2007.35.2.189" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">982</p><p class="content">M B Cope, P Jumbo-Lucioni, R G Walton, R A Kesterson, D B Allison, T R Nagy. (2007) No effect of dietary fat on short-term weight gain in mice treated with atypical antipsychotic drugs. <i><span class="NLM_source">International Journal of Obesity</span></i> <b>31</b>:6, 1014-1022<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.ijo.0803533" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">983</p><p class="content">F Reed Johnson, Semra ??zdemir, Ranjani Manjunath, A Brett Hauber, Steven P. Burch, Thomas R. Thompson. (2007) Factors That Affect Adherence to Bipolar Disorder Treatments. <i><span class="NLM_source">Medical Care</span></i> <b>45</b>:6, 545-552<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/MLR.0b013e318040ad90" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">984</p><p class="content">E. G. Severance, R. H. Yolken. (2007) Novel ?7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia. <i><span class="NLM_source">Genes, Brain and Behavior</span></i> <b>0</b>:0, 070514070132007-???<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1601-183X.2007.00323.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">985</p><p class="content">Marion A. Becker, M. Scott Young, Ezra Ochshorn, Ronald J. Diamond. (2007) The Relationship of Antipsychotic Medication Class and Adherence with Treatment Outcomes and Costs for Florida Medicaid Beneficiaries with Schizophrenia. <i><span class="NLM_source">Administration and Policy in Mental Health and Mental Health Services Research</span></i> <b>34</b>:3, 307-314<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s10488-006-0108-5" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">986</p><p class="content">Joseph Peuskens, Marc De Hert, Ann Mortimer. (2007) Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>22</b>:3, 145-152<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YIC.0b013e3280148c29" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">987</p><p class="content">Michael A. Escamilla, David C. Glahn. 2007. Clinical Endophenotypes: Implications for Genetic and Clinical Research. , 153-172. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/9781420019544.008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">988</p><p class="content">James N. Kimball. (2007) Electroconvulsive Therapy—An Outdated Treatment, or One Whose Time Has Come?. <i><span class="NLM_source">Southern Medical Journal</span></i> <b>100</b>:5, 462-463<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/SMJ.0b013e318046f8c1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">989</p><p class="content">David Taylor, Karen Hayhurst, Robert Kerwin. (2007) A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophrenia. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>22</b>:3, 133-136<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YIC.0b013e3280148219" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">990</p><p class="content">Paul Mackin, Sylvia Ruttledge. 2007. Physical Comorbidity in Bipolar Disorder. , 387-400. <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.3109/9781420021158.021" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">991</p><p class="content">Sylvie Chouinard, Amir Ali Sepehry, Emmanuel Stip. (2007) Oral Cholinesterase Inhibitor Add-on Therapy for Cognitive Enhancement in Schizophrenia. <i><span class="NLM_source">Clinical Neuropharmacology</span></i> <b>30</b>:3, 169-182<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/WNF.0b013e31802fa61a" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">992</p><p class="content">Diego Novick, Josep Maria Haro, David Suarez, Martin Lambert, Jean-Pierre L&eacute;pine, Dieter Naber. (2007) Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. <i><span class="NLM_source">Psychopharmacology</span></i> <b>191</b>:4, 1015-1022<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-007-0730-2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">993</p><p class="content">L. M. Spelman, P. I. Walsh, N. Sharifi, P. Collins, J. H. Thakore. (2007) Impaired glucose tolerance in first-episode drug-na&iuml;ve patients with schizophrenia. <i><span class="NLM_source">Diabetic Medicine</span></i> <b>24</b>:5, 481-485<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1464-5491.2007.02092.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">994</p><p class="content">Vural Ozdemir, Leif Bertilsson, Jun Miura, Erin Carpenter, Christopher Reist, Patricia Harper, Jolanta Wid&eacute;n, Jan-Olof Svensson, Lawrence J. Albers, James L. Kennedy, Laszlo Endrenyi, Werner Kalow. (2007) CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6–serotonin–dopamine crosstalk revisited. <i><span class="NLM_source">Pharmacogenetics and Genomics</span></i> <b>17</b>:5, 339-347<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/FPC.0b013e32801a3c10" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">995</p><p class="content">C. Arango, M. G&oacute;mez-Beneyto, J. Brenlla, C. Gast&oacute;, F. Sarramea-Crespo, L. Chamorro, X. Masramon, T. D&iacute;ez. (2007) A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>17</b>:6-7, 456-463<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2006.11.007" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">996</p><p class="content">Michael Linden, Franz X. Eich, Lena Pyrkosch. (2007) Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>22</b>:3, 175-178<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/YIC.0b013e3280148c19" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">997</p><p class="content">J. EDWIN NIEVES, KATHLEEN M. STACK, MEGAN E. HARRISON, JACK M. GORMAN. (2007) Dysphagia: A Rare Form of Dyskinesia?. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>13</b>:3, 199-201<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.pra.0000271663.40211.56" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">998</p><p class="content">Gary S. Linn, Robert T. O’Keeffe, Kenneth Lifshitz, Charles Schroeder, Daniel C. Javitt. (2007) Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine. <i><span class="NLM_source">Psychopharmacology</span></i> <b>192</b>:1, 27-38<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-007-0771-6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">999</p><p class="content">Kevin R Scott, Anna M Barrett. (2007) Dementia syndromes: evaluation and treatment. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>7</b>:4, 407-422<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/14737175.7.4.407" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1000</p><p class="content">Patrick F. Sullivan, Richard S.E. Keefe, Leslie A. Lange, Ethan M. Lange, T. Scott Stroup, Jeffrey Lieberman, Patricia F. Maness. (2007) NCAM1 and Neurocognition in Schizophrenia. <i><span class="NLM_source">Biological Psychiatry</span></i> <b>61</b>:7, 902-910<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.biopsych.2006.07.036" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1001</p><p class="content">Robert Rosenheck, Marvin Swartz, Joseph McEvoy, T Scott Stroup, Sonia Davis, Richard SE Keefe, John Hsiao, Jeffrey Lieberman. (2007) Second-generation antipsychotics: reviewing the cost–effectiveness component of the CATIE trial. <i><span class="NLM_source">Expert Review of Pharmacoeconomics &amp; Outcomes Research</span></i> <b>7</b>:2, 103-111<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/14737167.7.2.103" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1002</p><p class="content">Michael Riedel, Norbert M&uuml;ller, Martin Strassnig, Ilja Spellmann, Emanuel Severus, Hans-J&uuml;rgen M&ouml;ller. (2007) Quetiapine in the treatment of schizophrenia and related disorders. <i><span class="NLM_source">Neuropsychiatric Disease and Treatment</span></i> <b>3</b>:2, 219-235<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2147/nedt.2007.3.2.219" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1003</p><p class="content">Linda Chang, Daniel Alicata, Thomas Ernst, Nora Volkow. (2007) Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. <i><span class="NLM_source">Addiction</span></i> <b>102</b>, 16-32<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1360-0443.2006.01782.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1004</p><p class="content">M. Neovius, J. Eberhard, E. Lindstr&ouml;m, S. Levander. (2007) Weight development in patients treated with risperidone: a 5-year naturalistic study. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>115</b>:4, 277-285<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2006.00899.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1005</p><p class="content">T Skelly, A P Pinheiro, L A Lange, P F Sullivan. (2007) Is rs7566605, a SNP near INSIG2, associated with body mass in a randomized clinical trial of antipsychotics in schizophrenia?. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>12</b>:4, 321-322<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.mp.4001956" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1006</p><p class="content">I. Lipkovich, W. Deberdt, J.G. Csernansky, P. Buckley, J. Peuskens, S. Kollack-Walker, Y. Zhang, H. Liu-Seifert, J.P. Houston. (2007) Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy. <i><span class="NLM_source">Journal of Psychiatric Research</span></i> <b>41</b>:3-4, 305-310<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.jpsychires.2006.07.016" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1007</p><p class="content">Mathias Zink, Anna Kuwilsky, Udo Knopf. (2007) Olanzapine-Associated Bilateral Eyelid Edema. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>27</b>:2, 214-215<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.jcp.0000264968.69958.28" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1008</p><p class="content">Robin Emsley. (2007) The relationships between antipsychotic dose and efficacy, and the time to treatment response. <i><span class="NLM_source">Psychiatrie und Psychotherapie</span></i> <b>3</b>:1, 9-13<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11326-007-0039-0" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1009</p><p class="content">Xinhua S Ren, Shirley Qian, Lewis E Kazis. (2007) An alternative approach to measuring treatment persistence with antipsychotic agents among patients with schizophrenia in the Veterans Health Administration. <i><span class="NLM_source">Neuropsychiatric Disease and Treatment</span></i> <b>3</b>:2, 277-284<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2147/nedt.2007.3.2.277" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1010</p><p class="content">H. A. Nasrallah. (2007) The case for long-acting antipsychotic agents in the post-CATIE era. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>115</b>:4, 260-267<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2006.00982.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1011</p><p class="content">L. Citrome. (2007) Paliperidone: quo vadis?. <i><span class="NLM_source">International Journal of Clinical Practice</span></i> <b>61</b>:4, 653-662<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1742-1241.2007.01321.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1012</p><p class="content">Deborra M. Torres. (2007) Quality Toolbox: Evidence-Based Monitoring for Metabolic Syndrome in Clients with Chronic Schizophrenia. <i><span class="NLM_source">Journal for Healthcare Quality</span></i> <b>29</b>:2, 48-56<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1945-1474.2007.tb00184.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1013</p><p class="content">Herbert Y. Meltzer. 2007. Atypical Antipsychotic Drugs: Mechanism of Action. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/9780470101001.hcn034" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1014</p><p class="content">Andrea Fagiolini, Arianna Goracci. (2007) The long term — Maximising potential for rehabilitation in patients with schizophrenia. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>17</b>, S123-S129<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2007.02.006" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1015</p><p class="content">Pierre Thomas. (2007) The stable patient with schizophrenia — From antipsychotic effectiveness to adherence. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>17</b>, S115-S122<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2007.02.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1016</p><p class="content">Julia M. Lappin, Marta Di Forti, Robin M. Murray. (2007) Foreword: Improved understanding and treatment of schizophrenia. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>17</b>, v-vi<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2007.02.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1017</p><p class="content">Josep Maria Haro, David Suarez, Diego Novick, Jacqueline Brown, Judith Usall, Dieter Naber. (2007) Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>17</b>:4, 235-244<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2006.09.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1018</p><p class="content">Roy H. Perlis. (2007) Use of treatment guidelines in clinical decision making in bipolar disorder: a pilot survey of clinicians. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>23</b>:3, 467-475<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/030079906X167444" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1019</p><p class="content">BRADLEY FREEMAN, WOODBURNE LEVY, JACK M. GORMAN. (2007) Successful Monotherapy Treatment with Aripiprazole in a Patient with Schizophrenia and Prolactinoma. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>13</b>:2, 120-124<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.pra.0000265771.47153.a0" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1020</p><p class="content">Houman Homayoun, Bita Moghaddam. (2007) Fine-Tuning of Awake Prefrontal Cortex Neurons by Clozapine: Comparison With Haloperidol and N-Desmethylclozapine. <i><span class="NLM_source">Biological Psychiatry</span></i> <b>61</b>:5, 679-687<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.biopsych.2006.05.016" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1021</p><p class="content">Laurent Bardin, Agn??s Auclair, Mark S. Kleven, Eric P.M. Prinssen, Wouter Koek, Adrian Newman-Tancredi, Ronan Depoort??re. (2007) Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. <i><span class="NLM_source">Behavioural Pharmacology</span></i> <b>18</b>:2, 103-118<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/FBP.0b013e3280ae6c96" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1022</p><p class="content">Susanne Th&uuml;mmler, Fabrice Duprat, Michel Lazdunski. (2007) Antipsychotics inhibit TREK but not TRAAK channels. <i><span class="NLM_source">Biochemical and Biophysical Research Communications</span></i> <b>354</b>:1, 284-289<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.bbrc.2006.12.199" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1023</p><p class="content">H. P. Dietz. (2007) Bias in research and conflict of interest: why should we care?. <i><span class="NLM_source">International Urogynecology Journal</span></i> <b>18</b>:3, 241-243<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00192-006-0236-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1024</p><p class="content">L. Fredrik Jarskog, Seiya Miyamoto, Jeffrey A. Lieberman. (2007) Schizophrenia: New Pathological Insights and Therapies. <i><span class="NLM_source">Annual Review of Medicine</span></i> <b>58</b>:1, 49-61<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1146/annurev.med.58.060904.084114" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1025</p><p class="content">P. F. Buckley, S. M. Stahl. (2007) Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul-de-sac?. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>115</b>:2, 93-100<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2007.00992.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1026</p><p class="content">Karen L Houseknecht, Alan S Robertson, William Zavadoski, E Michael Gibbs, David E Johnson, Hans Rollema. (2007) Acute Effects of Atypical Antipsychotics on Whole-Body Insulin Resistance in Rats: Implications for Adverse Metabolic Effects. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>32</b>:2, 289-297<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.npp.1301209" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1027</p><p class="content">Michelle Kramer, George Simpson, Valentinas Maciulis, Stuart Kushner, Ujjwala Vijapurkar, Pilar Lim, Mari??lle Eerdekens. (2007) Paliperidone Extended-Release Tablets for Prevention of Symptom Recurrence in Patients With Schizophrenia. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>27</b>:1, 6-14<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/JCP.0b013e31802dda4a" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1028</p><p class="content">Andrew J. Goudie, Jon C. Cole, Harry R. Sumnall. (2007) Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats. <i><span class="NLM_source">Behavioural Pharmacology</span></i> <b>18</b>:1, 9-17<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/FBP.0b013e328014138d" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1029</p><p class="content">Pierre Chue. (2007) Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. <i><span class="NLM_source">Neuropsychiatric Disease and Treatment</span></i> <b>3</b>:1, 13-39<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2147/nedt.2007.3.1.13" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1030</p><p class="content">Julie Marchand, Sylvain Grignon. (2007) A Case-Control Study of Patients With Resistant Schizophrenia After Clozapine Discontinuation. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>27</b>:1, 90-91<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00004714-200702000-00019" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1031</p><p class="content">Salvatore Gentile. (2007) Extrapyramidal Adverse Events Associated With Atypical Antipsychotic Treatment of Bipolar Disorder. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>27</b>:1, 35-45<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.jcp.0000246217.34024.53" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1032</p><p class="content">Murray A Raskind, Brianna L Burke, Norman J Crites, Andre M Tapp, Dennis D Rasmussen. (2007) Olanzapine-Induced Weight Gain and Increased Visceral Adiposity is Blocked by Melatonin Replacement Therapy in Rats. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>32</b>:2, 284-288<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.npp.1301093" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1033</p><p class="content">Ming Li, Paul J Fletcher, Shitij Kapur. (2007) Time Course of the Antipsychotic Effect and the Underlying Behavioral Mechanisms. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>32</b>:2, 263-272<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.npp.1301110" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1034</p><p class="content">Arzu Gunes, Maria Gabriella Scordo, Peeter Jaanson, Marja-Liisa Dahl. (2007) Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. <i><span class="NLM_source">Psychopharmacology</span></i> <b>190</b>:4, 479-484<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-006-0622-x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1035</p><p class="content">A Nussbaum, ST Stroup, Abraham Nussbaum. 2007. Paliperidone for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD006369" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1036</p><p class="content">Muhammad Qutayba Almerie, Hassan Alkhateeb, Adib Essali, Hosam E Matar, Emtithal Rezk, Muhammad Qutayba Almerie. 2007. Cessation of medication for people with schizophrenia already stable on chlorpromazine. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD006329" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1037</p><p class="content">G Rua&ntilde;o, J W Goethe, C Caley, S Woolley, T R Holford, M Kocherla, A Windemuth, J de Leon. (2007) Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. <i><span class="NLM_source">Molecular Psychiatry</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.mp.4001944" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1038</p><p class="content">PETER J. WEIDEN. (2007) EPS Profiles: The Atypical Antipsychotics. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>13</b>:1, 13-24<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00131746-200701000-00003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1039</p><p class="content">Chi-Un Pae, Ashwin A. Patkar, Tae-Youn Jun, Chul Lee, Prakash S. Masand, In-Ho Paik. (2007) Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. <i><span class="NLM_source">Depression and Anxiety</span></i> <b>24</b>:7, 522-526<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/da.20244" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1040</p><p class="content">Zheng Lu, Jian Hu, Chih-Ken Chen, Tsuo-Hung Lan, Gregorio L. Diokno, Byoung Yong Lee, Heather McElroy, Gavan Harrison, Qiuqing Ang. (2007) Effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychotics. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>31</b>:1, 32-40<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2006.06.006" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1041</p><p class="content">Brian K. Cooke, Louis T. Magas, Katherine S. Virgo, Bernard Feinberg, Adit Adityanjee, Frank E. Johnson. (2007) Appendectomy for appendicitis in patients with schizophrenia. <i><span class="NLM_source">The American Journal of Surgery</span></i> <b>193</b>:1, 41-48<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.amjsurg.2006.06.034" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1042</p><p class="content">Jeff J Guo, Paul E Keck, Patricia K Corey-Lisle, Hong Li, Dongming Jiang, Raymond Jang, Gilbert J L'Italien. (2007) Risk of Diabetes Mellitus Associated with Atypical Antipsychotic Use Among Medicaid Patients with Bipolar Disorder: A Nested Case-Control Study. <i><span class="NLM_source">Pharmacotherapy</span></i> <b>27</b>:1, 27-35<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1592/phco.27.1.27" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1043</p><p class="content">Lewis Warrington, Ilise Lombardo, Antony Loebel, Kathleen Ice. (2007) Ziprasidone for the Treatment of Acute Manic or Mixed Episodes Associated with Bipolar Disorder. <i><span class="NLM_source">CNS Drugs</span></i> <b>21</b>:10, 835-849<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200721100-00004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1044</p><p class="content">Giovan B Cassano, Andrea Fagiolini, Lorenzo Lattanzi, Palmiero Monteleone, Cinzia Niolu, Emilio Sacchetti, Alberto Siracusano, Antonio Vita. (2007) Aripiprazole in the Treatment??of Schizophrenia. <i><span class="NLM_source">Clinical Drug Investigation</span></i> <b>27</b>:1, 1-13<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00044011-200727010-00001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1045</p><p class="content">Andrea Poyastro Pinheiro, Richard S.E. Keefe, Tara Skelly, Megan Olarte, Keren Leviel, Leslie A. Lange, Ethan M. Lange, T. Scott Stroup, Jeffrey Lieberman, Patrick F. Sullivan. (2007) <i>AKT1</i> and neurocognition in schizophrenia. <i><span class="NLM_source">Australian and New Zealand Journal of Psychiatry</span></i> <b>41</b>:2, 169-177<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/00048670601109956" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1046</p><p class="content">Hans-J??rgen M??ller. (2007) Long-Acting Injectable Risperidone for the Treatment of Schizophrenia. <i><span class="NLM_source">Drugs</span></i> <b>67</b>:11, 1541-1566<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00003495-200767110-00003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1047</p><p class="content">Tracy Swainston Harrison, Greg L Plosker, Susan J Keam. (2007) Extended-Release Intramuscular Naltrexone in Alcohol Dependence in Adults: Profile Report1. <i><span class="NLM_source">CNS Drugs</span></i> <b>21</b>:1, 83-87<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200721010-00007" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1048</p><p class="content">Sandra L. Tunis, Douglas E. Faries, Michael D. Stensland, Donald P. Hay, Bruce J. Kinon. (2007) An examination of factors affecting persistence with initial anti&shy;psychotic treatment in patients with schizophrenia*. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>23</b>:1, 97-104<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/030079907X162665" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1049</p><p class="content">Marie-Jos&eacute;e Poulin, Jean-Philippe Chaput, V&eacute;ronique Simard, Pierre Vincent, Jo&euml;lle Bernier, Yvan Gauthier, Guy Lanct&ocirc;t, Jacynthe Saindon, Annick Vincent, Solange Gagnon, Angelo Tremblay. (2007) Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. <i><span class="NLM_source">Australian and New Zealand Journal of Psychiatry</span></i> <b>41</b>:12, 980-989<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/00048670701689428" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1050</p><p class="content">Peter M Haddad, Sonu G Sharma. (2007) Adverse Effects of Atypical Antipsychotics. <i><span class="NLM_source">CNS Drugs</span></i> <b>21</b>:11, 911-936<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200721110-00004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1051</p><p class="content">Peter F Buckley, Donna A Wirshing, Prameet Bhushan, Joseph M Pierre, Seth A Resnick, William C Wirshing. (2007) Lack of Insight in Schizophrenia. <i><span class="NLM_source">CNS Drugs</span></i> <b>21</b>:2, 129-141<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200721020-00004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1052</p><p class="content">Brandon A. Gaudiano, Ivan W. Miller, James D. Herbert. (2007) The Treatment of Psychotic Major Depression: Is There a Role for Adjunctive Psychotherapy?. <i><span class="NLM_source">Psychotherapy and Psychosomatics</span></i> <b>76</b>:5, 271-277<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1159/000104703" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1053</p><p class="content">William G Honer, Allen E Thornton, Megan Sherwood, G ??William MacEwan, Tom S Ehmann, Richard Williams, Lili C Kopala, Ric Procyshyn, Alasdair M Barr. (2007) Conceptual and Methodological Issues??in the Design of Clinical Trials??of Antipsychotics for the Treatment??of Schizophrenia. <i><span class="NLM_source">CNS Drugs</span></i> <b>21</b>:9, 699-714<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200721090-00001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1054</p><p class="content">Robert Kerwin. (2007) When Should Clozapine Be Initiated in Schizophrenia?. <i><span class="NLM_source">CNS Drugs</span></i> <b>21</b>:4, 267-278<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200721040-00002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1055</p><p class="content">Rajender R. Aparasu, Vinod Bhatara. (2007) Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003–2004*. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>23</b>:1, 49-56<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/030079906X158075" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1056</p><p class="content">Eromona Whiskey, David Taylor. (2007) Restarting Clozapine after Neutropenia. <i><span class="NLM_source">CNS Drugs</span></i> <b>21</b>:1, 25-35<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200721010-00003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1057</p><p class="content">Salvatore Gentile. (2007) Atypical Antipsychotics for the Treatment of Bipolar Disorder. <i><span class="NLM_source">CNS Drugs</span></i> <b>21</b>:5, 367-387<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200721050-00002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1058</p><p class="content"> (2007) Industry Supported Satellite Symposia. <i><span class="NLM_source">Australian and New Zealand Journal of Psychiatry</span></i> <b>41</b>:s2, A239-A242<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/00048670701724639" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1059</p><p class="content">Martha Sajatovic, Peijun Chen, Philipp Dines, Edwin R Shirley. (2007) Psychoeducational Approaches to Medication Adherence in Patients with Bipolar Disorder. <i><span class="NLM_source">Disease Management &amp; Health Outcomes</span></i> <b>15</b>:3, 181-192<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00115677-200715030-00006" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1060</p><p class="content">Kayla L. Metzger, Jody M. Shoemaker, Jonathan B. Kahn, Christina R. Maxwell, Yuling Liang, Jan Tokarczyk, Stephen J. Kanes, Meredith Hans, Anthony M. Lowman, Nily Dan, Karen I. Winey, Neal R. Swerdlow, Steven J. Siegel. (2006) Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits. <i><span class="NLM_source">Psychopharmacology</span></i> <b>190</b>:2, 201-211<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-006-0616-8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1061</p><p class="content">T J Raedler, F P Bymaster, R Tandon, D Copolov, B Dean. (2006) Towards a muscarinic hypothesis of schizophrenia. <i><span class="NLM_source">Molecular Psychiatry</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.mp.4001924" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1062</p><p class="content">Alexander B. Niculescu. (2006) Polypharmacy in oligopopulations: what psychiatric genetics can teach biological psychiatry. <i><span class="NLM_source">Psychiatric Genetics</span></i> <b>16</b>:6, 241-244<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.ypg.0000242195.74268.f9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1063</p><p class="content">Philip E Lee, Sudeep S Gill, Paula Rochon. (2006) Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia. <i><span class="NLM_source">Neuropsychiatric Disease and Treatment</span></i> <b>2</b>:4, 521-529<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2147/nedt.2006.2.4.521" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1064</p><p class="content">Takahiko Nagamine. (2006) Hypoglycemia associated with insulin hypersecretion following the addition of olanzapine to conventional antipsychotics. <i><span class="NLM_source">Neuropsychiatric Disease and Treatment</span></i> <b>2</b>:4, 583-585<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2147/nedt.2006.2.4.583" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1065</p><p class="content">Leslie Citrome. (2006) A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. <i><span class="NLM_source">Neuropsychiatric Disease and Treatment</span></i> <b>2</b>:4, 427-443<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2147/nedt.2006.2.4.427" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1066</p><p class="content">D. Misdrahi. (2006) L’observance th&eacute;rapeutique : un objectif essentiel. <i><span class="NLM_source">L'Enc&eacute;phale</span></i> <b>32</b>:6, 1076-1079<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0013-7006(06)72689-6" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1067</p><p class="content">Kathleen L. Benson. (2006) Sleep in Schizophrenia: Impairments, Correlates, and Treatment. <i><span class="NLM_source">Psychiatric Clinics of North America</span></i> <b>29</b>:4, 1033-1045<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psc.2006.08.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1068</p><p class="content">Kathleen E. Pierson. (2006) Is There an Anti-Fat Bias among Schizophrenia Patients?. <i><span class="NLM_source">Obesity</span></i> <b>14</b>:12, 2305-2305<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/oby.2006.270" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1069</p><p class="content">P. TYRER. (2006) <i><span class="NLM_source">The British Journal of Psychiatry</span></i> <b>189</b>:6, 576-576<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1192/bjp.189.6.576" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1070</p><p class="content">SHINSUKE NAKANISHI, HIROSHI KUNUGI, ROBIN M. MURRAY, SEIJI NOJIMA, TOYOAKI OGAWA, TOSHIHIKO TAKAHASHI. (2006) Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia. <i><span class="NLM_source">Psychiatry and Clinical Neurosciences</span></i> <b>60</b>:6, 751-757<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1440-1819.2006.01591.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1071</p><p class="content">Raymond C. Love, Warachal E. Faison, David L. Sultzer. (2006) An Evidence-Based Approach to Optimizing the Management of Psychotic Disorders in the Long-Term Care Setting. <i><span class="NLM_source">The Consultant Pharmacist</span></i> <b>21</b>:0, 1-28<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.4140/TCP.sA.2006.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1072</p><p class="content">I. R. De Oliveira, M. F. Juruena. (2006) Treatment of psychosis: 30<img src="/entityImage/?code=FFFD&amp;eTag=1cqp96h" alt="" class="entityD" />years of progress. <i><span class="NLM_source">Journal of Clinical Pharmacy and Therapeutics</span></i> <b>31</b>:6, 523-534<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1365-2710.2006.00784.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1073</p><p class="content">Terence A. Ketter, Dan W. Haupt. (2006) Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>22</b>:12, 2345-2353<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/030079906X148616" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1074</p><p class="content">Bruce J. Kinon, Hong Liu-Seifert, David H. Adams, Leslie Citrome. (2006) Differential Rates of Treatment Discontinuation in Clinical Trials as a Measure of Treatment Effectiveness for Olanzapine and Comparator Atypical Antipsychotics for Schizophrenia. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>26</b>:6, 632-637<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.jcp.0000245563.06660.0f" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1075</p><p class="content">Xiaoduo Fan, Ellen J. Anderson, Paul M. Copeland, Christina P. Borba, Dana D. Nguyen, Oliver Freudenreich, Donald C. Goff, David C. Henderson. (2006) Higher Fasting Serum Insulin Is Associated with Increased Resting Energy Expenditure in Nondiabetic Schizophrenia Patients. <i><span class="NLM_source">Biological Psychiatry</span></i> <b>60</b>:12, 1372-1377<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.biopsych.2006.05.006" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1076</p><p class="content">Bernard J Carroll, Robert T Rubin. (2006) Is Mifepristone Useful in Psychotic Depression?. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>31</b>:12, 2793-2794<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.npp.1301170" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1077</p><p class="content">B. Millet. (2006) L’&eacute;valuation &agrave; long terme des traitements antipsychotiques. <i><span class="NLM_source">L'Enc&eacute;phale</span></i> <b>32</b>:6, 1072-1075<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0013-7006(06)76288-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1078</p><p class="content">Kristin L. Bigos, Robert R. Bies, Bruce G. Pollock. (2006) Population Pharmacokinetics in Geriatric Psychiatry. <i><span class="NLM_source">American Journal of Geriatric Psychiatry</span></i> <b>14</b>:12, 993-1003<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.JGP.0000224330.73063.6c" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1079</p><p class="content">David A. Smelson, Sandra L. Tunis, Allen W. Nyhuis, Douglas E. Faries, Bruce J. Kinon, Haya Ascher-Svanum. (2006) Antipsychotic Treatment Discontinuation Among Individuals With Schizophrenia and Co-occurring Substance Use. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>26</b>:6, 666-667<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.jcp.0000245562.99036.92" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1080</p><p class="content">Josep Maria Haro, Diego Novick, David Suarez, Jordi Alonso, Jean Pierre L??pine, Mark Ratcliffe. (2006) Remission and Relapse in the Outpatient Care of Schizophrenia. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>26</b>:6, 571-578<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.jcp.0000246215.49271.b8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1081</p><p class="content">Alan D. Schmetzer, John J. Wernert. (2006) Point–Counterpoint: The Importance of “Open Access” to Psychotropics for our Patients. <i><span class="NLM_source">Psychiatric Quarterly</span></i> <b>77</b>:4, 329-334<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11126-006-9018-7" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1082</p><p class="content">Richard M. Bloch, Sy Atezaz Saeed, Jeanne C. Rivard, Christina Rausch. (2006) Lessons Learned in Implementing Evidence-Based Practices: Implications for Psychiatric Administrators. <i><span class="NLM_source">Psychiatric Quarterly</span></i> <b>77</b>:4, 309-318<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11126-006-9016-9" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1083</p><p class="content">Joseph T. Coyle. (2006) Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis. <i><span class="NLM_source">Cellular and Molecular Neurobiology</span></i> <b>26</b>:4-6, 363-382<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s10571-006-9062-8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1084</p><p class="content">H. Steven Moffic. (2006) Ethical Principles for Psychiatric Administrators: The Challenge of Formularies. <i><span class="NLM_source">Psychiatric Quarterly</span></i> <b>77</b>:4, 319-327<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11126-006-9017-8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1085</p><p class="content">F GIANFRANCESCO, K RAJAGOPALAN, M SAJATOVIC, R WANG. (2006) Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. <i><span class="NLM_source">Psychiatry Research</span></i> <b>144</b>:2-3, 177-189<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.psychres.2006.02.006" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1086</p><p class="content">Richard C. Hermann, Jeffrey A. Chan, James L. Zazzali, Debra Lerner. (2006) Aligning Measurement-based Quality Improvement with Implementation of Evidence-based Practices. <i><span class="NLM_source">Administration and Policy in Mental Health and Mental Health Services Research</span></i> <b>33</b>:6, 636-645<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s10488-006-0055-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1087</p><p class="content">J. Jaime Caro, Krista F. Huybrechts, James G. Xenakis, Judith A. O’Brien, Krithika Rajagopalan, Karen Lee. (2006) Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials*. <i><span class="NLM_source">Current Medical Research and Opinion</span></i> <b>22</b>:11, 2233-2242<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1185/030079906X148265" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1088</p><p class="content">RAJIV TANDON, STEVEN D. TARGUM, HENRY A. NASRALLAH, RUTH ROSS. (2006) Strategies for Maximizing Clinical Effectiveness in the Treatment of Schizophrenia. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>12</b>:6, 348-363<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00131746-200611000-00003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1089</p><p class="content">Alexandra Ward, Khajak Ishak, Irina Proskorovsky, Jaime Caro. (2006) Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with Schizophrenia in Quebec and Saskatchewan: A retrospective database study. <i><span class="NLM_source">Clinical Therapeutics</span></i> <b>28</b>:11, 1912-1921<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.clinthera.2006.11.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1090</p><p class="content">S. Jorda, R. Klein, L. Cailhol, D. Fenieys, P. Birmes, A. Andr&eacute;oli, L. Schmitt. (2006) Une dimension de&nbsp;la&nbsp;barri&egrave;re au&nbsp;traitement et&nbsp;sa&nbsp;fid&eacute;lit&eacute; chez&nbsp;des&nbsp;patients hospitalis&eacute;s. <i><span class="NLM_source">Annales M&eacute;dico-psychologiques, revue psychiatrique</span></i> <b>164</b>:9, 750-755<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.amp.2006.08.005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1091</p><p class="content">Maria A. Rettenbacher, Christoph Ebenbichler, Alex Hofer, Georg Kemmler, Susanne Baumgartner, Monika Edlinger, Martina Hummer, Monika Lechleitner, W. Wolfgang Fleischhacker. (2006) Early changes of plasma lipids during treatment with atypical antipsychotics. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>21</b>:6, 369-372<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.yic.0000224786.75664.3b" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1092</p><p class="content">F. GIANFRANCESCO, R. H. WANG, J. PESA, K. RAJAGOPALAN. (2006) Hospitalisation risks in the treatment of schizophrenia in a Medicaid population: comparison of antipsychotic medications. <i><span class="NLM_source">International Journal of Clinical Practice</span></i> <b>60</b>:11, 1419-1424<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1742-1241.2006.01161.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1093</p><p class="content">W. W. Fleischhacker, M. Hummer. (2006) Pharmakotherapie der Schizophrenie. <i><span class="NLM_source">Der Nervenarzt</span></i> <b>77</b>:S03, S77-S98<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00115-006-2194-8" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1094</p><p class="content">Max Marshall, John Rathbone, Max Marshall. 2006. Early Intervention for psychosis. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD004718.pub2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1095</p><p class="content">Mouhamad Mansour, Anas Alomar, Khaled Boobes, Mohamad Awf Mouchli, Mouhamad Mansour. 2006. Intermittent drug techniques for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD006196" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1096</p><p class="content">Stephanie K. Thacker, Marla K. Perna, Jeffery J. Ward, Tori L. Schaefer, Michael T. Williams, Richard M. Kostrzewa, Russell W. Brown. (2006) The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole. <i><span class="NLM_source">European Journal of Neuroscience</span></i> <b>24</b>:7, 2075-2083<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1460-9568.2006.05048.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1097</p><p class="content">Tamas Treuer, Jamie Karagianis. (2006) Is Hunger a Driver of the Cognitive Development?. <i><span class="NLM_source">Neuropsychopharmacology</span></i> <b>31</b>:10, 2326-2327<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.npp.1301144" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1098</p><p class="content">Ana Cristina Chaves, Mary V. Seeman. (2006) Sex Selection Bias in Schizophrenia Antipsychotic Trials. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>26</b>:5, 489-494<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.jcp.0000236652.78168.ee" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1099</p><p class="content">Bruce J. Kinon, Douglas L. Noordsy, Hong Liu-Seifert, Angela H. Gulliver, Haya Ascher-Svanum, Sara Kollack-Walker. (2006) Randomized, Double-blind 6-Month Comparison of Olanzapine and Quetiapine in Patients With Schizophrenia or Schizoaffective Disorder With Prominent Negative Symptoms and Poor Functioning. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>26</b>:5, 453-461<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.jcp.0000236658.16286.25" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1100</p><p class="content">Raisa Andrezina, Richard C. Josiassen, Ronald N. Marcus, Dan A. Oren, George Manos, Elyse Stock, William H. Carson, Taro Iwamoto. (2006) Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. <i><span class="NLM_source">Psychopharmacology</span></i> <b>188</b>:3, 281-292<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-006-0541-x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1101</p><p class="content">F RODRIGUEZARTALEJO. (2006) Valoraci&oacute;n y control del riesgo metab&oacute;lico y cardiovascular en los pacientes con esquizofrenia<img src="/entityImage/?code=2606&amp;eTag=1cqp96h" alt="" class="entityD" />. <i><span class="NLM_source">Medicina Cl&iacute;nica</span></i> <b>127</b>:14, 542-548<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1157/13093733" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1102</p><p class="content">John Robert Bola, Klaus Lehtinen, Jukka Aaltonen, Viljo R??kk??l??inen, Erkka Syv??lahti, Ville Lehtinen. (2006) Predicting Medication-Free Treatment Response in Acute Psychosis. <i><span class="NLM_source">The Journal of Nervous and Mental Disease</span></i> <b>194</b>:10, 732-739<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.nmd.0000243080.90255.88" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1103</p><p class="content">Stefan Gebhardt, Fabian H&auml;rtling, Markus Hanke, Markus Mittendorf, Frank M. Theisen, Karin Wolf-Ostermann, Phillip Grant, Matthias Martin, Christian Fleischhaker, Eberhard Schulz, Helmut Remschmidt. (2006) Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. <i><span class="NLM_source">European Child &amp; Adolescent Psychiatry</span></i> <b>15</b>:7, 371-382<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00787-006-0544-5" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1104</p><p class="content">Marie Cahir. (2006) British Association for Psychopharmacology Summer Meeting. <i><span class="NLM_source">Expert Opinion on Pharmacotherapy</span></i> <b>7</b>:14, 2007-2010<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14656566.7.14.2007" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1105</p><p class="content">David Shannahoff-Khalsa. (2006) A Perspective on the Emergence of Meditation Techniques for Medical Disorders. <i><span class="NLM_source">The Journal of Alternative and Complementary Medicine</span></i> <b>12</b>:8, 709-713<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1089/acm.2006.12.709" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1106</p><p class="content">Siegfried Kasper. (2006) Optimisation of long-term treatment in schizophrenia: Treating the true spectrum of symptoms. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>16</b>, S135-S141<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2006.06.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1107</p><p class="content">Pat Levitt, Philip Ebert, Karoly Mirnics, Vishwajit L. Nimgaonkar, David A. Lewis. (2006) Making the Case for a Candidate Vulnerability Gene in Schizophrenia: Convergent Evidence for Regulator of G-Protein Signaling 4 (RGS4). <i><span class="NLM_source">Biological Psychiatry</span></i> <b>60</b>:6, 534-537<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.biopsych.2006.04.028" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1108</p><p class="content"> (2006) Cost-Effectiveness of Olanzapine as a First-Line Treatment: A Response to Comment. <i><span class="NLM_source">Value in Health</span></i> <b>9</b>:5, 358<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1524-4733.2006.00126.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1109</p><p class="content">Joseph T. Coyle. (2006) Substance use disorders and schizophrenia: A question of shared glutamatergic mechanisms. <i><span class="NLM_source">Neurotoxicity Research</span></i> <b>10</b>:3-4, 221-233<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/BF03033359" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1110</p><p class="content">MOHAMED A. AZIZ, ANDREA PEPLER, CONNIE MCNEELY, JACK M. GORMAN. (2006) Remission of Positive and Negative Symptoms in Refractory Schizophrenia with a Combination of Haloperidol and Quetiapine: Two Case Studies. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>12</b>:5, 332-336<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00131746-200609000-00011" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1111</p><p class="content">David A Lewis, Guillermo Gonzalez-Burgos. (2006) Pathophysiologically based treatment interventions in schizophrenia. <i><span class="NLM_source">Nature Medicine</span></i> <b>12</b>:9, 1016-1022<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/nm1478" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1112</p><p class="content">Philip Gorwood. (2006) Meeting everyday challenges: Antipsychotic therapy in the real world. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>16</b>, S156-S162<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2006.06.002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1113</p><p class="content">Eva Lindstr&ouml;m, Sten Levander. (2006) Sertindole: efficacy and safety in schizophrenia. <i><span class="NLM_source">Expert Opinion on Pharmacotherapy</span></i> <b>7</b>:13, 1825-1834<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14656566.7.13.1825" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1114</p><p class="content">Maria B. Raeder, Johan Fern&oslash;, Audun O. Vik-Mo, Vidar M. Steen. (2006) SREBP Activation by Antipsychotic- and Antidepressant-Drugs in Cultured Human Liver Cells: Relevance for Metabolic Side-Effects?. <i><span class="NLM_source">Molecular and Cellular Biochemistry</span></i> <b>289</b>:1-2, 167-173<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11010-006-9160-4" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1115</p><p class="content">Ira D. Glick, Ziv Shkedy, Andreas Schreiner. (2006) Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>21</b>:5, 261-266<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00004850-200609000-00003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1116</p><p class="content">Lori E. Moss, Nutan Atre Vaidya. (2006) Electroconvulsive Therapy as an Alternative Treatment for Obese Patients With Mood Disorders. <i><span class="NLM_source">The Journal of ECT</span></i> <b>22</b>:3, 223-225<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.yct.0000230363.04240.9c" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1117</p><p class="content">Dan W. Haupt. (2006) Differential metabolic effects of antipsychotic treatments. <i><span class="NLM_source">European Neuropsychopharmacology</span></i> <b>16</b>, S149-S155<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.euroneuro.2006.06.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1118</p><p class="content">Daniel J. Luchins. (2006) In the Aftermath of CATIE: How Should Administrators Value Atypical Antipsychotic Medications?. <i><span class="NLM_source">Administration and Policy in Mental Health and Mental Health Services Research</span></i> <b>33</b>:5, 541-543<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s10488-006-0049-z" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1119</p><p class="content">Daniel J M&uuml;ller, James L Kennedy. (2006) Genetics of antipsychotic treatment emergent weight gain in schizophrenia. <i><span class="NLM_source">Pharmacogenomics</span></i> <b>7</b>:6, 863-887<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2217/14622416.7.6.863" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1120</p><p class="content">Barrat Luft, David Taylor. (2006) A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. <i><span class="NLM_source">Expert Opinion on Pharmacotherapy</span></i> <b>7</b>:13, 1739-1748<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14656566.7.13.1739" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1121</p><p class="content">Samuel Keith. (2006) Advances in psychotropic formulations. <i><span class="NLM_source">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span></i> <b>30</b>:6, 996-1008<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.pnpbp.2006.03.031" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1122</p><p class="content">Gabriele Fischer, Beate Kayer. (2006) Substanzabh&auml;ngigkeit vom Morphintyp – State-of-the-Art der Erhaltungstherapie mit synthetischen Opioiden. <i><span class="NLM_source">Psychiatrie und Psychotherapie</span></i> <b>2</b>:2, 39-54<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11326-006-0022-1" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1123</p><p class="content">Frank Gianfrancesco, Krithika Rajagopalan, Ruey-hua Wang. (2006) Hospitalization Risks in the Treatment of Schizophrenia. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>26</b>:4, 401-404<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.jcp.0000231536.79175.cd" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1124</p><p class="content">F COUSIN, J CHABANNES, M GUEDJ, B LACHAUX, J PASCAL. (2006) Approche th&eacute;rapeutique d’une population de patients pr&eacute;sentant des troubles psychotiques aigus ou chroniques : enqu&ecirc;te R&Eacute;ALIT&Eacute; (Recherche &Eacute;pid&eacute;miologique sur l’Activit&eacute; de la Loxapine et ses Indications en Th&eacute;rapeutique quotidiennE). <i><span class="NLM_source">L'Enc&eacute;phale</span></i> <b>32</b>:4, 466-473<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0013-7006(06)76188-7" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1125</p><p class="content">L. CITROME, T. SCOTT STROUP. (2006) Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?. <i><span class="NLM_source">International Journal of Clinical Practice</span></i> <b>60</b>:8, 933-940<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1742-1241.2006.01044.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1126</p><p class="content">R. Kerwin. (2006) CATIE for clinicians. <i><span class="NLM_source">International Journal of Clinical Practice</span></i> <b>60</b>:8, 892-893<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1742-1241.2006.01043.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1127</p><p class="content">Daniel Luchins. (2006) In the Aftermath of CATIE: How Should Administrators Value Atypical Antipsychotic Medications?. <i><span class="NLM_source">Administration and Policy in Mental Health and Mental Health Services Research</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s10488-006-0081-z" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1128</p><p class="content">R. I. G. Holt, R. C. Peveler. (2006) Antipsychotic drugs and diabetes—an application of the Austin Bradford Hill criteria. <i><span class="NLM_source">Diabetologia</span></i> <b>49</b>:7, 1467-1476<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00125-006-0279-3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1129</p><p class="content">Chanoch Miodownik, Vladimir Lerner. (2006) Quetiapine: efficacy, tolerability and safety in schizophrenia. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>6</b>:7, 983-992<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/14737175.6.7.983" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1130</p><p class="content">Georges M. Gharabawi, Robert A. Lasser, Cynthia A. Bossie, Young Zhu, Xavier Amador. (2006) Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>21</b>:4, 233-240<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00004850-200607000-00006" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1131</p><p class="content">RAHN KENNEDY BAILEY, JAMES B. ADAMS, DEBORAH M. UNGER. (2006) Atypical Antipsychotics: A Case Study in New Era Risk Management. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>12</b>:4, 253-258<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00131746-200607000-00008" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1132</p><p class="content">David Taylor. (2006) Risperidone long-acting injection in practice - more questions than answers?. <i><span class="NLM_source">Acta Psychiatrica Scandinavica</span></i> <b>114</b>:1, 1-2<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1111/j.1600-0447.2006.00810.x" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1133</p><p class="content">Ren-Rong Wu, Jing-Ping Zhao, Zhe-Ning Liu, Jin-Guo Zhai, Xiao-Feng Guo, Wen-Bing Guo, Jing-Song Tang. (2006) Effects of typical and atypical antipsychotics on glucose–insulin homeostasis and lipid metabolism in first-episode schizophrenia. <i><span class="NLM_source">Psychopharmacology</span></i> <b>186</b>:4, 572-578<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00213-006-0384-5" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1134</p><p class="content">DILEK MEMIS, FATMA BAYRAK, DEMET TOKATLIOGLU, JACK M. GORMAN. (2006) Neuroleptic Malignant Syndrome: A Case Report. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>12</b>:4, 259-262<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00131746-200607000-00009" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1135</p><p class="content">Matcheri S. Keshavan, Mary Roberts, Daniela Wittmann. (2006) Guidelines for clinical treatment of early course schizophrenia. <i><span class="NLM_source">Current Psychiatry Reports</span></i> <b>8</b>:4, 329-334<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11920-006-0070-7" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1136</p><p class="content">Kurt Rasmussen. (2006) Creating more effective antidepressants: clues from the clinic. <i><span class="NLM_source">Drug Discovery Today</span></i> <b>11</b>:13-14, 623-631<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.drudis.2006.05.004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1137</p><p class="content">Ana Szarfman, Joseph M Tonning, Jonathan G Levine, P. Murali Doraiswamy. (2006) Atypical Antipsychotics and Pituitary Tumors: A Pharmacovigilance Study. <i><span class="NLM_source">Pharmacotherapy</span></i> <b>26</b>:6, 748-758<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1592/phco.26.6.748" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1138</p><p class="content">Kimberly H Littrell, Richard G Petty, Nicole M Wolf. (2006) Olanzapine: a 5-year perspective. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>6</b>:6, 811-821<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/14737175.6.6.811" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1139</p><p class="content">Michael Krebs, Karolina Leopold, Axel Hinzpeter, Martin Schaefer. (2006) Current schizophrenia drugs: efficacy and side effects. <i><span class="NLM_source">Expert Opinion on Pharmacotherapy</span></i> <b>7</b>:8, 1005-1016<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1517/14656566.7.8.1005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1140</p><p class="content">Enrique ??lvarez, Antonio Ciudad, Jos?? Manuel Olivares, Manuel Bouso??o, Juan Carlos G??mez. (2006) A Randomized, 1-Year Follow-up Study of Olanzapine and Risperidone in the Treatment of Negative Symptoms in Outpatients with Schizophrenia. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>26</b>:3, 238-249<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.jcp.0000222513.63767.de" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1141</p><p class="content">W Wolfgang Fleischhacker, Christian G Widschwendter. (2006) Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other. <i><span class="NLM_source">Current Opinion in Internal Medicine</span></i> <b>5</b>:3, 232-238<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.yco.0000214336.21754.8c" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1142</p><p class="content">Jose de Leon. (2006) AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry. <i><span class="NLM_source">Expert Review of Molecular Diagnostics</span></i> <b>6</b>:3, 277-286<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/14737159.6.3.277" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1143</p><p class="content">Meera Narasimhan, Prakash Masand. (2006) Metabolic syndrome in patients with schizophrenia: CATIE results. <i><span class="NLM_source">Current Psychiatry Reports</span></i> <b>8</b>:3, 213-214<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s11920-006-0025-z" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1144</p><p class="content">J. M. A. Sitsen. (2006) Antipsychotica bij schizofrenie: ja, maar welke?. <i><span class="NLM_source">Medisch-Farmaceutische Mededelingen</span></i> <b>44</b>:5, 136-137<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/BF03058780" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1145</p><p class="content">Julia Engl, Alexander Tschoner, Markus Laimer, Maria Rettenbacher, W. Wolfgang Fleischhacker, Josef R. Patsch, Christoph Ebenbichler. (2006) Metabolische Nebenwirkungen von Antipsychotika der neuen Generation. <i><span class="NLM_source">Wiener klinische Wochenschrift</span></i> <b>118</b>:7-8, 196-206<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/s00508-006-0584-3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1146</p><p class="content">Mahesh B Jayaram, Prakash Hosalli, T S Stroup, Mahesh B Jayaram. 2006. Risperidone versus olanzapine for schizophrenia. . <br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1002/14651858.CD005237.pub2" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1147</p><p class="content">Bruce J. Kinon, Ilya Lipkovich, S. Beth Edwards, David H. Adams, Haya Ascher-Svanum, Samuel G. Siris. (2006) A 24-Week Randomized Study of Olanzapine Versus Ziprasidone in the Treatment of Schizophrenia or Schizoaffective Disorder in Patients with Prominent Depressive Symptoms. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>26</b>:2, 157-162<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.jcp.0000204137.82298.06" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1148</p><p class="content">Alex J. Mitchell. (2006) High Medication Discontinuation Rates in Psychiatry. <i><span class="NLM_source">Journal of Clinical Psychopharmacology</span></i> <b>26</b>:2, 109-112<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.jcp.0000205845.36042.ba" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1149</p><p class="content">Igor Elman, David Borsook, Scott E Lukas. (2006) Food Intake and Reward Mechanisms in Patients with Schizophrenia: Implications for Metabolic Disturbances and Treatment with Second-Generation Antipsychotic Agents. <i><span class="NLM_source">Neuropsychopharmacology</span></i><br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.npp.1301051" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1150</p><p class="content">Kelvin L Chou, Joseph H Friedman. (2006) Are atypical antipsychotics associated with a reduced risk of developing parkinsonism?. <i><span class="NLM_source">Nature Clinical Practice Neurology</span></i> <b>2</b>:3, 132-133<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/ncpneuro0129" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1151</p><p class="content">Diana O. Perkins. (2006) What have we learned from CATIE about the pharmacologic treatment of schizophrenia?. <i><span class="NLM_source">Current Psychosis &amp; Therapeutics Reports</span></i> <b>4</b>:1, 35-39<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/BF02629412" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1152</p><p class="content">Rajiv Tandon. (2006) Pharmacologic treatment of schizophrenia: Current status and future trends. <i><span class="NLM_source">Current Psychosis &amp; Therapeutics Reports</span></i> <b>4</b>:1, 40-49<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/BF02629413" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1153</p><p class="content">EMILY E. LAZAROU, GLENN CATALANO, MARIA C. CATALANO, YOLANDA C. LEON, JACK M. GORMAN. (2006) The Psychological Effects of Leech Therapy After Penile Auto-Amputation. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>12</b>:2, 119-123<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00131746-200603000-00009" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1154</p><p class="content">Nathaniel S. Lehrman. (2006) Rethinking Schizophrenia: Its Original Nature, Its Drug-Altered Character, and Thoughts About Its Treatment. <i><span class="NLM_source">Ethical Human Psychology and Psychiatry</span></i> <b>8</b>:1, 69-76<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1891/ehpp.8.1.69" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1155</p><p class="content">V BAOSVICENTE. (2006) Eficacia de los nuevos antipsic&oacute;ticos frente a los viejos en el paciente con trastornos mentales graves. <i><span class="NLM_source">Atenci&oacute;n Primaria</span></i> <b>37</b>:4, 185-186<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1157/13085944" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1156</p><p class="content">Robert J. Constantine, Sybil M. Richard, Richard C. Surles, David Medvedeff, Naakesh A. Dewan, Lonnie Mann, Janis M. Williamson, Rajiv Tandon. (2006) Optimizing pharmacotherapy of schizophrenia: Tools for the psychiatrist. <i><span class="NLM_source">Current Psychosis &amp; Therapeutics Reports</span></i> <b>4</b>:1, 5-11<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/BF02629408" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1157</p><p class="content">Stefan Leucht. (2006) Translating research into clinical practice: critical interpretation of clinical trials in schizophrenia. <i><span class="NLM_source">International Clinical Psychopharmacology</span></i> <b>21</b>:Supplement 2, S1-S10<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/01.yic.0000194382.18825.78" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1158</p><p class="content">Davis, John M., . (2006) The Choice of Drugs for Schizophrenia. <i><span class="NLM_source">New England Journal of Medicine</span></i> <b>354</b>:5, 518-520<br /><a class="ref nowrap" href="/doi/full/10.1056/NEJMe058298">Full Text</a> <!-- ${xml_link: 10.1056%2FNEJMe058298} --></p></li> <li><p class="number">1159</p><p class="content">T. Scott Stroup, Wayne M. Alves, Robert M. Hamer, Jeffrey A. Lieberman. (2006) Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. <i><span class="NLM_source">Nature Reviews Drug Discovery</span></i> <b>5</b>:2, 133-146<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/nrd1956" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1160</p><p class="content">J. de Leon. (2006) Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19. <i><span class="NLM_source">Psychosomatics</span></i> <b>47</b>:1, 75-85<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1176/appi.psy.47.1.75" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1161</p><p class="content">Tom Valeo. (2006) ON FDA POLICY ON ANTIPSYCHOTICS AND OTHER DRUGS, EXPERTS SAY ‘SHOW US THE DATA’. <i><span class="NLM_source">Neurology</span></i> <b>6</b>:4, 20-21<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00132985-200602210-00010" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1162</p><p class="content"> (2006) Antipsychotic Drugs and Schizophrenia. <i><span class="NLM_source">New England Journal of Medicine</span></i> <b>354</b>:3, 298-300<br /><a class="ref nowrap" href="/doi/full/10.1056/NEJMc052822">Full Text</a> <!-- ${xml_link: 10.1056%2FNEJMc052822} --></p></li> <li><p class="number">1163</p><p class="content">James M Stone, Lyn S Pilowsky. (2006) Antipsychotic drug action: targets for drug discovery with neurochemical imaging. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>6</b>:1, 57-64<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/14737175.6.1.57" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1164</p><p class="content">Josep Maria Haro, Luis Salvador-Carulla. (2006) The SOHO (Schizophrenia Outpatient Health Outcome) Study. <i><span class="NLM_source">CNS Drugs</span></i> <b>20</b>:4, 293-301<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200620040-00003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1165</p><p class="content">Timothy D. Nelson, Ric G. Steele. (2006) Beyond Efficacy and Effectiveness: A Multifaceted Approach to Treatment Evaluation.. <i><span class="NLM_source">Professional Psychology: Research and Practice</span></i> <b>37</b>:4, 389-397<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1037/0735-7028.37.4.389" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1166</p><p class="content">DONNA A. WIRSHING, REBECCA A. SMITH, ZACHARY D. ERICKSON, SHIRLEY J. MENA, WILLIAM C. WIRSHING. (2006) A Wellness Class for Inpatients with Psychotic Disorders. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>12</b>:1, 24-29<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00131746-200601000-00004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1167</p><p class="content">Shitij Kapur, Ofer Agid, Romina Mizrahi, Ming Li. (2006) How antipsychotics work—From receptors to reality. <i><span class="NLM_source">Neurotherapeutics</span></i> <b>3</b>:1, 10-21<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.nurx.2005.12.003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1168</p><p class="content">Pinhas N Dannon, Katherine Lowengrub, Yehudit Gonopolski, Moshe Kotler. (2006) Current and emerging somatic treatment strategies in psychotic major depression. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>6</b>:1, 73-80<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/14737175.6.1.73" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1169</p><p class="content">T R Insel, E M Scolnick. (2006) Cure therapeutics and strategic prevention: raising the bar for mental health research. <i><span class="NLM_source">Molecular Psychiatry</span></i> <b>11</b>:1, 11-17<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/sj.mp.4001777" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1170</p><p class="content">GLENN W. CURRIER, ROSSELLA MEDORI. (2006) Orally Versus Intramuscularly Administered Antipsychotic Drugs in Psychiatric Emergencies. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>12</b>:1, 30-40<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00131746-200601000-00005" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1171</p><p class="content">Steven M. Silverstein, Michi Hatashita-Wong, Sandra Wilkniss, Andrew Bloch, Thomas Smith, Adam Savitz, Richard McCarthy, Michael Friedman, Ken Terkelsen. (2006) Behavioral rehabilitation of the &quot;treatment-refractory&quot; schizophrenia patient: Conceptual foundations, interventions, and outcome data.. <i><span class="NLM_source">Psychological Services</span></i> <b>3</b>:3, 145-169<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1037/1541-1559.3.3.145" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1172</p><p class="content">STEPHEN B. LEVINE. (2006) The PDE-5 Inhibitors and Psychiatry. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>12</b>:1, 46-49<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00131746-200601000-00007" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1173</p><p class="content">Miguel Bernardo, Jose Ram??n Azanza, Carlos Rubio-Terr??s, Javier Rejas. (2006) Cost-Effectiveness Analysis of Schizophrenia Relapse Prevention. <i><span class="NLM_source">Clinical Drug Investigation</span></i> <b>26</b>:8, 447-457<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00044011-200626080-00003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1174</p><p class="content">Richard C Shelton. (2006) Olanzapine/fluoxetine combination for bipolar depression. <i><span class="NLM_source">Expert Review of Neurotherapeutics</span></i> <b>6</b>:1, 33-39<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/14737175.6.1.33" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1175</p><p class="content">Edward M. Scolnick, Tracey Petryshen, Pamela Sklar. (2006) Schizophrenia: Do the Genetics and Neurobiology of Neuregulin Provide a Pathogenesis Model?. <i><span class="NLM_source">Harvard Review of Psychiatry</span></i> <b>14</b>:2, 64-77<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/10673220600642960" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1176</p><p class="content">Salvatore Gentile. (2006) Long-Term Treatment with Atypical Antipsychotics and the Risk of Weight Gain. <i><span class="NLM_source">Drug Safety</span></i> <b>29</b>:4, 303-319<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00002018-200629040-00002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1177</p><p class="content">Richard Balon. (2006) A Review of: “The $800 Million Pill. The Truth Behind the Cost of New Drugs. By Merrill Goozner;”. <i><span class="NLM_source">Annals of Clinical Psychiatry</span></i> <b>18</b>:1, 72-73<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/10401230600648320" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1178</p><p class="content">Emmanuel Stip, Karyne Anselmo, Marcel Wolfe, Christiane Lessard, Pierre Landry. (2006) Long-Term Treatment with Atypical Antipsychotics and Risk of Weight Gain. <i><span class="NLM_source">Drug Safety</span></i> <b>29</b>:6, 550-552<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00002018-200629060-00009" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1179</p><p class="content">F. Limosin. (2006) Apport des antipsychotiques atypiques dans la prise en charge &agrave; long terme de la schizophr&eacute;nie. <i><span class="NLM_source">L Enc&eacute;phale</span></i> <b>32</b>:6, 1065<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016%2FS0013-7006%2806%2976287-X" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1180</p><p class="content">Josep Maria Haro, Diego Novick, Mark Belger, Peter B. Jones. (2006) Antipsychotic type and&nbsp;correlates of&nbsp;antipsychotic treatment discontinuation in&nbsp;the&nbsp;outpatient treatment of&nbsp;schizophrenia. <i><span class="NLM_source">European Psychiatry</span></i> <b>21</b>:1, 41-47<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/j.eurpsy.2005.12.001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1181</p><p class="content">L KENNEDY. (2006) Effectiveness of Antipsychotic Drugs in Patients With Chronic SchizophreniaLieberman JA, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (Columbia Univ, New York; et al) N Engl J Med 353:1209–1223, 2005&sect;. <i><span class="NLM_source">Yearbook of Endocrinology</span></i> <b>2006</b>, 25-27<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1016/S0084-3741(08)70268-3" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1182</p><p class="content">Dennis A Revicki, Clark Paramore, Anne M Rentz. (2005) Incorporating pharmacoeconomic and health outcomes into randomized clinical trials. <i><span class="NLM_source">Expert Review of Pharmacoeconomics &amp; Outcomes Research</span></i> <b>5</b>:6, 695-703<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1586/14737167.5.6.695" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1183</p><p class="content"> (2005) Efficacit&eacute; des antipsychotiques de nouvelle g&eacute;n&eacute;ration dans le traitement de la schizophr&eacute;nie. <i><span class="NLM_source">PSN</span></i> <b>3</b>:5, 261-261<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1007/BF03006251" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1184</p><p class="content">DANA J. H. NIEHAUS, DAN J. STEIN, LIEZL KOEN, CHRISTINE LOCHNER, JACQUELINE E. MULLER, N. IRENE MBANGA, ROBIN A. EMSLEY, JACK M. GORMAN. (2005) A Case of &quot;Ifufunyane&quot;: A Xhosa Culture-Bound Syndrome. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>11</b>:6, 411-413<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00131746-200511000-00009" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1185</p><p class="content">Simon Frantz. (2005) Study shows newer schizophrenia treatments no more effective than old. <i><span class="NLM_source">Nature Reviews Drug Discovery</span></i> <b>4</b>:11, 872-872<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1038/nrd1896" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1186</p><p class="content">MICHAEL H. ALLEN, GLENN W. CURRIER, DANIEL CARPENTER, RUTH W. ROSS, JOHN P. DOCHERTY. (2005) Introduction: Methods, Commentary, and Summary. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>11</b>:Supplement 1, 5-25<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00131746-200511001-00002" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1187</p><p class="content">SIMON C. BURTON. (2005) Strategies for Improving Adherence to Second-Generation Antipsychotics in Patients with Schizophrenia by Increasing Ease of Use. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>11</b>:6, 369-378<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00131746-200511000-00003" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1188</p><p class="content">John Oldham. (2005) The Risk of Unintended Consequences. <i><span class="NLM_source">Journal of Psychiatric Practice</span></i> <b>11</b>:6, 359<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1097/00131746-200511000-00001" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1189</p><p class="content">M. J. Kikkert, A. H. Schene, M. W. J. Koeter, D. Robson, A. Born, H. Helm, M. Nose, C. Goss, G. Thornicroft, R. J. Gray. (2005) Medication Adherence in Schizophrenia: Exploring Patients', Carers' and Professionals' Views. <i><span class="NLM_source">Schizophrenia Bulletin</span></i> <b>32</b>:4, 786-794<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1093/schbul/sbl011" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1190</p><p class="content">Freedman, Robert, . (2005) The Choice of Antipsychotic Drugs for Schizophrenia. <i><span class="NLM_source">New England Journal of Medicine</span></i> <b>353</b>:12, 1286-1288<br /><a class="ref nowrap" href="/doi/full/10.1056/NEJMe058200">Full Text</a> <!-- ${xml_link: 10.1056%2FNEJMe058200} --></p></li> <li><p class="number">1191</p><p class="content">Siegfried Kasper. (2005) Treatment challenges in the acute hospital setting. <i><span class="NLM_source">World Journal of Biological Psychiatry</span></i> <b>6</b>:4, 210-211<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.1080/15622970500355417" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> <li><p class="number">1192</p><p class="content">Corrado Barbui, Camilla Lintas, Mauro Percudani. (2005) Head-To-Head Comparison of the Costs of Atypical Antipsychotics. <i><span class="NLM_source">CNS Drugs</span></i> <b>19</b>:11, 935-950<br /> <!--noindex--><a class="ref" href="http://dx.doi.org/10.2165/00023210-200519110-00004" target="_blank" title="Opens new window"> CrossRef </a> <!--/noindex--></p></li> </ol> </div> </dd> <!--DiscussionReplacer_Tab_--> <dt class="letters" id="lettersTab"> Letters </dt> <dd id="letters"> <div class="letterContent" rel="10.1056/NEJMoa051688"></div> </dd> </dl> </div> <div id="rightRail" class=""> <!-- omit the institutional logo from the following pages --> <!-- toolsContainer --> <div id="toolsContainer"> <!-- toolsBox --> <div id="toolsBox"> <h3>Tools</h3> <ul class="firstGroup"> <li class="downloadPDF"> <a href="/doi/pdf/10.1056/NEJMoa051688" class="zone-tools-articlePdf"> PDF </a> </li> <li class="printPage"> <a href="/doi/full/10.1056/NEJMoa051688" class="viewType-Print viewClass-Print event-zone-tools-articlePrint"> Print </a> </li> <li class="downloadCitation"> <a href="/action/showCitFormats?doi=10.1056%2FNEJMoa051688" class="viewType-Layer viewClass-MediumLayer event-zone-tools-downloadCitation"> Download Citation </a> </li> <li class="downloadSlides"> <a href="/action/showPowerPoint?doi=10.1056%2FNEJMoa051688" id="downloadSlides" class="viewType-Normal event-zone-tools-slideset"> Slide Set </a> </li> </ul> <ul class="secondGroup"> <li class="emailPage"> <a href="/action/showMailPage?href=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;title=Effectiveness+of+Antipsychotic+Drugs+in+Patients+with+Chronic+Schizophrenia&amp;doi=10.1056%2FNEJMoa051688" class="viewType-Layer viewClass-MediumLayer event-zone-tools-articleEmail"> E-Mail </a> </li> <li class="savePage"> <a href="/action/addTag?uactid=savePage&amp;uacturi=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;doi=10.1056%2FNEJMoa051688" id="savePage" class="viewType-Layer viewClass-MediumLayer event-zone-tools-articleSave"> Save </a> </li> <li class="getAlert"> <a href="/action/addCitationAlert?context=add&amp;uactid=getAlert&amp;uacturi=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;doi=10.1056%2FNEJMoa051688" id="getAlert" class="viewType-Layer viewClass-MediumLayer event-zone-tools-articleEmailAlert"> Article Alert </a> </li> <li class="reprints"><a href="/page/about-nejm/reprints-and-permissions" class="zone-tools-reprintsPermissions">Reprints &amp; Permissions</a></li> <li class="addThisIcon"><a href="http://www.addthis.com/bookmark.php" class="addthis_button zone-tools-share-click" target="_blank">Share/Bookmark</a></li> </ul> </div> <!-- /toolsBox --> <!-- toolsAd --> <div class="toolsAd"> <div class="bottomAd"> <div class="ad"> <div id="CM8ShowAd1329516014296" title="MicroTools" class="MicroTools CM8"> <noscript> <a href="http://web.checkm8.com/adam/ep/click/mms.nej.articles/MicroTools"><img src="http://web.checkm8.com/adam/noscript?cat=mms.nej.articles&amp;page=1329516014296&amp;format=MicroTools" border="0" alt="Advertisement" /></a> </noscript> </div> </div> </div> </div> <!-- /toolsAd --> </div> <!-- /toolsContainer --> <div id="related"> <div id="relatedContent"> <h3>Related Articles</h3> <ul> <li><p class="articleType"> <pub-title xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" title-type="toc-heading-title" title-length="standard" title-usage="default" translit-method="none" is-translated="false" media-type="text-xml" source="default" xml:lang="EN"> Editorial </pub-title></p><p class="articleLink"><a href="/doi/full/10.1056/NEJMe058200">The Choice of Antipsychotic Drugs for Schizophrenia</a></p><p class="articleDate">September 22, 2005 | R. Freedman</p></li> <li><p class="articleType"> <pub-title xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" title-type="toc-heading-title" title-length="standard" title-usage="default" translit-method="none" is-translated="false" media-type="text-xml" source="default" xml:lang="EN"> Correspondence </pub-title></p><p class="articleLink"><a href="/doi/full/10.1056/NEJMc052822">Antipsychotic Drugs and Schizophrenia</a></p><p class="articleDate">January 19, 2006</p></li> </ul> </div> <div id="topics"> <h3>Topics</h3> <ul> <li><a href="/browse?subtopic=14_7">Lipids</a></li> <li><a href="/browse?subtopic=7_1">Psychiatry General</a></li> <li><a href="/browse?subtopic=7_5">Schizophrenia</a></li> </ul> </div> <div id="moreIn"> <h3>More In</h3> <ul> <li><a href="/browse?category=research">Research</a></li> <li><a href="/toc/nejm/353/12/">September 22, 2005</a></li> </ul> </div> </div> <div id="rightRailAd"> <div class="bannerAdTower"> <div class="rightTower"> <div id="CM8ShowAd1329516014297" title="MedRectangle" class="MedRectangle CM8"> <noscript> <a href="http://web.checkm8.com/adam/ep/click/mms.nej.articles/MedRectangle"><img src="http://web.checkm8.com/adam/noscript?cat=mms.nej.articles&amp;page=1329516014297&amp;format=MedRectangle" border="0" alt="Advertisement" /></a> </noscript> </div> </div> </div> </div> <div id="trendsBox"> <h3>Trends: Most Viewed <span>(Last Week)</span></h3> <ul> <li> <p class="articleLink"> <a href="/doi/full/10.1056/NEJMimc1109704">A Startling Decline</a> </p> <p class="articleDate">February 9, 2012</p> </li> <li> <p class="articleLink"> <a href="/doi/full/10.1056/NEJMicm1105315">Deep Sulcus Sign</a> </p> <p class="articleDate">February 9, 2012</p> </li> <li> <p class="articleLink"> <a href="/doi/full/10.1056/NEJMra1104650">IgG4-Related Disease</a> </p> <p class="articleDate">February 9, 2012</p> </li> </ul> <p class="moreTrends"><a href="/journal-articles">More Trends</a></p> <div class="bottomAd"> <div class="ad"> <div id="CM8ShowAd1329516014302" title="MicroTrends" class="MicroTrends CM8"> <noscript> <a href="http://web.checkm8.com/adam/ep/click/mms.nej.articles/MicroTrends"><img src="http://web.checkm8.com/adam/noscript?cat=mms.nej.articles&amp;page=1329516014302&amp;format=MicroTrends" border="0" alt="Advertisement" /></a> </noscript> </div> </div> </div> </div> <!-- placeholder id=null, description=N-siteWide-email --> <div class="emailAlert"> <a href="/action/clickThrough?id=1132&amp;url=%2Faction%2FcdfProxy%3Faction%3Dcampaign%26promo%3D%26cpc%3DGMMODULELP%26alertType%3Dcustom%26alertCode%3Dnejm-toc%26backURI%3Dhttp%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa051688&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476"><img src="/sda/1132/eTOC_signUp.gif" /></a> </div> <!-- placeholder id=null, description=N-ad-article-rightRail-1 --> <a href="/action/clickThrough?id=2886&amp;url=http%3A%2F%2Fnejm200.nejm.org%2F%3Fquery%3Dcm&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476" target="_blank"><img src="/sda/2886/Marketing_200_awareness_300x150.jpg" /></a> </div> <script type="text/javascript"> $("#cdfRegister").attr("href", $("#cdfRegister").attr('href') + "&url=" + window.location.href);</script> </div> <div id="footer"> <!-- placeholder id=null, description=N-ad-footer-1 --> <div class="rightAd"> <a href="/action/clickThrough?id=2078&amp;url=%2Fcontinuing-medical-education&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476"><img src="/sda/2078/CME_300Exams_175x48.gif" /></a> </div> <dl> <dt> Content: </dt> <dd> <a href="/" tabindex="100">Home</a> </dd> <dd> <a href="/toc/nejm/medical-journal">Current Issue</a> </dd> <dd> <a href="/medical-article-index">Articles</a> </dd> <dd> <a href="/medical-index">Issue Index</a> </dd> <dd> <a href="/medical-specialties">Specialties &amp; Topics</a> </dd> <dd> <a href="/multimedia">Multimedia &amp; Images</a> </dd> <dd> <a href="/medical-index">Archive 1812-1989</a> </dd> </dl> <dl> <dt> Information For: </dt> <dd> <a href="/action/cdfProxy?action=authorCenter">Authors</a> </dd> <dd> <a href="/action/cdfProxy?action=authorCenter">Reviewers</a> </dd> <dd> <a href="/page/about-nejm/products-and-services">Subscribers</a> </dd> <dd> <a href="/page/institution/resource-center">Institutions</a> </dd> <dd> <a href="/media">Media</a> </dd> <dd> <a href="/page/about-nejm/how-to-advertise">Advertisers</a> </dd> </dl> <dl> <dt> Services: </dt> <dd> <a href="/action/cdfProxy?action=subscribe&amp;promo=ONFLNSA1">Subscribe</a> </dd> <dd> <a href="/action/cdfProxy?action=renew&amp;promo=ONFLNRA1">Renew</a> </dd> <dd> <a href="/action/cdfProxy?action=payBill&amp;promo=BNFLNBA1" rel="nofollow">Pay Bill</a> </dd> <dd> <a href="/action/cdfProxy?action=activate&amp;promo=ONFLNAA1">Activate Subscription</a> </dd> <dd> <a href="/nejm-account" rel="nofollow">Create or Manage Account</a> </dd> <dd> <a href="/nejm-alerts">Alerts</a> </dd> <dd> <a href="/action/showPodcastsFeeds">RSS &amp; Podcasts</a> </dd> <dd> <a href="/action/cdfProxy?action=authorCenter" rel="nofollow">Submit a Manuscript</a> </dd> <dd> <a href="/page/about-nejm/help" rel="nofollow">Help</a> </dd> </dl> <dl> <dt> Resources: </dt> <dd> <a href="http://www.nejmjobs.org/">Physician Jobs</a> </dd> <dd> <a href="/page/about-nejm/reprints-and-permissions" rel="nofollow">Reprints &amp; Permissions</a> </dd> <dd> <a href="/medical-conference">Medical Meetings</a> </dd> <dd> <a href="/page/about-nejm/upcoming-medical-conventions">Conventions</a> </dd> <dd> <a href="/page/about-nejm/frequently-asked-questions" rel="nofollow">FAQs</a> </dd> <dd> <a href="http://www.jwatch.org/">Journal Watch</a> </dd> </dl> <dl> <dt> NEJM: </dt> <dd> <a href="/page/about-nejm/history-and-mission">About</a> </dd> <dd> <a href="/page/about-nejm/products-and-services">Product Information</a> </dd> <dd> <a href="/page/about-nejm/editors-and-publishers" rel="nofollow">Editors &amp; Publishers</a> </dd> <dd> <a href="/page/about-nejm/terms-of-use" rel="nofollow">Terms of Use</a> </dd> <dd> <a href="/page/about-nejm/privacy-policy" rel="nofollow">Privacy Policy</a> </dd> <dd> <a href="/page/about-nejm/copyright-information" rel="nofollow">Copyright</a> </dd> <dd> <a href="/page/about-nejm/advertising-policy" rel="nofollow">Advertising Policies</a> </dd> <dd> <a href="/contact-nejm" rel="nofollow">Contact Us</a> </dd> </dl> <dl> <dt> CME: </dt> <dd> <a href="/page/cme/weekly-cme-program">Weekly CME Program</a> </dd> <dd> <a href="/continuing-medical-education">Browse Weekly Exams</a> </dd> <dd> <a href="/continuing-medical-education/cme-info">Your CME Activity</a> </dd> <dd> <a href="/action/cdfProxy?action=cmeWeekly&amp;url=http%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;promo=ONF4NA1V"> Purchase Exams </a> </dd> <dd> <a href="/page/cme/review-cme">Review CME Program</a> </dd> </dl> <div class="socialNetworking"> <div class="head"> Follow us </div> <ul> <li> <a href="http://www.facebook.com/TheNewEnglandJournalofMedicine" class="facebook"><img src="http://cdn.nejm.org/img/facebook.gif" alt="Facebook" /></a> </li> <li> <a href="http://twitter.com/nejm" class="twitter"><img src="http://cdn.nejm.org/img/twitter.gif" alt="Twitter" /></a> </li> <li> <a href="http://www.youtube.com/nejmvideo" class="youTube"><img src="http://cdn.nejm.org/img/youtube.gif" alt="YouTube" /></a> </li> <li> <a href="http://blogs.nejm.org/now/" class="nowNejmBlog"><img src="http://cdn.nejm.org/img/nowatnejm.gif" alt="Now@NEJM Blog" /></a> </li> </ul> </div> <!-- placeholder id=null, description=N-ad-footer-2 --> </div> <div class="corners dropDown dropDown-myNejm"> <dl class="column"> <dt> <a href="/nejm-account">My Account</a> </dt> <dt> <a href="/nejm-alerts">My Alerts</a> </dt> <dt> <a href="/nejm-saved-items">My Saved Items</a> </dt> <dt> <a href="/continuing-medical-education/cme-info">My CME Exams</a> </dt> </dl> </div> <div class="corners dropDown dropDown-articles"> <dl class="column more"> <dt> Article Category </dt> <dd> <a href="/medical-articles/research">Research</a> </dd> <dd> <a href="/medical-articles/review">Reviews</a> </dd> <dd> <a href="/medical-articles/clinical-cases">Clinical Cases</a> </dd> <dd> <a href="/medical-articles/perspective">Perspective</a> </dd> <dd> <a href="/medical-articles/commentary">Commentary</a> </dd> <dd> <a href="/medical-articles/other">Other</a> </dd> <dd class="moreLink"> <a href="/medical-article-index">Browse all articles</a> </dd> </dl> <dl class="column multimedia more"> <dt> Multimedia </dt> <dd> <a href="/multimedia/medical-videos">Videos in Clinical Medicine</a> </dd> <dd> <a href="/multimedia/images-in-clinical-medicine">Images in Clinical Medicine</a> </dd> <dd> <a href="/multimedia/interactive-medical-case">Interactive Medical Cases</a> </dd> <dd> <a href="/multimedia/audio-summary">Weekly Audio Summaries</a> </dd> <dd class="moreLink"> <a href="/multimedia">Browse all multimedia</a> </dd> </dl> </div> <div class="corners dropDown dropDown-issueArchive"> <dl class="column more"> <dd> <a href="/toc/nejm/medical-journal">This Week</a> </dd> <dd> <a href="/toc/nejm/lastweek">Last Week</a> </dd> <dd class="moreLink"> <a href="/medical-index">Browse full index</a> </dd> </dl> </div> <div class="corners dropDown dropDown-topics"> <dl class="column more"> <!-- placeholder id=null, description=N-menu-selectedSpecialties --> <dt> Selected Specialties </dt> <dd> <a href="/action/clickThrough?id=1367&amp;url=%2Fcardiology&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476">Cardiology</a> </dd> <dd> <a href="/action/clickThrough?id=1367&amp;url=%2Fendocrinology&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476">Endocrinology</a> </dd> <dd> <a href="/action/clickThrough?id=1367&amp;url=%2Fgastroenterology&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476">Gastroenterology</a> </dd> <dd> <a href="/action/clickThrough?id=1367&amp;url=%2Fgenetics&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476">Genetics</a> </dd> <dd> <a href="/action/clickThrough?id=1367&amp;url=%2Foncology-hematology&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476">Hematology/Oncology</a> </dd> <dd> <a href="/action/clickThrough?id=1367&amp;url=%2Finfectious-disease&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476">Infectious Disease</a> </dd> <dd> <a href="/action/clickThrough?id=1367&amp;url=%2Fnephrology&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476">Nephrology</a> </dd> <dd> <a href="/action/clickThrough?id=1367&amp;url=%2Fneurology-neurosurgery&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476">Neurology/Neurosurgery</a> </dd> <dd> <a href="/action/clickThrough?id=1367&amp;url=%2Fgynecology-obstetrics&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476">Obstetrics/Gynecology</a> </dd> <dd> <a href="/action/clickThrough?id=1367&amp;url=%2Fpediatrics&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476">Pediatrics</a> </dd> <dd> <a href="/action/clickThrough?id=1367&amp;url=%2Fclinical-practice-center&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476">Primary Care/Hospitalist</a> </dd> <dd> <a href="/action/clickThrough?id=1367&amp;url=%2Fpulmonary&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476">Pulmonary/Critical Care</a> </dd> <dd> <a href="/action/clickThrough?id=1367&amp;url=%2Fsurgery&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476">Surgery</a> </dd> <dd class="moreLink"> <a href="/action/clickThrough?id=1367&amp;url=%2Fmedical-specialties&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476">Browse all Specialties &amp; Topics</a> </dd> </dl> <dl class="column more"> <!-- placeholder id=null, description=N-menu-featuredTopics --> <dt> Featured Topics </dt> <dd> <a href="/action/clickThrough?id=1366&amp;url=%2Fclinical-practice-center&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476">Clinical Practice Center</a> </dd> <dd> <a href="/action/clickThrough?id=1366&amp;url=%2Fhealth-policy-and-reform&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa051688&amp;pubId=40060476">Health Policy and Reform</a> </dd> </dl> </div> <div class="corners dropDown dropDown-authors"> <dl> <dd> <a href="/action/cdfProxy?action=authorCenter">Author Center</a> </dd> <dd> <a href="/action/cdfProxy?action=authorCenter">Submit a Manuscript or Letter</a> </dd> <dd> <a href="/action/cdfProxy?action=authorCenter">Track a Manuscript</a> </dd> <dd> <a href="/action/cdfProxy?action=authorCenter">Help</a> </dd> </dl> </div> <script type="text/javascript">/* <![CDATA[ */var google_conversion_id = 1070139620;var google_conversion_language = "en";var google_conversion_format = "3";var google_conversion_color = "666666";var google_conversion_label = "_s1RCLTo-QEQ5JGk_gM";var google_conversion_value = 0;/* ]]> */</script> <script type="text/javascript" src="http://www.googleadservices.com/pagead/conversion.js"></script> <noscript> <div style="display:inline;"> <img height="1" width="1" style="border-style:none;" alt="" src="http://www.googleadservices.com/pagead/conversion/1070139620/?label=_s1RCLTo-QEQ5JGk_gM&amp;guid=ON&amp;script=0" /> </div> </noscript> <div id="copyright"> <p>NEJM.org Copyright &copy; 2012 <a href="http://www.massmed.org/">Massachusetts Medical Society</a>. All rights reserved.</p> </div> <!--[if IE]></div><![endif]--> <script language="javascript" src="http://nejm.resultspage.com/autosuggest/searchbox_suggest_v1.js" type="text/javascript"></script> <script language="javascript" type="text/javascript"> try { __SLI_customisations[ __SLI_ApplicationName ][ 'ShowBrandingFooter' ] = false; sli_load(); } catch (ex) { // If SLI scripts cannot be loaded, disable search hints }</script> <input id="showLayers" type="hidden" value="true" /> <!-- placeholder id=null, description=N-Layers_CONFIG --> <!-- placeholder id=null, description=N-ad-lauchLayer-1 --> <!-- placeholder id=null, description=N-ad-promoLayer-1 --> <input id="IsInstitution" type="hidden" value="false" /> <input id="IsSubscriber" type="hidden" value="true" /> <input id="CustomerId" type="hidden" value="" /> <input id="firstAd" type="hidden" value="" /> <input id="secondAd" type="hidden" value="" /> <script type="text/javascript"> jQuery.extend(jQuery.mmsLayers.config, { rules: [{ "name": "Launch Layer Ad", "frequency": 30, "showOnPage": 1, "enabled": true, "cookieName": "MarketingLaunchLayer", "styleClass": "launchLayer" }, { "name": "Promo Layer Ad", "frequency": 42, "enabled": true, "cookieName": "PromoLayer", "styleClass": "promoLayer" }, { "name": "Iperceptions - Ion Layer Ad", "enabled": true, "cookieName":"Iperceptions" }] }); </script> </body> </html>
298	single	medical care and jehovah's witnesses	What are the medical or health care practices followed by members of the Jehovah's Witnesses religion?	clueweb12-0301wb-25-33844	2	<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml" xmlns:fb="http://www.facebook.com/2008/fbml" dir="ltr" lang="en"> <head> <base href="http://www.noblood.org/" /> <!--[if IE]></base><![endif]--> <meta http-equiv="Page-Exit" content="BlendTrans(Duration=0)" /> <meta http-equiv="Page-Enter" content="BlendTrans(Duration=0)" /> <link rel="icon" href="http://www.noblood.org/animated_favicon1.gif" type="image/gif" /> <meta name="google-site-verification" content="a4Emtkyr33VdiazW3Q6iLUTXPy107sx56KPP4WadSrQ" /> <meta http-equiv="Content-Type" content="text/html; charset=utf-8" /> <meta id="e_vb_meta_bburl" name="vb_meta_bburl" content="http://www.noblood.org" /> <meta name="generator" content="vBulletin 4.1.1" /> <meta name="keywords" content="" /> <meta name="description" content="Knocking - Jehovah's Witnesses and Blood" /> <meta property="fb:app_id" content="172443966126528" /> <meta property="og:site_name" content="noblood" /> <meta property="og:description" content="Knocking - Jehovah's Witnesses and Blood" /> <meta property="og:url" content="http://www.noblood.org/content/213-knocking-_jehovah-27s_witnesses_and_blood" /> <meta property="og:type" content="article" /> <meta property="og:image" content="http://www.noblood.org/apple-touch-icon.png" /> <script type="text/javascript" src="http://yui.yahooapis.com/2.7.0/build/yuiloader-dom-event/yuiloader-dom-event.js?v=411"></script> <script type="text/javascript" src="http://yui.yahooapis.com/2.7.0/build/connection/connection-min.js?v=411"></script> <script type="text/javascript"><!-- var SESSIONURL = ""; var SECURITYTOKEN = "guest"; var IMGDIR_MISC = "images/misc"; var IMGDIR_BUTTON = "images/buttons"; var vb_disable_ajax = parseInt("0", 10); var SIMPLEVERSION = "411"; var BBURL = "http://www.noblood.org"; var LOGGEDIN = 0 > 0 ? true : false; var THIS_SCRIPT = "vbcms"; var RELPATH = "content.php?r=213-knocking-_jehovah-27s_witnesses_and_blood"; var PATHS = {forum : ""}// --></script> <script type="text/javascript" src="http://www.noblood.org/clientscript/vbulletin-core.js?v=411"></script> <link rel="alternate" type="application/rss+xml" title="noblood RSS Feed" href="http://www.noblood.org/external.php?type=RSS2" /> <link rel="stylesheet" type="text/css" href="http://www.noblood.org/css.php?styleid=8&amp;langid=1&amp;d=1308790419&amp;td=ltr&amp;sheet=bbcode.css,editor.css,popupmenu.css,reset-fonts.css,vbulletin.css,vbulletin-chrome.css,vbulletin-formcontrols.css,,vbseo_buttons.css" /> <!--[if lt IE 8]> <link rel="stylesheet" type="text/css" href="http://www.noblood.org/css.php?styleid=8&amp;langid=1&amp;d=1308790419&amp;td=ltr&amp;sheet=popupmenu-ie.css,vbulletin-ie.css,vbulletin-chrome-ie.css,vbulletin-formcontrols-ie.css,editor-ie.css" /> <![endif]--> <link href="https://plus.google.com/100079634908993380654" rel="publisher" /> <link rel="alternate" type="application/rss+xml" title="noblood - CMS RSS Feed" href="http://www.noblood.org/external.php?do=rss&amp;type=newcontent&amp;sectionid=1&amp;days=120&amp;count=10" /> <title>noblood - Knocking - Jehovah's Witnesses and Blood</title> <link rel="stylesheet" type="text/css" href="http://www.noblood.org/css.php?styleid=8&amp;langid=1&amp;d=1308790419&amp;td=ltr&amp;sheet=widgets.css,vbcms.css,postbit-lite.css,postlist.css,lightbox.css,overlay.css,tagcloud.css" /> <!--[if lt IE 8]> <link rel="stylesheet" type="text/css" href="http://www.noblood.org/css.php?styleid=8&amp;langid=1&amp;d=1308790419&amp;td=ltr&amp;sheet=widgets-ie.css,vbcms-ie.css,postbit-lite-ie.css,postlist-ie.css,lightbox-ie.css,overlay-ie.css,tagcloud-ie.css" /> <![endif]--> <!--[if lt IE 7]> <script type="text/javascript"> window.LESS_THAN_IE7 = true; </script> <![endif]--> <script type="text/javascript" src="http://www.noblood.org/clientscript/vbulletin_overlay.js?v=411"></script> <script type="text/javascript" src="http://www.noblood.org/clientscript/vbulletin_cms.js?v=411"></script> <script type="text/javascript" src="http://www.noblood.org/clientscript/vbulletin_ajax_htmlloader.js?v=411"> </script> <link rel="stylesheet" type="text/css" href="http://www.noblood.org/css.php?styleid=8&amp;langid=1&amp;d=1308790419&amp;td=ltr&amp;sheet=additional.css" /> <script type="text/javascript" src="vbseo/resources/scripts/vbseo_ui.js?v=a4"></script> <script type="text/javascript"> YAHOO.util.Event.onDOMReady(function (){ vbseoui = new vBSEO_UI("php"); vbseoui.page_init(Array('postbody','blogbit','content','postcontainer','vbseo_like_postbit')); });</script> <script type="text/javascript"><!--window.google_analytics_uacct = 'RJMM-W44VY-3F4Q';var _gaq = _gaq || [];_gaq.push(['_setAccount', 'RJMM-W44VY-3F4Q'],['_setVar', 'usergroup-1-Unregistered / Not Logged In'],['_trackPageview']);(function() {var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);})();//--></script> </head> <body style="text-align:left"> <div class="above_body"> <!-- closing tag is in template navbar --> <div id="header" class="floatcontainer doc_header"> <div> <a name="top" href="http://www.noblood.org" class="logo-image"><img src="http://www.noblood.org/images/styles/bluesenseless/logo.gif" alt="noblood" /></a> </div> <div id="toplinks" class="toplinks"> <ul class="nouser"> <li><a href="http://www.noblood.org/signup" rel="nofollow">Register</a></li> <li><a rel="help" href="http://www.noblood.org/faq">Help</a></li> <li> <script type="text/javascript" src="http://www.noblood.org/clientscript/vbulletin_md5.js?v=411"></script> <form id="navbar_loginform" action="http://www.noblood.org/login.php?do=login" method="post" onsubmit="md5hash(vb_login_password, vb_login_md5password, vb_login_md5password_utf, 0)"> <fieldset id="logindetails" class="logindetails"> <div> <div> <input type="text" class="textbox default-value" name="vb_login_username" id="navbar_username" size="10" accesskey="u" tabindex="101" value="User Name" /> <input type="password" class="textbox" tabindex="102" name="vb_login_password" id="navbar_password" size="10" /> <input type="text" class="textbox default-value" tabindex="102" name="vb_login_password_hint" id="navbar_password_hint" size="10" value="Password" style="display:none;" /> <input type="submit" class="loginbutton" tabindex="104" value="Log in" title="Enter your username and password in the boxes provided to login, or click the 'register' button to create a profile for yourself." accesskey="s" /> </div> </div> </fieldset> <div id="remember" class="remember"> <label for="cb_cookieuser_navbar"><input type="checkbox" name="cookieuser" value="1" id="cb_cookieuser_navbar" class="cb_cookieuser_navbar" accesskey="c" tabindex="103" /> Remember Me?</label> </div> <input type="hidden" name="s" value="" /> <input type="hidden" name="securitytoken" value="guest" /> <input type="hidden" name="do" value="login" /> <input type="hidden" name="vb_login_md5password" /> <input type="hidden" name="vb_login_md5password_utf" /> </form> <script type="text/javascript"> YAHOO.util.Dom.setStyle('navbar_password_hint', "display", "inline"); YAHOO.util.Dom.setStyle('navbar_password', "display", "none"); vB_XHTML_Ready.subscribe(function() { // YAHOO.util.Event.on('navbar_username', "focus", navbar_username_focus); YAHOO.util.Event.on('navbar_username', "blur", navbar_username_blur); YAHOO.util.Event.on('navbar_password_hint', "focus", navbar_password_hint); YAHOO.util.Event.on('navbar_password', "blur", navbar_password); }); function navbar_username_focus(e) { // var textbox = YAHOO.util.Event.getTarget(e); if (textbox.value == 'User Name') { // textbox.value=''; textbox.style.color='#303030'; } } function navbar_username_blur(e) { // var textbox = YAHOO.util.Event.getTarget(e); if (textbox.value == '') { // textbox.value='User Name'; textbox.style.color='#828282'; } } function navbar_password_hint(e) { // var textbox = YAHOO.util.Event.getTarget(e); YAHOO.util.Dom.setStyle('navbar_password_hint', "display", "none"); YAHOO.util.Dom.setStyle('navbar_password', "display", "inline"); YAHOO.util.Dom.get('navbar_password').focus(); } function navbar_password(e) { // var textbox = YAHOO.util.Event.getTarget(e); if (textbox.value == '') { YAHOO.util.Dom.setStyle('navbar_password_hint', "display", "inline"); YAHOO.util.Dom.setStyle('navbar_password', "display", "none"); } } </script> </li> <li id="fb_headerbox" class="hidden"> <a id="fb_loginbtn" href="http://www.noblood.org/content/213-knocking-_jehovah-27s_witnesses_and_blood#"><img src="http://www.noblood.org/images/misc/facebook_login.gif" alt="The Facebook Platform" /></a></li> </ul> </div> <div class="ad_global_header"> <div id="ad_global_header1"></div> </div> <hr /> </div> <div id="navbar" class="navbar"> <ul id="navtabs" class="navtabs floatcontainer"> <li class="selected"> <a class="navtab" href="http://www.noblood.org/content/">Home</a> <ul class="floatcontainer"> <li><a href="http://www.noblood.org/content/">The Front Page</a></li> <li><a href="http://www.noblood.org/content/section/5-news/">The Pulse (News)</a></li> </ul></li> <li><a class="navtab" href="http://www.noblood.org/forums">Forum</a></li> <li><a class="navtab" href="http://www.noblood.org/downloads/">Downloads</a></li> <li><a class="navtab" href="http://www.noblood.org/search.php?do=getdaily&amp;contenttype=vBForum_Post" accesskey="2">What's New?</a></li> <li><a class="navtab" href="http://www.noblood.org/donations" target="_self"> <u>Support NoBlood</u></a></li> <li><a class="navtab" href="http://www.noblood.org/bloodless-medicine-surgery-hospital-directory" target="_self"> Hospital Directory</a></li> <li><a class="navtab" href="http://www.noblood.org/transfusion-alternatives-blood-management-resources-map" target="_self"> Resources Map</a></li> </ul> <div id="globalsearch" class="globalsearch"> <form action="http://www.noblood.org/search.php?do=process" method="post" id="navbar_search" class="navbar_search"> <input type="hidden" name="securitytoken" value="guest" /> <input type="hidden" name="do" value="process" /> <span class="textboxcontainer"><span><input type="text" value="" name="query" class="textbox" tabindex="99" /></span></span> <span class="buttoncontainer"><span><input type="image" class="searchbutton" src="images/buttons/search.png" name="submit" onclick="document.getElementById('navbar_search').submit;" tabindex="100" /></span></span> </form> <ul class="navbar_advanced_search"> <li><a href="http://www.noblood.org/search.php" accesskey="4">Advanced Search</a></li> </ul> </div> </div> </div> <!-- closing div for above_body --> <div class="body_wrapper"> <div id="breadcrumb" class="breadcrumb"> <ul class="floatcontainer"> <li class="navbithome"><a href="http://www.noblood.org/forums" accesskey="1"><img src="http://www.noblood.org/images/misc/navbit-home.png" alt="Home" /></a></li> <li class="navbit"><a href="http://www.noblood.org/content/">Home</a></li> <li class="navbit"><a href="http://www.noblood.org/content/section/134-library/">Library</a></li> <li class="navbit"><a href="http://www.noblood.org/content/section/118-articles/">Articles</a></li> <li class="navbit lastnavbit"><span>Knocking - Jehovah's Witnesses and Blood</span></li> </ul> <hr /> </div> <div style="text-align:center; padding:10px;"> <a rel="nofollow" href="http://www.noblood.org/rbs_banner.php?id=4&amp;userid=0" target="_blank"><img src="http://www.noblood.org/_files/ads/93FB.png" border="0" alt="Please click to visit Nationwide Childrens Hospital's website." /></a> </div> <form action="http://www.noblood.org/profile.php?do=dismissnotice" method="post" id="notices" class="notices"> <input type="hidden" name="do" value="dismissnotice" /> <input type="hidden" name="s" value="" /> <input type="hidden" name="securitytoken" value="guest" /> <input type="hidden" id="dismiss_notice_hidden" name="dismiss_noticeid" value="" /> <input type="hidden" name="url" value="" /> <div id="vbseo_vhtml_0"></div> </form> <div class="vbcms_content"> <div id="doc3" class="yui-tvb-r3"> <div id="bd"> <div id="yui-main"> <div class="yui-b"> <div class="yui-u yui-panel"> <ul class="list_no_decoration widget_list" id="widgetlist_column1"> <li> <!-- styles defined in template: headinclude --> <div class="article_width" id="article_content"> <div class="title"> <h1 class="article_title cms_article_title"><span>Knocking - Jehovah's Witnesses and Blood</span> </h1> </div> <div class="article_author_date_comment_container"> <div class="fullwidth"> <div> <div align="right"> <iframe id="fb_likeframe" style="height:25px" src="http://www.facebook.com/plugins/like.php?href=http%3A%2F%2Fwww.noblood.org%2Fcontent%2F213-knocking-_jehovah-27s_witnesses_and_blood&amp;layout=standard&amp;show_faces=false&amp;width=450&amp;a ction=like&amp;font=tahoma&amp;colorscheme=light&amp;height=27" scrolling="no" frameborder="0" allowtransparency="true"></iframe> </div> </div> <div class="article_username_container"> by <div class="popupmenu memberaction"> <a class="username offline " href="http://www.noblood.org/members/editorial-team" title="Editorial Team is offline"><strong>Editorial Team</strong></a> </div> </div> <div class="article_rating_container"> <div class="popupmenu cmsratingmenu" id="cmsrating"> <h6><a class="popupctrl" href="javascript://" id="cmsrating_current">Rate this article</a></h6> <form action="http://www.noblood.org/content/?213/rate" method="post" id="cms_cmsrate_form"> <ul class="popupbody popuphover"> <li><label for="r5"><span class="rating5 cmsrating right"> <input type="radio" name="vote" value="5" id="r5" tabindex="1" /> </span></label></li> <li><label for="r4"><span class="rating4 cmsrating right"> <input type="radio" name="vote" value="4" id="r4" tabindex="1" /> </span></label></li> <li><label for="r3"><span class="rating3 cmsrating right"> <input type="radio" name="vote" value="3" id="r3" tabindex="1" /> </span></label></li> <li><label for="r2"><span class="rating2 cmsrating right"> <input type="radio" name="vote" value="2" id="r2" tabindex="1" /> </span></label></li> <li><label for="r1"><span class="rating1 cmsrating right"> <input type="radio" name="vote" value="1" id="r1" tabindex="1" /> </span></label></li> <li class="formsubmit"><input type="submit" class="button" value="Vote Now" tabindex="1" /></li> </ul> <input type="hidden" name="s" value="" /> <input type="hidden" name="securitytoken" value="guest" /> </form> <script type="text/javascript" src="http://www.noblood.org/clientscript/cms_ajax_rate.js?v=411"></script> <script type="text/javascript"> <!-- var nodeid = 213; vB_AJAX_CMSRate_Init('cms_cmsrate_form'); //--> </script> </div> </div> <div class="cms_clear"></div> <div class="article_username_container"> &nbsp;Number of Views: 15850 &nbsp; </div> </div> </div> <div class="clear"></div> <div class="article cms_clear restore postcontainer"> The therapeutic use of blood dates back to antiquity. <p>However, only in the early 20th century did scientists discover various blood types and develop workable transfusion techniques and blood-banking methods. Large-scale use of blood transfusions first took place on the battlefields of World War II, and Americans flocked to blood drives to do their part for wounded troops.</p> <p>In succeeding decades, scientists continued to hone technologies to test, store and administer blood, learning both from medical successes and failures how to improve outcomes. As understanding of the complex properties of blood advanced, doctors have been able to separate blood into major and minor fractions for targeted use in treating specific conditions. They have worked to produce effective blood screening tests to detect blood-borne illnesses, tracking systems to eliminate human error, and bloodconservation methods to circumvent chronic donor-blood shortages and transfusion-related complications.</p> <p>Despite the fact that advances in blood technologies have been credited with saving countless lives, the blood industry has also had its share of difficulties and negative press. In the 1980s and 1990s, headlines announced numerous lawsuits brought by victims of tainted-blood scandals and transfusion-matching errors. For instance, by 1985, about 47 percent of Canadian hemophiliacs became infected with HIV from contaminated coagulants. A jittery public read about similar scandals in France, Switzerland and Germany. Such incidents fueled widespread fears about the integrity of the blood supply because of new forms of hepatitis, West Nile virus, Chagas’ disease, Lyme disease and Mad Cow disease. Scientists continue to improve screening tests for such diseases and have greatly reduced the risks.</p> <p>As doctors worked to cope with these medical challenges, they found an unlikely partner in Jehovah’s Witnesses. In previous years, headlines often reported about Witnesses and doctors locked in battle over the right to determine treatment. Witnesses sought good medical care, but they flatly refused blood transfusions for themselves and their children on religious grounds, even if critically sick or injured. Doctors, not wishing to be deprived of an important treatment option, sometimes refused to treat or operate on Witnesses. In cases of life-threatening illness or injuries, judges often issued emergency court orders, allowing doctors to override patient objections and transfuse if necessary. Witnesses too went to court, arguing for patient autonomy and the patient’s right of informed consent. This tension between medical science and religious conviction created ethical dilemmas for medical professionals and Witness patients alike.</p> <p>The blood-supply crises of the 1980s and 1990s, however, coincided with a marked easing of tensions between the medical profession and Witness patients. Forced by the HIV epidemic and blood shortages to seek alternatives to transfusions of donated blood, doctors found the Witnesses willing to test new therapies and surgical techniques that would maximize the body’s own blood-producing capacity and minimize blood loss during surgery. Doctors to date have successfully performed a wide variety of treatments and surgical procedures without blood, including open-heart surgery and organ transplants. Medical studies have demonstrated the therapeutic benefits of blood-conservation strategies, prompting some doctors and surgeons to recommend the use of less or no blood for all their patients. As of 2006, there are 142 hospitals and over 100,000 doctors in the United States that offer some version of bloodless treatment to all patients regardless of religious beliefs. (See “Blood Conservation Strategies” on page 28)</p> <p>In pursuing their own rights, Jehovah’s Witnesses played a crucial role in securing for all adults the right to choose treatment options and to refuse certain types of medical care. Critical situations still arise in which doctors consider blood an indispensable treatment.</p> <p>Patients’ rights allow adult Witnesses to refuse potentially life-saving transfusions. However, legally doctors have the right to administer blood to minor children.</p> <p>On an organizational level, the Witnesses have worked proactively to build a better working relationship with doctors and hospital administrators by setting up liaison committees that direct Witness patients to hospitals willing to use bloodless technology.</p> <a name="Religion_and_Medicine"></a> <h1>Religion and Medicine</h1> <p>While secular society may feel that religious opinions on health matters overreach personal freedom and autonomy, world religions have historically taken ethical positions on health, dietary and medical issues. Religious views toward new technologies are often cautious at first and then moderate over time. For example, in the early 20th century, numerous religious communities objected to small-pox vaccinations. When doctors began experimenting with human organ transplants in the late 1960s, major religions, including Catholicism, Judaism and Islam, issued warnings against the practice. Some objected because the procedure involved cutting an organ from a living body; others, like the Witnesses, viewed transplantation as a form of cannibalism. Although the practice has now gained acceptance by most religions, certain branches of the Jewish and Muslim faiths continue to disagree over the issue of transplants.</p> <p>The rapid advance of medical research continues to pose new religious dilemmas over life and death. Religious thinkers have been forced to consider scientific technology when dealing with such theological issues as defining the moment of conception and the moment of death. Questions relating to fertility, contraception, abortion and stem-cell research will likely be the focus of religious debates for a long time to come.</p> <a name="Blood_Conservation_Strategies"></a> <h1>Blood Conservation Strategies</h1> <ul> <li><b>Cell Saver</b>: A blood salvage method that collects blood from the incision site and returns it to the patient, maintaining continuous connection as an extension of the circulatory system.</li> <li><b>Erythropoietin (EPO)</b>: A hormone, now genetically engineered, that stimulates the bone marrow to produce red blood cells.</li> <li><b>Argon Beam Coagulator</b>: An electrocautery device that controls small-artery bleeding and is often used in surgeries on organs that bleed easily.</li> <li><b>Microwave Coagulating and Harmonic Scalpels</b>: Use microwave and high-speed vibration, respectively, to cause coagulation.</li> <li><b>Nonblood Fluids</b>: Ringer’s lactate, dextran, hetastarch and saline are used to maintain blood volume, which prevent shock and facilitate red-cell circulation.</li> </ul> <p>Lecture Series: JEHOVAH’S WITNESSES AND MEDICINE Dr. Arthur Caplan, University of Pennsylvania</p> <p>Lecture Segments on DVD</p> <ul> <li>C1: Saying No to Blood</li> <li>C2: Jehovah’s Witnesses + AIDS = Bloodless Surgery</li> <li>C3: Ethical Dilemmas</li> <li>C4: Bloodless Mavericks vs. Transfusion Conservatives</li> <li>C5: Children and Bloodless Surgery</li> <li>C6: Medical Legacy</li> </ul> <a name="Discussion_Prompts"></a> <h1>Discussion Prompts</h1> <ul> <li>What emotional and ethical issues come into play for Witnesses who refuse blood transfusions? How should medical professionals balance their commitment to save lives with their obligation to respect patient autonomy? Dr. Caplan remarks that medical science improved because of its willingness to accommodate the Witnesses. Yet advancement always involves the risk of failure. Discuss the pros and cons of innovation versus conservatism in the medical field. [Segments C3, C4]</li> <li>Consider Dr. Caplan’s remarks about medical paternalism and patient autonomy. Do you see the initially adversarial relationship between Witnesses and doctors as unnecessary, or was it an inevitable part of the process of change? What part did each side play in the debates as they played out? [Segment C1]</li> <li>What irony does Dr. Caplan note in respect to the children of Jehovah’s Witnesses? Should the State have the authority to overrule parental objections when it comes to minors? In hospitals that perform bloodless surgery on adults, what factors should they consider in deciding whether or not to do the same for children if their parents request it? [Segment C5]</li> <li>The AIDS crisis and the religious views of Jehovah’s Witnesses acted as catalysts for revolutionary changes in blood therapies and in patient autonomy. As with other aspects of Witness history, their fight for patients’ rights has overlapped with the efforts of groups that they do not support, such as abortion rights activists. How much credit should the Witnesses be given for these advances, the benefits of which extend beyond their group? In what ways has the Witness position directly affected you or your family? [Segments C2, C6]</li> <li>Name examples of religious or ethical beliefs that have implications for physical health and medical choices. Should treatment of physical health always take priority over such beliefs? When, if ever, should society or the law intervene in the practice of such beliefs? What legal principles are relevant in debates over bodily determination?</li> </ul> <a name="The_Bible_and_Blood"></a> <h1>The Bible and Blood</h1> <p>Jehovah’s Witnesses refuse to take in blood or its major components primarily for religious reasons: blood is sacred and should only be used as God designates. Witnesses base their position on an interpretation of Bible texts that prohibit the taking of blood into the body for the purpose of sustaining the body’s functions. They refer to the following Biblical passages:</p> <ul> <li>Genesis 9:3-4: “Every moving animal that is alive may serve as food for you….Only flesh with its soul—its blood—you must not eat.” *Leviticus 17:14: “You must not eat the blood of any sort of flesh, because the soul of every sort of flesh is its blood.”</li> <li>Acts 15:29: “Keep abstaining … from blood.”</li> </ul> <p>Although the first two passages refer to blood taken as food, the Witnesses argue that the prohibition includes intravnous transfusions, which may bypass the digestive system but still nourish the body. This would include use of the patient’s own pre-stored blood.</p> <p>The official organizational position rejects the taking in of whole blood or its four major components, namely, red blood cells, white blood cells, plasma, and platelets. However, advancements in blood technology have enabled doctors to fractionate these components even further, extracting elements such as clotting factors, immune globulin, and hemoglobin. In cases of treatments involving such blood derivatives, individual Jehovah’s Witnesses are allowed to decide for themselves which blood fractions, if any, are personally acceptable. This difference of opinion is tolerated within the congregation, and each Witness is encouraged at all times to carry a legally-executed document stating his or her choices.</p> <a name="What_About_Transplants.3F"></a> <h1>What About Transplants?</h1> <p>Like other religions, Jehovah’s Witnesses at first considered organ transplants as morally wrong, equivalent to cannibalism. However, beginning in 1980, Jehovah’s Witnesses were told they should decide for themselves whether receiving an organ or tissue transplant was acceptable or not. The organ unquestionably contains blood, which is why some Witnesses will refuse it. But other Witnesses rationalize that the intent is to receive the organ, not the residual blood that remains in it.</p> <a name="Related_Articles"></a> <h2>Related Articles</h2> <p><a id="cwdoc119" href="http://www.noblood.org/content/227-pediatric_court_orders" title="Pediatric Court Orders">Pediatric Court Orders</a>|<a id="cwdoc51" href="http://www.noblood.org/content/179-erythropoietin_-28epo-29" title="Erythropoietin (EPO)">Erythropoietin (EPO)</a>|<a id="cwdoc5" href="http://www.noblood.org/content/142-acute_normovolemic_hemodilution" title="Acute Normovolemic Hemodilution">Acute Normovolemic Hemodilution (ANH)</a>|<a id="cwdoc6" href="http://www.noblood.org/content/143-advance_directive" title="Advance Directive">Prepare Now For a Possible Medical Emergency</a>|<a id="cwdoc49" href="http://www.noblood.org/content/178-epidural_blood_patch" title="Epidural Blood Patch">Epidural Blood Patch (EBP)</a>| [[Patients_Who_Refuse_Blood_Transfusions_-_FAQs<a id="cwdoc87" href="http://www.noblood.org/content/209-intraoperative_blood_salvage" title="Intraoperative blood salvage">Intraoperative blood salvage</a>|Blood Fractions Guide</p> <div class="vbseo_buttons" id="lkbtn_3.213.-1"> <ul class="vbseo_links"> <li class="vbseo_share"><a href="http://www.noblood.org/content/213-knocking-_jehovah-27s_witnesses_and_blood#">Share</a> <ul class="vbseo_share_body"> <li class="header">Share this post on</li> <li class="right"><img src="http://www.noblood.org/vbseo/resources/images/forum/digg.gif" width="18px" height="18px" /><a rel="nofollow" href="http://digg.com/submit?phase=2&amp;amp;url=http%3A%2F%2Fwww.noblood.org%2Fcontent%2F213-knocking-_jehovah-27s_witnesses_and_blood&amp;amp;title=Knocking+-+Jehovah%27s+Witnesses+and+Blood"></a></li> <li class="left"><img src="http://www.noblood.org/vbseo/resources/images/forum/delicious.gif" width="18px" height="18px" /><a rel="nofollow" href="http://del.icio.us/post?url=http%3A%2F%2Fwww.noblood.org%2Fcontent%2F213-knocking-_jehovah-27s_witnesses_and_blood&amp;amp;title=Knocking+-+Jehovah%27s+Witnesses+and+Blood"></a></li> <li class="right"><img src="http://www.noblood.org/vbseo/resources/images/forum/technorati.gif" width="18px" height="18px" /><a rel="nofollow" href="http://technorati.com/faves/?add=http%3A%2F%2Fwww.noblood.org%2Fcontent%2F213-knocking-_jehovah-27s_witnesses_and_blood"></a></li> <li class="left"><img src="http://www.noblood.org/vbseo/resources/images/forum/twitter.png" width="18px" height="18px" /><a rel="nofollow" href="http://twitter.com/home?status=Knocking+-+Jehovah%27s+Witnesses+and+Blood http%3A%2F%2Fwww.noblood.org%2Fcontent%2F213-knocking-_jehovah-27s_witnesses_and_blood"></a></li> </ul> </li> </ul> <div class="vbseo_liked" style="display:none"></div> </div> </div> <script type="text/javascript" src="http://www.noblood.org/clientscript/vbulletin_lightbox.js?v=411"></script> <script type="text/javascript"> <!-- vBulletin.register_control("vB_Lightbox_Container", "article_content", 1); //--> </script> <div class="cmslinks"> <sub class="article_promoted_text"> <span id="articletagcontainer_{$contentid}"> Tags : <span id="articletaglist_126"> <ul class="commalist"> <li><a href="http://www.noblood.org/tags/acute%20normovolemic%20hemodilution.html">acute normovolemic hemodilution</a></li> <li><a href="http://www.noblood.org/tags/advance%20directive.html">advance directive</a></li> <li><a href="http://www.noblood.org/tags/blood%20fractions.html">blood fractions</a></li> <li><a href="http://www.noblood.org/tags/documentary.html">documentary</a></li> <li><a href="http://www.noblood.org/tags/epidural%20blood%20patch.html">epidural blood patch</a></li> <li><a href="http://www.noblood.org/tags/erythropoietin%20%28epo%29.html">erythropoietin (epo)</a></li> <li><a href="http://www.noblood.org/tags/intraoperative%20blood%20salvage.html">intraoperative blood salvage</a></li> <li><a href="http://www.noblood.org/tags/pbs%20documentary.html">pbs documentary</a></li> <li><a href="http://www.noblood.org/tags/pediatric%20court%20orders.html">pediatric court orders</a></li> </ul> <img src="http://www.noblood.org/images/misc/11x11progress.gif" id="tag_form_progress" class="inlineimg hidden" alt="" /> </span> </span> </sub> </div> </div> </li> </ul> </div> </div> </div> <div class="yui-b yui-sidebar"> <ul class="list_no_decoration widget_list" id="widgetlist_column2"> <li><script type="text/javascript"><!-- var IMGDIR_MISC = "images/misc"; var vb_disable_ajax = parseInt("0", 10); /* Start Sections Widget Configuration */ vbGlobal_SHOW_ALL_TREE_ELEMENTS_THRESHOLD = parseInt("20"); /* End Seections Widget Configuration */// --></script><script type="text/javascript" src="http://yui.yahooapis.com/2.7.0/build/treeview/treeview-min.js"></script> <!-- start treeview css --><script type="text/javascript"> if (window.loadVbCss) { loadVbCss("http://yui.yahooapis.com/2.7.0/build/treeview/assets/skins/sam/treeview.css",true); }</script> <!-- end treeview css --> <!-- custom treeview styles defined at template: headinclude --> <!-- END VB Tree-Menu Implementation of YUI TreeView --> <div class="cms_widget"> <div class="block"> <div class="cms_widget_header"> <h3><img src="http://www.noblood.org/images/cms/sections.png" alt="" /> Sections</h3> </div> <div class="cms_widget_content widget_content"> <div class="vb-tree-menu"> <ul> <li><a href="http://www.noblood.org/content/section/5-news/">The Pulse (News)</a></li> <li><a href="http://www.noblood.org/content/section/113-prepare-now/">Prepare Now</a></li> <li><a href="http://www.noblood.org/content/section/134-library/">Library</a> <ul> <li><a href="http://www.noblood.org/content/section/118-articles/">Articles</a></li> <li><a href="http://www.noblood.org/content/section/116-glossary/">Glossary</a></li> <li><a href="http://www.noblood.org/content/section/136-quotes/">Quotes</a></li> </ul> </li> </ul> </div> <noscript> <div class="cms_widget_sectionnav"> <div class="cms_widget_sectionnav_page"> <div class="main_menuitem" style="text-indent:20px"> <a href="http://www.noblood.org/content/section/5-news/">The Pulse (News)</a> </div> <div class="main_menuitem" style="text-indent:20px"> <a href="http://www.noblood.org/content/section/113-prepare-now/">Prepare Now</a> </div> <div class="main_menuitem" style="text-indent:20px"> <a href="http://www.noblood.org/content/section/134-library/">Library</a> </div> <div class="active_menuitem" style="text-indent:40px"> <a href="http://www.noblood.org/content/section/118-articles/">Articles</a> </div> <div class="main_menuitem" style="text-indent:40px"> <a href="http://www.noblood.org/content/section/116-glossary/">Glossary</a> </div> <div class="main_menuitem" style="text-indent:40px"> <a href="http://www.noblood.org/content/section/136-quotes/">Quotes</a> </div> </div> </div> </noscript> </div> </div> </div><script type="text/javascript"> initVbTreeMenus(false);</script> </li> <li> <div class="cms_widget"> <div class="block"> <div class="cms_widget_header"> <h3><img src="http://www.noblood.org/images/site_icons/html.png" alt="" /> Please Visit Our Sponsors</h3> </div> <div class="cms_widget_content_restore_widget_content"> <style><!-- #ads {text-align:center;padding: 0px; width:200px;} #ads h3 {font-size: 11px;font-weight:normal;} #ads img {border:none;padding: 1px;}--></style> <div id="ads"> <a onclick="_gaq.push(['_trackEvent', 'Outgoing', 'www.sanramonmedctr.com', '/en-US/ourServices/medicalServices/Pages/BloodConservationProgramatSanRamon.aspx']);" href="http://www.sanramonmedctr.com/en-US/ourServices/medicalServices/Pages/BloodConservationProgramatSanRamon.aspx"><img src="http://www.noblood.org/_files/ads/65.png" width="200" height="50" title="San Ramon Regional Medical Center - San Ramon, California - We're known for our advanced inpatient and outpatient medical and surgical services, including minimally invasive surgical technology. We also offer many other quality services, such as cardiac cancer care, oncology and orthopedics." /></a> <br /> <a onclick="_gaq.push(['_trackEvent', 'Outgoing', 'rainbowbabies.org', '/']);" href="http://rainbowbabies.org/"><img src="http://www.noblood.org/_files/ads/48.png" width="120" height="70" title="Rainbow Babies &amp; Children's Hospital - Cleveland, Ohio - Located on the campus of University Hospitals Case Medical Center in Cleveland, Ohio, University Hospitals Rainbow Babies &amp; Children's Hospital is a 244-bed, full-service pediatric hospital and academic medical center, solely dedicated to the health care needs of children. A trusted leader in children's health care for more than 125 years, UH Rainbow Babies &amp; Children's Hospital consistently ranks among the top children's hospitals in the nation. As the region's premier resource for pediatric referrals, UH Rainbow Babies &amp; Children's Hospital's dedicated team of more than 1,300 pediatric specialists uses the most advanced treatments and latest innovations to deliver the complete range of pediatric specialty services to approximately 9,000 inpatients and 550,000 outpatients each year. Learn more at RainbowBabies.org.Among the nation's leading academic medical centers, University Hospitals Case Medical Center is the primary affiliate of Case Western Reserve University School of Medicine, a nationally recognized leader in medical research and education. " /></a> <br /> <a onclick="_gaq.push(['_trackEvent', 'Outgoing', 'www.pennhealth.com', '/bloodless/']);" href="http://www.pennhealth.com/bloodless/"><img src="http://www.noblood.org/_files/ads/88.png" width="160" height="46" title="Pennsylvania Hospital - Philadelphia, PA - Bloodless medicine and surgery is a safe and effective method of treating patients without using whole blood or blood products such as red cells, white cells, platelets and plasma. Patients choose non-blood treatment for religious, personal, ethical or medical reasons. Some patients choose non-blood medicine or surgical management over concern about the nation's blood supply." /></a> <br /> <a onclick="_gaq.push(['_trackEvent', 'Outgoing', 'www.nationwidechildrens.org', '/heart-surgery']);" href="http://www.nationwidechildrens.org/heart-surgery"><img src="http://www.noblood.org/_files/ads/93.png" width="130" height="50" title="Nationwide Children's Hospital - Columbus, OH - Cardiothoracic surgeons at The Heart Center at Nationwide Children's use a variety of surgical techniques - from minimally invasive to open heart - to repair congenital and acquired heart defects ranging from the most straightforward to the extremely complex. We are experts in the treatment of complex newborn heart conditions including Hypoplastic Left Heart Syndrome. We also are highly skilled in blood conservation surgery for those patients who require it, such as those of the Jehovah Witness faith." /></a> <br /> <a onclick="_gaq.push(['_trackEvent', 'Outgoing', 'www.atlantamedcenter.com', '/CWSContent/atlantamedcenter/ourServices/medicalServices/BloodlessMedicineSurgery/']);" href="http://www.atlantamedcenter.com/CWSContent/atlantamedcenter/ourServices/medicalServices/BloodlessMedicineSurgery/"><img src="http://www.noblood.org/_files/ads/96.png" width="160" height="40" title="Atlanta Medical Center - Atlanta, Georgia - Atlanta Medical Center's Bloodless Medicine and Surgery program offers blood conservation services and a coordinator 24-hours a day. Services include: physician referrals, assistance with outpatient services, scheduling, information for family member accommodations, and out-of-town lodging." /></a> <br /> <a onclick="_gaq.push(['_trackEvent', 'Outgoing', 'www.palmdaleregional.com', '/Hospital-Services-O-Z/Transfusion-Free-Medicine']);" href="http://www.palmdaleregional.com/Hospital-Services-O-Z/Transfusion-Free-Medicine"><img src="http://www.noblood.org/_files/ads/97.png" width="160" height="40" title="Palmdale Regional Medical Center - Our Transfusion-Free Medicine and Surgery Program is affiliated with a growing network of specially trained surgeons and medical professionals who respect the wishes of their patients. " /></a> <br /> <a onclick="_gaq.push(['_trackEvent', 'Outgoing', 'community.e-baptisthealth.com', '/services/noblood/index.html']);" href="http://community.e-baptisthealth.com/services/noblood/index.html"><img src="http://www.noblood.org/_files/ads/67.png" width="90" height="40" title="Baptist Health - Jacksonville, Florida - Religious convictions and concerns about the safety of the blood supply are only a few reasons for choosing bloodless medicine and surgery." /></a> <br /> <a onclick="_gaq.push(['_trackEvent', 'Outgoing', 'www.hahnemannhospital.com', '/CWSContent/hahnemannhospital']);" href="http://www.hahnemannhospital.com/CWSContent/hahnemannhospital"><img src="http://www.noblood.org/_files/ads/68.png" width="50" height="50" title="Hahnemann University Hospital - Philadelphia, Pennsylvania - Hahnemann University Hospital's bloodless program is the only program in Philadelphia based at an academic medical center. Hahnemann provides specialized care for patients requiring challenging medical procedures and/or services such as organ transplantation, complex heart surgeries, gynecologic oncology, high risk obstetrics, etc. It is also widely known for programs in orthopedics, stroke, cancer, newborn intensive care, and cardiology and is a designated Level I Trauma Center for adults in Philadelphia." /></a> <br /> <a onclick="_gaq.push(['_trackEvent', 'Outgoing', 'www.hackensackumc.org', '/']);" href="http://www.hackensackumc.org/"><img src="http://www.noblood.org/_files/ads/72.png" width="50" height="50" title="Hackensack University Medical Center - Hackensack, New Jersey - The distinction of becoming the first program in the state to achieve accreditation from the Association for Blood Conservation, (formerly known as The National Association of Bloodless Medicine and Surgery) has solidified the reputation of The Center for Bloodless Medicine and Surgery at Hackensack University Medical Center as being on the forefront of providing medical and surgical care without the use of transfused blood products." /></a> <h3></h3> </div> </div> </div> </div> </li> </ul> </div> </div> </div> </div> <div id="ad_global_above_footer"> <script type="text/javascript"><!--google_ad_client = "ca-pub-8143203669238634";/* 468x60abvfoot */google_ad_slot = "5470339864";google_ad_width = 468;google_ad_height = 60;//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script> </div> <div id="footer" class="floatcontainer footer"> <form action="http://www.noblood.org/forums" method="get" id="footer_select" class="footer_select"> <select name="styleid" onchange="switch_id(this, 'style')"> <optgroup label="Quick Style Chooser"> <option value="8" class="" selected="selected">-- Blue</option> <option value="9" class="">-- Default vBulletin</option> <option value="7" class="">-- vB4 Default Style</option> </optgroup> </select> </form> <ul id="footer_links" class="footer_links"> <li><a href="http://www.noblood.org/sendemail/" rel="nofollow" accesskey="9">Contact Us</a></li> <li><a href="http://www.noblood.org">noblood</a></li> <li><a href="http://www.noblood.org/library-records/297-privacy-policy">Privacy Statement</a></li> <li><a href="http://www.noblood.org/library-records/296-terms-service">Terms of Service</a></li> <li><a href="http://www.noblood.org/content/213-knocking-_jehovah-27s_witnesses_and_blood#top" onclick="document.location.hash='top'; return false;">Top</a></li> </ul> <script type="text/javascript"> <!-- // Main vBulletin Javascript Initialization vBulletin_init(); //--> </script> </div> <div id="footer_copyright" class="shade footer_copyright"> <!-- Do not remove this copyright notice --> <!-- Do not remove this copyright notice --> </div> <div id="footer_morecopyright" class="shade footer_morecopyright"> <!-- Do not remove cronimage or your scheduled tasks will cease to function --> <img src="http://www.noblood.org/cron.php?rand=1329628490" alt="" width="1" height="1" border="0" /> <!-- Do not remove cronimage or your scheduled tasks will cease to function --> Copyright &copy; 1996 - 2011, NoBlood, Inc. </div> </div> <!-- closing div for body_wrapper --> <div class="below_body"> <br /> <script type="text/javascript" src="http://www.noblood.org/clientscript/vbulletin_facebook.js?v=411"></script> <script type="text/javascript" src="http://connect.facebook.net/en_US/all.js"></script> <script type="text/javascript"><!--YAHOO.util.Event.onDOMReady( function() { vBfb = new vB_Facebook({ appid : "172443966126528", connected : 0, active : 0, autoreg : 0, feed_newthread : 1, feed_postreply : 1, feed_blogentry : 1, feed_blogcomment : 1, feed_newarticle : 1, feed_articlecomment : 1 }); });--></script> <div id="fb-root"></div> </div> <script type="text/javascript">//<![CDATA[var vbseo_jshtml = new Array();vbseo_jshtml[0] = "<ol> <li class=\"restore\" id=\"navbar_notice_1000\"> <div id=\"featured_box\"><img style=\"float: left; padding-right: 10px; padding-top: 5px; padding-bottom: 5px; \" src=\"http://www.noblood.org/map/images/about_noblood_img_150x100.jpg\"/> <h2 class=\"title\"><a href=\"http://www.noblood.org/about/\"><span style=\"font-size:18px;\">Welcome to the latest in bloodless medicine and blood transfusion alternatives.</span></a></h2> <div class=\"thumb_about\"> <p class=\"imgTagline\"></p> </div> <h2>We are a community of medical professionals and members of the public who are responding to the worldwide concern about the efficacy, cost and availability of donor blood.</h2> <p class=\"teaser\"><b>You are currently viewing this site as a guest.</b> <a href=\"http://www.noblood.org/signin/\" title=\"Sign in to your account.\"><span style=\"color:red\"><u>Sign in</u></span></a> or <a href=\"http://www.noblood.org/signup/\" title=\"Create your new account.\"><span style=\"color:red\"><u>sign up</u></span></a> to gain full access to the many resources and services available at noblood. If you have any problems with the registration process or your account login, please <a href=\"http://www.noblood.org/sendemail/\"><b>Contact Us</b></a>.</p> </div></li> </ol>";for(var vi=0;vi<vbseo_jshtml.length;vi++)if(fetch_object("vbseo_vhtml_"+vi))fetch_object("vbseo_vhtml_"+vi).innerHTML = vbseo_jshtml[vi];//]]></script> </body> </html>
253	faceted	tooth abscess	What treatments are available for a tooth abscess?	clueweb12-1300wb-34-06797	2	<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <head> <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /> <meta name="description" content="Sunnyvale Emergency Dentist offers emergency treatment for different types of dental abscesses, tooth abscess, gum abscess, acute abscess, chronic abscess, dental infection, root canal treatment, medication for infection, dentist in Sunnyvale" /> <meta name="keywords" content="Sunnyvale dentist, dental abscess, tooth abscess, periapical abscess, gum abscess, periodontal abscess, acute abscess, chronic abscess, bone cyst, dental infection, root canal treatment, medication for infection, pain in biting, pain in chewing, swelling, pus, Sunnyvale, Mountain View, Santa Clara, Cupertino, Campbell, Los Altos, Palo Alto, Sunnyvale dentist" /> <meta name="city" content="Sunnyvale, San Jose, Mountain View, Cupertino, Campbell, Palo Alto, Foster City, Fremont, Los Altos, Santa Clara, Saratoga, San Francisco, Morgain Hill, San Jose" /> <meta name="State" content="California, CA" /> <title>Sunnyvale Dentist Emergency Treatment-Dental Abscess-Tooth Abscess-Gum Abscess</title> <link href="../../antonious.css" rel="stylesheet" type="text/css" /> <script type="text/javascript"><!--function MM_swapImgRestore() { //v3.0 var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;}function MM_preloadImages() { //v3.0 var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array(); var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++) if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}}function MM_findObj(n, d) { //v4.01 var p,i,x; if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) { d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);} if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n]; for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document); if(!x && d.getElementById) x=d.getElementById(n); return x;}function MM_swapImage() { //v3.0 var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3) if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}}var message="Thanks For Visiting Sunnyvale Dental Care";///////////////////////////////////function clickIE4(){if (event.button==2){alert(message);return false;}}function clickNS4(e){if (document.layers||document.getElementById&&!document.all){if (e.which==2||e.which==3){alert(message);return false;}}}if (document.layers){document.captureEvents(Event.MOUSEDOWN);document.onmousedown=clickNS4;}else if (document.all&&!document.getElementById){document.onmousedown=clickIE4;}document.oncontextmenu=new Function("alert(message);return false")// --> </script> <style type="text/css"><!--body { background-color: #3E3B33;}--></style> </head> <body onload="MM_preloadImages('../../images/espanol_br_08.gif','../../images/images_espanolrollover_03_03.gif')"> <table width="800" align="center" cellpadding="0" cellspacing="0"> <tbody> <tr> <td rowspan="3" align="left" valign="bottom" class="border_lft"><img src="../../images/border_lft_03.gif" alt="border_lft_03" width="16" height="769" /></td> <td height="46" align="left" valign="middle" bgcolor="#4C0E0D"> <table align="center" cellpadding="0" cellspacing="0"> <tbody> <tr> <td class="phonenumbers">(408) 720-0900 &nbsp; • &nbsp; (877) 9 Dental</td> <td><img src="../../images/25x25.gif" alt="25x25" width="115" height="25" /></td> <td align="right" valign="top"><p><span class="doctorname">Nasser Antonious, DDS, MAGD, FICOI</span><br /> <span class="doctorname2">Master of the Academy of General Dentistry</span><br /> <span class="doctorname2">Fellow of the International Congress of Oral Implantologists</span></p></td> </tr> </tbody> </table></td> <td rowspan="3" align="left" valign="bottom" class="border_rgt"><img src="../../images/border_rgt_05.gif" alt="border_rgt_05" width="15" height="769" /></td> </tr> <tr> <td align="left" valign="top" bgcolor="#711A13"> <table cellspacing="0" cellpadding="0"> <tbody> <tr> <td align="left" valign="top"><img src="../../images/images27.jpg" alt="Sunnyvale Dentist Emergency Treatment-Dental Abscess, Gum Abscess" width="790" height="326" /></td> </tr> <tr> <td height="40" align="left" valign="top" bgcolor="#581414" class="nav_bg"> <table width="788" cellpadding="0" cellspacing="0"> <tbody> <tr> <td colspan="8" align="left" valign="top"><img src="../../images/25x25.gif" alt="25x25" width="25" height="17" /></td> </tr> <tr> <td width="88" align="left" valign="top"><a href="../../index.html" class="menu">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;home</a></td> <td width="91" align="left" valign="top"><a href="../../Sunnyvale-Dentist/Sunnyvale-Dentistry/Sunnyvale-Dental-Information.html" class="menu">who we are</a></td> <td width="90" align="left" valign="top"><a href="../../Sunnyvale-Dentist/Sunnyvale-Dentistry/Sunnyvale-Dental-Services.html" class="menu">what we do</a></td> <td width="110" align="left" valign="top"><a href="../../Cosmetic-Dentistry/Cosmetic-Dentist/Sunnyvale-Dentist-Smiles.html" class="menu">smile gallery</a></td> <td width="134" align="left" valign="top"><a href="../../Dental-Information/Oral-Dental-Information.html" class="menu">patient resources</a></td> <td width="95" align="left" valign="top"><a href="../../Dental-Insurance/Dental-Financials/Dental-Financing-Financials.html" class="menu">financials</a></td> <td width="92" align="left" valign="top"><a href="../../Sunnyvale-Dentist/Sunnyvale-Dentistry/Sunnyvale-Dentist-Information.html" class="menu">contact us</a></td> <td width="86" align="left" valign="top"><a href="https://www.ident.ws/template_include/pi_login.jsp?site=6038" target="_blank" class="menu">patient login</a></td> </tr> </tbody> </table></td> </tr> <tr> <td align="left" valign="top"> <table width="750" align="center" cellpadding="0" cellspacing="0"> <tbody> <tr> <td height="38" colspan="3" align="right" valign="middle"> <table cellspacing="0" cellpadding="0"> <tbody> <tr> <td><a href="../../other/underconstruction.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image19','','../../images/images_espanolrollover_03_03.gif',1)"><img src="../../images/images_espanolbutton_03.gif" alt="images_espanolbutton_03" name="Image19" width="117" height="34" border="0" id="Image19" /></a></td> </tr> </tbody> </table></td> </tr> <tr> <td colspan="3" align="left" valign="top"><img src="../../images/contentborder_top_03.gif" alt="contentborder_top_03" width="748" height="1" /></td> </tr> <tr> <td width="1" align="left" valign="top" class="contentborder_lftExtend"><img src="../../images/contentborder_left_05.gif" alt="contentborder_left_05" width="1" height="291" /></td> <td width="745" align="left" valign="top"> <table cellspacing="0" cellpadding="0"> <tbody> <tr> <td align="left" valign="top"><a href="../../index.html" class="breadcrumbpre">Sunnyvale Dentistry Home</a><span class="darrow"> &gt;&gt; </span><a href="../../Dental-Information/Oral-Dental-Information.html" class="breadcrumbpre"> Dental Patient Resources</a><span class="darrow"> &gt;&gt; </span> <a href="../../Dental-Emergency/Emergency-Dentist/Tooth-Gum-Abscess.html" class="breadcrumb">Dental Abscess, Gum Abscess</a></td> <td align="left" valign="top">&nbsp;</td> <td align="left" valign="top">&nbsp;</td> </tr> <tr> <td align="left" valign="top"> <table align="right" cellpadding="0" cellspacing="0"> <tbody> <tr> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class="bodytext">back to <a href="javascript: history.go(-1)" class="link">Previous Page</a></td> <td>&nbsp;</td> </tr> </tbody> </table> <p class="welcome_subtitle"><a name="top" id="top"></a>Dental Abscess, Gum Abscess</p> <table width="500" align="center" cellpadding="0" cellspacing="0"> <tbody> <tr> <td class="horizontal_line">&nbsp;</td> </tr> </tbody> </table> <ul type="disc"> <li class="bodytext"><a class="link" href="#1">Introduction</a></li> <li class="bodytext"><a class="link" href="#2">What You Can Do</a></li> <li class="bodytext"><a class="link" href="#3">What Dr Antonious Will Do</a></li> </ul> <table width="500" align="center" cellpadding="0" cellspacing="0"> <tbody> <tr> <td class="horizontal_line">&nbsp;</td> </tr> </tbody> </table> <p class="bodytext"><strong>&nbsp;</strong><strong>Introduction<a name="1"> </a></strong></p> <p class="bodytext">When tissues in the mouth are injured or get irritated, bacteria may get into the area and cause an infection and a painful, pus-filled swelling. If the pus can't drain, the area will get more swollen and painful. This is known as an abscess. An abscess is your body's attempt to contain an infection and prevent it from spreading to other areas. <br /> <br /> Abscesses can form very quickly, often within 24 to 48 hours of when the infection starts. There are two main types of abscesses: </p> <p class="bodytext"><strong>A gum, or periodontal, abscess</strong> is usually caused by an infection in the small space, or pocket, between the teeth and gums. This may happen when food particles get trapped between the gum and tooth. In more advanced cases of periodontal disease, bacteria can build up in deep pockets under the surface of the gums. <br /> <br /> <strong>A tooth-related abscess</strong>, called a periapical abscess (located at the tip of the tooth root), occurs within the tooth itself when the nerve is dead or dying. <br /> This type of abscess can spread to the bone surrounding the tip of the root. <br /> Most abscesses are painful, which means that people usually get treatment right away. In some cases, however, the infection causes little or no pain — or people ignore the discomfort and wait for it to go away. This can result in a chronic abscess, in which the infection lasts for months or even years. <br /><br /> When abscesses aren't treated promptly, the infection can damage nearby tissues or teeth. The build-up of scar tissue caused by the infection may result in the development of a hollow tunnel of tissue called a fistula or &quot;sinus tract.&quot; Pus from the abscess may drain through this &quot;artificial&quot; tunnel to an opening on the surface, and may be seen in the mouth as a pimple that comes and goes. People with sinus tracts may feel a small bump in their mouths, or may have a strange taste in their mouths due to the drainage of pus. <br /><br /> In some cases, a chronic abscess can form a cyst in the bone. The cyst has to be removed surgically. There also are rare instances in which the infection spreads to the surrounding tissues and causes serious health problems. </p> <p class="bodytext"> <strong>What You Can Do</strong><strong><a name="2"> </a></strong> <br /> </p> <p class="bodytext">Abscesses are always serious because the infection may spread to other parts of the body. <br /> <br /> If you can see or feel a pimple-like swelling on the gum, you may want to try rinsing your mouth several times a day with a mild salt-water solution (1/2 teaspoon of salt in 8 ounces of water). This may help draw the pus toward the surface and allow pressure in the area to be relieved temporarily. In all cases of abscess, you need to see your dentist as soon as possible. </p> <p class="bodytext"> <strong>What Dr Antonious Will Do </strong> <strong><a name="3"> </a></strong></p> <p class="bodytext">Most gum abscesses will heal quickly once the area is cleaned thoroughly, the trapped material is allowed to escape, and the source of the infection is treated. <br /> If a sinus tract has formed, your dentist will need to trace it back to the source of the infection. Dr Antonious will insert a probe into the tunnel and take an X-ray to see where the infection started. Once the source of the infection is identified and cleaned out, the sinus tract usually will close on its own. <br /><br /> If the infection started inside a tooth, your dentist may start root canal treatment by making a small hole in the tooth to allow the abscess to drain. This type of abscess typically occurs only when the tooth nerve is damaged or is already dead. The tooth will need a filling or a crown following successful root canal treatment. <br /><br /> If the abscess is severe or the tooth is badly damaged, you may need to have the tooth removed. <br /><br /> Superficial abscesses in the gums usually can be treated by cleaning out the debris or bacteria that has become trapped and washing out the area thoroughly. Your dentist calls this procedure aspiration, incision and drainage. More serious periodontal abscesses often can be cleared up by the same method. However, the periodontal disease that caused the infection will require more intensive treatment to prevent another infection. <br /> <br /> Your dentist may give you a prescription for antibiotics to help the abscess heal and prevent the spread of the infection to other parts of your body<br /> </p> <p class="bodytext"><a href="#top" class="link">back to the top&raquo;</a><br /> <a href="../../Dental-Emergency/Dental-Patients-Emergencies.html" class="link">back to Dental Emergencies/Pain</a> </p> <table align="right" cellpadding="0" cellspacing="0"> <tbody> <tr> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class="bodytext">back to <a href="javascript: history.go(-1)" class="link">Previous Page</a></td> <td>&nbsp;</td> </tr> </tbody> </table> </td> <td align="left" valign="top" class="vertical_line">&nbsp;</td> <td width="217" align="left" valign="top"> <table width="0" align="center" cellpadding="5" cellspacing="0"> <tbody> <tr> <td bgcolor="#FFFFFF"><img src="../../images/images_contact.jpg" alt="Treatment For Dental Emergency-Sunnyvale Emergency Dental Care" width="151" height="227" /></td> </tr> </tbody> </table> <table cellpadding="0" cellspacing="0"> <tbody> <tr> <td width="25" rowspan="6" align="left" valign="top"><img src="../../images/25x25.gif" alt="25x25" width="25" height="25" /></td> <td align="left" valign="top">&nbsp;</td> <td width="164" align="left" valign="top">&nbsp;</td> </tr> <tr> <td width="12" height="10" align="center" valign="middle"><img src="../../images/arrow_14.gif" alt="arrow" width="6" height="7" /></td> <td align="left" valign="top"><a href="../../Sunnyvale-Dentist/Sunnyvale-Dentistry/Dental-Practice-Information.html" class="callout">Take a Virtual Tour</a></td> </tr> <tr> <td align="center" valign="middle"><img src="../../images/arrow_14.gif" alt="arrow" width="6" height="7" /></td> <td align="left" valign="top"><a href="../../Sunnyvale-Dentist/Sunnyvale-Dentistry/Sunnyvale-Dental-Promotions.html" class="callout">Dental Promotions</a></td> </tr> <tr> <td align="center" valign="middle"><img src="../../images/arrow_14.gif" alt="arrow" width="6" height="7" /></td> <td align="left" valign="top"><a href="../../General-Dentist/New-Patient-Promotions.html" class="callout">New Patients</a></td> </tr> <tr> <td align="center" valign="middle"><img src="../../images/arrow_14.gif" alt="arrow" width="6" height="7" /></td> <td align="left" valign="top"><a href="../../Sunnyvale-Dentist/Sunnyvale-Dentistry/Sunnyvale-Dental-Referral.html" class="callout">Refer a Friend</a></td> </tr> <tr> <td align="center" valign="middle"><img src="../../images/arrow_14.gif" alt="arrow" width="6" height="7" /></td> <td align="left" valign="top"><a href="../../Children-Dentistry/Kids-Dentist/Pediatric-Dentist-Dentistry.html" class="callout">Fun Links For Kids</a></td> </tr> <tr> <td align="left" valign="top">&nbsp;</td> <td align="center" valign="middle"><img src="../../images/arrow_14.gif" alt="arrow" width="6" height="7" /></td> <td align="left" valign="top"><a href="../../Sunnyvale-Dentist/Sunnyvale-Dentistry/Dental-Dentist-Appointment.html" class="callout">Dental Appointment Request</a></td> </tr> </tbody> </table></td> </tr> <tr> <td align="left" valign="top">&nbsp;</td> <td align="left" valign="top">&nbsp;</td> <td align="left" valign="top">&nbsp;</td> </tr> </tbody> </table></td> <td width="2" align="right" valign="top" class="contentborder_rgtExtend"><img src="../../images/contentborder_rgt_06.gif" alt="contentborder_rgt_06" width="1" height="291" /></td> </tr> <tr> <td colspan="3" align="left" valign="top"><img src="../../images/contentborder_btm_03.gif" alt="contentborder_btm_03" width="748" height="1" /></td> </tr> </tbody> </table></td> </tr> <tr> <td align="left" valign="top">&nbsp;</td> </tr> <tr> <td align="left" valign="top">&nbsp;</td> </tr> </tbody> </table></td> </tr> <tr> <td align="left" valign="bottom" bgcolor="#711A13"><img src="../../images/border_btm_10.gif" alt="border_btm_10" width="788" height="18" /></td> </tr> <tr> <td align="left" valign="bottom">&nbsp;</td> <td align="center" valign="top" class="addressfooter"> <table width="100%" border="0"> <tbody> <tr> <td align="center"><a href="http://www.sunnyvaledentalcare.net/index.html" class="sitemaplink">Sunnyvale Dentistry Home</a>&nbsp;&nbsp; | &nbsp;&nbsp;<a href="http://www.sunnyvaledentalcare.net/Sunnyvale-Dentist/Sunnyvale-Dentistry/Sunnyvale-Dental-Information.html" class="sitemaplink">Who We Are</a>&nbsp;&nbsp; | &nbsp; &nbsp;<a href="http://www.sunnyvaledentalcare.net/Sunnyvale-Dentist/Sunnyvale-Dentistry/Sunnyvale-Dental-Services.html" class="sitemaplink">What We Do</a>&nbsp;&nbsp; |&nbsp;&nbsp; <a href="http://www.sunnyvaledentalcare.net/Cosmetic-Dentistry/Cosmetic-Dentist/Sunnyvale-Dentist-Smiles.html" class="sitemaplink">Smile Gallery</a>&nbsp;&nbsp; | &nbsp; &nbsp;<a href="http://www.sunnyvaledentalcare.net/Dental-Information/Oral-Dental-Information.html" class="sitemaplink">Dental Patient Resources</a>&nbsp;&nbsp; |&nbsp;&nbsp; <a href="http://www.sunnyvaledentalcare.net/Dental-Insurance/Dental-Financials/Dental-Financing-Financials.html" class="sitemaplink">Dental Financials </a> &nbsp;&nbsp; |&nbsp;&nbsp; <a href="http://www.sunnyvaledentalcare.net/Sunnyvale-Dentist/Sunnyvale-Dentistry/Sunnyvale-Dentist-Information.html" class="sitemaplink">Contact Us</a> </td> </tr> <tr> <td align="center"> <a href="https://www.ident.ws/template_include/pi_login.jsp?site=6038" class="sitemaplink">Patient Login</a> &nbsp;&nbsp; |&nbsp;&nbsp;<a href="http://www.sunnyvaledentalcare.net/Sunnyvale-Dentist/Sunnyvale-Dentistry/Dental-Practice-Information.html" class="sitemaplink">Take A Virtual Tour</a> &nbsp;&nbsp;|&nbsp;&nbsp; <a href="http://www.sunnyvaledentalcare.net/Sunnyvale-Dentist/Sunnyvale-Dentistry/Sunnyvale-Dental-Promotions.html" class="sitemaplink">Dental Promotions</a> &nbsp;&nbsp;|&nbsp;&nbsp;<a href="http://www.sunnyvaledentalcare.net/General-Dentist/New-Patient-Promotions.html" class="sitemaplink">New Patients</a> &nbsp;&nbsp;|&nbsp;&nbsp; <a class="sitemaplink" href="http://www.sunnyvaledentalcare.net/Sunnyvale-Dentist/Sunnyvale-Dentistry/Sunnyvale-Dental-Referral.html">Refer A Friend</a>&nbsp;&nbsp;|&nbsp;&nbsp;<a href="http://www.sunnyvaledentalcare.net/Children-Dentistry/Kids-Dentist/Pediatric-Dentist-Dentistry.html" class="sitemaplink">Fun Links For Kids</a>&nbsp;&nbsp;|&nbsp;&nbsp;<a class="sitemaplink" href="http://www.sunnyvaledentalcare.net/Sunnyvale-Dentist/Sunnyvale-Dentistry/Dental-Dentist-Appointment.html">Dental Appointment Request</a> </td> </tr> <tr> <td align="center"> <a class="sitemaplink" href="http://www.sunnyvaledentalcare.net/Preventive-Dentistry/Preventive-Conservative-Dentistry.html">Preventive Dentistry</a> &nbsp;&nbsp;|&nbsp;&nbsp; <a class="sitemaplink" href="http://www.sunnyvaledentalcare.net/Cosmetic-Dentistry/Cosmetic-Dentist-Care.html">Cosmetic Dentistry</a> &nbsp;&nbsp;|&nbsp;&nbsp; <a class="sitemaplink" href="http://www.sunnyvaledentalcare.net/Dental-Fillings/Dental-Conservative-Fillings.html">Cosmetic Dental Fillings</a> &nbsp;&nbsp;|&nbsp;&nbsp;<a class="sitemaplink" href="http://www.sunnyvaledentalcare.net/Cosmetic-Dentistry/Cosmetic-Dentist/Crowns-Caps-Dentist.html">Porcelain Crowns</a> &nbsp;&nbsp;|&nbsp;&nbsp; <a class="sitemaplink" href="http://www.sunnyvaledentalcare.net/Cosmetic-Dentistry/Cosmetic-Dentist/Porcelain-Bridge-Dentist.html">Porcelain Bridges</a> &nbsp;&nbsp;|&nbsp;&nbsp; <a class="sitemaplink" href="http://sunnyvaledentalcare.net/Teeth-Whitening/Zoom-Bleaching/Zoom-Teeth-Whitening.html">Zoom Teeth Whitening/Bleaching</a> </td> </tr> <tr> <td align="center"> <a class="sitemaplink" href="http://www.sunnyvaledentalcare.net/Invisalign-Orthodontics/Clear-Braces/Clear-Braces-Dentist.html">Invisalign Orthodontics/Braces</a> &nbsp;&nbsp;|&nbsp;&nbsp; <a class="sitemaplink" href="http://www.sunnyvaledentalcare.net/Gum-Disease/Gum-Disease-Periodontitis.html">Periodontal/Gum Disease Treatment</a> &nbsp;&nbsp;|&nbsp;&nbsp; <a class="sitemaplink" href="http://www.sunnyvaledentalcare.net/Root-Canals/Root-Canal-Treatment.html">Root Canal Treatment</a> &nbsp;&nbsp;|&nbsp;&nbsp;<a class="sitemaplink" href="http://www.sunnyvaledentalcare.net/Teeth-Extraction/Oral-Surgery/Wisdom-Teeth-Extractions.html">Wisdom Teeth Extractions</a></td> </tr> <tr> <td align="center"> <a class="sitemaplink" href="http://www.sunnyvaledentalcare.net/Implant-Dentistry/Dental-Implants/Dental-Implants-Dentist.html">Dental Implants</a> &nbsp;&nbsp;|&nbsp;&nbsp; <a class="sitemaplink" href="http://www.sunnyvaledentalcare.net/Children-Dentistry/Children-Kids-Dentistry.html">Pediatric/Children Preventive Dentistry</a> &nbsp;&nbsp;|&nbsp;&nbsp;<a class="sitemaplink" href="http://www.sunnyvaledentalcare.net/Elderly-Dentistry/Geriatric-Dentistry/Elderly-Geriatric-Dentistry.html">Geriatric/Elderly Dentistry</a> &nbsp;&nbsp;|&nbsp;&nbsp; <a class="sitemaplink" href="http://www.sunnyvaledentalcare.net/Denture-Dentistry/Denture-Partial-Dentistry.html">Dentures/Partials</a></td> </tr> <tr> <td align="center"> <a class="sitemaplink" href="http://www.sunnyvaledentalcare.net/Dental-Emergency/Dental-Patients-Emergencies.html">Dental Emergencies/Pain</a> &nbsp;&nbsp;|&nbsp;&nbsp; <a href="http://www.sunnyvaledentalcare.net/Dental-Emergency/Emergency-Dentist/Tooth-Gum-Abscess.html" class="sitemaplink">Dental Abscess/Gum Abscess</a>&nbsp;&nbsp;|&nbsp;&nbsp;<a href="http://www.sunnyvaledentalcare.net/Dental-Information/Oral-Education/Dental-Cavities-Caries.html" class="sitemaplink">Cavities/Dental Caries</a>&nbsp;&nbsp;|&nbsp;&nbsp;<a href="http://www.sunnyvaledentalcare.net/Dental-Pain/Emergency-Toothache/Sensitive-Teeth-Treatment.html" class="sitemaplink">Sensitive Teeth</a> </td> </tr> <tr> <td align="center"> <a href="http://www.sunnyvaledentalcare.net/Dental-Pain/Emergency-Toothache/Jaw-Joint-Pain.html" class="sitemaplink">Temporomandibular Joint (TMJ) Disorder (TMD)</a>&nbsp;&nbsp;|&nbsp;&nbsp;<a href="http://www.sunnyvaledentalcare.net/General-Dentist/New-Patient/Anxious-Sensitive-Patient.html" class="sitemaplink">Sedation Dentistry</a>&nbsp;&nbsp;|&nbsp;&nbsp;<a href="http://www.sunnyvaledentalcare.net/Dental-Information/Oral-Education/Bad-Breath-Halitosis.html" class="sitemaplink">Bad Breath (Halitosis)</a></td> </tr> <tr> <td><p align="center">Nasser Antonious DDS is licensed as a general dentist in California. Sunnyvale Dental Care established since 1995<br /> Sunnyvale dentist, Nasser Antonious DDS welcomes new patients from all areas including Sunnyvale, Mountain View, Santa Clara, Cupertino, Campbell, San Jose, Saratoga, Los Altos, and Los Gatos<br /> General dentist, Preventive dentist, Cosmetic dentist, Invisalign dentist, Implant dentist, Children dentist, Sedation dentist</p></td> </tr> <tr> <td><p align="center"> Sunnyvale Dental Care&nbsp;&nbsp; | &nbsp;&nbsp;152 W. El Camino Real&nbsp;&nbsp; | &nbsp;&nbsp;Sunnyvale, CA 94087 |&nbsp;&nbsp; (408) 720-0900&nbsp;&nbsp; |&nbsp;&nbsp; <a href="http://www.sunnyvaledentalcare.net/Sunnyvale-Dentist/Sunnyvale-Dentistry/Sunnyvale-Dentist-Terms.html" class="termslink">Terms of Use</a>&nbsp;&nbsp;|&nbsp;&nbsp; <a href="http://www.sunnyvaledentalcare.net/Sunnyvale-Dentist/Sunnyvale-Dentistry/Dental-Patient-Privacy.html" class="termslink">Privacy Policy</a>&nbsp;&nbsp;|&nbsp;&nbsp; <a href="http://www.sunnyvaledentalcare.net/Sunnyvale-Dentist/Sunnyvale-Dentistry/Sunnyvale-Dentist-Sitemap.html" class="termslink">Site Map</a></p></td> </tr> <tr> <td>&nbsp;</td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </body> </html>
276	single	how has african american music influence history	How has African American music influenced history, including cultural history?	clueweb12-0000wb-27-12940	2	<html> <head> <style type="text/css"> TEXT-DECORATION: none}A:visited { TEXT-DECORATION: none}A:active { TEXT-DECORATION: none}A:hover { TEXT-DECORATION: bold}A:hover { COLOR: #FFCC99}</style> </head> <body bgcolor="#000000" background="margin5.jpg" body="" text="#EEEEEE" link="#66FFFF" vlink="#FF3366" topmargin="0" leftmargin="0" alink="#C5927C"> <meta http-equiv="refresh" content="200" /> <meta name="Author" content="Smith/McIver.com" /> <meta name="description" content="African Music of the Disapora offers information on the history of music from the African Diaspora. From the beginnings to contemporary history." /> <meta name="Keywords" content="Michael Jackson, Smith/McIver, Gospel, Jazz, The Blues, Soul, Zydeco,African Music, African-Americans, middle passage, dance traditions, New World, Colonial sources of information, northern colonies, Pinkster festivals, drums and singing, lection Day celebrations, Place Congo, The Soul Music Center, Holy Hip Hop 2005, The Tyler Perry Collection, Steve Harvey - Don't Trip, The Ultimate Collection B.B. King, Very Best of the Clovers, Sexy Ways: The Best of Hank Ballard &amp; the Midnighters, Destiny's Child, Alicia Keys, Usher-Rolling Stone Cover, Nowhere to Run - The Story of Soul Music" /> <title>African American Music: From the beginnings to contemporary Black musical history.</title> <div align="left"> <table border="1" width="100%" height="20%" bgcolor="#000000" cellspacing="0" cellpadding="0"> <tbody> <tr> <td width="100%"> <p> </p> <center> <script type="text/javascript"><!--google_ad_client = "ca-pub-3792579270987634";/* index */google_ad_slot = "5443689110";google_ad_width = 728;google_ad_height = 90;//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script> </center> <p align="center"><b><font color="#999999" face="vogue" size="4"><b>African American Music</b></font> <br /><font size="2"><font color="eeeeee">Presented by <i>Smith/McIver</i> </font></font></b></p></td> <td width="70%" valign="middle"> </td> </tr> <tr> <td width="100%" height="29" bgcolor="#eeeeee" colspan="2"><font color="#805C58" face="Trebuchet Ms"> <a href="http://www.amazon.com/exec/obidos/ASIN/0802139957/africangenesis&quot;"></a><a href="http://afgen.com" target="" =""=""> </a> <center> <a href="http://afgen.com" target="" =""=""></a> <a href="http://astore.amazon.com/soulmusic-20"><font color="000000"><font size="4"><u>The Soul Music Center</u></font></font></a> || <a href="http://mcivr.singorama.hop.clickbank.net/" target="_top"> <font size="4"><font color="000000"><u>How to Sing with a Full Vocal Range</u></font></font></a> </center> <table border="0" cellpadding="0" cellspacing="0" align="right"> <tbody> <tr> <td> <center> <script type="text/javascript"><!--google_ad_client = "pub-3792579270987634";google_ad_width = 728;google_ad_height = 15;google_ad_format = "728x15_0ads_al_s";google_ad_channel = "afgen.com";google_color_border = "FFFFFF";google_color_bg = "eeeeee";google_color_link = "000000";google_color_text = "000000";google_color_url = "000000";//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script> </center></td> <td> <form action="http://afgen.com/afgen_search_results.html" id="cse-search-box"> <div> <input type="hidden" name="cx" value="partner-pub-3792579270987634:81x04vyl18j" /> <input type="hidden" name="cof" value="FORID:10" /> <input type="hidden" name="ie" value="ISO-8859-1" /> <input type="text" name="q" size="20" /> <input type="submit" name="sa" value="Search" /> </div> </form><script type="text/javascript" src="http://www.google.com/cse/brand?form=cse-search-box&amp;lang=en"></script></td> </tr> </tbody> </table></font></td> </tr> </tbody> </table> </div> <table> </table> <table width="23%" border="0" cellpadding="0" cellspacing="0" align="left"> <tbody> <tr> <td width="0125" valign="top"> <p> <img src="blunoteCLR.gif" /></p><p> <a href="african_home.html"><img src="button7.jpg" border="1" alt="African Music" /></a><br /> <a href="zydeco_home.html"><img src="button8.jpg" border="1" alt="Zydeco Music" /></a> </p><p><a href="top50.html"><font color="000000"><b>Top 50 Music <br />Quotations </b></font></a> </p><p> <a href="black_music.html"><font color="000000"><b>Black Music:<br /> Archives:</b></font></a> </p><p> <a href="http://afgen.com" a="" target="" =""=""> <img src="holy_hop.jpg" width="110" height="150" alt="Holy Hip Hop (2005) - DVD" /></a><br /> <font size="2"><b>Holy Hip Hop<br /> (2005) - DVD</b></font> </p><p> <a href="http://afgen.com" a="" target="" =""=""> <img src="tyler_perry.jpg" width="110" height="150" alt="The Tyler Perry Collection (I Can Do Bad All By Myself/Madea's Class Reunion/Meet the Browns/Madea's Family Reunion) (2006) -DVD" /></a><br /> <font size="2"><b>The Tyler Perry<br /> Collection - DVD</b></font> </p><p> <a href="http://afgen.com" a="" target="" =""=""> <img src="steve_harvey.jpg" width="110" height="150" alt="Steve Harvey - Don't Trip... He Ain't Through With Me Yet! (2006) - DVD" /></a> <br /><font size="2"><b>Steve Harvey <br /> Don't Trip - DVD</b></font> </p><p> <a href="http://www.amazon.com/exec/obidos/ASIN/B0007QJ1PM/africangenesis"> <img src="bb_king5.jpg" width="130" height="130" alt="The Ultimate Collection B.B. King" /><br /> <font size="2"><font color="000000"><b>The Ultimate Collection <br /> B.B. King</b></font></font></a><font size="2"><font color="000000"> </font></font> </p><p> <font color="000090"><b>Remembering:</b></font> <a href="http://www.amazon.com/exec/obidos/ASIN/B00000346L/africangenesis"> <img src="clovers.jpg" alt="Very Best of the Clovers - Five Stars" /><br /><font size="2"><font color="000000">Very Best of the Clovers</font></font></a> </p><p> <font color="000000"><font face="arial"><font size="2"></font></font></font> <a href="http://www.amazon.com/exec/obidos/ASIN/B000003358" africangenesis=""></a><img src="midnighters.jpg" alt="Sexy Ways: The Best of Hank Ballard &amp; the Midnighters" /><br /><font size="2"><font color="000000">Sexy Ways: The Best of<br /> Hank Ballard &amp; <br />the Midnighters</font></font> </p><p></p> <center> </center></td> </tr> </tbody> </table> <table width="49%" border="0" cellpadding="0" cellspacing="10" align="left"> <tbody> <tr> <td width="350" valign="top"> <center> <a href="http://www.amazon.com/gp/redirect.html?ie=UTF8&amp;location=http%3A%2F%2Fwww.amazon.com%2Fgp%2Fentity%2FMichael-Jackson%2FB000APU04Q&amp;tag=africangenesis&amp;linkCode=ur2&amp;camp=1789&amp;creative=390957"><font size="4"><font color="c00000"><b>Michael Jackson, 1958-2009</b></font></font></a> <font size="4"><font color="c00000"><img src="https://www.assoc-amazon.com/e/ir?t=africangenesis&amp;l=ur2&amp;o=1" width="1" height="1" border="0" alt="" style="border:none !important; margin:0px !important;" /></font></font> </center> <p> <font size="2"><font color="ffff00">This Web Site offers information on the history and the latest recordings in the field's of Gospel, Jazz, The Blues, Soul, Zydeco and African Music.From the beginnings to contemporary history.</font></font> <font size="2"></font></p><p><font size="2"> <font color="eeeeee">The contributions ofAfrican-Americans to the history of music in theUnited States began with the arrival of the firstBlacks on the mainland in 1619. AlthoughAfricans who were sold into slavery were stripped oftheir possessions, clamped into irons, andwedged into foul vessels to make the dreaded&quot;middle passage&quot; from Africa to America, theynevertheless brought with them to the new land their memories of the rich music and dance traditions of the lands of their ancestors. Theyremembered the importance of music in theWest African way of life�how almost everyactivity was accompanied by music appropriateto the occasion and how special kinds of musicwere provided for festivals (called &quot;customs&quot; inAfrica)� and they continued these practices inthe New World.</font></font></p><p><font size="2"><font color="eeeeee"> Colonial sources of information includenumerous references to the huge slave festivalsthat took place in the northern colonies. Perhapsworthy of special mention are the Pinkster festivals held in various cities of New York state, inwhch African-Americans danced traditionaldances to the music of drums and singing, whilelarge crowds of white spectators watched the&quot;exotic&quot; scenes. In New England, &quot;lection Day&quot;celebrations drew similar crowds of whites towatch slaves and free blacks parade, dance, andsing to the accompaniment of drums,woodwinds, and string instruments. Annual fairsprovided similar opportunities in Philadelphia, Pa.,and in New Orleans, La., the transplanted Africans staged traditional dances on Sunday afternoons in the Place Congo.</font></font></p></td> </tr> </tbody> </table> <table width="20%" border="0" cellpadding="0" cellspacing="10" align="right"> <tbody> <tr> <td width="20" valign="top"> <ul> <a href="gospel.html"><img src="gospel1a.gif" alt="Gospel Music" /></a> <br /> <p> <a href="bluslink.html"><img src="blues1a.gif" alt="The Blues" /></a><br /> </p> <p> <a href="jazlinks.html"><img src="jazz_button1.gif" alt="Jazz Music" /></a><br /> </p> <p> <a href="soul_hiphop.html"><img src="soul1.gif" alt="Soul / Hip-Hop Music" /></a><br /> </p> <p></p> </ul> <img src="robert.jpg" alt="Robert Johnson" /><br /><font size="1"></font> <center> <font size="1">Robert Johnson</font> <p> <a href="jazz_art.html"><img src="jazz_art.jpg" /></a> <alt="jazz art="" prints"=""> </alt="jazz></p> </center></td> </tr> </tbody> </table> <p><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /> </p> <table border="1" cellpadding="0" cellspacing="0" align="right"> <tbody> <tr> <td> <script type="text/javascript"><!--google_ad_client = "ca-pub-3792579270987634";/* gospel history */google_ad_slot = "1521910111";google_ad_width = 120;google_ad_height = 600;//--></script><script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script></td> </tr> </tbody> </table> <center> <a href="african_mango_diet.html"><font size="3"><font face="helvetica"><font color="eeeeee"><u><b>The Health Benefits of African Mango </b></u></font></font></font></a> <font size="3"><br /> <a href="http://www.amazon.com/exec/obidos/redirect?tag=africangenesis&amp;path=tg/browse/-/301597/104-4923043-1975146?tag-id=africangenesis&amp;placement=video-browse-find-148x50.gif"><img src="cinema.gif" alt="African American Cinema" /></a> <a href="http://www.amazon.com/exec/obidos/external-search?tag=africangenesis&amp;keyword=african+american+music&amp;mode=books"><img src="jazbooks.gif" alt="African American Music" /></a> <img src="bann05.gif" /><br /> <object classid="clsid:D27CDB6E-AE6D-11cf-96B8-444553540000" codebase="http://fpdownload.macromedia.com/get/flashplayer/current/swflash.cab" id="Player_12922316-a52b-4add-b31e-6ad08e574ef0" width="336px" height="280px"> <param name="movie" value="http://ws.amazon.com/widgets/q?ServiceVersion=20070822&amp;MarketPlace=US&amp;ID=V20070822%2FUS%2Fafricangenesis%2F8014%2F12922316-a52b-4add-b31e-6ad08e574ef0&amp;Operation=GetDisplayTemplate"></param><param name="quality" value="high"></param><param name="bgcolor" value="#FFFFFF"></param><param name="allowscriptaccess" value="always"></param><embed src="http://ws.amazon.com/widgets/q?ServiceVersion=20070822&amp;MarketPlace=US&amp;ID=V20070822%2FUS%2Fafricangenesis%2F8014%2F12922316-a52b-4add-b31e-6ad08e574ef0&amp;Operation=GetDisplayTemplate" id="Player_12922316-a52b-4add-b31e-6ad08e574ef0" quality="high" bgcolor="#ffffff" name="Player_12922316-a52b-4add-b31e-6ad08e574ef0" allowscriptaccess="always" type="application/x-shockwave-flash" align="middle" height="280px" width="336px" /></object> <noscript> <a href="http://ws.amazon.com/widgets/q?ServiceVersion=20070822&amp;MarketPlace=US&amp;ID=V20070822%2FUS%2Fafricangenesis%2F8014%2F12922316-a52b-4add-b31e-6ad08e574ef0&amp;Operation=NoScript"><br />Amazon.com Widgets</a> </noscript></font> </center> <font size="3"> <p> </p><p> </p><p></p> <center> <a href="ray_charles_concord.html"><font size="3"><font face="arial"><font color="#FFFF00"><u><b>Some of Ray Charles� most cherished hits <br />and classic albums available digitally for the first time ever</b></u></font></font></font></a> <font size="3"> <p> </p> <table border="0" cellpadding="0" cellspacing="0" align="center"> <tbody> <tr> <td><script type="text/javascript"><!--google_ad_client = "pub-3792579270987634";/* 300x250, created 8/11/10 */google_ad_slot = "7494198148";google_ad_width = 300;google_ad_height = 250;//--></script><script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script></td> </tr> </tbody> </table> <hr width="60%" color="#eeeeee" size="2" /><p></p> <center> <a href="mailto:mcivr2@yahoo.com"><img src="envelope.gif" alt="Send Mail" border="1" /></a> <p><font size="2"><font color="eeeeee">Bookmark this page!<br /> <input type="button" value="Add Favorite" onclick="addToFavorites()" /></font></font> </p> <p> <a href="http://astore.amazon.com/soulmusic-20"><font color="66ffff"><font size="4"><u>The Soul Music Center</u></font></font></a></p> <p> <a href="http://afgen.com" a="" target="" =""=""> <img src="soul_music.jpg" alt="Nowhere to Run: The Story of Soul Music (Paperback) - by Gerri Hirshey" border="1" /></a> </p> <p></p> <blockquote> <blockquote> <blockquote> <blockquote> <blockquote> <blockquote> <a href="http://mcivr.instrument.hop.clickbank.net/" target="_top"><img src="master_music_pro.gif" /></a> <p></p> </blockquote> </blockquote> </blockquote> </blockquote> </blockquote> </blockquote> </center> <script src="http://www.google-analytics.com/urchin.js" type="text/javascript"> </script> <script type="text/javascript"> _uacct = "UA-1842759-1";urchinTracker();</script> </font> </center></font> </body> </html>
287	single	carotid cavernous fistula treatment	What treatments are available for CCFT, carotid cavernous fistula?	clueweb12-0508wb-75-03227	2	<html> <!-- #BeginTemplate "/Templates/HKMJ.dwt" --> <!-- DW6 --> <head> <!-- #BeginEditable "doctitle" --> <title>HKMJ - Abstract - v12n4 - 310</title> <script language="JavaScript" type="text/JavaScript"><!--function MM_swapImgRestore() { //v3.0 var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;}function MM_preloadImages() { //v3.0 var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array(); var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++) if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}}function MM_findObj(n, d) { //v4.01 var p,i,x; if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) { d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);} if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n]; for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document); if(!x && d.getElementById) x=d.getElementById(n); return x;}function MM_swapImage() { //v3.0 var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3) if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}}//--></script> <!-- #EndEditable --> <meta http-equiv="Content-Type" content="text/html; charset=utf-8" /> <link rel="stylesheet" href="http://www.hkmj.org/styles/HKMJ.css" type="text/css" /> <script type="text/javascript"><!--//preload imagesvar image1=new Image()image1.src="http://www.hkmj.org/content/Images/2012-banner02.jpg"var image2=new Image()image2.src="http://www.hkmj.org/content/Images/banner01.gif"//--></script> <script language="JavaScript"><!--//-->//--></script> <!-- Script to create a drop-down menu effect using layers.--> <script language="JavaScript"><!--// big() makes selected layer longer (height property)function big(lyr) {document.all[lyr].style.height='119px'; }/* small() makes selected layer shorter (height property)*/function small(lyr) {document.all[lyr].style.height='17px';}/* start() makes all layers short to start with (height property)*/function start() {document.all.About.style.height='17px';document.all.Authors.style.height='17px';document.all.Subscriptions.style.height='17px';document.all.Jobs.style.height='17px';document.all.Advertisements.style.height='17px';document.all.Resources.style.height='17px'; }//-- !>function MM_preloadImages() { //v3.0 var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array(); var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++) if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}}function MM_swapImgRestore() { //v3.0 var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;}function MM_swapImage() { //v3.0 var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3) if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}}function MM_openBrWindow(theURL,winName,features) { //v2.0 window.open(theURL,winName,features);}function MM_goToURL() { //v3.0 var i, args=MM_goToURL.arguments; document.MM_returnValue = false; for (i=0; i<(args.length-1); i+=2) eval(args[i]+".location='"+args[i+1]+"'");}function MM_timelinePlay(tmLnName, myID) { //v1.2 //Copyright 1998, 1999, 2000, 2001, 2002, 2003, 2004 Macromedia, Inc. All rights reserved. var i,j,tmLn,props,keyFrm,sprite,numKeyFr,firstKeyFr,propNum,theObj,firstTime=false; if (document.MM_Time == null) MM_initTimelines(); //if *very* 1st time tmLn = document.MM_Time[tmLnName]; if (myID == null) { myID = ++tmLn.ID; firstTime=true;}//if new call, incr ID if (myID == tmLn.ID) { //if Im newest setTimeout('MM_timelinePlay("'+tmLnName+'",'+myID+')',tmLn.delay); fNew = ++tmLn.curFrame; for (i=0; i<tmLn.length; i++) { sprite = tmLn[i]; if (sprite.charAt(0) == 's') { if (sprite.obj) { numKeyFr = sprite.keyFrames.length; firstKeyFr = sprite.keyFrames[0]; if (fNew >= firstKeyFr && fNew <= sprite.keyFrames[numKeyFr-1]) {//in range keyFrm=1; for (j=0; j<sprite.values.length; j++) { props = sprite.values[j]; if (numKeyFr != props.length) { if (props.prop2 == null) sprite.obj[props.prop] = props[fNew-firstKeyFr]; else sprite.obj[props.prop2][props.prop] = props[fNew-firstKeyFr]; } else { while (keyFrm<numKeyFr && fNew>=sprite.keyFrames[keyFrm]) keyFrm++; if (firstTime || fNew==sprite.keyFrames[keyFrm-1]) { if (props.prop2 == null) sprite.obj[props.prop] = props[keyFrm-1]; else sprite.obj[props.prop2][props.prop] = props[keyFrm-1]; } } } } } } else if (sprite.charAt(0)=='b' && fNew == sprite.frame) eval(sprite.value); if (fNew > tmLn.lastFrame) tmLn.ID = 0; } }}function MM_findObj(n, d) { //v4.01 var p,i,x; if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) { d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);} if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n]; for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document); if(!x && d.getElementById) x=d.getElementById(n); return x;}function MM_initTimelines() { //v4.0 //MM_initTimelines() Copyright 1997 Macromedia, Inc. All rights reserved. var ns = navigator.appName == "Netscape"; var ns4 = (ns && parseInt(navigator.appVersion) == 4); var ns5 = (ns && parseInt(navigator.appVersion) > 4); var macIE5 = (navigator.platform ? (navigator.platform == "MacPPC") : false) && (navigator.appName == "Microsoft Internet Explorer") && (parseInt(navigator.appVersion) >= 4); document.MM_Time = new Array(1); document.MM_Time[0] = new Array(0); document.MM_Time["Timeline1"] = document.MM_Time[0]; document.MM_Time[0].MM_Name = "Timeline1"; document.MM_Time[0].fps = 10; document.MM_Time[0].lastFrame = 0; for (i=0; i<document.MM_Time.length; i++) { document.MM_Time[i].ID = null; document.MM_Time[i].curFrame = 0; document.MM_Time[i].delay = 1000/document.MM_Time[i].fps; }}//--></script> <!-- End of script to create a drop-down menu effect using layers.--> </head> <body bgcolor="#FFFFFF" text="#000000" onload="start();MM_preloadImages('http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_1_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_2_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_4_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_5_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_6_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_1_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_2_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_3_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_1_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/job_1_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/ad_1_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_1_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_2_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_3_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_over.png','http://www.hkmj.org/content/Images/button/search_2.png','http://www.hkmj.org/content/Images/button/cme_2.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_4_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_5_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_1_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_2_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_4_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_5_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_6_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_1_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_1_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_2_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_3_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_1_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_2_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_3_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_4_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_5_over.png','http://www.hkmj.org/content/Images/button/current_issue_2.png','http://www.hkmj.org/content/Images/button/past_issues_2.png','http://www.hkmj.org/content/Images/button/supplement_4.jpg','http://www.hkmj.org/content/Images/button/submission_2.png','http://www.hkmj.org/content/Images/button/tell_2.png','http://www.hkmj.org/content/Images/button/subscribe_2.png','http://www.hkmj.org/content/Images/button/contact_2.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_1_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/ad_1_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_1_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_2_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_2_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_2_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_3_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_3_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_3_over.png','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_over.png','http://www.hkmj.org/content/Images/button/toc_2.gif','http://www.hkmj.org/content/Images/button/full_2.gif','../../content/Images/button/toc_2.gif','../../content/Images/button/full_2.gif');MM_timelinePlay('Timeline1')"> <table width="950" border="0" bordercolor="#FFFFFF" height="123"> <tbody> <tr> <td height="73" width="214" align="center"><a href="../../index.html"><img src="http://www.hkmj.org/content/Images/misc/hkmjnew.jpg" width="160" height="96" border="0" /></a></td> <td width="740" height="73" bgcolor="#999999"> <table width="422" border="0" align="center" bordercolor="#FFFFFF" height="63"> <tbody> <tr> <td> <div align="center"> <a href="javascript:slidelink()"> <img src="http://www.hkmj.org/content/Images/2012-banner02.jpg" name="slide" border="0" width="470" height="65" /></a> </div> <script type="text/javascript"><!--var step=1var whichimage=1function slideit(){if (!document.images)returndocument.images.slide.src=eval("image"+step+".src")whichimage=stepif (step<2)step++elsestep=1setTimeout("slideit()",11000)}slideit()function slidelink(){if (whichimage==1)window.open("http://www.hktdc.com/hkmedicalfair?DCSext.dept=5&WT.mc_id=1521308")else if (whichimage==2)window.open("http://www.hkmj.org/advertisements/advertisements.html")}//--></script> </td> </tr> </tbody> </table> </td> </tr> <tr bordercolor="#660000" bgcolor="#660000" height="24"> <td colspan="2" height="26"> <img src="http://www.hkmj.org/content/Images/misc/trans30h.gif" width="5" height="17" align="middle" /> <!--This is the 1st column of nav bar--> <div id="About" style="position:absolute; width:124px; height:65px; z-index:50; left: 26px; overflow: hidden; visibility: visible" onmouseover="big('About')" ;="" onmouseout="small('About')"> <a><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about.png" width="124" height="17" border="0" name="Image112" /></a> <a href="../../about/scope.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image1151','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_1_over.png','Image115','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_1_over.png',1)"><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_1_up.png" width="124" height="17" border="0" name="Image1151" /></a> <a href="../../about/eo.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image116','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_2_over.png',1)"><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_2_up.png" width="124" height="17" border="0" name="Image116" /></a> <a href="../../about/website.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image1121','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_4_over.png',1)"><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_4_up.png" width="124" height="17" border="0" name="Image1121" /></a> <a href="../../about/medline.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image113','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_5_over.png',1)"><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_5_up.png" width="124" height="17" border="0" name="Image113" /></a> <a href="../../about/contact.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image114','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_6_over.png',1)"><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_6_up.png" width="124" height="17" border="0" name="Image114" /></a> </div> <!--end of nav bar 1--> <!--This is the 2nd column of nav bar--> <div id="Authors" style="position:absolute; width:97px; height:51px; z-index:40; left: 151px; overflow: hidden; visibility: visible" onmouseover="big('Authors')" ;="" onmouseout="small('Authors')"> <strong></strong> <div align="center"> <a><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_up.png" width="97" height="17" border="0" name="Image112" /></a> <font face="Arial"><a href="../../author/policy.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image1151','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_1_over.png','Image1152','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_1_over.png','Image115','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_1_over.png',1)"><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_1_up.png" width="97" height="17" border="0" name="Image1152" /></a></font> <a href="../../author/style.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image116','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_2_over.png','Image117','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_2_over.png','Image11','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_2_over.png',1)"><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_2_up.png" width="97" height="17" border="0" name="Image117" /></a> <font face="Arial"><a href="../../author/forauthors.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image1112','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_3_over.png','Image111','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_3_over.png',1)"><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_3_up.png" width="97" height="17" border="0" name="Image1112" /></a></font> </div> </div> <!--end of nav bar 2--> <!--This is the 3rd column of nav bar--> <div id="Subscriptions" style="position:absolute; width:136px; height:109px; z-index:30; left: 250px; overflow: hidden; visibility: visible" onmouseover="big('Subscriptions')" ;="" onmouseout="small('Subscriptions')"> <div align="center"> <a><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub.png" width="136" height="17" border="0" name="Image112" /></a> <font face="Arial"><a href="../../subscription/subscribe.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image1151','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_1_over.png','Image1152','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_1_over.png','Image1153','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_1_over.png','Image115','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_1_over.png',1)"><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_1_up.png" width="136" height="17" border="0" name="Image1153" /></a></font> <a href="../../subscription/reprint.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image44','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_2_over.png',1)"><img name="Image44" border="0" src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_2_up.png" width="136" height="17" /></a> <font face="Arial"><a href="../../subscription/permission.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image42','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_3_over.png',1)"><img name="Image42" border="0" src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_3_up.png" width="136" height="17" /></a><a href="../../subscription/maillist.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image43','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_4_over.png',1)"><img name="Image43" border="0" src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_4_up.png" width="136" height="17" /></a><a href="../../cme/cme.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image45','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_5_over.png',1)"><img name="Image45" border="0" src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_5_up.png" width="136" height="17" /></a></font> </div> </div> <!--end of nav bar 3--> <!--This is the 4th column of nav bar--> <div id="Jobs" style="position:absolute; width:117px; height:34px; z-index:30; left: 389px; overflow: hidden; visibility: visible" onmouseover="big('Jobs')" ;="" onmouseout="small('Jobs')"> <div align="center"> <a><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/job.png" width="117" height="17" border="0" name="Image112" /></a> <font face="Arial"><a href="../../update/jobs.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image1151','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_1_over.png','Image1152','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_1_over.png','Image1153','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_1_over.png','Image115','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/job_1_over.png',1)"><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/job_1_up.png" width="117" height="17" border="0" name="Image115" /></a></font> </div> </div> <!--end of nav bar 4--> <!--This is the 5th column of nav bar--> <div id="Advertisements" style="position:absolute; width:124px; height:34px; z-index:30; left: 509px; overflow: hidden; visibility: visible" onmouseover="big('Advertisements')" ;="" onmouseout="small('Advertisements')"> <div align="center"> <a><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/ad_up.png" width="124" height="17" border="0" name="Image112" /></a> <font face="Arial"><a href="../../advertisements/advertisements.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image1151','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_1_over.png','Image1152','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_1_over.png','Image115','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_1_over.png','Image115311','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/ad_1_over.png','Image11531','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/ad_1_over.png',1)"><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/ad_1_up.png" width="124" height="17" border="0" name="Image115311" /></a></font> <font face="Arial"></font> </div> </div> <!--end of nav bar 5--> <!--This is the 6th column of nav bar--> <div id="Resources" style="position:absolute; width:93px; height:85px; z-index:30; left: 636px; overflow: hidden; visibility: visible" onmouseover="big('Resources')" ;="" onmouseout="small('Resources')"> <div align="center"> <a><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_up.png" width="97" height="17" border="0" name="Image112" /></a> <font face="Arial"><a href="../../resources/links.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image1151','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_1_over.png','Image1152','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_1_over.png','Image115','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_1_over.png','Image115311','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/ad_1_over.png','Image11531','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_1_over.png',1)"><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_1_up.png" width="97" height="17" border="0" name="Image11531" /></a></font> <a href="../../resources/press.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image116','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_2_over.png','Image117','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_2_over.png','Image118','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_2_over.png','Image119','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/ad_2_over.png','Image11','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_2_over.png',1)"><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_2_up.png" width="97" height="17" border="0" name="Image11" /></a> <font face="Arial"><a href="../../resources/supp.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image1111','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_3_over.png','Image1112','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_3_over.png','Image1113','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_3_over.png','Image1114','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/ad_over.png','Image111','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_3_over.png',1)"><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_3_up.png" width="97" height="17" border="0" name="Image111" /></a><a href="../../searchsite" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image1111','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/about_3_over.png','Image1112','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/author_3_over.png','Image1113','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/sub_3_over.png','Image1114','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/ad_over.png','Image1115','','http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_4_over.png',1)"><img src="http://www.hkmj.org/templates/new%20nav%20bar%20buttons1/re_4_up.png" width="97" height="17" border="0" name="Image1115" /></a></font> </div> </div> <!--end of nav bar 6--> </td> </tr> <tr bgcolor="#CCCCCC"> <td height="2" colspan="2"> <table width="100%" border="0" height="20" bordercolor="#CCCCCC"> <tbody> <tr> <td width="384" height="44"> <form action="" method="get" name="miniSearchForm" id="miniSearchForm" onsubmit="GenRequest2()"> <div align="right"> <font face="Arial, Helvetica, sans-serif" size="-3">Search HKMJ:</font> <input name="query" type="text" id="Subject" size="20" maxlength="255" /> <input type="submit" value="Go" name="submit" class="normal" /> <input type="hidden" name="fuzzy" value="No" /> <input type="hidden" name="phonic" value="No" /> <input type="hidden" name="natLang" value="No" /> <input type="hidden" name="stemming" value="Yes" /> <input type="hidden" name="natLang" value="No" /> <input type="hidden" name="maxFiles" value="10" /> <input name="sort" type="hidden" id="sort" value="date" /> <input name="index" type="hidden" id="index" value="D:\Inetpub\hkmj_search\abstracts" /> <input name="request" type="hidden" value="" /> <input name="requeststr" type="hidden" value="" /> <input name="cmd" type="hidden" value="search" /> <input name="SearchForm" type="hidden" value="%%SearchForm%%" /> <input name="message" type="hidden" value="" /> <script language="JavaScript"><!--function GenRequest2(){ f = document.forms['miniSearchForm'] f.query.value = trim(f.query.value) q = "" q2 = "" tArr = f.query.value.split(" ") for(var i = 0; i < tArr.length; i++){ if (trim(tArr[i]) != ""){ q = q + "*" + tArr[i] + "*" //q = q + tArr[i] q2 = q2 + tArr[i] if (i < (tArr.length-1)){ q = q + " or " q2 = q2 + ", " } } } f.request.value = q f.requeststr.value = q2 if (trim(q) != ""){ f.action = "/searchsite/search_abstract_result.asp" }else{ f.message.value = "Please input searching criteria." }}function ltrim ( s ){return s.replace( /^\s*/, "" )}function rtrim ( s ){return s.replace( /\s*$/, "" );}function trim ( s ){return rtrim(ltrim(s));}//--> </script> </div> </form> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table border="0" width="728" bordercolor="#FFFFFF"> <tbody> <tr> <td width="138" height="412" rowspan="9" bgcolor="#FFFFFF" valign="top"> <p><font color="#336699" size="2" face="Arial, Helvetica, sans-serif"><a href="http://www.hkmj.org/abstracts/v18n1/TOC.htm" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('current issue','','http://www.hkmj.org/content/Images/button/current_issue_2.png',1)"><img name="current issue" border="0" src="http://www.hkmj.org/content/Images/button/current_issue_1.png" width="138" height="20" align="top" /></a></font> <font color="#336699" size="2" face="Arial, Helvetica, sans-serif"><a href="../../update/index_vol.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('past issues','','http://www.hkmj.org/content/Images/button/past_issue_2.png',1)"><img name="past issues" border="0" src="http://www.hkmj.org/content/Images/button/past_issue_1.png" width="138" height="20" align="top" /></a></font> <font color="#336699" size="2" face="Arial, Helvetica, sans-serif"><b><a href="../../searchsite" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('cme1','','http://www.hkmj.org/content/Images/button/search_2.png',1)"><img name="cme1" border="0" src="http://www.hkmj.org/content/Images/button/search_1.png" width="138" height="20" /></a></b></font><font color="#336699" size="2" face="Arial, Helvetica, sans-serif"><b><a href="../../cme/cme.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('cme','','http://www.hkmj.org/content/Images/button/cme_2.png',1)"><img name="cme" border="0" src="http://www.hkmj.org/content/Images/button/cme_1.png" width="138" height="20" /></a><a href="../../resources/supp.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('supplement','','http://www.hkmj.org/content/Images/button/supplement_4.png',1)"><img name="supplement" border="0" src="http://www.hkmj.org/content/Images/button/supplement_3.png" width="138" height="20" align="top" /></a> <a href="../../author/submission.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('submission','','http://www.hkmj.org/content/Images/button/submission_2.png',1)"><img name="submission" border="0" src="http://www.hkmj.org/content/Images/button/submission_1.png" width="138" height="40" align="top" /></a> </b></font> <font color="#336699" size="2" face="Arial, Helvetica, sans-serif"><a href="http://www.hkmj.org/video/index.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('video','','http://www.hkmj.org/content/Images/button/video_2.png',1)"><img name="video" border="0" src="http://www.hkmj.org/content/Images/button/video_1.png" width="138" height="20" align="top" /></a></font> <font color="#336699" size="2" face="Arial, Helvetica, sans-serif"><b></b></font><font color="#336699" size="2" face="Arial, Helvetica, sans-serif"><b><a href="http://www.hkmj.org/subscription/mailto.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('tell','','http://www.hkmj.org/content/Images/button/tell_2.png',1)"><img name="tell" border="0" src="http://www.hkmj.org/content/Images/button/tell_1.png" width="138" height="20" /></a><a href="http://www.hkmj.org/subscription/maillist.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('alert','','http://www.hkmj.org/content/Images/button/subscribe_2.png',1)"><img name="alert" border="0" src="http://www.hkmj.org/content/Images/button/subscribe_1.png" width="138" height="20" align="top" /></a><a href="http://www.hkmj.org/about/contact.html" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('contact','','http://www.hkmj.org/content/Images/button/contact_2.png',1)"><img name="contact" border="0" src="http://www.hkmj.org/content/Images/button/contact_1.png" width="138" height="20" align="top" /></a></b></font></p> <p align="center"><a href="http://www.hkmjforum.org" target="_blank"><img src="http://www.hkmj.org/content/Images/2010-image-01.jpg" width="120" height="60" border="0" /> </a></p> <p align="center"><a href="http://www.hkmj.org/video/index.html"><img src="http://www.hkmj.org/content/Images/2010-image-02.jpg" width="120" height="60" border="0" /> </a></p> <p align="center"><a href="http://www.hkmj.org/cme/cme.html"><img src="http://www.hkmj.org/content/Images/2010-image-03.jpg" width="120" height="60" border="0" /> </a></p> <p align="center"><a href="http://www.hkmj.org/update/bopa.html"><img src="http://www.hkmj.org/content/Images/2010-image-07.jpg" width="120" height="60" border="0" /></a></p> <p align="center"><a href="http://www.hkmj.org/resources/press.html"><img src="http://www.hkmj.org/content/Images/2010-image-04.jpg" width="120" height="60" border="0" /></a></p> <p align="center"><a href="http://www.hkmj.org/update/jobs.html"><img src="http://www.hkmj.org/content/Images/2010-image-05.jpg" width="120" height="60" border="0" /></a></p> <p align="center"><a href="http://www.hkmj.org/resources/supp.html"><img src="http://www.hkmj.org/content/Images/2010-image-06.jpg" width="120" height="60" border="0" /></a></p> <p align="center">&nbsp;</p> </td> <td width="580" height="412" rowspan="9" bgcolor="#FFFFFF" valign="top"> <!-- #BeginEditable "content" --> <table border="0" bordercolor="#FFFFFF" width="550"> <tbody> <tr> <td><img src="http://www.hkmj.org/content/Images/page%20heads/abstracts.gif" width="350" height="30" /></td> </tr> <tr> <td class="normal" height="150"> <p class="heading2">Transvenous embolisation of a carotid-trigeminal cavernous fistula</p> <p><span class="normal">YL Chan, KK Shing, KC Wong, WS Poon<br /> Department of Diagnostic Radiology and Organ Imaging, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong (now at the Magnus Magnetic Resonance and Ultrasound Diagnostic Centre, G3 and G3a, Mirror Tower, 61 Mody Road, Tsimshatsui, Hong Kong)</span> </p><p><span class="normal"> <br /> </span>A carotid cavernous fistula is an abnormal communication between the internal carotid artery and the cavernous sinus. Rarely, this communication is associated with a persistent primitive trigeminal artery, with or without a trigeminal artery aneurysm. We report a case of spontaneous carotid-trigeminal cavernous fistula in which the persistent trigeminal artery was shown only on vertebral artery injection. The absence of an associated trigeminal artery aneurysm allowed a transvenous approach for endovascular treatment with coils and complete obliteration of the cavernous fistula. </p><p><br /> </p><p class="normal">Hong Kong Med J 2006;12:310-2<br /> <br /></p> <p class="normal">Key words: Carotid-cavernous sinus fistula; Embolization, therapeutic; Trigeminal nerve</p> </td> </tr> <tr> <td> </td> </tr> <tr> <td class="heading2" height="2">&nbsp;</td> </tr> <tr> <td class="heading2" height="2"><a href="../v12n4/TOC.htm" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('abstract14','','../../content/Images/button/toc_2.gif',1)"><img name="abstract14" border="0" src="http://www.hkmj.org/content/Images/button/toc_1.gif" width="85" height="15" align="right" /></a><a href="http://www.hkmj.org/article_pdfs/hkm0608p310.pdf" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('full14','','../../content/Images/button/full_2.gif',1)"><img name="full14" border="0" src="http://www.hkmj.org/content/Images/button/full_1.gif" width="76" height="15" align="right" /></a></td> </tr> <tr> <td class="normal">&nbsp;</td> </tr> <tr> <td class="normal">View this abstract indexed in MEDLINE: </td> </tr> <tr> <td><a href="http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;term=%22Hong%2BKong%2BMed%2BJ%22%5BJour%5D"><img src="http://www.hkmj.org/content/Images/misc/medline.gif" width="125" height="32" border="0" /></a></td> </tr> <tr> <td>&nbsp;</td> </tr> </tbody> </table> <p>&nbsp;</p> <!-- #EndEditable --></td> </tr> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> <tr> </tr> </tbody> </table> <table width="933" border="0" bordercolor="#FFFFFF" height="53"> <tbody> <tr> <td height="56" bgcolor="#FFFFFF"> <div align="center"> <a href="http://www.hkmj.org/"><img src="http://www.hkmj.org/content/Images/misc/hkmjnew.jpg" width="160" height="96" border="0" /></a> </div> </td> <td height="56" bgcolor="#FFFFFF"> <table width="702" border="0" align="center" bordercolor="#FFFFFF" height="32" bgcolor="#999999"> <tbody> <tr> <td width="656" bgcolor="#999999"> <div align="center"> <a href="http://www.hkmj.org/HKMJ/author/forauthors.html"><img src="http://www.hkmj.org/content/Images/ad/HKMJ_ad_big9.gif" width="350" height="50" border="0" /></a> </div> </td> <td width="36" height="73" bgcolor="#999999"> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table width="934" border="0" bordercolor="#FFFFFF" height="26"> <tbody> <tr> <td width="928" height="15"> <div align="center"> <p><font face="Arial, Helvetica, sans-serif" size="-3">The Hong Kong Medical Journal is a continuation of the former Journal of the Hong Kong Medical Association.<br /> The Hong Kong Medical Journal is published by the Hong Kong Academy of Medicine and the Hong Kong Medical Association. <br /> Copyright &copy; 1995-2011 HKAM. All rights reserved.<br /> <a href="http://www.hkmj.org/HKMJ/index.html">URL: http://www.hkmj.org</a><br /> Layout, design, and revisions&nbsp;Copyright &copy; 2012 HKAM. </font><font face="Arial, Helvetica, sans-serif" size="-2">Revised 4 Feb 2012</font></p> </div> </td> </tr> </tbody> </table> <!-- Start of StatCounter Code --> <script type="text/javascript" language="javascript">var sc_project=2669437; var sc_invisible=0; var sc_partition=26; var sc_security="5b760f23"; </script> <script type="text/javascript" language="javascript" src="http://www.statcounter.com/counter/frames.js"></script> <noscript> <a href="http://www.statcounter.com/" target="_blank"><img src="http://c27.statcounter.com/counter.php?sc_project=2669437&amp;java=0&amp;security=5b760f23&amp;invisible=0" alt="blog stats" border="0" /></a> </noscript> <!-- End of StatCounter Code --> <!-- #EndTemplate --> </body> </html>
279	faceted	game theory	Find books on game theory.	clueweb12-0300wb-42-24588	3	<html> <head> <meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1" /> <meta name="keywords" content="Books On Game Theory,Sociology books,Academic Sociology,Book,Sociology Literature,Behavioral Game Theory,economics,Behavior,Books on Sociology,Game Theory for Applied Economists,Evolutionary Game Theory,Sociology books,Game Theory books" /> <meta name="GENERATOR" content="Microsoft FrontPage 3.0" /> <title>Books - Game theory develops general mathematical formulas and algorithms toidentify optimal strategies and to predict the outcome of interactions. Game Theory is thescience of strategy and attempts to determine what actions different players such astrading partners, employers, unions or even organised crime groups should take to securethe best outcome for themselves. Game theory studies strategic interaction in competitiveand cooperative environments. Only fifty years old, it has already revolutionizedeconomics, and is spreading rapidly to a wide variety of fields including conflict andwar. Oskar Morgenstern and mathematician John von Neumann also contributed immensely.</title> <meta name="Microsoft Border" content="tlrb, default" /> </head> <body> <!--msnavigation--> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td> <div align="center"> <center> <table border="0" cellpadding="3" cellspacing="3" width="100%"> <tbody> <tr> <td width="100%"><p align="center"><script type="text/javascript"><!--google_ad_client = "pub-7155683963322350";/* 728x15 */google_ad_slot = "2640728797";google_ad_width = 728;google_ad_height = 15;//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script></p></td> </tr> </tbody> </table> </center> </div> <div align="center"> <center> <table border="0" cellpadding="3" cellspacing="3" width="100%" height="18"> <tbody> <tr> <td height="8"><p align="right"><small><small><a href="books_magazines_great_discount.htm"><script type="text/javascript"><!--google_ad_client = "pub-7155683963322350";/* bordtop72815link */google_ad_slot = "2847474107";google_ad_width = 728;google_ad_height = 15;//--></script></a></small></small></p></td> </tr> </tbody> </table> </center> </div> <div align="center"> <center> <table border="0" cellpadding="3" cellspacing="3" width="100%"> <tbody> <tr> <td width="100%" bgcolor="#000000"><p align="center"><a href="http://www.sociologyindex.com/"><font color="#FFFFFF" size="6"><strong><span style="color: rgb(255,255,255)">Sociology Index</span></strong></font></a></p></td> </tr> </tbody> </table> </center> </div><p>&nbsp;</p></td> </tr> <!--msnavigation--> </tbody> </table> <!--msnavigation--> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td valign="top" width="1%"> <div align="center"> <center> <table border="0" cellpadding="3" cellspacing="3" width="160" height="600"> <tbody> <tr> <td width="160" rowspan="2" valign="top"><script type="text/javascript"><!--google_ad_client = "pub-7155683963322350";/* 160x600 */google_ad_slot = "7483391527";google_ad_width = 160;google_ad_height = 600;//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script></td> </tr> </tbody> </table> </center> </div><p>&nbsp;</p><p>&nbsp;</p> <div align="center"> <center> <table border="0" cellpadding="0" cellspacing="0" width="160" height="90"> <tbody> <tr> <td valign="top" height="1"><script type="text/javascript"><!--google_ad_client = "pub-7155683963322350";/* 160x90, leftlink1 */google_ad_slot = "5780332226";google_ad_width = 160;google_ad_height = 90;//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script></td> </tr> </tbody> </table> </center> </div><p>&nbsp;</p><p>&nbsp;</p></td> <td valign="top" width="24"></td> <!--msnavigation--> <td valign="top"> <!--webbot bot="HTMLMarkup" TAG="XBOT" StartSpan --><iframe src="http://rcm.amazon.com/e/cm?t=wwwsociologyi-20&amp;o=1&amp;p=48&amp;l=ur1&amp;category=kindle&amp;banner=0Y98S4SYN0MXZ8260582&amp;f=ifr" width="728" height="90" scrolling="no" border="0" marginwidth="0" style="border:none;" frameborder="0">&lt;!--webbot BOT=&quot;HTMLMarkup&quot; endspan --&gt;&lt;!--webbot bot=&quot;HTMLMarkup&quot; TAG=&quot;XBOT&quot; StartSpan --&gt;</iframe> <!--webbot BOT="HTMLMarkup" endspan --><h1>Books On Game Theory</h1><p><strong><font size="3" color="#0000FF"><span style="color: rgb(0,0,255)"><a href="index.htm" style="color: rgb(0,0,255)">Sociologyindex</a>, <a href="sociology_books.htm" style="color: rgb(0,0,255)">Sociology Books 2012</a>, </span></font><a href="game_theory.htm"><font size="4" color="#0000FF">Game Theory</font></a></strong></p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0521841704/qid=1129130761/sr=1-29/ref=sr_1_29?v=glance%26s=books">EvolutionaryGame Theory, Natural Selection, and Darwinian Dynamics</a><br /></strong>Book by <em>Thomas L. Vincent, Joel S. Brown</em> </p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0691090394/qid=1129125797/sr=1-7/ref=sr_1_7?v=glance%26s=books">BehavioralGame Theory : Experiments in Strategic Interaction</a></strong> Book by <em>Colin F.Camerer </em></p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/140394167X/qid=1129132874/sr=1-76/ref=sr_1_76?v=glance%26s=books">Advancesin Understanding Strategic Behaviour : Game Theory, Experiments and Bounded Rationality</a></strong>Book by <em>Steffen Huck</em> (Editor) </p><p><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0805076999/qid=1129125797/sr=1-8/ref=sr_1_8?v=glance%26s=books"><strong>TheSurvival Game : How Game Theory Explains the Biology of Cooperation and Competition</strong></a>Book by <em>David P. Barash</em></p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0486434974/qid=1129131604/sr=1-49/ref=sr_1_49?v=glance%26s=books">GameTheory and Politics</a></strong> Book by <em>Steven J. Brams </em></p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0486296725/qid=1129125797/sr=1-1/ref=sr_1_1?v=glance%26s=books">GameTheory: A Nontechnical Introduction</a></strong> Book by&nbsp; <em>Morton D. Davis </em></p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0691003955/qid=1129125797/sr=1-2/ref=sr_1_2?v=glance%26s=books">GameTheory for Applied Economists</a> </strong>Book by <em>Robert Gibbons</em> </p><p><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0674341163/qid=1129125797/sr=1-3/ref=sr_1_3?v=glance%26s=books"><strong>GameTheory: Analysis of Conflict</strong></a> Book by <em>Roger B. Myerson </em></p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0195128958/qid=1129125797/sr=1-4/ref=sr_1_4?v=glance%26s=books">AnIntroduction to Game Theory</a></strong> Book by <em>Martin J. Osborne</em></p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0262650401/qid=1129125797/sr=1-5/ref=sr_1_5?v=glance%26s=books">ACourse in Game Theory</a> </strong>Book by <em>Martin J. Osborne, Ariel Rubinstein</em> </p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0691009430/qid=1129125797/sr=1-6/ref=sr_1_6?v=glance%26s=books">GameTheory Evolving</a> </strong>Book by <em>Herbert Gintis</em></p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0071400206/qid=1129125797/sr=1-10/ref=sr_1_10?v=glance%26s=books">GameTheory at Work: How to Use Game Theory to Outthink and Outmaneuver Your Competition</a></strong>Book by <em>James D. Miller</em></p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0691011923/qid=1129128169/sr=1-11/ref=sr_1_11?v=glance%26s=books">Classicsin Game Theory</a> </strong>Book by <em>Harold William Kuhn</em> (Editor)</p><p><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0262023636/qid=1129128169/sr=1-12/ref=sr_1_12?v=glance%26s=books"><strong>GameTheory and the Social Contract, Vol. 1: Playing Fair</strong></a> Book by <em>Ken Binmore </em></p><p><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0674341112/qid=1129128169/sr=1-13/ref=sr_1_13?v=glance%26s=books"><strong>GameTheory and the Law</strong></a> by <em>Douglas G. Baird, Robert H. Gertner, Randal C.Picker </em></p> <div align="center"> <center> <table border="0" cellpadding="3" cellspacing="3" width="100%"> <tbody> <tr> <td><p align="center"><script type="text/javascript"><!--google_ad_client = "pub-7155683963322350";/* textimage336x280 */google_ad_slot = "3273947362";google_ad_width = 336;google_ad_height = 280;//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script></p></td> </tr> </tbody> </table> </center> </div><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/354026082X/qid=1129129302/sr=1-41/ref=sr_1_41?v=glance%26s=books">Modelsin Cooperative Game Theory : Crisp, Fuzzy, and Multi-Choice Games</a></strong> (LectureNotes in Economics and Mathematical Systems) </p><p><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/1584883006/qid=1129131387/sr=1-39/ref=sr_1_39?v=glance%26s=books"><strong>IntroducingGame Theory and its Applications</strong></a> Book by <em>Elliot Mendelson</em></p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0415250951/qid=1129132472/sr=1-54/ref=sr_1_54?v=glance%26s=books">GameTheory: A Critical Text</a> </strong>Book by <em>Shaun P. Hargreaves Heap, YanisVaroufakis </em></p><p><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0415259878/qid=1129133233/sr=1-83/ref=sr_1_83?v=glance%26s=books"><strong>GameTheory and Economic Analysis (Routledge Advances in Game Theory)</strong>&nbsp; </a>Bookby <em>Christian Schmidt</em> (Editor) </p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/1594542244/qid=1129133684/sr=1-91/ref=sr_1_91?v=glance%26s=books">GameTheory And Applications</a></strong> Book by <em>L. A. Petrosjan </em>(Editor), <em>V. V.Mazalov</em> (Editor) </p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/B00072NYEK/qid=1129134714/sr=1-33/ref=sr_1_33?v=glance%26s=books">Zero-sumgames (Teaching &amp; research materials)</a></strong> Book <em>Thomas C Schelling</em>(Nobel Laureate 2005 for Economics)<br /><br /><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/B0007EY7QW/qid=1129134714/sr=1-34/ref=sr_1_34?v=glance%26s=books">Prospectusfor a reorientation of game theory (P-1491)</a></strong> Book <em>Thomas C Schelling</em>(Nobel Laureate 2005 for Economics)<br /><br /><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/B0007EY7R6/qid=1129134714/sr=1-35/ref=sr_1_35?v=glance%26s=books">Thereciprocal fear of surprise attack (P-1342)</a> </strong>Book <em>Thomas C Schelling</em>(Nobel Laureate 2005 for Economics)</p><p><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0714655163/qid=1129134272/sr=1-2/ref=sr_1_2?v=glance%26s=books"><strong>ThomasSchelling and the Nuclear Age: Strategy as Social Science (Strategy and History)</strong></a>Book by <em>Robert Ayson</em></p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0521814626/qid=1129134272/sr=1-8/ref=sr_1_8?v=glance%26s=books">DecisionMaking using Game Theory : An Introduction for Managers</a></strong> by <em>Anthony Kelly</em></p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0262011549/qid=1129135065/sr=1-1/ref=sr_1_1?v=glance%26s=books">CollectedPapers, Vol. 1</a></strong> Robert Aumann's groundbreaking career in game theory hasspanned over 35 years. Book by <em>Robert J. Aumann </em></p><p><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0262011476/qid=1129135065/sr=1-4/ref=sr_1_4?v=glance%26s=books"><strong>RepeatedGames with Incomplete Information</strong></a> Book by <em>Robert J. Aumann</em></p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0821805258/qid=1129135065/sr=1-5/ref=sr_1_5?v=glance%26s=books">Topicsin Mathematical Economics in Game Theory: Essays in Honor of Robert J. Aumann</a></strong>(Fields Institute Communications, V. 23.) Book by <em>Myrna H. Wooders</em> (Editor) </p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0691034303/qid=1129129851/sr=1-17/ref=sr_1_17?v=glance%26s=books">GameTheory for Political Scientists</a> </strong>Book by <em>James D. Morrow </em></p><p><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/1587788071/qid=1129129851/sr=1-19/ref=sr_1_19?v=glance%26s=books"><strong>DecisionAnalysis, Game Theory, and Information (University Casebook Series)</strong></a> Book by <em>LouisKaplow, Steven Shavell</em></p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0471168130/qid=1129130997/sr=1-32/ref=sr_1_32?v=glance%26s=books">Gamingthe Market : Applying Game Theory to Create Winning Trading Strategies (Wiley Finance)</a></strong>Book by <em>Ronald B. Shelton </em></p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0444894284/qid=1129131604/sr=1-47/ref=sr_1_47?v=glance%26s=books">Handbookof Game Theory with Economic Applications Volume 3 (Handbooks in Economics)</a> </strong>Bookby <em>R. J. Aumann, S. Hart </em></p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0201847582/qid=1129129851/sr=1-18/ref=sr_1_18?v=glance%26s=books">GameTheory with Economic Applications (2nd Edition)</a><br /></strong>Book by <em>H. Scott Bierman, Luis Fernandez </em></p><p><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0883856379/qid=1129129851/sr=1-14/ref=sr_1_14?v=glance%26s=books"><strong>GameTheory and Strategy (New Mathematical Library)</strong></a> Book by <em>Philip D. Straffin</em><br />Mathematical Reviews</p><p><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/3540656286/qid=1129133233/sr=1-90/ref=sr_1_90?v=glance%26s=books">AGame Theory Analysis of Options: Contributions to the Theory of Financial Intermediationin Continuous Time</a></strong> Book by <em>Alexandre Ziegler </em></p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/1590334639/qid=1129129010/sr=1-27/ref=sr_1_27?v=glance%26s=books">Handbookof Game theory (CD-ROM)</a><br /></strong>Book by <em>L. A. Petrosjan</em> (Editor), <em>V. V. Mazalov </em>(Editor) </p><p><font size="4" color="#000000"><strong>Rewiews:</strong></font></p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0521841704/qid=1129130761/sr=1-29/ref=sr_1_29?v=glance%26s=books">EvolutionaryGame Theory, Natural Selection, and Darwinian Dynamics</a><br /></strong>Book by <em>Thomas L. Vincent, Joel S. Brown</em> <br />Many topics in natural selection are investigated within the context of Darwinian dynamicsand evolutionary game theory.<br />All of life is a game and evolution by natural selection is no exception. The evolutionarygame theory developed in this book provides the tools necessary for understanding many ofnature's mysteries, including co-evolution, speciation, extinction and the majorbiological questions regarding fit of form and function, diversity, procession, and thedistribution and abundance of life. Mathematics for the evolutionary game theory aredeveloped based on Darwin's postulates leading to the concept of a fitness generatingfunction (G-function). G-function is a tool that simplifies notation and plays animportant role developing Darwinian dynamics that drive natural selection. Naturalselection may result in special outcomes such as the evolutionarily stable strategy (ESS).An ESS maximum principle is formulated and its graphical representation as an adaptivelandscape illuminates concepts such as adaptation, Fisher's Fundamental Theorem of NaturalSelection, and the nature of life's evolutionary game theory.</p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0486434974/qid=1129131604/sr=1-49/ref=sr_1_49?v=glance%26s=books">GameTheory and Politics</a></strong> Book by <em>Steven J. Brams </em><br />In this illuminating and instructive survey, Brams demonstrates both the insights and thepitfalls that can result from applying game theoretic models to the analysis of problemsin political science. Using real-life examples, he shows how game theory can explain andelucidate complex political situations, from warfare to presidential vetoes. In thesecases and others, game theorys mathematical structure provides a rigorous,consistent method for formulating, analyzing, and solving strategic problems. </p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0486296725/qid=1129125797/sr=1-1/ref=sr_1_1?v=glance%26s=books">GameTheory : A Nontechnical Introduction</a></strong> Book by&nbsp; <em>Morton D. Davis </em><br />Fascinating, accessible introduction to enormously important intellectual system withnumerous applications to social, economic, political problems. Newly revised editionoffers overview of game theory, then lucid coverage of the two-person zero-sum game withequilibrium points; the general, two-person zero-sum game; utility theory; other topics. </p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0691003955/qid=1129125797/sr=1-2/ref=sr_1_2?v=glance%26s=books">GameTheory for Applied Economists</a> </strong>Book by <em>Robert Gibbons</em> <br />Review<br />Lucid and detailed introduction to game theory in an explicitly economic context.<br />This book introduces one of the most powerful tools of modern economics to a wideaudience: those who will later construct or consume game-theoretic models. Robert Gibbonsaddresses scholars in applied fields within economics who want a serious and thoroughdiscussion of game theory but who may have found other works overly abstract. Gibbonsemphasizes the economic applications of the theory at least as much as the pure theoryitself; formal arguments about abstract games play a minor role. The applicationsillustrate the process of model building--of translating an informal description of amulti-person decision situation into a formal game-theoretic problem to be analyzed. Also,the variety of applications shows that similar issues arise in different areas ofeconomics, and that the same game-theoretic tools can be applied in each setting. In orderto emphasize the broad potential scope of the theory, conventional applications fromindustrial organization have been largely replaced by applications from labor, macro, andother applied fields in economics. The book covers four classes of games, and fourcorresponding notions of equilibrium: static games of complete information and Nashequilibrium, dynamic games of complete information and subgame-perfect Nash equilibrium,static games of incomplete information and Bayesian Nash equilibrium, and dynamic games ofincomplete information and perfect Bayesian equilibrium.</p><p style="margin-left: 5px"><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0674341163/qid=1129125797/sr=1-3/ref=sr_1_3?v=glance%26s=books"><strong>GameTheory: Analysis of Conflict</strong></a> Book by <em>Roger B. Myerson </em><br />An Elegant and Deep Treatment. <br />Reviewer: H. Gintis (Northampton, MA USA)<br />I just completed a game theory book (Game Theory Evolving, Princeton University Press,2000). To find the best way to present various materials, I went through virtually everygame theory book in existence. For the presentation of the basic material on normal andextensive form games, nothing even came close to this book in clarity of presentation anddepth of understanding of the issues. Most textbooks, even highly touted ones that aremathematically challenging, do not even come close, and rarely even present the materialin a coherent form at all.<br />I used to do a lot of carpentry, and I always knew the good carpenters from the run of themill. The latter talk about how to build stuff. The good ones talked about how you choose,preserve, treat, and sharpen your tools. Myerson is, for game theory, like the goodcarpenter, and this book is more about the nature of the tools of game theory than theirdeployment--although it is certainly that, too.<br />Game theory is the analysis of cooperation as much as conflict, and much, much else aswell. So is this book.<br />Reviewer: Adrian Peralta-Alva (Minneapolis, MN U.S.A)<br />I found this book very helpful in my first year of the Ph D in Economics. I also have usedMasColell and Kreps but Myerson was the only one that actually help me understandingcomplicated concepts as the always Hard Sequential Equilibrium. It is the only book thatcovers both, sequential and Perfect equilibrium with examples and solutions so that youunderstand what is going on. If you are willing to buy a Game Theory book I willdefinitely go for this one. If that is not enough you should also see that the costbenefit ratio of Myerson's book is undoubtly the best of any other one.</p><p style="margin-left: 5px"><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0195128958/qid=1129125797/sr=1-4/ref=sr_1_4?v=glance%26s=books"><strong>AnIntroduction to Game Theory</strong></a> Book by <em>Martin J. Osborne</em><br />The best introduction book that you will love!, October 26, 2004<br />Reviewer: bookworm (Boston)<br />I have quite a few game theory books, including the Fudenberg and Tirole, the Gibbons, theMayerson and the other Osborne book. This one is absolutely the best introductory book youwill find. The writing is extremely clear, with no unnecessary math, but with veryrigorous treatment of concepts and theorems. The author makes remarkable effort inexplaining the stuff, and succeeds beyond my expection in offering intuitions and ideasbehind the concepts and theorems. It is a perfect intro-level book, if what you want isthe combination of accessibility, rigor, and comprehensiveness. <br />the best introduction to game theory, December 16, 2003<br />Reviewer: &quot;luiedu&quot; (Berkeley, CA USA)<br />Osborne's book is the most complete introduction to game theory available. It's formal butalso reader friendly with a lot of examples. It's considerably better than the usual gametheory textbooks used in economics (Gibbons, Kreps and others). Simply great!</p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0262650401/qid=1129125797/sr=1-5/ref=sr_1_5?v=glance%26s=books">ACourse in Game Theory</a> </strong>Book by <em>Martin J. Osborne, Ariel Rubinstein</em> <br />A Course in Game Theory presents the main ideas of game theory at a level suitable forgraduate students and advanced undergraduates, emphasizing the theory's foundations andinterpretations of its basic concepts. The authors provide precise definitions and fullproofs of results, sacrificing generalities and limiting the scope of the material inorder to do so. The text is organized in four parts: strategic games, extensive games withperfect information, extensive games with imperfect information, and coalitional games. Itincludes over 100 exercises.<br />Martin J. Osborne is Professor of Economics at the University of Toronto. Ariel Rubinsteinis Professor of Economics at Tel Aviv University. </p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0691009430/qid=1129125797/sr=1-6/ref=sr_1_6?v=glance%26s=books">GameTheory Evolving</a> </strong>Book by <em>Herbert Gintis</em><br />Basic toolkit for the evolutionary study of social behavior. Reviewer: Todd I. Stark&quot;Cellular Wetware plus Books&quot; (Philadelphia, Pa USA).<br />Herb Gintis is an economist with a strong interest in the assumptions we make about humanrationality in our social, political, and economic theories. He has produced a remarkableand deceptively innovative text that could productively be used in a broad range offields.<br />The topic of game theory is interesting to many people because it describes interactionbetween competitors, presumably helping us pick the best strategy if the circumstances arewell enough understood. We might wonder whether the circumstances are well enoughunderstood in daily life to apply the methods of game theory to our own choices, since itusually to assume that we are rational competitors trying to maximize our own gain.<br />Game Theory Evolving addresses this fascinating question not from a theoreticalperspective so much as giving the reader the tools for investigating it themselves in twodistinct but complementary ways. <br />First, it provides practical problem-oriented chapters for learning the principles andthinking in terms of game theoretic methods. The problems are not the usual textbook&quot;who cares, anyway ?&quot; type. Rather they are fun and interesting to solve andoften lead to direct insights into real situations. <br />Second, it extends game theory into the realm of evolutionary thinking, so we not onlyunderstand strategic action but we get some deeper insight into how our historical needsshaped our behavior and even our thought processes. Game theory may help explain how welearned to cooperate and why under some conditions we tend to punish cheaters and treatpeople fairly even though it provides no apparent advantage to us.<br />Disguised as a lowly academic textbook, Game Theory Evolving is actually a basic toolkit,a passport into the remarkable modern study of evolutionary thinking about human nature,through a practical grounding in the mathematical techniques that have the potential tojoin our understanding of social sciences and biology.<br />'The first problem-oriented book in Game Theory.' Reviewer: Manuel A Ferreira - <br />Game Theory has to be taught with a strong enphasis on the developing the problem solvingcapabilities of the students, Nevertheless, the books you can find out there are verystrong in the math and the theory but weak, incomplete, and poor in the problems. This isthe first book I could find where the enphasis is made on the problems and on developingthe capacities of the reader/student in the field, not just for theoretical purposes,where problems are more than useful, but also in the empirical aplications of game theory.Theory in this book emerges from the problems since all the chapters are developed asproblems in themselves. It has also the probably the first extensive treatment in atextbook of evolutionary game theory. Given that this new field has become one ofextensive research in the field lately, this becomes a major contribution to the teachingof game theory. And the best part is that is fun to read!</p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0691090394/qid=1129125797/sr=1-7/ref=sr_1_7?v=glance%26s=books">BehavioralGame Theory : Experiments in Strategic Interaction</a></strong> (The Roundtable Series inBehavioral Economics) Book by <em>Colin F. Camerer </em><br />Review<br />It is certainly time that a book such as this be published. This volume will be a'one-stop shop' for learning about behavioral economics and is likely to be adopted ingraduate course in behavioral economics (and may even encourage people to offer such acourse). The introductory chapter does a good job of explaining the enterprise, behavioraleconomics, and providing some history and context.<br />Game theory, the formalized study of strategy, began in the 1940s by asking howemotionless geniuses should play games, but ignored until recently how average people withemotions and limited foresight actually play games. This book marks the first substantialand authoritative effort to close this gap. Colin Camerer, one of the field's leadingfigures, uses psychological principles and hundreds of experiments to develop mathematicaltheories of reciprocity, limited strategizing, and learning, which help predict what realpeople and companies do in strategic situations. Unifying a wealth of information fromongoing studies in strategic behavior, he takes the experimental science of behavioraleconomics a major step forward. He does so in lucid, friendly prose.<br />Behavioral game theory has three ingredients that come clearly into focus in this book:mathematical theories of how moral obligation and vengeance affect the way people bargainand trust each other; a theory of how limits in the brain constrain the number of steps of&quot;I think he thinks . . .&quot; reasoning people naturally do; and a theory of howpeople learn from experience to make better strategic decisions. Strategic interactionsthat can be explained by behavioral game theory include bargaining, games of bluffing asin sports and poker, strikes, how conventions help coordinate a joint activity, pricecompetition and patent races, and building up reputations for trustworthiness orruthlessness in business or life.<br />While there are many books on standard game theory that address the way ideally rationalactors operate, Behavioral Game Theory stands alone in blending experimental evidence andpsychology in a mathematical theory of normal strategic behavior. It is must reading foranyone who seeks a more complete understanding of strategic thinking, from professionaleconomists to scholars and students of economics, management studies, psychology,political science, anthropology, and biology.</p><p style="margin-left: 5px"><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0805076999/qid=1129125797/sr=1-8/ref=sr_1_8?v=glance%26s=books"><strong>TheSurvival Game : How Game Theory Explains the Biology of Cooperation and Competition</strong></a>Book by <em>David P. Barash</em><br />From Publishers Weekly<br />Game theory attempts to explain the dynamics of life as a series of individual games, eachinvolving specific moves that take place within a strictly delineated set of rules.Depending on whom you ask, it's either a brilliant tool for analyzing the complexities ofsocial life or hopelessly reductionist. Zoologist and professor of psychology Barash(coauthor of The Myth of Monogamy), who emphatically falls into the former camp, proves anapt popularizer of the basics of the field, and his book reads like an introductoryseminar led by a friendly professor with a slightly corny sense of humor. Readers who havenever heard of the Prisoner's Dilemma or the Game of Chicken will find Barash'sexplanations accessible, while those who are already familiar with the basics of gametheory can appreciate the wealth of historical, biological and hypothetical cases to whichhe applies its methods, ranging from the Bush administration's foreign policy in thespring of 2003 to the behavior of sponge-dwelling isopods in the Gulf of California.Though persuasive, game theory as laid out here and in other works (the best known beingRichard Dawkins's The Selfish Gene) can often seem harshly rational in its coldcalculations of life and death, and Barash himself writes in his conclusion, &quot;[F]or along time I have really loved game theory, and, for about as long, I've hated it.&quot; Bythe end of this highly readable introduction, readers will understand quite well what hemeans.--or a long time I have really loved game theory, and, for about as long, I've hatedit.&quot; By the end of this highly readable introduction, readers will understand quitewell what he means. <br />Copyright 2003 Reed Business Information, Inc.--This text refers to the Hardcover edition.<br />Review<br />&quot;Barash combines game theory with evolutionary biology, arguing that the strategicchoices people make as they go through life [are] encoded in their brains by millions ofyears of evolution . . . His examples-including farm economics, jungle mating strategiesand World War II battlefields-are convincing.&quot; -The Washington Post.</p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0071400206/qid=1129125797/sr=1-10/ref=sr_1_10?v=glance%26s=books">GameTheory at Work: How to Use Game Theory to Outthink and Outmaneuver Your Competition</a></strong>Book by <em>James D. Miller</em><br />Easy-to-Follow Strategies for Using Game Theory to Grab the Upper Hand in Every BusinessBattle<br />Game theory--the study of how competitors act, react, and interact in the strategicpursuit of their own self-interest--has become an essential competitive tool in today'sbusiness arena. Game Theory at Work provides examples of how businesspeople can use thistime-proven approach to successfully meet competitive challenges and, more often than not,claim the upper ground in each battle before it begins.<br />Game Theory at Work steers clear of the opaque mathematics and pedagogy that so oftenhamper practitioners of game theory, relying instead on lively case studies and examplesto illustrate its remarkable methods in action. Complex yet comprehensible, it providesyou with:<br />Methods for applying game theory to every facet of business <br />Strategies for instantly improving your position in virtually any negotiation <br />Game theory techniques to increase the output--and value--of each employee <br />At its essence, business is a game, albeit a profoundly serious game that must always beplayed to win. Game Theory at Work is the first plain-English examination of the use ofgame theory in business. Let it provide you with the intellectual tools you need toinstantly understand every game you're playing, use that knowledge to your advantage, andconsistently maximize your finish-line payoff.<br />&quot;Game Theory at Work won't teach you about power-chants, discuss the importance ofbalancing work and family, or inspire you to become a more caring leader. This book willinstead help you out-strategize, or at least keep up with, competitors inside and outsideyour company.&quot;--From the Introduction<br />Like Sun Tzu's timeless The Art of War, Game Theory at Work is about knowing youradversary as well as yourself. It is also about using that knowledge to prepare yourselffor victory.<br />But above all, this one-of-a-kind book is about dramatically improving your strategicinstincts and decision-making skills--and emerging victorious--in virtually any businessencounter.<br />Introduced by John von Neumann and Oskar Morgenstern in their 1944 book Theory of Gamesand Economic Behavior, and further honed through the decades by thought leaders includingNobel Prize winner John Nash, game theory analyzes strategic interactions in which theoutcomes of various choices depend on the choices of others. Game Theory at Work appliesthis innovative tool to the world of business, and provides a step-by-step framework forusing game theory to improve your on-the-job success in areas including:<br />Negotiating <br />Managing <br />Pricing <br />Positioning <br />Establishing strategic alliances <br />More than that, however, Game Theory at Work is a one-of-a-kind tool to battle the highcosts of indecision. It shows you how to enter any encounter confident in how others willact, and then use game theory to base your strategies and actions on this knowledge. Casestudies, puzzles, and, yes, games demonstrate why unexpected and often paradoxical resultsare the norm when humans compete, and help you use this fact to your advantage. And,chapter-ending lessons highlight essential rules learned.<br />... All in a book that is both absorbing and entertaining, designed to improve yourbusiness instincts without requiring the use of needless mathematics or theoreticalmumbo-jumbo.<br />Everything in life is competitive in one way or another, and game theory hasrevolutionized the art and science of what to look for--and how to act--when engaged incompetition. Game Theory at Work studies the use of game theory in today's hard-foughtbusiness arena, and shows you how to use it to gain maximum advantage in everyprofessional encounter, whatever your role in that encounter.</p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0691011923/qid=1129128169/sr=1-11/ref=sr_1_11?v=glance%26s=books">Classicsin Game Theory</a> </strong>Book by <em>Harold William Kuhn</em> (Editor)<br />Review<br />This volume assembles in one sourcebook the basic contributions to the field [of gametheory].<br />Classics in Game Theory assembles in one sourcebook the basic contributions to the fieldthat followed on the publication of Theory of Games and Economic Behavior by John vonNeumann and Oskar Morgenstern (Princeton, 1944). The theory of games, first given arigorous formulation by von Neumann in a in 1928, is a subfield of mathematics andeconomics that models situations in which individuals compete and cooperate with eachother. In the &quot;heroic era&quot; of research that began in the late 1940s, thefoundations of the current theory were laid; it is these fundamental contributions thatare collected in this volume. In the last fifteen years, game theory has become thedominant model in economic theory and has made significant contributions to politicalscience, biology, and international security studies. The central role of game theory ineconomic theory was recognized by the award of the Nobel Memorial Prize in EconomicScience in 1994 to the pioneering game theorists John C. Harsanyi, John Nash, and ReinhardSelten. The fundamental works for which they were honored are all included in this volume.<br />Harold Kuhn, himself a major contributor to game theory for his reformulation of extensivegames, has chosen eighteen essays that constitute the core of game theory as it existstoday. Drawn from a variety of sources, they will be an invaluable tool for researchers ingame theory and for a broad group of students of economics, political science, andbiology.</p><p style="margin-left: 5px"><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0262023636/qid=1129128169/sr=1-12/ref=sr_1_12?v=glance%26s=books"><strong>GameTheory and the Social Contract, Vol. 1: Playing Fair</strong></a> Book by <em>Ken Binmore </em><br />In Game Theory and the Social Contract, Ken Binmore argues that game theory provides asystematic tool for investigating ethical matters. His reinterpretation of classicalsocial contract ideas within a game-theoretic framework generates new insights into thefundamental questions of social philosophy. He clears the way for this ambitious endeavorby first focusing on foundational issues -- paying particular attention to the failings ofrecent attempts to import game -- theoretic ideas into social and political philosophy.<br />Binmore shows how ideas drawn from the classic expositions of Harsanyi and Rawls produce asynthesis that is consistent with the modern theory of noncooperative games. In theprocess, he notes logical weaknesses in other analyses of social cooperation andcoordination, such as those offered by Rousseau, Kant, Gauthier, and Nozick. Hepersuasively argues that much of the current literature elaborates a faulty analysis of anirrelevant game.<br />Game Theory and the Social Contract makes game-theoretic ideas more widely accessible tothose with only a limited knowledge of the field. Instructional material is woven into thenarrative, which is illustrated with many simple examples, and the mathematical contenthas been reduced to a minimum.<br />Ken Binmore is Professor of Economics at University College, London. His previous booksinclude Economic Organizations as Games, The Economics of Bargaining, Essays on theFoundations of Game Theory, and Fun and Games, an undergraduate textbook on game theory. </p><p style="margin-left: 5px"><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0674341112/qid=1129128169/sr=1-13/ref=sr_1_13?v=glance%26s=books"><strong>GameTheory and the Law</strong></a> by <em>Douglas G. Baird, Robert H. Gertner, Randal C.Picker </em><br />A pathbreaking work of importance and clarity<br />Reviewer: A reader<br />This book popularizes and extends a new approach (non-cooperative game theory) to theeconomic analysis of law. Readable and concise, this book is a must for students andscholars wishing to understand the ways in which legal rules can be usefully modeled asnon-cooperative games. As a professor in the discipline, I am awed by the important andbrilliant scholarship presented in this book with superb skill.<br />Great analysis of common strategic behavior problems, December 26, 2001<br />Reviewer: A reader<br />This is a great example of how the rigor of game theory can give startling insights intooutcomes of common situations. Although I'm no mathematician or economist, all businesspeople are at some point required to base their decisions on how they think others willbehave. This book provides some great frameworks for structuring that thought process.</p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/140394167X/qid=1129132874/sr=1-76/ref=sr_1_76?v=glance%26s=books">Advancesin Understanding Strategic Behaviour : Game Theory, Experiments and Bounded Rationality</a></strong>Book by <em>Steffen Huck</em> (Editor) <br />This volume contains sixteen original articles documenting recent progress inunderstanding strategic behavior. In their variety they reflect an entire spectrum ofcoexisting approaches: from orthodox game theory via behavioral game theory, boundedrationality and economic psychology to experimental economics. There are plenty of newmodels and insights but the book also illustrates the boundaries of what we know today andexplains the frontiers of tomorrow. </p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/354026082X/qid=1129129302/sr=1-41/ref=sr_1_41?v=glance%26s=books">Modelsin Cooperative Game Theory : Crisp, Fuzzy, and Multi-Choice Games</a></strong> (LectureNotes in Economics and Mathematical Systems) <br />Book by <em>Rodica Branzei, Dinko Dimitrov, Stef Tijs </em><br />This book investigates models in cooperative game theory in which the players have thepossibility to cooperate partially. In a crisp game the agents are either fully involvedor not involved at all in coperation with some other agents, while in a fuzzy game playersare allowed to cooperate with infinite many different participation levels, varying fromnon-cooperation to full cooperation. A multi-choice game describes the intermediate casein which each player may have a fixed number of activity levels. Different set andone-point solution concepts for these games are presented. The properties of thesesolution concepts and their interrelations on several classes of crisp, fuzzy, andmulti-choice games are studied. Applications of the investigated models to many economicsituations are indicated as well. </p><p style="margin-left: 5px"><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/1584883006/qid=1129131387/sr=1-39/ref=sr_1_39?v=glance%26s=books"><strong>IntroducingGame Theory and its Applications</strong></a> Book by <em>Elliot Mendelson</em><br />The first text to present a simple, intelligent guide to game theory, this book introducesconcepts from areas such as economics using applications, game theoretic notions, andresearch results. The author presents game theory in an intelligible manner for those whodo not have a strong background in the field of business or economics. Unlike othertextbooks currently on the market that presuppose a knowledge of economics or finance,this book contains a broad base of applications that appeal to a broader audience butrequires a minimal background in calculus, probability, and linear algebra. It contains areview the material on probability that readers need prior to taking a course on gametheory. </p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0471168130/qid=1129130997/sr=1-32/ref=sr_1_32?v=glance%26s=books">Gamingthe Market : Applying Game Theory to Create Winning Trading Strategies (Wiley Finance)</a></strong>Book by <em>Ronald B. Shelton </em><br />Gaming the Market: Applying Game Theory to Create Winning Trading Strategies is the firstbook to show investors how game theory is applicable to decisions about buying and sellingstocks, bonds, mutual funds, futures, and options. As a practical trading guide, Gamingthe Market will help investors master this revolutionary approach, and employ it to theiradvantage. <br />Although game theory has been studied since the 1940s, it has only recently been appliedto the world of finance. Game theory champions garnered the 1994 Nobel Prize in Economics,and, today, this theory is used to analyze everything from the baseball strike to FCCauctions. Increasingly, game theory is making its mark as a potent tool for traders. InGaming the Market, economist Ronald B. Shelton provides a model that enables traders topredict profitability and, as a result, make effective buy and sell decisions. <br />Stated simply, game theory is the study of conflict based on a formal approach to decisionmaking that views decisions as choices made in a game. Whether playing individually or ina group, each player in a conflict has more than one course of action available to him,and the outcome of the &quot;game&quot; depends on the interaction of the strategiespursued by each. Shelton offers real-world examples that reveal how the principles of gametheory drive financial markets and how these same principles can be used to developwinning investment strategies. Through Shelton's organized and preciseexplanationshe uses familiar games such as chess and checkers to illustrate hispoints readers gain a solid understanding of the key principles of game theorybefore applying them to actual financial market situations. <br />Gaming the Market examines the interaction between price fluctuations and risk acceptancelevels and gradually constructs a game theory model which proves that there areprobability-based formulas for determining the profitability of any given trade. <br />With appendixes on T-Bond futures, mathematical representations of the model, andQuickBasic code for calculating relative frequencies, Gaming the Market provides athorough overview of the rules and strategies of game theory. This indispensable referencewill prove invaluable to novice and seasoned players alike. <br />Are the markets a game? What are the rules? Who are the players? <br />How can you, as a player, come up with a winning strategy? <br />Now, acclaimed economist Ronald B. Shelton shows you how to master the power of gametheory in the first trader's guide to this revolutionary approach to investment decisions!<br />&quot;It's not often that a refreshingly new idea appears in the field of tradingstrategies or risk management, but Ronald B. Shelton has taken pieces from game theory andbetting strategies and transformed them into a new, visual way to make trading decisions.. . . He has been able to put a value on trading situations which can increase yourability to manage risk as well as clarify expectations both essential ingredientsfor success.&quot; from the Foreword by Perry Kaufman author of The New CommodityTrading Systems and Methods. <br />&quot;Gaming the Market is a very welcome and most useful new guide to playing profitablyin the biggest and most complex game ever devised  speculating in the financialmarkets. Investors and traders who study this book will gain valuable insights into thereal nature of the markets and will learn how to play the game to win.&quot; ThomasA. Bierovic, President, Synergy Futures. <br />&quot;Ronald B. Shelton has extended the field of excursion analysis with an innovativeand provocative book that is sure to be widely readand controversial. By examiningthe actual distributions of price excursion, he shows a technique to estimate your oddsgoing in on a new position, and within the context of game theory, how to evaluate thosechances. All traders and analysts seeking objective bases for trading will want to readthis book.&quot; John Sweeney, Technical Editor, Technical Analysis of Stocks andCommodities magazine. <br />In Gaming the Market, economist Ronald B. Shelton provides a model that enables traders topredict profitability and, as a result, make effective buy and sell decisions. Statedsimply, game theory is the study of conflict based on a formal approach to decision makingthat views decisions as choices made in a game. Whether playing individually or in agroup, each player in a conflict has more than one course of action available to him, andthe outcome of the &quot;game&quot; depends on the interaction of the strategies pursuedby each. Shelton offers real-world examples that reveal how the principles of game theorydrive financial markets - and how these same principles can be used to develop winninginvestment strategies. Through Shelton's organized and precise explanations - he usesfamiliar games such as chess and checkers to illustrate his points - readers gain a solidunderstanding of the key principles of game theory before applying them to actualfinancial market situations. Gaming the Market examines the interaction between pricefluctuations and risk acceptance levels and gradually constructs a game theory model whichproves that there are probability-based formulas for determining the profitability of anygiven trade.</p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0444894284/qid=1129131604/sr=1-47/ref=sr_1_47?v=glance%26s=books">Handbookof Game Theory with Economic Applications Volume 3 (Handbooks in Economics)</a> </strong>Bookby <em>R. J. Aumann, S. Hart </em><br />Journal of Economic Literature<br />Vol. 3 of a three-volume set surveying the state of the art in game theory.<br />Review<br />This is the third volume of the Handbook of Game Theory with Economic Applications. ...Theauthors are the most eminent practitioners in the field, including three Nobel Prinzewinners. Zentralblatt fur Mathematik, vol. 993, 2002 ...Volume 3 of a three-volume setsurveying the state of the art in game theory. Journal of Economic Literature ...No onecan keep up with the whole literature, so we have come to recognize these volumes asimmensely valuable. They are on almost everyone's shelf. ...I would love to see volumes 4,5, and 6, with more of what Aumann and Hart and their authors have given us. The Handbookhas become the first reference for anyone who wants to learn of game-theoretical resultsoutside their own area. It has been a long task for the editors but has greatly benefitedthe rest of us, and we are all grateful. Games and Economic Behavior, Vol. 46, no.1</p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0415250951/qid=1129132472/sr=1-54/ref=sr_1_54?v=glance%26s=books">GameTheory: A Critical Text</a> </strong>Book by <em>Shaun P. Hargreaves Heap, YanisVaroufakis </em><br />The ideal primer for those deterred by the technical nature of many textbooks, this titleprovides a clear explanation for the enduring popularity of game theory and its increasingcentrality to the teaching of economics.<br />Shaun Hargreaves-Heap is Professor of Economics at the University of East Anglia, UK.<br />Yanis Varoufakis is Senior Lecturer in Economics at the University of Sydney.</p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0415259878/qid=1129133233/sr=1-83/ref=sr_1_83?v=glance%26s=books">GameTheory and Economic Analysis (Routledge Advances in Game Theory)</a></strong> Book by <em>ChristianSchmidt</em> (Editor) <br />This book presents the huge variety of current contributions of game theory to economics.The impressive contributions fall broadly into two categories. Some lay out in a jargonfree manner a particular branch of the theory, the evolution of one of its concepts, or aproblem, that runs through its development. Others are original pieces of work that aresignificant to game theory as a whole. After taking the reader through a concise historyof game theory, the contributions include such themes as: *the connections between VonNeumann's mathematical game theory and the domain assigned to him today *the strategic useof information by game players *the problem of the coordination of strategic choicesbetween independent players *cooperative games and their place within the literature ofgames new developments in non-cooperative games *possible applications for game theory inindustrial and financial economics differential qualitative games and entry dissuasion.</p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/3540656286/qid=1129133233/sr=1-90/ref=sr_1_90?v=glance%26s=books">AGame Theory Analysis of Options: Contributions to the Theory of Financial Intermediationin Continuous Time</a></strong> Book by <em>Alexandre Ziegler </em><br />This book presents a method that combines game theory and option pricing in order toanalyze dynamic multiperson decision problems in continuous time and under uncertainty.The basic intuition of the method is to separate the problem of the valuation of payoffsfrom the analysis of strategic interactions. Whereas the former is to be handled usingoption pricing, the latter can be addressed by game theory. The text shows how bothinstruments can be combined and how game theory can be applied to complex problems ofcorporate finance and financial intermediation. Besides providing theoretical foundationsand serving as a guide to stochastic game theory modeling in continuous time, the textcontains numerous examples from the theory of corporate finance and financialintermediation. By combining arbitrage-free valuation techniques with strategic analysis,the game theory analysis of options actually provides the link between markets andorganizations.<br />Discusses Game Theory, and von Newmann's 1928 proof of the minimax theorem. Presents amethod combining instruments of economic theory to facilitate the analysis of dynamicmultiperson decision problems. Softcover. DLC: Options (Finance)--Prices--Mathematicalmodels. </p><p style="margin-left: 5px"><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0714655163/qid=1129134272/sr=1-2/ref=sr_1_2?v=glance%26s=books"><strong>ThomasSchelling and the Nuclear Age: Strategy as Social Science (Strategy and History)</strong></a>Book by <em>Robert Ayson</em><br />Introduction: In a scholarly career spanning over 50 years, Thomas Schelling (NobelLaureate 2005 for Economics) has made some of the most distinctive contributions tostrategic studies in the age of nuclear weapons.</p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0521814626/qid=1129134272/sr=1-8/ref=sr_1_8?v=glance%26s=books">DecisionMaking using Game Theory : An Introduction for Managers</a></strong> by <em>Anthony Kelly</em><br />Game theory is a key element in most decision making processes involving two or morepeople or organizations. This book explains how game theory can predict the outcome ofcomplex decision making processes, and how it can help to improve negotiation anddecision-making skills. It is grounded in well-established theory, yet the wide-ranginginternational examples used to illustrate its application offer a fresh approach to whatis becoming an essential weapon in the armory of the informed manager. The book isaccessibly written, explaining in simple terms the underlying mathematics behind games ofskill. It analyzes more sophisticated topics such as zero-sum games, mixed-motive games,and multi-person games, coalitions and power. Clear examples and helpful diagrams are usedthroughout, and the mathematics is kept to a minimum. Written for managers, students anddecision-makers in every field.<br />Text explains how game theory can predict the outcome of complex decision-makingprocesses, and how it can help improve negotiation and decision-making skills. Formanagers, students, and decision-makers in any field.</p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0262011549/qid=1129135065/sr=1-1/ref=sr_1_1?v=glance%26s=books">CollectedPapers, Vol. 1</a></strong> Robert Aumann's groundbreaking career in game theory hasspanned over 35 years. Book by <em>Robert J. Aumann </em><br />The papers are organized in several categories: general, knot theory, decision theory(utility and subjective probability), strategic games, coalitional games, and mathematicalmethods. Aumann has written an introduction to each of these groups that briefly describesthe content and background of each paper, including the motivation and the researchprocess, and relates it to other work in the collection and to work by others. There isalso a citation index that allows readers to trace the considerable body of literaturewhich cites Aumann's own work.<br />Robert J. Aumann (Nobel Laureate 2005 for Economics) is Professor of Mathematics and amember of the Center for Rationality and Interactive Decision Theory, The HebrewUniversity of Jerusalem. </p><p style="margin-left: 5px"><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0262011476/qid=1129135065/sr=1-4/ref=sr_1_4?v=glance%26s=books"><strong>RepeatedGames with Incomplete Information</strong></a> Book by <em>Robert J. Aumann</em><br />During the height of the Cold War, between 1965 and 1968, Robert Aumann, Michael Maschler,and Richard Stearns collaborated on research on the dynamics of arms control negotiationsthat has since become foundational to work on repeated games. These five seminal papersare collected here for the first time, with the addition of &quot;postscripts&quot;describing many of the developments since the papers were written. The basic model studiedthroughout the book is one in which players ignorant about the game being played mustlearn what they can from the actions of the others.<br />The original work, done under contract to the United States Arms Control and DisarmamentAgency, was intended to tackle the gradual disarmament problem, in which neither playerknew what his own payoff would be for any given agreement, because of uncertainty aboutthe other side's arsenal and weapons production technology. But the research soon becamemuch more generalized, covering information concealment and revelation, signaling andlearning, and related ideas in any repeated competitive situation.<br />The first four chapters of the book treat the competitive zero-sum side of the theory ofrepeated games. Chapter five takes up cooperative phenomena where one player may want tosignal information to another. An extensive bibliography covers all items mentioned in themain text, in the postscripts, and in the introduction. The bibliography also includes acompilation of published papers and books that refer to the original reports.<br />About the Author<br />Robert J. Aumann (Nobel Laureate 2005 for Economics) and Michael Maschler are bothprofessors of mathematics at the Hebrew University of Jerusalem. Richard Stearns isprofessor of computer science at the State University of New York at Albany. </p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0821805258/qid=1129135065/sr=1-5/ref=sr_1_5?v=glance%26s=books">Topicsin Mathematical Economics in Game Theory: Essays in Honor of Robert J. Aumann</a></strong>(Fields Institute Communications, V. 23.) Book by <em>Myrna H. Wooders</em> (Editor) <br />Since the publication of Theory of Games and Economic Behavior by von Neumann andMorgenstern, the concept of games has played an increasing role in economics. It alsoplays a role of growing importance in other sciences, including biology, politicalscience, and psychology. Many scientists have made seminal advances and continue to beleaders in the field, including Harsanyi, Shapley, Shubik, and Selten. Professor RobertAumann (Nobel Laureate 2005 for Economics), in addition to his important contributions togame theory and economics, made a number of significant contributions to mathematics. <br />This volume provides a collection of essays in mathematical economics and game theory,including cutting-edge research on noncooperative game theory and its foundations,bargaining theory, and general equilibrium theory. Also included is a reprint of Aumann'sclassic paper, &quot;Acceptable Points in General Cooperative $n$-Person Games&quot; andof the oft-cited, yet hard to find, paper by Maschler, &quot;The Worth of a CooperativeEnterprise to Each Member&quot;. This book illustrates the wide range of applications ofmathematics to economics, game theory, and social choice. <br />The volume is dedicated to Professor Robert J. Aumann (Nobel Laureate 2005 for Economics),Hebrew University, Jerusalem, Israel, for his contributions in mathematics and socialsciences. </p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0691034303/qid=1129129851/sr=1-17/ref=sr_1_17?v=glance%26s=books">GameTheory for Political Scientists</a> </strong>Book by <em>James D. Morrow </em><br />Review<br />James Morrow's superb book provides the best account of ideas from game theory tailored tothe interests of political scientists, which is currently available.<br />Game theory is the mathematical analysis of strategic interaction. In the fifty yearssince the appearance of von Neumann and Morgenstern's classic Theory of Games and EconomicBehavior (Princeton, 1944), game theory has been widely applied to problems in economics.Until recently, however, its usefulness in political science has been underappreciated, inpart because of the technical difficulty of the methods developed by economists. JamesMorrow's book is the first to provide a standard text adapting contemporary game theory topolitical analysis. It uses a minimum of mathematics to teach the essentials of gametheory and contains problems and their solutions suitable for advanced undergraduate andgraduate students in all branches of political science.<br />Morrow begins with classical utility and game theory and ends with current research onrepeated games and games of incomplete information. The book focuses on noncooperativegame theory and its application to international relations, political economy, andAmerican and comparative politics. Special attention is given to models of four topics:bargaining, legislative voting rules, voting in mass elections, and deterrence. Anappendix reviews relevant mathematical techniques. Brief bibliographic essays at the endof each chapter suggest further readings, graded according to difficulty. This rigorousbut accessible introduction to game theory will be of use not only to political scientistsbut also to psychologists, sociologists, and others in the social sciences.</p><p style="margin-left: 5px"><strong><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0201847582/qid=1129129851/sr=1-18/ref=sr_1_18?v=glance%26s=books">GameTheory with Economic Applications (2nd Edition)</a><br /></strong>Book by <em>H. Scott Bierman, Luis Fernandez </em><br />Emphasizes the application of game theoretical tools to understand important economicphenomena. Covers applications in the fields of labor economics, international trade,environmental economics, industrial organizations and more. Paper. DLC: Game theory. </p><p style="margin-left: 5px"><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/1587788071/qid=1129129851/sr=1-19/ref=sr_1_19?v=glance%26s=books"><strong>DecisionAnalysis, Game Theory, and Information (University Casebook Series)</strong></a> Book by <em>LouisKaplow, Steven Shavell</em><br />&quot;Decision Analysis, Game Theory, and Information&quot; is a spin-off title from a newcasebook written by a team of Harvard Law professors, &quot;Analytical Methods forLawyers,&quot; which was written to provide law students with an overview of basicbusiness and finance principles necessary for the study of law. <br />This work focuses on the theories of Decision Analysis, including decision trees andprobabilities, as well as Games and Information, with chapters on game theory, moralhazard and incentives, and more.<br />Louis Kaplow is the Finn M.W. Caspersen and Household International Professor of Law andEconomics at Harvard Law School and a Research Associate at the National Bureau ofEconomic Research. <br />Steven Shavell is the Samuel R. Rosenthal Professor of Law and Economics, Director of theJohn M. Olin Center for Law, Economics, and Business at Harvard Law School, as well asCo-Director of the Law and Economics Program at the National Bureau of Economic Research. </p><p style="margin-left: 5px"><a href="http://www.amazon.com/exec/obidos/redirect?link_code=ur2&amp;camp=1789&amp;tag=wwwsociologyi-20&amp;creative=9325&amp;path=tg/detail/-/0883856379/qid=1129129851/sr=1-14/ref=sr_1_14?v=glance%26s=books"><strong>GameTheory and Strategy (New Mathematical Library)</strong></a> Book by <em>Philip D. Straffin</em><br />Mathematical Reviews<br />Exercises at the end of each chapter (with answers provided in the back) and a list ofreferences invite the reader to get actively involved. Special care has been taken inpresenting interesting and diverse applications: among other things, Newcomb's problem andfree will as an application to philosophy. The author has succeeded in producing anoutstanding introductory textbook on game theory for an interdisciplinary audience at thecollege level. The reviewer has enjoyed reading it. <br />Review<br />'Game Theory and Strategy is an elegant, crystal-clear expository work. Key concepts areemphasized and clearly explained.' Nature. <!--msnavigation--></p></td> <td valign="top" width="24"></td> <td valign="top" width="1%"> <div align="center"> <center> <table border="0" cellpadding="3" cellspacing="3" width="160"> <tbody> <tr> <td width="160" height="600" valign="top"><script type="text/javascript"><!--google_ad_client = "pub-7155683963322350";/* image160600 */google_ad_slot = "9505254598";google_ad_width = 160;google_ad_height = 600;//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script></td> </tr> </tbody> </table> </center> </div><p>&nbsp;</p><p align="center"><big><big><big><a href="books_magazines_great_discount.htm">Books,E-Books Great Discounts</a></big></big></big></p></td> </tr> <!--msnavigation--> </tbody> </table> <!--msnavigation--> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tbody> <tr> <td> <div align="center"> <center> <table border="0" cellpadding="3" cellspacing="3" width="100%"> <tbody> <tr> <td></td> </tr> </tbody> </table> </center> </div> <div align="center"> <center> <table border="0" cellpadding="3" cellspacing="3" width="100%"> <tbody> <tr> <td width="100%" bgcolor="#000000"><p align="center"><a href="http://www.sociologyindex.com/"><font color="#FFFFFF" size="6"><strong><span style="color: rgb(255,255,255)">Sociology Index</span></strong></font></a></p></td> </tr> <tr> <td width="100%" bgcolor="#000000"><span style="color: rgb(255,255,255)"><strong><font color="#FFFFFF" size="6"></font></strong><p align="center"><strong><font color="#FFFFFF" size="6"></font><a href="sociology_books.htm" style="color: rgb(255,255,255)"><font size="3" color="#FFFFFF">Sociology Books 2011</font></a></strong></p></span></td> </tr> <tr> <td width="100%" bgcolor="#000000"><span style="color: rgb(255,255,255)"><strong><font size="3" color="#FFFFFF"></font></strong><p align="center"><strong><font size="3" color="#FFFFFF"></font></strong><font color="#FFFFFF" size="4"><a href="sociology_index_and_dictionary.htm"><span style="color: rgb(255,255,255); text-align: center; vertical-align: middle">Sociology Topical Subject Index</span></a></font></p></span></td> </tr> </tbody> </table> </center> </div> <div align="center"> <center> <table border="0" cellpadding="3" cellspacing="3" width="100%"> <tbody> <tr> <td></td> </tr> </tbody> </table> </center> </div><p>&nbsp;</p></td> </tr> <!--msnavigation--> </tbody> </table> </body> </html>
298	single	medical care and jehovah's witnesses	What are the medical or health care practices followed by members of the Jehovah's Witnesses religion?	clueweb12-0013wb-63-22659	3	<!DOCTYPE html PUBLIC "-//w3c//dtd html 4.0 transitional//en"> <html> <head> <meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1" /> <meta name="GENERATOR" content="Mozilla/4.7 [en] (Win98; I) [Netscape]" /> <title>WJM: Western Journal of Medicine</title> <!--This file created 30/4/99 9:57 by Claris Home Page version 3.0--> </head> <body bgcolor="#FFFFFF" background="back.gif" topmargin="0" leftmargin="10" marginwidth="10" marginheight="0"> &nbsp; <table border="0" cellspacing="0" cellpadding="0" width="590"> <tbody> <tr> <td width="120"><a href="http://www.bmjpg.com/ewjm/"><img src="logo.gif" border="0" height="45" width="120" /></a></td> <td width="470"><img src="masthead.gif" height="44" width="470" /></td> </tr> <tr> <td width="120">&nbsp;</td> <td width="470"><img src="padding.gif" height="20" width="10" /></td> </tr> </tbody> </table> <table border="0" cellspacing="0" cellpadding="0" width="590"> <tbody> <tr> <td valign="TOP" width="144"> <table border="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="TOP"></td> </tr> <tr> <td valign="TOP"></td> </tr> <tr> <td valign="TOP"></td> </tr> <tr> <td valign="TOP"></td> </tr> <tr> <td valign="TOP"></td> </tr> <tr> <td valign="TOP"></td> </tr> <tr> <td valign="TOP"></td> </tr> <tr> <td valign="TOP"></td> </tr> <tr> <td valign="TOP" height="21"></td> </tr> <tr> <td valign="TOP"></td> </tr> <tr> <td valign="TOP"><br /><font face="Arial"><font size="-2"><a href="http://www.ewjm.com/print.html">Getinfo about the printed version of wjm - and order a free sample</a></font></font></td> </tr> </tbody> </table></td> <td valign="TOP" width="470"> <table border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td>&nbsp;</td> <td valign="TOP" colspan="3"><b><font face="verdana, arial, helvetica, sans-serif">Recentdevelopments in medical care of Jehovah�s Witnesses</font></b><br />&nbsp;<br />&nbsp;</td> <td valign="TOP">&nbsp;</td> <td valign="TOP"><img src="cm.gif" height="17" width="100" /></td> </tr> <tr> <td height="113">&nbsp;</td> <td valign="TOP" height="113"> <table border="0" cellspacing="0" cellpadding="0" width="100%"> <tbody> <tr> <td valign="TOP" colspan="3">&nbsp;</td> </tr> <tr> <td valign="TOP" width="1" bgcolor="#000000"><img src="padding.gif" height="1" width="1" /></td> <td valign="TOP" width="5"><img src="padding.gif" height="1" width="5" /></td> <td valign="TOP" width="94"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">OsamuMuramoto</font></font></td> </tr> <tr> <td valign="TOP" width="1"><img src="padding.gif" height="1" width="1" /></td> <td valign="TOP" width="5"><img src="padding.gif" height="1" width="5" /></td> <td valign="TOP" width="94"><img src="padding.gif" height="1" width="89" /></td> </tr> <tr> <td valign="TOP" width="1"><img src="padding.gif" height="1" width="1" /></td> <td valign="TOP" width="5"><img src="padding.gif" height="1" width="5" /></td> <td valign="TOP" width="94"><img src="padding.gif" height="1" width="89" /></td> </tr> </tbody> </table></td> <td valign="TOP" height="113">&nbsp;</td> <td valign="TOP" colspan="3" height="113"><b><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Introduction</font></font></b><br /><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Since1945, the Watchtower Bible and Tract Society (WTS), the controlling religiousorganization of Jehovah's Witnesses (JWs), has promulgated to all its followersa doctrine to refuse blood and certain blood products for their medicaltreatment. They teach that the biblical command, &quot;you must not eat blood&quot;(Leviticus 17:12) and &quot;abstain from blood&quot; (Acts 15:29), means &quot;not takingit into our bodies at all,&quot; including prohibition of the medical use ofblood.<a href="#ref1">1</a> For the past half century, this doctrine hasbrought numerous challenges in medical care of JW patients, and occasionallytragic premature deaths. Although the doctrine is said to be an &quot;everlastinglaw&quot; of God, it has recently undergone major revisions. In this review,I will discuss some of these developments, which impact on the medicalcare of approximately ten-million adherents world-wide for whom blood treatmentmay be an issue.&nbsp;</font></font><br />&nbsp;<br />&nbsp;<br />&nbsp; <table border="" cellpadding="5" width="100%"> <tbody> <tr> <td><b><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">SummaryPoints</font></font></b> <ul> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Despiteprogress in bloodless medicine, the care of Jehovah's Witness patientswho refuse blood-based treatments is difficult .&nbsp;</font></font></li> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">An agreementsigned by the organization at the European Commission of Human Rights statesthat Jehovah's Witnesses should have free choice to receive blood transfusionswithout any control or sanction from the organization.&nbsp;</font></font></li> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">The recentemergence of reform Jehovah's Witnesses, who petition for a right to freedomof personal choice to accept or refuse blood transfusions, indicates agrowing diversity among the followers in their attitudes toward the bloodpolicy.&nbsp;</font></font></li> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">An individualizedapproach to each patient, respecting their diversity of beliefs and values,has become increasingly important.&nbsp;</font></font></li> </ul></td> </tr> </tbody> </table> <table border="" cellpadding="5" width="100%"> <tbody> <tr> <td><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Abbreviationsused in text: JW=Jehovah's Witness, WTS=Watchtower Bible and Tract Society;HIS=Hospital Information Service; HLC=Hospital Liaison Committee; AJWRB=AssociatedJehovah's Witnesses for Reform on Blood</font></font></td> </tr> </tbody> </table><p><b><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Distinctionbetween acceptable and unacceptable treatments</font></font></b><br /><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Forphysicians who treat JWs, one of the most puzzling aspects is that theyare, in fact, accepting many blood-based treatments despite their beliefin absolute abstinence from blood. Since this biblical law is said to beabsolute, it is unclear why the WTS does not teach its members to simplyrefuse all medical use of blood. On one hand, they teach that God prohibitsany intake of blood into the body regardless of the methods, whether eatingit in the biblical era, or infusing it in modern medicine. On the otherhand, they have meticulously sorted out various methods of blood intakein medical settings, and classified them either as acceptable or unacceptable,depending on the method. As new blood-based treatments become available,such classification has become a daunting task.&nbsp;</font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Table1 summarizes the current policy and practice of prohibited and acceptabletreatments. Table 2 shows the complex conditions under which the same orsimilar material or procedure may become acceptable or unacceptable. Informationin these tables is a composite from WTS publications, including their advancedirective form, as well as articles by JW physicians.<a href="#ref2">2</a>,<a href="#ref6">6</a>Many JWs do not understand or remember such complicated regulations.&nbsp;</font></font><br />&nbsp;<br />&nbsp;<br />&nbsp;</p> <table border="" cellpadding="2" width="100%"> <tbody> <tr> <td valign="TOP" colspan="2"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2"><b>Table1</b> <i>Current policy and practice of WTS on prohibited and acceptabletreatments</i></font></font></td> </tr> <tr> <td valign="TOP"><b><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">ProhibitedBlood Components and Procedures&nbsp;</font></font></b></td> <td valign="TOP"><b><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">AcceptableBlood Components and Procedures&nbsp;</font></font></b></td> </tr> <tr> <td valign="TOP"> <dir> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Wholeblood&nbsp;</font></font></li> </dir></td> <td valign="TOP"> <dir> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Plasmaproteins (albumin, globulin, fibrin)&nbsp;</font></font></li> </dir></td> </tr> <tr> <td valign="TOP"> <dir> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Red bloodcells&nbsp;</font></font></li> </dir></td> <td valign="TOP"> <dir> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Clottingfactors&nbsp;</font></font></li> </dir></td> </tr> <tr> <td valign="TOP"> <dir> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Platelets&nbsp;</font></font></li> </dir></td> <td valign="TOP"> <dir> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Stem cells&nbsp;</font></font></li> </dir></td> </tr> <tr> <td valign="TOP"> <dir> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Plasma&nbsp;</font></font></li> </dir></td> <td valign="TOP"> <dir> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Hemodilution,cell saver&nbsp;</font></font></li> </dir></td> </tr> <tr> <td valign="TOP"> <dir> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Hemoglobinsolution&nbsp;</font></font></li> </dir></td> <td valign="TOP"> <dir> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Bone marrowtransplants&nbsp;</font></font></li> </dir></td> </tr> <tr> <td valign="TOP"> <dir> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Storedautologous blood&nbsp;</font></font></li> </dir></td> <td valign="TOP"> <dir> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Extracorporealcirculation&nbsp;</font></font></li> <br /> <font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">(heart-lungmachine, dialysis, plasmapheresis)&nbsp;</font></font> </dir></td> </tr> <tr> <td valign="TOP"> <dir> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Blooddonation&nbsp;</font></font></li> </dir></td> <td valign="TOP"> <dir> <li><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Use ofdonated blood (to take acceptable components)&nbsp;</font></font></li> </dir></td> </tr> </tbody> </table> <table border="" cellpadding="5" width="100%"> <tbody> <tr> <td valign="TOP" colspan="3"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2"><b>Table2</b> <i>Complex conditions that make similar components/procedures acceptableor unacceptable</i></font></font></td> </tr> <tr> <td valign="TOP">&nbsp;</td> <td valign="TOP"><b><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">JWsMay Not Accept ....</font></font></b></td> <td valign="TOP"><b><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">JWsMay Accept ....&nbsp;</font></font></b></td> </tr> <tr> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Wholeblood<a href="#ref2">2</a></font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFtaken as &quot;blood transfusion&quot; #&nbsp;</font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFtaken as contained in bone marrow transplants<a href="#ref3">3</a></font></font></td> </tr> <tr> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Plasmaproteins<a href="#ref2">2</a></font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFtaken together as &quot;plasma&quot; #&nbsp;</font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFtaken separately as individual blood component (albumin, globulin, clottingfactors, fibrin)&nbsp;</font></font></td> </tr> <tr> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Whiteblood cells<a href="#ref2">2</a></font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFtaken as &quot;white blood cells&quot; #&nbsp;</font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFtaken as &quot;peripheral stem cells&quot;<a href="#ref4">4</a>,<a href="#ref5">5</a></font></font></td> </tr> <tr> <td valign="TOP" rowspan="2"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Autologousblood<a href="#ref2">2</a></font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFtube connection to the patient's body is interrupted #</font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFtube connection to the patient's body is maintained (hemodilution, cellsaver)&nbsp;</font></font></td> </tr> <tr> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFit is stored #&nbsp;</font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFtaken as &quot;peripheral stem cells&quot; (even if it is stored)<a href="#ref4">4</a></font></font></td> </tr> <tr> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Stemcells<a href="#ref6">6</a></font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFtaken from umbilical cord blood<a href="#ref7">7</a></font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFtaken from peripheral blood or bone marrow<a href="#ref3">3</a>,<a href="#ref4">4</a></font></font></td> </tr> <tr> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Majorprotein from prohibited component&nbsp;</font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFtaken from red blood cells (hemoglobin)<a href="#ref6">6</a> #&nbsp;</font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFtaken from plasma (albumin)<a href="#ref2">2</a></font></font></td> </tr> <tr> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Heart-lungmachine<a href="#ref2">2</a></font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFpatient's blood is used to prime the machine #</font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFpatient's blood is used to circulate in the machine&nbsp;</font></font></td> </tr> <tr> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Epiduralblood patch<a href="#ref8">8</a></font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFblood is removed from vein and injected</font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFinjecting syringe is connected to vein via tube&nbsp;</font></font></td> </tr> <tr> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Blooddonation<a href="#ref9">9</a></font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFdonated by JWs for use of JWs and others #</font></font></td> <td valign="TOP"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">IFdonated by non-JWs for use of JWs and others</font></font></td> </tr> <tr> <td valign="TOP" colspan="3"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Conditionsmarked by # are observed by JWs without exception. Other conditions areobserved by many JWs but with exceptions. For example, JWs never accepta heart-lung machine primed with blood, but most, if not all, JWs acceptthe machine as long as it is circulated with own blood.&nbsp;</font></font></td> </tr> </tbody> </table><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Thesefacts have prompted the WTS to form the &quot;Hospital Information Service&quot;(HIS) in its headquarters, a public relations office for the blood policy.It answers inquiries regarding &quot;no-blood&quot; treatment, and interprets therules and conditions for patients and doctors. The HIS researches medicalliterature, recommends various no-blood treatments, and provides referencesto cooperative physicians. In addition, more than 1200 &quot;Hospital LiaisonCommittees&quot;(HLCs), which consist of selected elders who received specialtraining from HIS, are established worldwide. Its members visit hospitalsto present the policy. They provide the same service as HIS locally, andcan intervene between JW patients and physicians as needed.&nbsp;</font></font></p><p><b><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Reformmovement inside JWs</font></font></b><br /><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Since1996, a growing number of JWs, including some members of HLCs, have expressedanonymously their dissent to the blood policy.<a href="#ref10">10</a> Theyformed a group called the Associated Jehovah's Witnesses for Reform onBlood (AJWRB).<a href="#ref11">11</a>,<a href="#ref12">12</a> They callfor a reform of the blood policy which, according to them, is plagued bya complicated web of contradictory rules and conditions strictly enforcedwithout biblical basis. Some members of HLCs have resigned because of whatthey call &quot;Pharisaic&quot; rules. The WTS has dismissed them as &quot;disaffectedones&quot; and discredited them because of AJWRB's anonymity.<a href="#ref13">13</a>,<a href="#ref14">14</a>However, according to AJWRB, it is not possible, other than anonymously,for a JW to voice any criticism of the WTS or propose any reform from withinthe organization, because such public expression almost certainly resultsin expulsion of the members.<a href="#ref12">12</a></font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Thesignificance of this reform movement for physicians is awareness of a growingdiversity of values and beliefs among individual JWs, who have long beenviewed as a uniform religious group. Such diversity requires physiciansto scrutinize the patient's premolded medical directive more closely andtake a more individualized approach.&nbsp;</font></font></p><p><b><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Freedomof choice in JWs' medical care</font></font></b><br /><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Althoughit is well known that the WTS has fought many years for freedom of choiceto refuse blood transfusions vis-&aacute;-vis legal authorities and medicalprofessions - members within the WTS are not accorded the same freedomof choice to receive blood transfusions without penalty. The fact thatthe very freedom that the WTS has demanded outside the organization hasbeen denied inside the organization is another major point of reform calledfor by the AJWRB. Any JW who openly and willfully receives a prohibitedblood-based treatment and does not repent of the action before a &quot;judicialcommittee&quot; will receive the harshest sanction of the religion, excommunicationor &quot;disfellowshipping.&quot; This is considered equal to betraying God and involvesshunning, or isolation from normal association or fellowship with familyand life-long friends who are members. Many former JWs testify to the psychologicaltrauma associated with leaving the religion.&nbsp;</font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Thispunitive measure may soon change. One of the most important developmentsof the blood policy of JWs in recent years is the public agreement establishedin 1998 between the WTS and the government of Bulgaria at the EuropeanCommission of Human Rights. The WTS agreed that JWs in Bulgaria &quot;shouldhave free choice&quot; to receive blood transfusions &quot;without any control orsanction on the part of the association.&quot;<a href="#ref15">15</a>,<a href="#ref16">16</a>This apparent compromise was made in exchange for registration of JWs asa religion in that country. The WTS has been reticent with their membersabout their promise of &quot;free choice&quot; in Bulgaria, and only issued a letterand a press release stating that there has been no change in the bloodpolicy.<a href="#ref16a">16a</a> Nevertheless, a WTS representative, quotingthe charter accepted by the Bulgarian government, now states that the WTS&quot;may not exercise control over free will of believers but allows them toexercise their conscience consistent with godly Bible principles.&quot; He alsostates that the WTS does not &quot;arbitrarily apply sanctions in connectionwith the medical care that Jehovah's Witnesses conscientiously seek forthemselves and children,&quot; and this, according to him, is the establishedbeliefs of JWs internationally.<a href="#ref14">14</a></font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Thesestatements appear to conflict with the enforced policy of expelling andostracizing those who conscientiously receive blood transfusions and donot repent. According to AJWRB, these WTS statements could be interpretedto mean that each member may exercise personal conscience to choose whichblood components are acceptable in medical treatment, since the &quot;godlyBible principles&quot; are silent over what is or is not acceptable in bloodcomponents. On the other hand, the statements allow the WTS to &quot;non-arbitrarilyapply sanctions&quot; and to continue to &quot;exercise control over free will.&quot;We should expect further clarification from the WTS to explain this discrepancy.In the meantime, it is an indication that JWs may soon be given the rightto choose their own medical care, including acceptance or refusal of blood,without organizational control.&nbsp;</font></font></p><p><b><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Ethicaland legal issues of the blood card and informed refusal</font></font></b><br /><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Theuse of the &quot;blood card,&quot; a wallet-sized advance directive created by theWTS and carried by JWs, has been controversial. The card is intended todocument the JW's informed refusal of blood in the event of an emergency.Yet, the validity of the card has been questioned, particularly when aJW patient presents to the emergency room unconscious and exsanguinating,with the blood card being the only expression of will.<a href="#ref17">17</a>There are two main reasons to challenge the validity of such cards.&nbsp;</font></font><br />&nbsp;</p> <table border="0" width="100%"> <tbody> <tr> <td valign="TOP" rowspan="2"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">First,it is unclear whether such a directive was signed as a spontaneous andpersonal decision, or as an obligation to comply with the organizationalrules as a member. Every year in January, new cards are handed out to allJWs to sign. Group leaders are instructed to ensure that every member signthe card during a private group meeting. Such a signing procedure couldbe coercive due to strong peer pressure.&nbsp;</font></font><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Second,there is a serious concern whether JWs were adequately informed of therisk versus benefit analysis of blood-based treatments when they signedthe card. In their official magazines, horrifying stories about tragiccases of blood-based treatments collected from medical journals and newsmedia have been presented, yet there has never been any article that objectivelyweighs the benefit of blood transfusions against the risk. Such biasedinformation raises serious concern about the validity of the informed refusalexpressed in the blood card.&nbsp;</font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">AsMigden and Braen stated,<a href="#ref17">17</a> it appears that the realpurpose of the blood card is not to ensure that JWs make an informed decisionregarding blood-based treatment, but rather to prevent JWs from receivingblood. Under such strict organizational directives imposed by the WTS,autonomy of JW patients, which is a prerequisite of informed consent, maybe suppressed. Considering these factors, Migden and Braen concluded thata good faith decision to transfuse an unconscious adult JW in emergentneed of blood is justified if the patient does not have a blood refusaladvance directive that is informed and can survive a high level of scrutiny.&nbsp;</font></font></p></td> <td valign="TOP" rowspan="2"></td> <td valign="TOP" width="150"><img src="proctor.gif" height="188" width="150" /></td> </tr> <tr> <td valign="TOP" width="150"><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">CatherynProctor, right, mother of Jadine Russell, a pedestrian who died after beinghit by a drunk driver, wipes away a tear outside the courtroom after thedriver's trial. The victim, a Jehovah's Witness, refused a blood transfusion,which the defense argued actually caused her death.</font></font><br /><i><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">VictoriaArocho/Associated Press.</font></font></i></td> </tr> </tbody> </table><br />&nbsp;<p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Inview of such potential problems of the blood card, the WTS in recent yearshas put more emphasis on filling out a full advance directive form forrefusal of blood, in conjunction with a health-care power of attorney (proxy)form prepared by the WTS for each state. JWs are encouraged to fill outthese forms and submit them for their health care providers to have onrecord. The forms include legal references for judges and hospital lawyerswho may question or challenge the legality of the blood policy. The formsdetail WTS-approved alternatives for blood treatment, and instruct as towhat treatments JWs must not accept under any circumstances, even to savetheir lives. The forms also list which blood components and proceduresmay be allowed and under what circumstances, subject to an individual'sconscience (see Table 1 and 2). The WTS now encourages JWs to indicateon the blood card that they have executed the advance directive forms oftheir state.&nbsp;</font></font></p><p><b><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Clinicalmanagement of JW patients</font></font></b><br /><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Whenno life-threatening condition exists, and alternative bloodless treatmentis readily available without excessive cost or risk, treatment of JWs shouldbe no different from other patients. They do not refuse other medical treatmentand are generally conscientious about their own health and respectful ofphysicians.&nbsp;</font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Majorethical controversy arises when there are limited or no alternatives toblood-based treatment. Until the WTS publishes more simplified rules, andallows all medical treatment decisions to be based on individual conscience,the care of such JW cases will remain complicated. It is not sufficentto either blindly comply with the pre-molded directive, or flatly refusetreatment and refer to another hospital or doctor.&nbsp;</font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Thepatient's personal beliefs and understanding of the risk versus benefitshould be carefully discussed in private conference. Religious discussionneed not be avoided since organizational control of patients' choices areinseparable from their religious conviction.<a href="#ref18">18</a> Onlya small number of JWs understand the complex rules and conditions of bloodpolicy of their own organization. For this reason, I recommend that anymedical professionals dealing with JW patients obtain a small brochureDo Jehovah's Witnesses Really Abstain From Blood? published by AJWRB <a href="#ref19">19</a>for reference in such discussions. It is written by JWs themselves andconcisely discusses the questions of the blood policy. It is also importantto seek ethics consultation in complicated cases.&nbsp;</font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Whatis acceptable or unacceptable treatment should ultimately be determinedby the individual patient, in concert with advice from treating physicians.Some JW patients may delegate their decision to the WTS and ask the HLCto intervene on their behalf. Others may be autonomous enough to make individualizeddecisions based on new perspectives.&nbsp;</font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Whateverdecision the patient makes, extra precaution must be taken to ensure theprivacy and confidentiality of those decisions. The WTS once publishedan article in its official magazine that encouraged JWs who work in themedical field to divulge confidential medical information of fellow JWpatients who secretly receive medical treatment prohibited by the WTS.<a href="#ref20">20</a></font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Life-threateningemergency treatment of exsanguinating JW patients continues to be problematic.There is no time to obtain informed consent to transfuse blood. Every effortshould be made to stabilize the patient so that valid and contemporaneousinformed consent can be obtained. If the patient is unable to express acontemporaneous decision and there is no valid advance directive, or thereis reasonable doubt about the validity of the blood card, emergency bloodtransfusions may be given until the patient is relieved from imminent dangerof death.<a href="#ref17">17</a></font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Thereare several reasons to support this course of action. First, emergencyexception to consent has been an established medicolegal principle. ThePennsylvania Supreme Court held that &quot;...where there is an emergency callingfor an immediate decision, nothing less than a fully conscious contemporaneousdecision by the patient will be sufficient to override evidence of medicalnecessity.&quot;<a href="#ref21">21</a> Second, JWs who were unconsciously transfusedare not subject to the religion's judicial process or sanctions. Third,as reviewed here, since there is an indication of change in the policyon the horizon, premature death at the present time due to blood loss mustbe averted.&nbsp;</font></font></p><p><b><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Treatmentof children</font></font></b><br /><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1">Childrenof JW parents should be given treatment independently from their parents'religion. As the Committee of Bioethics of the American Academy of Pediatricsstated, &quot;constitutional guarantees of freedom of religion do not permitchildren to be harmed through religious practices.&quot;<a href="#ref22">22</a>In emergency situations where there is risk of harm to the child by withholdingblood-based treatment, immediate danger should be relieved, including,if necessary, giving blood-based treatment. Decisions regarding &quot;matureminors&quot; or adolescent children are more problematic. The maturity of eachchild is different, and so is the child's understanding and commitmentto the blood policy. If there is any unsolved ethical or legal issue regardingJW children, it is most appropriate to obtain a court order before proceedingfurther.&nbsp;</font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-1"><b>Disclaimer/Disclosure</b>Views and opinions expressed herein are the author's and do not necessarilyreflect those of Kaiser Permanente and Northwest Permanente P.C. The authorhas served as a medical consultant to the AJWRB since 1997 without compensation.He has never been a Jehovah's Witness.&nbsp;</font></font></p><p><b><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">OsamuMuramoto&nbsp;</font></font></b></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">RegionalEthics Council and Department of Neurology,&nbsp;</font></font><br /><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">KaiserPermanente Northwest Division, and Northwest Permanente P.C.,&nbsp;</font></font><br /><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Portland,&nbsp;</font></font><br /><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Oregon&nbsp;</font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2"><b>Correspondenceto:</b> Dr Muramato&nbsp;</font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">KaiserEast Interstate Office, 3414 N.W.&nbsp;</font></font><br /><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">KaiserCenter Drive, Portland, OR 97227&nbsp;</font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2"><a href="mailto:muramotosa@kpnw.org">muramotosa@kpnw.org</a></font></font></p><p><b><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">Sourcesand References&nbsp;</font></font></b></p><p><a name="ref1"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">1.<i>You Can Live Forever in Paradise on Earth.</i> Brooklyn: Watch TowerBible and Tract Society of Pennsylvania, 1989, p216.&nbsp;</font></font></p><p><a name="ref2"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">2.Dixon JL, Smalley MG. Jehovah's Witnesses. The surgical/ethical challenge.<i>JAMA</i> 1981; 246:2471-2472.&nbsp;</font></font></p><p><a name="ref3"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">3.Questions from readers.<i> The Watchtower;</i> 1984 May 15:31.&nbsp;</font></font></p><p><a name="ref4"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">4.Kerridge I, Lowe M, Seldon M, Enno A, Deveridge S. Clinical and ethicalissues in the treatment of a Jehovah's Witness with acute myeloblasticleukemia.<i> Arch Intern Med </i>1998; 157:1753-1757.&nbsp;</font></font></p><p><a name="ref5"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">5.Muramoto O. Medical ethics in the treatment of Jehovah's Witnesses. <i>ArchIntern Med</i> 1998; 158:1155-1156.&nbsp;</font></font></p><p><a name="ref6"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">6.Malak J Jehovah's Witnesses and medicine: an overview of beliefs and issuesin their care.<i> J Med Assoc Ga</i> 1998; 87:322-327.&nbsp;</font></font></p><p><a name="ref7"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">7.Questions from readers.<i> The Watchtower</i>; 1997 Feb 1:29.&nbsp;</font></font></p><p><a name="ref8"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">8.Kanumilli V, Kaza R, Johnson C, Nowacki. Epidural blood patch for Jehovah'sWitness patient. <i>Anesth Analg</i> 1993; 77:872-873.&nbsp;</font></font></p><p><a name="ref9"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">9.Questions from readers. <i>The Watchtower</i>; 1961 Jan 15:64.&nbsp;</font></font></p><p><a name="ref10"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">10.Muramoto O. Bioethics of the refusal of blood by Jehovah's Witnesses: Part1. Should bioethical deliberation consider dissidents' views? <i>J MedEthics</i> 1998; 24:223-230.&nbsp;</font></font></p><p><a name="ref11"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">11.&quot;New Light on Blood. Official site of The Associated Jehovah's Witnessesfor Reform on Blood:&quot; <a href="http://www.visiworld.com/starter/newlight/index.htm" target="top">http://www.visiworld.com/starter/newlight/index.htm</a>.&nbsp;</font></font></p><p><a name="ref12"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">12.The Liberal Elder. Reply to Malyon on respecting the autonomy and motivesof Jehovah's Witness patients.<i> J Med Ethics</i> (Submitted for publication).&nbsp;</font></font></p><p><a name="ref13"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">13.Malyon D. Transfusion-free treatment of Jehovah's Witnesses: respectingthe autonomous patient's rights.<i> J Med Ethics</i> 1998; 24:302-307.&nbsp;</font></font></p><p><a name="ref14"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">14.Malyon D. Transfusion-free treatment of Jehovah's Witnesses: respectingthe autonomous patient's motives.<i> J Med Ethics </i>1998; 24:376-381.&nbsp;</font></font></p><p><a name="ref15"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">15.Communique issued by the Secretary to the European Commission of HumanRights. INFORMATION NOTE No. 148 on the 276th Session of the European Commissionof Human Rights. (Strasbourg, Monday 2 March-Friday 13 March 1998). <a href="http://194.250.50.201/eng/E276INFO.148.html">http://194.250.50.201/eng/E276INFO.148.html</a>.&nbsp;</font></font></p><p><a name="ref16"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">16.Muramoto O. Jehovah's Witnesses and blood transfusions. <i>Lancet</i> 1998;352:824.&nbsp;</font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">16a.Wilcox P. Jehovah's Witnesses and blood transfusions. <i>Lancet</i> 1999;353:757-758.&nbsp;</font></font></p><p><a name="ref17"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">17.Migden DR, Braen GR. The Jehovah's Witness blood refusal card: ethicaland medicolegal considerations for emergency physicians. <i>Acad EmergMed</i> 1998; 5:815-824.&nbsp;</font></font></p><p><a name="ref18"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">18.Muramoto O. Bioethics of the refusal of blood by Jehovah's Witnesses: Part2. A novel approach based on rational non-interventional paternalism. <i>JMed Ethics</i> 1998; 24:295-301.&nbsp;</font></font></p><p><a name="ref19"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">19.Do Jehovah's Witnesses really abstain from blood? Boise: The AssociatedJehovah's Witnesses for Reform on Blood. 1998 (available by writing toAJWRB, PO Box 190089 Boise, ID 83719-0089, or on-line at <a href="http://www.ajwrb.org/physicians/index.shtml">http://www.ajwrb.org/physicians/index.shtml</a>).&nbsp;</font></font></p><p><a name="ref20"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">20.&quot;A time to speak&quot; - when? <i>The Watchtower</i>; 1987 Sept 1:12.&nbsp;</font></font></p><p><a name="ref21"></a><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">21.Re Estate of Darrell Dorne, 534 A.2d 452 (Pa. 1987).&nbsp;</font></font></p><p><font face="Verdana, Arial, Helvetica, sans-serif"><font size="-2">22.American Academy of Pediatrics Committee on Bioethics. Religious objectionsto medical care. <i>Pediatrics</i> 1997; 99:279-281.&nbsp;</font></font></p></td> </tr> </tbody> </table><p>&nbsp;</p></td> <td valign="TOP" width="1" bgcolor="#FFFFFF"><img src="black.gif" height="1" width="1" /></td> </tr> </tbody> </table> </body> </html>
223	single	usda food pyramid	Find a description of the USDA food pyramid.	clueweb12-0707wb-62-22692	2	<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> <html> <head> <meta http-equiv="Content-Type" content="text/html; charset=ISO-8859-1" /> <meta name="Author" content="VitaminLore" /> <meta name="Language" content="en" /> <meta name="ContentID" content="2026006" /> <meta name="Category" content="Healthy_Eating" /> <meta name="Article" content="Food_Guide_Pyramid" /> <meta name="Description" content="www.vitaminlore.com Compare Food Pyramids of the various cultures which include the percentages of each group of food that make up a healthy diet." /> <meta name="Keywords" content=" Vitamins, Minerals,Supplements,Galore, vitamin, Food Guide Pyramid, Pyramid, Food Guide" /> <meta name="GENERATOR" content="Microsoft FrontPage 4.0" /> <meta name="ProgId" content="FrontPage.Editor.Document" /> <title> Eniva Vitamins, Minerals, Electrolyte Water, and Nutiritional Supplements www.vitaminlore.com: The Food Groups and the Food Pyramid</title> <link type="text/css" rel="stylesheet" href="../Styles/hnol7.css" /> <base target="_self" /> </head> <body> <img border="0" src="../images/vitaminloreLogo.gif" width="150" height="31" /> <a href="https://www.enivamembers.com/Step1.aspx?ID=vitaminlore"><img border="0" src="../images/btn_pcsignup.gif" width="165" height="38" /></a>&nbsp; <a href="http://www.enivamembers.com/products.aspx?ID=vitaminlore"><img border="0" src="../images/order_freegraphic1.gif" width="197" height="36" /></a> <p><script type="text/javascript"><!--google_ad_client = "pub-0625094460229847";google_ad_width = 728;google_ad_height = 90;google_ad_format = "728x90_as";google_ad_type = "text_image";google_ad_channel ="";google_color_border = "336699";google_color_bg = "FFFFFF";google_color_link = "0000FF";google_color_text = "000000";google_color_url = "008000";//--></script><script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script><script type="text/javascript"><!--google_ad_client = "pub-0625094460229847";google_ad_width = 728;google_ad_height = 15;google_ad_format = "728x15_0ads_al";google_ad_channel ="";google_color_border = "336699";google_color_bg = "FFFFFF";google_color_link = "0000FF";google_color_text = "000000";google_color_url = "008000";//--></script><script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script></p> <form method="get" action="http://www.google.com/custom" target="google_window"> <table border="0" bgcolor="#cccccc"> <tbody> <tr> <td nowrap="nowrap" valign="top" align="left" height="32"><a href="http://www.google.com/"><img src="http://www.google.com/logos/Logo_25gry.gif" border="0" alt="Google" align="middle" /></a></td> <td nowrap="nowrap"><input type="hidden" name="domains" value="www.vitaminlore.com;www.eniva.com" /><input type="text" name="q" size="64" maxlength="255" value="" /><input type="submit" name="sa" value="Search" /></td> </tr> <tr> <td>&nbsp;</td> <td nowrap="nowrap"> <table> <tbody> <tr> <td><input type="radio" name="sitesearch" value="" /><font size="-1" color="black">Web</font></td> <td><input type="radio" name="sitesearch" value="www.vitaminlore.com" checked="checked" /><font size="-1" color="black">www.vitaminlore.com</font></td> </tr> <tr> <td><input type="radio" name="sitesearch" value="www.eniva.com" /><font size="-1" color="black">www.eniva.com</font></td> <td></td> </tr> </tbody> </table><input type="hidden" name="client" value="pub-0625094460229847" /><input type="hidden" name="forid" value="1" /><input type="hidden" name="channel" value="5944742487" /><input type="hidden" name="ie" value="ISO-8859-1" /><input type="hidden" name="oe" value="ISO-8859-1" /><input type="hidden" name="safe" value="active" /><input type="hidden" name="cof" value="GALT:#008000;GL:1;DIV:#336699;VLC:663399;AH:center;BGC:FFFFFF;LBGC:336699;ALC:0000FF;LC:0000FF;T:000000;GFNT:0000FF;GIMP:0000FF;LH:21;LW:100;L:http://www.vitaminlore.com/images/vitaminloreLogo.gif;S:http://;LP:1;FORID:1" /><input type="hidden" name="hl" value="en" /></td> </tr> </tbody> </table> </form>.&nbsp; <p class="Article-Title">The Food Groups and the Food Pyramid</p> <div id="sidebar" class="sidebar"> <a name="sidebar"></a> <ul class="sidebar"> </ul> </div> <p align="center"><img border="1" src="Food_Guide_Pyramid_USDA.jpg" height="350" width="488" alt="Food_Guide_Pyramid_USDA.jpg" /></p> <p><span class="Heading">The Food Pyramid:</span> The Food Pyramid is a visualimage illustrating the percentages of each group of food that make up a healthydiet.</p> <p>The US Department of Agriculture (USDA) created the Food Pyramid, which wasupdated to its current form in 1991. The most recent update represents a shiftin thinking in American nutrition. Nutritionists used to recommend a diet highin protein. They now call for the average adult to consume less <a href="../Food_Guide/Meat_And_Poultry.htm">meat</a>,while recommending greater consumption of <a href="../Food_Guide/Vegetables.htm">vegetables</a>,<a href="../Food_Guide/Fruit.htm">fruits</a>, and <a href="../Food_Guide/Grains.htm">grains</a>.</p> <p>The Food Pyramid, with its recommended servings, represents what the diet andnutrition experts consider to be the most solid, reliable, well-researchedthinking to date. It provides a good model for healthy eating. The basicpyramid, developed by the USDA and the U.S. Department of Health and HumanServices, is only one model, however. This pyramid has been adapted for ethnicpreferences and there are now pyramids for the Mediterranean diet, the Asiandiet and the Latin American diet. Other diets, such as the Hawaiian diet, canalso be placed on a food pyramid.</p> <p><span class="Heading">How the Food Pyramid is constructed:</span> The foodpyramid has four levels.</p> <p>1. At its base, the foundation of a healthy diet, are <a href="../Food_Guide/Bread.htm">bread</a>,<a href="../Food_Guide/Grains.htm">grains</a>, and <a href="../Food_Guide/Cereals.htm">cereals</a>.They should compose the largest percentage of what you consume.</p> <p>2. Next come two food groups (<a href="../Food_Guide/Vegetables.htm">vegetables</a>and <a href="../Food_Guide/Fruit.htm">fruits</a>) which, together, occupy thesecond tier of the pyramid.</p> <p>3. On an even higher, smaller level you find the next two food groups: the <a href="../Food_Guide/Milk.htm">milk</a>and <a href="../Food_Guide/Meat_And_Poultry.htm">meat</a> groups.</p> <p>4. In the small triangle at the top of the pyramid sit <a href="../Food_Guide/Fats_And_Oils.htm">fatsand oils</a> and <a href="../Food_Guide/Sweeteners.htm">sugars</a>.</p> <p><span class="Heading">How to use the Food Pyramid:</span> Follow these simplesteps.</p> <p>1. Determine your calorie requirement</p> <p>2. Translate your calorie requirement into daily food group allowances</p> <p>3. Use the food group allowances to help you plan your meals and snacks</p> <p>4. Record what you eat and check it against your daily allowances for eachgroup</p> <p>5. Use the <a href="Food_Diary.htm">Food Diary</a> to record the areas whereyou are typically over your daily allowances</p> <p>6. Try to alter the diet to be closer to your target</p> <p><span class="Heading">How to fine-tune the Food Pyramid:</span> There aresome challenges to using the USDA Food Pyramid. The first is that you need toput some distinction in your food choices, according to your particular dietarygoals. For instance, if you are concerned about your weight, you will want tomake your choices in the meat group from among those with lower fat content. Thefood pyramid doesn’t distinguish between hot dogs and lean chicken breast, sothese distinctions are up to you.</p> <p>After you have gone through this exercise a few times, you may find there aresome foods that do not fit your diet plan. For instance, pizza may not be thebest choice if you are trying to cut down on carbohydrates and fat, because ittakes up too much of your daily allowance of each. If you don’t want toconsume <a href="../Food_Guide/Milk.htm">milk</a> products, you may want tosubstitute additional carbohydrates.</p> <p><b>Variations on the pyramid</b>: These variations on the USDA Food Pyramidare based on diets from regions with historically lower chronic disease rates.They may be worth considering if your family has a history of <a href="../Concern/Cardiovascular_Disease.htm">heartdisease</a>, <a href="../Concern/Cancer_Diet.htm">cancer</a>, <a href="../Concern/Hypertension.htm">highblood pressure</a> or <a href="../Concern/Diabetes.htm">diabetes</a>.</p> <p align="center"><img border="1" src="Food_Guide_Pyramid_Med.jpg" height="350" width="512" alt="Food_Guide_Pyramid_Med.jpg" /></p> <p class="Heading" style="margin-bottom:0; margin-top:2em;">The MediterraneanPyramid</p> <p>The Mediterranean diet begins with the same basis of lots of <a href="../Food_Guide/Grains.htm">grains</a>,fresh <a href="../Food_Guide/Fruit.htm">fruits</a>, and <a href="../Food_Guide/Vegetables.htm">vegetables</a>.Major differences from the USDA pyramid include:</p> <p>•&nbsp;Using olive oil as the primary fat<br />•&nbsp;Allowing for only moderate amounts of <a href="../Food_Guide/Milk.htm">milk</a>products<br />•&nbsp;Using <a href="../Food_Guide/Fish_And_Seafood.htm">fish</a> and <a href="../Food_Guide/Meat_And_Poultry.htm">poultry</a>,rather than red <a href="../Food_Guide/Meat_And_Poultry.htm">meat</a>, as themain source of high protein food from animals<br />•&nbsp;Including wine with meals</p> <p align="center"><img border="1" src="Food_Guide_Pyramid_Asian.jpg" height="350" width="512" alt="Food_Guide_Pyramid_Asian.jpg" /></p> <p class="Heading" style="margin-bottom:0; margin-top:2em;">The Asian Pyramid</p> <p class="List-Caption">Major differences from the USDA pyramid include:</p> <p>•&nbsp;Featuring <a href="../Food_Guide/Rice.htm">rice</a> and <a href="../Food_Guide/Pasta.htm">noodles</a>as part of the <a href="../Food_Guide/Grains.htm">grain</a> group<br />•&nbsp;Putting <a href="../Food_Guide/Fish_And_Seafood.htm">fish</a> andshellfish and <a href="../Food_Guide/Dairy_Foods.htm">dairy</a> in the samesection of the pyramid<br />•&nbsp;Avoiding milk. Most Asians lack sufficient amounts of <a href="../Supp/Lactase.htm">lactase</a>,the enzyme required to digest lactose.</p> <p align="center"><img border="1" src="Food_Guide_Pyramid_Latin.jpg" height="350" width="455" alt="Food_Guide_Pyramid_Latin.jpg" /></p> <p class="Heading" style="margin-bottom:0; margin-top:2em;">The Latin AmericanPyramid</p> <p>The Latin diet features <a href="../Food_Guide/Tortillas.htm">tortillas</a>, <a href="../Food_Guide/Legumes.htm">beans</a>,and rice in the grains section.</p> <p><span class="Heading">Determining your caloric requirements:</span> Thenumber of food servings a person needs depends upon his or her sex, age,activity level, and body type. Each individual can use these personal parametersto determine the amount of food he or she should consume in an average day. TheUSDA has set the following average calorie levels as desirable for the followinggroups.</p> <ul> <li>1,600 calories a day for children, inactive women, and older adults.</li> <li>2,200 calories a day for moderately active women, inactive men, and teenage girls.</li> <li>2,800 calories a day for teenage boys, active women, and active men.</li> <li>2,200 to 2,800 calories a day for <a href="../Concern/Pregnancy.htm">pregnant</a> and breastfeeding women.</li> </ul> <p>These are ballpark figures for calculating each person’s requirements.After considering all factors, you might want to place yourself somewherebetween these benchmarks.</p> <p><span class="Heading">Converting calories to food group servings:</span> Onceyou know your daily caloric need, you can convert that to servings from the foodpyramid by multiplying your calorie allowance by the following recommendedpercentages.</p> <ul> <li>60% calories from carbohydrates</li> <li>10% calories from protein</li> <li>30% calories from fat (one-third or less from saturated fats)</li> </ul> <p><span class="Heading">Note:</span> If you are adjusting your fat downward,increase your carbohydrates by the same percentage.</p> <p><b>Serving comparisons by three calorie levels (USDA</b>):</p> <div> <table border="1" class="Introductory" width="100%" cellpadding="5" cellspacing="0"> <colgroup> <col width="25%" valign="top" span="4" /> </colgroup> <thead> <tr> <th>&nbsp;</th> <th><b>Sedentary women, some older adults, and children</b></th> <th><b>Sedentary men, moderately active women, and teen girls</b></th> <th><b>Teen boys, active men and women</b></th> </tr> <tr> <th><b>Food Group, Fat, Sugars</b></th> <th><b>About 1,600 calories</b></th> <th><b>About 2,200 calories</b></th> <th><b>About 2,800 calories</b></th> </tr> </thead> <tbody> <tr> <td><a href="../Food_Guide/Bread.htm">Bread</a></td> <td>6 servings</td> <td>9 servings</td> <td>11 servings</td> </tr> <tr> <td><a href="../Food_Guide/Vegetables.htm">Vegetable</a></td> <td>3 servings</td> <td>4 servings</td> <td>5 servings</td> </tr> <tr> <td><a href="../Food_Guide/Fruit.htm">Fruit</a></td> <td>2 servings</td> <td>3 servings</td> <td>4 servings</td> </tr> <tr> <td><a href="../Food_Guide/Meat_And_Poultry.htm">Meat</a></td> <td>2–3 servings</td> <td>2–3 servings</td> <td>2–3 servings</td> </tr> <tr> <td><a href="../Food_Guide/Milk.htm">Milk</a></td> <td>2–3 servings</td> <td>2–3 servings</td> <td>2–3 servings</td> </tr> <tr> <td>Total fat</td> <td>36 grams (20%) <p>53 grams (30%)</p> </td> <td>49 grams (20%) <p>73 grams (30%)</p> </td> <td>62 grams (20%) <p>93 grams (30%)</p> </td> </tr> <tr> <td>Total added sugars</td> <td>24 grams (6 tsp)</td> <td>32 grams (8 tsp)</td> <td>44 grams (11 tsp)</td> </tr> </tbody> </table> </div> <p><span class="Heading">Many foods are mixed:</span> In reality, most foodscontain mixtures of protein, carbohydrates, and fat, so you need to be a bitmore creative with your estimating. If you eat an apple, it’s obvious you haveeaten one serving of fruit. But if you eat a taco salad, your calculationbecomes more complex. Depending on how it’s made, it could provide twoservings of the vegetable group, one bread group, one meat group, and asignificant portion of your daily fat. Eventually, you may be able to eyeball ameal and tell right away what you are getting, but in the beginning it’s agood idea to measure and calculate the equivalent amounts from each of the foodgroups. If you are eating a packaged, mixed food, the calculations have alreadybeen made for you.</p> <p class="List-Caption">Here are some examples of how this works:</p> <ul style="margin-top:.5em;"> <li>Carbohydrates only: <a href="../Food_Guide/Carrots.htm">carrots</a>, <a href="../Food_Guide/Bananas.htm">bananas</a>, <a href="../Food_Guide/Broccoli.htm">broccoli</a></li> <li>Carbohydrates and protein: <a href="../Food_Guide/Grains.htm">grains</a>, breads, dried beans</li> <li>Carbohydrates and <a href="../Food_Guide/Fats_And_Oils.htm">fats</a>: wheat germ, donut, pie</li> <li>Protein only: liquid protein</li> <li>Protein and fats: <a href="../Food_Guide/Eggs.htm">eggs</a>, cheese, <a href="../Food_Guide/Fish_And_Seafood.htm">fish</a>, <a href="../Food_Guide/Meat_And_Poultry.htm">meats</a> of any kind</li> <li>Fats only: oils, margarine</li> <li>All three: <a href="../Food_Guide/Milk.htm">milk</a>, <a href="../Food_Guide/Peanut_Butter.htm">peanut butter</a>, whole grains</li> </ul> <p><span class="Heading">Steps for the beginner:</span> Follow these simplesteps to determine where your calories are coming from.</p> <p>1. Use either the <a href="Food_Labels.htm">food label</a> from preparedfoods or your recipe to determine the food groups and amounts contained incombination foods.</p> <p>2. Figure out what portion you will consume.</p> <p>3. Divide your portion (as a percent) into the total.</p> <p>4. Record the amount from each food group.</p> <p>5. Determine how this food fits into the food pyramid (number of servings itrepresents).</p> <p>6. Record it in your <a href="Food_Diary.htm">food diary</a>.</p> <p>7. Stay flexible and strive for balance.</p> <p>You can occasionally indulge in a small piece of dessert if you forgo othersources of sugar, fat, and refined flour that same day. This requires stayingespecially aware and honest with yourself about how much and how often youindulge. Trading off does not mean binging and fasting. That unhealthy patternhas no place in healthy eating. Trading off means making sure, over a period ofseveral days, you achieve a balance that meets your nutritional requirements.</p> <p><span class="Heading">What counts as a serving?</span> At first, figuring outwhat counts as a serving may seem a little tricky. Some servings are close towhat people would typically consume at a meal; others are much smaller. Forinstance, a single serving of rice is only one-half cup whereas people are morelikely to consume a cup. A hamburger bun is two to three servings (depending onsize). This is not a problem as long as you factor this in before you plan yourday’s servings. It is more important for people who are trying to keep a levelblood sugar, which is achieved by distributing carbohydrates evenly throughoutthe day.</p> <p>When calculating your servings of each food group, be sure to focus on thelabels of packaged foods. They contain a great deal of valuable information. Tolearn more about food labels and how to read them, go to the section on <a href="Food_Labels.htm">FoodLabels</a>.</p> <p><span class="Heading">Food Groups and their typical servings:</span> The USDAprovides recommended servings for each of the food groups in the pyramid.</p> <p><span class="Sub-Heading"><a href="../Food_Guide/Bread.htm">Bread Group</a></span><br />USDA recommends six to eleven servings from this group. In general, the groupincludes a wide variety of cereals, breads, rice and pasta. If you have adietary goal of eating more whole foods, you will want to choose these foods intheir “brown” or whole grain form as: brown rice, whole grain bread, pastaand whole grain cereals.</p> <p class="List-Caption">Typical bread servings are:</p> <ul style="margin-top:.5em;"> <li>One slice of bread (1 oz.)</li> <li>1/2 bagel (small)</li> <li>One ounce of cereal flakes</li> <li>1/2 cup grain, rice or pasta</li> <li>Five to six small crackers</li> </ul> <p><span class="Sub-Heading"><a href="../Food_Guide/Vegetables.htm">VegetableGroup</a></span><br />USDA recommends three to five servings from this group. There is a wideselection of organic and conventional vegetables available in this country. Manyare imported from other countries, as well. Check the labels to determine theorigin.</p> <p class="List-Caption">Typical vegetable servings are:</p> <ul style="margin-top:.5em;"> <li>One cup raw leafy vegetables</li> <li>1/2 cup cooked or raw non-leafy vegetables</li> <li>1/4 cup vegetable juice</li> </ul> <p><span class="Sub-Heading"><a href="../Food_Guide/Fruit.htm">Fruit Group</a></span><br />USDA recommends three to five servings from this group. There is a wideselection of <a href="Organic_Foods_And_Products.htm">organic</a> andconventional fruits grown in this country and imported from other countries.Check the labels to determine the origin.</p> <p class="List-Caption">Typical fruit servings are:</p> <ul style="margin-top:.5em;"> <li>One medium piece of fruit</li> <li>1/2 cup chopped fresh, cooked or canned fruit</li> <li>1 1/2 ounces dried fruit</li> <li>3/4 cup <a href="../Food_Guide/Juices.htm">fruit juice</a></li> </ul> <p><span class="Sub-Heading"><a href="../Food_Guide/Milk.htm">Milk Group</a></span><br />USDA recommends two to three servings from this group. There is a wide selectionof products in this group including: milk, yogurt, cheese, kefir, and creamcheese. These are healthful foods when eaten in moderation.</p> <p class="List-Caption">Typical milk servings are:</p> <ul style="margin-top:.5em;"> <li>One cup milk or yogurt</li> <li>1/2 ounce of natural cheese</li> <li>Two ounces processed cheese</li> </ul> <p><span class="Sub-Heading"><a href="../Food_Guide/Meat_And_Poultry.htm">MeatGroup</a></span><br />USDA recommends 5–7 ounces per day from this group. The group includes meat,poultry, fish, and dried beans. These are healthful, high-protein foods wheneaten in the recommended amounts.</p> <p class="List-Caption">Typical meat servings are:</p> <ul style="margin-top:.5em;"> <li>three ounces meat</li> <li>three ounces of <a href="../Food_Guide/Fish_And_Seafood.htm">fish</a></li> <li>three ounces of poultry</li> <li>1/3 cup <a href="../Food_Guide/Nuts_And_Seeds.htm">nuts</a></li> <li>two tablespoons nut butter</li> <li>1/2 cup cooked dried beans</li> <li>one <a href="../Food_Guide/Eggs.htm">egg</a></li> </ul> <p><span class="Sub-Heading"><a href="../Food_Guide/Fats_And_Oils.htm">Fats</a>,sweets, and alcoholic beverages</span><br />These should be eaten sparingly. Oil is necessary to a healthy diet, but smallamounts used in salad dressings and food preparation fill that need. Fat andsugars should been kept at a minimum and saved for special treats. Consumealcohol in moderation.</p> <p class="List-Caption">The USDA recommends NOT MORE THAN:</p> <ul style="margin-top:.5em;"> <li>53–96 grams of fat (1 Tbsp olive oil contains 14 grams)</li> <li>6–18 teaspoons sugar in all foods</li> </ul> <div id="Copyright-Notice" class="Copyright-Notice"> <a name="Copyright-Notice"></a> <hr /> <img border="0" src="../images/vitaminloreLogo.gif" width="150" height="31" alt="../Images/LogoCpyrt.gif" /> <p class="Copyright">Copyright � 2002 VitaminLore, Inc.&nbsp; All rights reserved.&nbsp;www.VitaminLore.com</p> <p><a href="http://www.enivamembers.com/products.aspx?ID=vitaminlore">Click here Buy Vitamins and Nutritional Supplements at very low prices..</a></p> <p><a href="http://www.enivamembers.com/products.aspx?ID=vitaminlore">Buy Brand name Vitamins for less from www.vitaminlore.com. VitaminLore.</a></p> <p class="Fineprint">The information presented in <em>VitaminLore</em> is for informational purposes only and was created by a team of U.S. registered dietitians and food experts. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements, making dietary changes, or before making any changes in prescribed medications.</p> <hr /> </div> </body> </html>
227	single	i will survive lyrics	Find the lyrics to the song "I Will Survive".	clueweb12-0106wb-94-12162	3	<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"> <html> <head> <meta http-equiv="content-type" content="text/html; charset=utf-8" /> <title>will - filmy o will w www.e-brzdac.com</title> <meta name="Description" content="Filmy na temat will" /> <meta http-equiv="Content-Language" content="pl" /> <meta name="robots" content="index,follow" /> <link href="http://www.e-brzdac.com/default.css" rel="stylesheet" type="text/css" /> <meta http-equiv="Content-type" content="text/html; charset=utf-8" /> </head> <body> <div id="wrapper"> <div id="header"> <div id="logo"> <h1><a href="http://www.e-brzdac.com"><img src="http://www.e-brzdac.com/images/logo.png" title="E-brzdac" /></a></h1> </div> </div> <div id="page"> <div id="page-bgtop"> <div id="content"> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/W-w3WfgpcGg.html">Bruno Mars - It Will Rain [Official Music Video]</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/W-w3WfgpcGg/0.jpg" /><br />Available now on iTunes! atlr.ec &copy; 2011 WMG From the Twilight Saga :Breaking Dawn Part -1 Original Motion Picture Soundtrack available now on iTunes! atlr.ec Directed By: Phil Pinto &amp; Bruno Mars Movie in theaters 11.18.11 brunomars.com http twitter.com elektra.com<br /><a href="http://www.e-brzdac.com/tag/bruno">bruno</a> <a href="http://www.e-brzdac.com/tag/mars">mars</a> <a href="http://www.e-brzdac.com/tag/it">it</a> <a href="http://www.e-brzdac.com/tag/will">will</a> <a href="http://www.e-brzdac.com/tag/rain">rain</a> <a href="http://www.e-brzdac.com/tag/official">official</a> <a href="http://www.e-brzdac.com/tag/twilight">twilight</a> <a href="http://www.e-brzdac.com/tag/breaking">breaking</a> <a href="http://www.e-brzdac.com/tag/dawn">dawn</a> <a href="http://www.e-brzdac.com/tag/soundtrack">soundtrack</a> <a href="http://www.e-brzdac.com/tag/music">music</a> <a href="http://www.e-brzdac.com/tag/pop">pop</a> <a href="http://www.e-brzdac.com/tag/Twilight+%28series%29">Twilight (series)</a> <a href="http://www.e-brzdac.com/tag/Twilight+%282008+Film%29">Twilight (2008 Film)</a> <a href="http://www.e-brzdac.com/tag/New">New</a> <a href="http://www.e-brzdac.com/tag/Bella">Bella</a> <a href="http://www.e-brzdac.com/tag/Edward">Edward</a> <a href="http://www.e-brzdac.com/tag/Bella+Swan">Bella Swan</a> <a href="http://www.e-brzdac.com/tag/Cullen">Cullen</a> <a href="http://www.e-brzdac.com/tag/Stewart">Stewart</a> <a href="http://www.e-brzdac.com/tag/Kristen">Kristen</a> <a href="http://www.e-brzdac.com/tag/Moon">Moon</a> <a href="http://www.e-brzdac.com/tag/Elektra">Elektra</a> <a href="http://www.e-brzdac.com/tag/Records">Records</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/-x0GuCfN_tY.html">I Will Be - Avril Lavigne (lyrics)</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/-x0GuCfN_tY/0.jpg" /><br />Avril's I Will Be with some lyrics and a few pictures. Wanna request a song? Leave a comment on my channel or message me!<br /><a href="http://www.e-brzdac.com/tag/avril">avril</a> <a href="http://www.e-brzdac.com/tag/lavigne">lavigne</a> <a href="http://www.e-brzdac.com/tag/iwill">iwill</a> <a href="http://www.e-brzdac.com/tag/be">be</a> <a href="http://www.e-brzdac.com/tag/lyrics">lyrics</a> <a href="http://www.e-brzdac.com/tag/words">words</a> <a href="http://www.e-brzdac.com/tag/Christine">Christine</a> <a href="http://www.e-brzdac.com/tag/Lx">Lx</a> <a href="http://www.e-brzdac.com/tag/Lil">Lil</a> <a href="http://www.e-brzdac.com/tag/Chris">Chris</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/L8q6f4CvINE.html">Leona Lewis - I Will Be</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/L8q6f4CvINE/0.jpg" /><br />Music video by Leona Lewis performing I Will Be. YouTube view counts pre-VEVO: 661066 (c) 2009 Simco Limited exclusively licensed to Sony Music Entertainment UK<br /><a href="http://www.e-brzdac.com/tag/Leona">Leona</a> <a href="http://www.e-brzdac.com/tag/Lewis">Lewis</a> <a href="http://www.e-brzdac.com/tag/Syco">Syco</a> <a href="http://www.e-brzdac.com/tag/Music">Music</a> <a href="http://www.e-brzdac.com/tag/Pop">Pop</a> <a href="http://www.e-brzdac.com/tag/leonalewis">leonalewis</a> <a href="http://www.e-brzdac.com/tag/VEVO">VEVO</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/O8muJIOznsg.html">The Beatles--I Will</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/O8muJIOznsg/0.jpg" /><br />Set to I Will from the White Album<br /><a href="http://www.e-brzdac.com/tag/John">John</a> <a href="http://www.e-brzdac.com/tag/Lennon">Lennon</a> <a href="http://www.e-brzdac.com/tag/Paul">Paul</a> <a href="http://www.e-brzdac.com/tag/mccartney">mccartney</a> <a href="http://www.e-brzdac.com/tag/George">George</a> <a href="http://www.e-brzdac.com/tag/Harrison">Harrison</a> <a href="http://www.e-brzdac.com/tag/Ringo">Ringo</a> <a href="http://www.e-brzdac.com/tag/Starr">Starr</a> <a href="http://www.e-brzdac.com/tag/Beatles">Beatles</a> <a href="http://www.e-brzdac.com/tag/classicrocker">classicrocker</a> <a href="http://www.e-brzdac.com/tag/1965">1965</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/qg1ckCkm8YI.html">Will It Blend? - iPhone</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/qg1ckCkm8YI/0.jpg" /><br />Everybody knows that the iPhone can make phone calls, play movies &amp; music, surf the web, and a lot more. But, Will It Blend? That is the question. Tell us what to blend next here on.fb.me<br /><a href="http://www.e-brzdac.com/tag/will">will</a> <a href="http://www.e-brzdac.com/tag/it">it</a> <a href="http://www.e-brzdac.com/tag/blend">blend</a> <a href="http://www.e-brzdac.com/tag/iphone">iphone</a> <a href="http://www.e-brzdac.com/tag/blendtec">blendtec</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/N_CnGUDv5kQ.html">Leona Lewis-I Will Be w/lyrics</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/N_CnGUDv5kQ/0.jpg" /><br />Leona Lewis I Will Be with lyrics There's nothing I could say to you Nothing I could ever do to make you see What you mean to me All the pain, the tears I cried Still you never said goodbye and now I know How far you'd go I know I let you down But it's not like that now This time I'll never let you go I will be, all that you want And get myself together Cause you keep me from falling apart All my life, I'll be with you forever To get you through the day And make everything okay I thought that I had everything I didn't know what life could bring But now I see, honestly You're the one thing I got right The only one I let inside Now I can breathe, cause you're here with me And if I let you down I'll turn it all around Cause I would never let you go I will be, all that you want And get myself together Cause you keep me from falling apart All my life, I'll be with you forever [I Will Be lyrics on www.metrolyrics.com] To get you through the day And make everything okay I will be, all that you want And get myself together Cause you keep me from falling apart All my life, I'll be with you forever To get you through the day And make everything okay Cause without you I cant sleep I'm not gonna ever, ever let you leave You're all I've got, you're all I want Yeah And without you I don't know what I'd do I can never, ever live a day without you Here with me, do you see, You're all I need And I will be, all that you want And get myself together Cause you keep me from falling apart All &lt;b&gt;...&lt;/b&gt;<br /><a href="http://www.e-brzdac.com/tag/Leona">Leona</a> <a href="http://www.e-brzdac.com/tag/Lewis">Lewis</a> <a href="http://www.e-brzdac.com/tag/Will">Will</a> <a href="http://www.e-brzdac.com/tag/Be">Be</a> <a href="http://www.e-brzdac.com/tag/lyrics">lyrics</a> <a href="http://www.e-brzdac.com/tag/lilmooprincess1994">lilmooprincess1994</a> <a href="http://www.e-brzdac.com/tag/Lil">Lil</a> <a href="http://www.e-brzdac.com/tag/Moo">Moo</a> <a href="http://www.e-brzdac.com/tag/Princess">Princess</a> <a href="http://www.e-brzdac.com/tag/1994">1994</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/30PqLGidLeM.html">Natalie Cole - This will be 1975</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/30PqLGidLeM/0.jpg" /><br />Natalie Cole - This will be 1975 This will be an everlasting love This will be the one I've waited for This will be the first time anyone has loved me I'm so glad you found me in time And I'm so glad that you rectified my mind This will be an everlasting love for me Loving you is some kind of wonderful Because you've shown me just how much you care You've given me the thrill of a lifetime And made me believe you've got more thrills to spare This will be an everlasting love Oh yes it will now You've brought a lot of sunshine into my life You filled me with happiness I never knew You gave me more joy than I ever dreamed of And no one, no one can take the place of you This will be You and me Yessirree Eternally Hugging and squeezing and kissing and pleasing Together forever through rain and whatever Yeah Yeah Yeah Yeah You and me So long as I'm living true love I'll be giving To you I'll be saving 'cause you're so deserving Hey You're so deserving You're so deserving Yeah Yeah Yeah Oh ... Love Love Love Love ... From now on, From now on, From now on, From now on ...<br /><a href="http://www.e-brzdac.com/tag/Pop">Pop</a> <a href="http://www.e-brzdac.com/tag/70s">70s</a> <a href="http://www.e-brzdac.com/tag/US">US</a> <a href="http://www.e-brzdac.com/tag/Natalie">Natalie</a> <a href="http://www.e-brzdac.com/tag/Cole">Cole</a> <a href="http://www.e-brzdac.com/tag/This">This</a> <a href="http://www.e-brzdac.com/tag/will">will</a> <a href="http://www.e-brzdac.com/tag/be">be</a> <a href="http://www.e-brzdac.com/tag/an">an</a> <a href="http://www.e-brzdac.com/tag/everlasting">everlasting</a> <a href="http://www.e-brzdac.com/tag/love">love</a> <a href="http://www.e-brzdac.com/tag/the">the</a> <a href="http://www.e-brzdac.com/tag/one">one</a> <a href="http://www.e-brzdac.com/tag/I%27ve">I've</a> <a href="http://www.e-brzdac.com/tag/waited">waited</a> <a href="http://www.e-brzdac.com/tag/for">for</a> <a href="http://www.e-brzdac.com/tag/first">first</a> <a href="http://www.e-brzdac.com/tag/time">time</a> <a href="http://www.e-brzdac.com/tag/anyone">anyone</a> <a href="http://www.e-brzdac.com/tag/has">has</a> <a href="http://www.e-brzdac.com/tag/loved">loved</a> <a href="http://www.e-brzdac.com/tag/me">me</a> <a href="http://www.e-brzdac.com/tag/1975">1975</a> <a href="http://www.e-brzdac.com/tag/I%27m">I'm</a> <a href="http://www.e-brzdac.com/tag/so">so</a> <a href="http://www.e-brzdac.com/tag/glad">glad</a> <a href="http://www.e-brzdac.com/tag/you">you</a> <a href="http://www.e-brzdac.com/tag/found">found</a> <a href="http://www.e-brzdac.com/tag/in">in</a> <a href="http://www.e-brzdac.com/tag/And">And</a> <a href="http://www.e-brzdac.com/tag/that">that</a> <a href="http://www.e-brzdac.com/tag/rectified">rectified</a> <a href="http://www.e-brzdac.com/tag/my">my</a> <a href="http://www.e-brzdac.com/tag/mind">mind</a> <a href="http://www.e-brzdac.com/tag/fritz">fritz</a> <a href="http://www.e-brzdac.com/tag/51347">51347</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/wgQq8TTty9A.html">will i - rent</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/wgQq8TTty9A/0.jpg" /><br />Will I lose my dignity will someone care will i wake tomorrow from this nightmare<br /><a href="http://www.e-brzdac.com/tag/will">will</a> <a href="http://www.e-brzdac.com/tag/rent">rent</a> <a href="http://www.e-brzdac.com/tag/Jean">Jean</a> <a href="http://www.e-brzdac.com/tag/8686">8686</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/uzUozo1628U.html">Will Smith - Switch</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/uzUozo1628U/0.jpg" /><br />Music video by Will Smith performing Switch. (C) 2004 Interscope Records<br /><a href="http://www.e-brzdac.com/tag/Will">Will</a> <a href="http://www.e-brzdac.com/tag/Smith">Smith</a> <a href="http://www.e-brzdac.com/tag/Overbrook%2FInterscope">Overbrook/Interscope</a> <a href="http://www.e-brzdac.com/tag/Hip">Hip</a> <a href="http://www.e-brzdac.com/tag/Hop">Hop</a> <a href="http://www.e-brzdac.com/tag/VEVO">VEVO</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/dXLpXu9T7j0.html">TV On The Radio - Will Do</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/dXLpXu9T7j0/0.jpg" /><br />Music video by TV On The Radio performing Will Do. (C) 2011 Interscope Records<br /><a href="http://www.e-brzdac.com/tag/TV">TV</a> <a href="http://www.e-brzdac.com/tag/On">On</a> <a href="http://www.e-brzdac.com/tag/The">The</a> <a href="http://www.e-brzdac.com/tag/Radio">Radio</a> <a href="http://www.e-brzdac.com/tag/Will">Will</a> <a href="http://www.e-brzdac.com/tag/Do">Do</a> <a href="http://www.e-brzdac.com/tag/DGC%2FInterscope">DGC/Interscope</a> <a href="http://www.e-brzdac.com/tag/Alternative">Alternative</a> <a href="http://www.e-brzdac.com/tag/tvon">tvon</a> <a href="http://www.e-brzdac.com/tag/VEVO">VEVO</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/f4K6ZxDwi34.html">Rammstein - Ich Will</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/f4K6ZxDwi34/0.jpg" /><br />Give A Beer: nov.io I want - Rammstein &quot;Ich will&quot; (German for I want) With the english lyrics I want I want you to trust me I want you to believe me I want to feel your eyes on me I want to control every heartbeat I want to hear your voices I want to disturb the peace I want you to see me well I want you to understand me I want your fantasy I want your energy I want to see your hands I want to go down in applause Do you see me? Do you understand me? Do you feel me? Do you hear me? Can you hear me? (We hear you) Can you see me? (We see you) Can you feel me? (We feel you) I don't understand you I want We want you to trust us We want you to believe everything from us We want to see your hands We want to go down in applause - yeah Can you hear me? (We hear you) Can you see me? (We see you) Can you feel me? (We feel you) I can't hear you Can you hear us? (We hear you) Can you see us? (We see you) Can you feel us? (We feel you) I can't hear you I want<br /><a href="http://www.e-brzdac.com/tag/Ich">Ich</a> <a href="http://www.e-brzdac.com/tag/Will">Will</a> <a href="http://www.e-brzdac.com/tag/Rammstein">Rammstein</a> <a href="http://www.e-brzdac.com/tag/video">video</a> <a href="http://www.e-brzdac.com/tag/Want">Want</a> <a href="http://www.e-brzdac.com/tag/rock">rock</a> <a href="http://www.e-brzdac.com/tag/alternative">alternative</a> <a href="http://www.e-brzdac.com/tag/world">world</a> <a href="http://www.e-brzdac.com/tag/music">music</a> <a href="http://www.e-brzdac.com/tag/teil">teil</a> <a href="http://www.e-brzdac.com/tag/nazi">nazi</a> <a href="http://www.e-brzdac.com/tag/jew">jew</a> <a href="http://www.e-brzdac.com/tag/necenzurat">necenzurat</a> <a href="http://www.e-brzdac.com/tag/thenecenzurat">thenecenzurat</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/ht7mvCg2DYY.html">Camp Rock / Who Will I Be FULL HQ w/LYRICS</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/ht7mvCg2DYY/0.jpg" /><br />==== LYRICS HERE ==== See my other videos for see ALL the songs from Camp Rock Soundtrack FULL and in HQ! Mitchie Torres / Demi Lovato LYRICS Whoa... Yeah.Yeah.Yeah.Yeah! How to choose? Who to be? Well let's see There are so many choices now Play guitar, be a movie star In my head a voice says Why not, try everything? Why stop, reach for any dream? I can rock, 'cuz it's my life. And now's the time Who will i be? It's up to me All the never-ending possibilities That I can see There's nothing that i can't do Who will i be? Yes, I believe I get to make the future what I want to If I can become anyone and know the choice is up to me Who will I be? Yeah yeah.. If I decide, I'm the girl to change the world I can do it any time. Opportunity right in front of me And the choice is all mine Why not, try everything? Why stop, reach for any dream? I can rock, cause it's my life. And now's the time Who will i be? It's up to me All the never ending possibilities That I can see There's nothing that i can't do Who will i be? Yes, I believe I get to make the future what I want to If I can become anyone and know the choice is up to me Who will I be? I wanna find the who I am inside. Who will I be? I wanna show the, the way that I can shine... Yeah...Oh yeah..yeah.. Who will i be? It's up to me All the never ending possibilities That I can see There's nothing that i can't do Who will i be? Yes, I believe I get to make the future what I want to If I can become anyone and know the choice is &lt;b&gt;...&lt;/b&gt;<br /><a href="http://www.e-brzdac.com/tag/camp">camp</a> <a href="http://www.e-brzdac.com/tag/rock">rock</a> <a href="http://www.e-brzdac.com/tag/who">who</a> <a href="http://www.e-brzdac.com/tag/will">will</a> <a href="http://www.e-brzdac.com/tag/be">be</a> <a href="http://www.e-brzdac.com/tag/jonas">jonas</a> <a href="http://www.e-brzdac.com/tag/brothers">brothers</a> <a href="http://www.e-brzdac.com/tag/demi">demi</a> <a href="http://www.e-brzdac.com/tag/lovato">lovato</a> <a href="http://www.e-brzdac.com/tag/full">full</a> <a href="http://www.e-brzdac.com/tag/hq">hq</a> <a href="http://www.e-brzdac.com/tag/lyrics">lyrics</a> <a href="http://www.e-brzdac.com/tag/julisol">julisol</a> <a href="http://www.e-brzdac.com/tag/902401">902401</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/ZBR2G-iI3-I.html">I Will Survive</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/ZBR2G-iI3-I/0.jpg" /><br />Gloria Gaynor I Will Survive At first I was afraid I was petrified. Kept thinking I could never live without you by my side. But then I spent so many nights Thinking how you did me wrong. And I grew strong! And I learned how to get along! So now you're back from out of space. I just walked in to find you here with that sad look upon your face. I should have changed that stupid lock! I should have made you leave your key! If I had known for just one second you'd be back to bother me. Go on now, go, walk out that door! Just turn around now‚ cause you're not welcome any more. Weren't you the one who tried to hurt (crush) me with goodbye? Did I crumble Did I lay down and die Oh no, not I! I will survive! Oh and as long as I know how to love I know I stay alive. I've got all my life to live, I've got all my love to give. And I'll survive! I will survive! Hey, hey. It took all the strength I had not to fall apart. Kept tryin' hard to mend the pieces of my broken heart! And I spent oh so many nights just feeling sorry for myself. I used to cry! But now I hold my head up high. And you see me somebody new! I'm not that chained-up little person still in love with you. And so you feel like droppin' in, and just expect me to be free, now I'm saving all my loving for someone who is loving me! Go on now...<br /><a href="http://www.e-brzdac.com/tag/Gloria">Gloria</a> <a href="http://www.e-brzdac.com/tag/Gaynor">Gaynor</a> <a href="http://www.e-brzdac.com/tag/I">I</a> <a href="http://www.e-brzdac.com/tag/Will">Will</a> <a href="http://www.e-brzdac.com/tag/Survive">Survive</a> <a href="http://www.e-brzdac.com/tag/Wesley">Wesley</a> <a href="http://www.e-brzdac.com/tag/Tai">Tai</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/euzLGUmb2MM.html">Radiohead - I Will</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/euzLGUmb2MM/0.jpg" /><br />faizal.iits.com.my Radiohead - I Will<br /><a href="http://www.e-brzdac.com/tag/Radiohead">Radiohead</a> <a href="http://www.e-brzdac.com/tag/i%27ll">i'll</a> <a href="http://www.e-brzdac.com/tag/muhammadfaizalahmad">muhammadfaizalahmad</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/cJjORU0lLwA.html">Leona Lewis - I Will Be</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/cJjORU0lLwA/0.jpg" /><br />Yet another leaked track from the spirit album!!<br /><a href="http://www.e-brzdac.com/tag/xfactor">xfactor</a> <a href="http://www.e-brzdac.com/tag/leona">leona</a> <a href="http://www.e-brzdac.com/tag/leonalewis">leonalewis</a> <a href="http://www.e-brzdac.com/tag/sprit">sprit</a> <a href="http://www.e-brzdac.com/tag/Prit">Prit</a> <a href="http://www.e-brzdac.com/tag/Luvz">Luvz</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/2OSKE6LB848.html">Christina Aguilera - I Will Be (Lyrics + Download link)</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/2OSKE6LB848/0.jpg" /><br />Download mp3: www.zshare.net Lyrics: The world seems so cold When I face so much all alone A little scared to move on And knowing how fast I have grown And I wonder just where I fit in Hold a vision of life in my head Oh yes I will be Strong on my own I will see through the rain I will find my way I will keep on Traveling this road Till I finally reach my dream Till I'm living, and I'm breathing My destiny, yeah yeah I can't let go now Even when darkness surrounds But if I hold on, yeah I will show the world All the things that you never expected to see From little old me, this pittsburgh girl And I wonder just where my place is Close my eyes and I remind myself this Oh yeah yeah I will be Strong on my own I will see through the rain I will find my way I will keep on Traveling this road Till I finally reach my dream Till I'm living, and I'm breathing My destiny, ohh It comforts me Ooh it keeps me Alive each day of my life Always guiding me Providing me With the hope I desperately need Well I gotta believe There's something out there meant for me Oh I get on my knees Praying I will receive The courage to grow and the faith to know That I will be Strong on my own I will see through the rain I will find my way I will keep on Traveling this road Till I finally reach my dream Till I'm living, and I'm breathing My destiny<br /><a href="http://www.e-brzdac.com/tag/Christina">Christina</a> <a href="http://www.e-brzdac.com/tag/Aguilera">Aguilera</a> <a href="http://www.e-brzdac.com/tag/Will">Will</a> <a href="http://www.e-brzdac.com/tag/Be">Be</a> <a href="http://www.e-brzdac.com/tag/onlybalto">onlybalto</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/oSbSK1WNtXs.html">Jimmy Wayne - I Will</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/oSbSK1WNtXs/0.jpg" /><br />Music video by Jimmy Wayne performing I Will. (C) 2008 The Valory Music Co.<br /><a href="http://www.e-brzdac.com/tag/Jimmy">Jimmy</a> <a href="http://www.e-brzdac.com/tag/Wayne">Wayne</a> <a href="http://www.e-brzdac.com/tag/The">The</a> <a href="http://www.e-brzdac.com/tag/Valory">Valory</a> <a href="http://www.e-brzdac.com/tag/Music">Music</a> <a href="http://www.e-brzdac.com/tag/Co.">Co.</a> <a href="http://www.e-brzdac.com/tag/Country">Country</a> <a href="http://www.e-brzdac.com/tag/VEVO">VEVO</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/nIjVuRTm-dc.html">Maroon 5 - She Will Be Loved</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/nIjVuRTm-dc/0.jpg" /><br />Music video by Maroon 5 performing She Will Be Loved. (C) 2004 OctoScope Music, LLC<br /><a href="http://www.e-brzdac.com/tag/Maroon">Maroon</a> <a href="http://www.e-brzdac.com/tag/A%26amp%3BM">A&amp;M</a> <a href="http://www.e-brzdac.com/tag/Octone">Octone</a> <a href="http://www.e-brzdac.com/tag/Records">Records</a> <a href="http://www.e-brzdac.com/tag/Pop">Pop</a> <a href="http://www.e-brzdac.com/tag/VEVO">VEVO</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/iAP9AF6DCu4.html">The Calling - Wherever You Will Go</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/iAP9AF6DCu4/0.jpg" /><br />Music video by The Calling performing Wherever You Will Go. (C) 2001 BMG<br /><a href="http://www.e-brzdac.com/tag/The">The</a> <a href="http://www.e-brzdac.com/tag/Calling">Calling</a> <a href="http://www.e-brzdac.com/tag/RCA">RCA</a> <a href="http://www.e-brzdac.com/tag/Records">Records</a> <a href="http://www.e-brzdac.com/tag/Label">Label</a> <a href="http://www.e-brzdac.com/tag/Pop">Pop</a> <a href="http://www.e-brzdac.com/tag/VEVO">VEVO</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/AzvSP8kx0JU.html">Who Will I Be- Demi Lovato (Mitchie Torres)</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/AzvSP8kx0JU/0.jpg" /><br />please comment/rate/subscribe/fav i worked really hard and i spent 4 hours just downloading the movie so yea ! i tried to make it as good as i could with the clipss some parts go togetherr thankss ! oh and I LOVE CAMP ROCK !!!! Credits demi lovato Camp Rock Disney Windows Movie Maker<br /><a href="http://www.e-brzdac.com/tag/demi">demi</a> <a href="http://www.e-brzdac.com/tag/lovato">lovato</a> <a href="http://www.e-brzdac.com/tag/therealdemilovato">therealdemilovato</a> <a href="http://www.e-brzdac.com/tag/selena">selena</a> <a href="http://www.e-brzdac.com/tag/gomez">gomez</a> <a href="http://www.e-brzdac.com/tag/camp">camp</a> <a href="http://www.e-brzdac.com/tag/rock">rock</a> <a href="http://www.e-brzdac.com/tag/who">who</a> <a href="http://www.e-brzdac.com/tag/will">will</a> <a href="http://www.e-brzdac.com/tag/be">be</a> <a href="http://www.e-brzdac.com/tag/mitchie">mitchie</a> <a href="http://www.e-brzdac.com/tag/torres">torres</a> <a href="http://www.e-brzdac.com/tag/disney">disney</a> <a href="http://www.e-brzdac.com/tag/clips">clips</a> <a href="http://www.e-brzdac.com/tag/movie">movie</a> <a href="http://www.e-brzdac.com/tag/windows">windows</a> <a href="http://www.e-brzdac.com/tag/maker">maker</a> <a href="http://www.e-brzdac.com/tag/Musicluva">Musicluva</a> <a href="http://www.e-brzdac.com/tag/132">132</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/Tth-8wA3PdY.html">I will survive - Gloria Gaynor</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/Tth-8wA3PdY/0.jpg" /><br />*If you like the songs I upload, please subscribe, but all credit for the songs must be directed towards their respective owners. No credit for the songs themselves is taken by myself, I only make the songs available to other youtube users*<br /><a href="http://www.e-brzdac.com/tag/70%27s">70's</a> <a href="http://www.e-brzdac.com/tag/gloria">gloria</a> <a href="http://www.e-brzdac.com/tag/gaynor">gaynor</a> <a href="http://www.e-brzdac.com/tag/music">music</a> <a href="http://www.e-brzdac.com/tag/classics">classics</a> <a href="http://www.e-brzdac.com/tag/hits">hits</a> <a href="http://www.e-brzdac.com/tag/70">70</a> <a href="http://www.e-brzdac.com/tag/sand">sand</a> <a href="http://www.e-brzdac.com/tag/80">80</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/0K2r5mmktLc.html">Natalia Kills - Free ft. will.i.am</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/0K2r5mmktLc/0.jpg" /><br />Natalia Kills performing Free. (C) 2011 Interscope Records<br /><a href="http://www.e-brzdac.com/tag/Natalia">Natalia</a> <a href="http://www.e-brzdac.com/tag/Kills">Kills</a> <a href="http://www.e-brzdac.com/tag/Free">Free</a> <a href="http://www.e-brzdac.com/tag/Will">Will</a> <a href="http://www.e-brzdac.com/tag/Am">Am</a> <a href="http://www.e-brzdac.com/tag/A%26amp%3BM">A&amp;M</a> <a href="http://www.e-brzdac.com/tag/Pop">Pop</a> <a href="http://www.e-brzdac.com/tag/VEVO">VEVO</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/cyVzjoj96vs.html">Sesame Street: Will.i.am's Song &quot;What I Am&quot;</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/cyVzjoj96vs/0.jpg" /><br />Will.i.am sings &quot;What I Am&quot; as part of Sesame Street's 41st season premiering September 27th on PBS KIDS. If you're watching videos with your preschooler and would like to do so in a safe, child-friendly environment, please join us at www.sesamestreet.org Sesame Street is a production of Sesame Workshop, a nonprofit educational organization which also produces Pinky Dinky Doo, The Electric Company, and other programs for children around the world.<br /><a href="http://www.e-brzdac.com/tag/sesame+street">sesame street</a> <a href="http://www.e-brzdac.com/tag/will.i.am">will.i.am</a> <a href="http://www.e-brzdac.com/tag/sings+song">sings song</a> <a href="http://www.e-brzdac.com/tag/what+i+am">what i am</a> <a href="http://www.e-brzdac.com/tag/elmo">elmo</a> <a href="http://www.e-brzdac.com/tag/big+bird">big bird</a> <a href="http://www.e-brzdac.com/tag/muppets">muppets</a> <a href="http://www.e-brzdac.com/tag/zoe">zoe</a> <a href="http://www.e-brzdac.com/tag/rosita">rosita</a> <a href="http://www.e-brzdac.com/tag/abby">abby</a> <a href="http://www.e-brzdac.com/tag/will+i+am">will i am</a> <a href="http://www.e-brzdac.com/tag/black+eyed+peas">black eyed peas</a> <a href="http://www.e-brzdac.com/tag/Sesame">Sesame</a> <a href="http://www.e-brzdac.com/tag/Street">Street</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/c9erHKnztSA.html">TV On The Radio - Will Do (audio)</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/c9erHKnztSA/0.jpg" /><br />Buy: TV On The Radio - Will Do goo.gl TV On The Radio - Nine Types Of Light In Stores April 12, 2011 tvontheradio.com http facebook.com #ninetypesoflight<br /><a href="http://www.e-brzdac.com/tag/TV+On+The+Radio">TV On The Radio</a> <a href="http://www.e-brzdac.com/tag/Will+Do">Will Do</a> <a href="http://www.e-brzdac.com/tag/Nine+Types+of+Light">Nine Types of Light</a> <a href="http://www.e-brzdac.com/tag/%23ninetypesoflight">#ninetypesoflight</a> <a href="http://www.e-brzdac.com/tag/Brooklyn">Brooklyn</a> <a href="http://www.e-brzdac.com/tag/New+York">New York</a> <a href="http://www.e-brzdac.com/tag/Dave+Sitek">Dave Sitek</a> <a href="http://www.e-brzdac.com/tag/Tunde+Adebimpe">Tunde Adebimpe</a> <a href="http://www.e-brzdac.com/tag/Kyp+Malone">Kyp Malone</a> <a href="http://www.e-brzdac.com/tag/Jaleel+Bunton">Jaleel Bunton</a> <a href="http://www.e-brzdac.com/tag/Gerard+Smith">Gerard Smith</a> <a href="http://www.e-brzdac.com/tag/Interscope">Interscope</a> <a href="http://www.e-brzdac.com/tag/Geffen">Geffen</a> <a href="http://www.e-brzdac.com/tag/AM">AM</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/1RnPB76mjxI.html">Usher - OMG ft. will.i.am</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/1RnPB76mjxI/0.jpg" /><br />Music video by Usher featuring will.i.am performing OMG. (C) 2010 LaFace Records, a unit of Sony Music Entertainment<br /><a href="http://www.e-brzdac.com/tag/Usher">Usher</a> <a href="http://www.e-brzdac.com/tag/featuring">featuring</a> <a href="http://www.e-brzdac.com/tag/will.i.am">will.i.am</a> <a href="http://www.e-brzdac.com/tag/laface">laface</a> <a href="http://www.e-brzdac.com/tag/Records">Records</a> <a href="http://www.e-brzdac.com/tag/R%26amp%3BB">R&amp;B</a> <a href="http://www.e-brzdac.com/tag/VEVO">VEVO</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/lswB6q2t_6c.html">Natalie Cole - This Will Be (An Everlasting Love)</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/lswB6q2t_6c/0.jpg" /><br />(C) 1975 WMG All copyright claims go to its rightful owner. This song is for entertainment purposes only. Please enjoy! Rightfully owned by: WMG<br /><a href="http://www.e-brzdac.com/tag/Natalie">Natalie</a> <a href="http://www.e-brzdac.com/tag/Cole">Cole</a> <a href="http://www.e-brzdac.com/tag/Kah">Kah</a> <a href="http://www.e-brzdac.com/tag/Pow">Pow</a> <a href="http://www.e-brzdac.com/tag/84">84</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/ZlShC-GxFNw.html">The Beatles - I Will</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/ZlShC-GxFNw/0.jpg" /><br />My New Channel : www.youtube.com Clips from live performances<br /><a href="http://www.e-brzdac.com/tag/The">The</a> <a href="http://www.e-brzdac.com/tag/beatles">beatles</a> <a href="http://www.e-brzdac.com/tag/white">white</a> <a href="http://www.e-brzdac.com/tag/album">album</a> <a href="http://www.e-brzdac.com/tag/will">will</a> <a href="http://www.e-brzdac.com/tag/lennon">lennon</a> <a href="http://www.e-brzdac.com/tag/mccartney">mccartney</a> <a href="http://www.e-brzdac.com/tag/ringo">ringo</a> <a href="http://www.e-brzdac.com/tag/harrison">harrison</a> <a href="http://www.e-brzdac.com/tag/joaped">joaped</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/zUJqYx4Z9js.html">will.i.am - Heartbreaker ft. Cheryl Cole</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/zUJqYx4Z9js/0.jpg" /><br />Music video by will.i.am performing Heartbreaker. (C) 2008 Interscope Records<br /><a href="http://www.e-brzdac.com/tag/will.i.am">will.i.am</a> <a href="http://www.e-brzdac.com/tag/Interscope">Interscope</a> <a href="http://www.e-brzdac.com/tag/Pop">Pop</a> <a href="http://www.e-brzdac.com/tag/william">william</a> <a href="http://www.e-brzdac.com/tag/VEVO">VEVO</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/eOofWzI3flA.html">Skrillex - Rock n Roll (Will Take You to the Mountain)</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/eOofWzI3flA/0.jpg" /><br />Here's a video shot from the last eight months of touring I've done... Took a long time to edit this down and pick the right shots since there were too many good times to choose from. Hope you enjoy this... -Skril (Download this track atlr.ec Download this track atlr.ec Directed by Jason Ano for One &amp; Only Productions Additional footage provided by Cru Joness &copy; 2011 WMG<br /><a href="http://www.e-brzdac.com/tag/touring+official+Captain+Ahab">touring official Captain Ahab</a> <a href="http://www.e-brzdac.com/tag/The">The</a> <a href="http://www.e-brzdac.com/tag/Official">Official</a> <a href="http://www.e-brzdac.com/tag/Skrillex">Skrillex</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/m3-hY-hlhBg.html">Whitney Houston - How Will I Know</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/m3-hY-hlhBg/0.jpg" /><br />Music video by Whitney Houston performing How Will I Know. (C) 1991 Arista Records, Inc.<br /><a href="http://www.e-brzdac.com/tag/Whitney">Whitney</a> <a href="http://www.e-brzdac.com/tag/Houston">Houston</a> <a href="http://www.e-brzdac.com/tag/Arista">Arista</a> <a href="http://www.e-brzdac.com/tag/Pop">Pop</a> <a href="http://www.e-brzdac.com/tag/whitneyhouston">whitneyhouston</a> <a href="http://www.e-brzdac.com/tag/VEVO">VEVO</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/pMLH1av5o1c.html">Demi Lovato- Who Will I Be (with Lyrics)</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/pMLH1av5o1c/0.jpg" /><br />myspace.com/callmeshady Woaahh, oh Yeah, yeah, yeah, yeah! How to choose who to be, well let's see There's so many choices now Play guitar, be a movie star In my head, a voice says Why not try everything Why stop reach for any dream I can rock cuz it's my life And now's the time Who will I be It's up to me All the never-ending possibilities That I can see There's nothing that I can't do Who will I be Yes, I believe I get to make the future what I want to If I can become anyone and know the choice is up to me Who will I be Yeah, yeah! If I decide I'm the girl to change the world I can do it anytime Oppurtunity right in front of me And the choice is all mine Why not try everything Why stop reach for any dream I can rock cuz it's my life And now's the time Who will I be It's up to me All the never-ending possibilities That I can see There's nothing that I can't do Who will I be Yes, I believe I get to make the future what I want to If I can become anyone and know the choice is up to me Who will I be I want to find that who I am inside Who will I be I want to show that the way that I can shine Yeah Woahh, yeah Who will I be It's up to me All the neverending possibilities And I can see There's nothing that I can't do Who will I be (yeah) As I believe I get to make the future what I want to If I can think of anyone that know the choice is up to me (yeah) Who will I be Woah, oh. Who will I be Who will I be!<br /><a href="http://www.e-brzdac.com/tag/demi">demi</a> <a href="http://www.e-brzdac.com/tag/lovato">lovato</a> <a href="http://www.e-brzdac.com/tag/camp">camp</a> <a href="http://www.e-brzdac.com/tag/rock">rock</a> <a href="http://www.e-brzdac.com/tag/who">who</a> <a href="http://www.e-brzdac.com/tag/will">will</a> <a href="http://www.e-brzdac.com/tag/be">be</a> <a href="http://www.e-brzdac.com/tag/with">with</a> <a href="http://www.e-brzdac.com/tag/lyrics">lyrics</a> <a href="http://www.e-brzdac.com/tag/full">full</a> <a href="http://www.e-brzdac.com/tag/song">song</a> <a href="http://www.e-brzdac.com/tag/mitchie">mitchie</a> <a href="http://www.e-brzdac.com/tag/torres">torres</a> <a href="http://www.e-brzdac.com/tag/callmeshady">callmeshady</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/pqky5B179nM.html">will.i.am, Nicki Minaj - Check It Out</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/pqky5B179nM/0.jpg" /><br />Music video by will.i.am, Nicki Minaj performing Check It Out. (C) 2010 Interscope Records iTunes UK bit.ly - includes a version featuring Cheryl Cole<br /><a href="http://www.e-brzdac.com/tag/Check">Check</a> <a href="http://www.e-brzdac.com/tag/it">it</a> <a href="http://www.e-brzdac.com/tag/out">out</a> <a href="http://www.e-brzdac.com/tag/video">video</a> <a href="http://www.e-brzdac.com/tag/will">will</a> <a href="http://www.e-brzdac.com/tag/and">and</a> <a href="http://www.e-brzdac.com/tag/nicki">nicki</a> <a href="http://www.e-brzdac.com/tag/black">black</a> <a href="http://www.e-brzdac.com/tag/eyed">eyed</a> <a href="http://www.e-brzdac.com/tag/peas">peas</a> <a href="http://www.e-brzdac.com/tag/minaj">minaj</a> <a href="http://www.e-brzdac.com/tag/pink">pink</a> <a href="http://www.e-brzdac.com/tag/Friday">Friday</a> <a href="http://www.e-brzdac.com/tag/will.i.am">will.i.am</a> <a href="http://www.e-brzdac.com/tag/rich">rich</a> <a href="http://www.e-brzdac.com/tag/lee">lee</a> <a href="http://www.e-brzdac.com/tag/Korean">Korean</a> <a href="http://www.e-brzdac.com/tag/william">william</a> <a href="http://www.e-brzdac.com/tag/VEVO">VEVO</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/GK5O5-LPB7g.html">Wolfgang Gartner feat. will.i.am - Forever (Official Video)</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/GK5O5-LPB7g/0.jpg" /><br />Buy the single here: goo.gl UK fans download now: bit.ly Buy the remixes here: goo.gl Wolfgang Gartner feat. will.i.am - Forever Ultra Records www.ultrarecords.com<br /><a href="http://www.e-brzdac.com/tag/Wolfgang">Wolfgang</a> <a href="http://www.e-brzdac.com/tag/Gartner">Gartner</a> <a href="http://www.e-brzdac.com/tag/feat.">feat.</a> <a href="http://www.e-brzdac.com/tag/will.i.am">will.i.am</a> <a href="http://www.e-brzdac.com/tag/Forever">Forever</a> <a href="http://www.e-brzdac.com/tag/ultra">ultra</a> <a href="http://www.e-brzdac.com/tag/records">records</a> <a href="http://www.e-brzdac.com/tag/official">official</a> <a href="http://www.e-brzdac.com/tag/video">video</a> <a href="http://www.e-brzdac.com/tag/dance">dance</a> <a href="http://www.e-brzdac.com/tag/house">house</a> <a href="http://www.e-brzdac.com/tag/trance">trance</a> <a href="http://www.e-brzdac.com/tag/pop">pop</a> <a href="http://www.e-brzdac.com/tag/electro">electro</a> <a href="http://www.e-brzdac.com/tag/hip">hip</a> <a href="http://www.e-brzdac.com/tag/hop">hop</a> <a href="http://www.e-brzdac.com/tag/rap">rap</a> <a href="http://www.e-brzdac.com/tag/black">black</a> <a href="http://www.e-brzdac.com/tag/eyed">eyed</a> <a href="http://www.e-brzdac.com/tag/peas">peas</a> <a href="http://www.e-brzdac.com/tag/will">will</a> <a href="http://www.e-brzdac.com/tag/am">am</a> <a href="http://www.e-brzdac.com/tag/william">william</a> <a href="http://www.e-brzdac.com/tag/sperm">sperm</a> <a href="http://www.e-brzdac.com/tag/sex">sex</a> <a href="http://www.e-brzdac.com/tag/skateboarding">skateboarding</a> <a href="http://www.e-brzdac.com/tag/old">old</a> <a href="http://www.e-brzdac.com/tag/senior">senior</a> <a href="http://www.e-brzdac.com/tag/citizen">citizen</a> <a href="http://www.e-brzdac.com/tag/home">home</a> <a href="http://www.e-brzdac.com/tag/life">life</a> <a href="http://www.e-brzdac.com/tag/baby">baby</a> <a href="http://www.e-brzdac.com/tag/pool">pool</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/XomQLhjCYYk.html">will.i.am - I Got It From My Mama</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/XomQLhjCYYk/0.jpg" /><br />Music video by will.i.am performing I Got It From My Mama. (C) 2007 Interscope Records<br /><a href="http://www.e-brzdac.com/tag/will.i.am">will.i.am</a> <a href="http://www.e-brzdac.com/tag/Interscope">Interscope</a> <a href="http://www.e-brzdac.com/tag/Pop">Pop</a> <a href="http://www.e-brzdac.com/tag/william">william</a> <a href="http://www.e-brzdac.com/tag/VEVO">VEVO</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/1A3Yh2l4D28.html">I Will-Beatles Cover</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/1A3Yh2l4D28/0.jpg" /><br />Singing a favorite Beatles song for my dad. :) Happy labor day!<br /><a href="http://www.e-brzdac.com/tag/Jasmine">Jasmine</a> <a href="http://www.e-brzdac.com/tag/Commerce">Commerce</a> <a href="http://www.e-brzdac.com/tag/Beatles">Beatles</a> <a href="http://www.e-brzdac.com/tag/Will">Will</a> <a href="http://www.e-brzdac.com/tag/cover">cover</a> <a href="http://www.e-brzdac.com/tag/for">for</a> <a href="http://www.e-brzdac.com/tag/dad">dad</a> <a href="http://www.e-brzdac.com/tag/labor">labor</a> <a href="http://www.e-brzdac.com/tag/day">day</a> <a href="http://www.e-brzdac.com/tag/2008">2008</a> <a href="http://www.e-brzdac.com/tag/jasminecommercemusic">jasminecommercemusic</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/33YcYLumEDk.html">(Titanic Theme) My Heart Will Go On - Sungha Jung</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/33YcYLumEDk/0.jpg" /><br />Sungha Jung 2nd Album 'Irony' now availble at www.sunghajung.com http Sungha's 1st CD'Perfect Blue' is now available. &quot;My Heart Will Go On&quot; is the theme song of the 1997 blockbuster film Titanic. With music by James Horner, lyrics by Will Jennings, and production by Walter Afanasieff, it was recorded by C&eacute;line Dion. Originally released in 1997 on Dion's album Let's Talk About Love, it went to number 1 all over the world, including the United States, United Kingdom and Australia. My Heart Will Go On was released in Australia and Germany on December 8, 1997, and in the rest of the world in January and February 1998.[1] It became one of the best-selling singles of all time, and was the world's best selling single of 1998.<br /><a href="http://www.e-brzdac.com/tag/sungha">sungha</a> <a href="http://www.e-brzdac.com/tag/jung">jung</a> <a href="http://www.e-brzdac.com/tag/titanic">titanic</a> <a href="http://www.e-brzdac.com/tag/%27my">'my</a> <a href="http://www.e-brzdac.com/tag/heart">heart</a> <a href="http://www.e-brzdac.com/tag/will">will</a> <a href="http://www.e-brzdac.com/tag/go">go</a> <a href="http://www.e-brzdac.com/tag/on%27">on'</a> <a href="http://www.e-brzdac.com/tag/celine">celine</a> <a href="http://www.e-brzdac.com/tag/dion">dion</a> <a href="http://www.e-brzdac.com/tag/fingerstyle">fingerstyle</a> <a href="http://www.e-brzdac.com/tag/Sungha%27s">Sungha's</a> <a href="http://www.e-brzdac.com/tag/1st">1st</a> <a href="http://www.e-brzdac.com/tag/CD%27Perfect">CD'Perfect</a> <a href="http://www.e-brzdac.com/tag/Blue%27">Blue'</a> <a href="http://www.e-brzdac.com/tag/is">is</a> <a href="http://www.e-brzdac.com/tag/now">now</a> <a href="http://www.e-brzdac.com/tag/available.">available.</a> <a href="http://www.e-brzdac.com/tag/Visit">Visit</a> <a href="http://www.e-brzdac.com/tag/www.sunghajung.com">www.sunghajung.com</a> <a href="http://www.e-brzdac.com/tag/jwcfree">jwcfree</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/fFwwSARPyWU.html">Demi Lovato--Who Will I Be With Lyrics + Download</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/fFwwSARPyWU/0.jpg" /><br />READ!!!! Download link below(: thanks for all the awesome support! i have like almost 188000 views!! (: its amazing(: more videos will be coming your way(: love you!! :D lol in a friendly way(: Ps. GO Team JACOB!! :D (c)Walt Disney Co. NO COPYRIGHT INTENDED!! uhm i forgot to put in the video that the Credits Song is This Is Me -- Demi Lovato! Plzz subscribe!! and comment! Download Link! www.sendspace.com *got From meg90795*<br /><a href="http://www.e-brzdac.com/tag/Demi">Demi</a> <a href="http://www.e-brzdac.com/tag/Lovato">Lovato</a> <a href="http://www.e-brzdac.com/tag/Who">Who</a> <a href="http://www.e-brzdac.com/tag/Will">Will</a> <a href="http://www.e-brzdac.com/tag/Be">Be</a> <a href="http://www.e-brzdac.com/tag/With">With</a> <a href="http://www.e-brzdac.com/tag/Lyrics">Lyrics</a> <a href="http://www.e-brzdac.com/tag/camp">camp</a> <a href="http://www.e-brzdac.com/tag/rock">rock</a> <a href="http://www.e-brzdac.com/tag/pop">pop</a> <a href="http://www.e-brzdac.com/tag/Dreamgirl">Dreamgirl</a> <a href="http://www.e-brzdac.com/tag/1691">1691</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/fqvMrfnc410.html">Camp Rock- Who will i Be- Lyrics</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/fqvMrfnc410/0.jpg" /><br />Camp Rock- Who will i Be- Lyrics Sorry to Melissaann2658 veiws who love my Randomness. I love Joe jonas!!!!!!!! Camp Rock rulz!!! I can't wait for camp rock 2!!! Camp Rock Lyrics! Camp Rock- Who will i Be- Lyrics<br /><a href="http://www.e-brzdac.com/tag/Camp">Camp</a> <a href="http://www.e-brzdac.com/tag/Rock-">Rock-</a> <a href="http://www.e-brzdac.com/tag/Who">Who</a> <a href="http://www.e-brzdac.com/tag/will">will</a> <a href="http://www.e-brzdac.com/tag/Be-">Be-</a> <a href="http://www.e-brzdac.com/tag/Lyrics">Lyrics</a> <a href="http://www.e-brzdac.com/tag/Melissaann">Melissaann</a> <a href="http://www.e-brzdac.com/tag/2658">2658</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/1r9ghI7YcL0.html">The Pussycat Dolls - Beep ft. will.i.am</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/1r9ghI7YcL0/0.jpg" /><br />Music video by The Pussycat Dolls performing Beep. (C) 2005 A&amp;M Records<br /><a href="http://www.e-brzdac.com/tag/The">The</a> <a href="http://www.e-brzdac.com/tag/Pussycat">Pussycat</a> <a href="http://www.e-brzdac.com/tag/Dolls">Dolls</a> <a href="http://www.e-brzdac.com/tag/Pop">Pop</a> <a href="http://www.e-brzdac.com/tag/VEVO">VEVO</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/ti3CKuU3FRs.html">Lil Wayne Feat. Drake - She Will [New Song 2011]</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/ti3CKuU3FRs/0.jpg" /><br />No Copyright Infringement Intended.<br /><a href="http://www.e-brzdac.com/tag/lil+wayne">lil wayne</a> <a href="http://www.e-brzdac.com/tag/drake">drake</a> <a href="http://www.e-brzdac.com/tag/she+will">she will</a> <a href="http://www.e-brzdac.com/tag/lil+wayne+she+will">lil wayne she will</a> <a href="http://www.e-brzdac.com/tag/drake+she+will">drake she will</a> <a href="http://www.e-brzdac.com/tag/lil+wayne+feat.+drake">lil wayne feat. drake</a> <a href="http://www.e-brzdac.com/tag/she+will+lil+wayne">she will lil wayne</a> <a href="http://www.e-brzdac.com/tag/she+will+drake">she will drake</a> <a href="http://www.e-brzdac.com/tag/lil+wayne+2011">lil wayne 2011</a> <a href="http://www.e-brzdac.com/tag/drake+new+song">drake new song</a> <a href="http://www.e-brzdac.com/tag/she+will+lyrics">she will lyrics</a> <a href="http://www.e-brzdac.com/tag/lyrics+she+will">lyrics she will</a> <a href="http://www.e-brzdac.com/tag/she+will+by+lil+wayne">she will by lil wayne</a> <a href="http://www.e-brzdac.com/tag/she+will+by+drake">she will by drake</a> <a href="http://www.e-brzdac.com/tag/new+song">new song</a> <a href="http://www.e-brzdac.com/tag/new+single">new single</a> <a href="http://www.e-brzdac.com/tag/2011">2011</a> <a href="http://www.e-brzdac.com/tag/lyrics">lyrics</a> <a href="http://www.e-brzdac.com/tag/Fast">Fast</a> <a href="http://www.e-brzdac.com/tag/Music">Music</a> <a href="http://www.e-brzdac.com/tag/HQ">HQ</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/zBUJztI884M.html">Queen - We Will Rock You and We Are The Champion (Live)</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/zBUJztI884M/0.jpg" /><br />Hahahahahaha u guys will love it!!!!<br /><a href="http://www.e-brzdac.com/tag/Queen">Queen</a> <a href="http://www.e-brzdac.com/tag/rock">rock</a> <a href="http://www.e-brzdac.com/tag/live">live</a> <a href="http://www.e-brzdac.com/tag/riverdusk">riverdusk</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/5OFThORmR-s.html">When Will Time End?</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/5OFThORmR-s/0.jpg" /><br />It now seems that our entire universe is living on borrowed time. How long it can survive depends on whether Stephen Hawking's theory checks out. Special thanks to Ivan Bridgewater for use of footage. Time is flying by on this busy, crowded planet... as life changes and evolves from second to second. And yet the arc of human lifespan is getting longer: 65 years is the global average ... way up from just 20 in the Stone Age. Modern science, however, provides a humbling perspective. Our lives... indeed the life span of the human species... is just a blip compared to the age of the universe, at 13.7 billion years and counting. It now seems that our entire universe is living on borrowed time... And that even it may be just a blip within the grand sweep of deep time. Scholars debate whether time is a property of the universe... or a human invention. What's certain is that we use the ticking of all kinds of clocks... from the decay of radioactive elements to the oscillation of light beams... to chart and measure a changing universe... to understand how it works and what drives it. Our own major reference for the passage of time is the 24-hour day... the time it takes the Earth to rotate once. Well, it's actually 23 hours, 56 minutes and 4.1 seconds... approximately... if you're judging by the stars, not the sun. Earth acquired its spin during its birth, from the bombardment of rocks and dust that formed it. But it's gradually losing that rotation to drag from the moon's gravity &lt;b&gt;...&lt;/b&gt;<br /><a href="http://www.e-brzdac.com/tag/black+holes">black holes</a> <a href="http://www.e-brzdac.com/tag/maya">maya</a> <a href="http://www.e-brzdac.com/tag/mayan">mayan</a> <a href="http://www.e-brzdac.com/tag/hawking">hawking</a> <a href="http://www.e-brzdac.com/tag/supernova">supernova</a> <a href="http://www.e-brzdac.com/tag/space">space</a> <a href="http://www.e-brzdac.com/tag/universe">universe</a> <a href="http://www.e-brzdac.com/tag/ufo">ufo</a> <a href="http://www.e-brzdac.com/tag/aliens">aliens</a> <a href="http://www.e-brzdac.com/tag/creation">creation</a> <a href="http://www.e-brzdac.com/tag/solar">solar</a> <a href="http://www.e-brzdac.com/tag/system">system</a> <a href="http://www.e-brzdac.com/tag/2012">2012</a> <a href="http://www.e-brzdac.com/tag/comets">comets</a> <a href="http://www.e-brzdac.com/tag/asteroids">asteroids</a> <a href="http://www.e-brzdac.com/tag/cosmos">cosmos</a> <a href="http://www.e-brzdac.com/tag/cosmic">cosmic</a> <a href="http://www.e-brzdac.com/tag/stars">stars</a> <a href="http://www.e-brzdac.com/tag/galaxies">galaxies</a> <a href="http://www.e-brzdac.com/tag/planets">planets</a> <a href="http://www.e-brzdac.com/tag/nobel">nobel</a> <a href="http://www.e-brzdac.com/tag/mars">mars</a> <a href="http://www.e-brzdac.com/tag/sun">sun</a> <a href="http://www.e-brzdac.com/tag/moon">moon</a> <a href="http://www.e-brzdac.com/tag/earth">earth</a> <a href="http://www.e-brzdac.com/tag/greeks">greeks</a> <a href="http://www.e-brzdac.com/tag/adam">adam</a> <a href="http://www.e-brzdac.com/tag/eve">eve</a> <a href="http://www.e-brzdac.com/tag/bible">bible</a> <a href="http://www.e-brzdac.com/tag/nasa">nasa</a> <a href="http://www.e-brzdac.com/tag/doomsday">doomsday</a> <a href="http://www.e-brzdac.com/tag/hubble">hubble</a> <a href="http://www.e-brzdac.com/tag/science">science</a> <a href="http://www.e-brzdac.com/tag/religion">religion</a> <a href="http://www.e-brzdac.com/tag/computers">computers</a> <a href="http://www.e-brzdac.com/tag/nature">nature</a> <a href="http://www.e-brzdac.com/tag/outdoors">outdoors</a> <a href="http://www.e-brzdac.com/tag/Rip">Rip</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/xZbKHDPPrrc.html">Doris Day - Que Sera Sera</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/xZbKHDPPrrc/0.jpg" /><br />When I was just a little girl I asked my mother what will I be Will I be pretty will I be rich Here's what she said to me Que Sera Sera Whatever will be will be The future's not ours to see Que Sera Sera What will be will be When I grew up and fell in love I asked my sweetheart what lies ahead Will we have rainbows day after day Here's what my sweetheart said Que Sera Sera Whatever will be will be The future's not ours to see Que Sera Sera What will be will be Now I have children of my own They ask their mother what will I be Will I be handsome will I be rich I tell them tenderly Que Sera Sera Whatever will be will be The future's not ours to see Que Sera Sera What will be will be Que Sera Sera<br /><a href="http://www.e-brzdac.com/tag/Doris">Doris</a> <a href="http://www.e-brzdac.com/tag/Day">Day</a> <a href="http://www.e-brzdac.com/tag/Que">Que</a> <a href="http://www.e-brzdac.com/tag/Sera">Sera</a> <a href="http://www.e-brzdac.com/tag/zennmann">zennmann</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/ghSJsEVf0pU.html">We Are The Ones Song by will.i.am - Obama</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/ghSJsEVf0pU/0.jpg" /><br />people say Obama's words are just words... but... when was the last time &quot;words&quot; weren't important...???... when was the last time a great leader didn't use words to lead...??... when was the last time a person didn't use words to describe how they felt...?... when was the last time &quot;words&quot; weren't empowering...?... and we can all recall the last time &quot;words&quot; were used to divide us and install fear... Bush used words to fear us into voting for him the second time around... terror this... terror that... nuclear here... weapons of mass destruction there... and those words effected a lot of people's choices... &quot;enough is enough&quot;... let's rebuild... let's change ourselves... let's allow positivity to guide us... let's take action.... let's activate our passion... we are Americans.... and this is the first time in forever that someone running for president represents &quot;US&quot;... some say this is all excitement... I call it &quot;proud to be an American&quot;... some say this whole Obama movement is &quot;cult like&quot;... well... if it comes across cult like... then... the cult is called America... the Obama movement is connecting America. and it has made &quot;US&quot; realize our importance... the youth is excited and activated... adults are passionate and motivated... the elderly are proud to know the country they built is in safe hands... we are one... for too long politics has been corrupt... separate from the American people... with agendas that go against what the American people &quot;need&quot;... education &lt;b&gt;...&lt;/b&gt;<br /><a href="http://www.e-brzdac.com/tag/We">We</a> <a href="http://www.e-brzdac.com/tag/Are">Are</a> <a href="http://www.e-brzdac.com/tag/The">The</a> <a href="http://www.e-brzdac.com/tag/Ones">Ones</a> <a href="http://www.e-brzdac.com/tag/Song">Song</a> <a href="http://www.e-brzdac.com/tag/by">by</a> <a href="http://www.e-brzdac.com/tag/will.i.am">will.i.am</a> <a href="http://www.e-brzdac.com/tag/Obama">Obama</a> <a href="http://www.e-brzdac.com/tag/Yes">Yes</a> <a href="http://www.e-brzdac.com/tag/Can">Can</a> <a href="http://www.e-brzdac.com/tag/illwilly">illwilly</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/IOfKAPGfd6k.html">Connie Talbot - I will always love you LIVE *High Quality*</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/IOfKAPGfd6k/0.jpg" /><br />Connie talbot in a Tawian Variety show call Millionstars and sing &quot;I will alway love you&quot;<br /><a href="http://www.e-brzdac.com/tag/Connie">Connie</a> <a href="http://www.e-brzdac.com/tag/Talbot">Talbot</a> <a href="http://www.e-brzdac.com/tag/tawian">tawian</a> <a href="http://www.e-brzdac.com/tag/millionstars">millionstars</a> <a href="http://www.e-brzdac.com/tag/ave">ave</a> <a href="http://www.e-brzdac.com/tag/%E5%B0%8F%E5%BA%B7%E5%B0%BCyear">小康尼year</a> <a href="http://www.e-brzdac.com/tag/old">old</a> <a href="http://www.e-brzdac.com/tag/whitney">whitney</a> <a href="http://www.e-brzdac.com/tag/houston">houston</a> <a href="http://www.e-brzdac.com/tag/xdeath">xdeath</a> <a href="http://www.e-brzdac.com/tag/Lo">Lo</a> <a href="http://www.e-brzdac.com/tag/Rdz">Rdz</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/T6fVDAjs9f0.html">-The Three Degrees- -When will see you again-</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/T6fVDAjs9f0/0.jpg" /><br />The very firts record...<br /><a href="http://www.e-brzdac.com/tag/Oldies">Oldies</a> <a href="http://www.e-brzdac.com/tag/Threes">Threes</a> <a href="http://www.e-brzdac.com/tag/Degrees">Degrees</a> <a href="http://www.e-brzdac.com/tag/Easy">Easy</a> <a href="http://www.e-brzdac.com/tag/Music">Music</a> <a href="http://www.e-brzdac.com/tag/36">36</a> </p> </div> </div> <div class="post"> <h2 class="title"><a href="http://www.e-brzdac.com/film/glBwJWdSqCY.html">Monte Montgomery: When Will I</a></h2> <div class="entry"> <p><img src="http://i.ytimg.com/vi/glBwJWdSqCY/0.jpg" /><br />Classic 1999 live TV performance. Check out Monte online at www.montemontgomery.net and http<br /><a href="http://www.e-brzdac.com/tag/Monte">Monte</a> <a href="http://www.e-brzdac.com/tag/Montgomery">Montgomery</a> <a href="http://www.e-brzdac.com/tag/Chris">Chris</a> <a href="http://www.e-brzdac.com/tag/Maresh">Maresh</a> <a href="http://www.e-brzdac.com/tag/Phil">Phil</a> <a href="http://www.e-brzdac.com/tag/Bass">Bass</a> <a href="http://www.e-brzdac.com/tag/Austin">Austin</a> <a href="http://www.e-brzdac.com/tag/Texas">Texas</a> <a href="http://www.e-brzdac.com/tag/live">live</a> <a href="http://www.e-brzdac.com/tag/acoustic">acoustic</a> <a href="http://www.e-brzdac.com/tag/guitar">guitar</a> <a href="http://www.e-brzdac.com/tag/Wonders">Wonders</a> <a href="http://www.e-brzdac.com/tag/Of">Of</a> <a href="http://www.e-brzdac.com/tag/Mona">Mona</a> <a href="http://www.e-brzdac.com/tag/Vie">Vie</a> </p> </div> </div> </div> <div id="sidebar"> <ul> <li> <h2>Losowe filmy</h2> <ul> <li><a href="http://www.e-brzdac.com/6186.html">Młody perkusista (7</a></li> <li><a href="http://www.e-brzdac.com/1619.html">W przymierzalni</a></li> <li><a href="http://www.e-brzdac.com/6128.html">MMA</a></li> <li><a href="http://www.e-brzdac.com/2043.html">Football Skills</a></li> <li><a href="http://www.e-brzdac.com/530.html">Eminem - Mosh</a></li> <li><a href="http://www.e-brzdac.com/3881.html">Korn - Somebody, Som</a></li> <li><a href="http://www.e-brzdac.com/1675.html">Rammstein - Benzin</a></li> <li><a href="http://www.e-brzdac.com/360.html">I like To MOO</a></li> <li><a href="http://www.e-brzdac.com/2446.html">Michael Jackson - Sm</a></li> <li><a href="http://www.e-brzdac.com/5245.html">Świecidełka 2</a></li> </ul></li> <li><h2>Tagi</h2> <ul> <li><a href="http://www.e-brzdac.com/tag/włatcy+m&oacute;ch">Włatcy m&oacute;ch</a></li> <li><a href="http://www.e-brzdac.com/tag/Big+Brother">Big Brother</a></li> <li><a href="http://www.e-brzdac.com/tag/Ferrari">Samochody Ferrari</a></li> <li><a href="http://www.e-brzdac.com/tag/Rihanna">Piosenki Rihanna</a></li> <li><a href="http://www.e-brzdac.com/tag/Timbaland">Teledyski Timbalanda</a></li> <li><a href="http://www.e-brzdac.com/tag/Pekin+2008">Olimpiada w Pekinie 2008</a></li> <li><a href="http://www.e-brzdac.com/tag/Adidas">Reklamy Adidas</a></li> <li><a href="http://www.e-brzdac.com/tag/Kajakarstwo">Kajakarstwo</a></li> <li><a href="http://www.e-brzdac.com/tag/Funny+kid">Zabawne dzieci</a></li> <li><a href="http://www.e-brzdac.com/tag/Luxury+Cars">Luksusowe samochody</a></li> <li><a href="http://www.e-brzdac.com/tag/Models+Women">Piękne kobiety</a></li> <li><a href="http://www.e-brzdac.com/tag/Cartoons">Kresk&oacute;wki</a></li> <li><a href="http://www.e-brzdac.com/tag/Doda">Teledyski Doda</a></li> <li><a href="http://www.e-brzdac.com/tag/Asus+eeePC">Laptop Asus EeePC</a></li> <li><a href="http://www.e-brzdac.com/tag/iPhone+3G">Apple iPhone 3G</a></li> <li><a href="http://www.e-brzdac.com/tag/Sports+cars">Samochody sportowe</a></li> </ul></li> </ul> </div> <!-- end div#sidebar --> <div style="clear: both; height: 1px"></div> </div> </div> <!-- end div#page --> <div id="footer"> <div id="footer"> &nbsp; <p>&copy; 2007 E-brzdac.com .<br />Kopiowanie i zamieszczanie dowolnej treści bez zgody autora zabronione.</p> </div> <!-- end div#footer --> </div> <!-- end div#wrapper --> </div> </body> </html>
284	single	where to find morel mushrooms	What are the best places to find morel mushrooms growing?	clueweb12-1715wb-55-08772	2	<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"> <html> <head> <title>Drummond Island Morel Mushrooming</title> <meta name="keywords" content="Morel Mushrooming, Morel Mushrooming, Morel Mushrooming, mushrooming, picking morels, michigan morels, upper michigan mushrooming, morels, mushrooms, michigan" /> <meta name="description" content="Welcome to the Drummond Island Morel Mushrooming page. Morels grow abundantly around Drummond. Please click here for more information and mushroom hunt here on the island." /> <meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1" /> <link rel="stylesheet" type="text/css" href="css/site.css?rand=1034184339" media="screen" /> <style type="text/css" media="screen"><!-- #randomBCKground { background-image: url("header/images/5_02.jpg"); } div#bannersdiv br { display: none; } --> </style> <script type="text/javascript" src="http://www.google.com/jsapi?key=ABQIAAAAUBeURkuGdaEtxXeMmKvn2hQWPLrr1lsNVeeIYTkeTwwg_pQTtRRRcssG2CpmEOdeGLdH3xVMXBnxNA"></script> <script type="text/javascript">//<![CDATA[ google.load("maps", "2"); var gdir; function load() { if (GBrowserIsCompatible()) { gdir = new google.maps.Directions(); google.maps.Event.addListener(gdir, "load", handleCalc); } } function ZipCalc() { var Zip = document.getElementById('ZipInput').value; if (Zip.length != 5) { document.getElementById("ZipOutput").innerHTML = 'Invalid Zipcode.'; } else { gdir.load("from: 49726 to: " + Zip, {getSteps: true}); } } function handleCalc() { document.getElementById("ZipOutput").innerHTML = 'Aprox. distance: ' + gdir.getDistance().html; } window.onload = load; try { window.onunload = google.maps.Unload; } catch (err) { }//]]></script> <script type="text/javascript"> var oMapWindow = null; function signal() { if (!oMapWindow || oMapWindow.closed) { oMapWindow = window.open('', 'map'); } } function reShowMap() { oMapWindow = window.open('drummond_island_map.html', 'map', 'resizable=no,location=no,menubar=no,scrollbars=no,status=no,toolbar=no,fullscreen=no,dependent=no,width=1000,height=700,left=0,top=0,status'); } function showMap() { if (!oMapWindow || oMapWindow.closed) { reShowMap(); } else { oMapWindow.focus(); } oMapWindow.focus(); } sfHover = function() { var sfEls = document.getElementById("MainMenu").getElementsByTagName("LI"); for (var i=0; i<sfEls.length; i++) { if (sfEls[i].className.indexOf('VGC_MENU_DADDY') != -1) { sfEls[i].style.marginBottom = '-3px'; } sfEls[i].onmouseover=function() { this.className += " sfhover"; } sfEls[i].onmouseout=function() { this.className=this.className.replace(new RegExp(" sfhover\\b"), ""); } } var sfEls = document.getElementById("PMainMenu").getElementsByTagName("LI"); for (var i=0; i<sfEls.length; i++) { sfEls[i].onmouseover=function() { this.className+=" sfhover"; } sfEls[i].onmouseout=function() { this.className=this.className.replace(new RegExp(" sfhover\\b"), ""); } } } if (window.attachEvent && navigator.appName.match(/Microsoft/)) { window.attachEvent("onload", sfHover); } var AC_FL_RunContent = 0; </script> <script type="text/javascript" src="js/AC_RunActiveContent.js"></script> </head> <body> <div id="CENTERALL"> <div id="VGCHeader"></div> <div id="randomBCKground"></div> <div id="VGCMenuBackground"> <ul id="PMainMenu"> <li><a href="index.php?page=Home">Home</a></li> <li><a href="http://www.drummondislandchamber.com/calendar.php" onclick="window.open(this.href,'','resizable=yes,location=no,menubar=no,scrollbars=no,status=no,toolbar=no,fullscreen=no,dependent=no,width=1000,height=700,left=0,top=0,status'); return false" target="_blank">Events</a></li> <li><a href="http://www.drummondislandchamber.com/search.php?c=5">Lodging</a></li> <li><a href="http://www.drummondislandchamber.com/search.php?c=8">Restaurants-Bars</a></li> <li><a href="http://www.drummondislandchamber.com/search.php?c=9">Services</a></li> <li><a href="http://www.drummondislandchamber.com/search.php?c=7">Recreation</a></li> <li><a href="http://www.drummondislandchamber.com/search.php?c=6">Shopping</a></li> <li><a href="http://www.drummondislandchamber.com/search.php?c=10">Real Estate</a></li> <li><a href="mailto:drummondislandtourism@alphacomm.net" target="_blank">Contact Us</a></li> </ul> </div> <div id="Container"> <table border="0" cellpadding="0" cellspacing="0" id="VGCMainTable"> <colgroup> <col width="174" /> </colgroup> <colgroup> <col width="600" /> </colgroup> <tbody> <tr> <td id="VGCPanel" valign="top"> <img src="header/home/v_menu_top.jpg" alt="" height="74" width="174" border="0" /> <ul id="MainMenu"> <li class="VGC_MENU_DADDY"><a href="#">Golf Tournaments</a> <ul> <li><a href="http://www.drummondislandchamber.com/media/1303833510.pdf" target="_blank">DI Golf Classic</a></li> <li><a href="http://www.drummondislandchamber.com/media/1303833656.pdf" target="_blank">Trail Groomer Fundraiser</a></li> </ul></li> <li class="VGC_MENU_DADDY"><a href="#">Fall Festival </a> <ul> <li><a href="http://www.drummondislandfallfestival.com/home.html" target="_blank">Fall Festival Website</a></li> </ul></li> <li class="VGC_MENU_DADDY"><a href="#">General Info</a> <ul> <li><a href="index.php?page=Drummond_Island_Sailing">Drummond Island Sailing</a></li> <li><a href="index.php?page=Puddingstone">Puddingstone</a></li> <li><a href="index.php?page=Mushrooming">Mushrooming</a></li> <li><a href="index.php?page=Shipping_Lanes">Shipping Lanes</a></li> <li><a href="index.php?page=Dolomite">Dolomite</a></li> <li><a href="index.php?page=Catching_the_Ferry">Catching the Ferry</a></li> <li><a href="index.php?page=DI_Township_Park_and_Heritage_Trail">DI Township Park and Heritage Trail</a></li> <li><a href="index.php?page=Historical_Museum">Historical Museum</a></li> <li><a href="http://www.drummondislandchamber.com/index.php?page=Big_Shoal">Big Shoal</a></li> <li><a href="http://www.drummondislandchamber.com/index.php?page=Harbor_Island_NWR">Harbor Island NWR</a></li> <li><a href="index.php?page=The_North_Channel">The North Channel</a></li> <li><a href="http://www.geocaching.com/seek/nearest.aspx?lat=46.0141102&amp;lng=-83.6546194&amp;dist=25" target="_blank">GeoCaching</a></li> </ul></li> <li><a href="http://www.drummondislandchamber.com/drummond_island_map.html" onclick="showMap(); return false;" target="_blank">Map</a></li> <li class="VGC_MENU_DADDY"><a href="#">Kayaking</a> <ul> <li><a href="index.php?page=Kayaking_Drummond">Kayaking Drummond</a></li> <li><a href="index.php?page=The_First_People">The First People</a></li> <li><a href="index.php?page=Safety_Tips">Safety Tips</a></li> <li><a href="index.php?page=Weather">Weather</a></li> <li><a href="index.php?page=Whitney_Bay">Whitney Bay</a></li> <li><a href="index.php?page=Pigeon_Cove_Flooding">Pigeon Cove Flooding</a></li> <li><a href="index.php?page=Cultural">Cultural</a></li> <li><a href="index.php?page=DI_Heritage_Trail">DI Heritage Trail</a></li> <li><a href="index.php?page=Island_Explorer_H20_Trail">Island Explorer H20 Trail</a></li> <li><a href="index.php?page=Fort_St_Joseph">Fort St Joseph</a></li> <li><a href="index.php?page=Lime_Island">Lime Island</a></li> <li><a href="index.php?page=Harbor_Island_NWR">Harbor Island NWR</a></li> <li><a href="index.php?page=Cedar_Island">Cedar Island</a></li> <li><a href="index.php?page=Hatchery">Hatchery</a></li> <li><a href="index.php?page=Scammon_Cove">Scammon Cove</a></li> <li><a href="index.php?page=Big_Shoal">Big Shoal</a></li> <li><a href="index.php?page=Lumber_Mill_Ruins">Lumber Mill Ruins</a></li> <li><a href="index.php?page=DeTour_Passage">DeTour Passage</a></li> </ul></li> <li class="VGC_MENU_DADDY"><a href="#">Shipwrecks</a> <ul> <li><a href="index.php?page=Fishing_Tug_Alice_C">Fishing Tug Alice C</a></li> <li><a href="index.php?page=Steamer_Two_Myrtles">Steamer Two Myrtles</a></li> <li><a href="index.php?page=Steamer_Superior">Steamer Superior</a></li> <li><a href="index.php?page=Steamer_John_W_Cullen">Steamer John W Cullen</a></li> <li><a href="index.php?page=Barge_Sainte_Marie">Barge Sainte Marie</a></li> <li><a href="index.php?page=Tug_General">Tug General</a></li> <li><a href="index.php?page=George_H_Ely">George H Ely</a></li> <li><a href="index.php?page=Barque_Monarch">Barque Monarch</a></li> <li><a href="index.php?page=Schooner_Barge_Delaware">Schooner Barge Delaware</a></li> <li><a href="index.php?page=Steamer_JC_Ford">Steamer JC Ford</a></li> <li><a href="index.php?page=EJ_Laway_Jr">EJ Laway Jr</a></li> <li><a href="index.php?page=The_Mystery_Barge">The Mystery Barge</a></li> <li><a href="index.php?page=Steamer_Agnes_W">Steamer Agnes W</a></li> <li><a href="index.php?page=Sunken_Crane">Sunken Crane</a></li> <li><a href="index.php?page=Schooner_John_B_Merrill">Schooner John B Merrill</a></li> <li><a href="index.php?page=Tug_Silver_Spray">Tug Silver Spray</a></li> <li><a href="index.php?page=Schooner_Barge_Troy">Schooner Barge Troy</a></li> </ul></li> <li><a href="index.php?page=DeTour_Reef_Light">DeTour Reef Light</a></li> <li class="VGC_MENU_DADDY"><a href="#">Rare</a> <ul> <li><a href="index.php?page=Drummond_Rare">Drummond Rare</a></li> <li><a href="index.php?page=Alvar">Alvar</a></li> <li><a href="index.php?page=Fossil_Ledges">Fossil Ledges</a></li> </ul></li> <li><a href="index.php?page=Birding">Birding</a></li> <li><a href="index.php?page=ATV_ORV">ATV ORV</a></li> <li><a href="index.php?page=Golfing">Golfing</a></li> <li><a href="index.php?page=Camping">Camping</a></li> <li class="VGC_MENU_DADDY"><a href="#">Fishing</a> <ul> <li><a href="index.php?page=Premier_Fishing_Destination">Premier Fishing Destination</a></li> <li><a href="index.php?page=Catch_a_Dream">Catch a Dream</a></li> </ul></li> <li><a href="index.php?page=Hiking">Hiking</a></li> <li><a href="index.php?page=Hunting">Hunting</a></li> <li><a href="index.php?page=Winter">Winter</a></li> <li><a href="index.php?page=Snowmobile_Trail_Report">Snowmobile Trail Report</a></li> <li><a href="index.php?page=Transportation">Transportation</a></li> <li><a href="index.php?page=Community_Organizations">Community Organizations</a></li> <li><a href="http://www.drummondislandchamber.com/index.php?page=Photo_Gallery">Photo Gallery</a></li> <li><a href="index.php?page=Thank_You">Thank You</a></li> <li><a href="index.php?page=Site_Map">Site Map</a></li> <li><a href="index.php?page=DI_5yr_Recreation_Plan">DI 5yr Recreation Plan</a></li> </ul> <div style="width: 150px; margin: 2px 14px;"> <img src="header/images/mileage_READY.jpg" alt="" height="82" width="145" border="0" /> </div> <div style="width: 150px; margin: 2px 12px;"> <script type="text/javascript"> document.write('<label for="ZipInput">Your Zip:</label> <input type="text" id="ZipInput" value="" size="5" maxlength="5" />'); document.write('<br />'); document.write('<div id="ZipOutput"></div>'); document.write('<button type="button" id="ZipButton" onclick="ZipCalc();">Get Distance!</button>'); </script> <noscript> <span>Javascript must be enabled for the distance calculator to work.</span> </noscript> </div> <div style="width: 150px; margin: 10px 0px 0px 19px;"> <a href="http://www.weatherforyou.com/weather/michigan/drummond+island.html" target="_blank"><img src="http://www.weatherforyou.net/fcgi-bin/hw3/hw3.cgi?config=png&amp;forecast=zone&amp;alt=hwizonemicro&amp;place=drummond+island&amp;state=mi&amp;country=us&amp;hwvbg=&amp;hwvtc=&amp;daysonly=3" width="140" height="65" border="0" alt="Drummond Island, Michigan, weather forecast" /></a> </div> <div style="width: 150px; margin: 2px 11px;"> <a href="http://www.facebook.com/DrummondIsland#!/pages/Drummond-Island-MI/203197723049113" target="_blank"><img src="dita_badge.jpg" width="150" height="198" border="0" alt="Join the Drummond Island Michigan Facebook" /></a> </div> <div id="bannersdiv" style="width: 150px; margin: 2px 11px;"> <a href="http://www.drummondisland.com" target="_blank" class="VGC_BANNER"><img src="/media/1239236324.png" alt="The Rock Golf Course" title="The Rock Golf Course" border="0" /></a> <br /> <a href="http://www.drummondonline.com/" target="_blank" class="VGC_BANNER"><img src="/media/1239647297.jpg" alt="D.I. Vacation Properties" title="D.I. Vacation Properties" border="0" /></a> <br /> <a href="http://www.diyachthaven.com/" target="_blank" class="VGC_BANNER"><img src="/media/1239648865.jpg" alt="D.I. Yacht Haven" title="D.I. Yacht Haven" border="0" /></a> <br /> </div> </td> <td id="VGCContent" valign="top"><p> <meta name="generator" content="Adobe GoLive" /></p> <table cellspacing="0" cellpadding="0" width="100%" border="0"> <tbody> <tr> <td> <div align="left"> <font face="Arial" size="2"><strong><font size="3"><a title="Morel Mushrooming in the Upper Peninsula of Michigan! Come and experience mushrooming on Drummond Island!" href="http://www.drummondislandchamber.com/index.php?page=Mushrooming">MORELS</a> </font></strong><br /><br />Morchella, the true morel, is a genus of edible <span>mushrooms closely related to anatomically simpler cup fungi. &nbsp;These distinctive mushrooms appear honeycomb-like in that the upper portion is composed of a network of ridges with pits between them.&nbsp;</span>If you are a first time hunter, you should make your first hunting expedition with someone who knows what a good morel looks like.</font> </div></td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" width="100%" border="0"> <tbody> <tr> <td><font face="Arial" size="2"><img class="" height="226" alt="Mushrooms, Morel Mushrooms, Morchella, True Morel - Morel Mushrooming in the Upper Peninsula of Michigan! Come and experience mushrooming on Drummond Island!" hspace="7" width="300" vspace="6" border="1" src="/images/Morel_Mushrooming.jpg" /><br /><font size="1">Photo by G. Harman</font></font></td> <td> <div> <div> <font face="Arial"><font size="2">These <span>ascocarps are prized by gourmet cooks, particularly for French cuisine.&nbsp;Commercial value aside, morels are hunted by thousands of people every year simply for their taste and the joy of the hunt.&nbsp;The fruit bodies of the Morchella are highly polymorphic in appearance, exhibiting variations in shape, color and size; this has contributed to uncertainties regarding taxonomy. Some authors suggest that the genus only contains as few as 3 to 6 species, while others place up to 50 species in the genus.&nbsp;</span></font></font> </div> </div></td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" width="100%" border="0"> <tbody> <tr> <td><p class="MsoNormal" style="margin: 0in 0in 0pt"><font face="Arial" size="2">Phylogenetic analysis based on both RFLP and restriction enzyme analysis of the 28S ribosomal RNA gene support the former hypothesis, i.e., that the genus is comprised of only a few species with considerable phenotypic variation.<br /><br />Morels grow abundantly in the two and sometimes three years immediately following a <span>forest fire. However, where fire suppression is practiced, they may grow regularly in small amounts in the same spot year after year.&nbsp;</span>Typically they are found in moist areas, around dying or dead Elm trees, Sycamore and Ash trees, old apple orchards and maybe even in your own back yard.&nbsp;Ground cover varies and it is very likely that each patch of mushrooms you come across may be growing in totally different conditions.&nbsp;Commercial pickers and buyers in </font><span><font face="Arial" size="2">North America will follow forest fires to gather morels.&nbsp;The Finnish name, huhtasieni, refers to huhta, area cleared for agriculture by slash and burn method.&nbsp;These spots may be jealously guarded by mushroom pickers, as the mushrooms are a delicacy and sometimes a cash crop.<br /></font></span><font face="Arial" size="2"><br />Morels have not yet been successfully farmed on a large scale, and the commercial morel industry is largely based on the harvest of wild mushrooms.<br /></font><font face="Arial" size="2"><br />Morels are a feature of many cuisines, including </font><span><font face="Arial" size="2">Provencal.&nbsp;Though morels are typically sold dried or canned, they can be purchased fresh.&nbsp;When preparing fresh morels for consumption, soaking them may ruin their delicate flavor.&nbsp;Due to their natural porousness, morels may contain trace amounts of soil which cannot be washed out.&nbsp;One of the best and simplest ways to enjoy morels is by gently sauteeing them in butter, cracking pepper on top and sprinkling with salt.<br /></font></span><font face="Arial" size="2"><br />Many people dry out the morels for long term storage.&nbsp;When they are ready to eat them, they simply soak the morels until they reabsorbe moisture.&nbsp;Often, these mushroooms are not nearly as good to eat as if they were fresh.&nbsp;Other people freeze or can their mushrooms.<br /></font><font face="Arial" size="2"><br />For those who love to cook the morel mushroom is a delicacy.&nbsp;The elusive morel can be found on Drummond Island in the Spring.&nbsp;Most are found around Corned Beef Junction.&nbsp;You do need to be vigilant in your search as there are false morels that can make you sick; but the rewards of finding the true morel is worth it.&nbsp;Drummond Island has both the white and black morel mushrooms.&nbsp;Morels are only found with a trained eye and persistence.&nbsp;Usually the best time to harvest the morels on Drummond Island is Mother’s Day weekend.<br /></font><font face="Arial" size="2"><br />So to the person who appreciates the morel, I suggest bringing your Mom for a fun weekend; start by taking Mom out for breakfast at any of the nice restaurants on the Island, followed by a fun day of hide and seek with the morel mushrooms.&nbsp;Then you can enjoy making dinner with your delicious fresh picked morels back at your cottage.&nbsp;As the weekend comes to an end you can see how much fun the family had and look forward to making this a family tradition.</font></p></td> </tr> </tbody> </table> </td> </tr> <tr> <td id="VGCFooter" colspan="2"> <div style="margin: 0px 0px 0px 174px;"> <span class="footertext"> Drummond Island Tourism Association<br /> P.O.Box 200 Drummond Island, MI 49726<br /> 906-493-5245 or 800-737-8666<br /> Email:<a href="mailto:drummondislandtourism@alphacomm.net"> drummondislandtourism@alphacomm.net</a> </span> </div> </td> </tr> </tbody> </table> <div style="margin: 0px 0px 0px 174px;"> <br /> <br /> <span class="copyrightsmall">Copyright &copy; 2009 - 2012 Drummond Island Tourism Association</span> <br /> <br /> <br /> <br /> <a title="Web Design" href="http://www.superiorweb.net" target="_blank"><img src="header/VGCfooter.jpg" alt="Michigan Website Design" height="77" width="350" border="0" /></a> </div> </div> </div> </body> </html>
221	single	electoral college 2008 results	What were the results of the electoral college for the 2008 US presidential race?	clueweb12-1117wb-84-30543	2	<!DOCTYPE html> <html b:version="2" class="v2" dir="ltr"> <head> <meta content="IE=EmulateIE7" http-equiv="X-UA-Compatible" /> <meta content="width=1100" name="viewport" /> <meta content="text/html; charset=UTF-8" http-equiv="Content-Type" /> <script type="text/javascript">(function() { var a=window;function c(b){this.t={};this.tick=function(b,i,d){d=void 0!=d?d:(new Date).getTime();this.t[b]=[d,i]};this.tick("start",null,b)}var f=new c;a.jstiming={Timer:c,load:f};try{var g=null;a.chrome&&a.chrome.csi&&(g=Math.floor(a.chrome.csi().pageT));null==g&&a.gtbExternal&&(g=a.gtbExternal.pageT());null==g&&a.external&&(g=a.external.pageT);g&&(a.jstiming.pt=g)}catch(h){};a.tickAboveFold=function(b){var e=0;if(b.offsetParent){do e+=b.offsetTop;while(b=b.offsetParent)}b=e;750>=b&&a.jstiming.load.tick("aft")};var j=!1;function k(){j||(j=!0,a.jstiming.load.tick("firstScrollTime"))}a.addEventListener?a.addEventListener("scroll",k,!1):a.attachEvent("onscroll",k); })();</script> <meta content="true" name="MSSmartTagsPreventParsing" /> <meta content="blogger" name="generator" /> <link href="http://www.the-richmonder.com/favicon.ico" rel="icon" type="image/x-icon" /> <link href="http://www.the-richmonder.com/2008/07/sunday-electoral-college-projection.html" rel="canonical" /> <link rel="alternate" type="application/atom+xml" title="The Richmonder - Atom" href="http://www.the-richmonder.com/feeds/posts/default" /> <link rel="alternate" type="application/rss+xml" title="The Richmonder - RSS" href="http://www.the-richmonder.com/feeds/posts/default?alt=rss" /> <link rel="service.post" type="application/atom+xml" title="The Richmonder - Atom" href="http://www.blogger.com/feeds/19190919/posts/default" /> <link rel="EditURI" type="application/rsd+xml" title="RSD" href="http://www.blogger.com/rsd.g?blogID=19190919" /> <link rel="alternate" type="application/atom+xml" title="The Richmonder - Atom" href="http://www.the-richmonder.com/feeds/7912099311551272278/comments/default" /> <!--[if IE]><script type="text/javascript" src="http://www.blogger.com/static/v1/jsbin/3804583874-ieretrofit.js"></script><![endif]--> <!--[if IE]> <script> (function() { var html5 = ("abbr,article,aside,audio,canvas,datalist,details," + "figure,footer,header,hgroup,mark,menu,meter,nav,output," + "progress,section,time,video").split(','); for (var i = 0; i < html5.length; i++) { document.createElement(html5[i]); } try { document.execCommand('BackgroundImageCache', false, true); } catch(e) {} })(); </script> <![endif]--> <title>The Richmonder: Sunday electoral college projection</title> <link type="text/css" rel="stylesheet" href="http://www.blogger.com/static/v1/widgets/1563318330-widget_css_2_bundle.css" /> <link type="text/css" rel="stylesheet" href="http://www.blogger.com/dyn-css/authorization.css?targetBlogID=19190919&amp;zx=0486d9bf-6fb2-4310-9112-d327e773a550" /> <style type="text/css">#navbar-iframe { display:block }</style> <style id="page-skin-1" type="text/css"><!--/*-----------------------------------------------Blogger Template StyleName: TravelDesigner: Sookhee LeeURL: www.plyfly.net----------------------------------------------- *//* Variable definitions====================<Variable name="keycolor" description="Main Color" type="color" default="#539bcd"/><Group description="Page Text" selector="body"><Variable name="body.font" description="Font" type="font"default="normal normal 13px 'Trebuchet MS',Trebuchet,sans-serif"/><Variable name="body.text.color" description="Text Color" type="color" default="#bbbbbb"/></Group><Group description="Backgrounds" selector=".body-fauxcolumns-outer"><Variable name="body.background.color" description="Outer Background" type="color" default="#539bcd"/><Variable name="content.background.color" description="Main Background" type="color" default="transparent"/></Group><Group description="Links" selector=".main-outer"><Variable name="link.color" description="Link Color" type="color" default="#ff9900"/><Variable name="link.visited.color" description="Visited Color" type="color" default="#b87209"/><Variable name="link.hover.color" description="Hover Color" type="color" default="#ff9900"/></Group><Group description="Blog Title" selector=".header h1"><Variable name="header.font" description="Font" type="font"default="normal normal 60px 'Trebuchet MS',Trebuchet,sans-serif"/><Variable name="header.text.color" description="Text Color" type="color" default="#ffffff" /></Group><Group description="Blog Description" selector=".header .description"><Variable name="description.text.color" description="Description Color" type="color"default="#000000" /></Group><Group description="Tabs Text" selector=".tabs-inner .widget li a"><Variable name="tabs.font" description="Font" type="font"default="normal bold 16px 'Trebuchet MS',Trebuchet,sans-serif"/><Variable name="tabs.text.color" description="Text Color" type="color" default="#ffffff"/><Variable name="tabs.selected.text.color" description="Selected Color" type="color" default="#ffffff"/></Group><Group description="Tabs Background" selector=".tabs-outer .PageList"><Variable name="tabs.background.color" description="Background Color" type="color" default="transparent"/><Variable name="tabs.selected.background.color" description="Selected Color" type="color" default="transparent"/></Group><Group description="Date Header" selector=".main-inner h2.date-header"><Variable name="date.font" description="Font" type="font"default="normal normal 14px 'Trebuchet MS',Trebuchet,sans-serif"/><Variable name="date.text.color" description="Text Color" type="color" default="#000000"/></Group><Group description="Post Title" selector="h3.post-title a"><Variable name="post.title.font" description="Font" type="font"default="normal bold 20px 'Trebuchet MS',Trebuchet,sans-serif"/><Variable name="post.title.text.color" description="Text Color" type="color"default="#ffffff"/></Group><Group description="Post Background" selector=".column-center-inner"><Variable name="post.background.color" description="Background Color" type="color"default="transparent"/><Variable name="post.background.url" description="Post Background URL" type="url" default="none"/></Group><Group description="Gadget Title Color" selector="h2"><Variable name="widget.title.font" description="Font" type="font"default="normal bold 14px 'Trebuchet MS',Trebuchet,sans-serif"/><Variable name="widget.title.text.color" description="Title Color" type="color" default="#ffffff"/></Group><Group description="Gadget Text" selector=".footer-inner .widget, .sidebar .widget"><Variable name="widget.font" description="Font" type="font"default="normal normal 13px 'Trebuchet MS',Trebuchet,sans-serif"/><Variable name="widget.text.color" description="Text Color" type="color" default="#000000"/></Group><Group description="Gadget Links" selector=".sidebar .widget"><Variable name="widget.link.color" description="Link Color" type="color" default="#000000"/><Variable name="widget.link.visited.color" description="Visited Color" type="color" default="#1909b8"/><Variable name="widget.alternate.text.color" description="Alternate Color" type="color" default="#ffffff"/></Group><Group description="Sidebar Background" selector=".column-left-inner .column-right-inner"><Variable name="widget.outer.background.color" description="Background Color" type="color" default="transparent" /><Variable name="widget.border.bevel.color" description="Bevel Color" type="color" default="transparent" /></Group><Variable name="body.background" description="Body Background" type="background"color="#145088" default="$(color) none repeat-x scroll top center"/><Variable name="content.background" description="Content Background" type="background"color="transparent" default="$(color) none repeat scroll top center"/><Variable name="comments.background" description="Comments Background" type="background"default="#cccccc none repeat scroll top center"/><Variable name="content.imageBorder.top.space" description="Content Image Border Top Space" type="length" default="0"/><Variable name="content.imageBorder.top" description="Content Image Border Top" type="url" default="none"/><Variable name="content.margin" description="Content Margin Top" type="length" default="20px"/><Variable name="content.padding" description="Content Padding" type="length" default="20px"/><Variable name="content.posts.padding" description="Posts Content Padding" type="length" default="10px"/><Variable name="tabs.background.gradient" description="Tabs Background Gradient" type="url"default="url(http://www.blogblog.com/1kt/travel/bg_black_50.png)"/><Variable name="tabs.selected.background.gradient" description="Tabs Selected Background Gradient" type="url"default="url(http://www.blogblog.com/1kt/travel/bg_black_50.png)"/><Variable name="widget.outer.background.gradient" description="Sidebar Gradient" type="url"default="url(http://www.blogblog.com/1kt/travel/bg_black_50.png)"/><Variable name="footer.background.gradient" description="Footer Background Gradient" type="url" default="none"/><Variable name="mobile.background.overlay" description="Mobile Background Overlay" type="string"default="transparent none repeat scroll top left"/><Variable name="mobile.button.color" description="Mobile Button Color" type="color" default="#ffffff" /><Variable name="startSide" description="Side where text starts in blog language" type="automatic" default="left"/><Variable name="endSide" description="Side where text ends in blog language" type="automatic" default="right"/>*//* Content----------------------------------------------- */body {font: normal normal 13px 'Trebuchet MS',Trebuchet,sans-serif;color: #000000;background: #145088 none no-repeat scroll center center;}html body .region-inner {min-width: 0;max-width: 100%;width: auto;}a:link {text-decoration:none;color: #1800ff;}a:visited {text-decoration:none;color: #1909b8;}a:hover {text-decoration:underline;color: #ff1700;}.content-outer .content-cap-top {height: 0;background: transparent none repeat-x scroll top center;}.content-outer {margin: 0 auto;padding-top: 20px;}.content-inner {background: transparent url(http://www.blogblog.com/1kt/travel/bg_black_70.png) repeat scroll top left;background-position: left -0;background-color: transparent;padding: 20px;}.main-inner .date-outer {margin-bottom: 2em;}/* Header----------------------------------------------- */.header-inner .Header .titlewrapper,.header-inner .Header .descriptionwrapper {padding-left: 10px;padding-right: 10px;}.Header h1 {font: normal normal 60px 'Trebuchet MS',Trebuchet,sans-serif;color: #ffffff;}.Header h1 a {color: #ffffff;}.Header .description {font-size: 130%;}/* Tabs----------------------------------------------- */.tabs-inner {margin: 1em 0 0;padding: 0;}.tabs-inner .section {margin: 0;}.tabs-inner .widget ul {padding: 0;background: transparent url(http://www.blogblog.com/1kt/travel/bg_black_50.png) repeat scroll top center;}.tabs-inner .widget li {border: none;}.tabs-inner .widget li a {display: inline-block;padding: 1em 1.5em;color: #ffffff;font: normal bold 16px 'Trebuchet MS',Trebuchet,sans-serif;}.tabs-inner .widget li.selected a,.tabs-inner .widget li a:hover {position: relative;z-index: 1;background: transparent url(http://www.blogblog.com/1kt/travel/bg_black_50.png) repeat scroll top center;color: #ffffff;}/* Headings----------------------------------------------- */h2 {font: normal bold 14px 'Trebuchet MS',Trebuchet,sans-serif;color: #0c007f;}.main-inner h2.date-header {font: normal normal 14px 'Trebuchet MS',Trebuchet,sans-serif;color: #000000;}.footer-inner .widget h2,.sidebar .widget h2 {padding-bottom: .5em;}/* Main----------------------------------------------- */.main-inner {padding: 20px 0;}.main-inner .column-center-inner {padding: 20px 0;}.main-inner .column-center-inner .section {margin: 0 20px;}.main-inner .column-right-inner {margin-left: 20px;}.main-inner .fauxcolumn-right-outer .fauxcolumn-inner {margin-left: 20px;background: #ffffff none repeat scroll top left;}.main-inner .column-left-inner {margin-right: 20px;}.main-inner .fauxcolumn-left-outer .fauxcolumn-inner {margin-right: 20px;background: #ffffff none repeat scroll top left;}.main-inner .column-left-inner,.main-inner .column-right-inner {padding: 15px 0;}/* Posts----------------------------------------------- */h3.post-title {margin-top: 20px;}h3.post-title a {font: normal bold 30px 'Trebuchet MS',Trebuchet,sans-serif;color: #170a4c;}h3.post-title a:hover {text-decoration: underline;}.main-inner .column-center-outer {background: #ffffff none repeat scroll top left;_background-image: none;}.post-body {line-height: 1.4;position: relative;}.post-header {margin: 0 0 1em;line-height: 1.6;}.post-footer {margin: .5em 0;line-height: 1.6;}#blog-pager {font-size: 140%;}#comments {background: #cccccc none repeat scroll top center;padding: 15px;}#comments .comment-author {padding-top: 1.5em;}#comments h4,#comments .comment-author a,#comments .comment-timestamp a {color: #170a4c;}#comments .comment-author:first-child {padding-top: 0;border-top: none;}.avatar-image-container {margin: .2em 0 0;}/* Comments----------------------------------------------- */#comments a {color: #170a4c;}.comments .comments-content .icon.blog-author {background-repeat: no-repeat;background-image: url(data:image/png;base64,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);}.comments .comments-content .loadmore a {border-top: 1px solid #170a4c;border-bottom: 1px solid #170a4c;}.comments .comment-thread.inline-thread {background: #ffffff;}.comments .continue {border-top: 2px solid #170a4c;}/* Widgets----------------------------------------------- */.sidebar .widget {border-bottom: 2px solid #cc0000;padding-bottom: 10px;margin: 10px 0;}.sidebar .widget:first-child {margin-top: 0;}.sidebar .widget:last-child {border-bottom: none;margin-bottom: 0;padding-bottom: 0;}.footer-inner .widget,.sidebar .widget {font: normal normal 13px 'Trebuchet MS',Trebuchet,sans-serif;color: #0c007f;}.sidebar .widget a:link {color: #0c007f;text-decoration: none;}.sidebar .widget a:visited {color: #b81809;}.sidebar .widget a:hover {color: #0c007f;text-decoration: underline;}.footer-inner .widget a:link {color: #1800ff;text-decoration: none;}.footer-inner .widget a:visited {color: #1909b8;}.footer-inner .widget a:hover {color: #1800ff;text-decoration: underline;}.widget .zippy {color: #b81809;}.footer-inner {background: transparent none repeat scroll top center;}/* Mobile----------------------------------------------- */body.mobile {padding: 0 10px;background-size: 100% auto;}body.mobile .AdSense {margin: 0 -10px;}.mobile .body-fauxcolumn-outer {background: transparent none repeat scroll top left;}.mobile .footer-inner .widget a:link {color: #0c007f;text-decoration: none;}.mobile .footer-inner .widget a:visited {color: #b81809;}.mobile-post-outer a {color: #170a4c;}.mobile-link-button {background-color: #1800ff;}.mobile-link-button a:link, .mobile-link-button a:visited {color: #ffffff;}.mobile-index-contents {color: #000000;}.mobile .tabs-inner .PageList .widget-content {background: transparent url(http://www.blogblog.com/1kt/travel/bg_black_50.png) repeat scroll top center;color: #ffffff;}.mobile .tabs-inner .PageList .widget-content .pagelist-arrow {border-left: 1px solid #ffffff;}--></style> <style id="template-skin-1" type="text/css"><!--body {min-width: 1190px;}.content-outer, .content-fauxcolumn-outer, .region-inner {min-width: 1190px;max-width: 1190px;_width: 1190px;}.main-inner .columns {padding-left: 260px;padding-right: 260px;}.main-inner .fauxcolumn-center-outer {left: 260px;right: 260px;/* IE6 does not respect left and right together */_width: expression(this.parentNode.offsetWidth -parseInt("260px") -parseInt("260px") + 'px');}.main-inner .fauxcolumn-left-outer {width: 260px;}.main-inner .fauxcolumn-right-outer {width: 260px;}.main-inner .column-left-outer {width: 260px;right: 100%;margin-left: -260px;}.main-inner .column-right-outer {width: 260px;margin-right: -260px;}#layout {min-width: 0;}#layout .content-outer {min-width: 0;width: 800px;}#layout .region-inner {min-width: 0;width: auto;}--></style> <script type="text/javascript">(function(){if(-1!=navigator.userAgent.indexOf("Mobile")&&-1!=navigator.userAgent.indexOf("WebKit")&&-1==navigator.userAgent.indexOf("iPad")||-1!=navigator.userAgent.indexOf("Opera Mini")){var a;a:{var b=window.location.href,c=b.split("?");switch(c.length){case 1:a=b+"?m=1";break a;case 2:a=0<=c[1].search("(^|&)m=")?null:b+"&m=1";break a;default:a=null}}a&&window.location.replace(a)};})();</script> <script type="text/javascript">if (window.jstiming) window.jstiming.load.tick('headEnd');</script> </head> <body class="loading"> <div class="navbar section" id="navbar"> <div class="widget Navbar" id="Navbar1"> <script type="text/javascript"> function setAttributeOnload(object, attribute, val) { if(window.addEventListener) { window.addEventListener("load", function(){ object[attribute] = val; }, false); } else { window.attachEvent('onload', function(){ object[attribute] = val; }); } } </script> <iframe src="http://www.blogger.com/navbar.g?targetBlogID=19190919&amp;blogName=The+Richmonder&amp;publishMode=PUBLISH_MODE_HOSTED&amp;navbarType=BLUE&amp;layoutType=LAYOUTS&amp;searchRoot=http://www.the-richmonder.com/search&amp;blogLocale=en_US&amp;homepageUrl=http://www.the-richmonder.com/&amp;targetPostID=7912099311551272278&amp;vt=-5795159402047051412" marginwidth="0" marginheight="0" scrolling="no" frameborder="0" height="30px" width="100%" id="navbar-iframe" allowtransparency="true" title="Blogger Navigation and Search"></iframe> <div></div> <script type="text/javascript">(function() {var script = document.createElement('script');script.type = 'text/javascript';script.src = '//pagead2.googlesyndication.com/pagead/js/google_top.js';var head = document.getElementsByTagName('head')[0];if (head) {head.appendChild(script);}})();</script> </div> </div> <div class="body-fauxcolumns"> <div class="fauxcolumn-outer body-fauxcolumn-outer"> <div class="cap-top"> <div class="cap-left"></div> <div class="cap-right"></div> </div> <div class="fauxborder-left"> <div class="fauxborder-right"></div> <div class="fauxcolumn-inner"></div> </div> <div class="cap-bottom"> <div class="cap-left"></div> <div class="cap-right"></div> </div> </div> </div> <div class="content"> <div class="content-fauxcolumns"> <div class="fauxcolumn-outer content-fauxcolumn-outer"> <div class="cap-top"> <div class="cap-left"></div> <div class="cap-right"></div> </div> <div class="fauxborder-left"> <div class="fauxborder-right"></div> <div class="fauxcolumn-inner"></div> </div> <div class="cap-bottom"> <div class="cap-left"></div> <div class="cap-right"></div> </div> </div> </div> <div class="content-outer"> <div class="content-cap-top cap-top"> <div class="cap-left"></div> <div class="cap-right"></div> </div> <div class="fauxborder-left content-fauxborder-left"> <div class="fauxborder-right content-fauxborder-right"></div> <div class="content-inner"> <header> <div class="header-outer"> <div class="header-cap-top cap-top"> <div class="cap-left"></div> <div class="cap-right"></div> </div> <div class="fauxborder-left header-fauxborder-left"> <div class="fauxborder-right header-fauxborder-right"></div> <div class="region-inner header-inner"> <div class="header section" id="header"> <div class="widget Header" id="Header1"> <div id="header-inner"> <a href="http://www.the-richmonder.com/" style="display: block"><img alt="The Richmonder" height="487px; " id="Header1_headerimg" src="http://1.bp.blogspot.com/-52ojik-6We4/T0lCabXYSDI/AAAAAAAAHB4/UuhFPre_gPY/s1600/masthead_1200px.jpg" style="display: block" width="1200px; " /></a> </div> </div> </div> </div> </div> <div class="header-cap-bottom cap-bottom"> <div class="cap-left"></div> <div class="cap-right"></div> </div> </div> </header> <div class="tabs-outer"> <div class="tabs-cap-top cap-top"> <div class="cap-left"></div> <div class="cap-right"></div> </div> <div class="fauxborder-left tabs-fauxborder-left"> <div class="fauxborder-right tabs-fauxborder-right"></div> <div class="region-inner tabs-inner"> <div class="tabs section" id="crosscol"></div> <div class="tabs section" id="crosscol-overflow"></div> </div> </div> <div class="tabs-cap-bottom cap-bottom"> <div class="cap-left"></div> <div class="cap-right"></div> </div> </div> <div class="main-outer"> <div class="main-cap-top cap-top"> <div class="cap-left"></div> <div class="cap-right"></div> </div> <div class="fauxborder-left main-fauxborder-left"> <div class="fauxborder-right main-fauxborder-right"></div> <div class="region-inner main-inner"> <div class="columns fauxcolumns"> <div class="fauxcolumn-outer fauxcolumn-center-outer"> <div class="cap-top"> <div class="cap-left"></div> <div class="cap-right"></div> </div> <div class="fauxborder-left"> <div class="fauxborder-right"></div> <div class="fauxcolumn-inner"></div> </div> <div class="cap-bottom"> <div class="cap-left"></div> <div class="cap-right"></div> </div> </div> <div class="fauxcolumn-outer fauxcolumn-left-outer"> <div class="cap-top"> <div class="cap-left"></div> <div class="cap-right"></div> </div> <div class="fauxborder-left"> <div class="fauxborder-right"></div> <div class="fauxcolumn-inner"></div> </div> <div class="cap-bottom"> <div class="cap-left"></div> <div class="cap-right"></div> </div> </div> <div class="fauxcolumn-outer fauxcolumn-right-outer"> <div class="cap-top"> <div class="cap-left"></div> <div class="cap-right"></div> </div> <div class="fauxborder-left"> <div class="fauxborder-right"></div> <div class="fauxcolumn-inner"></div> </div> <div class="cap-bottom"> <div class="cap-left"></div> <div class="cap-right"></div> </div> </div> <!-- corrects IE6 width calculation --> <div class="columns-inner"> <div class="column-center-outer"> <div class="column-center-inner"> <div class="main section" id="main"> <div class="widget Blog" id="Blog1"> <div class="blog-posts hfeed"> <!-- google_ad_section_start(name=default) --> <div class="date-outer"> <h2 class="date-header"><span>Sunday, July 13, 2008</span></h2> <div class="date-posts"> <div class="post-outer"> <div class="post hentry"> <a name="7912099311551272278"></a> <h3 class="post-title entry-title">Sunday electoral college projection</h3> <div class="post-header"> <div class="post-header-line-1"></div> </div> <div class="post-body entry-content" id="post-body-7912099311551272278"> I'm starting a new feature here at The Richmond Democrat: the Sunday electoral college roundup. The American people love to look at poll results, and the mainstream media is only too glad to pander to this interest. More often than not, the poll that big corporate media likes to cite most of all is the national presidential poll, a sample of a trivial number of people that has almost no value. Why? Because the national popular vote won't decide the outcome of the election: the electoral college will. <br /> <br />Unfortunately, the big corporate media outlets will persist in putting out national polls with tiny samples, despite the fact that these polls can be deceiving. For example, what good does it do Obama to blow McCain out in New York, Illinois, and California if he loses everywhere else? What good does it do McCain to blow Obama out in Utah, Idaho or Alaska. A blowout in any given state will not result in a candidate receiving any more electoral votes than a narrow win, but it could distort a national poll. Better then to go state by state and award the electoral votes than to look at a made up national poll figure that means nothing. <br /> <br />So from now through the election, I will be surveying the latest state polls from <a href="http://www.pollster.com/">Pollster.com</a>, adding up the electoral votes, and presenting the totals to you. My methodology will be pretty simple. I will look at the <a href="http://www.pollster.com/">Pollster.com</a> data, make note of which candidate is ahead in each state's polls, and award electoral votes accordingly. All tied states will be awarded to John S. McCain. To the extent I depart from this method for any reason, I will disclose it and explain my reasons for doing so under the heading &quot;Special Assumptions.&quot; Now, with my reasoning and general assumptions out of the way, let's look at this week's numbers. The electoral college projection for July 13, 2008 is: <br /> <br /> <span style="color: rgb(102, 51, 255); font-weight: bold;font-size:180%;">Barack H. Obama - 306 Electoral Votes</span> <br /> <br /> <span style="color: rgb(204, 0, 0); font-weight: bold;font-size:180%;">John S. McCain - 229 Electoral Votes</span> <br /> <br />If the election was held today, it looks as though Barack H. Obama would win by a healthy margin in the electoral college. <br /> <br />Special Assumptions for July 13, 2008: <br /> <br />(1) The <a href="http://www.pollster.com/08-ND-Pres-GE-MvO.php">latest polls in North Dakota suggest a tie</a> between Obama and McCain. I have therefore awarded North Dakota's 3 electoral votes to John S. McCain. <br /> <br />(2) The latest poll in South Carolina suggests that Bob Barr will siphon off sufficient support from John McCain to throw the state to Barack Obama. I regard this poll with some skepticism, however, so I am awarding South Carolina's 8 electoral votes to John McCain, even though <a href="http://www.pollster.com/08-SC-Pres-GE-MvO.php">this latest poll suggests he may lose</a> narrowly to Obama. <div style="clear: both;"></div> </div> <div class="post-footer"> <div class="post-footer-line post-footer-line-1"> <span class="post-author vcard">Posted by<span class="fn">Staff</span></span> <span class="post-timestamp">at<a class="timestamp-link" href="http://www.the-richmonder.com/2008/07/sunday-electoral-college-projection.html" rel="bookmark" title="permanent link"><abbr class="published" title="2008-07-13T19:47:00-04:00">7:47 PM</abbr></a></span> <span class="post-comment-link"></span> <span class="post-icons"><span class="item-action"><a href="http://www.blogger.com/email-post.g?blogID=19190919&amp;postID=7912099311551272278" title="Email Post"><img alt="" class="icon-action" height="13" src="http://img1.blogblog.com/img/icon18_email.gif" width="18" /></a></span><span class="item-control blog-admin pid-751683491"><a href="http://www.blogger.com/post-edit.g?blogID=19190919&amp;postID=7912099311551272278&amp;from=pencil" title="Edit Post"><img alt="" class="icon-action" height="18" src="http://img2.blogblog.com/img/icon18_edit_allbkg.gif" width="18" /></a></span></span> <span class="post-backlinks post-comment-link"></span> <div class="post-share-buttons goog-inline-block"> <a class="goog-inline-block share-button sb-email" href="http://www.blogger.com/share-post.g?blogID=19190919&amp;postID=7912099311551272278&amp;target=email" target="_blank" title="Email This"><span class="share-button-link-text">Email This</span></a> <a class="goog-inline-block share-button sb-blog" href="http://www.blogger.com/share-post.g?blogID=19190919&amp;postID=7912099311551272278&amp;target=blog" onclick="window.open(this.href, &quot;_blank&quot;, &quot;height=270,width=475&quot;); return false;" target="_blank" title="BlogThis!"><span class="share-button-link-text">BlogThis!</span></a> <a class="goog-inline-block share-button sb-twitter" href="http://www.blogger.com/share-post.g?blogID=19190919&amp;postID=7912099311551272278&amp;target=twitter" target="_blank" title="Share to Twitter"><span class="share-button-link-text">Share to Twitter</span></a> <a class="goog-inline-block share-button sb-facebook" href="http://www.blogger.com/share-post.g?blogID=19190919&amp;postID=7912099311551272278&amp;target=facebook" onclick="window.open(this.href, &quot;_blank&quot;, &quot;height=430,width=640&quot;); return false;" target="_blank" title="Share to Facebook"><span class="share-button-link-text">Share to Facebook</span></a> <div class="goog-inline-block dummy-container"> <g:plusone source="blogger" href="http://www.the-richmonder.com/2008/07/sunday-electoral-college-projection.html" size="medium" width="300" annotation="inline" /> </div> </div> </div> <div class="post-footer-line post-footer-line-2"> <span class="post-labels">Labels:<a href="http://www.the-richmonder.com/search/label/2008%20Presidential%20Race" rel="tag">2008 Presidential Race</a>,<a href="http://www.the-richmonder.com/search/label/Barack%20Obama" rel="tag">Barack Obama</a>,<a href="http://www.the-richmonder.com/search/label/Electoral%20College%20Projection" rel="tag">Electoral College Projection</a>,<a href="http://www.the-richmonder.com/search/label/John%20McCain" rel="tag">John McCain</a></span> </div> <div class="post-footer-line post-footer-line-3"></div> </div> </div> <div class="comments" id="comments"> <a name="comments"></a> <h4> 1 comments: </h4> <div id="Blog1_comments-block-wrapper"> <dl class="avatar-comment-indent" id="comments-block"> <dt class="comment-author " id="c5630203177006477116"> <a name="c5630203177006477116"></a> <div class="avatar-image-container avatar-stock"> <span dir="ltr"><a href="http://www.blogger.com/profile/07860792846652677912" rel="nofollow" onclick="" class="avatar-hovercard" id="av-0-07860792846652677912"><img src="http://img2.blogblog.com/img/b16-rounded.gif" width="16" height="16" alt="" title="S" /></a></span> </div> <a href="http://www.blogger.com/profile/07860792846652677912" rel="nofollow">S</a>said... </dt> <dd class="comment-body" id="Blog1_cmt-5630203177006477116"> <p>Thank you for your use of alternative polls, but the real issue is not how well Obama or McCain might do in the closely divided battleground states, but that we shouldn't have battleground states and spectator states in the first place. Every vote in every state should be politically relevant in a presidential election. And, every vote should be equal. We should have a national popular vote for President in which the White House goes to the candidate who gets the most popular votes in all 50 states. <br /><br />The National Popular Vote bill would guarantee the Presidency to the candidate who receives the most popular votes in all 50 states (and DC). The bill would take effect only when enacted, in identical form, by states possessing a majority of the electoral vote -- that is, enough electoral votes to elect a President (270 of 538). When the bill comes into effect, all the electoral votes from those states would be awarded to the presidential candidate who receives the most popular votes in all 50 states (and DC). <br /><br />Because of state-by-state enacted rules for winner-take-all awarding of their electoral votes, recent candidates with limited funds have concentrated their attention on a handful of closely divided &quot;battleground&quot; states. Two-thirds of the visits and money were focused in just six states; 88% on 9 states, and 99% of the money went to just 16 states. Two-thirds of the states and people have been merely spectators to the presidential election.<br /><br />Another shortcoming of the current system is that a candidate can win the Presidency without winning the most popular votes nationwide.<br /><br />The National Popular Vote bill has been approved by 20 legislative chambers (one house in Colorado, Arkansas, Maine, Massachusetts, North Carolina, and Washington, and two houses in Maryland, Illinois, Hawaii, California, New Jersey, Rhode Island, and Vermont). It has been enacted into law in Hawaii, Illinois, New Jersey, and Maryland. These states have 50 (19%) of the 270 electoral votes needed to bring this legislation into effect.<br /><br />See http://www.NationalPopularVote.com</p> </dd> <dd class="comment-footer"> <span class="comment-timestamp"><a href="http://www.the-richmonder.com/2008/07/sunday-electoral-college-projection.html?showComment=1216055460000#c5630203177006477116" title="comment permalink">1:11 PM, July 14, 2008</a><span class="item-control blog-admin pid-1722871370"><a class="comment-delete" href="http://www.blogger.com/delete-comment.g?blogID=19190919&amp;postID=5630203177006477116" title="Delete Comment"><img src="//www.blogger.com/img/icon_delete13.gif" /></a></span></span> </dd> </dl> </div> <p class="comment-footer"><a href="http://www.blogger.com/comment.g?blogID=19190919&amp;postID=7912099311551272278" onclick="">Post a Comment</a></p> <div id="backlinks-container"> <div id="Blog1_backlinks-container"> <a name="links"></a> <h4></h4> <p class="comment-footer"><a class="comment-link" href="" id="Blog1_backlinks-create-link" target="_blank"></a></p> </div> </div> </div> </div> </div> </div> <!-- google_ad_section_end --> </div> <div class="blog-pager" id="blog-pager"> <span id="blog-pager-newer-link"><a class="blog-pager-newer-link" href="http://www.the-richmonder.com/2008/07/great-speech-by-hillary-clinton.html" id="Blog1_blog-pager-newer-link" title="Newer Post">Newer Post</a></span> <span id="blog-pager-older-link"><a class="blog-pager-older-link" href="http://www.the-richmonder.com/2008/07/major-bushmccain-supporter-caught-on.html" id="Blog1_blog-pager-older-link" title="Older Post">Older Post</a></span> <a class="home-link" href="http://www.the-richmonder.com/">Home</a> </div> <div class="clear"></div> <div class="post-feeds"> <div class="feed-links"> Subscribe to: <a class="feed-link" href="http://www.the-richmonder.com/feeds/7912099311551272278/comments/default" target="_blank" type="application/atom+xml">Post Comments (Atom)</a> </div> </div> <script type="text/javascript">window.___gcfg = {'lang': 'en_US'};window.___gapisync = false;(function() {var po = document.createElement('script');po.type = 'text/javascript';po.async = true;po.src = 'https://apis.google.com/js/plusone.js';var s = document.body.getElementsByTagName('script')[0];s.parentNode.insertBefore(po, s);})();</script> </div> </div> </div> </div> <div class="column-left-outer"> <div class="column-left-inner"> <aside> <div class="sidebar section" id="sidebar-left-1"> <div class="widget HTML" id="HTML14"> <h2 class="title">Local Weather</h2> <div class="widget-content"> <a href="http://www.wunderground.com/cgi-bin/findweather/getForecast?query=zmw:23223.1.99999&amp;bannertypeclick=wu_bluestripes"><img src="http://weathersticker.wunderground.com/cgi-bin/banner/ban/wxBanner?bannertype=wu_bluestripes&amp;airportcode=KRIC&amp;ForcedCity=Richmond&amp;ForcedState=VA" alt="Click for Richmond, Virginia Forecast" height="90" width="160" /></a> </div> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=HTML&amp;widgetId=HTML14&amp;action=editWidget&amp;sectionId=sidebar-left-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;HTML14&quot;));" target="configHTML14" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> <div class="widget AdSense" id="AdSense2"> <div class="widget-content"> <script type="text/javascript"><!--google_ad_client="pub-8421503559745163";google_ad_host="pub-1556223355139109";google_ad_width=160;google_ad_height=600;google_ad_format="160x600_as";google_ad_type="text_image";google_ad_host_channel="0001";google_color_border="FFFFFF";google_color_bg="FFFFFF";google_color_link="073763";google_color_url="0A0ACE";google_color_text="000000";//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=AdSense&amp;widgetId=AdSense2&amp;action=editWidget&amp;sectionId=sidebar-left-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;AdSense2&quot;));" target="configAdSense2" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> </div> <div class="widget HTML" id="HTML9"> <h2 class="title">On Twitter</h2> <div class="widget-content"> <a href="http://twitter.com/JCWilmore" class="twitter-follow-button" data-show-count="false">Follow @JCWilmore</a> <script src="http://platform.twitter.com/widgets.js" type="text/javascript"></script> </div> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=HTML&amp;widgetId=HTML9&amp;action=editWidget&amp;sectionId=sidebar-left-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;HTML9&quot;));" target="configHTML9" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> <div class="widget AdSense" id="AdSense3"> <div class="widget-content"> <script type="text/javascript"><!--google_ad_client="pub-8421503559745163";google_ad_host="pub-1556223355139109";google_ad_width=160;google_ad_height=600;google_ad_format="160x600_as";google_ad_type="text_image";google_ad_host_channel="0001";google_color_border="FFFFFF";google_color_bg="FFFFFF";google_color_link="336699";google_color_url="336699";google_color_text="333333";//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=AdSense&amp;widgetId=AdSense3&amp;action=editWidget&amp;sectionId=sidebar-left-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;AdSense3&quot;));" target="configAdSense3" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> </div> <div class="widget HTML" id="HTML10"> <h2 class="title">Visit My VPAP.org Profile</h2> <div class="widget-content"> <a href="http://www.vpap.org/vendors/profile/index/84539">The Richmonder</a> </div> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=HTML&amp;widgetId=HTML10&amp;action=editWidget&amp;sectionId=sidebar-left-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;HTML10&quot;));" target="configHTML10" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> <div class="widget LinkList" id="LinkList3"> <h2>From the Left</h2> <div class="widget-content"> <ul> <li><a href="http://armchairgeneralist.typepad.com/">Armchair Generalist</a></li> <li><a href="http://blacknell.net/dynamic/">Blacknell.net</a></li> <li><a href="http://blueridgedata.blogspot.com/">Blue Ridge Data</a></li> <li><a href="http://www.bluevirginia.us/">Blue Virginia</a></li> <li><a href="http://blueweeds.typepad.com/blue_weeds/">blueweeds</a></li> <li><a href="http://coarsecrackedcorn.blogspot.com/">Coarse Cracked Corn</a></li> <li><a href="http://www.equalityloudoun.org/#blog">Equality Loudoun</a></li> <li><a href="http://fdhub.net/">Fan District Hub</a></li> <li><a href="http://fred2blue.wordpress.com/">Fred2Blue</a></li> <li><a href="http://graniterocksound.blogspot.com/">Granite Rock Sound</a></li> <li><a href="http://vagreatblueheron.wordpress.com/">Great Blue Heron</a></li> <li><a href="http://thegreenmiles.blogspot.com/">The Green Miles</a></li> </ul> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=LinkList&amp;widgetId=LinkList3&amp;action=editWidget&amp;sectionId=sidebar-left-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;LinkList3&quot;));" target="configLinkList3" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> </div> <div class="widget Subscribe" id="Subscribe1"> <div style="white-space:nowrap"> <h2 class="title">The Richmonder's Feeds</h2> <div class="widget-content"> <div class="subscribe-wrapper subscribe-type-POST"> <div class="subscribe expanded subscribe-type-POST" id="SW_READER_LIST_Subscribe1POST" style="display:none;"> <div class="top"> <span class="inner" onclick="return(_SW_toggleReaderList(event, &quot;Subscribe1POST&quot;));"><img class="subscribe-dropdown-arrow" src="http://img2.blogblog.com/img/widgets/arrow_dropdown.gif" /><img align="absmiddle" alt="" border="0" class="feed-icon" src="http://img1.blogblog.com/img/icon_feed12.png" />Posts</span> <div class="feed-reader-links"> <a class="feed-reader-link" href="http://www.google.com/ig/add?source=bstp&amp;feedurl=http%3A%2F%2Fwww.the-richmonder.com%2Ffeeds%2Fposts%2Fdefault" target="_blank"><img src="http://img1.blogblog.com/img/widgets/subscribe-google.png" /></a> <a class="feed-reader-link" href="http://www.netvibes.com/subscribe.php?url=http%3A%2F%2Fwww.the-richmonder.com%2Ffeeds%2Fposts%2Fdefault" target="_blank"><img src="http://img1.blogblog.com/img/widgets/subscribe-netvibes.png" /></a> <a class="feed-reader-link" href="http://www.newsgator.com/ngs/subscriber/subext.aspx?url=http%3A%2F%2Fwww.the-richmonder.com%2Ffeeds%2Fposts%2Fdefault" target="_blank"><img src="http://img1.blogblog.com/img/widgets/subscribe-newsgator.png" /></a> <a class="feed-reader-link" href="http://add.my.yahoo.com/content?url=http%3A%2F%2Fwww.the-richmonder.com%2Ffeeds%2Fposts%2Fdefault" target="_blank"><img src="http://img1.blogblog.com/img/widgets/subscribe-yahoo.png" /></a> <a class="feed-reader-link" href="http://www.the-richmonder.com/feeds/posts/default" target="_blank"><img align="absmiddle" class="feed-icon" src="http://img1.blogblog.com/img/icon_feed12.png" /> Atom </a> </div> </div> <div class="bottom"></div> </div> <div class="subscribe" id="SW_READER_LIST_CLOSED_Subscribe1POST" onclick="return(_SW_toggleReaderList(event, &quot;Subscribe1POST&quot;));"> <div class="top"> <span class="inner"><img class="subscribe-dropdown-arrow" src="http://img2.blogblog.com/img/widgets/arrow_dropdown.gif" /><span onclick="return(_SW_toggleReaderList(event, &quot;Subscribe1POST&quot;));"><img align="absmiddle" alt="" border="0" class="feed-icon" src="http://img1.blogblog.com/img/icon_feed12.png" />Posts</span></span> </div> <div class="bottom"></div> </div> </div> <div class="subscribe-wrapper subscribe-type-PER_POST"> <div class="subscribe expanded subscribe-type-PER_POST" id="SW_READER_LIST_Subscribe1PER_POST" style="display:none;"> <div class="top"> <span class="inner" onclick="return(_SW_toggleReaderList(event, &quot;Subscribe1PER_POST&quot;));"><img class="subscribe-dropdown-arrow" src="http://img2.blogblog.com/img/widgets/arrow_dropdown.gif" /><img align="absmiddle" alt="" border="0" class="feed-icon" src="http://img1.blogblog.com/img/icon_feed12.png" />Comments</span> <div class="feed-reader-links"> <a class="feed-reader-link" href="http://www.google.com/ig/add?source=bstp&amp;feedurl=http%3A%2F%2Fwww.the-richmonder.com%2Ffeeds%2F7912099311551272278%2Fcomments%2Fdefault" target="_blank"><img src="http://img1.blogblog.com/img/widgets/subscribe-google.png" /></a> <a class="feed-reader-link" href="http://www.netvibes.com/subscribe.php?url=http%3A%2F%2Fwww.the-richmonder.com%2Ffeeds%2F7912099311551272278%2Fcomments%2Fdefault" target="_blank"><img src="http://img1.blogblog.com/img/widgets/subscribe-netvibes.png" /></a> <a class="feed-reader-link" href="http://www.newsgator.com/ngs/subscriber/subext.aspx?url=http%3A%2F%2Fwww.the-richmonder.com%2Ffeeds%2F7912099311551272278%2Fcomments%2Fdefault" target="_blank"><img src="http://img1.blogblog.com/img/widgets/subscribe-newsgator.png" /></a> <a class="feed-reader-link" href="http://add.my.yahoo.com/content?url=http%3A%2F%2Fwww.the-richmonder.com%2Ffeeds%2F7912099311551272278%2Fcomments%2Fdefault" target="_blank"><img src="http://img1.blogblog.com/img/widgets/subscribe-yahoo.png" /></a> <a class="feed-reader-link" href="http://www.the-richmonder.com/feeds/7912099311551272278/comments/default" target="_blank"><img align="absmiddle" class="feed-icon" src="http://img1.blogblog.com/img/icon_feed12.png" /> Atom </a> </div> </div> <div class="bottom"></div> </div> <div class="subscribe" id="SW_READER_LIST_CLOSED_Subscribe1PER_POST" onclick="return(_SW_toggleReaderList(event, &quot;Subscribe1PER_POST&quot;));"> <div class="top"> <span class="inner"><img class="subscribe-dropdown-arrow" src="http://img2.blogblog.com/img/widgets/arrow_dropdown.gif" /><span onclick="return(_SW_toggleReaderList(event, &quot;Subscribe1PER_POST&quot;));"><img align="absmiddle" alt="" border="0" class="feed-icon" src="http://img1.blogblog.com/img/icon_feed12.png" />Comments</span></span> </div> <div class="bottom"></div> </div> </div> <div style="clear:both"></div> </div> </div> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=Subscribe&amp;widgetId=Subscribe1&amp;action=editWidget&amp;sectionId=sidebar-left-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;Subscribe1&quot;));" target="configSubscribe1" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> <div class="widget LinkList" id="LinkList5"> <h2>More Lefties</h2> <div class="widget-content"> <ul> <li><a href="http://heartlandofvirginia.wordpress.com/">Heartland of Virginia</a></li> <li><a href="http://leftofthehill.blogspot.com/">Left of the Hill</a></li> <li><a href="http://mosquito-blog.blogspot.com/">Mosquito Blog</a></li> <li><a href="http://offkstreet.blogspot.com/">Off K Street</a></li> <li><a href="http://zenhuber.blogspot.com/">Pen and Sword</a></li> <li><a href="http://www.pineviewfarm.net/weblog/">Pine View Farm</a></li> <li><a href="http://hoosierinva.blogspot.com/">Sisyphus</a></li> <li><a href="http://www.slantblog.blogspot.com/">SLANTblog - F.T. Rea</a></li> <li><a href="http://starcityharbinger.com/">Star City Harbinger</a></li> <li><a href="http://vbdems.blogspot.com/">VB Dems</a></li> <li><a href="http://www.vbprogressives.com/">Virginia Beach Progressives</a></li> <li><a href="http://virginiadem.wordpress.com/">Virginia Dem</a></li> <li><a href="http://vivianpaige.wordpress.com/">Vivian J. Paige</a></li> <li><a href="http://waldo.jaquith.org/">Waldo Jaquith</a></li> <li><a href="http://rockdem.blogspot.com/">We will RockDem</a></li> <li><a href="http://xcurmudgeon.blogspot.com/">X CURMUDGEON</a></li> </ul> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=LinkList&amp;widgetId=LinkList5&amp;action=editWidget&amp;sectionId=sidebar-left-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;LinkList5&quot;));" target="configLinkList5" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> </div> <div class="widget HTML" id="HTML4"> <h2 class="title">Book Store</h2> <div class="widget-content"> <iframe src="http://rcm.amazon.com/e/cm?lt1=_blank&amp;bc1=000000&amp;IS2=1&amp;bg1=FFFFFF&amp;fc1=000000&amp;lc1=0000FF&amp;t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;m=amazon&amp;f=ifr&amp;md=10FE9736YVPPT7A0FBG2&amp;asins=0195038630" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;asins=0061733636&amp;fc1=000000&amp;IS2=1&amp;lt1=_blank&amp;m=amazon&amp;lc1=0000FF&amp;bc1=000000&amp;bg1=FFFFFF&amp;f=ifr" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;asins=1568584172&amp;fc1=000000&amp;IS2=1&amp;lt1=_blank&amp;m=amazon&amp;lc1=0000FF&amp;bc1=000000&amp;bg1=FFFFFF&amp;f=ifr" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;asins=B002MU0UME&amp;fc1=000000&amp;IS2=1&amp;lt1=_blank&amp;m=amazon&amp;lc1=0000FF&amp;bc1=000000&amp;bg1=FFFFFF&amp;f=ifr" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?lt1=_blank&amp;bc1=000000&amp;IS2=1&amp;bg1=FFFFFF&amp;fc1=000000&amp;lc1=0000FF&amp;t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;m=amazon&amp;f=ifr&amp;md=10FE9736YVPPT7A0FBG2&amp;asins=0375405445" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?lt1=_blank&amp;bc1=000000&amp;IS2=1&amp;bg1=FFFFFF&amp;fc1=000000&amp;lc1=0000FF&amp;t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;m=amazon&amp;f=ifr&amp;md=10FE9736YVPPT7A0FBG2&amp;asins=1400040310" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?lt1=_blank&amp;bc1=000000&amp;IS2=1&amp;bg1=FFFFFF&amp;fc1=000000&amp;lc1=0000FF&amp;t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;m=amazon&amp;f=ifr&amp;md=10FE9736YVPPT7A0FBG2&amp;asins=0684807610" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?lt1=_blank&amp;bc1=000000&amp;IS2=1&amp;bg1=FFFFFF&amp;fc1=000000&amp;lc1=0000FF&amp;t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;m=amazon&amp;f=ifr&amp;md=10FE9736YVPPT7A0FBG2&amp;asins=0684813637" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?lt1=_blank&amp;bc1=000000&amp;IS2=1&amp;bg1=FFFFFF&amp;fc1=000000&amp;lc1=0000FF&amp;t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;m=amazon&amp;f=ifr&amp;md=10FE9736YVPPT7A0FBG2&amp;asins=1416542108" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?lt1=_blank&amp;bc1=000000&amp;IS2=1&amp;bg1=FFFFFF&amp;fc1=000000&amp;lc1=0000FF&amp;t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;m=amazon&amp;f=ifr&amp;md=10FE9736YVPPT7A0FBG2&amp;asins=0671456547" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?lt1=_blank&amp;bc1=000000&amp;IS2=1&amp;bg1=FFFFFF&amp;fc1=000000&amp;lc1=0000FF&amp;t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;m=amazon&amp;f=ifr&amp;md=10FE9736YVPPT7A0FBG2&amp;asins=034538623X" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?lt1=_blank&amp;bc1=000000&amp;IS2=1&amp;bg1=FFFFFF&amp;fc1=000000&amp;lc1=0000FF&amp;t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;m=amazon&amp;f=ifr&amp;md=10FE9736YVPPT7A0FBG2&amp;asins=0345405013" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?lt1=_blank&amp;bc1=000000&amp;IS2=1&amp;bg1=FFFFFF&amp;fc1=000000&amp;lc1=0000FF&amp;t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;m=amazon&amp;f=ifr&amp;md=10FE9736YVPPT7A0FBG2&amp;asins=0394499735" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?lt1=_blank&amp;bc1=000000&amp;IS2=1&amp;bg1=FFFFFF&amp;fc1=000000&amp;lc1=0000FF&amp;t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;m=amazon&amp;f=ifr&amp;md=10FE9736YVPPT7A0FBG2&amp;asins=067973371X" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?lt1=_blank&amp;bc1=000000&amp;IS2=1&amp;bg1=FFFFFF&amp;fc1=000000&amp;lc1=0000FF&amp;t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;m=amazon&amp;f=ifr&amp;md=10FE9736YVPPT7A0FBG2&amp;asins=0394528360" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> </div> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=HTML&amp;widgetId=HTML4&amp;action=editWidget&amp;sectionId=sidebar-left-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;HTML4&quot;));" target="configHTML4" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> </div> </aside> </div> </div> <div class="column-right-outer"> <div class="column-right-inner"> <aside> <div class="sidebar section" id="sidebar-right-1"> <div class="widget BlogList" id="BlogList1"> <h2 class="title">Civil War Sesquicentennial</h2> <div class="widget-content"> <div class="blog-list-container" id="BlogList1_container"> <ul id="BlogList1_blogs"> <li style="display: block;"> <div class="blog-icon"> <input type="hidden" value="http://www.civilwar-online.com/favicon.ico" /> </div> <div class="blog-content"> <div class="blog-title"> <a href="http://www.civilwar-online.com/" target="_blank">The American Civil War</a> </div> <div class="item-content"> <div class="item-thumbnail"> <a href="http://www.civilwar-online.com/" target="_blank"><img alt="" border="0" height="72" src="http://1.bp.blogspot.com/-Sb1oWFiyzUs/T29r5BuX_-I/AAAAAAAAHa8/RkkB7Cn9Yi8/s72-c/css_louisiana_blue_print.jpg" width="72" /></a> </div> <span class="item-title"><a href="http://www.civilwar-online.com/2012/03/march-25-1862-halleck-concerned-about.html" target="_blank">March 25, 1862: Halleck concerned about Confederate ironclads in New Orleans</a></span> - <span class="item-snippet">Union Major General Henry W. Halleck, in command of the Department of the Mississippi, had gotten word that the Confederates were constructing powerful ir...</span> <div class="item-time"> 19 hours ago </div> </div> </div> <div style="clear: both;"></div></li> </ul> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=BlogList&amp;widgetId=BlogList1&amp;action=editWidget&amp;sectionId=sidebar-right-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;BlogList1&quot;));" target="configBlogList1" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> </div> </div> <div class="widget HTML" id="HTML2"> <h2 class="title">Join RCDC</h2> <div class="widget-content"> <a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://www.richmond-democrats.com/p/upcoming-elections.html"><img style="display:block; margin:0px auto 10px; text-align:center;cursor:pointer; cursor:hand;width: 200px; height: 290px;" src="http://1.bp.blogspot.com/-Cm1EfiRutkU/TtKKdmIa9zI/AAAAAAAAGC4/nvlb10lAEQc/s400/rcdcrecruiting-web-200px.jpg" border="0" alt="" id="BLOGGER_PHOTO_ID_5679754321124325170" /></a> </div> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=HTML&amp;widgetId=HTML2&amp;action=editWidget&amp;sectionId=sidebar-right-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;HTML2&quot;));" target="configHTML2" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> <div class="widget HTML" id="HTML13"> <h2 class="title">E. Wayne Powell for Congress</h2> <div class="widget-content"> <a href="http://www.ewaynepowell.com/" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}"><img style="display:block; margin:0px auto 10px; text-align:center;cursor:pointer; cursor:hand;width: 160px; height: 160px;" src="http://1.bp.blogspot.com/-z-cnTnRgS5o/Tsxf3sdYHkI/AAAAAAAAGA0/cq72ALhj_YU/s400/Wayne-Powell-Official-Portrait-160px.jpg" border="0" alt="" id="BLOGGER_PHOTO_ID_5678018640639172162" /></a> <div style="text-align: center;"> <span class="Apple-style-span" style="font-size:x-small;"><span class="Apple-style-span" style="color:#666666;">Paid for and authorized by </span></span> </div> <div style="text-align: center;"> <span class="Apple-style-span" style="font-size:x-small;"><span class="Apple-style-span" style="color:#666666;">Powell for Congress</span></span> </div> </div> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=HTML&amp;widgetId=HTML13&amp;action=editWidget&amp;sectionId=sidebar-right-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;HTML13&quot;));" target="configHTML13" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> <div class="widget AdSense" id="AdSense1"> <div class="widget-content"> <script type="text/javascript"><!--google_ad_client="pub-8421503559745163";google_ad_host="pub-1556223355139109";google_ad_width=160;google_ad_height=600;google_ad_format="160x600_as";google_ad_type="text_image";google_ad_host_channel="0001";google_color_border="FFFFFF";google_color_bg="FFFFFF";google_color_link="336699";google_color_url="336699";google_color_text="333333";//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=AdSense&amp;widgetId=AdSense1&amp;action=editWidget&amp;sectionId=sidebar-right-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;AdSense1&quot;));" target="configAdSense1" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> </div> <div class="widget LinkList" id="LinkList1"> <h2>Syndicators</h2> <div class="widget-content"> <ul> <li><a href="http://newstex.com/products/blog_index.php">Newstex Blogs on Demand</a></li> <li><a href="http://www.rvablogs.com/">RVA Blogs</a></li> <li><a href="http://www.vapoliticalblogs.com/">Virginia Political Blogs</a></li> </ul> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=LinkList&amp;widgetId=LinkList1&amp;action=editWidget&amp;sectionId=sidebar-right-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;LinkList1&quot;));" target="configLinkList1" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> </div> <div class="widget HTML" id="HTML1"> <h2 class="title">Leftyblogs Virginia</h2> <div class="widget-content"> <script type="text/javascript" language="javascript" src="http://www.leftyblogs.com/cgi-bin/blogwire.cgi?feed=virginia&amp;site=therichmonder.blogspot.com&amp;tz=est&amp;n=10"></script> </div> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=HTML&amp;widgetId=HTML1&amp;action=editWidget&amp;sectionId=sidebar-right-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;HTML1&quot;));" target="configHTML1" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> <div class="widget HTML" id="HTML5"> <h2 class="title">Camera Store</h2> <div class="widget-content"> <iframe src="http://rcm.amazon.com/e/cm?lt1=_blank&amp;bc1=000000&amp;IS2=1&amp;bg1=FFFFFF&amp;fc1=000000&amp;lc1=0000FF&amp;t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as4&amp;m=amazon&amp;f=ifr&amp;ref=ss_til&amp;asins=B0042X9LC4" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?lt1=_blank&amp;bc1=000000&amp;IS2=1&amp;bg1=FFFFFF&amp;fc1=000000&amp;lc1=0000FF&amp;t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as4&amp;m=amazon&amp;f=ifr&amp;ref=ss_til&amp;asins=B003ZSHNEA" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?lt1=_blank&amp;bc1=000000&amp;IS2=1&amp;bg1=FFFFFF&amp;fc1=000000&amp;lc1=0000FF&amp;t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;m=amazon&amp;f=ifr&amp;md=10FE9736YVPPT7A0FBG2&amp;asins=B001MJ03U0" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;asins=B001ENOZY4&amp;fc1=000000&amp;IS2=1&amp;lt1=_blank&amp;m=amazon&amp;lc1=0000FF&amp;bc1=000000&amp;bg1=FFFFFF&amp;f=ifr" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;asins=B00267S7TQ&amp;fc1=000000&amp;IS2=1&amp;lt1=_blank&amp;m=amazon&amp;lc1=0000FF&amp;bc1=000000&amp;bg1=FFFFFF&amp;f=ifr" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;asins=B000VJX7DW&amp;fc1=000000&amp;IS2=1&amp;lt1=_blank&amp;m=amazon&amp;lc1=0000FF&amp;bc1=000000&amp;bg1=FFFFFF&amp;f=ifr" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> <p></p> <iframe src="http://rcm.amazon.com/e/cm?t=therichmondde-20&amp;o=1&amp;p=8&amp;l=as1&amp;asins=B000O161X0&amp;fc1=000000&amp;IS2=1&amp;lt1=_blank&amp;m=amazon&amp;lc1=0000FF&amp;bc1=000000&amp;bg1=FFFFFF&amp;f=ifr" style="width:120px;height:240px;" scrolling="no" marginwidth="0" marginheight="0" frameborder="0"></iframe> </div> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=HTML&amp;widgetId=HTML5&amp;action=editWidget&amp;sectionId=sidebar-right-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;HTML5&quot;));" target="configHTML5" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> <div class="widget BlogArchive" id="BlogArchive1"> <h2>Blog Archive</h2> <div class="widget-content"> <div id="ArchiveList"> <div id="BlogArchive1_ArchiveList"> <ul class="flat"> <li class="archivedate"><a href="http://www.the-richmonder.com/2012_03_01_archive.html">March 2012</a> (60) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2012_02_01_archive.html">February 2012</a> (37) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2012_01_01_archive.html">January 2012</a> (43) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2011_12_01_archive.html">December 2011</a> (40) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2011_11_01_archive.html">November 2011</a> (22) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2011_10_01_archive.html">October 2011</a> (38) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2011_09_01_archive.html">September 2011</a> (22) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2011_08_01_archive.html">August 2011</a> (30) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2011_07_01_archive.html">July 2011</a> (41) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2011_06_01_archive.html">June 2011</a> (46) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2011_05_01_archive.html">May 2011</a> (41) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2011_04_01_archive.html">April 2011</a> (33) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2011_03_01_archive.html">March 2011</a> (44) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2011_02_01_archive.html">February 2011</a> (24) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2011_01_01_archive.html">January 2011</a> (39) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2010_12_01_archive.html">December 2010</a> (12) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2010_11_01_archive.html">November 2010</a> (29) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2010_10_01_archive.html">October 2010</a> (87) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2010_09_01_archive.html">September 2010</a> (42) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2010_08_01_archive.html">August 2010</a> (67) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2010_07_01_archive.html">July 2010</a> (77) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2010_06_01_archive.html">June 2010</a> (107) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2010_05_01_archive.html">May 2010</a> (74) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2010_04_01_archive.html">April 2010</a> (64) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2010_03_01_archive.html">March 2010</a> (79) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2010_02_01_archive.html">February 2010</a> (27) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2010_01_01_archive.html">January 2010</a> (31) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2009_12_01_archive.html">December 2009</a> (27) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2009_11_01_archive.html">November 2009</a> (17) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2009_10_01_archive.html">October 2009</a> (10) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2009_09_01_archive.html">September 2009</a> (26) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2009_08_01_archive.html">August 2009</a> (40) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2009_07_01_archive.html">July 2009</a> (17) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2009_06_01_archive.html">June 2009</a> (4) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2009_05_01_archive.html">May 2009</a> (7) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2009_04_01_archive.html">April 2009</a> (46) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2009_03_01_archive.html">March 2009</a> (41) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2009_02_01_archive.html">February 2009</a> (20) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2009_01_01_archive.html">January 2009</a> (22) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2008_12_01_archive.html">December 2008</a> (26) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2008_11_01_archive.html">November 2008</a> (45) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2008_10_01_archive.html">October 2008</a> (102) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2008_09_01_archive.html">September 2008</a> (163) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2008_08_01_archive.html">August 2008</a> (48) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2008_07_01_archive.html">July 2008</a> (60) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2008_06_01_archive.html">June 2008</a> (15) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2008_05_01_archive.html">May 2008</a> (12) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2008_04_01_archive.html">April 2008</a> (17) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2008_03_01_archive.html">March 2008</a> (13) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2008_02_01_archive.html">February 2008</a> (46) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2008_01_01_archive.html">January 2008</a> (53) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2007_12_01_archive.html">December 2007</a> (40) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2007_11_01_archive.html">November 2007</a> (42) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2007_10_01_archive.html">October 2007</a> (62) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2007_09_01_archive.html">September 2007</a> (69) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2007_08_01_archive.html">August 2007</a> (56) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2007_07_01_archive.html">July 2007</a> (50) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2007_06_01_archive.html">June 2007</a> (70) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2007_05_01_archive.html">May 2007</a> (68) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2007_04_01_archive.html">April 2007</a> (71) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2007_03_01_archive.html">March 2007</a> (83) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2007_02_01_archive.html">February 2007</a> (13) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2007_01_01_archive.html">January 2007</a> (93) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2006_12_01_archive.html">December 2006</a> (42) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2006_11_01_archive.html">November 2006</a> (45) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2006_10_01_archive.html">October 2006</a> (43) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2006_09_01_archive.html">September 2006</a> (46) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2006_08_01_archive.html">August 2006</a> (62) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2006_07_01_archive.html">July 2006</a> (67) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2006_06_01_archive.html">June 2006</a> (81) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2006_05_01_archive.html">May 2006</a> (86) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2006_04_01_archive.html">April 2006</a> (80) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2006_03_01_archive.html">March 2006</a> (123) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2006_02_01_archive.html">February 2006</a> (96) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2006_01_01_archive.html">January 2006</a> (99) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2005_12_01_archive.html">December 2005</a> (93) </li> <li class="archivedate"><a href="http://www.the-richmonder.com/2005_11_01_archive.html">November 2005</a> (34) </li> </ul> </div> </div> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=BlogArchive&amp;widgetId=BlogArchive1&amp;action=editWidget&amp;sectionId=sidebar-right-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;BlogArchive1&quot;));" target="configBlogArchive1" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> </div> </div> </aside> </div> </div> </div> <div style="clear: both"></div> <!-- columns --> </div> <!-- main --> </div> </div> <div class="main-cap-bottom cap-bottom"> <div class="cap-left"></div> <div class="cap-right"></div> </div> </div> <footer> <div class="footer-outer"> <div class="footer-cap-top cap-top"> <div class="cap-left"></div> <div class="cap-right"></div> </div> <div class="fauxborder-left footer-fauxborder-left"> <div class="fauxborder-right footer-fauxborder-right"></div> <div class="region-inner footer-inner"> <div class="foot section" id="footer-1"> <div class="widget HTML" id="HTML7"> <h2 class="title">Amazon</h2> <div class="widget-content"> <iframe src="http://rcm.amazon.com/e/cm?t=therichmondde-20&amp;o=1&amp;p=48&amp;l=ur1&amp;category=amazonhomepage&amp;f=ifr" width="728" height="90" scrolling="no" border="0" marginwidth="0" style="border:none;" frameborder="0"></iframe> </div> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=HTML&amp;widgetId=HTML7&amp;action=editWidget&amp;sectionId=footer-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;HTML7&quot;));" target="configHTML7" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> </div> <table border="0" cellpadding="0" cellspacing="0" class="section-columns columns-2"> <tbody> <tr> <td class="first columns-cell"> <div class="foot section" id="footer-2-1"> <div class="widget HTML" id="HTML6"> <h2 class="title">Jazz Greats</h2> <div class="widget-content"> <iframe src="http://rcm.amazon.com/e/cm?t=therichmondde-20&amp;o=1&amp;p=12&amp;l=ur1&amp;category=100greatestjazzartistsofalltime&amp;banner=1ADY6BF00E10XV3YJQR2&amp;f=ifr" width="300" height="250" scrolling="no" border="0" marginwidth="0" style="border:none;" frameborder="0"></iframe> </div> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=HTML&amp;widgetId=HTML6&amp;action=editWidget&amp;sectionId=footer-2-1" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;HTML6&quot;));" target="configHTML6" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> </div></td> <td class="columns-cell"> <div class="foot section" id="footer-2-2"> <div class="widget HTML" id="HTML3"> <h2 class="title">Admin</h2> <div class="widget-content"> <!-- Site Meter --> <script type="text/javascript" src="http://s26.sitemeter.com/js/counter.js?site=s26therichmonder"></script> <noscript> <a href="http://s26.sitemeter.com/stats.asp?site=s26therichmonder" target="_top"><img src="http://s26.sitemeter.com/meter.asp?site=s26therichmonder" alt="Site Meter" border="0" /></a> </noscript> <!-- Copyright (c)2009 Site Meter --> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script> <script type="text/javascript">try {var pageTracker = _gat._getTracker("UA-1647619-9");pageTracker._trackPageview();} catch(err) {}</script> <!--NetworkedBlogs Start--> <style type="text/css"><!--.networkedblogs_widget a {text-decoration:none;color:#3B5998;font-weight:normal;}.networkedblogs_widget .networkedblogs_footer a {text-decoration:none;color:#FFFFFF;font-weight:normal;}--></style> <div id="networkedblogs_container" style="height:180px;padding-top:20px;"> <div id="networkedblogs_above"></div> <div id="networkedblogs_widget" style="width:120px;margin:0px auto;padding:0px 0px 3px 0px;font-family:'lucida grande',tahoma,Verdana,Arial,Sans-Serif;font-size:11px;font-weight:normal;text-decoration:none;background:#3B5998 none repeat scroll 0% 0%;border:none;line-height:13px;"> <div id="networkedblogs_header" style="padding:1px 1px 2px 3px;text-align:left;"> <a href="http://www.facebook.com/apps/application.php?id=9953271133" style="text-decoration:none;color:#FFFFFF;font-weight:normal;font-size:11px;background-repeat:no-repeat;">NetworkedBlogs</a> </div> <div id="networkedblogs_body" style="background-color:#FFFFFF;color:#444444;padding:4px;border-left:1px solid #D8DFEA;border-right:1px solid #D8DFEA;text-align:left;"> <table cellpadding="0" cellspacing="0"> <tbody> <tr> <td><span style="color:#777777;">Blog:</span></td> </tr> <tr> <td><a target="_blank" href="http://networkedblogs.com/blog/the_richmonder/" style="text-decoration:none;color:#3B5998;">The Richmonder</a></td> </tr> <tr> <td> <div style="padding:0px;padding-top:5px;color:#777777;"> Topics: </div></td> </tr> <tr> <td><a target="_blank" href="http://networkedblogs.com/topic/politics" style="text-decoration:none;color:#3b5998;">Politics</a>, <a target="_blank" href="http://networkedblogs.com/topic/news" style="text-decoration:none;color:#3b5998;">News</a>, <a target="_blank" href="http://networkedblogs.com/topic/virginia" style="text-decoration:none;color:#3b5998;">Virginia</a></td> </tr> <tr> <td> <div id="networkedblogs_badges"> &nbsp; </div></td> </tr> <tr> <td> <div style="padding:0px;text-align:center;"> <a target="_blank" href="http://networkedblogs.com/blog/the_richmonder/?ahash=49d9bbc7bd2f491e62a76098a16d353f" style="text-decoration:none;color:#666666;font-weight:normal;font-size:10px;">Follow my blog</a> </div></td> </tr> </tbody> </table> </div> </div> <div id="networkedblogs_below" class="networkedblogs_below"></div> </div> <script type="text/javascript"><!--if(typeof(networkedblogs)=="undefined"){networkedblogs = {};networkedblogs.blogId=473505;networkedblogs.shortName="the_richmonder";}--></script> <script type="text/javascript" src="http://widget.networkedblogs.com/getwidget?bid=473505"></script> <!--NetworkedBlogs End--> </div> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=HTML&amp;widgetId=HTML3&amp;action=editWidget&amp;sectionId=footer-2-2" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;HTML3&quot;));" target="configHTML3" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> </div></td> </tr> </tbody> </table> <!-- outside of the include in order to lock Attribution widget --> <div class="foot section" id="footer-3"> <div class="widget Attribution" id="Attribution1"> <div class="widget-content" style="text-align: center;"> The Richmonder &copy; 2009-2012. Travel template. Powered by <a href="http://www.blogger.com" target="_blank">Blogger</a>. </div> <div class="clear"></div> <span class="widget-item-control"><span class="item-control blog-admin"><a class="quickedit" href="http://www.blogger.com/rearrange?blogID=19190919&amp;widgetType=Attribution&amp;widgetId=Attribution1&amp;action=editWidget&amp;sectionId=footer-3" onclick="return _WidgetManager._PopupConfig(document.getElementById(&quot;Attribution1&quot;));" target="configAttribution1" title="Edit"><img alt="" height="18" src="http://img1.blogblog.com/img/icon18_wrench_allbkg.png" width="18" /></a></span></span> <div class="clear"></div> </div> </div> </div> </div> <div class="footer-cap-bottom cap-bottom"> <div class="cap-left"></div> <div class="cap-right"></div> </div> </div> </footer> <!-- content --> </div> </div> <div class="content-cap-bottom cap-bottom"> <div class="cap-left"></div> <div class="cap-right"></div> </div> </div> </div> <script type="text/javascript"> window.setTimeout(function() { document.body.className = document.body.className.replace('loading', ''); }, 10); </script> <script type="text/javascript">if (window.jstiming) window.jstiming.load.tick('widgetJsBefore');</script> <script type="text/javascript" src="http://www.blogger.com/static/v1/widgets/2628719693-widgets.js"></script> <script type="text/javascript">if (typeof(BLOG_attachCsiOnload) != 'undefined' && BLOG_attachCsiOnload != null) { window['blogger_templates_experiment_id'] = "templatesV2";window['blogger_blog_id'] = '19190919';BLOG_attachCsiOnload('item_'); }_WidgetManager._Init('http://www.blogger.com/rearrange?blogID\x3d19190919','http://www.the-richmonder.com/2008/07/sunday-electoral-college-projection.html','19190919');_WidgetManager._SetPageActionUrl('http://www.blogger.com/display?blogID\x3d19190919','APq4FmAdHZWtIuJ8rjjgh0DbdXgQ6SwyMk3wohsf-4k51t2s-Wx7bOrMmKsIj5FEBJh9_0lOFbGtLvnHDr5owV75xaRs4uwEOg\x3d\x3d','AOuZoY7__7VfW2R717iuklU_7EbOs1zS9Q:1332770488039');_WidgetManager._SetDataContext([{'name': 'blog', 'data': {'bloggerUrl': 'http://www.blogger.com', 'title': 'The Richmonder', 'pageType': 'item', 'url': 'http://www.the-richmonder.com/2008/07/sunday-electoral-college-projection.html', 'canonicalUrl': 'http://www.the-richmonder.com/2008/07/sunday-electoral-college-projection.html', 'canonicalHomepageUrl': 'http://www.the-richmonder.com/', 'homepageUrl': 'http://www.the-richmonder.com/', 'blogspotFaviconUrl': 'http://www.the-richmonder.com/favicon.ico', 'enabledCommentProfileImages': true, 'searchLabel': '', 'searchQuery': '', 'pageName': 'Sunday electoral college projection', 'pageTitle': 'The Richmonder: Sunday electoral college projection', 'encoding': 'UTF-8', 'locale': 'en-US', 'isPrivate': false, 'isMobile': false, 'mobileClass': '', 'languageDirection': 'ltr', 'feedLinks': '\74link rel\75\42alternate\42 type\75\42application/atom+xml\42 title\75\42The Richmonder - Atom\42 href\75\42http://www.the-richmonder.com/feeds/posts/default\42 /\76\n\74link rel\75\42alternate\42 type\75\42application/rss+xml\42 title\75\42The Richmonder - RSS\42 href\75\42http://www.the-richmonder.com/feeds/posts/default?alt\75rss\42 /\76\n\74link rel\75\42service.post\42 type\75\42application/atom+xml\42 title\75\42The Richmonder - Atom\42 href\75\42http://www.blogger.com/feeds/19190919/posts/default\42 /\76\n\74link rel\75\42EditURI\42 type\75\42application/rsd+xml\42 title\75\42RSD\42 href\75\42http://www.blogger.com/rsd.g?blogID\07519190919\42 /\76\n\74link rel\75\42alternate\42 type\75\42application/atom+xml\42 title\75\42The Richmonder - Atom\42 href\75\42http://www.the-richmonder.com/feeds/7912099311551272278/comments/default\42 /\76\n', 'meTag': '', 'openIdOpTag': '', 'imageSrcTag': '', 'latencyHeadScript': '\74script type\75\42text/javascript\42\76(function() { var a\75window;function c(b){this.t\75{};this.tick\75function(b,i,d){d\75void 0!\75d?d:(new Date).getTime();this.t[b]\75[d,i]};this.tick(\42start\42,null,b)}var f\75new c;a.jstiming\75{Timer:c,load:f};try{var g\75null;a.chrome\46\46a.chrome.csi\46\46(g\75Math.floor(a.chrome.csi().pageT));null\75\75g\46\46a.gtbExternal\46\46(g\75a.gtbExternal.pageT());null\75\75g\46\46a.external\46\46(g\75a.external.pageT);g\46\46(a.jstiming.pt\75g)}catch(h){};a.tickAboveFold\75function(b){var e\0750;if(b.offsetParent){do e+\75b.offsetTop;while(b\75b.offsetParent)}b\75e;750\76\75b\46\46a.jstiming.load.tick(\42aft\42)};var j\75!1;function k(){j||(j\75!0,a.jstiming.load.tick(\42firstScrollTime\42))}a.addEventListener?a.addEventListener(\42scroll\42,k,!1):a.attachEvent(\42onscroll\42,k);\n })();\74/script\076', 'mobileHeadScript': '', 'adsenseClientId': 'pub-8421503559745163', 'analyticsAccountNumber': '', 'ieCssRetrofitLinks': '\74!--[if IE]\76\74script type\75\42text/javascript\42 src\75\42http://www.blogger.com/static/v1/jsbin/3804583874-ieretrofit.js\42\76\74/script\76\n\74![endif]--\076', 'view': '', 'dynamicViewsCommentsSrc': '//www.blogblog.com/dynamicviews/f75e48f708466c7f/js/comments.js', 'dynamicViewsScriptSrc': '//www.blogblog.com/dynamicviews/28ee9dac758a380a'}}, {'name': 'skin', 'data': {'vars': {'mobile_background_overlay': 'transparent none repeat scroll top left', 'tabs_selected_background_gradient': 'url(http://www.blogblog.com/1kt/travel/bg_black_50.png)', 'tabs_background_color': 'transparent', 'content_padding': '20px', 'widget_link_visited_color': '#b81809', 'tabs_selected_background_color': 'transparent', 'footer_background_gradient': 'none', 'link_hover_color': '#ff1700', 'post_title_text_color': '#170a4c', 'content_background': 'transparent url(http://www.blogblog.com/1kt/travel/bg_black_70.png) repeat scroll top left', 'description_text_color': '#000000', 'widget_font': 'normal normal 13px \47Trebuchet MS\47,Trebuchet,sans-serif', 'body_text_color': '#000000', 'link_visited_color': '#1909b8', 'post_background_color': '#ffffff', 'post_title_font': 'normal bold 30px \47Trebuchet MS\47,Trebuchet,sans-serif', 'tabs_text_color': '#ffffff', 'endSide': 'right', 'startSide': 'left', 'tabs_font': 'normal bold 16px \47Trebuchet MS\47,Trebuchet,sans-serif', 'widget_outer_background_gradient': 'none', 'content_posts_padding': '20px', 'widget_link_color': '#0c007f', 'body_font': 'normal normal 13px \47Trebuchet MS\47,Trebuchet,sans-serif', 'content_imageBorder_top': 'none', 'comments_background': '#cccccc none repeat scroll top center', 'date_text_color': '#000000', 'mobile_button_color': '#ffffff', 'widget_outer_background_color': '#ffffff', 'widget_title_font': 'normal bold 14px \47Trebuchet MS\47,Trebuchet,sans-serif', 'widget_title_text_color': '#0c007f', 'widget_text_color': '#0c007f', 'content_margin': '20px', 'keycolor': '#694ff4', 'link_color': '#1800ff', 'content_background_color': 'transparent', 'header_font': 'normal normal 60px \47Trebuchet MS\47,Trebuchet,sans-serif', 'header_text_color': '#ffffff', 'widget_border_bevel_color': '#cc0000', 'content_imageBorder_top_space': '0', 'date_font': 'normal normal 14px \47Trebuchet MS\47,Trebuchet,sans-serif', 'tabs_selected_text_color': '#ffffff', 'body_background_color': '#145088', 'post_background_url': 'none', 'tabs_background_gradient': 'url(http://www.blogblog.com/1kt/travel/bg_black_50.png)', 'widget_alternate_text_color': '#b81809'}, 'override': ''}}, {'name': 'view', 'data': {'classic': {'name': 'classic', 'url': '/?view\75classic'}, 'flipcard': {'name': 'flipcard', 'url': '/?view\75flipcard'}, 'magazine': {'name': 'magazine', 'url': '/?view\75magazine'}, 'mosaic': {'name': 'mosaic', 'url': '/?view\75mosaic'}, 'sidebar': {'name': 'sidebar', 'url': '/?view\75sidebar'}, 'snapshot': {'name': 'snapshot', 'url': '/?view\75snapshot'}, 'timeslide': {'name': 'timeslide', 'url': '/?view\75timeslide'}}}]);_WidgetManager._RegisterWidget('_BlogListView', new _WidgetInfo('BlogList1', 'sidebar-right-1', null, document.getElementById('BlogList1'), {'numItemsToShow': 0, 'totalItems': 1}, 'displayModeFull'));_WidgetManager._RegisterWidget('_HTMLView', new _WidgetInfo('HTML2', 'sidebar-right-1', null, document.getElementById('HTML2'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_HTMLView', new _WidgetInfo('HTML13', 'sidebar-right-1', null, document.getElementById('HTML13'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_AdSenseView', new _WidgetInfo('AdSense1', 'sidebar-right-1', null, document.getElementById('AdSense1'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_LinkListView', new _WidgetInfo('LinkList1', 'sidebar-right-1', null, document.getElementById('LinkList1'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_HTMLView', new _WidgetInfo('HTML1', 'sidebar-right-1', null, document.getElementById('HTML1'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_HTMLView', new _WidgetInfo('HTML5', 'sidebar-right-1', null, document.getElementById('HTML5'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_BlogArchiveView', new _WidgetInfo('BlogArchive1', 'sidebar-right-1', null, document.getElementById('BlogArchive1'), {'languageDirection': 'ltr'}, 'displayModeFull'));_WidgetManager._RegisterWidget('_HTMLView', new _WidgetInfo('HTML14', 'sidebar-left-1', null, document.getElementById('HTML14'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_AdSenseView', new _WidgetInfo('AdSense2', 'sidebar-left-1', null, document.getElementById('AdSense2'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_HTMLView', new _WidgetInfo('HTML9', 'sidebar-left-1', null, document.getElementById('HTML9'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_AdSenseView', new _WidgetInfo('AdSense3', 'sidebar-left-1', null, document.getElementById('AdSense3'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_HTMLView', new _WidgetInfo('HTML10', 'sidebar-left-1', null, document.getElementById('HTML10'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_LinkListView', new _WidgetInfo('LinkList3', 'sidebar-left-1', null, document.getElementById('LinkList3'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_SubscribeView', new _WidgetInfo('Subscribe1', 'sidebar-left-1', null, document.getElementById('Subscribe1'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_LinkListView', new _WidgetInfo('LinkList5', 'sidebar-left-1', null, document.getElementById('LinkList5'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_HTMLView', new _WidgetInfo('HTML4', 'sidebar-left-1', null, document.getElementById('HTML4'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_HTMLView', new _WidgetInfo('HTML3', 'footer-2-2', null, document.getElementById('HTML3'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_HTMLView', new _WidgetInfo('HTML6', 'footer-2-1', null, document.getElementById('HTML6'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_AttributionView', new _WidgetInfo('Attribution1', 'footer-3', null, document.getElementById('Attribution1'), {'attribution': 'The Richmonder &#169; 2009-2012. Travel template. Powered by \74a href\75\47http://www.blogger.com\47 target\75\47_blank\47\76Blogger\74/a\76.'}, 'displayModeFull'));_WidgetManager._RegisterWidget('_HTMLView', new _WidgetInfo('HTML7', 'footer-1', null, document.getElementById('HTML7'), {}, 'displayModeFull'));_WidgetManager._RegisterWidget('_HeaderView', new _WidgetInfo('Header1', 'header'));_WidgetManager._RegisterWidget('_NavbarView', new _WidgetInfo('Navbar1', 'navbar'));_WidgetManager._RegisterWidget('_BlogView', new _WidgetInfo('Blog1', 'main', null, document.getElementById('Blog1'), {'cmtInteractionsEnabled': false, 'showBacklinks': true, 'postId': '7912099311551272278', 'lightboxEnabled': true, 'lightboxModuleUrl': 'http://www.blogger.com/static/v1/jsbin/519181205-lbx.js', 'lightboxCssUrl': 'http://www.blogger.com/static/v1/v-css/3397631820-lightbox_bundle.css'}, 'displayModeFull'));</script> </body> </html>
240	single	presidential middle names	Find a list of the full names of US presidents.	clueweb12-1509wb-80-07144	2	<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml" dir="ltr" lang="en-US"> <head profile="http://gmpg.org/xfn/11"> <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /> <title>WORLDmag.com | McCain’s (massive?) mistake | Kristin Chapman</title> <meta name="description" content="The hubbub is slow to die after John McCain condemned&nbsp;conservative radio talk-show host Bill Cunningham for opening a Cincinnati rally by taking aim at Barack Obama. Conservatives like Rush Limbaugh and Sean Hannity wasted no time in responding, denouncing McCain’s actions&nbsp;on the airwaves as millions of conservative Republican voters listened.Analysts are now saying McCain may [...]" /> <meta property="og:title" content="WORLDmag.com | McCain’s (massive?) mistake | Kristin Chapman" /> <meta property="og:description" content="The hubbub is slow to die after John McCain condemned&nbsp;conservative radio talk-show host Bill Cunningham for opening a Cincinnati rally by taking aim at Barack Obama. Conservatives like Rush Limbaugh and Sean Hannity wasted no time in responding, denouncing McCain’s actions&nbsp;on the airwaves as millions of conservative Republican voters listened.Analysts are now saying McCain may [...]" /> <meta name="verify-v1" content="Vnf4XY6ul7Zc/Khzp6gfrmEI2qeMfFDqVGK9jsaCmFY=" /> <link href="/wp-content/themes/worldmag/favicon.ico" rel="shortcut icon" type="image/x-icon" /> <link rel="stylesheet" href="/wp-content/themes/worldmag/style.css?ver=2" type="text/css" media="screen" /> <link rel="stylesheet" href="/wp-content/themes/worldmag/print.css" type="text/css" media="print" /> <link rel="stylesheet" href="/wp-content/themes/worldmag/thickbox.css" type="text/css" media="screen" /> <link rel="alternate" type="application/rss+xml" title="WORLDmag.com | Community RSS Feed" href="http://online.worldmag.com/feed/" /> <link rel="pingback" href="http://online.worldmag.com/xmlrpc.php" /> <script type="text/javascript" src="http://online.worldmag.com/wp-content/themes/worldmag/js/jquery-1.2.6.min.js"></script> <script type="text/javascript" src="http://online.worldmag.com/wp-content/themes/worldmag/js/jquery.cookie.js"></script> <script type="text/javascript" src="http://online.worldmag.com/wp-content/themes/worldmag/js/thickbox-compressed.js"></script> <script type="text/javascript" src="http://online.worldmag.com/wp-content/themes/worldmag/js/worldfunc2.js"></script> <script type="text/javascript" src="/flash/swfobject.js"></script> <script type="text/javascript"> var menuTimer = 0; $(function(){ $('#print_options').css({opacity:0}); $('#print_button,#print_options,#print_options *') .css({cursor:'pointer'}) .hover( function(){ clearTimeout(menuTimer); $('#print_options').show().stop().animate({opacity:.75},400); }, function(){ clearTimeout(menuTimer); menuTimer = setTimeout(function(){ $('#print_options').animate({opacity:0},400,function(){ $('#print_options').hide(); }); },500); }); $('#print_comments').toggle( function(){ $('#comments').attr('id','comments2'); $('#print_comments img').attr('src','/wp-content/themes/worldmag/images/checkbox2.png'); }, function(){ $('#comments2').attr('id','comments'); $('#print_comments img').attr('src','/wp-content/themes/worldmag/images/checkbox.png'); } ); });</script> <link rel="alternate" type="application/rss+xml" title="WORLDmag.com | Community &raquo; McCain’s (massive?) mistake Comments Feed" href="http://online.worldmag.com/2008/02/29/mccains-massive-mistake/feed/" /> <link rel="stylesheet" id="wp-email-css" href="http://online.worldmag.com/wp-content/plugins/wp-email/email-css.css?ver=2.50" type="text/css" media="all" /> <link rel="stylesheet" id="sociable-front-css-css" href="http://online.worldmag.com/wp-content/plugins/sociable/sociable.css?ver=2.8.4" type="text/css" media="" /> <script type="text/javascript" src="http://online.worldmag.com/wp-includes/js/jquery/jquery.js?ver=1.3.2"></script> <link rel="EditURI" type="application/rsd+xml" title="RSD" href="http://online.worldmag.com/xmlrpc.php?rsd" /> <link rel="wlwmanifest" type="application/wlwmanifest+xml" href="http://online.worldmag.com/wp-includes/wlwmanifest.xml" /> <link rel="index" title="WORLDmag.com | Community" href="http://online.worldmag.com" /> <link rel="start" title="Breaking free" href="http://online.worldmag.com/2007/07/26/breaking-free/" /> <link rel="prev" title="Hagee hearts McCain: A “grotesque double standard?”" href="http://online.worldmag.com/2008/02/29/hagee-hearts-mccain-a-grotesque-double-standard/" /> <link rel="next" title="The face of Russia’s new leader" href="http://online.worldmag.com/2008/02/29/the-face-of-russias-new-leader/" /> <meta name="generator" content="WordPress 2.8.4" /> <script language="javascript" type="text/javascript"> <!-- Begin function ddrc_popup(URL,WIDTH,HEIGHT) { day = new Date(); id = day.getTime(); eval("ddrcpage" + id + " = window.open(URL, '" + id + "', 'toolbar=0,scrollbars=0,location=0,statusbar=0,menubar=0,resizable=0,width=' + WIDTH + ',height=' + HEIGHT + '');"); } // End --> </script> <script type="text/javascript">var AKPC_IDS = "";</script> </head> <body> <div id="page"> <div id="pageTop"> <div id="site_masthead"> <a href="http://www.worldmag.com/" class="logo"> <img src="/wp-content/themes/worldmag/images/world_community.gif" alt="WorldMag.com Community" class="masthead" /><br /> </a> <div class="noPrint ads"> <a href="http://www.gwnews.com/N0GIWEB1 " onclick="openWindow('http://www.worldmag.com/media/counter.cfm?ad=734'); return false;" target="_blank"><img src="http://media.worldmag.com/images/media/GWN180x73.jpg" alt="" /></a> </div> </div> <table id="pageTopNav" width="100%"> <tbody> <tr> <td><a href="http://www.worldmag.com/">Home</a></td> <td><a href="/">Community&nbsp;Home</a></td> <td><a href="/cat/newsdesk/">News&nbsp;Desk</a></td> <td><a href="/cat/commentary/">Commentary</a></td> <td><a href="/archives/">Community&nbsp;Archives</a></td> <td><a href="http://www.worldmag.com/podcast/">Radio</a></td> <td><a href="http://www.worldmag.com/world_contact_us.cfm">Contact&nbsp;Us</a></td> <td><a href="http://www.worldmag.com/s2/">Subscribe</a></td> <td class="last"><a href="https://www.worldmag.com/s2/donate.cfm">Donate</a></td> </tr> </tbody> </table> <div style="clear:both;"></div> </div> <!--end #pageTop--> <div style="clear:both;"></div> <div id="pageLft"> <div id="leftNav"> <script type="text/javascript"> $(function(){ var origW = ''; $('.current_cover').hover( function(){ origW = $(this).outerWidth(); $(this).css('width','auto'); }, function(){ $(this).css({width:origW+'px'}); } ); }); </script> <a class="menumain2" href="http://www.worldmag.com/archives/2012-04-21" target="_parent">CURRENT ISSUE</a> <div id="leftcurrentissue" style="height:142px; position: relative;"> <a class="current_cover" style="display:block; width:108px; height:142px; position:absolute; top:0px; left:18px; overflow:hidden;" href="http://www.worldmag.com/archives/2012-04-21" target="_parent"> <img src="http://www.worldmag.com/images/covers/2012-04-21tn.jpg" border="0" alt="World Magazine: Apr 21, 2012" /> </a> </div> <p class="leadin"> <a href="http://www.worldmag.com/articles/19378" class="headline" target="_parent">Ballot boxing</a> <br />Supporters of Voter ID laws say they block obvious avenue to election fraud <br /> <a href="http://www.worldmag.com/articles/19378" class="link" target="_parent">FULL STORY</a> </p> <a class="menumain" href="http://www.worldmag.com/archives/2012-04-21" target="_parent">Table of Contents</a> <a class="menumain" href="http://www.worldmag.com/archives/2012-04-21/ezine" target="_parent">E-zine/pdf Version</a> <a class="menumain" href="#" onclick="return showMenu('menusection1');">iPad Version</a> <div id="menusection1" class="menusection"> <p><a class="leftlink" href="http://www.worldmag.com/s2/ipad.cfm" target="_parent">iPad subscriptions</a> <a class="leftlink" href="http://itunes.apple.com/us/app/world-magazine/id424126267?mt=8" target="_parent">Download app</a> <a class="leftlink" href="http://www.worldmag.com/ipad/" target="_parent">iPad app info</a> <a class="leftlink" href="http://www.worldmag.com/ipad/help.cfm" target="_parent">iPad app help</a></p> </div> <a class="menumain" href="#" onclick="return showMenu('menusection2');">Kindle Version</a> <div id="menusection2" class="menusection"> <p><a class="leftlink" href="http://www.amazon.com/WORLD-Magazine/dp/B005YHGI0K/" target="_parent">WORLD Magazine</a> <a class="leftlink" href="http://www.amazon.com/WORLDmag-com-Web-Extras/dp/B0062BFDBW/" target="_parent">Web Extras</a> <a class="leftlink" href="http://www.amazon.com/WORLDmag-com-Community-Commentary/dp/B0062AZKKW/" target="_parent">Commentary Columns</a></p> </div> <a class="menumain" href="http://www.worldmag.com/howtomobile.cfm">Mobile Version</a> <a class="menumain" href="#" onclick="return showMenu('menusection3');">RSS/Social Media</a> <div id="menusection3" class="menusection"> <p><a class="leftlink" href="http://www.worldmag.com/rss/" target="_parent">WORLD Magazine</a> <a class="leftlink" href="http://www.worldmag.com/popular/rss/" target="_parent">WORLD Popular Articles</a> <a class="leftlink" href="http://www.worldmag.com/nowshowing/rss/" target="_parent">WORLD Movie Reviews</a> <a class="leftlink" href="/feed/" target="_parent">Community</a> <a class="leftlink" href="/cat/newsdesk/feed/" target="_parent">News Desk</a> <a class="leftlink" href="/cat/commentary/feed/" target="_parent">Commentary</a> <a class="leftlink" href="http://www.facebook.com/pages/WORLD-Magazine/28814095885" target="_blank">WORLD on Facebook</a> <a class="leftlink" href="http://twitter.com/WORLD_mag" target="_blank">WORLD on Twitter</a> </p> </div> <a class="menumain" href="#" onclick="return showMenu('menusection4');">Featured Content</a> <div id="menusection4" class="menusection"> <p> <a class="leftlink" href="http://www.worldmag.com/9-11/" target="_parent">9/11 Remembrances</a> <a class="leftlink" href="http://www.worldmag.com/covers/" target="_parent">WORLD Covers</a> <a class="leftlink" href="http://www.worldmag.com/campaign2012/" target="_parent">Campaign 2012</a> <a class="leftlink" href="http://www.worldmag.com/roevwade/" target="_parent">Roe v. Wade</a> <a class="leftlink" href="http://www.worldmag.com/booksissue/" target="_parent">Books Issue</a> <a class="leftlink" href="http://www.worldmag.com/compassion/" target="_parent">Hope Award</a> <a class="leftlink" href="http://www.worldmag.com/daniel/" target="_parent">Daniel of the Year</a> <a class="leftlink" href="http://www.worldmag.com/olaskyseries/" target="_parent">Marvin Olasky series</a> <a class="leftlink" href="http://www.worldmag.com/editorialcartoons/" target="_parent">Political Cartoons</a> <a class="leftlink" href="http://www.worldmag.com/nowshowing/" target="_parent">Movie Reviews</a> <a class="leftlink" href="http://www.worldmag.com/books/" target="_parent">Books</a> <a class="leftlink" href="http://www.worldmag.com/music/" target="_parent">Music</a> </p> </div> <a class="menumain" href="http://www.worldmag.com/archives/" target="_parent">Archives</a> <a class="menumain" href="#" onclick="return showMenu('menusection5');">Classifieds</a> <div id="menusection5" class="menusection"> <p><a class="leftlink" href="http://www.worldmag.com/classifieds/" target="_parent">Classified Ad Listings</a> <a class="leftlink" href="http://www.worldmag.com/classifieds/submit.cfm" target="_parent"><strong>Submit Classified Ad</strong></a></p> </div> <a class="menumain2" href="http://www.worldmag.com/webextra/" target="_parent">WEB EXTRAS</a> <a href="#" class="menumain2" onclick="return showMenu('menusection8');">News/Commentary</a> <div id="menusection8" class="menusection"> <a class="leftlink" href="/">Front Page</a> <a class="leftlink" href="/cat/commentary/">Commentary</a> <a class="leftlink" href="/cat/newsdesk/">News Desk</a> </div> <a class="menumain2" href="http://www.worldmag.com/columnists/" target="_parent">COLUMNISTS</a> <a class="menumain2" href="http://www.worldmag.com/nowshowing/" target="_parent">Movie Reviews</a> <a class="menumain2" href="http://www.worldmag.com/podcast/" target="_parent">Radio</a> <a href="#" class="menumain2" onclick="return showMenu('menusection9');">OTHER WORLD NEWS GROUP WEBSITES</a> <div id="menusection9" class="menusection"> <a class="leftlink" href="http://www.worldoncampus.com/" target="_parent">WORLD on Campus</a> <a class="leftlink" href="http://www.worldcalifornia.com/" target="_parent">WORLD California</a> <a class="leftlink" href="http://www.world-newyork.com/" target="_parent">WORLD New York</a> <a class="leftlink" href="http://www.worldvirginia.com/" target="_parent">WORLD Virginia</a> </div> <a href="http://www.worldmag.com/media/" class="menumain2" target="_blank">Media Guide</a> <a href="#" class="menumain2" onclick="return showMenu('menusection10');">CUSTOMER SUPPORT</a> <div id="menusection10" class="menusection"> <a class="leftlink" href="http://www.worldmag.com/world_about_us.cfm" target="_parent">About Us</a> <a class="leftlink" href="http://www.worldmag.com/world_contact_us.cfm" target="_parent">Contact Us</a> <a class="leftlink" href="http://www.worldmag.com/s2/donate.cfm" target="_parent">Donations</a> <a class="leftlink" href="http://www.worldmag.com/subscribe/fundraising.cfm" target="_parent">Fundraising</a> <a class="leftlink" href="http://www.worldamg.com/s2/damaged.cfm" target="_parent">Lost/Damaged Issues</a> <a class="leftlink" href="http://www.worldamg.com/s2/" target="_parent">Subscribe</a> <a class="leftlink" href="http://www.worldamag.com/webtechFAQ2.cfm" target="_parent">Subscriber Help</a> <a class="leftlink" href="http://www.worldmag.com/cs/" target="_parent">Subscriber Login</a> <a class="leftlink" href="http://www.worldmag.com/websitepolicies.cfm" target="_parent">Website Policies</a> <a class="leftlink" href="http://www.worldmag.com/websitehelp.cfm" target="_parent">Website Help</a> <a class="leftlink" href="http://www.worldmag.com/s2/pay_invoice.cfm" target="_parent" style="color:#bf1f24;"><b>Pay Invoice</b></a> </div> <a href="#" class="menumain2" onclick="return showMenu('menusection11');">Subscribe</a> <div id="menusection11" class="menusection"> <a class="leftlink" href="https://www.worldmag.com/s2/subscribe.cfm" target="_parent">US Subscription</a> <a class="leftlink" href="https://www.worldmag.com/s2/renew.cfm" target="_parent">US Renewal</a> <a class="leftlink" href="https://www.worldmag.com/s2/gift.cfm" target="_parent">US Gift Sub</a> <a class="leftlink" href="https://www.worldmag.com/s2/renew_gift.cfm" target="_parent">US Gift Renewal</a> <br /> <a class="leftlink" href="https://www.worldmag.com/s2/canadian.cfm" target="_parent">Canadian Subscription</a> <a class="leftlink" href="https://www.worldmag.com/s2/renew_canadian.cfm" target="_parent">Canadian Renewal</a> <a class="leftlink" href="https://www.worldmag.com/s2/gift_can.cfm" target="_parent">Canadian Gift Sub</a> <a class="leftlink" href="https://www.worldmag.com/s2/renew_gift_can.cfm" target="_parent">Canadian Gift Renewal</a> <br /> <a class="leftlink" href="https://www.worldmag.com/s2/international.cfm" target="_parent">Intl Subscription</a> <a class="leftlink" href="https://www.worldmag.com/s2/renew_international.cfm" target="_parent">Intl Renewal</a> <a class="leftlink" href="https://www.worldmag.com/s2/gift_intl.cfm" target="_parent">Intl Gift Sub</a> <a class="leftlink" href="https://www.worldmag.com/s2/renew_gift_intl.cfm" target="_parent">Intl Gift Renewal</a> <br /> <a class="leftlink" href="https://www.worldmag.com/s2/online.cfm" target="_parent">Online-Only Sub</a> <a class="leftlink" href="https://www.worldmag.com/s2/renew_online.cfm" target="_parent">Online-Only Renewal</a> <br /> <a class="leftlink" href="https://www.worldmag.com/subscribe/fundraising.cfm" target="_parent">Fundraising</a> <a class="leftlink" href="https://www.worldmag.com/mypastor/" target="_parent">Pastor Referral</a> <br /> <a class="leftlink" href="https://www.worldmag.com/s2/pay_invoice.cfm" target="_parent" style="color:#bf1f24;"><b>Pay Invoice</b></a> </div> <a href="https://www.worldmag.com/s2/donate.cfm" class="menumain2">Donate</a> <a href="http://www.worldmag.com/store/" class="menumain2">Store</a> </div> <div id="logoAds"> <a href="http://www.facebook.com/pages/WORLD-Magazine/28814095885" target="_blank"><img border="0" alt="WORLD on Facebook" src="http://www.worldmag.com/images/Facebook_Badge.gif" /></a> <a href="http://twitter.com/WORLD_mag" onclick="openWindow('http://www.worldmag.com/media/counter.cfm?ad=957'); return false;" target="_blank"><img src="http://media.worldmag.com/images/media/twitterlogo2.jpg" alt="" /></a> <a href="http://www.youtube.com/user/WORLDMagMedia" onclick="openWindow('http://www.worldmag.com/media/counter.cfm?ad=949'); return false;" target="_blank"><img src="http://media.worldmag.com/images/media/YouTube.gif" alt="" /></a> <a href=" http://www.bsecure.com/?318602" onclick="openWindow('http://www.worldmag.com/media/counter.cfm?ad=563'); return false;" target="_blank"><img src="http://media.worldmag.com/images/media/world_banner_111X40.gif" alt="" /></a> <a href="http://www.gwnews.com/N0GIWEB4 " onclick="openWindow('http://www.worldmag.com/media/counter.cfm?ad=744'); return false;" target="_blank"><img src="http://media.worldmag.com/images/media/GWN111x40.jpg" alt="" /></a> <a href="http://familyfacts.org/?utm_source=strategicmktg&amp;utm_medium=banner&amp;utm_campaign=worldmag" onclick="openWindow('http://www.worldmag.com/media/counter.cfm?ad=869'); return false;" target="_blank"><img src="http://media.worldmag.com/images/media/FamilyFacts 111x40.gif" alt="" /></a> </div> </div> <!--end #pageLft --> <div id="pageRgt"> <div class="sidebar"> <ul> <li id="rightsearchform"> <form method="get" id="searchform" action="http://online.worldmag.com/"> <input type="text" value="" name="s" id="s" /> <label for="s" id="slabel" style="display: none; ">Search Community</label> <input type="image" style="position:relative; top:2px;" src="http://online.worldmag.com/wp-content/themes/worldmag/images/go_button.gif" /> </form> </li> <li><a href="https://www.worldmag.com/s2/donate.cfm" onclick="openWindow('http://www.worldmag.com/media/counter.cfm?ad=864'); return false;" target="_blank"><img src="http://media.worldmag.com/images/media/Donate-btn.jpg" alt="" /></a></li> <li> <div id="registerblock"> <img src="http://online.worldmag.com/wp-content/themes/worldmag/images/logintocomment.gif" alt="Login to Comment" border="0" /> <br /> <div class="rightpad"> <form name="loginform" id="loginform" action="http://online.worldmag.com/wp-login.php" method="post"> <table border="0" cellspacing="2" cellpadding="0"> <tbody> <tr> <td>login:</td> <td><input type="text" tabindex="10" size="20" value="" class="input" id="user_login" name="log" style="width: 100px;" /> </td> </tr> <tr> <td>password:</td> <td> <input id="user_pass" class="input" type="password" tabindex="20" size="20" value="" name="pwd" style="width: 100px;" /> </td> </tr> <tr> <td>&nbsp;</td> <td> <input id="rememberme" type="checkbox" tabindex="90" value="forever" name="rememberme" /> Remember Me</td> </tr> <tr> <td>&nbsp;</td> <td><input type="image" src="http://online.worldmag.com/wp-content/themes/worldmag/images/login_button.gif" alt="Login" /></td> </tr> </tbody> </table> <input type="hidden" name="redirect_to" value="/2008/02/29/mccains-massive-mistake/" /> </form> <a href="/wp-register.php">Join the fray!</a> Complete our simple, privacy-guaranteed registration. <div class="whyjoin"> <a href="/whyregister.php" target="_blank" onclick="return popup(this.href);">Why do I need to register?</a> </div> </div> </div> </li> <li><a href=" http://www.bhpublishinggroup.com/books/products.asp?p=9781433672781" onclick="openWindow('http://www.worldmag.com/media/counter.cfm?ad=936'); return false;" target="_blank"><img src="http://media.worldmag.com/images/media/BH-CommandsofChristWorldMagBanner.jpg" alt="" /></a></li> <li><a href="http://www.gcc.edu/microsite" onclick="openWindow('http://www.worldmag.com/media/counter.cfm?ad=942'); return false;" target="_blank"><img src="http://media.worldmag.com/images/media/180x156_static.jpg" alt="" /></a></li> <li id="menuPopPosts" class="sideBarMenu"> <h2>Popular Posts</h2> <ul> <li><a href="http://online.worldmag.com/2012/04/10/thats-not-fair/">That's not fair?</a></li> <li><a href="http://online.worldmag.com/2012/04/12/40-days-of-pro-evil-prayer/">40 days of pro-evil prayer</a></li> <li><a href="http://online.worldmag.com/2012/04/03/the-virtue-of-questioning-science/">The virtue of questioning ‘science'</a></li> <li><a href="http://online.worldmag.com/2012/04/10/titanic-the-reality/"><i>Titanic</i>: The reality</a></li> <li><a href="http://online.worldmag.com/2012/04/09/bubba-golf/">Bubba Golf</a></li> <li class="sideBarMenuBtm"><a href="/active/" class="readMore">More &gt;&gt;</a></li> </ul> </li> <li><a href="http://med.covenant.edu/" onclick="openWindow('http://www.worldmag.com/media/counter.cfm?ad=895'); return false;" target="_blank"><img src="http://media.worldmag.com/images/media/covnantgrad.jpg" alt="" /></a></li> <li><a href=" http://www.bsecure.com/?318602" onclick="openWindow('http://www.worldmag.com/media/counter.cfm?ad=565'); return false;" target="_blank"><img src="http://media.worldmag.com/images/media/world_banner_180X75.gif" alt="" /></a></li> <li id="twitterFeed" class="sideBarMenu"><h2><span class="feed"><a href="http://twitter.com/statuses/user_timeline/16423253.rss">feed</a></span>WORLD on Twitter</h2> <div class="sideBarMenuTitle"> <img src="/images/red_arrow.gif" width="6" height="9" border="0" style="margin-right: 4px;" /> Andr&eacute;e Seu on ‘the grace of life’ <br /> <a href="http://t.co/ApI6BAwy" target="_parent">http://t.co/ApI6BAwy</a> <br /> <a href="http://twitter.com/WORLD_mag/statuses/192256700336701442" target="_parent">About a minute ago</a> </div> <div class="sideBarMenuTitle"> <img src="/images/red_arrow.gif" width="6" height="9" border="0" style="margin-right: 4px;" /> &quot;This Is News from WORLD Magazine&quot;: Buffett rule bites the dust in the Senate, and DOW was up Monday <br /> <a href="http://t.co/vT7fN9H8" target="_parent">http://t.co/vT7fN9H8</a> <br /> <a href="http://twitter.com/WORLD_mag/statuses/192241936420175874" target="_parent">About an hour ago</a> </div> <div class="sideBarMenuTitle"> <img src="/images/red_arrow.gif" width="6" height="9" border="0" style="margin-right: 4px;" /> In the zone?: Employment and real estate markets will likely feed or starve recovery @WarrenColeSmith <br /> <a href="http://t.co/4ULEXMrO" target="_parent">http://t.co/4ULEXMrO</a> <br /> <a href="http://twitter.com/WORLD_mag/statuses/192227131781156864" target="_parent">About an hour ago</a> </div> <div class="sideBarMenuTitle"> <img src="/images/red_arrow.gif" width="6" height="9" border="0" style="margin-right: 4px;" /> WORLD Radio: Justice Dept. goes after e-book publishers, plus Instagram: From zero to $1 billion in 18 months <br /> <a href="http://t.co/kTvRPzTP" target="_parent">http://t.co/kTvRPzTP</a> <br /> <a href="http://twitter.com/WORLD_mag/statuses/192057422221803520" target="_parent">About 13 hours ago</a> </div> <a href="http://twitter.com/WORLD_Mag" class="sideBarMenuMore">Follow Us On Twitter &gt;&gt;</a> </li> <li><a href="http://zph.com/ads/index.php?id=643&amp;cm_mmc=PM-_-WITDORJ-_-Feb12-_-WRLDM180x156 " onclick="openWindow('http://www.worldmag.com/media/counter.cfm?ad=948'); return false;" target="_blank"><img src="http://media.worldmag.com/images/media/WalkingDustRabbiJesus_180x156.gif" alt="" /></a></li> <li><a href="http://www.trnty.edu/" onclick="openWindow('http://www.worldmag.com/media/counter.cfm?ad=450'); return false;" target="_blank"><img src="http://media.worldmag.com/images/media/WORLD_WEB_Trinity5.jpg" alt="" /></a></li> <li><a href="http://www.cardonationwizard.com/world-magazine/info/car-donation.html" onclick="openWindow('http://www.worldmag.com/media/counter.cfm?ad=953'); return false;" target="_blank"><img src="http://media.worldmag.com/images/media/CarDonor-ad-180x7311.jpg" alt="" /></a></li> <li></li> <li id="menuPrevPosts" class="sideBarMenu"><h2>Previous Posts</h2> <ul> <li><a href="http://online.worldmag.com/2012/04/" title="April 2012">April 2012</a></li> <li><a href="http://online.worldmag.com/2012/03/" title="March 2012">March 2012</a></li> <li><a href="http://online.worldmag.com/2012/02/" title="February 2012">February 2012</a></li> <li><a href="http://online.worldmag.com/2012/01/" title="January 2012">January 2012</a></li> <li><a href="http://online.worldmag.com/2011/12/" title="December 2011">December 2011</a></li> <li><a href="http://online.worldmag.com/2011/11/" title="November 2011">November 2011</a></li> <li><a href="http://online.worldmag.com/2011/10/" title="October 2011">October 2011</a></li> <li><a href="http://online.worldmag.com/2011/09/" title="September 2011">September 2011</a></li> <li><a href="http://online.worldmag.com/2011/08/" title="August 2011">August 2011</a></li> <li><a href="http://online.worldmag.com/2011/07/" title="July 2011">July 2011</a></li> <li><a href="http://online.worldmag.com/2011/06/" title="June 2011">June 2011</a></li> <li><a href="http://online.worldmag.com/2011/05/" title="May 2011">May 2011</a></li> <li><a href="http://online.worldmag.com/2011/04/" title="April 2011">April 2011</a></li> <li><a href="http://online.worldmag.com/2011/03/" title="March 2011">March 2011</a></li> <li><a href="http://online.worldmag.com/2011/02/" title="February 2011">February 2011</a></li> <li><a href="http://online.worldmag.com/2011/01/" title="January 2011">January 2011</a></li> <li><a href="http://online.worldmag.com/2010/12/" title="December 2010">December 2010</a></li> <li><a href="http://online.worldmag.com/2010/11/" title="November 2010">November 2010</a></li> <li><a href="http://online.worldmag.com/2010/10/" title="October 2010">October 2010</a></li> <li><a href="http://online.worldmag.com/2010/09/" title="September 2010">September 2010</a></li> <li><a href="http://online.worldmag.com/2010/08/" title="August 2010">August 2010</a></li> <li><a href="http://online.worldmag.com/2010/07/" title="July 2010">July 2010</a></li> <li><a href="http://online.worldmag.com/2010/06/" title="June 2010">June 2010</a></li> <li><a href="http://online.worldmag.com/2010/05/" title="May 2010">May 2010</a></li> <li><a href="http://online.worldmag.com/2010/04/" title="April 2010">April 2010</a></li> <li><a href="http://online.worldmag.com/2010/03/" title="March 2010">March 2010</a></li> <li><a href="http://online.worldmag.com/2010/02/" title="February 2010">February 2010</a></li> <li><a href="http://online.worldmag.com/2010/01/" title="January 2010">January 2010</a></li> <li><a href="http://online.worldmag.com/2009/12/" title="December 2009">December 2009</a></li> <li><a href="http://online.worldmag.com/2009/11/" title="November 2009">November 2009</a></li> <li><a href="http://online.worldmag.com/2009/10/" title="October 2009">October 2009</a></li> <li><a href="http://online.worldmag.com/2009/09/" title="September 2009">September 2009</a></li> <li><a href="http://online.worldmag.com/2009/08/" title="August 2009">August 2009</a></li> <li><a href="http://online.worldmag.com/2009/07/" title="July 2009">July 2009</a></li> <li><a href="http://online.worldmag.com/2009/06/" title="June 2009">June 2009</a></li> <li><a href="http://online.worldmag.com/2009/05/" title="May 2009">May 2009</a></li> <li><a href="http://online.worldmag.com/2009/04/" title="April 2009">April 2009</a></li> <li><a href="http://online.worldmag.com/2009/03/" title="March 2009">March 2009</a></li> <li><a href="http://online.worldmag.com/2009/02/" title="February 2009">February 2009</a></li> <li><a href="http://online.worldmag.com/2009/01/" title="January 2009">January 2009</a></li> <li><a href="http://online.worldmag.com/2008/12/" title="December 2008">December 2008</a></li> <li><a href="http://online.worldmag.com/2008/11/" title="November 2008">November 2008</a></li> <li><a href="http://online.worldmag.com/2008/10/" title="October 2008">October 2008</a></li> <li><a href="http://online.worldmag.com/2008/09/" title="September 2008">September 2008</a></li> <li><a href="http://online.worldmag.com/2008/08/" title="August 2008">August 2008</a></li> <li><a href="http://online.worldmag.com/2008/07/" title="July 2008">July 2008</a></li> <li><a href="http://online.worldmag.com/2008/06/" title="June 2008">June 2008</a></li> <li><a href="http://online.worldmag.com/2008/05/" title="May 2008">May 2008</a></li> <li><a href="http://online.worldmag.com/2008/04/" title="April 2008">April 2008</a></li> <li><a href="http://online.worldmag.com/2008/03/" title="March 2008">March 2008</a></li> <li><a href="http://online.worldmag.com/2008/02/" title="February 2008">February 2008</a></li> <li><a href="http://online.worldmag.com/2008/01/" title="January 2008">January 2008</a></li> <li><a href="http://online.worldmag.com/2007/12/" title="December 2007">December 2007</a></li> <li><a href="http://online.worldmag.com/2007/11/" title="November 2007">November 2007</a></li> <li><a href="http://online.worldmag.com/2007/10/" title="October 2007">October 2007</a></li> <li><a href="http://online.worldmag.com/2007/09/" title="September 2007">September 2007</a></li> <li><a href="http://online.worldmag.com/2007/08/" title="August 2007">August 2007</a></li> <li><a href="http://online.worldmag.com/2007/07/" title="July 2007">July 2007</a></li> <li><a href="http://online.worldmag.com/2007/06/" title="June 2007">June 2007</a></li> <li class="sideBarMenuBtm"><a href="/archives/" class="readMore">More &gt;&gt;</a></li> </ul> </li> </ul> </div> </div> <!--end #pageRgt --> <div id="content" class="pagePost"> <a name="postPageTop"></a> <div class="post" id="post-14849"> <!-- Post Category --> <div class="sectionTitle"> <a href="http://online.worldmag.com/cat/campaign2008/" title="View all posts in Campaign 2008" rel="category tag">Campaign 2008</a>, <a href="http://online.worldmag.com/cat/newsdesk/" title="View all posts in News Desk" rel="category tag">News Desk</a> <a href="javascript:window.print()" id="print_button"><img src="/wp-content/themes/worldmag/images/ico_print.gif" alt="Print" /> Click to Print</a> <div id="print_options"> <span id="print_comments"></span> <img src="/wp-content/themes/worldmag/images/checkbox.png" alt="Print Comments" />Include Comments </div> </div> <!-- Post Header --> <h2>McCain’s (massive?) mistake</h2> <!-- Post Author (left) and #Comments (right) --> <div class="postByComm"> <div class="postAvatar"> <img alt="" src="/avatars/Kristin-Chapman_poster.gif" class="avatar avatar-35 avatar-default" height="35" width="35" /> </div> <div class="postComm"> <span class="postCommBg"><a href="#comments">74 Comments</a></span> </div> <div style="width:300px; float:left;"> <div class="postBy"> Written by <a href="http://online.worldmag.com/author/chapman/" title="Posts by Kristin Chapman">Kristin Chapman</a> </div> <div class="postDate" style="clear:left; width:250px;"> February 29, 2008, 7:10 AM </div> </div> <div class="clear"></div> </div> <!-- end div.postByComm --> <!-- Post Content --> <div class="postContent"> <p>The hubbub is slow to die after John McCain <a href="http://www.latimes.com/news/politics/la-na-mccain27feb27,1,6349050.story">condemned</a>&nbsp;conservative radio talk-show host Bill Cunningham for opening a Cincinnati rally by taking aim at Barack Obama. Conservatives like Rush Limbaugh and Sean Hannity wasted no time in responding, denouncing McCain’s actions&nbsp;on the airwaves as millions of conservative Republican voters listened.</p> <p>Analysts are now saying McCain may have made a <a href="http://news.cincinnati.com/apps/pbcs.dll/article?AID=2008802280383">massive mistake</a>, as he’s already on rocky ground with conservatives–a group he really can’t afford to alienate any more:</p> <blockquote> <p>“Yes, John McCain needs those people if he has any hope of winning in November,” said Jason Johnson, a political science professor at Hiram College in northeast Ohio.</p> <p>“It’s going to be hard for them to support him, now that they’ve heard him stab one of their heroes in the back,” he said.</p> </blockquote> <p>Do you think the incident will hurt McCain’s efforts to appeal to conservatives?</p> <script type="text/javascript">AKPC_IDS += "14849,";</script> </div> <!-- Post Data (Categories, Keywords, RSS, Share Links, etc.) --> <div class="postData"> <div class="postDataLft"> <div class="postTopic"> Topic: <a href="http://online.worldmag.com/cat/campaign2008/" title="View all posts in Campaign 2008" rel="category tag">Campaign 2008</a>, <a href="http://online.worldmag.com/cat/newsdesk/" title="View all posts in News Desk" rel="category tag">News Desk</a> </div> <div class="postKeywords"> &nbsp; </div> <div class="postInfo"> You can skip to the end and leave a response. Pinging is currently not allowed. </div> </div> <!-- end div.postDataLft --> <div class="postDataRgt"> <div class="postEmailFriend"> <a href="http://online.worldmag.com/2008/02/29/mccains-massive-mistake/emailpopup/" onclick="email_popup(this.href); return false;" title="Email a friend" rel="nofollow">Email a friend</a> </div> <div class="postRSS"> <a href="http://online.worldmag.com/2008/02/29/mccains-massive-mistake/feed/">RSS 2.0</a> </div> <div class="postShare"> <a href="#" onclick="$('#sociablediv').show(); return false;">Share this:</a> </div> </div> <!-- end div.postDataRgt --> <div id="sociablediv" style="display: none; clear:both;" onclick="$('#sociablediv').hide();"> <div id="sociablebox"> <a href="#" onclick="return false;" style="display:block; width:58px; padding:2px 1px; float:right;"><img src="/wp-content/themes/worldmag/images/closebox.gif" alt="close box" width="58" height="12" border="0" /></a> <div class="sociable"> <ul> <li class="sociablefirst"><a rel="nofollow" id="facebook" href="javascript:window.location='http%3A%2F%2Fwww.facebook.com%2Fshare.php%3Fu%3Dhttp%253A%252F%252Fonline.worldmag.com%252F2008%252F02%252F29%252Fmccains-massive-mistake%252F%26amp%3Bt%3DMcCain%2527s%2520%2528massive%253F%2529%2520mistake';" title="Facebook"><img src="http://online.worldmag.com/wp-content/plugins/sociable/images/facebook.png" title="Facebook" alt="Facebook" class="sociable-hovers" /></a></li> <li><a rel="nofollow" id="twitter" href="javascript:window.location='http%3A%2F%2Ftwitter.com%2Fhome%3Fstatus%3DMcCain%2527s%2520%2528massive%253F%2529%2520mistake%2520-%2520http%253A%252F%252Fonline.worldmag.com%252F2008%252F02%252F29%252Fmccains-massive-mistake%252F';" title="Twitter"><img src="http://online.worldmag.com/wp-content/plugins/sociable/images/twitter.png" title="Twitter" alt="Twitter" class="sociable-hovers" /></a></li> <li><a rel="nofollow" id="del.icio.us" href="javascript:window.location='http%3A%2F%2Fdelicious.com%2Fpost%3Furl%3Dhttp%253A%252F%252Fonline.worldmag.com%252F2008%252F02%252F29%252Fmccains-massive-mistake%252F%26amp%3Btitle%3DMcCain%2527s%2520%2528massive%253F%2529%2520mistake%26amp%3Bnotes%3DThe%2520hubbub%2520is%2520slow%2520to%2520die%2520after%2520John%2520McCain%2520condemned%2526%2523160%253Bconservative%2520radio%2520talk-show%2520host%2520Bill%2520Cunningham%2520for%2520opening%2520a%2520Cincinnati%2520rally%2520by%2520taking%2520aim%2520at%2520Barack%2520Obama.%2520Conservatives%2520like%2520Rush%2520Limbaugh%2520and%2520Sean%2520Hannity%2520wasted%2520no%2520time%2520in%2520responding%252C';" title="del.icio.us"><img src="http://online.worldmag.com/wp-content/plugins/sociable/images/delicious.png" title="del.icio.us" alt="del.icio.us" class="sociable-hovers" /></a></li> <li><a rel="nofollow" id="digg" href="javascript:window.location='http%3A%2F%2Fdigg.com%2Fsubmit%3Fphase%3D2%26amp%3Burl%3Dhttp%253A%252F%252Fonline.worldmag.com%252F2008%252F02%252F29%252Fmccains-massive-mistake%252F%26amp%3Btitle%3DMcCain%2527s%2520%2528massive%253F%2529%2520mistake%26amp%3Bbodytext%3DThe%2520hubbub%2520is%2520slow%2520to%2520die%2520after%2520John%2520McCain%2520condemned%2526%2523160%253Bconservative%2520radio%2520talk-show%2520host%2520Bill%2520Cunningham%2520for%2520opening%2520a%2520Cincinnati%2520rally%2520by%2520taking%2520aim%2520at%2520Barack%2520Obama.%2520Conservatives%2520like%2520Rush%2520Limbaugh%2520and%2520Sean%2520Hannity%2520wasted%2520no%2520time%2520in%2520responding%252C';" title="Digg"><img src="http://online.worldmag.com/wp-content/plugins/sociable/images/digg.png" title="Digg" alt="Digg" class="sociable-hovers" /></a></li> <li><a rel="nofollow" id="mixx" href="javascript:window.location='http%3A%2F%2Fwww.mixx.com%2Fsubmit%3Fpage_url%3Dhttp%253A%252F%252Fonline.worldmag.com%252F2008%252F02%252F29%252Fmccains-massive-mistake%252F%26amp%3Btitle%3DMcCain%2527s%2520%2528massive%253F%2529%2520mistake';" title="Mixx"><img src="http://online.worldmag.com/wp-content/plugins/sociable/images/mixx.png" title="Mixx" alt="Mixx" class="sociable-hovers" /></a></li> <li><a rel="nofollow" id="myspace" href="javascript:window.location='http%3A%2F%2Fwww.myspace.com%2FModules%2FPostTo%2FPages%2F%3Fu%3Dhttp%253A%252F%252Fonline.worldmag.com%252F2008%252F02%252F29%252Fmccains-massive-mistake%252F%26amp%3Bt%3DMcCain%2527s%2520%2528massive%253F%2529%2520mistake';" title="MySpace"><img src="http://online.worldmag.com/wp-content/plugins/sociable/images/myspace.png" title="MySpace" alt="MySpace" class="sociable-hovers" /></a></li> <li><a rel="nofollow" id="newsvine" href="javascript:window.location='http%3A%2F%2Fwww.newsvine.com%2F_tools%2Fseed%26amp%3Bsave%3Fu%3Dhttp%253A%252F%252Fonline.worldmag.com%252F2008%252F02%252F29%252Fmccains-massive-mistake%252F%26amp%3Bh%3DMcCain%2527s%2520%2528massive%253F%2529%2520mistake';" title="NewsVine"><img src="http://online.worldmag.com/wp-content/plugins/sociable/images/newsvine.png" title="NewsVine" alt="NewsVine" class="sociable-hovers" /></a></li> <li><a rel="nofollow" id="reddit" href="javascript:window.location='http%3A%2F%2Freddit.com%2Fsubmit%3Furl%3Dhttp%253A%252F%252Fonline.worldmag.com%252F2008%252F02%252F29%252Fmccains-massive-mistake%252F%26amp%3Btitle%3DMcCain%2527s%2520%2528massive%253F%2529%2520mistake';" title="Reddit"><img src="http://online.worldmag.com/wp-content/plugins/sociable/images/reddit.png" title="Reddit" alt="Reddit" class="sociable-hovers" /></a></li> <li><a rel="nofollow" id="yahoo! bookmarks" href="javascript:window.location='http%3A%2F%2Fbookmarks.yahoo.com%2Ftoolbar%2Fsavebm%3Fu%3Dhttp%253A%252F%252Fonline.worldmag.com%252F2008%252F02%252F29%252Fmccains-massive-mistake%252F%26amp%3Bt%3DMcCain%2527s%2520%2528massive%253F%2529%2520mistake%26opener%3Dbm%26amp%3Bei%3DUTF-8%26amp%3Bd%3DThe%2520hubbub%2520is%2520slow%2520to%2520die%2520after%2520John%2520McCain%2520condemned%2526%2523160%253Bconservative%2520radio%2520talk-show%2520host%2520Bill%2520Cunningham%2520for%2520opening%2520a%2520Cincinnati%2520rally%2520by%2520taking%2520aim%2520at%2520Barack%2520Obama.%2520Conservatives%2520like%2520Rush%2520Limbaugh%2520and%2520Sean%2520Hannity%2520wasted%2520no%2520time%2520in%2520responding%252C';" title="Yahoo! Bookmarks"><img src="http://online.worldmag.com/wp-content/plugins/sociable/images/yahoomyweb.png" title="Yahoo! Bookmarks" alt="Yahoo! Bookmarks" class="sociable-hovers" /></a></li> <li class="sociablelast"><a rel="nofollow" id="stumbleupon" href="javascript:window.location='http%3A%2F%2Fwww.stumbleupon.com%2Fsubmit%3Furl%3Dhttp%253A%252F%252Fonline.worldmag.com%252F2008%252F02%252F29%252Fmccains-massive-mistake%252F%26amp%3Btitle%3DMcCain%2527s%2520%2528massive%253F%2529%2520mistake';" title="StumbleUpon"><img src="http://online.worldmag.com/wp-content/plugins/sociable/images/stumbleupon.png" title="StumbleUpon" alt="StumbleUpon" class="sociable-hovers" /></a></li> </ul> </div> </div> </div> <div class="clear"></div> </div> <!--end div.postData--> </div> <!-- end div.post --> <div class="comments" id="comments"> <!-- You can start editing here. --> <h2 class="commentHdr"><span class="backToTop"><a href="#postPageTop">back to top</a></span>74 Comments to “McCain’s (massive?) mistake”</h2> <ol class="commentList"> <li class="commentOdd" id="comment-278455"> <span class="commentTop"> <img alt="" src="http://www.gravatar.com/avatar/8e15625d6c158ec48f374efb77bd2714?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Peter Leavitt</span> 02.29.08 AT 7:48 AM </span> <div class="comment" style="margin-top:4px;"> <p>This shouldn’t hurt McCain. He takes Obama at his word that he is a Christian. Actually, the real question about Obama is not that <i>Hussein</i> is his middle name but whether he holds garden variety secular-liberal anti-American views that would deter him from whole heartedly defending American interests.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278455', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278466"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 02.29.08 AT 8:31 AM </span> <div class="comment" style="margin-top:4px;"> <p>McCain’s denouncement shows that he puts decency and fairness above cheap political points — a position that many on the right apparently don’t agree with.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278466', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278470"> <span class="commentTop"> <img alt="kBells" src="http://www.gravatar.com/avatar/e2262441c34d5c0ba6d4929b90203076?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">kBells</span> 02.29.08 AT 8:37 AM </span> <div class="comment" style="margin-top:4px;"> <p>Obama need to grow a ticker skin if he wants to play with the grown ups. Way worse things have been said about republicans and even Hilary. But McCain had no choice but to apologize if he didn’t want to branded a racist</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278470', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278472"> <span class="commentTop"> <img alt="kBells" src="http://www.gravatar.com/avatar/e2262441c34d5c0ba6d4929b90203076?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">kBells</span> 02.29.08 AT 8:39 AM </span> <div class="comment" style="margin-top:4px;"> <p>Wait! Am I going to be called a racist for using Obama and skin in the same sentence?</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278472', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278474"> <span class="commentTop"> <img alt="" src="http://www.gravatar.com/avatar/8e15625d6c158ec48f374efb77bd2714?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Peter Leavitt</span> 02.29.08 AT 8:44 AM </span> <div class="comment" style="margin-top:4px;"> <p>KBells, watch yourself! The very word <i>skin</i> can get you in politically-correct jail.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278474', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278478"> <span class="commentTop"> <img alt="NJLawyer" src="http://www.gravatar.com/avatar/04e25cc48f049112d756c323bc4d7da8?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">NJLawyer</span> 02.29.08 AT 8:53 AM </span> <div class="comment" style="margin-top:4px;"> <p>I think McCain did the right thing by repudiating the commments. While I would like to know just how much Islam has been an influence on Obama and I think that’s fair game, it’s petty to pick on a man’s name. It’s childish. By repudiating something small like this, McCain will be in a better position to question Obama in other ways. He’s running a fine line, and so far he’s done well. I think it’s nice that he’s trying to run a civilized campaign.</p> <p>KBells is right. Obama will have to grow a thicker skin because if he doesn’t, that’ll backfire on him, too.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278478', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278482"> <span class="commentTop"> <img alt="adios" src="http://www.gravatar.com/avatar/205f4c82286a8015a36518ea60db7685?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">adios</span> 02.29.08 AT 8:58 AM </span> <div class="comment" style="margin-top:4px;"> <p>The massive mistake is by the Cunninghams, Limbaughs, Coulters, and Hannitys of this world is that think they are the GOP and that this kind of drivel is power.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278482', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278483"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 02.29.08 AT 8:59 AM </span> <div class="comment" style="margin-top:4px;"> <p>If Obama wins the nomination I expect the remaining campaign before November will be vigorous and spirited. They’re both fighters. But I hope that any effort by Republicans to trade on fear and prejudice will backfire on them. </p> <p>Obama can do nothing about his middle name or his family history. What matters is only who he is.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278483', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278484"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 02.29.08 AT 9:03 AM </span> <div class="comment" style="margin-top:4px;"> <p>KBells at #3: <i>But McCain had no choice but to apologize if he didn’t want to branded a racist</i></p> <p>McCain had no choice but to apologize if he didn’t want to look like a hatemonger playing to baser elements of the voters — or at best, look like he was approving of someone else who was. </p> <p>It’s not the same thing.</p> <p>To his credit, McCain is trying to run a campaign based on valid political issues important to the country. Unfortunately some of his smaller-minded supporters are undermining that effort.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278484', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278487"> <span class="commentTop"> <img alt="Harris" src="http://www.gravatar.com/avatar/efbd811450e478bdc38e6977bb21b558?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Harris</span> 02.29.08 AT 9:07 AM </span> <div class="comment" style="margin-top:4px;"> <p>This is an appeal to the center. Both McCain and Obama are signaling a move away from the previous forms of partisanship; both hold out for a vision that is possible to vigorously disagree while also upholding higher ideals. </p> <p>Much as Cunningham served up red meat for the faithful, it is also alienating the center moderates whom McCain needs to win, all the more since Obama will appeal to them along these very lines. </p> <p>Of course as a Dem, I would encourage conservatives to continue the politics by epithet, it only makes winning that much easier. As a citizen, I welcome McCain’s understanding that we are better than this.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278487', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278488"> <span class="commentTop"> <img alt="Travis Birkenstock" src="http://www.gravatar.com/avatar/673cd69c8766cf41c5a3fa792ed2f1bf?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Travis Birkenstock</span> 02.29.08 AT 9:09 AM </span> <div class="comment" style="margin-top:4px;"> <p>What I like about McCain is that he marches to his own drum, and does, we he thinks is right, consequences be damned.</p> <p>Cunningham’s remarks about Obama and Clinton made him and members of the audience uncomfortable, so he called Cunningham on it. McCain being McCain. It’s both his strength and weakness.</p> <p>The sense of entitlement that the right wing media (Hannity, Limbaugh, Ingraham, et. al.) thinks they have on the GOP electorate is breathtaking. They want to turn anti-McCainism into their own cottage industry solely for the sake of protecting their relationship with their listeners. How dare McCain takes his message directly to the voters! He should bow before us ask for us to deliver our listerner base to him in the fall. That’s how it’s supposed to work! Egos. Egads.</p> <p>I don’t understand the comments above that Obama needs to grow a thicker skin. I don’t think Obama even responded to the Cunningham remarks, other than to have a spokesman simply accept McCain’s apology and move on. </p> <p>The Obama camp has done well so far in this regard, e.g., President Clinton’s South Carolina comments comparing Obama to Jesse Jackson. Rather than get in a big huff about it (something Hilary frequently does to her detriment) they let the comments get out there and speak for themselves, with little direct response. The “above the fray” approach seems to be working well for him.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278488', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278501"> <span class="commentTop"> <img alt="NJLawyer" src="http://www.gravatar.com/avatar/04e25cc48f049112d756c323bc4d7da8?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">NJLawyer</span> 02.29.08 AT 9:28 AM </span> <div class="comment" style="margin-top:4px;"> <p>Adios has a point. Those she mentions do not represent me, and I would be shocked by McCain if he fell in with their way of doing things.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278501', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278514"> <span class="commentTop"> <img alt="kBells" src="http://www.gravatar.com/avatar/e2262441c34d5c0ba6d4929b90203076?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">kBells</span> 02.29.08 AT 9:42 AM </span> <div class="comment" style="margin-top:4px;"> <p>#11. You have a point. But Obama doesn’t have to respond. He has tons of people looking for racism under every rock and pointing it out with great indignation.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278514', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278531"> <span class="commentTop"> <a href="http://renaissanceguy.wordpress.com" rel="external nofollow" title="Visit Kyle A’s website" class="snap_noshots"><img alt="Kyle A" src="http://www.gravatar.com/avatar/fd9afd2fb240190adc6890143db20420?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /></a> BY <span class="commentBy"><a href="http://renaissanceguy.wordpress.com" rel="external nofollow" class="url">Kyle A</a></span> 02.29.08 AT 9:59 AM </span> <div class="comment" style="margin-top:4px;"> <p>Oh, my word! Bill Cunningham has a snappy wit and was hired by McCain’s campaign to warm up the audience before McCain spoke. What did they think Cunningham was going to do–give a dry speech about economic theory? </p> <p>It’s politics, people. Part of the fun–and the strategy–of politics is to make your opponent look bad. Of course there should be limits,–I’m not saying that politicians should say just <i>anything</i>–but a joke or two about the other guy should be fair game.</p> <p>I still don’t understand why saying Obama’s full name is a problem. Would somebody like to explain it to me? </p> <p>SteveG, noted, “Obama can do nothing about his middle name or his family history. What matters is only who he is.”</p> <p>Does that mean SteveG admits that his middle name and family history are a <i>problem</i>?</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278531', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278540"> <span class="commentTop"> <img alt="Graceland" src="http://www.gravatar.com/avatar/9ebc2aee2ee2f1b6a550df7c05396788?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Graceland</span> 02.29.08 AT 10:10 AM </span> <div class="comment" style="margin-top:4px;"> <p><i>I still don’t understand why saying Obama’s full name is a problem. Would somebody like to explain it to me?</i></p> <p>Kyle, surely you know the answer to this. In general, no, it is not a problem to mention a candidate’s full name. But we all know that Obama’s name (especially his middle name) is unique. Obama has never (to my knowledge) gone by “Hussein”, so there is no good reason to bring it up. I’m not aware of anyone talking about McCain’s middle name. </p> <p>As many have said before, there is much more about Obama that is worth criticizing. Those who are childish enough to continually call him “Hussein” should just start criticizing him for what really bothers them–his heritage.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278540', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278552"> <span class="commentTop"> <img alt="Anlir" src="http://www.gravatar.com/avatar/7101e7bf184d79680e75a3341b1daf83?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Anlir</span> 02.29.08 AT 10:31 AM </span> <div class="comment" style="margin-top:4px;"> <p>Yeah, I saw Cunningham on TV the other night after McCain slapped him down, and he was livid. He was going on about how dare McCain talk to him that way and that he has the power to destroy him politically. And then he dropped the big one – he he said he’s he’s gonna vote for Hillary. He said he would actively campaign for her and work for McCain’s defeat.</p> <p>And I thought, yep, that shows you how far off the deep end conservatives have gone in this country.</p> <p>I couldn’t be happier to see conservatives tearing each other apart. The American people are looking at it and thinking “no way I’m gonna give these jerks (to put it kindly) another chance”.</p> <p>This is all the conservatives have this time around: the politics of personal destruction. I admire McCain for standing up to it.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278552', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278555"> <span class="commentTop"> <img alt="jjf" src="http://www.gravatar.com/avatar/e8785989c0b502d7ea59ab9311b80c04?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">jjf</span> 02.29.08 AT 10:39 AM </span> <div class="comment" style="margin-top:4px;"> <p>The world has too many political analysts.</p> <p>Many voters (myself included) find their “horse race” mentality irritating. McCain repudiated Cunningham’s pettiness, and it was the right thing to do. It was evidence of McCain’s character that he would speak honestly and not pander to a base he badly needs. So for analysts to swoop in and declare an honest and right response “a mistake” on tactical grounds is somewhat galling. </p> <p>And I’m floored by the stupidity of the childish games that the Cunninghams and Clintons are playing:</p> <blockquote> <p>“What?” (innocently batting the eyes) “It’s just his middle name. Are you saying there’s something wrong with his middle name?” </p> </blockquote> <p>Who buys that crap?</p> <p>No, there’s nothing wrong with his middle name. No one says there is. But there <i>is</i> something wrong with manipulative propaganda attempting to induce in voters a sub-rational association of Barack Obama with terrorists.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278555', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278557"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 02.29.08 AT 10:40 AM </span> <div class="comment" style="margin-top:4px;"> <p>Kyle A at #14:</p> <p><i>I still don’t understand why saying Obama’s full name is a problem. Would somebody like to explain it to me?</i></p> <p>I’ve explained it to you twice and Graceland in #15 is taking another shot. </p> <p>By now you either understand it and are still playing dumb, or you’re stupid. And I don’t think you’re stupid. </p> <p>This game grows boring, Kyle. </p> <p><i>SteveG, noted, “Obama can do nothing about his middle name or his family history. What matters is only who he is.”</i></p> <p><i>Does that mean SteveG admits that his middle name and family history are a problem?</i></p> <p>Not at all. They are not a problem, but they do give small-minded people who have nothing but fear and ignorance working in their favor an opportunity to raise false fears. </p> <p>But as I said, Obama can do nothing about that. He had no say in the circumstances of his birth or his naming, and he can’t stop bigots from trying to make hay with them. </p> <p>McCain, to his credit, is not taking that road. Here’s hoping his supporters will follow his example.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278557', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278559"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 02.29.08 AT 10:42 AM </span> <div class="comment" style="margin-top:4px;"> <p><i>Who buys that crap?</i></p> <p>Kyle A does.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278559', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278567"> <span class="commentTop"> <img alt="jjf" src="http://www.gravatar.com/avatar/e8785989c0b502d7ea59ab9311b80c04?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">jjf</span> 02.29.08 AT 10:59 AM </span> <div class="comment" style="margin-top:4px;"> <p>Then I’ll state it with a simple syllogism or two:</p> <p>Calling a person by their given name is not wrong.</p> <p>But (1) using manipulative propaganda is wrong.</p> <p>(2) Any attempt to subrationally associate Barack Obama with enemies of America is a use of manipulative propaganda.<br />(3) Some uses of Obama’s middle name are attempts to subrationally associate him with enemies of America.<br />Therefore, (4) some uses of Obama’s middle name are manipulative proganda.</p> <p>Therefore (by #1 &amp; #4), some uses of Obama’s middle name are wrong.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278567', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278570"> <span class="commentTop"> <a href="http://thereformedcactus.blogspot.com" rel="external nofollow" title="Visit Ivan the Terrible’s website" class="snap_noshots"><img alt="Ivan the Terrible" src="http://www.gravatar.com/avatar/5cc4deeec3c1362978560e1a35014914?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /></a> BY <span class="commentBy"><a href="http://thereformedcactus.blogspot.com" rel="external nofollow" class="url">Ivan the Terrible</a></span> 02.29.08 AT 11:00 AM </span> <div class="comment" style="margin-top:4px;"> <p>Wow, suddenly middle names are “off limits” because mentioning them might be name calling? or offensive?<br />McCain threw Bill Cunningham under the “Straight Talk Express” (tip of the hat to David Limbaugh).<br />I guess then we can no longer use the following:<br />John Fitzgerald Kennedy<br />Franklin Delano Roosevelt<br />Hillary Rodham Clinton<br />George W. Bush<br />William Howard Taft<br />Dwight David Eisenhower<br />Feel free to add your own. <img src="http://online.worldmag.com/wp-includes/images/smilies/icon_smile.gif" alt=":-)" class="wp-smiley" /></p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278570', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278596"> <span class="commentTop"> <img alt="NJLawyer" src="http://www.gravatar.com/avatar/04e25cc48f049112d756c323bc4d7da8?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">NJLawyer</span> 02.29.08 AT 11:30 AM </span> <div class="comment" style="margin-top:4px;"> <p>Hussein is a Muslim name, and we have a right to discuss any Muslim influence on Obama. SteveG seems to think we have nothing to fear from Obama. I don’t know that. The Farrakhan business bothers me. And I still don’t know the truth about the Canadian/Nafta controversy. While I don’t think Obama’s middle name in and off itself is a problem, by making it “off limits” you’re also making how he got that name off limits and that might actually be relevant. We know where Bush got the W in his name, why can’t we know where Hussein comes from? </p> <p>Hillary Clinton quoted from Obama’s book that he himself wrote he’s a blank slate. (He’s right.) Why can’t we talk about what makes Obama who he is? That you protect this guy is more offensive than what Cunningham did mainly because Cunningham was “nastily” honest, while you’re trying to keep the lid on something which may or may not be of relevance. Why the kabosh on free speech?</p> <p>Fear-mongering is one thing, and it’s not nice, and the way this fellow and Rush and all those other guys work things up isn’t necessarily “civilized.” By the same token, there shouldn’t be anything that’s off limits in a presidential campaign. There are ways of bringing up topics that are hardhitting, but not offensive.</p> <p>Why can’t we dissect Obama the way we dissect McCain or Clinton?</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278596', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278598"> <span class="commentTop"> <img alt="Anlir" src="http://www.gravatar.com/avatar/7101e7bf184d79680e75a3341b1daf83?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Anlir</span> 02.29.08 AT 11:33 AM </span> <div class="comment" style="margin-top:4px;"> <p>Let’s not kid ourselves – we all know exactly why Barack’s middle name is being used by the conservatives. </p> <p>It’s a blatant appeal to prejudice and fear.</p> <p>Now we shouldn’t be shocked at such behavior for it has been a standard M.O. for the conservatives for quite some time.</p> <p>Non-the-less it needs to be stood up to.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278598', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278602"> <span class="commentTop"> <a href="http://thereformedcactus.blogspot.com" rel="external nofollow" title="Visit Ivan the Terrible’s website" class="snap_noshots"><img alt="Ivan the Terrible" src="http://www.gravatar.com/avatar/5cc4deeec3c1362978560e1a35014914?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /></a> BY <span class="commentBy"><a href="http://thereformedcactus.blogspot.com" rel="external nofollow" class="url">Ivan the Terrible</a></span> 02.29.08 AT 11:40 AM </span> <div class="comment" style="margin-top:4px;"> <p>ANLIR writes:<br />“Now we shouldn’t be shocked at such behavior for it has been a standard M.O. for the conservatives for quite some time.”<br />Really? and the left does not engage in the same fear mongering of name calling from the likes of Howard Dean, HRC herself, and other assorted leftists? Same M.O., same “blatant appeal to prejudice and fear.”<br />What needs to be stood up too is myopia.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278602', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278604"> <span class="commentTop"> <img alt="Graceland" src="http://www.gravatar.com/avatar/9ebc2aee2ee2f1b6a550df7c05396788?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Graceland</span> 02.29.08 AT 11:41 AM </span> <div class="comment" style="margin-top:4px;"> <p><i>While I don’t think Obama’s middle name in and off itself is a problem, by making it “off limits” you’re also making how he got that name off limits and that might actually be relevant.</i></p> <p>It’s not off limits. I agree that his background is completely relevant, but talk about his background. Don’t just throw “Hussein” around as if it means something in and of itself. </p> <p>Like I said before, people who call Obama by his middle name need to be adult enough to talk about what they truly have a problem with…but they never will. They will continue to call him “Hussein” and leave it at that because they are afraid to question his ethnicity directly.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278604', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278606"> <span class="commentTop"> <img alt="" src="http://www.gravatar.com/avatar/8e15625d6c158ec48f374efb77bd2714?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Peter Leavitt</span> 02.29.08 AT 11:45 AM </span> <div class="comment" style="margin-top:4px;"> <p>Spengler in the Asia Times has a fascinating article,<a href="http://www.atimes.com/atimes/Global_Economy/JA29Dj06.html" rel="nofollow">Obama’s women reveal his secret</a> , in which he argues that Obama was much more influenced by his mother, the anthropoligist Ann Dunham’s anti Americanism than his father’s Islam. The following is an excerpt:</p> <p><i>Barack Obama received at least some instruction in the Islamic faith of his father and went with him to the mosque, but the importance of this experience is vastly overstated by conservative commentators who seek to portray Obama as a Muslim of sorts. Radical anti-Americanism, rather than Islam, was the reigning faith in the Dunham household. In the Muslim world of the 1960s, nationalism rather than radical Islam was the ideology of choice among the enraged. Radical Islam did not emerge as a major political force until the nationalism of a Gamal Abdel Nasser or a Sukarno failed.<br />Barack Obama is a clever fellow who imbibed hatred of America with his mother’s milk, but worked his way up the elite ladder of education and career. He shares the resentment of Muslims against the encroachment of American culture, although not their religion. He has the empathetic skill set of an anthropologist who lives with his subjects, learns their language, and elicits their hopes and fears while remaining at emotional distance. That is, he is the political equivalent of a sociopath. The difference is that he is practicing not on a primitive tribe but on the population of the United States.</i></p> <p>Spengler is a pseudonymous for someone reputed to be a brilliant PhD Australian anthropoligist withe a Judeo-Christian point of view. His core view is that the U.S. and the West are under severe attack from both within by the hard-edged secularists and from without by the Jihadis.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278606', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278613"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 02.29.08 AT 12:08 PM </span> <div class="comment" style="margin-top:4px;"> <p>Ivan and Kyle:</p> <p>If John McCain’s middle name was Stalin and Democrats made a point to call him “John Stalin McCain,” you’d object, and rightly. </p> <p>JJF in #17 has it exactly right. This eye-batting innocence while asking “What’s wrong with saying his middle name” is a childish game. </p> <p>But all by means, continue. I will enjoy you making yourself look small and desperate.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278613', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278623"> <span class="commentTop"> <a href="http://thereformedcactus.blogspot.com" rel="external nofollow" title="Visit Ivan the Terrible’s website" class="snap_noshots"><img alt="Ivan the Terrible" src="http://www.gravatar.com/avatar/5cc4deeec3c1362978560e1a35014914?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /></a> BY <span class="commentBy"><a href="http://thereformedcactus.blogspot.com" rel="external nofollow" class="url">Ivan the Terrible</a></span> 02.29.08 AT 12:42 PM </span> <div class="comment" style="margin-top:4px;"> <p>STEVEG-<br />“Small and desperate?” Now who’s playing eye batting games?<br />I merely pointed out that what is good for the goose, is good for the gander. In other words it is wrong for one side, no matter which one, to complain while at the same time engaging in the same behavior.<br />If McCain’s middle name were “Stalin” it would be his middle name, period.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278623', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278634"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 02.29.08 AT 12:56 PM </span> <div class="comment" style="margin-top:4px;"> <p><i>If McCain’s middle name were “Stalin” it would be his middle name, period.</i> </p> <p>Probably so. Make in Vladimir. </p> <p>You know perfectly well the reason people use Obama’s middle name, to create a suggestion or a perception of a connection between him and bad Middle Eastern people. </p> <p>How are the Democrats “engaging in the same behavior?”</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278634', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278644"> <span class="commentTop"> <a href="http://renaissanceguy.wordpress.com" rel="external nofollow" title="Visit Kyle A’s website" class="snap_noshots"><img alt="Kyle A" src="http://www.gravatar.com/avatar/fd9afd2fb240190adc6890143db20420?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /></a> BY <span class="commentBy"><a href="http://renaissanceguy.wordpress.com" rel="external nofollow" class="url">Kyle A</a></span> 02.29.08 AT 1:09 PM </span> <div class="comment" style="margin-top:4px;"> <p>NJ Lawyer: “. . .it’s petty to pick on a man’s name.”</p> <p>Is <i>saying</i> a man’s name the same as picking on a man’s name?</p> <p>GRACELAND: “But we all know that Obama’s name (especially his middle name) is unique.”</p> <p>It’s not unique. That’s the problem. It is a very common and very meaningful Muslim name, and that’s why he and his supporters don’t want anyone using it.</p> <p>GRACELAND: “I’m not aware of anyone talking about McCain’s middle name.”</p> <p>Okay, here goes. John Sidney McCain. Ooh! Did I do something wrong by using his full name? Should I apologize?</p> <p>JJF: “No, there’s nothing wrong with his middle name. No one says there is.”</p> <p>Either that’s true, or it’s not. If there’s nothing wrong with his middle name then there should be nothing wrong with saying it. If there is something wrong with his middle name, then it should be open to discussion.</p> <p>SteveG: “This game grows boring, Kyle.”</p> <p>I’m sorry if it bores you. I am playing stupid but with a very good reason. I want people to face this issue head on. If saying a man’s full name gets people in trouble, then I think we should be able to discuss what it is about the name that is a problem.</p> <p>It has never been a problem to use any other president’s or presidential candidate’s middle name. Is it bad if I call the other leading Democrat Hillary Diane Rodham Clinton? It’s a very pretty name. I’m sure it wouldn’t bother her for somebody to mention that it’s her full name.</p> <p>SteveG: “He had no say in the circumstances of his birth or his naming, and he can’t stop bigots from trying to make hay with them.”</p> <p>I just don’t buy it SteveG. If somebody says his full name, it’s not that person’s responsiblity if bigots make hay with it. It’s a fact about him, and what people make of that fact is up to them. Now, if somebody were to call George Bush something like George Adolf Bush, then there would be a problem, since that’s not acutally his name.</p> <p>SteveG: “If John McCain’s middle name was Stalin and Democrats made a point to call him “John Stalin McCain,” you’d object, and rightly.”</p> <p>I hope that I wouldn’t, although something inside me might compel me to do so. I think that if McCain had been given the middle name Stalin and he didn’t want to be associated with the dictator, he might change it. Or he might just go ahead and use it openly to show that he wasn’t embarrassed by or ashamed of it.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278644', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278656"> <span class="commentTop"> <img alt="Kay" src="http://www.gravatar.com/avatar/83cb59be05c14fd02fc41b725f484f2b?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">KayVee</span> 02.29.08 AT 1:45 PM </span> <div class="comment" style="margin-top:4px;"> <p>Kyle – If Barack’s middle name was “Arthur,” would anyone bother to call him “Barack Arthur Obama?” Of course not, because Arthur is just a name, there is no tie-in to anything political. But his middle name is “Hussein,” therefore there <b>is</b> a tie-in to America’s enemies. To call him by his full name is to not-so-subtly hint that he’s beholden to those who would destroy us.</p> <p>McCain was correct to disavow Cunningham for using a personal attack on the opposition candidate during the introduction, it has no place in the campaign.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278656', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278694"> <span class="commentTop"> <img alt="krm" src="http://www.gravatar.com/avatar/cdd561970444669eb522b12d07559641?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">krm</span> 02.29.08 AT 2:40 PM </span> <div class="comment" style="margin-top:4px;"> <p>I am one of those conservatives who are a liitle leery of McCain.</p> <p>My opinion of McCain went up considerably withhis action there. The ‘Hussein’ stuff is crap. McCain is fully right to disvow it.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278694', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278698"> <span class="commentTop"> <img alt="Anlir" src="http://www.gravatar.com/avatar/7101e7bf184d79680e75a3341b1daf83?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Anlir</span> 02.29.08 AT 2:51 PM </span> <div class="comment" style="margin-top:4px;"> <p>Kayvee,</p> <p>Ivan and Kyle know exactly what they’re doing by using Barack’s middle name. They’re deliberately playing to people’s fears and prejudice. What they’re doing is a prime example of politics taking precedence over principle. I think McCain understands the principle of decency and respect. I don’t think some of his supporters do though.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278698', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278699"> <span class="commentTop"> <img alt="NJLawyer" src="http://www.gravatar.com/avatar/04e25cc48f049112d756c323bc4d7da8?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">NJLawyer</span> 02.29.08 AT 2:51 PM </span> <div class="comment" style="margin-top:4px;"> <p>No, saying a man’s name is not petty, but that’s not what Cunningham was doing. He was emphasizing the name Hussein to associate it with Islam, and yes, you’re right — to a Muslim the name Hussein has great meaning. There is a better way of discussing this issue AND there is a better way of working up a crowd. What Cunningham did was meant to be incendiary. Peter Leavitt has supplied the type of information I have been looking for with respect to Obama. That’s the way this “problem” should be handled. With facts, talked about openly. Don’t we have a right to know if Obama is “beholden” to those who would destroy us? I think we do, just do it “politely” employing fundamental fairness.</p> <p>Obama didn’t choose his own name. It may have had meaning for his parents, but it may just be a middle name to him. However, his admiring his minister who admires Farrakhan is a problem for me.</p> <p>I remember ABC playing a tape of Howard Dean attacking Christians a few days before his famous scream. They only played it once and no one else played it. Before Anlir cites to conservative MO, he should take a long hard look at his own “side.” Howard Dean was pure hatred on that tape, and he was the one running for president! (Cunningham is not the candidate.)</p> <p>For me, this isn’t so much about Obama’s middle name, but rather why he is being treated with kid gloves. I’ve certainly said mean things about Shrill Hill, but I think she is getting a raw deal here.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278699', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278702"> <span class="commentTop"> <img alt="NJLawyer" src="http://www.gravatar.com/avatar/04e25cc48f049112d756c323bc4d7da8?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">NJLawyer</span> 02.29.08 AT 2:54 PM </span> <div class="comment" style="margin-top:4px;"> <p>And yes, in Kyle’s defense, we would ALL want to know why McCain’s parents gave him the middle name of “Stalin” if that had been the case. Be honest! I certainly would.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278702', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278709"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 02.29.08 AT 2:57 PM </span> <div class="comment" style="margin-top:4px;"> <p>Kyle A at #30: <i>I’m sorry if it bores you. I am playing stupid but with a very good reason. I want people to face this issue head on. If saying a man’s full name gets people in trouble, then I think we should be able to discuss what it is about the name that is a problem.</i></p> <p>You answered that yourself: <i>It’s not unique. That’s the problem. It is a very common and very meaningful <b>Muslim</b> name, and that’s why he and his supporters don’t want anyone using it.</i></p> <p>But Obama is not a Muslim.<br />Nor is beholden to Muslims.<br />Using his name when he himself does not routinely use it is a cheap tactic intended to associate him with Muslims. </p> <p>It is a lie.<br />It is bearing false witness, if indirectly. </p> <p>Are you sure that is really something you want to be defending? </p> <p>The rubber morals of some Christians can be really astonishing sometimes.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278709', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278714"> <span class="commentTop"> <img alt="" src="http://www.gravatar.com/avatar/8e15625d6c158ec48f374efb77bd2714?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy"><a href="http://snipurl.com/1yk6k" rel="external nofollow" class="url">Night Train</a></span> 02.29.08 AT 3:13 PM </span> <div class="comment" style="margin-top:4px;"> <p><i>Obama can do nothing about his middle name or his family history.</i></p> <p>Nonsense. People change their names all the time. But poor, helpless Obama can do nothing about his name?</p> <p>By the way, as a kid he went by Barry. As an adult, he chose to go by Obama to get “back to his roots”, so why’s he ashamed of Hussein all of a sudden?</p> <p>And since when is using a man’s full name considered “attacking” him?</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278714', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278715"> <span class="commentTop"> <a href="http://renaissanceguy.wordpress.com" rel="external nofollow" title="Visit Kyle A’s website" class="snap_noshots"><img alt="Kyle A" src="http://www.gravatar.com/avatar/fd9afd2fb240190adc6890143db20420?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /></a> BY <span class="commentBy"><a href="http://renaissanceguy.wordpress.com" rel="external nofollow" class="url">Kyle A</a></span> 02.29.08 AT 3:15 PM </span> <div class="comment" style="margin-top:4px;"> <p>First, I am no McCain supporter. I will not vote for him, as I have stated on this blog and on my own blog.</p> <p>Second, I realize that Obama is not a Muslim and that his name does not mean that he has connections with Islam. </p> <p>My main point in all this is that the saying of a person’s name should not be spooking Obama or his supporters. The fact that it they are upset by it means something, I think. I want to hear from them what it means. From what they have said, the problem stems from how they think some people will perceive Obama once they know what his full name is. So, he and his supporters need to make sure that they put out information about him and his background that puts people at ease.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278715', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278717"> <span class="commentTop"> <img alt="NJLawyer" src="http://www.gravatar.com/avatar/04e25cc48f049112d756c323bc4d7da8?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">NJLawyer</span> 02.29.08 AT 3:17 PM </span> <div class="comment" style="margin-top:4px;"> <p>The inability of some liberals who have sworn off Christianity to be willing to discuss the name Hussein is also astonishing. I’m getting a feeling that some would like to limit freedom of speech! Why must saying the name “Hussein” be off limits? Are we having a “control” problem here? Or don’t you think the American people can figure out when someone’s being shafted?</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278717', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278719"> <span class="commentTop"> <img alt="Anlir" src="http://www.gravatar.com/avatar/7101e7bf184d79680e75a3341b1daf83?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Anlir</span> 02.29.08 AT 3:19 PM </span> <div class="comment" style="margin-top:4px;"> <p>Kyle is being obtuse. He knows very good and well that what people are upset about is the pandering to fear and prejudice by invoking Barack’s middle name.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278719', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278726"> <span class="commentTop"> <a href="http://renaissanceguy.wordpress.com" rel="external nofollow" title="Visit Kyle A’s website" class="snap_noshots"><img alt="Kyle A" src="http://www.gravatar.com/avatar/fd9afd2fb240190adc6890143db20420?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /></a> BY <span class="commentBy"><a href="http://renaissanceguy.wordpress.com" rel="external nofollow" class="url">Kyle A</a></span> 02.29.08 AT 3:26 PM </span> <div class="comment" style="margin-top:4px;"> <p>“Using his name when he himself does not routinely use it is a cheap tactic intended to associate him with Muslims.”</p> <p>It’s his name. Nobody’s making that up.</p> <p>“It is a lie.<br />It is bearing false witness, if indirectly.”</p> <p>Then Wikipedia must be lying. They use his full name to head their article about him.</p> <p><a href="http://en.wikipedia.org/wiki/Barack_Obama" rel="nofollow">http://en.wikipedia.org/wiki/Barack_Obama</a></p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278726', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278730"> <span class="commentTop"> <a href="http://renaissanceguy.wordpress.com" rel="external nofollow" title="Visit Kyle A’s website" class="snap_noshots"><img alt="Kyle A" src="http://www.gravatar.com/avatar/fd9afd2fb240190adc6890143db20420?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /></a> BY <span class="commentBy"><a href="http://renaissanceguy.wordpress.com" rel="external nofollow" class="url">Kyle A</a></span> 02.29.08 AT 3:29 PM </span> <div class="comment" style="margin-top:4px;"> <p>Oh, and even if he were a full-fledged Muslim with ties to other prominent Muslims, what’s wrong with that from the liberal perspective?????</p> <p>Are you anti-Muslim now? Or just afraid of people knowing your position?</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278730', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278731"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 02.29.08 AT 3:33 PM </span> <div class="comment" style="margin-top:4px;"> <p>Kyle, Anlir’s right, you ARE being obtuse. </p> <p>It’s using a true fact (his name) to insinuate a falsehood. It’s lying indirectly by saying something true with the intent that others will infer more than you actually said and come away with a false conclusion … to which you can innocently bat your eyes and say “I never said he was Muslim! I just pointed out 1,500 times that he has an Arabic middle name, in a knowing tone.” </p> <p>Just like like Bush never actually said Saddam Hussein was connected to 9/11 — he just implied it repeatedly and let millions of people draw that connection. </p> <p>I agree that it would be better if Obama would just start using the name and disarm the people trying to do this … and as politically savvy as he is, I’m a little surprised he hasn’t. Nevertheless, the dishonesty of the tactic is obvious.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278731', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278741"> <span class="commentTop"> <img alt="lawdawg3" src="http://www.gravatar.com/avatar/906774d86d983745a7aa3ddea15ab030?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">lawdawg3</span> 02.29.08 AT 3:54 PM </span> <div class="comment" style="margin-top:4px;"> <p>I am a conservative republican who has not missed an election since Reagan was in office when I was first of voting age. I am not sure that I can pull the lever for McCain in November. For the first time in my life I have no candidate for President of the United States which I in any way believe will provide the proper leadership in office. It grieves me to not vote, but principles are important to me, and I cannot support Mr. McCain without deep regret.I loathe everything that Senator Clinton and Senator Obama stand for, but Senator McCain is a loose cannon on deck who shoots conservatives as often as liberals. I am praying about whether to vote or not for President. I will vote in the other elections in November. What a horrible position we are in as conservatives this year!</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278741', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278742"> <span class="commentTop"> <img alt="Travis Birkenstock" src="http://www.gravatar.com/avatar/673cd69c8766cf41c5a3fa792ed2f1bf?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Travis Birkenstock</span> 02.29.08 AT 3:55 PM </span> <div class="comment" style="margin-top:4px;"> <p><i> “Barack Obama is a clever fellow who imbibed hatred of America with his mother’s milk”<br /></i></p> <p>Wow. This is going to be a great campaign. I’m already twice as proud as Michelle Obama.</p> <p>Pretty good metaphor though.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278742', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278749"> <span class="commentTop"> <img alt="Dav" src="http://www.gravatar.com/avatar/40af70f33b6620ff9582f2bd3cb02e24?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Dav</span> 02.29.08 AT 4:01 PM </span> <div class="comment" style="margin-top:4px;"> <p>If McCain wins the nomination, conservatives (of whom I am among the most far right) will have to vote for him. It’s truly a tragedy, and a vote for the best of a despicable, sickening lot, but that’s our only option.<br />Sucks to be us right now.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278749', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278758"> <span class="commentTop"> <img alt="Anlir" src="http://www.gravatar.com/avatar/7101e7bf184d79680e75a3341b1daf83?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Anlir</span> 02.29.08 AT 4:13 PM </span> <div class="comment" style="margin-top:4px;"> <p>One of the most discouraging things about America is the attempts by partisan extremists at both ends of the political spectrum to “poison the well” and ruin political discourse in this country. </p> <p>On WorldMag we mostly see the attempts coming from the right, with an occasional contribution from someone on the left. </p> <p>Led by the partisan extremists, people are losing the ability to treat their opponents with respect and decency. It make destroying one’s political opponents more important than doing what’s right for America. It makes the ability to get anything done or solve our country’s problems almost impossible. </p> <p>Basically you’ve got half the country screaming at the other half and refusing to listen to anything they have to say. </p> <p>If there is one thing I’ve learned from my time on here it’s that conservative Christians are not exempt from the trend.</p> <p>Barack Obama, in my opinion, represents a chance to move this country beyond such bitter partisanship. He does give people hope that things can be better in America. Our conservative friends are mightily attempting to snuff out that hope. They may well succeed in November. I hope enough of my fellow Americans are ready to strike out a new path.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278758', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278761"> <span class="commentTop"> <img alt="NJLawyer" src="http://www.gravatar.com/avatar/04e25cc48f049112d756c323bc4d7da8?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">NJLawyer</span> 02.29.08 AT 4:18 PM </span> <div class="comment" style="margin-top:4px;"> <p>So, you would prefer that Obama not address this? Just do it and get it over with — or maybe there’s something there?</p> <p>LawDawg3: We’ve had this discussion on the blog before. I would like to urge you to vote. You write that McCain shoots conservatives as often as he shoots liberals, but that you loathe everything Clinton and Obama stand for. (I do, too!) May I ask you to consider mitigating the damage that a Clinton or Obama presidency would do to the country? I, of course, am concerned with judges, and the next president will in all probability be nominating Supreme Court justices (and judges) who will influence the court for the next 30 years. I implore you not to hand that to a Democrat! I also urge you to consider Obama’s lack of experience. Again, I implore you not to allow the country to fall prey to that! Many of us are unhappy with Mr. McCain’s tendencies, but I do believe that of the three, and that’s what we have to work with, he’s the most experienced, he understands the problem with the jihadists, and I do think with his centrist views (many of which I do not agree with), that he might be the one to finally end this bitter divisiveness in the country. I can only see more of the same with Clinton or Obama at the helm because what they want — government control of everything — will have to be vigorously opposed. I urge you to remember that America is not the earthly kingdom of God, but it is the world’s best hope. I will be praying that you will find it in your heart to join those of us who consider the consequences of not voting — an Obama or Clinton presidency — so frightening that you will join us in mitigating the damage by preventing them from coming to power.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278761', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278785"> <span class="commentTop"> <img alt="Anlir" src="http://www.gravatar.com/avatar/7101e7bf184d79680e75a3341b1daf83?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Anlir</span> 02.29.08 AT 5:15 PM </span> <div class="comment" style="margin-top:4px;"> <p>Re: #48</p> <p>1. Why should Obama address this? His middle name is of no more import than if it were John, or Edward, or Michael. </p> <p>2. The demand that he address it is coming from the far-right and the Republicans. It’s political pandering of the highest order.</p> <p>3. Anytime you have the party faithful holding their nose to vote for their party’s candidate, that doesn’t bode well for them winning the election. Other people look at it and think “If their own party can’t stand them, I’m sure not gonna vote for him (or her)”.</p> <p>4. Fear and negativity are what the Republicans have going for them this time around. Their mantra: “If you vote for the Democrats horrible things will happen to the country”. They’re running from Bush’s record as fast as they can, they don’t like their own party’s candidate, and they sure as heck don’t like the other party’s candidates. </p> <p>5. Rather than tell Americans what the Republicans would do to make this country better, they’re going on and on about how horrible things will be if the Democrats win. They attempting to scare people into voting for them. That’s a bad sign for the Republicans. You can scare people once or twice, but then they stop believing you.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278785', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278788"> <span class="commentTop"> <img alt="llama" src="http://www.gravatar.com/avatar/c259fd06631bd8f47df52f0af692548e?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">llama</span> 02.29.08 AT 5:19 PM </span> <div class="comment" style="margin-top:4px;"> <p>Obama says we need change and that he can work with the other side of the aisle to get things done.</p> <p>The fact is that he hasn’t worked with the other side of the aisle at all being the most liberal socialist in congress. But McCain has actually tried to work with the other side of the aisle on many issues and is the leader of the entire Senate at doing so. </p> <p>Obamma can’t use his supposed willingness to compromise for the right solution when McCain is the master at it.</p> <p>This incident only shows once again that McCain does know know to play well with others and tries to do the right thing as he sees it even if against his party mouthpieces and hard liners. He realizes that being a moderate is a virtue and a wise course most always – even though he was a right to be the hard liner in congress on Iraq.</p> <p>There is much to admire about this man and much to want to vote for – regardless of Hannity. Limbaugh, Coulter etc against him on this. They have been for him on the War as they should be but just wrong on this issue as they were on McCain-Feingold. No one is right all the time.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278788', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278813"> <span class="commentTop"> <img alt="NJLawyer" src="http://www.gravatar.com/avatar/04e25cc48f049112d756c323bc4d7da8?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">NJLawyer</span> 02.29.08 AT 6:08 PM </span> <div class="comment" style="margin-top:4px;"> <p>Anlir, I disagree with you. I think Obama should address it, unless he’s ashamed of his youth and his upbringing. We know a lot about the Kennedys and the Bushes and the Clintons. Why not Obama? What are you afraid of? I think we have a right to discuss everything, and I think we have a right to discuss Obama’s links to Louis Farrakhan without people like you calling us racists or panderers. Again, there seem to be some topics that liberals want to control, they seem to be against freedom of speech and freedom of thought. How unAmerican. How undemocratic.</p> <p>I disagree with McCain on many issues, but surprise, surprise, I disagreed with George Bush on a lot issues, too. Most notably immigration, something Bush and McCain are closer in agreement on than I am. But yes, I’m party faithful.</p> <p>Horrible things WILL happen if either Clinton or Obama become president. That’s not fear, it’s the truth. What I find absolutely dumbfounding is that Democrats jump on a bandwagon for change and don’t ask what is behind it! Even Hillary Clinton is questioning what Obama means, and you won’t listen to her. Do any liberals ever ask questions? Before I logged on here, I read an article from the LA Times wherein McCain and Phil Gramm went after the Dems on NAFTA. As Phil Gramm said: if the Dems don’t think we can compete with the Canadians, there’s a problem. The only people who are pandering are Obama and Clinton who are telling Americans that they’ll renegotiate NAFTA to help save American jobs. And we still don’t know if Obama and Clinton had their people contact the Canadians to say “gee, we really don’t mean what we’re saying; we’re just trying to win an election, but don’t worry, we don’t mean it.” I would think liberals such as yourself would be deeply offended by such a tactic, but then again, I just accused you all of not questioning and not thinking, so I really shouldn’t be surprised.</p> <p>Thank you, Llama, for pointing out that McCain HAS worked with both sides of the aisle. I think because of that, he is the one who can bring some common sense to Washington.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278813', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278846"> <span class="commentTop"> <img alt="Luke" src="http://www.gravatar.com/avatar/5bf384cf95f0c59202b47159244fec46?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Luke</span> 02.29.08 AT 7:29 PM </span> <div class="comment" style="margin-top:4px;"> <p>This has actually been addressed at top GOP strategy secessions. I’m not going to look for a link now, but several news outlets carried the piece. At a closed door meeting of state party leaders, Karl Rove himself warned Republicans that continuing to refer to him as Barak Hussein Obama would continue to perpetuate the notion that all Republicans are narrow minded and unopen to a diversified party. He advised everyone in the GOP to refer to him by his honorific Sen. Obama. </p> <p>I am, however, naturally over joyed that Bill Cunningham is proving destructive to GOP interests once again. Gill ‘em hell, Bill!</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278846', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278853"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 02.29.08 AT 7:50 PM </span> <div class="comment" style="margin-top:4px;"> <p>NJLawyer at #51: <i>Anlir, I disagree with you. I think Obama should address it, unless he’s ashamed of his youth and his upbringing. We know a lot about the Kennedys and the Bushes and the Clintons. Why not Obama? What are you afraid of? I think we have a right to discuss everything, and I think we have a right to discuss Obama’s links to Louis Farrakhan without people like you calling us racists or panderers. Again, there seem to be some topics that liberals want to control, they seem to be against freedom of speech and freedom of thought. How unAmerican. How undemocratic.</i></p> <p>Oh for pete’s sake. </p> <p>His “ties” to Farrakhan have been addressed — there are none. His church’s magazine, which Obama doesn’t control, gave Farrakhan an honor that Obama didn’t determine. Farrakhan gave Obama an endorsement that he didn’t seek. What you’re suggesting is guilt by association. There’s no evidence that Obama has any sympathy for or direct connection to Farrakhan. </p> <p>There’s nothing about his middle name to address. His parents gave it to him for whatever reason, end of story. It’s the far right that’s trying to make an issue of it. </p> <p>Liberals are against freedom of speech? Get real. Nobody’s saying you can’t say whatever you want to. But when what you’re saying is that something is an issue when it isn’t, expect to be told so.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278853', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278867"> <span class="commentTop"> <img alt="NJLawyer" src="http://www.gravatar.com/avatar/04e25cc48f049112d756c323bc4d7da8?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">NJLawyer</span> 02.29.08 AT 8:35 PM </span> <div class="comment" style="margin-top:4px;"> <p>SteveG writes: “What you’re suggesting is guilt by association.”</p> <p>To some degree that’s true! I would disassociate myself from a church that honored Farrakhan. And Obama has not done that. If I went to meetings at a church that endorsed David Duke, I think something could be inferred from that, and you would be the first to bring that up.</p> <p>Yes, liberals can be against free speech. Very much so. See the flap over the fairness doctrine. See hate speech legislation. See this flap right here. Liberals even do it to each other. You guys don’t want to allow Hillary Clinton to put a commercial on about experience (Who’s picking up the phone in the White House?) You guys don’t even want to let her talk about her experience, which is certainly more than Obama’s, though the three things she claims give her experience are pretty thin. Only service on the one committee (Armed services? I can’t remember) fits the bill. (Giving a speech and life in the White House with Bill is not “experience.”) But hey, you guys don’t even want her to talk about that! She’s mean for pointing out that he’s inexperienced. How do you expect her to campaign against him? It’s crazy!</p> <p>Every election, except for Washington’s (though I’m sure someone can find something) has had its dirty tricks and nastiness and low blows. That’s politics. SteveG claims “Nobody’s saying you can’t say whatever you want to.” But this whole thread is all about that. Don’t mention the name Hussein! Well … Hussein, Hussein, Hussein! Obama didn’t have the standard upbringing other presidents in the past century have had. We have a right to examine that upbringing. It made Obama who he is. For people who are still calling Bush a drunk when his presidency is almost over (and he hasn’t been drinking), I think you all should just face up to the fact that you don’t want your precious B-HO to be treated like a real candidate. Why this hands off attitude?</p> <p>I’m not advocating being nasty about B-HO’s name. I think McCain was right to repudiate Cunningham. But I am advocating finding out as much about Obama as possible, and the liberals here don’t like that for some reason. We’re supposed to accept that package as it is offered without unwrapping it. For people who claim to have a lock on intelligence, you’d think the liberals would be unwrapping it themselves. That’s not being done.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278867', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278874"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 02.29.08 AT 8:56 PM </span> <div class="comment" style="margin-top:4px;"> <p>NJLawyer at #54: <i>To some degree that’s true! I would disassociate myself from a church that honored Farrakhan. And Obama has not done that. If I went to meetings at a church that endorsed David Duke, I think something could be inferred from that, and you would be the first to bring that up.</i></p> <p>And that’s a fair point, I think. But it seems that Obama has found good things in the church and has not been involved in anything to do with Farrakhan. So I can see where that might be a stumbling block for some, but unless his own positions and proposals reflect Farrakhan’s influence — and so far as I can tell they don’t — it doesn’t trouble me. </p> <p><i><br />Yes, liberals can be against free speech. Very much so. See the flap over the fairness doctrine. See hate speech legislation. See this flap right here.</i></p> <p>All those are arguable. The Fairness Doctrine in particular was intended to provide a balanced political dialogue. If you couple the ability to present only one side, and media ownership through conglomerations, you can (and indeed, have) create a situation where one side has much greater access to the airwaves than the other. </p> <p>I’m not a fan of Hate Speech codes myself. I prefer to let bad ideas be fought with better ideas. </p> <p><i>Liberals even do it to each other. You guys don’t want to allow Hillary Clinton to put a commercial on about experience (Who’s picking up the phone in the White House?) You guys don’t even want to let her talk about her experience, which is certainly more than Obama’s, though the three things she claims give her experience are pretty thin.</i></p> <p>Whoa. Who has said she can’t air that ad or talk about her experience? Expressing an opinion isn’t the same as trying to shut down the other person’s ability to speak. </p> <p><i><br />Every election, except for Washington’s (though I’m sure someone can find something) has had its dirty tricks and nastiness and low blows. That’s politics. SteveG claims “Nobody’s saying you can’t say whatever you want to.” But this whole thread is all about that. Don’t mention the name Hussein! Well … Hussein, Hussein, Hussein!</i></p> <p>See? Obviously you <i>can</i> say it. Nobody’s oppressing your free speech to do so. But people who think that playing up is middle name is a cheap shot designed to appeal to the baser instincts of some have a right to say that too. </p> <p>I think you’re conflating actual suppression of free speech — and Hate Speech codes are the only real example of that here — with dissenting speech from others. Saying that I think it’s a cheap trick to refer to Obama by all three names is in no way stopping anybody from doing it. </p> <p><i><br /> Obama didn’t have the standard upbringing other presidents in the past century have had. We have a right to examine that upbringing. It made Obama who he is.</i></p> <p>Sure. Who has said otherwise? </p> <p>But that’s more than just pointing out that his middle name is Hussein. It requires examining his background and analyzing his character today. </p> <p><i>For people who are still calling Bush a drunk when his presidency is almost over (and he hasn’t been drinking), I think you all should just face up to the fact that you don’t want your precious B-HO to be treated like a real candidate. Why this hands off attitude?</i></p> <p>How is it any different than Bush’s supporters objecting to his past alcoholism being brought up? People who are loyal to a candidate will naturally object to unfair criticism (and sometimes to fair criticism) of their candidate. </p> <p>That’s not censorship, it’s just meeting opinion with opinion. </p> <p><i><br />I’m not advocating being nasty about B-HO’s name. I think McCain was right to repudiate Cunningham. But I am advocating finding out as much about Obama as possible, and the liberals here don’t like that for some reason.</i></p> <p>I don’t think that’s true. I haven’t encountered anybody who has objected to real assessment of his background. </p> <p>It’s the sleazy innuendo (”his middle name is Hussein, we know what that means,” or the slanderous story Fox was trying to peddle a few months back that he was schooled in a Madrassa) that we object to.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278874', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278883"> <span class="commentTop"> <img alt="NJLawyer" src="http://www.gravatar.com/avatar/04e25cc48f049112d756c323bc4d7da8?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">NJLawyer</span> 02.29.08 AT 9:42 PM </span> <div class="comment" style="margin-top:4px;"> <p>SteveG, just because it doesn’t trouble you, doesn’t mean it can’t be examined. Something rubs off in church, for good or for ill. Obama has said he reveres his minister. His minister reveres Farrakhan. If A = B, and B = C, A = C. I find it very odd that there are no big name blacks other than Oprah surrounding this guy. Why is that? I can see why no Al Sharpton or Jesse Jackson, but other than Oprah and a few actors, where are the prominent blacks? Even Oprah has backed off. There’s something off here. It’s all very controlled.</p> <p>You’re just wrong on the Fairness Doctrine and still bent out of shape that the conservatives listen to talk radio. Examine why Air America (wasn’t that what it was called?) didn’t make a go of it. Be honest.</p> <p>Haven’t you heard the commmentary about Hillary’s ad? The way it is portrayed? Come on….the news reporters are not being fair to her.</p> <p>It may be that the way to get the issue of Obama’s upbringing out in the open is to say his name, but every time someone says it, the automatic response is “racism.” Only Peter Leavitt offered some factual information about Obama. The liberals here have not. Nor has the MSM examined his upbringing. I distinctly remember news reports and “specials” examining the lives of previous presidents. Haven’t seen any on Obama. (I guess that’s because if they did that, they might have to do one on McCain, and golly gee whiz, let’s not let that record get out!) Haven’t seen one on Hillary either. Do you hear anything about her being a follower of that socialist Arlinsky (not sure of the name there, but you know who I mean). Why don’t we hear about her thesis being locked up? Why won’t she release it? Why don’t you want it releasedif you’re all so proud of her?</p> <p>If you can talk about Bush’s alcoholism, and talk about it all you want, you should be able to examine Obama. That’s not being done. The point is you’re still beating up someone who is essentially a dead horse (certainly a lame duck!), but you get your knickers in a twist over someone saying “Hussein!” You seek to silence your critics with the word “racist” every time the name comes up in an effort to keep them from going further and examining this guy’s history. That’s not honest!</p> <p>Why don’t you guys ask questions about your own candidates? Afraid of what you’ll find? Liberals always accuse conservatives of not thinking, but you guys just walk down the primrose path like Stepford wives.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278883', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278891"> <span class="commentTop"> <img alt="Anlir" src="http://www.gravatar.com/avatar/7101e7bf184d79680e75a3341b1daf83?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Anlir</span> 02.29.08 AT 10:25 PM </span> <div class="comment" style="margin-top:4px;"> <p>NJLawyer’s demand that Barack Obama speak about his middle name is a blatant attempt to stoke the fears and prejudice of people. It’s political mudslinging of the worst order. She can claim perfect innocence, but we all know what she (and her fellow conservatives) are trying to do by exploiting this matter.</p> <p>Let’s keep the focus on where it belongs: the conservative’s attempts to fan the flames of fear and prejudice.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278891', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278892"> <span class="commentTop"> <img alt="Kiyoshi" src="http://www.gravatar.com/avatar/084fc62de610eb60233057257b44af20?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Kiyoshi</span> 02.29.08 AT 10:30 PM </span> <div class="comment" style="margin-top:4px;"> <p>It says something about where the conservative movement has gone when William F. Buckley’s passing is overshadowed by the obnoxious comments of a conservative radio shock jock.</p> <p>Conservatism would be more attractive to me if it jettisoned the stupidity of Limbaugh and Cunningham and returned to the lively wit of Buckley, Nisbet, and Scruton.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278892', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278896"> <span class="commentTop"> <a href="http://renaissanceguy.wordpress.com" rel="external nofollow" title="Visit Kyle A’s website" class="snap_noshots"><img alt="Kyle A" src="http://www.gravatar.com/avatar/fd9afd2fb240190adc6890143db20420?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /></a> BY <span class="commentBy"><a href="http://renaissanceguy.wordpress.com" rel="external nofollow" class="url">Kyle A</a></span> 02.29.08 AT 10:45 PM </span> <div class="comment" style="margin-top:4px;"> <p>Anlir: “Why should Obama address this? His middle name is of no more import than if it were John, or Edward, or Michael.”</p> <p>Then why does it matter that Bill Cunningham said it. I guess we’ve come full circle; here I am asking again.</p> <p>Either his name matters or it doesn’t. Either it’s a problem or it isn’t. You can’t have it both ways.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278896', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278898"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 02.29.08 AT 10:50 PM </span> <div class="comment" style="margin-top:4px;"> <p>It isn’t a problem Kyle. </p> <p>People trying to insinuate that it is a problem, is the problem. </p> <p>If you don’t get it by now, you’re not going to.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278898', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278900"> <span class="commentTop"> <img alt="Anlir" src="http://www.gravatar.com/avatar/7101e7bf184d79680e75a3341b1daf83?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Anlir</span> 02.29.08 AT 10:59 PM </span> <div class="comment" style="margin-top:4px;"> <p>Kyle doesn’t want to get it. People who are blind partisans are interested in tearing down their political opponents by any means necessary. Our conservative friends have gone negative. It’s all they have left to try and stave off a Democratic victory in November. They’re running scared. They may yet pull it off by appealing to people’s worst fears and prejudice. But there is growing evidence that the American people are tired of it.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278900', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278934"> <span class="commentTop"> <img alt="NJLawyer" src="http://www.gravatar.com/avatar/04e25cc48f049112d756c323bc4d7da8?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">NJLawyer</span> 03.01.08 AT 8:57 AM </span> <div class="comment" style="margin-top:4px;"> <p>Kiyoshi writes: “Conservatism would be more attractive to me if it jettisoned the stupidity of Limbaugh and Cunningham and returned to the lively wit of Buckley, Nisbet, and Scruton.”</p> <p>Can’t argue with that. </p> <p>Anlir, I don’t care if Obama says his name or not. What I care about is that his background will be explored just as the background of every other candidate has been explored. That has NOT happened.</p> <p>Yes, let’s keep the focus clear: we don’t know anything about Obama, and we should. Evidently merely asking for information sends the liberals into a tizzy. Merely asking for information gets a non-liberal the label of racist. That’s sick and wrong, but typical of liberals who have this need never to think and never to question.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278934', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278941"> <span class="commentTop"> <img alt="NJLawyer" src="http://www.gravatar.com/avatar/04e25cc48f049112d756c323bc4d7da8?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">NJLawyer</span> 03.01.08 AT 9:24 AM </span> <div class="comment" style="margin-top:4px;"> <p>Are we allowed to talk about Tony Rezko or is that off limits, too?</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278941', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278952"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 03.01.08 AT 10:04 AM </span> <div class="comment" style="margin-top:4px;"> <p>Night Train at #37: <i>Nonsense. People change their names all the time. But poor, helpless Obama can do nothing about his name?</i></p> <p>And if he did, or if he had in the past, people like Cunningham and Kyle A would be going around saying “His middle name used to be Hussein but he changed it to Herbert. Why did he change it? What’s he trying to hide?”</p> <p>Once his mom and dad gave him the name, there was nothing he could do. Changing it legally would not erase it from memory — or the public record.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278952', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-278960"> <span class="commentTop"> <img alt="Anlir" src="http://www.gravatar.com/avatar/7101e7bf184d79680e75a3341b1daf83?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Anlir</span> 03.01.08 AT 10:19 AM </span> <div class="comment" style="margin-top:4px;"> <p>NJLawyer’s contention that we don’t know anything about Obama is hogwash. There are 2 books out by Obama himself that cover his life in great detail, from childhood on up. His life as an Illinois representative is in the public domain for all to see, as is his short senate record. He’s also released his tax returns.</p> <p>One gets the feeling that NJLawyer is upset because she and her fellow conservatives haven’t been able to find enough dirt to destroy Barack Obama. And make no mistake – that is their goal.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278960', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-278965"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 03.01.08 AT 10:30 AM </span> <div class="comment" style="margin-top:4px;"> <p>NJLawyer, here you go:</p> <p><a href="http://www.washingtonpost.com/wp-dyn/content/article/2007/11/28/AR2007112802757.html?hpid=topnews" rel="nofollow">Foes use Obama’s Muslim ties to fuel rumors about him</a></p> <p><a href="http://en.wikipedia.org/wiki/Barack_Obama" rel="nofollow">wikipedia bio</a></p> <p><a href="http://www.sourcewatch.org/index.php?title=Barack_Obama" rel="nofollow">Info on his political career including specifics of what he’s done while in the Senate</a></p> <p><a href="http://pewforum.org/religion08/profile.php?CandidateID=4" rel="nofollow">Links to several articles via The Pew Forum</a></p> <p><a href="http://www.azcentral.com/news/articles/0227obama-muslimmyth0227-ON.html" rel="nofollow">Obama addresses rumors</a></p> <p><a href="http://www.nypost.com/seven/01182008/postopinion/editorials/baracks_un_righteous_rev_760599.htm" rel="nofollow">An article about Wright and Farrakhan</a></p> <p>Google is your friend.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=278965', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-279027"> <span class="commentTop"> <img alt="Sawgunner" src="http://www.gravatar.com/avatar/e014e39a07e170966eef534b3802b05d?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">Sawgunner</span> 03.01.08 AT 2:53 PM </span> <div class="comment" style="margin-top:4px;"> <p>Do Muslims respect Barack enough to not assassinate him as a former Muslim turned Christian??<br />Has anyone heard or read Barack’s testimony?<br />Solid??</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=279027', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-279037"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 03.01.08 AT 3:39 PM </span> <div class="comment" style="margin-top:4px;"> <p>Sawgunner: From one of the links I offered in #66 (the one labeled “Obama addresses rumors:”</p> <p><i>The Democratic candidate says repeatedly that he’s a Christian who took the oath of office on a family Bible. Yet on the Internet and on talk radio – and in a campaign introduction for John McCain this week – he is often depicted, falsely, as a Muslim with shadowy ties and his middle name, Hussein, is emphasized as a reminder of Iraq’s former leader.</i></p> <p><i>“If anyone is still puzzled about the facts, in fact I have never been a Muslim,” he told the Jewish leaders in Cleveland.</i></p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=279037', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-279158"> <span class="commentTop"> <img alt="NJLawyer" src="http://www.gravatar.com/avatar/04e25cc48f049112d756c323bc4d7da8?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">NJLawyer</span> 03.02.08 AT 2:58 PM </span> <div class="comment" style="margin-top:4px;"> <p>Anlir, when I say that we don’t know things about Obama, I’m saying that the media is not making these things generally known. I know more about Britney Spears, more than I’d ever want to know, just by watching tv. I don’t have to google her! That’s not happening with Obama. People shouldn’t have to google for one side and not the other. The media is protecting Obama, and that’s unfair to Hillary and in the long run, unfair to all of us if he becomes the nominee.</p> <p>I told you guys the other day that I don’t get upset when I post, and truth be told, I don’t get upset about politics. I don’t know how this turns out come November, but I don’t know how you’ll get “change” out of Obama. It can be shown — and will be shown if he is the nominee — that when it came to votes on judges or laws that Obama hasn’t reached across the aisle. He is far left and votes that way. He doesn’t compromise. (McCain — to his credit — works with the other side.) Whatever happens in November, God is in control, and we will get the government we deserve.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=279158', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-279159"> <span class="commentTop"> <img alt="NJLawyer" src="http://www.gravatar.com/avatar/04e25cc48f049112d756c323bc4d7da8?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">NJLawyer</span> 03.02.08 AT 2:59 PM </span> <div class="comment" style="margin-top:4px;"> <p>I noticed that you guys aren’t talking about Tony Rezko and how Obama is involved with Chicago politics. Too dirty for you to mention?</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=279159', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-279160"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 03.02.08 AT 3:06 PM </span> <div class="comment" style="margin-top:4px;"> <p><a href="http://www.suntimes.com/news/politics/124171,CST-NWS-obama05.article" rel="nofollow">Obama and Rezko</a></p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=279160', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-279168"> <span class="commentTop"> <img alt="NJLawyer" src="http://www.gravatar.com/avatar/04e25cc48f049112d756c323bc4d7da8?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">NJLawyer</span> 03.02.08 AT 4:52 PM </span> <div class="comment" style="margin-top:4px;"> <p>SteveG, I put my response in another thread today. We should know as much about this from tv as we do about Britney Spears. I’ve seen Charlie Gibson on ABC do a stories on this girl on the 1/2 hour news. Considering we know that Entertainment Tonight, etc., will follow her every move, I think the major news outlets could run a real story on Obama and those who have influenced him, given him money, etc. Who’s more important — Britney or a candidate for the presidency? That’s all I’m sayin’.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=279168', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li class="commentOdd" id="comment-279169"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 03.02.08 AT 5:19 PM </span> <div class="comment" style="margin-top:4px;"> <p>For my money, the less I know about Britney Spears, the better. Point taken.</p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=279169', 500, 500)">Report comment to moderator</a></font></p> </div> </li> <li id="comment-279182"> <span class="commentTop"> <img alt="SteveG" src="http://www.gravatar.com/avatar/c148afa57c4a25a0e5b902d2a490cac0?s=35&amp;d=http%3A%2F%2Fonline.worldmag.com%2Fwp-content%2Fthemes%2Fworldmag%2Fimages%2FicoAvatar.gif&amp;r=PG" class="avatar avatar-35 avatar-default" height="35" width="35" /> BY <span class="commentBy">SteveG</span> 03.02.08 AT 7:38 PM </span> <div class="comment" style="margin-top:4px;"> <p>Sawgunner: Barack Obama: </p> <p><i>“I am a devout Christian. I have been a member of the same church for 20 years. I pray to Jesus every night,” he declared at an earlier appearance in the rural southern Ohio town of Nelsonville.</i></p> <p><a href="http://apnews.myway.com/article/20080302/D8V5I2A81.html" rel="nofollow">Article</a></p> <p align="right"><font point-size="8"><a href="javascript:void(0)" title="" onmouseover="window.status=''; return true" onmouseout="window.status=''; return true" onclick="ddrc_popup('http://online.worldmag.com/wp-content/plugins/dd-report-comments/report.php?c=279182', 500, 500)">Report comment to moderator</a></font></p> </div> </li> </ol> <div id="comment_stuff"> <h2 class="commentJoin"><span class="backToTop"><a href="#postPageTop">back to top</a></span>Join The Conversation</h2> <p>You need to be a registered user of WORLDmag.com's Community section to &quot;join the conversation.&quot;</p> <p>If you are not a member yet, what are you waiting for? <a href="http://online.worldmag.com/wp-login.php?redirect_to=http%3A%2F%2Fonline.worldmag.com%2F2008%2F02%2F29%2Fmccains-massive-mistake%2F">Register / Login Now!</a></p> </div> </div> <!-- Prev/Next Navigation --> <div class="postNav"> <div class="postNext"> <a href="http://online.worldmag.com/2008/02/29/the-face-of-russias-new-leader/">The face of Russia’s new leader</a> &raquo; </div> <div class="postPrev"> &laquo; <a href="http://online.worldmag.com/2008/02/29/hagee-hearts-mccain-a-grotesque-double-standard/">Hagee hearts McCain: A “grotesque double standard?”</a> </div> <div class="clear"></div> </div> <div class="noPrint" style="border-top:1px solid #999999; text-align: center; padding: 20px 0px 8px 0px; margin: 20px 0px 15px 0px; clear:both;"> <a style="margin-left: -20px;" href="https://www.worldmag.com/s2/donate.cfm" target="_parent"><img src="http://www.worldmag.com/s2/images/worldmovers_584x131.jpg" alt="Donate to WORLD Movers" width="584" height="131" border="0" /></a> </div> </div> <!--end #content --> <div id="avatar_footer" style="display: none;"> <a href="http://www.sterling-adventures.co.uk/blog/">Adventures</a> </div> <div id="copyright"> <p>Copyright &copy; 2012 God's World Publications. All rights reserved. <br />Articles may not be reproduced without permission.</p> </div> <div id="footer"> <table id="pageBtmNav" width="100%"> <tbody> <tr> <td width="10%" class="last">&nbsp;</td> <td><a href="http://www.worldmag.com/world_about_us.cfm">About&nbsp;Us</a></td> <td><a href="/writers/">Meet&nbsp;the&nbsp;Writers</a></td> <td><a href="/regulars/">Meet&nbsp;the&nbsp;Regulars</a></td> <td><a href="http://www.worldmag.com/websitepolicies.cfm">Website&nbsp;Policies</a></td> <td><a href="http://www.worldmag.com/websitehelp.cfm">Website&nbsp;Help</a></td> <td><a href="http://www.worldmag.com/world_contact_us.cfm">Contact&nbsp;Us</a></td> <td class="last"><a href="http://www.worldmag.com/s2/">Subscribe</a></td> <td width="10%" class="last">&nbsp;</td> </tr> </tbody> </table> <script type="text/javascript">/* <![CDATA[ */var emailL10n = { ajax_url: "http://online.worldmag.com/wp-content/plugins/wp-email/wp-email.php", max_allowed: "5", text_error: "The Following Error Occurs:", text_name_invalid: "- Your Name is empty/invalid", text_email_invalid: "- Your Email is empty/invalid", text_remarks_invalid: "- Your Remarks is invalid", text_friend_names_empty: "- Friend Name(s) is empty", text_friend_name_invalid: "- Friend Name is empty/invalid: ", text_max_friend_names_allowed: "- Maximum 5 Friend Names allowed", text_friend_emails_empty: "- Friend Email(s) is empty", text_friend_email_invalid: "- Friend Email is invalid: ", text_max_friend_emails_allowed: "- Maximum 5 Friend Emails allowed", text_friends_tally: "- Friend Name(s) count does not tally with Friend Email(s) count", text_image_verify_empty: "- Image Verification is empty"};/* ]]> */</script> <script type="text/javascript" src="http://online.worldmag.com/wp-content/plugins/wp-email/email-js.js?ver=2.50"></script> <script type="text/javascript">jQuery(function() { jQuery.post("index.php",{ak_action:"api_record_view", ids: AKPC_IDS, type:"single"}, false, "json");});</script> </div> <!-- end #footer --> </div> <!--end #page--> <a id="displaypromotion" style="display: none;" href="/wp-content/themes/worldmag/promoteWorld.php?height=417&amp;width=521" class="thickbox">&nbsp;</a> <!-- www.hitslink.com/ web tools statistics hit counter code --> <script type="text/javascript" id="wa_u"></script> <script type="text/javascript">//<![CDATA[// Begin Variable Declarationswa_account="90919396919A88908D939B929E98"; wa_location=26;wa_pageName=location.pathname; // you can customize the page name here// End Variable Declarationsdocument.cookie='__support_check=1';wa_hp='http';wa_rf=document.referrer;wa_sr=window.location.search;wa_tz=new Date();if(location.href.substr(0,6).toLowerCase()=='https:')wa_hp='https';wa_data='&an='+escape(navigator.appName)+ '&sr='+escape(wa_sr)+'&ck='+document.cookie.length+'&rf='+escape(wa_rf)+'&sl='+escape(navigator.systemLanguage)+'&av='+escape(navigator.appVersion)+'&l='+escape(navigator.language)+'&pf='+escape(navigator.platform)+'&pg='+escape(wa_pageName);wa_data=wa_data+'&cd='+screen.colorDepth+'&rs='+escape(screen.width+ ' x '+screen.height)+'&tz='+wa_tz.getTimezoneOffset()+'&je='+ navigator.javaEnabled();wa_img=new Image();wa_img.src=wa_hp+'://counter.hitslink.com/statistics.asp'+'?v=1&s='+wa_location+'&eacct='+wa_account+wa_data+'&tks='+wa_tz.getTime();document.getElementById('wa_u').src=wa_hp+'://counter.hitslink.com/track.js'; //]]></script> <!-- End www.hitslink.com/ statistics web tools hit counter code --> </body> </html>
253	faceted	tooth abscess	What treatments are available for a tooth abscess?	clueweb12-0602wb-15-18498	2	<html xmlns:adam="urn:DataProcessor" xmlns:ax="http://www.adam.com" xmlns:exsl="http://exslt.org/common"> <head></head> <body onload="ADAM();sectionNav()"> ﻿ <title>Tooth abscess</title> <meta name="Keywords" content="abscess,dental,infection,periapical,tooth,toothache," /> <link rel="stylesheet" type="text/css" media="screen" href="/includes/main.css" /> <!--[if IE 6]> <link rel="stylesheet" type="text/css" href="/includes/ie.css" /><![endif]--> <link rel="stylesheet" type="text/css" media="print, handheld" href="/includes/print.css" /> <link rel="stylesheet" type="text/css" media="screen" href="/includes/adam.css" /> <script type="text/javascript" src="/includes/scripts.js"></script> <script language="javascript" src="../../graphics/global/jquery-1.3.2.min.js"> </script> <script type="text/javascript" src="../../graphics/global/swfobject.js"> </script> <script language="javascript" type="text/javascript"><!-- function ADAM() { } --></script> <script type="text/javascript" src="http://default.adam.com/graphics/global/swfobject.js"> </script> <!--these are 4 new added divs below befor the start of the gloal navigation...--> <div id="nonFooter"> <div id="container"> <div id="header"> <!--<div id="logo"><img src="/images/memorial-healthcare-logo.gif" width="298" height="68" alt="Memorial Healthcare Systems" /><p>3501 Johnson St. Hollywood, Florida 33021 (954) 987-2000</p></div>--> <h1 id="logo"><a href="http://www.mhs.net/index.cfm">Memorial Healthcare System</a></h1> <div id="search"> <form action="http://search.mhs.net/search" method="get"> <div class="textentry"> <input id="str" name="q" type="text" size="20" maxlength="50" /> </div> <input type="hidden" name="site" value="All" /> <input type="hidden" name="client" value="mhs" /> <input type="hidden" name="output" value="xml_no_dtd" /> <input type="hidden" name="proxystylesheet" value="mhs" /> <input type="submit" value="Search" name="searchbutton" id="searchbutton" alt="Search" style="width: 70px; height: 20px; color: #fff; background-image: url('http://www.mhs.net/images/search.jpg'); border: none;" /> </form> </div> </div> <!--closes Div ID "header"--> <div id="sitenav"> <!--new div wrapper for the main nav --> <div id="p7EPM_1" class="p7EPM54"> <div id="p7EPMt_1" class="p7epm_trigs"> <ul> <li class="t1"><a href="/aboutus/" id="p7EPMtrg1_1" class="paddingTop10">About Memorial<br /> Healthcare System</a></li> <li class="t2"><a href="/services/" id="p7EPMtrg1_2" class="paddingTop20">Health Services</a></li> <li class="t3"><a href="/patients/healthcare-services-amenities.cfm" id="p7EPMtrg1_3" class="paddingTop20">Patients &amp; Visitors</a></li> <li class="t4"><a href="/physicians/" id="p7EPMtrg1_4" class="paddingTop20">Find a Physician</a></li> <li class="t5"><a href="/locations/" id="p7EPMtrg1_5" class="paddingTop20">Locations</a></li> <li class="t6"><a href="/library/hie multimedia/200000.html" id="p7EPMtrg1_6" class="paddingTop20">Health Library</a></li> <li class="t7"><a href="/career-center/" id="p7EPMtrg1_7" class="paddingTop20">Career Center</a></li> </ul> <!--<ul><li class="paddingTop2"><a href="#">Home</a></li><li class="paddingTop2"><a href="#">How to Give</a></li><li class="paddingTop2"><a href="#">Contact</a></li></ul>---> <div class="p7epm_ie5clear"> &nbsp; </div> </div> <div id="p7EPMdw_1"> <div id="p7EPMw1_1" class="p7epm_cwrapper"> <div id="p7EPMc1_1" class="p7epm_content pan1"> <table width="450" border="0" cellpadding="0" cellspacing="0"> <tbody> <tr> <td width="225" valign="top"> <p><strong>Hollywood's Top Rated Hospital...</strong></p> <ul> <li><a href="/aboutus/">Overview Information</a></li> <li><a href="/aboutus/accreditations.cfm">Accreditations, Licenses, Memberships</a></li> <li><a href="/aboutus/annual-report.cfm">Annual Reports</a></li> <li><a href="/aboutus/health-care-service-awards.cfm">Awards</a></li> <li><a href="/aboutus/board-of-commissioners.cfm">Board of Commissioners</a></li> <li><a href="/aboutus/financial.cfm">Financial Overview</a></li> <li><a href="/aboutus/about-us-visions.cfm">Mission &amp; Vision Statements</a></li> <li><a href="/memorial-experience/">The Memorial Experience</a></li> <li><a href="/press-releases/">Press Releases</a></li> <li><a href="/vendorinformation/">Vendor Information</a></li> <li><a href="/aboutus/video-library.cfm">Video Library</a></li> </ul></td> <td width="225" valign="top"> <p><strong>Community Information...</strong></p> <ul> <li><a href="/community/calendars-schedules.cfm">Calendars &amp; Schedules</a></li> <li><a href="/community/community-services.cfm">Community Services &amp; Outreach Programs</a></li> <li><a href="/community/blood-donation-services.cfm">Donating Blood</a></li> <li><a href="http:/www.memorialpembroke.com/services/memory-center/leezasplace.cfm">Leeza's Place</a></li> <li><a href="/community/senior-health-care-services.cfm">Senior Partners</a></li> <li><a href="/community/health-care-support-groups.cfm">Support Groups</a></li> <li><a href="/community/community-awards.cfm">Prestigious Awards for Excellence in Community Service</a></li> <li><a href="/community/volunteer-work.cfm">Volunteering at Memorial</a></li> </ul></td> </tr> </tbody> </table> </div> </div> <div id="p7EPMw1_2" class="p7epm_cwrapper"> <div id="p7EPMc1_2" class="p7epm_content pan2"> <table width="675" border="0" cellpadding="0" cellspacing="0"> <tbody> <tr> <td width="225" valign="top"> <p><strong>Adult Services...</strong></p> <ul> <li><a href="/services/adult-day-care-center/">Adult Day Care Center</a></li> <li><a href="/services/bariatrics/">Bariatrics/Weight-Loss Surgery</a></li> <li><a href="/services/behavioral-health/">Behavioral Health Center</a></li> <li><a href="/services/cancerinstitute/">Cancer Institute</a></li> <li><a href="http://www.memorialregional.com/services/cardiac/">Cardiac &amp; Vascular Institute</a></li> <li><a href="/services/diabetes-treatment/">Diabetes Centers</a></li> <li><a href="/services/familybirthplace/">Family Birthplace</a></li> <li><a href="http://www.memorialfitnesscenter.com/">Fitness Centers</a></li> <li><a href="http://www.memorialregionalsouth.com/services/senior-care/">Geriatric Care Program</a></li> <li><a href="/services/homehealth-services/">Home Health Services</a></li> </ul></td> <td width="225" valign="top"> <p>&nbsp;</p> <ul> <li><a href="/services/lymphedema-treatment/">Lymphedema Program</a></li> <li><a href="/services/neuroscience-services/">Neuroscience Center</a></li> <li><a href="/services/outpatient-services/">Outpatient Services</a></li> <li><a href="http://www.memorialpembroke.com/services/robotics/">Robotic Institute</a></li> <li><a href="http:/www.memorialregional.com/services/sickle-cell-treatment/">Sickle Cell</a></li> <li><a href="/services/sleep-disorder-treatment/">Sleep Study Program</a></li> <li><a href="http://www.memorialregionalsouth.com/services/spine-center/">Spine Center</a></li> <li><a href="/services/thoracic-surgery/">Thoracic Surgery </a></li> <li><a href="/services/women-breast-imaging-services/">Women's Breast Imaging Center </a></li> <li><a href="/services/womens-healthcare-services/">Women's Services </a></li> <li><a href="http://www.memorialpembroke.com/services/wound-center/">Wound Care</a></li> </ul></td> <td width="225" valign="top"> <p><strong>Pediatric Services...</strong></p> <ul> <li><a href="http://www.jdch.com/">Pediatrics</a></li> <li><a href="http://www.jdch.com/html/medical-specialities/hematology-oncology/index.html">Pediatric Cancer</a></li> <li><a href="http://www.jdch.com/html/medical-specialities/cardiac/index.html">Pediatric Cardiac Center</a></li> <li><a href="http://www.jdch.com/html/medical-specialities/craniofacial/index.html">Pediatric Cleft &amp; Craniofacial Center</a></li> <li><a href="http://www.jdch.com/html/medical-specialities/pulmonary/index.html">Pediatric Cystic Fibrosis &amp; Pulmonary Center </a></li> <li><a href="http://www.jdch.com/html/medical-specialities/endocrine/index.html">Pediatric Endocrinology</a></li> <li><a href="http://www.jdch.com/html/medical-specialities/in-house-departments/nicu.cfm">Neonatal ICU</a></li> <li><a href="http://www.jdch.com/html/medical-specialities/neurology/index.cfm">Pediatric Neuroscience</a></li> <li><a href="http://www.jdch.com/html/medical-specialities/nephrology/index.html">Pediatric Nephrology &amp; Hypertension</a></li> <li><a href="http://www.jdch.com/html/medical-specialities/orthopedics/">Pediatric Orthopaedics</a></li> </ul></td> </tr> </tbody> </table> </div> </div> <div id="p7EPMw1_3" class="p7epm_cwrapper"> <div id="p7EPMc1_3" class="p7epm_content pan3"> <table width="375" border="0" cellpadding="0" cellspacing="0"> <tbody> <tr> <td width="185" valign="top"> <p><strong>General Information...</strong></p> <ul> <li><a href="/patients/healthcare-services-amenities.cfm">Amenities &amp; Conveniences</a></li> <li><a href="/locations/">Directions &amp; Parking</a></li> <li><a href="/patients/health-care-preparation.cfm">Preparing For Your Visit</a></li> <li><a href="/patients/patient-care/">Patient- &amp; Family-Centered Care</a></li> <li><a href="/safety-quality/">Safety &amp; Quality</a></li> <li><a href="/patients/health-care-translation.cfm">Special Services</a></li> <li><a href="/patients/visiting-memorial-healthcare.cfm">Visiting a Patient</a></li> <li><a href="/patients/maternity-care.cfm">Web Nursery</a></li> </ul></td> <td width="190" valign="top"><p><strong>Patient Information...</strong></p> <ul> <li><a href="/patients/insuranceplans.cfm">Insurance Plans</a></li> <li><a href="/patients/medical-records-center/">Medical Records</a></li> <li><a href="/patients/medicare.cfm">Medicare Advantage Plans</a></li> <li><a href="https://www.mhs.net/secure/advanceregistration/">Outpatient Online Pre-Registration</a></li> <li><a href="https://www.mhs.net/secure/scheduling/">Outpatient Scheduling</a></li> <li><a href="/patients/billing/">Pay Your Bill</a></li> </ul></td> </tr> </tbody> </table> </div> </div> <div id="p7EPMw1_6" class="p7epm_cwrapper"> <div id="p7EPMc1_6" class="p7epm_content pan6"> <table width="300" border="0" cellpadding="0" cellspacing="0"> <tbody> <tr> <td width="300" valign="top"> <p><strong>Take Charge of Your Health...</strong></p> <ul> <li><a href="/library/hie multimedia/diseidxa.html">Research a Disease or Condition</a></li> <li><a href="/library/hie multimedia/sympidxa.html">Lookup a Symptom</a></li> <li><a href="/library/hie multimedia/testidxa.html">Learn About a Test</a></li> <li><a href="/library/hie multimedia/surgidxa.html">Prepare for a Surgery or Procedure</a></li> <li><a href="/library/hie multimedia/dischargeidxa.html">What to do After Being Discharged</a></li> </ul> <p><strong>Get More Out of Your Care...</strong></p> <ul> <li><a href="/library/hie multimedia/selfcareidxa.html">Self-Care Instructions</a></li> <li><a href="/library/hie multimedia/questionsidxa.html">Questions to Ask Your Doctor</a></li> <li><a href="/library/hie multimedia/nutridxa.html">Nutrition, Vitamins &amp; Special Diets</a></li> </ul> <p><strong>Understand an Emergency...</strong></p> <ul> <li><a href="/library/hie multimedia/acciidxa.html">Injuries </a></li> <li><a href="/library/hie multimedia/poisidxa.html">Poisons</a></li> </ul></td> </tr> </tbody> </table> </div> </div> <div id="p7EPMw1_7" class="p7epm_cwrapper"> <div id="p7EPMc1_7" class="p7epm_content pan7"> <table width="275" border="0" cellpadding="0" cellspacing="0"> <tbody> <tr> <td width="275" valign="top"> <p><strong>Ranked Among the Best...</strong></p> <ul> <li><a href="https://sh.webhire.com/Public/782/">Search for Jobs Now</a></li> <li><a href="https://sh.webhire.com/profiler/login_page.pfl?ACCT_NAME=Memorial">Login</a></li> <li><a href="/career-center/employment-benefits.cfm">Benefits</a></li> <li><a href="/career-center/working-at-memorial.cfm">Life at Memorial</a></li> <li><a href="/career-center/employment-scholarships.cfm">Scholarships</a></li> <li><a href="https://sh.webhire.com/public/782/referral/program/?WT.mc_id=career">Employee Referral Program</a></li> <li><a href="/career-center/employment-relocation.cfm">Relocation</a></li> <li><a href="/career-center/pharmacy-residency.cfm">Pharmacy Residency Program</a></li> </ul></td> </tr> </tbody> </table> </div> </div> </div> <!--[if IE 5]><style>.p7epm_trigs {width: 100%;} .p7epm_ie5clear {clear: both;} .p7epm_content, .p7epm_content li a {height: 1%;}</style><![endif]--> <!--[if IE 6]><style>.p7epm_trigs, .p7epm_content div {zoom: 1;} .p7epm_trigs a {height: auto !important;}</style><![endif]--> <script type="text/javascript"><!--P7_opEPM('p7EPM_1',0,1,1,1,0,1000,0,1,250,0,0,1);//--> </script> </div> </div> <!--closes Div ID "sitenav"--> <!-- new divs to controll new layout --> <div id="wrapper"> <div id="content"> <div id="sectionnav"> <div id="navtitle"> <h2>Health Library</h2> <div id="navtitleend"> &nbsp; </div> </div> <div id="p7TMM_1" class="p7TMM03"> <p>&nbsp;</p> <ul class="p7TMM"> <li><a href="http://www.mhs.net/library/hie multimedia/200000.html">Health Library</a></li> <li><a href="http://www.mhs.net/library/hie multimedia/diseidxa.html">Research a Disease or Condition</a></li> <li><a href="http://www.mhs.net/library/hie multimedia/sympidxa.html">Lookup a Symptom</a></li> <li><a href="http://www.mhs.net/library/hie multimedia/testidxa.html">Learn About a Test</a></li> <li><a href="http://www.mhs.net/library/hie multimedia/surgidxa.html">Prepare for a Surgery or Procedure</a></li> <li><a href="http://www.mhs.net/library/hie multimedia/dischargeidxa.html">What to do After Being Discharged</a></li> <li><a href="http://www.mhs.net/library/hie multimedia/selfcareidxa.html">Self-Care Instructions</a></li> <li><a href="http://www.mhs.net/library/hie multimedia/questionsidxa.html">Questions to Ask Your Doctor</a></li> <li><a href="http://www.mhs.net/library/hie multimedia/nutridxa.html">Nutrition, Vitamins &amp; Special Diets</a></li> <li><a href="http://www.mhs.net/library/hie multimedia/acciidxa.html">Injuries </a></li> <li><a href="http://www.mhs.net/library/hie multimedia/poisidxa.html">Poisons</a></li> </ul> <!--[if lte IE 6]><style>.p7TMM03 .p7TMM, .p7TMM03 a, .p7TMM03 li {height:1%;}</style><![endif]--> <!--[if IE 5]><style>.p7TMM03 a, .p7TMM03 a {overflow: visible !important;}</style><![endif]--> <script type="text/javascript"><!--P7_TMMop('p7TMM_1',3,0,0,3,1,1,0,0,-1);//--> </script> <div id="p7TMM03end"> &nbsp; </div> </div> <div id="enews"> <a href="http://www.mhs.net/contact/subscribe.cfm"><img src="http://www.mhs.net/images/enews_signup.jpg" width="232" height="136" /></a> </div> </div> <img src="http://www.mhs.net/images/healthlibrary_banner.jpg" width="695" height="214" alt="Memorial Healthcare System Health Library" id="banner" /> <div id="contentmain" class="bannercontent"> <!-- below here is where exisiting content will merge with new layout --> <div id="contentmainfill"> <div> <div class="ADAMContent" align="center"> <style type="text/css"> .ADAMContent {Width: 545;position: relative;margin: 0px auto;top: 0;z-index: 0;}</style> <script language="javascript"><!-- function ADAMSearchRedirect(queryString) { var resultCount = ''; if (resultCount == '') resultCount = 20; document.location = '../../Product Not configured/26/000001.html' + queryString + '&count=' + resultCount; } function checkEnter(event) { var iAscii = event.keyCode ? event.keyCode : event.which ? event.which : event.charCode; if (iAscii == null) return false; if (iAscii == 13) ADAMDefaultSearch('Article'); } function ADAMToggleMedicalSearch() { var taxoCheck = document.getElementById('ADAMMedicalCodeCheckBox'); var taxoPullDown = document.getElementById('ADAMTaxaVocab'); if (taxoCheck.checked) taxoPullDown.style.display = "inline"; else taxoPullDown.style.display = "none"; } function ADAMDefaultSearch(searchScope) { var searchBox = document.getElementById('ADAMSearchBox'); if (searchBox.value == '') { alert('Please be more specific with your search.'); searchBox.focus(); } else { ADAMSearchRedirect('&keyword=' + searchBox.value + '&searchScope=' + searchScope); } } --></script> <style type="text/css"> .ADAMContent { Width: 545; position: relative; margin: 0px auto; top: 0; z-index: 0; } </style> <script language="javascript"><!-- var strSTFTitle = "Tooth abscess"; var strGid = "001060"; var strPid = 1; var refUrl = ""; function makeSTSWin() { remote= window.open("","makeSTSWin","height=490,width=400,resizeable=no,scrollbars=yes,status=no,toolbar=no,directories=no,menubar=no,location=no"); remote.location.href = "pages/SendToFriend.aspx?productId=118&pid=" + strPid + "&gid=" + strGid + "&ref=" + refUrl + "&title=" + escape(strSTFTitle); if (remote.opener == null) remote.opener = window; if (window.focus) { remote.focus(); } } function printPage() { remote= window.open("","printContent","height=590,width=700,resizeable=yes,scrollbars=yes,status=yes,toolbar=yes,directories=yes,menubar=yes,location=no"); remote.location.href = "content.aspx?print=1&productId=118&pid=" + strPid + "&gid=" + strGid; if (remote.opener == null) remote.opener = window; if (window.focus) { remote.focus(); } } --></script> <script language="javascript"><!-- var strSTFTitle = "Tooth abscess"; var strGid = "001060"; var strPid = 1; var refUrl = ""; function makeSTSWin() { remote= window.open("","makeSTSWin","height=490,width=400,resizeable=no,scrollbars=yes,status=no,toolbar=no,directories=no,menubar=no,location=no"); remote.location.href = "pages/SendToFriend.aspx?productId=118&pid=" + strPid + "&gid=" + strGid + "&ref=" + refUrl + "&title=" + escape(strSTFTitle); if (remote.opener == null) remote.opener = window; if (window.focus) { remote.focus(); } } function printPage() { remote= window.open("","printContent","height=590,width=700,resizeable=yes,scrollbars=yes,status=yes,toolbar=yes,directories=yes,menubar=yes,location=no"); remote.location.href = "content.aspx?print=1&productId=118&pid=" + strPid + "&gid=" + strGid; if (remote.opener == null) remote.opener = window; if (window.focus) { remote.focus(); } } --></script> <style type="text/css" id="CarePoints CSS">.ADAMRightNavTnail_me{ text-align: center; min-height:80px; width: 100px; margin: 0px; margin-bottom: 0px; padding: 0px; padding-top: 5px; padding-bottom: 5px; float: left; font-size: 10px;}.ADAMRightNav_me{ width: 204px; float: right; margin: 5px; margin-left: 20px; z-index: 9;}.referenceNavigation_me{ height: auto; width: 204px; float: right; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; font-size: 11px; text-align:left; vertical-align:text-top; margin: 5px; margin-left: 0px; z-index: 10; font-family: Verdana, Geneva, sans-serif;}.referenceNavigationBody_me{ height: auto; width: auto; background-image:url(../../graphics/global/rhn_bg.gif); padding-bottom: 5px; padding-left: 0px; padding-right: 0px; padding-top: 0px; position: relative;}.referenceNavigationHeader2_me{ height: 10px; width: auto; background-image:url(../../graphics/global/rhn_bg_cs.jpg); padding-bottom: 5px; padding-left: 5px; padding-right: 2px; padding-top: 5px; font-weight: bold; position: relative;}.referenceNavigationHeader_me{ height: 10px; width: auto; background-image:url(../../graphics/global/rhn_bg_head.jpg); padding-bottom: 5px; padding-left: 5px; padding-right: 2px; padding-top: 5px; font-weight: bold; position: relative;}.referenceNavigationBody_me{ height: auto; width: 100%; background-image:url(../../graphics/global/rhn_bg.gif); padding-bottom: 5px; padding-left: 0px; padding-right: 0px; padding-top: 0px; position: relative;}.referenceNavigationRelatedHeader_me{ height: 10px; width: 100%; background-image:url(../../graphics/global/rhn_bg.gif); padding-bottom: 5px; padding-left: 5px; padding-right: 2px; padding-top: 5px; font-weight: bold; position: relative;}.referenceNavigationRelatedHeaderWhite_me{ height: 30px; width: 100%; vertical-align:bottom; background-image:url(../../graphics/global/rhn_nav_bot.gif); background-repeat:no-repeat; padding-bottom: 0px; padding-left: 5px; padding-right: 2px; padding-top: 0px; position: relative;}.referenceNavigationHeaderImage_me{ padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; float:inherit; background-image:url(../../graphics/global/rhn_nav_logo2.gif); background-repeat:no-repeat;}.referenceNavigationBullet_me{ font-size: 15px; color: #cccccc; padding-bottom: 3px; padding-left: 3px; padding-right: 3px; padding-top: 3px;}.referenceNavigationText_me{ font-size: 12px; padding-left: 5px; z-index: 11;}</style> <div class="ADAMRightNav_me"> <div class="referenceNavigation_me"> <img bprder="0" src="http://www.mhs.net/images/lib_sidebanner2.jpg" /> <div class="referenceNavigationBody_me"> <table cellpadding="0" cellspacing="0" border="0"> <tbody> <tr> <td class="referenceNavigationBullet_me">•</td> <td class="referenceNavigationText_me"><a href="../200000.html">Encyclopedia Home</a></td> </tr> <tr> <td class="referenceNavigationBullet_me">•</td> <td class="referenceNavigationText_me"><a href="../diseidxa.html">Diseases A-Z </a></td> </tr> <tr> <td class="referenceNavigationBullet_me">•</td> <td class="referenceNavigationText_me"><a href="../../Spanish HIE Multimedia/5/001060.html">Read Spanish version</a></td> </tr> </tbody> </table> </div> <div class="referenceNavigationHeader_me"> Memorial Services </div> <div class="referenceNavigationBody_me"> <table cellpadding="0" cellspacing="0" border="0"> <tbody> <tr> <td class="referenceNavigationBullet_me" style="padding-top: 8px; padding-bottom: 0px">•</td> <td class="referenceNavigationText_me" style="padding-top: 8px; padding-bottom: 0px"><a href="http://www.mhs.net/physicians/" onclick="adamPageTracker._trackPageview('/Exit-Links/FindPhysician');">Find A Physician</a></td> </tr> <tr> <td class="referenceNavigationBullet_me" style="padding-top: 8px; padding-bottom: 0px">•</td> <td class="referenceNavigationText_me" style="padding-top: 8px; padding-bottom: 0px"><a href="http://www.mhs.net/subscription/" onclick="adamPageTracker._trackPageview('/Exit-Links/SubscribeNews');">Subscribe to our Health-e-News</a></td> </tr> </tbody> </table> </div> <div class="referenceNavigationHeader_me"> Images </div> <div class="referenceNavigationBody_me"> <div class="ADAMRightNavTnail"> <a href="../2/1121.html"><img border="0" alt="Tooth anatomy" src="../../graphics/tnail/1121t.jpg" /><br />Tooth anatomy</a> </div> <div class="ADAMRightNavTnail"> <a href="../2/9979.html"><img border="0" alt="Tooth abscess" src="../../graphics/tnail/9979t.jpg" /><br />Tooth abscess</a> </div> <div style="clear: both;"> &nbsp; </div> </div> <div class="referenceNavigationHeader_me"> Read More </div> <div class="referenceNavigationBody_me"> <table cellpadding="0" cellspacing="0" border="0"> <tbody> <tr> <td class="referenceNavigationBullet_me">•</td> <td class="referenceNavigationText_me"><a href="../1/001055.html">Dental cavities</a><br /></td> </tr> <tr> <td class="referenceNavigationBullet_me">•</td> <td class="referenceNavigationText_me"><a href="../1/003067.html">Toothaches</a><br /></td> </tr> <tr> <td class="referenceNavigationBullet_me">•</td> <td class="referenceNavigationText_me"><a href="../1/000855.html">Cellulitis</a><br /></td> </tr> <tr> <td class="referenceNavigationBullet_me">•</td> <td class="referenceNavigationText_me"><a href="../1/001047.html">Ludwig’s angina</a><br /></td> </tr> <tr> <td class="referenceNavigationBullet_me">•</td> <td class="referenceNavigationText_me"><a href="../1/000437.html">Osteomyelitis</a><br /></td> </tr> <tr> <td class="referenceNavigationBullet_me">•</td> <td class="referenceNavigationText_me"><a href="../1/000783.html">Brain abscess</a><br /></td> </tr> <tr> <td class="referenceNavigationBullet_me">•</td> <td class="referenceNavigationText_me"><a href="../1/001098.html">Endocarditis</a><br /></td> </tr> <tr> <td class="referenceNavigationBullet_me">•</td> <td class="referenceNavigationText_me"><a href="../1/000145.html">Pneumonia</a><br /></td> </tr> <tr> <td class="referenceNavigationBullet_me">•</td> <td class="referenceNavigationText_me"><a href="../1/007275.html">Root canal</a><br /></td> </tr> </tbody> </table> </div> <div class="referenceNavigationHeader_me"> More Features </div> <div class="referenceNavigationBody_me"> <table cellpadding="0" cellspacing="0" border="0"> <tbody> <tr> <td class="referenceNavigationBullet_me">•</td> <td class="referenceNavigationText_me"><a href="javascript:print();">Printer-friendly version</a></td> </tr> </tbody> </table> </div> <div class="referenceNavigationRelatedHeaderWhite_me"> &nbsp; </div> </div> </div> <h1>Tooth abscess</h1> <h3> Definition </h3> <span style="line-height:18px"><p>A tooth abscess is a collection of infected material (pus) resulting from a bacterial infection in the center of a tooth.</p></span> <h3> Alternative Names </h3> <span style="line-height:18px"><p>Periapical abscess; Dental abscess; Tooth infection; Abscess - tooth</p></span> <h3> Causes </h3> <span style="line-height:18px"><p>A tooth abscess is a complication of <a href="../1/001055.html">tooth decay</a>. It may also result from trauma to the tooth, such as when a tooth is broken or chipped. Openings in the tooth enamel allow bacteria to infect the center of the tooth (the pulp). Infection may spread out from the root of the tooth and to the bones supporting the tooth.</p><p>Infection results in a collection of pus (dead tissue, live and dead bacteria, white blood cells) and swelling of the tissues within the tooth. This causes a painful <a href="../1/003067.html">toothache</a>. If the pulp of the tooth dies, the toothache may stop, unless an abscess develops. This is especially true if the infection remains active and continues to spread and destroy tissue.</p></span> <h3> Symptoms </h3> <span style="line-height:18px"><p>The main symptom is a severe toothache. The pain is continuous and may be described as gnawing, sharp, shooting, or throbbing.</p><p>Other symptoms may include: </p> <ul> <li>Bitter taste in the mouth</li> <li><a href="../1/003058.html">Breath odor</a></li> <li>General discomfort, uneasiness, or ill feeling</li> <li><a href="../1/003090.html">Fever</a></li> <li>Pain when chewing</li> <li>Sensitivity of the teeth to hot or cold</li> <li><a href="../1/003097.html">Swollen glands</a> of the neck</li> <li>Swollen area of the upper or lower jaw -- a very serious symptom</li> </ul></span> <h3> Exams and Tests </h3> <span style="line-height:18px"><p>The patient will feel pain when the dentist taps the tooth. Biting or closing the mouth tightly also increases the pain. The gums may be swollen and red and may drain thick material.</p></span> <h3> Treatment </h3> <span style="line-height:18px"><p>The goals of treatment are to cure the infection, save the tooth, and prevent complications.</p><p>Antibiotics may be given to fight the infection. Warm salt-water rinses may be soothing. Over-the-counter pain relievers may relieve the toothache and fever.</p><p>Do NOT place aspirin directly over the tooth or gums, because this increases irritation of the tissues and can result in <a href="../1/001448.html">mouth ulcers</a>.</p><p>A root canal may be recommended in an attempt to save the tooth.</p><p>If there is a severe infection, the tooth may be removed or surgery may be needed to drain the abscess. Some people may need to be admitted to the hospital.</p></span> <h3> Outlook (Prognosis) </h3> <span style="line-height:18px"><p>Untreated abscesses may get worse and can lead to life-threatening complications.</p><p>Prompt treatment usually cures the infection. The tooth can usually be saved in many cases.</p></span> <h3> Possible Complications </h3> <span style="line-height:18px"> <ul> <li>Loss of the tooth</li> <li>Mediastinitis</li> <li>Sepsis</li> <li>Spread of infection to soft tissue (facial <a href="../1/000855.html">cellulitis</a>, <a href="../1/001047.html">Ludwig's angina</a>)</li> <li>Spread of infection to the jaw bone (<a href="../1/000437.html">osteomyelitis</a> of the jaw)</li> <li>Spread of infection to other areas of the body resulting in <a href="../1/000783.html">brain abscess</a>, <a href="../1/001098.html">endocarditis</a>, <a href="../1/000145.html">pneumonia</a>, or other complications</li> </ul></span> <h3> When to Contact a Medical Professional </h3> <span style="line-height:18px"><p>Call your dentist if you have a persistent, throbbing toothache.</p></span> <h3> Prevention </h3> <span style="line-height:18px"><p>Prompt treatment of dental caries reduces the risk of tooth abscess. Traumatized teeth should be examined promptly by the dentist.</p></span> <div> <hr /> <div class="ADAMReviewInfo"> Review Date: 2/22/2010 <br /> Reviewed By: Jack D Rosenberg, DDS, Advanced Dental Care, Palm Beach Gardens, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, M.D., MHA, Medical Director, A.D.A.M., Inc. </div> </div> <div class="ADAMDisclaimer"> <div class="ADAMURAC"> <script language="JavaScript" type="text/javascript"><!-- var URL = document.location.href; var SSL = URL.substr(0, 5); if (SSL == 'https') { document.write('<script src="https://ssl.adam.com/urac/urac.js" type="text/javascript"><' + '/script>'); } else { document.write('<script src="http://default.adam.com/urac/urac.js" type="text/javascript"><' + '/script>'); }--></script> </div> <div> The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. &copy; 1997- <script language="JavaScript" type="text/javascript"> var today = new Date() var year = today.getFullYear() document.write(year) </script> A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited. </div> <div align="center"> <a href="http://www.adam.com" target="_blank"><img src="../../graphics/global/hdr_ftradamlogo.gif" width="77" height="15" border="0" alt="adam.com" /></a> </div> </div> <table> <tbody> <tr> <td>&nbsp;</td> </tr> </tbody> </table> </div> </div> <br /> </div> <!--closes Div ID "contentmainfill"--> <div id="contentmainend"></div> <!--closes Div ID "contentmainend"--> </div> <!--closes Div ID "contentmain"--> <br style="clear:both" /> <!--div to control layout --> </div> <!--closes Div ID "content"--> &nbsp; </div> <!--closes Div ID "wrapper"--> </div> <!--closes Div ID "container"--> <div> <div id="footer"> <div id="footernav"> <div id="column1" class="column"> <h1>Contact Us</h1> <p>Memorial Healthcare System<br /> 3501 Johnson Street<br /> Hollywood, Florida 33021<br /> (954) 987-2000<br /> <a href="http://www.mhs.net/contact/">Contact Us Online</a></p> <ul> <li><a href="http://www.mhs.net/physicians/">Find a Physician</a></li> <li><a href="https://www.mhs.net/secure/scheduling/">Schedule an Appointment</a></li> </ul> </div> <div id="column2" class="column"> <h1>Locations</h1> <ul> <li><a href="http://www.memorialregional.com/">Memorial Regional Hospital</a></li> <li><a href="http://www.memorialregionalsouth.com/">Memorial Regional Hospital South</a></li> <li><a href="http://www.jdch.com/">Joe DiMaggio Children's Hospital</a></li> <li><a href="http://www.memorialwest.com/">Memorial Hospital West</a></li> <li><a href="http://www.memorialmiramar.com/">Memorial Hospital Miramar</a></li> <li><a href="http://www.memorialpembroke.com/">Memorial Hospital Pembroke</a></li> </ul> </div> <div id="column3" class="column"> <h1>Links</h1> <ul> <!--<li><a href="http://es.mhs.net/enes/">Espa&ntilde;ol</a></li> --> <li><a href="http://www.mhs.net/sitemap.cfm">Sitemap</a></li> <li><a href="http://www.mhs.net/foundations/index.cfm">How to Give</a></li> <li><a href="http://www.mhs.net/community/communitycalendar.cfm">Event Calendar</a></li> <li><a href="http://www.mhs.net/health-professionals/">Health Professionals</a></li> </ul> </div> <div id="column4" class="column"> <h1>Connect With Us</h1> <a href="http://www.mhs.net/contact/connectingwithmemorial.cfm"><img src="http://www.mhs.net/images/socialmedia_icons.gif" width="119" height="36" alt="Connect With Us" /></a> <h1>Legal &amp; Policy</h1> <ul> <li><a href="http://www.mhs.net/legal/disclaimer.cfm">Disclaimer</a></li> <li><a href="http://www.mhs.net/legal/webprivacypolicy.cfm">Privacy Policies</a></li> </ul> </div> <div id="copyright"> &copy; 2010 Memorial Healthcare System - All rights reserved. </div> <!--closes Div ID "copyright"--> </div> </div> <!--closes Div ID "footer"--> </div> <script type="text/javascript"> var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); </script> <script type="text/javascript"> try { var adamPageTracker = _gat._getTracker("UA-8736582-35"); adamPageTracker._trackPageview(); } catch(err) {} try { var adamGlobalPageTracker = _gat._getTracker("UA-7878983-1"); adamGlobalPageTracker._trackPageview(); } catch(err) {} </script> <script type="text/javascript"> try { var pageTracker = _gat._getTracker("UA-10400308-1"); pageTracker._trackPageview(); } catch(err) {} </script> </div> </body> </html>
257	faceted	holes by louis sachar	Find summaries of "Holes" by Louis Sachar.	clueweb12-1508wb-33-10427	2	<!DOCTYPE html> <html> <!-- google_ad_section_start(weight=ignore) --> <head> <meta charset="utf-8" /> <!-- facebook insights --> <meta property="fb:page_id" content="163456097039250" /> <title>Holes by Louis Sachar timeline | Timetoast timelines</title> <meta name="description" content="The Holes by Louis Sachar timeline. View the 'Holes by Louis Sachar' timeline, create your own timeline or just browse the timeline collection." /> <meta name="csrf-param" content="authenticity_token" /> <meta name="csrf-token" content="rkJPIWJjJU0rMZdvzL/7jsEHrXvErs4UcivDUhYm68k=" /> <meta name="keywords" content="timeline, interactive, create, historical, time, visualization, chronology, chronological, reference" /> <script>if (typeof window.Timetoast == "undefined" ) {var Timetoast = {};}</script> <link href="http://media.timetoast.com/stylesheets/master.css?1322761762" media="screen" rel="stylesheet" type="text/css" /> <link href="http://media.timetoast.com/stylesheets/style.css?1322761762" media="screen" rel="stylesheet" type="text/css" /> <script src="http://media.timetoast.com/javascripts/jquery.js?1322761762" type="text/javascript"></script> <script src="http://media.timetoast.com/javascripts/rails.js?1322761762" type="text/javascript"></script> <script src="http://media.timetoast.com/javascripts/swfobject.js?1322761762" type="text/javascript"></script> <script src="http://media.timetoast.com/javascripts/application.js?1322761762" type="text/javascript"></script> <link rel="alternate" type="application/rss+xml" title="rss" href="/timelines/95222.rss" /> <!-- start analytics --> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script> <script type="text/javascript">var pageTracker = _gat._getTracker("UA-1375530-2");pageTracker._initData();pageTracker._trackPageview();</script> <!-- end analytics --> <script src="http://media.timetoast.com/javascripts/iColorPicker-noLink.js?1322761762" type="text/javascript"></script> <script src="http://media.timetoast.com/javascripts/jquery.numeric.js?1322761762" type="text/javascript"></script> <script type="text/javascript"> $(document).ready(function(){ var scope = Timetoast.timelines.show; var passedTimelines = "95222"; scope.flash.flashVars.passedTimelines = passedTimelines; scope.flash.params.passedTimelines = passedTimelines; scope.embedVars.host = "www.timetoast.com"; scope.embedVars.passedTimelines = passedTimelines; scope.init(); }); </script> <script type="text/javascript"> var mp_protocol = (('https:' == document.location.protocol) ? 'https://' : 'http://'); document.write(unescape('%3Cscript src="' + mp_protocol + 'api.mixpanel.com/site_media/js/api/mixpanel.js" type="text/javascript"%3E%3C/script%3E')); </script> <script type="text/javascript"> try { var mpmetrics = new MixpanelLib('817e78661a692c2311ae37efdb5035e5'); } catch(err) { null_fn = function () {}; var mpmetrics = { track: null_fn, track_funnel: null_fn, register: null_fn, register_once: null_fn, register_funnel: null_fn }; } </script> </head> <!-- google_ad_section_end --> <body id="timelines" class="show"> <div id="container"> <div id="containerPadding"> <!-- google_ad_section_start(weight=ignore) --> <div id="header"> <div id="headerLogo"> <a href="http://www.timetoast.com/"><img alt="timetoast logo" class="logo" src="http://media.timetoast.com/images/timetoast_logo.png?1322761762" title="home" /></a> </div> <div id="headerNav"> <div id="navLinks"> <a href="/categories" class="start">browse</a> <a href="/users/sign_up">sign up!</a> <a href="/users/sign_in" class="end">sign in</a> </div> <div id="search"> <form action="http://www.timetoast.com/search/timelines" id="cse-search-box"> <input type="hidden" name="cx" value="partner-pub-3637961829875093:ehixnl-dg1y" /> <input type="hidden" name="cof" value="FORID:9" /> <input type="hidden" name="ie" value="UTF-8" /> <input type="text" name="q" size="20" /> <input alt="search" class="submit" id="searchbutton" name="sa" src="http://media.timetoast.com/images/btn_search.jpg?1322761762" type="image" /> </form> </div> </div> <script type="text/javascript" src="http://www.google.com/coop/cse/brand?form=cse-search-box&amp;lang=en"></script> </div> <div class="clear"></div> <!-- google_ad_section_end --> <div id="content"> <div class="leaderBoardUnit"> <script type="text/javascript"><!--google_ad_client = "pub-3637961829875093";/* 728x90, created 09/06/09 */google_ad_slot = "1310363593";google_ad_width = 728;google_ad_height = 90;//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script> </div> <div class="smallTextUnit"> <script type="text/javascript"><!-- google_ad_client = "ca-pub-3637961829875093"; /* small-text-ads-unit */ google_ad_slot = "1594475498"; google_ad_width = 200; google_ad_height = 90; //--> </script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"> </script> </div> <div class="clear"></div> <!-- google_ad_section_start --> <div id="showTimelineHeader"> <h1> Holes by Louis Sachar </h1> <div class="fadedText"> Timeline created by <a href="/users/83844">bump</a> </div> <div id="timeline-view-toggler"> <span id="timelineViewSelector" class="selected">Timeline</span> <span id="listViewSelector" class="unselected">Text view</span> </div> </div> <div class="flashTimeline"> <div id="swfTarget"></div> </div> <div id="timelineTable"> <table> <tbody> <tr> <th></th> <th><strong>Event Date:</strong></th> <th><strong>Event Title:</strong></th> <th><strong>Event Description:</strong></th> </tr> <tr class="even"> <td></td> <td>01/01/1998</td> <td><b>Hermes lost his shoes!</b></td> <td> Hermes losses his shoes so Stanley retrieves them..with his head. Stanley thinks it is a sign for him too take them to his dad, like destiny. He starts running and is picked up by a cop! Was he wrong about it being destiny? Image found at: http://www.flickr.com/photos/lachlanhardy/83702051/sizes/o/in/photostream/</td> </tr> <tr class="odd"> <td></td> <td>01/01/1998</td> <td><b>Onions</b></td> <td>The negro onion salesman claims onions can cure any sickness. aaahchoo! Image found at: http://www.flickr.com/photos/37587967@N00/1250556092/</td> </tr> <tr class="even"> <td></td> <td>05/01/1998</td> <td><b>CAMP</b></td> <td>Stanly finally gets to go to camp, but it is no Camp-Fun-and-Games. This camp is for kids who need to turn their life around. Can Stanley keep his cool or will he freak? Image found: http://www.flickr.com/photos/coljay72/2399545998/sizes/s/in/photostream/</td> </tr> <tr class="odd"> <td></td> <td>05/02/1998</td> <td><b>Fish</b></td> <td>Stanley is told to turn in anything of interest and he finds a fossil. The warden is after something very different and Stanley is curious what it could possibly be. found image at: http://www.flickr.com/photos/14405058@N08/2337690938/</td> </tr> <tr class="even"> <td></td> <td>05/03/1998</td> <td><b>Caveman</b></td> <td>THE CAVEMAN is here and his name is Stanley Yelnats! Found at: http://www.flickr.com/photos/51035555243@N01/2231011661/</td> </tr> <tr class="odd"> <td></td> <td>05/08/1998</td> <td><b>Teacher</b></td> <td>The onion man (Sam) and the teacher fall in love....but how long will it last? Found at: http://www.flickr.com/photos/maxiadrian/507141414/sizes/s/in/photostream/</td> </tr> <tr class="even"> <td></td> <td>05/09/1998</td> <td><b>Boat Accident.</b></td> <td>Onion is lost. The land of ever-growing onions is lost when the negro onion man is caught kissin Katherine and is run over by a boat... and it was no accident! And with great grief Katherine turns into...Kissin Kate! found at: http://www.flickr.com/photos/kanelstrand/3835911555/sizes/s/in/photostream/</td> </tr> <tr class="odd"> <td></td> <td>08/27/1998</td> <td><b>Golden Tube</b></td> <td>Stanley finds something of interest! So why is he not happy? Because X-ray smacks him in the head with a spade, and he gets blamed for stealing seeds from Mr. Sir. Who did the lipstick belong too? Whet does it mean? And whet is the warden looking for? The only thing they know about it is that it has the initials KK. Image found at: http://www.flickr.com/photos/30223382@N06/4236291276/</td> </tr> <tr class="even"> <td></td> <td>09/05/1998</td> <td><b>Reading Lessons.</b></td> <td>Stanley still digs but not all of his hole. He teaches Zero to read and Zero digs part of his hole. Found at: http://www.flickr.com/photos/dheuts/3811537169/sizes/s/in/photostream/</td> </tr> <tr class="odd"> <td></td> <td>09/09/1998</td> <td><b>Spade vs Face</b></td> <td>Everyone hates Zero! They keep making more mean jokes and finally Zero hits Mister Pen-Dance-Key in the face and runs off into the desert. Zero claims that he will never dig another hole. Can he live the rest of his life without digging another hole? How long is the rest of his life? Found at: http://www.flickr.com/photos/clickyfish/4462522260/sizes/s/in/photostream/</td> </tr> <tr class="even"> <td></td> <td>09/19/1998</td> <td><b>Sploosh?</b></td> <td>Zero is found by Stanley alive but unwell under a boat... A BOAT! Stanley wants Zero to come back to camp but Zero defies him and ofers him some sploosh. Sploosh is a liquid that is sealed tightly in jars. When Stanley sees how weak Zero is, Stanley is really concerned. Found at: http://www.flickr.com/photos/ontheheightsphotography/2121540049/sizes/s/in/photostream/</td> </tr> <tr class="odd"> <td></td> <td>09/19/1998</td> <td><b>God's Thumb?!</b></td> <td>Stanley follows the steps of his great grand father finding refuge on God's Thumb. Water, weeds, and...Onions? Found at: Pix made by...Me!</td> </tr> <tr class="even"> <td></td> <td>09/29/1998</td> <td><b>Zero's Last Hole!?</b></td> <td>Ok they head back to camp and start digging for...for...they don't know what, but they believe it may be valuable or important so they dig deeper....then wider...until...they....find... pic found at: http://www.flickr.com/photos/modrak/180005582/sizes/s/in/photostream/</td> </tr> <tr class="odd"> <td></td> <td>09/29/1998</td> <td><b>Is It More Than His Last Hole?</b></td> <td>Is It? Zero and Stanley get to work digging up the ground and what they found is odd for somthing so old, it was a suit case oddly out of place in this wasteland but little did they know of the monster inside. found at: http://www.google.co.th/imglanding?q=holes+movie+spotted+lizard&amp;um=1&amp;hl=en&amp;tbs=isch:1&amp;tbnid=JjY3Lsz_1csJLM:&amp;imgrefurl=http://jimcloer.blogspot.com/&amp;imgurl=http://3.bp.blogspot.com/_lZ5ScByiJxc/TF8QtFsR79I/AAAAAAAAAfI/ePJ1F05fFWI/s1600/Regal%2BHL.JPG&amp;zoom=1&amp;w=1600&amp;h=1126&amp;iact=</td> </tr> <tr class="even"> <td></td> <td>02/14/1999</td> <td><b>Sploosh..#2</b></td> <td>Well dad did it...he created something to completely extinguish the smell of foot odor. Go dad for making.....Sploosh! Found at: http://www.flickr.com/photos/mckenzieo/1910215868/sizes/s/in/photostream/</td> </tr> <tr class="odd"> <td></td> <td>02/15/1999</td> <td><b>The Dissection</b></td> <td>The suit case had diamonds! But they weren't worth much. Stanley suggested that they turn their attention to the documents and deeds. It was amazing how bits of paper are worth more than diamonds. found at: http://www.flickr.com/photos/swamibu/356865704/</td> </tr> <tr> <th></th> <th><strong>Timespan Dates:</strong></th> <th><strong>Timespan Title:</strong></th> <th><strong>Timespan Description:</strong></th> </tr> <tr class="even"> <td></td> <td>01/01/1998<br /> to 02/16/1999</td> <td><b>Holes</b></td> <td></td> </tr> </tbody> </table> </div> <!-- google_ad_section_end --> <div class="mpuUnit"> <script type="text/javascript"><!-- google_ad_client = "pub-3637961829875093"; /* 300x250, created 09/06/09 */ google_ad_slot = "4337956506"; google_ad_width = 300; google_ad_height = 250; //--> </script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"> </script> </div> <div class="timelineActions"> <a rel="nofollow" href="http://www.facebook.com/share.php?u=www.timetoast.com/timelines/95222" title="Post timeline link to facebook"><img src="/images/social/facebook.gif" alt="Twitter icon" class="icon" /></a>&nbsp; <a rel="nofollow" href="http://twitter.com/intent/tweet?text=Check%20out%20the%20'Holes%20by%20Louis%20Sachar'%20timeline%20on%20@timetoast&amp;url=http://www.timetoast.com/timelines/95222" title="Tweet this timeline"><img src="/images/social/twitter.png" alt="Twitter icon" class="icon" /></a>&nbsp; <span class="divider">|</span> <span id="sharing-options-toggler"> <a><img alt="Group" class="icon" src="http://media.timetoast.com/images/icons/group.png?1322761762" />&nbsp;Embed / Share</a> </span> <div id="sharingOptions" class="hideShowBox" style="display:none;"> <div id="hide-sharing-options-button" class="closeButton"> <span class="icon"><img alt="No" src="http://media.timetoast.com/images/icons/no.png?1322761762" /></span> </div> <h3>Share this timeline:</h3> <form id="sharingForm"> <fieldset> <p><img alt="Link" class="icon" src="http://media.timetoast.com/images/icons/link.png?1322761762" />&nbsp;Direct link: <input name="timelineURL" type="text" value="http://www.timetoast.com/timelines/95222" onclick="javascript:timelineURL.focus();timelineURL.select();" readonly="true" /></p> <p><img alt="Application_flash" class="icon" src="http://media.timetoast.com/images/icons/application_flash.gif?1322761762" />&nbsp;Embed code: <input name="timelineEmbedCode" type="text" value="&lt;object width=&quot;550&quot; height=&quot;400&quot;&gt;&lt;param name=&quot;movie&quot; value=&quot;http://www.timetoast.com/flash/TimelineViewer.swf?passedTimelines=95222&quot; /&gt;&lt;param name=&quot;passedTimelines&quot; value=&quot;95222&quot; /&gt;&lt;param name=&quot;allowScriptAccess&quot; value=&quot;always&quot;&gt;&lt;embed src=&quot;http://www.timetoast.com/flash/TimelineViewer.swf?passedTimelines=95222&quot; type=&quot;application/x-shockwave-flash&quot; passedTimelines=&quot;95222&quot; width=&quot;550&quot; height=&quot;400&quot; allowScriptAccess=&quot;always&quot; /&gt;&lt;/object&gt;" onclick="javascript:timelineEmbedCode.focus();timelineEmbedCode.select();" readonly="true" /></p> </fieldset> </form> <span id="embedCustomizer"> <hr /> <h4>Or customize the embed code:</h4> <form class="customizationForm"> <fieldset> <div class="widthAndHeightFields"> <div class="left"> <label for="widthInput">Width</label> <input id="widthInput" value="550" class="numeric" /> <br /> </div> <div class="right"> <label for="heightInput">Height</label> <input id="heightInput" value="400" class="numeric" /> <br /> </div> </div> <div class="clear"></div> <label for="colorPicker">Page background color</label> <input id="colorPicker" value="#FFFFFF" class="iColorPicker" type="text" /> <br /> <label for="generateButton"></label> <input id="generateButton" type="button" value="generate code" class="commit" /> <br /> <textarea id="generatedCodeField"></textarea> </fieldset> </form></span> </div> </div> <!-- google_ad_section_start(weight=ignore) --> <div id="timelineRating"> <div id="ratingResponse"></div> </div> <!-- google_ad_section_end --> <div id="tags"> <!-- google_ad_section_start --> <div id="tagList"> Tags: <span class="noTagsYet">Not tagged yet</span> </div> <!-- google_ad_section_end --> </div> <h3>You might like...</h3> <ul> <li><a href="/timelines/2011-2012-grade-7-ckhs" class="recommendation">2011-2012 Grade 7 @ CKHS</a></li> <li><a href="/timelines/rock-n-roll-history--2" class="recommendation">Rock 'n' Roll History</a></li> <li><a href="/timelines/the-gardening-year" class="recommendation">The Gardening Year</a></li> <li><a href="/timelines/41352" class="recommendation">Historical Documentation of Chicago Landmarks (Photo Courtesy: http://www.flickr.com/photos/swisscan/3045543537/)</a></li> <li><a href="/timelines/mexico-timeline-blake" class="recommendation">Mexico Timeline (Blake)</a></li> </ul> <h3>Comments <img alt="Comments" src="http://media.timetoast.com/images/icons/comments.png?1322761762" /></h3> <div id="comments"> <p>This timeline doesn't have any comments, you could be the first!</p> </div> <p>Members can tag, rate and comment on timelines. <a href="/users/sign_up">Sign up</a> or <a href="/users/sign_in">log in</a>!</p> <div class="clear"></div> </div> <!-- google_ad_section_start(weight=ignore) --> <div class="leaderBoardUnit"> <script type="text/javascript"><!--google_ad_client = "pub-3637961829875093";/* 728x90, created 09/06/09 */google_ad_slot = "1310363593";google_ad_width = 728;google_ad_height = 90;//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script> </div> <div class="smallTextUnit"> <script type="text/javascript"><!-- google_ad_client = "ca-pub-3637961829875093"; /* small-text-ads-unit */ google_ad_slot = "1594475498"; google_ad_width = 200; google_ad_height = 90; //--> </script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"> </script> </div> <div class="clear"></div> <div id="footer"> <div class="linkList"> <h3 class="linkListTitle">Spread the word</h3> <iframe src="http://www.facebook.com/plugins/like.php?app_id=229977800351474&amp;href=http%3A%2F%2Fwww.timetoast.com&amp;send=false&amp;layout=button_count&amp;width=124&amp;show_faces=false&amp;action=like&amp;colorscheme=light&amp;font&amp;height=21" scrolling="no" frameborder="0" style="border:none; overflow:hidden; width:140px; height:21px;" allowtransparency="true"></iframe> <a href="http://twitter.com/share" class="twitter-share-button" data-url="http://www.timetoast.com" data-text="Timetoast lets you create timelines and share them on the web" data-count="horizontal" data-via="timetoast">Tweet</a> <script type="text/javascript" src="http://platform.twitter.com/widgets.js"></script> <g:plusone size="medium" href="http://www.timetoast.com"></g:plusone> </div> <div class="linkList"> <h3 class="linkListTitle">Explore</h3> <ul> <li><a href="/popular">popular timelines</a></li> <li><a href="/browse/updated_timelines">updated timelines</a></li> <li><a href="/browse/latest_timelines">latest timelines</a></li> <li><a href="/categories">categories</a></li> </ul> </div> <div class="linkList"> <h3 class="linkListTitle">Find us on</h3> <ul> <li><a href="http://www.facebook.com/timetoast">facebook</a></li> <li><a href="http://twitter.com/timetoast">twitter</a></li> </ul> </div> <div class="linkList"> <h3 class="linkListTitle">Help</h3> <ul> <li><a href="/faq">faq</a></li> <li><a href="/about">about</a></li> <li><a href="/privacy" rel="nofollow">privacy</a></li> <li><a href="/terms">terms</a></li> </ul> </div> <div class="clear"></div> <div class="copyright"> Copyright &copy; 2011 timetoast, All rights reserved. </div> </div> </div> </div> <!-- Start Quantcast tag --> <script type="text/javascript">_qoptions={qacct:"p-2eYnEaVmgyyns"};</script> <script type="text/javascript" src="http://edge.quantserve.com/quant.js"></script> <noscript> <img src="http://pixel.quantserve.com/pixel/p-2eYnEaVmgyyns.gif" style="display: none;" border="0" height="1" width="1" alt="Quantcast" /> </noscript> <!-- End Quantcast tag --> <script type="text/javascript" src="https://apis.google.com/js/plusone.js"></script> <script type="text/javascript"> //mpmetrics.track_links(".className", "Tracking Name");</script> <!-- google_ad_section_end --> </body> </html>
285	faceted	magnesium rich foods	Which foods are rich in magnesium?	clueweb12-0006wb-91-14538	2	<!DOCTYPE html> <!--[if IE 6]><html id="ie6" dir="ltr" lang="en-US" xmlns:fb="http://www.facebook.com/2008/fbml" xmlns:addthis="http://www.addthis.com/help/api-spec" ><![endif]--> <!--[if IE 7]><html id="ie7" dir="ltr" lang="en-US" xmlns:fb="http://www.facebook.com/2008/fbml" xmlns:addthis="http://www.addthis.com/help/api-spec" ><![endif]--> <!--[if IE 8]><html id="ie8" dir="ltr" lang="en-US" xmlns:fb="http://www.facebook.com/2008/fbml" xmlns:addthis="http://www.addthis.com/help/api-spec" ><![endif]--> <!--[if !(IE 6) | !(IE 7) | !(IE 8) ]><!--> <html dir="ltr" lang="en-US" xmlns:fb="http://www.facebook.com/2008/fbml" xmlns:addthis="http://www.addthis.com/help/api-spec"> <!--<![endif]--> <head> <meta charset="UTF-8" /> <meta name="viewport" content="width=device-width" /> <title>Cashews: A Magnesium-Rich Food | Organic Cashew Nuts</title> <link rel="profile" href="http://gmpg.org/xfn/11" /> <link rel="stylesheet" type="text/css" media="all" href="http://organiccashewnuts.com/wp-content/themes/NomNom/style.css" /> <link rel="pingback" href="http://organiccashewnuts.com/xmlrpc.php" /> <!--[if lt IE 9]><script src="http://organiccashewnuts.com/wp-content/themes/twentyeleven/js/html5.js" type="text/javascript"></script><![endif]--> <!-- This site is optimized with the Yoast WordPress SEO plugin v1.1.5 - http://yoast.com/wordpress/seo/ --> <meta name="description" content="Learn everything there is to know about the Cashew Nut from its health benefits to the Taxonomy of the Cashew Tree. You'll also find the best Cashew Recipes including Cashew Chicken, Cashew Shrimp, Cashew Brittle, Chocolate Covered Cashews, and Cashew Butter. Come buy the best tasting gourmet jumbo organic cashews the world has to offer." /> <meta name="keywords" content="Cashew, cashew nut, cashew chicken recipe, cashew brittle recipe, cashew chicken, cashew brittle, chocolate covered cashew, cashew tree, cashew shrimp, cashew recipe, cashew butter, roasted cashew, cashew cookie, dry roasted cashew, cashew crunch recipe, cashew crunch, cashew cookie recipe, microwave cashew brittle, cashew butter recipe, chocolate covered cashew recipe, wasabi cashew, cashew nut chicken, honey roasted cashew, honey roasted cashew recipe, roasted cashew recipe, cashew wine, chocolate cashew, unsalted cashew, cashew cluster recipe, rosemary cashew, amish cashew crunch recipe, cashew chicken salad recipe, cinnamon cashew recipe, broccoli cashew salad, cashew salad, cashew candy recipe, cashew cookie shortbread, cashew roca, cashew turtles, candied cashew recipe, thai cashew chicken, thai cashew chicken recipe, amish cashew crunch recipe, cashew bar, cashew peanut brittle recipe, chicken and cashew stir fry, cashew cookie nougat, cashew recipe turtle, cashew recipe toffee, cashew chicken salad, how to roast cashew, cashew cluster, growing cashew nut, cashew nut grow, cashew grown, growing cashew, cashew grow, cashew gourmet pear, cashew pear, cashew fruit, cashew apple, cashew nut, cashew tree, cashew plant, cashew lou, dane cook cashew, cashew kansas city, cashew im let this, cashew i'm let this, cashew nut shell liquid, cashew liqid nut shell, cashew gift basket, cashew gift, cashew come from, cashew history, cashew us, cashew company exporting, cashew picture, origin of cashew, colossal cashew, bulk cashew, giant cashew, cashew wholesale, koeze cashew, koezes cashew, cashew in the shell, cashew nut shell, cashew and peanut, jumbo cashew, cashew distilled nut, planter cashew, gourmet cashew, cashew shells, raw cashew, benefit of cashew nut, cashew cholesterol, health benefit of cashew, calorie in cashew, cashew calorie, nutritional value of cashew, cashew nut tree cashew nutrition, cashew allergy" /> <link rel="canonical" href="http://organiccashewnuts.com/articles/cashews-magnesium-rich-food/" /> <!-- / Yoast WordPress SEO plugin. --> <link rel="alternate" type="application/rss+xml" title="Organic Cashew Nuts &raquo; Feed" href="http://organiccashewnuts.com/feed/" /> <link rel="alternate" type="application/rss+xml" title="Organic Cashew Nuts &raquo; Comments Feed" href="http://organiccashewnuts.com/comments/feed/" /> <script type="text/javascript">//<![CDATA[ // Google Analytics for WordPress by Yoast v4.2.3 | http://yoast.com/wordpress/google-analytics/ var _gaq = _gaq || []; _gaq.push(['_setAccount','UA-12154408-5']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); //]]></script> <link rel="alternate" type="application/rss+xml" title="Organic Cashew Nuts &raquo; Cashews: A Magnesium-Rich Food Comments Feed" href="http://organiccashewnuts.com/articles/cashews-magnesium-rich-food/feed/" /> <link rel="stylesheet" id="jquery-ui-1.8.13.custom.css-css" href="http://organiccashewnuts.com/wp-content/themes/NomNom/includes/css/jquery-ui-1.8.13.custom.css?ver=3.2.1" type="text/css" media="all" /> <script type="text/javascript" src="http://organiccashewnuts.com/wp-includes/js/l10n.js?ver=20101110"></script> <script type="text/javascript" src="http://organiccashewnuts.com/wp-includes/js/jquery/jquery.js?ver=1.6.1"></script> <script type="text/javascript" src="http://organiccashewnuts.com/wp-content/themes/NomNom/includes/js/superfish.js?ver=3.2.1"></script> <script type="text/javascript" src="http://organiccashewnuts.com/wp-includes/js/comment-reply.js?ver=20090102"></script> <link rel="EditURI" type="application/rsd+xml" title="RSD" href="http://organiccashewnuts.com/xmlrpc.php?rsd" /> <link rel="wlwmanifest" type="application/wlwmanifest+xml" href="http://organiccashewnuts.com/wp-includes/wlwmanifest.xml" /> <meta name="generator" content="WordPress 3.2.1" /> <link rel="shortlink" href="http://organiccashewnuts.com/?p=228" /> <style type="text/css">#main { clear: both; padding: 0;}#shop-cashew iframe { display: block; float: left; margin: 5px; padding: 5px;}#access li { display: block; float: left; position: relative; width: 120px; text-align: center;}#access a { color: #EEEEEE; display: block; line-height:1.2em; height: 50px; padding: 5px; text-decoration: none; width: 100px;}#access ul ul, #access2 ul ul { background: none repeat scroll 0 0 #333333; border-bottom-left-radius: 0.5em; border-bottom-right-radius: 0.5em; display: none; float: left; left: 0; margin: 0; padding: 0 0 8px; top: 55px; width: auto; z-index: 99999;}</style> <style>@import url(http://fonts.googleapis.com/css?family=Arimo);h1,h1.entry-title,h2,h3,h4,h5,h6,h3.widget-title, #site-title a,#footer h3 { font-family: 'Arimo', sans-serif; } </style> <script language="javascript"> var slider_effect = 'random'; var slider_speed = 500; var slider_pause = 5000; </script> </head> <body class="single single-post postid-228 single-format-standard custom-layouts sidebar-content-sidebar single-author three-column three-column"> <div id="page" class="hfeed"> <header id="branding" role="banner"> <!-- Begin secondary menu #access2 --> <nav id="access2" role="navigation"> <h3 class="assistive-text">Secondary menu</h3> <div class="skip-link"> <a class="assistive-text" href="#content" title="Skip to primary content">Skip to primary content</a> </div> <div class="skip-link"> <a class="assistive-text" href="#secondary" title="Skip to secondary content">Skip to secondary content</a> </div> </nav> <!-- end of #access2 --> <div id="nomnom-header"> <a href="http://organiccashewnuts.com/"> <img src="http://organiccashewnuts.com/wordpress/wp-content/uploads/2011/09/banner1.jpg" width="1000" height="120" alt="" /> </a> </div> <!-- end search with text on/off --> <nav id="access" role="navigation"> <h3 class="assistive-text">Main menu</h3> <div class="skip-link"> <a class="assistive-text" href="#content" title="Skip to primary content">Skip to primary content</a> </div> <div class="skip-link"> <a class="assistive-text" href="#secondary" title="Skip to secondary content">Skip to secondary content</a> </div> <div class="menu-main-menu-container"> <ul id="menu-main-menu" class="menu"> <li id="menu-item-213" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-213"><a href="http://organiccashewnuts.com/learn/">How can I learn more about Cashews?</a> <ul class="sub-menu"> <li id="menu-item-5" class="menu-item menu-item-type-taxonomy menu-item-object-category current-post-ancestor current-menu-parent current-post-parent menu-item-5"><a href="http://organiccashewnuts.com/category/articles/">Cashew Nut Articles</a></li> <li id="menu-item-7" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-7"><a href="http://organiccashewnuts.com/category/research/">Cashew Related Research</a></li> <li id="menu-item-6" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-6"><a href="http://organiccashewnuts.com/category/culture/">Organic food and Africal agriculture articles</a></li> </ul></li> <li id="menu-item-212" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-212"><a title="Where do Cashew nuts come from?" href="http://organiccashewnuts.com/source/">Where do Cashew nuts come from?</a></li> <li id="menu-item-8" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-8"><a title="How do I cook with Cashew nuts?" href="http://organiccashewnuts.com/category/recipes/">How do I cook with Cashew nuts?</a></li> <li id="menu-item-211" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-211"><a title="What are the health benefits of Cashews?" href="http://organiccashewnuts.com/health/">What are the health benefits of Cashews?</a> <ul class="sub-menu"> <li id="menu-item-214" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-214"><a href="http://organiccashewnuts.com/health/health-bibliographies/">Health Bibliographies</a></li> </ul></li> <li id="menu-item-210" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-210"><a title="Where can I buy Cashews?" href="http://organiccashewnuts.com/buy-cashews/">Where can I buy Cashews?</a></li> <li id="menu-item-190" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-190"><a href="mailto:info@organiccashewnuts.com">Contact Us</a></li> </ul> </div> </nav> <!-- #access --> </header> <!-- #branding --> <div id="header-sidebar" class="widget-area" role="complementary"> <div id="header-sidebar-1"> <aside id="adinj-6" class="widget adinjwidget"> <!--Ad Injection:widget_6--> <div style=""> <center> <script type="text/javascript"><!--google_ad_client = "ca-pub-7115713166241039";/* header */google_ad_slot = "8284179002";google_ad_width = 728;google_ad_height = 90;//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script> </center> </div> </aside> </div> <div id="header-sidebar-2"> <aside id="adinj-7" class="widget adinjwidget"> <!--Ad Injection:widget_7--> <form action="http://www.google.com/cse" id="cse-search-box" target="_blank"> <div> <input type="hidden" name="cx" value="partner-pub-7115713166241039:0627359119" /> <input type="hidden" name="ie" value="UTF-8" /> <input type="text" name="q" size="15" /> <input type="submit" name="sa" value="Search" /> </div> </form> <script type="text/javascript" src="http://www.google.com/coop/cse/brand?form=cse-search-box&amp;lang=en"></script> </aside> </div> </div> <div id="main"> <div id="primary"> <div id="content" role="main"> <nav id="nav-single"> <h3 class="assistive-text">Post navigation</h3> <span class="nav-previous"><a href="http://organiccashewnuts.com/culture/generating-and-analysing-data-on-child-labour-in-malawis-tea-industry/" rel="prev"><span class="meta-nav">←</span> Previous</a></span> <span class="nav-next"><a href="http://organiccashewnuts.com/recipes/cashew-brittle-recipe/" rel="next">Next <span class="meta-nav">→</span></a></span> </nav> <!-- #nav-single --> <article id="post-228" class="post-228 post type-post status-publish format-standard hentry category-articles"> <header class="entry-header"> <h1 class="entry-title">Cashews: A Magnesium-Rich Food</h1> <div class="entry-meta"> <span class="sep">Posted on </span> <a href="http://organiccashewnuts.com/articles/cashews-magnesium-rich-food/" title="9:44 am" rel="bookmark"><time class="entry-date" datetime="2011-09-28T09:44:55+00:00" pubdate="">September 28, 2011</time></a> <span class="by-author"> <span class="sep"> by </span> <span class="author vcard"><a class="url fn n" href="http://organiccashewnuts.com/author/admin/" title="View all posts by Cashew Admin" rel="author">Cashew Admin</a></span></span> </div> <!-- .entry-meta --> </header> <!-- .entry-header --> <div class="entry-content"> <!-- AddThis Button Begin --> <script type="text/javascript">var addthis_product = 'wpp-263';var addthis_config = {"data_track_clickback":true,"data_track_addressbar":false};if (typeof(addthis_share) == "undefined"){ addthis_share = [];}</script> <script type="text/javascript" src="//s7.addthis.com/js/250/addthis_widget.js#pubid=forestcarbon"></script> <h2>Magnesium-Rich Foods Cut Colon Cancer Risk</h2> <p>Are Cashews good for you? People are always asking what nutrients are found in cashews and whether cashews are good for you and your body. This cashew related article from the American Journal of Epidemiology, describes how magnesium-rich cashews cut the risk colon cancer.</p> <p>Researchers from the University of Minnesota have found that a diet rich in magnesium may help reduce the risk of developing colon cancer. As part of the Iowa Women’s Health Study, researchers followed almost 42,000 women aged 55-69 for 17 years.</p> <p>After taking age, calories, other nutrients and traditional risk factors for colon cancer into account, the women with the highest intake of magnesium (more than 351 milligrams a day) had a 23% lower risk of colon cancer compared to those with the lowest intake (less than 245 milligrams a day). Magnesium intake, however had little effect on rectal cancer.</p> <p>In the study, more than 90% of the women’s magnesium intakes came from food, not supplements. The current recommended intake of magnesium is 400 milligrams a day. Good sources include artichokes, avocados, bran cereal,&nbsp;<strong><a href="http://www.organiccashewnuts.com/cashewbenefits.htm">cashews</a>,&nbsp;</strong>dark chocolate, lentils, spinach and wheat germ.</p> <p><em>Source</em>: American Journal of Epidemiology, February 2006</p> <div class="addthis_toolbox addthis_default_style " addthis:url="http://organiccashewnuts.com/articles/cashews-magnesium-rich-food/" addthis:title="Cashews: A Magnesium-Rich Food "> <a class="addthis_button_facebook_like" fb:like:layout="button_count"></a> <a class="addthis_button_tweet"></a> <a class="addthis_counter addthis_pill_style"></a> </div> </div> <!-- .entry-content --> <footer class="entry-meta"> This entry was posted in <a href="http://organiccashewnuts.com/category/articles/" title="View all posts in Articles" rel="category tag">Articles</a> by <a href="http://organiccashewnuts.com/author/admin/">Cashew Admin</a>. Bookmark the <a href="http://organiccashewnuts.com/articles/cashews-magnesium-rich-food/" title="Permalink to Cashews: A Magnesium-Rich Food" rel="bookmark">permalink</a>. </footer> <!-- .entry-meta --> </article> <!-- #post-228 --> <!-- Recent Related posts switch --> <div id="recent"> Recent Related Posts </div> <div id="related" class="group"> <div class="story1"> <h2><a href="http://organiccashewnuts.com/articles/cashew-tree-its-importance-in-africa/" title="Cashew Tree: It’s importance in Africa" rel="bookmark">Cashew Tree: It’s importance in Africa</a></h2> <div class="date"> September 28, 2011 </div> <div class="theExcerpt"> <p>The environmental benefits of planting cashew trees are numerous. The presence of cashew orchards allows farmers to harvest large amounts of firewood from yearly pruning which greatly reduces stress on local forests by eliminating the need to cut down indigenous … <a href="http://organiccashewnuts.com/articles/cashew-tree-its-importance-in-africa/">Continue reading <span class="meta-nav">→</span></a></p> <div class="addthis_toolbox addthis_default_style " addthis:url="http://organiccashewnuts.com/articles/cashew-tree-its-importance-in-africa/" addthis:title="Cashew Tree: It’s importance in Africa "> <a class="addthis_button_facebook_like" fb:like:layout="button_count"></a> <a class="addthis_button_tweet"></a> <a class="addthis_counter addthis_pill_style"></a> </div> </div> </div> <div class="story2"> <h2><a href="http://organiccashewnuts.com/articles/african-cashews-to-indian-factories-how-the-continent-exports-its-profits-and-jobs/" title="African Cashews to Indian Factories: How the Continent Exports its Profits and Jobs" rel="bookmark">African Cashews to Indian Factories: How the Continent Exports its Profits and Jobs</a></h2> <div class="date"> September 19, 2011 </div> <div class="theExcerpt"> <p>East African Business THE EASTAFRICAN (Nairobi, Kenya) Monday, December 20, 2004 African Cashews to Indian Factories: How the Continent Exports its Profits and Jobs By WAIRAGALA WAKABI Africa Currently exports an estimated 95 per cent of its cashew nuts in … <a href="http://organiccashewnuts.com/articles/african-cashews-to-indian-factories-how-the-continent-exports-its-profits-and-jobs/">Continue reading <span class="meta-nav">→</span></a></p> <div class="addthis_toolbox addthis_default_style " addthis:url="http://organiccashewnuts.com/articles/african-cashews-to-indian-factories-how-the-continent-exports-its-profits-and-jobs/" addthis:title="African Cashews to Indian Factories: How the Continent Exports its Profits and Jobs "> <a class="addthis_button_facebook_like" fb:like:layout="button_count"></a> <a class="addthis_button_tweet"></a> <a class="addthis_counter addthis_pill_style"></a> </div> </div> </div> </div> <!-- #related --> <div id="comments"> <div id="respond"> <h3 id="reply-title">Leave a Reply <small><a rel="nofollow" id="cancel-comment-reply-link" href="/articles/cashews-magnesium-rich-food/#respond" style="display:none;">Cancel reply</a></small></h3> <form action="http://organiccashewnuts.com/wp-comments-post.php" method="post" id="commentform"> <p class="comment-notes">Your email address will not be published. Required fields are marked <span class="required">*</span></p> <p class="comment-form-author"><label for="author">Name</label> <span class="required">*</span><input id="author" name="author" type="text" value="" size="30" aria-required="true" /></p> <p class="comment-form-email"><label for="email">Email</label> <span class="required">*</span><input id="email" name="email" type="text" value="" size="30" aria-required="true" /></p> <p class="comment-form-url"><label for="url">Website</label><input id="url" name="url" type="text" value="" size="30" /></p> <p class="comment-form-comment"><label for="comment">Comment</label><textarea id="comment" name="comment" cols="45" rows="8" aria-required="true"></textarea></p> <p class="form-allowed-tags">You may use these <abbr title="HyperText Markup Language">HTML</abbr> tags and attributes: <code>&lt;a href=&quot;&quot; title=&quot;&quot;&gt; &lt;abbr title=&quot;&quot;&gt; &lt;acronym title=&quot;&quot;&gt; &lt;b&gt; &lt;blockquote cite=&quot;&quot;&gt; &lt;cite&gt; &lt;code&gt; &lt;del datetime=&quot;&quot;&gt; &lt;em&gt; &lt;i&gt; &lt;q cite=&quot;&quot;&gt; &lt;strike&gt; &lt;strong&gt; </code></p> <p class="form-submit"> <input name="submit" type="submit" id="submit" value="Post Comment" /> <input type="hidden" name="comment_post_ID" value="228" id="comment_post_ID" /><input type="hidden" name="comment_parent" id="comment_parent" value="0" /> </p> <p style="display: none;"><input type="hidden" id="akismet_comment_nonce" name="akismet_comment_nonce" value="e72168e17d" /></p> </form> </div> <!-- #respond --> <script type="text/javascript"> jQuery(document).ready(function() { jQuery('#commentform').submit(function() { _gaq.push( ['_setAccount','UA-12154408-5'], ['_trackEvent','comment','submit'] ); }); }); </script> </div> <!-- #comments --> </div> <!-- #content --> </div> <!-- #primary --> <div id="secondary" class="widget-area" role="complementary"> <aside id="adinj-5" class="widget adinjwidget"> <!--Ad Injection:widget_5--> <script type="text/javascript"><!--google_ad_client = "ca-pub-7115713166241039";/* sidebar2 */google_ad_slot = "1562637817";google_ad_width = 200;google_ad_height = 200;//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script> </aside> <aside id="text-4" class="widget widget_text"> <div class="textwidget"> <form method="post" action="http://oi.vresp.com?fid=dcd3a73048" target="vr_optin_popup" onsubmit="window.open( 'http://www.verticalresponse.com', 'vr_optin_popup', 'scrollbars=yes,width=600,height=450' ); return true;"> <div style="font-family: verdana; font-size: 11px; width: 160px; padding: 10px; border: 1px solid #405210; background: #ffffff"> <strong><span style="color: #333333;">Get Discounts on Cashew Nuts Purchases</span></strong> <br /> <br /> <label style="color: #333333;">Email Address:</label> <br /> <input name="email_address" size="15" style="margin-top: 5px; border: 1px solid #999; padding: 3px;" /> <br /> <input type="submit" value="Subscribe" style="margin-top: 5px; border: 1px solid #999; padding: 3px;" /> <br /> </div> </form> </div> </aside> </div> <!-- #secondary .widget-area --> <!-- Add our .extra-sidebar are for three column layouts --> <div id="extra-sidebar" class="widget-area" role="complementary"> <aside id="adinj-3" class="widget adinjwidget"> <!--Ad Injection:widget_3--> <script type="text/javascript"><!--google_ad_client = "ca-pub-7115713166241039";/* sidebar1 */google_ad_slot = "6394762272";google_ad_width = 160;google_ad_height = 600;//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script> </aside> </div> <!-- .extra-sidebar .widget-area --> <!-- This is the sidebar call for single post pages--> </div> <!-- #main --> <footer id="colophon" role="contentinfo"> <div id="site-generator"> <span class="wpcredits"><a href="http://wordpress.org/" title="Semantic Personal Publishing Platform" rel="generator">Powered by WordPress</a></span> :: <span class="credits"><a href="http://organiccashewnuts.com" title="Organic Cashew Nuts">Organic Cashew Nuts</a></span> </div> </footer> <!-- #colophon --> </div> <!-- #page --> <script type="text/javascript" src="http://organiccashewnuts.com/wp-includes/js/jquery/ui.core.js?ver=1.8.12"></script> <script type="text/javascript" src="http://organiccashewnuts.com/wp-includes/js/jquery/ui.widget.js?ver=1.8.12"></script> <script type="text/javascript" src="http://organiccashewnuts.com/wp-includes/js/jquery/ui.tabs.js?ver=1.8.12"></script> <!-- AddThis Button Begin --> <script type="text/javascript">var addthis_product = 'wpp-263';var addthis_config = {"data_track_clickback":true,"data_track_addressbar":false};if (typeof(addthis_share) == "undefined"){ addthis_share = [];}</script> <script type="text/javascript" src="//s7.addthis.com/js/250/addthis_widget.js#pubid=forestcarbon"></script> </body> </html>
286	single	common schizophrenia drugs	Which drugs are commonly used to treat the different stages of schizophrenia?	clueweb12-0406wb-60-02344	2	<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN"> <html> <head> <link href="usermods/css/navigation.css" rel="stylesheet" type="text/css" /> <!--[if gte IE 4 ]><style type="text/css">div.navsection {position:relative;top:18px;background-color:#ffffff;height:30px;width:570px;border:0px solid #ffffff;}div.navsection div {float:left;}div.navsection .range {border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;float:left;background-color:#ffffff;height:100%;width:35%;vertical-align:middle;} div.navsection .navPaging {border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;text-align:center;float:left;background-color:#ffffff;height:100%;width:34%;}div.navsection .pageSort {border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;text-align:right;vertical-align:middle;float:none;background-color:#ffffff;padding-top:12px;height:100%;width:100%;position:relative;right:7px;}div.navsection div {background-image: url('usermods/images/pagingBackground.gif');background-repeat: repeat-x}</style><![endif]--> <script language="JavaScript" src="usermods/javascript/tools.js" type="text/javascript"></script> <link rel="stylesheet" type="text/css" href="../UserMods/css/_INCstyles_.css" /> <link rel="stylesheet" type="text/css" href="../UserMods/css/www.healthmegamall.com/pageLayout.css" /> <link rel="stylesheet" type="text/css" href="../UserMods/css/www.healthmegamall.com/prodList.css" /> <link rel="stylesheet" type="text/css" href="../UserMods/css/www.healthmegamall.com/default_moz.css" /> <link rel="stylesheet" type="text/css" href="../UserMods/css/www.healthmegamall.com/prodList.css" /> <link rel="shortcut icon" href="/UserMods/Images/babeskin.ico" /> <meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1" /> <title>Schizophrenia at HealthMegaMall.com</title> <meta name="description" content="Schizophrenia - Get medical information on Schizophrenia in HealthMegaMall. The largest selection of Vitamins, Supplements, Home Medical Equipment and Discount Medical Supply Store." /> <meta name="keywords" content="medical products, home care equipment, hospital supplies, medical supply, bathroom safety, arthritis, splint, vitamins, joint pain, braces, rollator, erectile dysfunction, scooters" /> <script language="javascript" type="text/javascript">//<![CDATA[var cot_loc0=(window.location.protocol == "https:")? "https://secure.comodo.net/trustlogo/javascript/cot.js" :"http://www.trustlogo.com/trustlogo/javascript/cot.js";document.writeln('<scr' + 'ipt language="JavaScript" src="'+cot_loc0+'" type="text\/javascript">' + '<\/scr' + 'ipt>');//]]></script> <script src="http://www.google-analytics.com/urchin.js" type="text/javascript"> </script> <script type="text/javascript"> _uacct = "UA-167102-1"; urchinTracker(); </script> <script language="JavaScript" type="text/javascript"><!-- Yahoo! Inc.var ysm_accountid = "1DP5M6G7TCOR8C73BQR28TP5EPO";document.write("<SCR" + "IPT language='JavaScript' type='text/javascript' " + "SRC=//" + "srv1.wa.marketingsolutions.yahoo.com" + "/script/ScriptServlet" + "?aid=" + ysm_accountid + "></SCR" + "IPT>");// --></script> </head> <body bgcolor="#F3F7FE" id="healthmegamall"> <div align="center"> <br /> <!-- Page Container Table --> <table width="775" border="0" cellpadding="0" cellspacing="0"> <!-- Top Navigation Bar --> <tbody> <tr bgcolor="#FFFFFF"> <td colspan="4" align="right"> <div style="z-index: 1; width: 100%; height: 20px; background-color:#333366; layer-background-color:#333366; visibility:visible;"> <a href="http://www.healthmegamall.com" style="text-decoration:none;font-size:12;color:white" onmouseover="this.style.color='red'" onmouseout="this.style.color='white'">&nbsp;&nbsp;<b>Toll Free : 1-855-5-911-911</b></a>&nbsp;&nbsp; <span> <!--|</SPAN> <img align=middle margin-top=0 src="/UserMods/Images/shoppingCart.gif" ><A href="cart.asp" style="text-decoration:none;font-size:12;color:white" onmouseover="this.style.color='red'" onmouseout="this.style.color='white'"> &nbsp;<b>CART</b> </A>&nbsp;&nbsp; <SPAN>--> |</span> <a href="05_Gateway.asp?action=logon&amp;vartheme=2" style="text-decoration:none;font-size:12;color:white" onmouseover="this.style.color='red'" onmouseout="this.style.color='white'">&nbsp;&nbsp;<b> My &nbsp;Account</b></a>&nbsp;&nbsp; <span>|</span> <a href="support.asp?support=about" style="text-decoration:none;font-size:12;color:white" onmouseover="this.style.color='red'" onmouseout="this.style.color='white'">&nbsp;&nbsp;<b>About Us</b></a>&nbsp;&nbsp; <span>|</span> <a href="support.asp" style="text-decoration:none;font-size:12;color:white" onmouseover="this.style.color='red'" onmouseout="this.style.color='white'">&nbsp;&nbsp;<b>Help</b></a>&nbsp;&nbsp; <span>|</span> <a href="05_Gateway.asp?action=logon&amp;vartheme=2" style="text-decoration:none;font-size:12;color:white" onmouseover="this.style.color='red'" onmouseout="this.style.color='white'">&nbsp;&nbsp;<b>Logon</b></a>&nbsp;&nbsp; </div> <div class="topbannerbox"> <span class="topbannerbox_left"> <a href="http://www.healthmegamall.com"><img class="topbannerbox" id="logo" src="UserMods/Images/logo_healthmegamall.gif" border="0" alt="HealthMegaMall.com" /></a><br /> </span> </div> <div class="bannerline"> <table cellspacing="0" cellpadding="0"> <tbody> <tr> <td class="searchbkg01"><img src="UserMods\Images\header\Header_left.jpg" /></td> <td id="searchbkg01"> <div id="fontsearch"> <b>Search:</b> </div></td> <td id="searchbkg01">&nbsp;</td> <form action="search.asp" method="post" name="searchBox"></form> <td id="searchbkg01"> <select name="strSearchArea" size="1" value="" id="listsearch" onchange="swapText(window.document.advSearch.strSearchArea.options[selectedIndex].value);"> <!--<option value="">All Areas</option> <option value="conditions">Conditions</option> <option value="products">Products</option>--> <option value="">All Areas</option> <option value="products">Products</option> <option value="conditions">Health Articles</option> </select> </td> <td id="searchbkg01">&nbsp;</td> <td id="searchbkg01"><input type="text" name="strSearch" size="25" id="textsearch" /></td> <td id="header_03"> <div id="searchbtn"> <a href="#" onclick="searchBox.submit();" title="Search!"><img src="UserMods\Images\header\searchbtn.gif" /></a> </div></td> <td id="searchbkg02">&nbsp;</td> <td id="searchbkg02"> <div id="headrightbtn01_norm"> <a href="cart.asp" id="headrightbtn" title="Go to cart!"><img src="UserMods\Images\header\headrightbtn01.gif" /><span><strong>My Cart </strong></span></a> </div> </td> <td id="searchbkg02"> <div id="headrightbtn02"> <a href="support.asp#whatLowest" id="headrightbtn"><img src="UserMods\Images\header\headrightbtn02.gif" /><span><strong>Lowest Price<br />Guarantee!!!</strong></span></a> </div></td> <td id="searchbkg02"> <div id="headrightbtn03"> <a href="guarantee.asp" id="headrightbtn"><img src="UserMods\Images\header\headrightbtn03.gif" /><span><strong>Big 8<br />Guarantees!!!</strong></span></a> </div></td> <td id="searchbkg02" width="100%">&nbsp;</td> </tr> </tbody> </table> </div> </td> </tr> <!-- Body --> <tr bgcolor="#FFFFFF"> <td colspan="4" width="760" valign="top"> <!-- Main Shopping Cart Area --> <table> <tbody> <tr> <td valign="top"> <table> <tbody> <tr> <td> <div class="mainMenuProdList"> <div class="picButtons"> <img src="../UserMods/images/list_of_products.gif" width="97px" height="100%" /> </div> <div class="picButtons"> <img src="../UserMods/images/list_of_conditions.gif" width="97px" height="100%" /> </div> <script type="text/javascript"> if (navigator.appCodeName == "Mozilla"){ document.write("<div style='{display:block;}'>&nbsp;</div>");}</script> <div class="prodList_blueFade"> <div> <script type="text/javascript"> if (navigator.appCodeName == "Mozilla" || navigator.appCodeName == "Netscape"){ document.write("<img src='UserMods/misc_cleardot.gif' height=1 width=1>");} </script> <table cellspacing="0" cellpadding="0" height="40" width="100%"> <tbody> <tr> <td class="browse_products" style="padding-left:13;">Entire Categories</td> </tr> <tr> <form action="CategoryDisplay"></form> <td valign="top" align="left"> <table cellspacing="0" cellpadding="0"> <tbody> <tr> <td> <select onchange="location.href=this.options[selectedIndex].value" style="width:150;font-size:10px;margin-left:13;margin-right:13;padding:0;" name="categoryId"> <option value="prodlist-Health-Conditions.htm">All Categories</option><option value="prodlist-Addiction_s29.htm">Addiction</option><option value="prodlist-Anti-Aging_s15.htm">Anti-Aging</option><option value="prodlist-Anxiety_s23.htm">Anxiety</option><option value="prodlist-Blood-Disorders_s33.htm">Blood Disorders</option><option value="prodlist-Bones-Joints_s14.htm">Bones &amp; Joints</option><option value="prodlist-Diabetes_s20.htm">Diabetes</option><option value="prodlist-Glandular-Health_s13.htm">Glandular Health</option><option value="prodlist-Hair-Health_s25.htm">Hair Health</option><option value="prodlist-Heart-Health_s9.htm">Heart Health</option><option value="prodlist-Immune-System_s8.htm">Immune System</option><option value="prodlist-Kidney-Health_s34.htm">Kidney Health</option><option value="prodlist-Mens-Health_s21.htm">Men's Health</option><option value="prodlist-Mind-Mood_s22.htm">Mind &amp; Mood</option><option value="prodlist-Oral-Health_s37.htm">Oral Health</option><option value="prodlist-Respiratory-Health_s10.htm">Respiratory Health</option><option value="prodlist-Skin-Health_s35.htm">Skin Health</option><option value="prodlist-Sleep-Disorders_s32.htm">Sleep Disorders</option><option value="prodlist-Vitamins-Nutrition_s16.htm">Vitamins &amp; Nutrition</option><option value="prodlist-Weight-Loss_s11.htm">Weight Loss</option><option value="prodlist-Womens-Health_s24.htm">Women's Health</option> </select></td> </tr> </tbody> </table></td> </tr> </tbody> </table> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Addiction_s29.htm">Addiction</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Anti-Aging_s15.htm">Anti-Aging</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Anxiety_s23.htm">Anxiety</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Blood-Disorders_s33.htm">Blood Disorders</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Bones-Joints_s14.htm">Bones &amp; Joints</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Diabetes_s20.htm">Diabetes</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Glandular-Health_s13.htm">Glandular Health</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Hair-Health_s25.htm">Hair Health</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Heart-Health_s9.htm">Heart Health</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Immune-System_s8.htm">Immune System</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Kidney-Health_s34.htm">Kidney Health</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Mens-Health_s21.htm">Men's Health</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Mind-Mood_s22.htm">Mind &amp; Mood</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Oral-Health_s37.htm">Oral Health</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Respiratory-Health_s10.htm">Respiratory Health</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Skin-Health_s35.htm">Skin Health</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Sleep-Disorders_s32.htm">Sleep Disorders</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Vitamins-Nutrition_s16.htm">Vitamins &amp; Nutrition</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Weight-Loss_s11.htm">Weight Loss</a> </h1> </div> <div class="prodListMenuTop"> <div id="a" style="{width:11px;}"> </div> <h1 class="SideMenu"> <a class="sub_category_link" href="../prodList-Womens-Health_s24.htm">Women's Health</a> </h1> </div> <div> &nbsp; </div> </div> </div> </td> </tr> <tr> <td> </td> </tr> <tr> <td> </td> </tr> </tbody> </table> </td> <td valign="top"> <script language="JavaScript" type="text/javascript" src="usermods/javascript/prodlist.js"></script> <div align="right"> <span id="shrink_expand_box"> <a href="#" onclick="expandWindow('catHTMLLongBox')"><img src="/UserMods/butt_panel_expand_on.gif" name="expandButton" border="0" id="expandButton" alt="Expand Window" /></a> </span> <span id="fullscreen_box"> <a href="#" onclick="fullscreenWindow('catHTMLLongBox')"><img src="/UserMods/butt_panel_full_on.gif" name="fullscreenButton" border="0" id="fullscreenButton" alt="Full Screen" /></a> </span> </div> <div class="catHTMLLongDescTheme" align="left" id="catHTMLLongBox" style="height:275px;"> <div align="left"> </div> <div align="left"> <div class="indent10"> <a name="top"> </a> <a id="readNow" name="readNow"></a> <span class="subcatMainHeader">Schizophrenia </span> <p><b>On this Page</b></p> <ul> <li><a href="#1">What Is It?</a> </li> <li><a href="#2">What Causes Schizophrenia?</a> </li> <li><a href="#3">How Is It Treated?</a> </li> <li><a href="#4">How Can Other People Help?</a> </li> <li><a href="#5">What Is The Outlook?</a> </li> </ul> <a name="1"></a> <p class="subcatSubHeader">WHAT IS IT?</p> <p>Schizophrenia is a chronic, severe, and disabling <a hf="/events/locschiz.cfm"></a>brain disease. Approximately 1 percent of the population develops schizophrenia during their lifetime�more than 2 million Americans suffer from the illness in a given year. Although schizophrenia affects men and women with equal frequency, the disorder often appears earlier in men, usually in the late teens or early twenties, than in women, who are generally affected in the twenties to early thirties. People with schizophrenia often suffer terrifying symptoms such as hearing internal voices not heard by others, or believing that other people are reading their minds, controlling their thoughts, or plotting to harm them. These symptoms may leave them fearful and withdrawn. Their speech and behavior can be so disorganized that they may be incomprehensible or frightening to others. Available treatments can relieve many symptoms, but most people with schizohphrenia continue to suffer some symptoms throughout their lives; it has been estimated that nomore than one in five individuals recovers completely. </p> <p>This is a time of hope for people with schizophrenia and their families. Research is gradually leading to new and safer medications and unraveling the complex causes of the disease. Scientists are using many approaches from the study of molecular genetics to the study of populations to learn about schizophrenia. Methods of imaging the brain�s structure and function hold the promise of new insights into the disorder. </p> <p class="subcatSubHeaderSmaller">Schizophrenia as an Illness</p> <p>Schizophrenia is found all over the world. The severity of the symptoms and long-lasting, chronic pattern of schizophrenia often cause a high degree of disability. Medications and other treatments for schizophrenia, when used regularly and as prescribed, can help reduce and control the distressing symptoms of the illness. However, some people are not greatly helped by available treatments or may prematurely discontinue treatment because of unpleasant side effects or other reasons. Even when treatment is effective, persisting consequences of the illness�lost opportunities, stigma, residual symptoms, and medication side effects�may be very troubling. </p> <p>The first signs of schizophrenia often appear as confusing, or even shocking, changes in behavior. Coping with the symptoms of schizophrenia can be especially difficult for family members who remember how involved or vivacious a person was before they became ill. The sudden onset of severe psychotic symptoms is referred to as an �acute� phase of schizophrenia. �Psychosis,� a common condition in schizophrenia, is a state of mental impairment marked by hallucinations, which are disturbances of sensory perception, and/or delusions, which are false yet strongly held personal beliefs that result from an inability to separate real from unreal experiences. Less obvious symptoms, such as social isolation or withdrawal, or unusual speech, thinking, or behavior, may precede, be seen along with, or follow the psychotic symptoms. Some people have only one such psychotic episode; others have many episodes during a lifetime, but lead relatively normal lives during the interim periods. However, the individual with �chronic� schizophrenia, or a continuous or recurring pattern of illness, often does not fully recover normal functioning and typically requires long-term treatment, generally including medication,to control the symptoms. </p> <p class="subcatSubHeaderSmaller">Making a Diagnosis</p> <p>It is important to rule out other illnesses, as sometimes people suffer severe mental symptoms or even psychosis due to undetected underlying medical conditions. For this reason, a medical history should be taken and a physical examination and laboratory tests should be done to rule out other possible causes of the symptoms before concluding that a person has schizophrenia. In addition, since commonly abused drugs may cause symptoms resembling schizophrenia, blood or urine samples from the person can be tested at hospitals or physicians� offices for the presence of these drugs. </p> <p>At times, it is difficult to tell one mental disorder from another. For instance, some people with symptoms of schizophrenia exhibit prolonged extremes of elated or depressed mood, and it is important to determine whether such a patient has schizophrenia or actually has a manic-depressive (or bipolar) disorder or major depressive disorder. Persons whose symptoms cannot be clearly categorized are sometimes diagnosed as having a �schizoaffective disorder.� </p> <p class="subcatSubHeaderSmaller">Can Children Have Schizophrenia?</p> <p>Children over the age of five can develop schizophrenia, but it is very rare before adolescence. Although some people who later develop schizophrenia may have seemed different from other children at an early age, the psychotic symptoms of schizophrenia�hallucinations and delusions�are extremely uncommon before adolescence. </p> <p align="right"><a href="#top" class="link">Return to top</a> <a href="#top"><img src="../UserMods/Images/arrow_up.gif" alt="Return to top" border="0" /></a> </p> <p class="subcatSubHeader">The World of People With Schizophrenia </p> <p class="subcatSubHeaderSmaller">Distorted Perceptions of Reality</p> <p>People with schizophrenia may have perceptions of reality that are strikingly different from the reality seen and shared by others around them. Living in a world distorted by hallucinations and delusions, individuals with schizophrenia may feel frightened, anxious, and confused. </p> <p>In part because of the unusual realities they experience, people with schizophrenia may behave very differently at various times. Sometimes they may seem distant, detached, or preoccupied and may even sit as rigidly as a stone, not moving for hours or uttering a sound. Other times they may move about constantly�always occupied, appearing wide-awake, vigilant, and alert. </p> <p class="subcatSubHeaderSmaller">Hallucinations and Illusions</p> <p>Hallucinations and illusions are disturbances of perception that are common in people suffering from schizophrenia. Hallucinations are perceptions that occur without connection to an appropriate source. Although hallucinations can occur in any sensory form�auditory (sound), visual (sight), tactile (touch), gustatory (taste), and olfactory (smell)�hearing voices that other people do not hear is the most common type of hallucination in schizophrenia. Voices may describe the patient�s activities, carry on a conversation, warn of impending dangers, or even issue orders to the individual. Illusions, on the other hand, occur when a sensory stimulus is present but is incorrectly interpreted by the individual. </p> <p class="subcatSubHeaderSmaller">Delusions</p> <p>Delusions are false personal beliefs that are not subject to reason or contradictory evidence and are not explained by a person�s usual cultural concepts. Delusions may take on different themes. For example, patients suffering from paranoid-type symptoms�roughly one-third of people with schizophrenia�often have delusions of persecution, or false and irrational beliefs that they are being cheated, harassed, poisoned, or conspired against. These patients may believe that they, or a member of the family or someone close to them, are the focus of this persecution. In addition, delusions of grandeur, in which a person may believe he or she is a famous or important figure, may occur in schizophrenia. Sometimes the delusions experienced by people with schizophrenia are quite bizarre; for instance, believing that a neighbor is controlling their behavior with magnetic waves; that people on television are directing specialmessages to them; or that their thoughts are being broadcast aloud to others. </p> <p class="subcatSubHeaderSmaller">Disordered Thinking</p> <p>Schizophrenia often affects a person�s ability to �think straight.� Thoughts may come and go rapidly; the person may not be able to concentrate on one thought for very long and may be easily distracted, unable to focus attention. </p> <p>People with schizophrenia may not be able to sort out what is relevant and what is not relevant to a situation. The person may be unable to connect thoughts into logical sequences, with thoughts becoming disorganized and fragmented. This lack of logical continuity of thought, termed �thought disorder,� can make conversation very difficult and may contribute to social isolation. If people cannot make sense of what an individual is saying, they are likely to become uncomfortable and tend to leave that person alone. </p> <p class="subcatSubHeaderSmaller">Emotional Expression</p> <p>People with schizophrenia often show �blunted� or �flat� affect. This refers to a severe reduction in emotional expressiveness. A person with schizophrenia may not show the signs of normal emotion, perhaps may speak in a monotonous voice, have diminished facial expressions, and appear extremely apathetic. The person may withdraw socially, avoiding contact with others; and when forced to interact, he or she may have nothing to say, reflecting �impoverished thought.� Motivation can be greatly decreased, as can interest in or enjoyment of life. In some severe cases, a person can spend entire days doing nothing at all, even neglecting basic hygiene. These problems with emotional expression and motivation, which may be extremely troubling to family members and friends, are symptoms of schizophrenia�not character flaws or personal weaknesses. </p> <p class="subcatSubHeaderSmaller">Normal Versus Abnormal</p> <p>At times, normal individuals may feel, think, or act in ways that resemble schizophrenia. Normal people may sometimes be unable to �think straight.� They may become extremely anxious, for example, when speaking in front of groups and may feel confused, be unable to pull their thoughts together, and forget what they had intended to say. This is not schizophrenia. At the same time, people with schizophrenia do not always act abnormally. Indeed, some people with the illness can appear completely normal and be perfectly responsible, even while they experience hallucinations or delusions. An individual�s behavior may change over time, becoming bizarre if medication is stopped and returning closer to normal when receiving appropriate treatment. </p> <p class="subcatSubHeaderSmaller">Are People With Schizophrenia Likely To Be Violent?</p> <p>News and entertainment media tend to link mental illness and criminal violence; however, studies indicate that except for those persons with a record of criminal violence <em>before becoming ill</em>, and those with substance abuse or alcohol problems, people with Schizophrenia are not especially prone to violence. </p> <div class="border"> <p class="subcatSubHeaderSmaller">Substance Abuse</p> <p>Substance abuse is a common concern of the family and friends of people with schizophrenia. Since some people who abuse drugs may show symptoms similar to those of schizophrenia, people with schizophrenia may be mistaken for people �high on drugs.� while most researchers do not believe that substance abuse <i>causes</i> schizophrenia, people who have schizophrenia often abuse alcohol and/or drugs, and may have particularly bad reactions to certain drugs. Substance abuse can reduce the effectiveness of treatment for schizophrenia. Stimulants (such as amphetamines or cocaine) may cause major problems for patients with schizophrenia, as may PCP or marijuana. In fact, some people experience a worsening of their schizophrenic symptoms when they are taking such drugs. Substance abuse also reduces the likelihood that patients will follow the treatment plans recommended by their doctors. </p> <p class="subcatSubHeaderSmaller">Schizophrenia and Nicotine</p> <p>The most common form of substance use disorder in people with schizophrenia is nicotine dependence due to smoking. While the prevalence of smoking in the U.S. population is about 25 to 30 percent, the prevalence among people with schizophrenia is approximately three times as high. Research has shown that the relationship between smoking and schizophrenia is complex. Although people with schizophrenia may smoke to self medicate their symptoms, smoking interferes with the response to antipsychotic drugs. Several studies have found that schizophrenia patients who smoke need higher doses of antipsychotic medication. Quitting smoking may be especially difficult for people with schizophrenia, because the symptoms of nicotine withdrawal may cause a temporary worsening of schizophrenia symptoms. However, smoking cessation strategies that include nicotine replacement methods may be effective. Doctors should carefully monitor medication dosage and response when patients with schizophrenia either start or stop smoking. </p> </div> <p>Most individuals with schizophrenia are not violent; more typically, they are withdrawn and prefer to be left alone. Most violent crimes are not committed by persons with schizophrenia, and most persons with schizophrenia do not commit violent crimes. </p> <p>Substance abuse significantly raises the rate of violence in people with schizophrenia but also in people who do not have any mental illness. People with paranoid and psychotic symptoms, which can become worse if medications are discontinued, may also be at higher risk for violent behavior. When violence does occur, it is most frequently targeted at family members and friends, and more often takes place at home. </p> <p class="subcatSubHeaderSmaller">What About Suicide?</p> <p>Suicide is a serious danger in people who have schizophrenia. If an individual tries to commit suicide or threatens to do so, professional help should be sought immediately. People with schizophrenia have a higher rate of suicide than the general population. Approximately 10 percent of people with schizophrenia (especially younger adult males) commit suicide. Unfortunately, the prediction of suicide in people with schizophrenia can be especially difficult. </p> <p align="right"><a href="#top" class="link">Return to top</a> <a href="#top"><img src="../UserMods/Images/arrow_up.gif" alt="Return to top" border="0" /></a> </p> <p class="subcatSubHeader"><a name="2"></a>WHAT CAUSES SCHIZOPHRENIA?</p> <p>There is no known single cause of schizophrenia. Many diseases, such as heart disease, result from an interplay of genetic, environmental, and behavioral factors; and this may be the case for schizophrenia as well. Scientists do not yet understand all of the factors necessary to produce schizophrenia, but all the tools of modern biomedical research are being used to search for genes, critical moments in brain development, and environmental factors that may lead to the illness. </p> <p class="subcatSubHeaderSmaller">Is Schizophrenia Inherited?</p> <p>It has long been known that schizophrenia runs in families. People who have a close relative with schizophrenia are more likely to develop the disorder than are people who have no relatives with the illness. For example, a monozygotic (identical) twin of a person with schizophrenia has the highest risk�40 to 50 percent�of developing the illness. A child whose parent has schizophrenia has about a 10 percent chance. By comparison, the risk of schizophrenia in the general population is about 1 percent. </p> <p>Scientists are studying genetic factors in schizophrenia. It appears likely that multiple genes are involved in creating a predisposition to develop the disorder. In addition, factors such as prenatal difficulties like intrauterine starvation or viral infections, perinatal complications, and various nonspecific stressors, seem to influence the development of schizophrenia. However, it is not yet understood how the genetic predisposition is transmitted, and it cannot yet be accurately predicted whether a given person will or will not develop the disorder. </p> <p>Several regions of the human genome are being investigated to identify genes that may confer susceptibility for schizophrenia. The strongest evidence to date leads to chromosomes 13 and 6 but remains unconfirmed. Identification of specific genes involved in the development of schizophrenia will provide important clues into what goes wrong in the brain to produce and sustain the illness and will guide the development of new and better treatments. To learn more about the genetic basis for schizophrenia, the NIMH has established a Schizophrenia Genetics Initiative that is gathering data from a large number of families of people with the illness. </p> <p class="subcatSubHeaderSmaller">Is Schizophrenia Associated With a Chemical Defect in the Brain?</p> <p>Basic knowledge about brain chemistry and its link to schizophrenia is expanding rapidly. Neurotransmitters, substances that allow communication between nerve cells, have long been thought to be involved in the development of schizophrenia. It is likely, although not yet certain, that the disorder is associated with some imbalance of the complex, interrelated chemical systems of the brain, perhaps involving the neurotransmitters dopamine and glutamate. This area of research is promising. </p> <p class="subcatSubHeaderSmaller">Is Schizophrenia Caused by a Physical Abnormality in the Brain?</p> <p>There have been dramatic advances in neuroimaging technology that permit scientists to study brain structure and function in living individuals. Many studies of people with schizophrenia have found abnormalities in brain structure (for example, enlargement of the fluid-filled cavities, called the ventricles, in the interior of the brain, and decreased size of certain brain regions) or function (for example, decreased metabolic activity in certain brain regions). It should be emphasized that these abnormalities are quite subtle and are not characteristic of <em>all</em> people with schizophrenia, nor do they occur <em>only</em> in individuals with this illness. Microscopic studies of brain tissue after death have also shown small changes in distribution or number of brain cells in people with schizophrenia. It appears that many (but probably not all) of these changes are present before an individual becomes ill, and schizophrenia may be, in part, a disorder in development of the brain. </p> <p>Developmental neurobiologists funded by the National Institute of Mental Health (NIMH) have found that schizophrenia may be a developmental disorder resulting when neurons form inappropriate connections during fetal development. These errors may lie dormant until puberty, when changes in the brain that occur normally during this critical stage of maturation interact adversely with the faulty connections. This research has spurred efforts to identify prenatal factors that may have some bearing on the apparent developmental abnormality. </p> <p>In other studies, investigators using brain-imaging techniques have found evidence of early biochemical changes that may precede the onset of disease symptoms, prompting examination of the neural circuits that are most likely to be involved in producing those symptoms. Scientists working at the molecular level, meanwhile, are exploring the genetic basis for abnormalities in brain development and in the neurotransmitter systems regulating brain function. </p> <p align="right"><a href="#top" class="link">Return to top</a> <a href="#top"><img src="../UserMods/Images/arrow_up.gif" alt="Return to top" border="0" /></a> </p> <p class="subcatSubHeader"><a name="3"></a>HOW IS IT TREATED?</p> <p>Since schizophrenia may not be a single condition and its causes are not yet known, current treatment methods are based on both clinical research and experience. These approaches are chosen on the basis of their ability to reduce the symptoms of schizophrenia and to lessen the chances that symptoms will return. </p> <p class="subcatSubHeader">What About Medications?</p> <p>Antipsychotic medications have been available since the mid-1950s. They have greatly improved the outlook for individual patients. These medications reduce the psychotic symptoms of schizophrenia and usually allow the patient to function more effectively and appropriately. Antipsychotic drugs are the best treatment now available, but they do not �cure� schizophrenia or ensure that there will be no further psychotic episodes. The choice and dosage of medication can be made only by a qualified physician who is well trained in the medical treatment of mental disorders. The dosage of medication is individualized for each patient, since people may vary a great deal in the amount of drug needed to reduce symptoms without producing troublesome side effects. </p> <p>The large majority of people with schizophrenia show substantial improvement when treated with antipsychotic drugs. Some patients, however, are not helped very much by the medications and a few do not seem to need them. It is difficult to predict which patients will fall into these two groups and to distinguish them from the large majority of patients who <i>do</i> benefit from treatment with antipsychotic drugs. </p> <p>A number of new antipsychotic drugs (the so-called �atypical antipsychotics�) have been introduced since 1990. The first of these, clozapine (Clozaril�), has been shown to be more effective than other antipsychotics, although the possibility of severe side effects�in particular, a condition called agranulocytosis (loss of the white blood cells that fight infection)�requires that patients be monitored with blood tests every one or two weeks. Even newer antipsychotic drugs, such as risperidone (Risperdal�) and olanzapine (Zyprexa�), are safer than the older drugs or clozapine, and they also may be better tolerated. They may or may not treat the illness as well as clozapine, however. Several additional antipsychotics are currently under development. </p> <p>Antipsychotic drugs are often very effective in treating certain symptoms of schizophrenia, particularly hallucinations and delusions; unfortunately, the drugs may not be as helpful with other symptoms, such as reduced motivation and emotional expressiveness. Indeed, the older antipsychotics (which also went by the name of �neuroleptics�), medicines like haloperidol (Haldol�) or chlorpromazine (Thorazine�), may even produce side effects that resemble the more difficult to treat symptoms. Often, lowering the dose or switching to a different medicine may reduce these side effects; the newer medicines, including olanzapine (Zyprexa�), quetiapine (Seroquel�), and risperidone (Risperdal�), appear less likely to have this problem. Sometimes when people with schizophrenia become depressed, other symptoms can appear to worsen. The symptoms may improve with the addition of an antidepressant medication. </p> <p>Patients and families sometimes become worried about the antipsychotic medications used to treat schizophrenia. In addition to concern about side effects, they may worry that such drugs could lead to addiction. However, antipsychotic medications do not produce a �high� (euphoria) or addictive behavior in people who take them. </p> <p>Another misconception about antipsychotic drugs is that they act as a kind of mind control, or a �chemical straitjacket.� Anti-psychotic drugs used at the appropriate dosage do not �knock out� people or take away their free will. While these medications can be sedating, and while this effect can be useful when treatment is initiated particularly if an individual is quite agitated, the utility of the drugs is not due to sedation but to their ability to diminish the hallucinations, agitation, confusion, and delusions of a psychotic episode. Thus, antipsychotic medications should eventually help an individual with schizophrenia to deal with the world more rationally. </p> <p class="subcatSubHeaderSmaller">How Long Should People With Schizophrenia Take Antipsychotic Drugs?</p> <p>Antipsychotic medications reduce the risk of future psychotic episodes in patients who have recovered from an acute episode. Even with continued drug treatment, some people who have recovered will suffer relapses. Far higher relapse rates are seen when medication is discontinued. In most cases, it would not be accurate to say that continued drug treatment �prevents� relapses; rather, it reduces their intensity and frequency. The treatment of severe psychotic symptoms generally requires higher dosages than those used for maintenance treatment. If symptoms reappear on a lower dosage, a temporary increase in dosage may prevent a full-blown relapse. </p> <p>Because relapse of illness is more likely when antipsychotic medications are discontinued or taken irregularly, it is very important that people with schizophrenia work together with their doctors and family members to adhere to their treatment plan. <em>Adherence</em> to treatment refers to the degree to which patients follow the treatment plans decided upon with their doctors. Good adherence involves taking prescribed medication at the correct dose and proper times each day, attending clinic appointments, and/or carefully following other treatment procedures. Treatment adherence is often difficult for people with schizophrenia, but it can be made easier with the help of several strategies and can lead to improved quality of life. </p> <p>There are a variety of reasons why people with schizophrenia may not adhere to treatment. Patients may not believe they are ill and may deny the need for medication, or they may have such disorganized thinking that they cannot remember to take their daily doses. Family members or friends may not understand schizophrenia and may inappropriately advise the person with schizophrenia to stop treatment when he or she is feeling better. Physicians, who play an important role in helping their patients adhere to treatment, may neglect to ask patients how often they are taking their medications, or may be unwilling to accommodate a patient�s request to change dosages or try a new treatment. Some patients report that side effects of the medications seem worse than the illness itself. Further, substance abuse can interfere with the effectiveness of treatment, leading patients to discontinue medications. When a complicated treatment planis added to any of these factors, good adherence may become even more challenging. </p> <p>Fortunately, there are many strategies that patients, doctors, and families can use to improve adherence and prevent worsening of the illness. Some antipsychotic medications, including haloperidol (Haldol�), fluphenazine (Prolixin�), perphenazine (Trilafon�) and others, are available in long-acting injectable forms that eliminate the need to take pills every day. A major goal of current research on treatments for schizophrenia is to develop a wider variety of long-acting antipsychotics, especially the newer agents with milder side effects, which can be delivered through injection. Medication calendars or pill boxes labeled with the days of the week can help patients and caregivers know when medications have or have not been taken. Using electronic timers that beep when medications should be taken, or pairing medication taking with routine daily events like meals, can help patients remember and adhere to their dosing schedule. Engaging family members in observing oral medication taking by patients can help ensure adherence. In addition, through a variety of other methods of adherence monitoring, doctors can identify when pill taking is a problem for their patients and can work with them to make adherence easier. It is important to help motivate patients to continue takingtheir medications properly. </p> <p>In addition to any of these adherence strategies, patient and family education about schizophrenia, its symptoms, and the medications being prescribed to treat the disease is an important part of the treatment process and helps support the rationale for good adherence. </p> <p class="subcatSubHeaderSmaller">What About Side Effects?</p> <p>Antipsychotic drugs, like virtually all medications, have unwanted effects along with their beneficial effects. During the early phases of drug treatment, patients may be troubled by side effects such as drowsiness, restlessness, muscle spasms, tremor, dry mouth, or blurring of vision. Most of these can be corrected by lowering the dosage or can be controlled by other medications. Different patients have different treatment responses and side effects to various antipsychotic drugs. A patient may do better with one drug than another. </p> <p>The long-term side effects of antipsychotic drugs may pose a considerably more serious problem. Tardive dyskinesia (TD) is a disorder characterized by involuntary movements most often affecting the mouth, lips, and tongue, and sometimes the trunk or other parts of the body such as arms and legs. It occurs in about 15 to 20 percent of patients who have been receiving the older, �typical� antipsychotic drugs for many years, but TD can also develop in patients who have been treated with these drugs for shorter periods of time. In most cases, the symptoms of TD are mild, and the patient may be unaware of the movements. </p> <p>Antipsychotic medications developed in recent years all appear to have a much lower risk of producing TD than the older, traditional antipsychotics. The risk is not zero, however, and they can produce side effects of their own such as weight gain. In addition, if given at too high of a dose, the newer medications may lead to problems such as social withdrawal and symptoms resembling Parkinson�s disease, a disorder that affects movement. Nevertheless, the newer antipsychotics are a significant advance in treatment, and their optimal use in people with schizophrenia is a subject of much current research. </p> <p class="subcatSubHeaderSmaller">What About Psychosocial Treatments?</p> <p>Antipsychotic drugs have proven to be crucial in relieving the psychotic symptoms of schizophrenia�hallucinations, delusions, and incoherence�but are not consistent in relieving the behavioral symptoms of the disorder. Even when patients with schizophrenia are relatively free of psychotic symptoms, many still have extraordinary difficulty with communication, motivation, self-care, and establishing and maintaining relationships with others. Moreover, because patients with schizophrenia frequently become ill during the critical career-forming years of life (e.g., ages 18 to 35), they are less likely to complete the training required for skilled work. As a result, many with schizophrenia not only suffer thinking and emotional difficulties, but lack social and work skills and experience as well. </p> <p>It is with these psychological, social, and occupational problems that psychosocial treatments may help most. While psychosocial approaches have limited value for acutely psychotic patients (those who are out of touch with reality or have prominent hallucinations or delusions), they may be useful for patients with less severe symptoms or for patients whose psychotic symptoms are under control. Numerous forms of psychosocial therapy are available for people with schizophrenia, and most focus on improving the patient�s social functioning�whether in the hospital or community, at home, or on the job. Some of these approaches are described here. Unfortunately, the availability of different forms of treatment varies greatly from place to place. </p> <div class="border center"> <p class="subcatSubHeaderSmaller">Schizophrenia Is Not &quot;Split Personality&quot;</p> <p>There is a common notion that schizophrenia is the same as &quot;split personality��a Dr. Jekyll-Mr. Hyde switch in character. </p> <p>This is not correct. </p> </div> <p class="subcatSubHeaderSmaller">Rehabilitation</p> <p>Broadly defined, rehabilitation includes a wide array of non-medical interventions for those with schizophrenia. Rehabilitation programs emphasize social and vocational training to help patients and former patients overcome difficulties in these areas. Programs may include vocational counseling, job training, problem-solving and money management skills, use of public transportation, and social skills training. These approaches are important for the success of the community-centered treatment of schizophrenia, because they provide discharged patients with the skills necessary to lead productive lives outside the sheltered confines of a mental hospital. </p> <p class="subcatSubHeaderSmaller">Individual Psychotherapy</p> <p>Individual psychotherapy involves regularly scheduled talks between the patient and a mental health professional such as a psychiatrist, psychologist, psychiatric social worker, or nurse. The sessions may focus on current or past problems, experiences, thoughts, feelings, or relationships. By sharing experiences with a trained empathic person�talking about their world with someone outside it�individuals with schizophrenia may gradually come to understand more about themselves and their problems. They can also learn to sort out the real from the unreal and distorted. Recent studies indicate that supportive, reality-oriented, individual psychotherapy, and cognitive-behavioral approaches that teach coping and problem-solving skills, can be beneficial for outpatients with schizophrenia. However, psychotherapy is not a substitute for antipsychotic medication; it is most helpful once drug treatment first has relieved a patient�s psychotic symptoms. </p> <p class="subcatSubHeaderSmaller">Family Education</p> <p>Very often, patients with schizophrenia are discharged from the hospital into the care of their family; so it is important that family members learn all they can about schizophrenia and understand the difficulties and problems associated with the illness. It is also helpful for family members to learn ways to minimize the patient�s chance of relapse�for example, by using different treatment adherence strategies�and to be aware of the various kinds of outpatient and family services available in the period after hospitalization. Family �psychoeducation,� which includes teaching various coping strategies and problem-solving skills, may help families deal more effectively with their ill relative and may contribute to an improved outcome for the patient. </p> <p class="subcatSubHeaderSmaller">Self-Help Groups</p> <p>Self-help groups for people and families dealing with schizophrenia are becoming increasingly common. Although not led by a professional therapist, these groups may be therapeutic because members provide continuing mutual support as well as comfort in knowing that they are not alone in the problems they face. Self-help groups may also serve other important functions. Families working together can more effectively serve as advocates for needed research and hospital and community treatment programs. Patients acting as a group rather than individually may be better able to dispel stigma and draw public attention to such abuses as discrimination against the mentally ill. </p> <p>Family and peer support and advocacy groups are very active and provide useful information and assistance for patients and families of patients with schizophrenia and other mental disorders. A list of some of these organizations is included at the back of this booklet. </p> <p align="right"><a href="#top" class="link">Return to top</a> <a href="#top"><img src="../UserMods/Images/arrow_up.gif" alt="Return to top" border="0" /></a> </p> <p class="subcatSubHeader"><a name="4"></a>HOW CAN OTHER PEOPLE HELP?</p> <p>A patient's support system may come from several sources, including the family, a professional residential or day program provider, shelter operators, friends or roommates, professional case managers, churches and synagogues, and others. Because many patients live with their families, the following discussion frequently uses the term &quot;family.&quot; However, this should not be taken to imply that families ought to be the primary support system. </p> <p>There are numerous situations in which patients with schizophrenia may need help from people in their family or community. Often, a person with schizophrenia will resist treatment, believing that delusions or hallucinations are real and that psychiatric help is not required. At times, family or friends may need to take an active role in having them seen and evaluated by a professional. The issue of civil rights enters into any attempts to provide treatment. Laws protecting patients from involuntary commitment have become very strict, and families and community organizations may be frustrated in their efforts to see that a severely mentally ill individual gets needed help. These laws vary from state to state; but generally, when people are dangerous to themselves or others due to a mental disorder, the police can assist in getting them an emergency psychiatric evaluation and, if necessary, hospitalization. In some places, staff from a local community mental health center can evaluate an individual's illness at home if he or she will not voluntarilygo in for treatment. </p> <p>Sometimes only the family or others close to the person with schizophrenia will be aware of strange behavior or ideas that the person has expressed. Since patients may not volunteer such information during an examination, family members or friends should ask to speak with the person evaluating the patient so that all relevant information can be taken into account. </p> <p>Ensuring that a person with schizophrenia continues to get treatment after hospitalization is also important. A patient may discontinue medications or stop going for follow-up treatment, often leading to a return of psychotic symptoms. Encouraging the patient to continue treatment and assisting him or her in the treatment process can positively influence recovery. Without treatment, some people with schizophrenia become so psychotic and disorganized that they cannot care for their basic needs, such as food, clothing, and shelter. All too often, people with severe mental illnesses such as schizophrenia end up on the streets or in jails, where they rarely receive the kinds of treatment they need. </p> <p>Those close to people with schizophrenia are often unsure of how to respond when patients make statements that seem strange or are clearly false. For the individual with schizophrenia, the bizarre beliefs or hallucinations seem quite real�they are not just &quot;imaginary fantasies.&quot; Instead of �going along with � a person's delusions, family members or friends can tell the person that they do not see things the same way or do not agree with his or her conclusions, while acknowledging that things may appear otherwise to the patient. </p> <p>It may also be useful for those who know the person with schizophrenia well to keep a record of what types of symptoms have appeared, what medications (including dosage) have been taken, and what effects various treatments have had. By knowing what symptoms have been present before, family members may know better what to look for in the future. Families may even be able to identify some &quot;early warning signs&quot; of potential relapses, such as increased withdrawal or changes in sleep patterns, even better and earlier than the patients themselves. Thus, return of psychosis may be detected early and treatment may prevent a full-blown relapse. Also, by knowing which medications have helped and which have caused troublesome side effects in the past, the family can help those treating the patient to find the best treatment more quickly. </p> <p>In addition to involvement in seeking help, family, friends, and peer groups can provide support and encourage the person with schizophrenia to regain his or her abilities. It is important that goals be attainable, since a patient who feels pressured and/or repeatedly criticized by others will probably experience stress that may lead to a worsening of symptoms. Like anyone else, people with schizophrenia need to know when they are doing things right. A positive approach may be helpful and perhaps more effective in the long run than criticism. This advice applies to everyone who interacts with the person. </p> <p align="right"><a href="#top" class="link">Return to top</a> <a href="#top"><img src="../UserMods/Images/arrow_up.gif" alt="Return to top" border="0" /></a> </p> <p class="subcatSubHeader"><a name="5"></a>WHAT IS THE OUTLOOK?</p> <p>The outlook for people with schizophrenia has improved over the last 25 years. Although no totally effective therapy has yet been devised, it is important to remember that many people with the illness improve enough to lead independent, satisfying lives. As we learn more about the causes and treatments of schizophrenia, we should be able to help more patients achieve successful outcomes. </p> <p>Studies that have followed people with schizophrenia for long periods, from the first episode to old age, reveal that a wide range of outcomes is possible. When large groups of patients are studied, certain factors tend to be associated with a better outcome�for example, a pre-illness history of normal social, school, and work adjustment. However, the current state of knowledge does not allow for a sufficiently accurate prediction of long-term outcome. </p> <p>Given the complexity of schizophrenia, the major questions about this disorder�its cause or causes, prevention, and treatment�must be addressed with research. The public should beware of those offering &quot;the cure&quot; for (or &quot;the cause&quot; of) schizophrenia. Such claims can provoke unrealistic expectations that, when unfulfilled, lead to further disappointment. Although progress has been made toward better understanding and treatment of schizophrenia, continued investigation is urgently needed. As the lead Federal agency for research on mental disorders, NIMH conducts and supports a broad spectrum of mental illness research from molecular genetics to large-scale epidemiologic studies of populations. It is thought that this wide-ranging research effort, including basic studies on the brain, will continue to illuminate processes and principles important for understanding the causes of schizophrenia and for developing more effective treatments. </p> <p align="right"><a href="#top" class="link">Return to top</a> <a href="#top"><img src="../UserMods/Images/arrow_up.gif" alt="Return to top" border="0" /></a> </p> <p class="subcatSubHeader">&nbsp;</p> </div> </div> </div> <div class="getHeader"> Schizophrenia </div> <div class="prodList_mainMenuShadow"> <img src="/usermods/menu_separater.gif" width="100%" height="7" /> </div> <div class="prodlistProdDisplay"> <div></div> <div id="ProdListprodDisplayDiv"> <div id="item" class="ProdList_product_display"> <form method="post" action="http://www.healthmegamall.com/cart.asp" name="additem"> <a style="{text-decoration:none;}" onmouseover="onLink('1', 'Div11', 'Span231', 'Span241', 'span251');" onmouseout="offLink('1', 'Div11', 'Span231', 'Span241', 'span251')" href="prodView-Gamma-E-Tocopherol-with-Sesame-Lignans-60-softgels_c581_p847.htm"> <div id="Div11" class="prodListPic"> <img height="202px" width="115px" src="/prodimages/LEF_00759_sm.jpg" alt="SKU: LEF-00759" title="SKU: LEF-00759" border="0" /> </div> <div> <span id="Span231" class="font12grey" style="{text-decoration:none;}">Gamma E Tocopherol with Sesame Lignans,60 softgels...</span> <br /> <span id="Span241" class="font12grey" style="{text-decoration:none;}">LEF-00759</span> <br /> <font class="font12" style="{font-weight:bold;color:#FF9900;text-decoration:none;}">[ Free Shipping* ]</font> <span id="span251" class="font12grey" style="{text-decoration:none;}"><b>$24.00</b></span> </div> </a> <div> <div style="{float:left;}"> <input type="text" name="Quantity" size="1,5" value="1" /> <input type="hidden" name="action" value="additem" /> <input type="hidden" name="idProduct" value="847" /> <input type="hidden" name="idCategory" value="581" /> <input type="hidden" name="idSuperCategory" value="" /> <input type="hidden" name="varTheme" value="2" /> </div> <div> <input type="image" name="add" src="../UserMods/butt_add.gif" /> </div> </div> </form> </div> <div id="item" class="ProdList_product_display"> <form method="post" action="http://www.healthmegamall.com/cart.asp" name="additem"> <a style="{text-decoration:none;}" onmouseover="onLink('1', 'Div12', 'Span232', 'Span242', 'span252');" onmouseout="offLink('1', 'Div12', 'Span232', 'Span242', 'span252')" href="prodView-Potassium-Iodide-130-mg-14-tablets_c581_p316.htm"> <div id="Div12" class="prodListPic"> <img height="202px" width="115px" src="/prodimages/LEF-00577_sm.jpg" alt="SKU: LEF-00577" title="SKU: LEF-00577" border="0" /> </div> <div> <span id="Span232" class="font12grey" style="{text-decoration:none;}">Potassium Iodide, 130 mg, 14 tablets...</span> <br /> <span id="Span242" class="font12grey" style="{text-decoration:none;}">LEF-00577</span> <br /> <font class="font12" style="{font-weight:bold;color:#FF9900;text-decoration:none;}">[ Free Shipping* ]</font> <span id="span252" class="font12grey" style="{text-decoration:none;}"><b>$5.21</b></span> </div> </a> <div> <div style="{float:left;}"> <input type="text" name="Quantity" size="1,5" value="1" /> <input type="hidden" name="action" value="additem" /> <input type="hidden" name="idProduct" value="316" /> <input type="hidden" name="idCategory" value="581" /> <input type="hidden" name="idSuperCategory" value="" /> <input type="hidden" name="varTheme" value="2" /> </div> <div> <input type="image" name="add" src="../UserMods/butt_add.gif" /> </div> </div> </form> </div> <div id="item" class="ProdList_product_display"> <form method="post" action="http://www.healthmegamall.com/cart.asp" name="additem"> <a style="{text-decoration:none;}" onmouseover="onLink('1', 'Div13', 'Span233', 'Span243', 'span253');" onmouseout="offLink('1', 'Div13', 'Span233', 'Span243', 'span253')" href="prodView-Ginkgo-Biloba-Certified-Extract-120-mg-365-caps_c581_p865.htm"> <div id="Div13" class="prodListPic"> <img height="202px" width="115px" src="/prodimages/LE_00778_sm.jpg" alt="SKU: LEF-00778" title="SKU: LEF-00778" border="0" /> </div> <div> <span id="Span233" class="font12grey" style="{text-decoration:none;}">Ginkgo Biloba Certified Extract�, 120 mg, 365 caps...</span> <br /> <span id="Span243" class="font12grey" style="{text-decoration:none;}">LEF-00778</span> <br /> <font class="font12" style="{font-weight:bold;color:#FF9900;text-decoration:none;}">[ Free Shipping* ]</font> <span id="span253" class="font12grey" style="{text-decoration:none;}"><b>$34.50</b></span> </div> </a> <div> <div style="{float:left;}"> <input type="text" name="Quantity" size="1,5" value="1" /> <input type="hidden" name="action" value="additem" /> <input type="hidden" name="idProduct" value="865" /> <input type="hidden" name="idCategory" value="581" /> <input type="hidden" name="idSuperCategory" value="" /> <input type="hidden" name="varTheme" value="2" /> </div> <div> <input type="image" name="add" src="../UserMods/butt_add.gif" /> </div> </div> </form> </div> <div id="item" class="ProdList_product_display"> <form method="post" action="http://www.healthmegamall.com/cart.asp" name="additem"> <a style="{text-decoration:none;}" onmouseover="onLink('1', 'Div14', 'Span234', 'Span244', 'span254');" onmouseout="offLink('1', 'Div14', 'Span234', 'Span244', 'span254')" href="prodView-Methylcobalamin-5-mg-60-sublingual-lozenges_c581_p290.htm"> <div id="Div14" class="prodListPic"> <img height="202px" width="115px" src="/prodimages/LE_00537_sm.jpg" alt="SKU: LEF-00537" title="SKU: LEF-00537" border="0" /> </div> <div> <span id="Span234" class="font12grey" style="{text-decoration:none;}">Methylcobalamin, 5 mg 60 sublingual lozenges...</span> <br /> <span id="Span244" class="font12grey" style="{text-decoration:none;}">LEF-00537</span> <br /> <font class="font12" style="{font-weight:bold;color:#FF9900;text-decoration:none;}">[ Free Shipping* ]</font> <span id="span254" class="font12grey" style="{text-decoration:none;}"><b>$24.00</b></span> </div> </a> <div> <div style="{float:left;}"> <input type="text" name="Quantity" size="1,5" value="1" /> <input type="hidden" name="action" value="additem" /> <input type="hidden" name="idProduct" value="290" /> <input type="hidden" name="idCategory" value="581" /> <input type="hidden" name="idSuperCategory" value="" /> <input type="hidden" name="varTheme" value="2" /> </div> <div> <input type="image" name="add" src="../UserMods/butt_add.gif" /> </div> </div> </form> </div> </div> <div id="ProdListprodDisplayDiv"> <div id="item" class="ProdList_product_display"> <form method="post" action="http://www.healthmegamall.com/cart.asp" name="additem"> <a style="{text-decoration:none;}" onmouseover="onLink('1', 'Div15', 'Span235', 'Span245', 'span255');" onmouseout="offLink('1', 'Div15', 'Span235', 'Span245', 'span255')" href="prodView-SAMe-S-Adenosyl-Methionine-200-mg-50-tablets_c581_p263.htm"> <div id="Div15" class="prodListPic"> <img height="202px" width="115px" src="/prodimages/LE_00453_sm.jpg" alt="SKU: LEF-00453" title="SKU: LEF-00453" border="0" /> </div> <div> <span id="Span235" class="font12grey" style="{text-decoration:none;}">SAMe S-Adenosyl-Methionine, 200 mg 50 tablets...</span> <br /> <span id="Span245" class="font12grey" style="{text-decoration:none;}">LEF-00453</span> <br /> <font class="font12" style="{font-weight:bold;color:#FF9900;text-decoration:none;}">[ Free Shipping* ]</font> <span id="span255" class="font12grey" style="{text-decoration:none;}"><b>$27.00</b></span> </div> </a> <div> <div style="{float:left;}"> <input type="text" name="Quantity" size="1,5" value="1" /> <input type="hidden" name="action" value="additem" /> <input type="hidden" name="idProduct" value="263" /> <input type="hidden" name="idCategory" value="581" /> <input type="hidden" name="idSuperCategory" value="" /> <input type="hidden" name="varTheme" value="2" /> </div> <div> <input type="image" name="add" src="../UserMods/butt_add.gif" /> </div> </div> </form> </div> <div id="item" class="ProdList_product_display"> <form method="post" action="http://www.healthmegamall.com/cart.asp" name="additem"> <a style="{text-decoration:none;}" onmouseover="onLink('1', 'Div16', 'Span236', 'Span246', 'span256');" onmouseout="offLink('1', 'Div16', 'Span236', 'Span246', 'span256')" href="prodView-Phosphatidylserine-PS-100-mg-100-capsules_c581_p210.htm"> <div id="Div16" class="prodListPic"> <img height="202px" width="115px" src="/prodimages/LE_00368_sm.jpg" alt="SKU: LEF-00368" title="SKU: LEF-00368" border="0" /> </div> <div> <span id="Span236" class="font12grey" style="{text-decoration:none;}">Phosphatidylserine (PS), 100 mg 100 capsules...</span> <br /> <span id="Span246" class="font12grey" style="{text-decoration:none;}">LEF-00368</span> <br /> <font class="font12" style="{font-weight:bold;color:#FF9900;text-decoration:none;}">[ Free Shipping* ]</font> <span id="span256" class="font12grey" style="{text-decoration:none;}"><b>$40.50</b></span> </div> </a> <div> <div style="{float:left;}"> <input type="text" name="Quantity" size="1,5" value="1" /> <input type="hidden" name="action" value="additem" /> <input type="hidden" name="idProduct" value="210" /> <input type="hidden" name="idCategory" value="581" /> <input type="hidden" name="idSuperCategory" value="" /> <input type="hidden" name="varTheme" value="2" /> </div> <div> <input type="image" name="add" src="../UserMods/butt_add.gif" /> </div> </div> </form> </div> <div id="item" class="ProdList_product_display"> <form method="post" action="http://www.healthmegamall.com/cart.asp" name="additem"> <a style="{text-decoration:none;}" onmouseover="onLink('1', 'Div17', 'Span237', 'Span247', 'span257');" onmouseout="offLink('1', 'Div17', 'Span237', 'Span247', 'span257')" href="prodView-TMG-Trimethylglycine-500-mg-180-tablets_c581_p206.htm"> <div id="Div17" class="prodListPic"> <img height="202px" width="115px" src="/prodimages/LE_00359_sm.jpg" alt="SKU: LEF-00359" title="SKU: LEF-00359" border="0" /> </div> <div> <span id="Span237" class="font12grey" style="{text-decoration:none;}">TMG - Trimethylglycine, 500 mg, 180 tablets...</span> <br /> <span id="Span247" class="font12grey" style="{text-decoration:none;}">LEF-00359</span> <br /> <font class="font12" style="{font-weight:bold;color:#FF9900;text-decoration:none;}">[ Free Shipping* ]</font> <span id="span257" class="font12grey" style="{text-decoration:none;}"><b>$13.50</b></span> </div> </a> <div> <div style="{float:left;}"> <input type="text" name="Quantity" size="1,5" value="1" /> <input type="hidden" name="action" value="additem" /> <input type="hidden" name="idProduct" value="206" /> <input type="hidden" name="idCategory" value="581" /> <input type="hidden" name="idSuperCategory" value="" /> <input type="hidden" name="varTheme" value="2" /> </div> <div> <input type="image" name="add" src="../UserMods/butt_add.gif" /> </div> </div> </form> </div> <div id="item" class="ProdList_product_display"> <form method="post" action="http://www.healthmegamall.com/cart.asp" name="additem"> <a style="{text-decoration:none;}" onmouseover="onLink('1', 'Div18', 'Span238', 'Span248', 'span258');" onmouseout="offLink('1', 'Div18', 'Span238', 'Span248', 'span258')" href="prodView-Folic-Acid-B12-200-Caps_c581_p200.htm"> <div id="Div18" class="prodListPic"> <img height="202px" width="115px" src="/prodimages/LE_00347_sm.jpg" alt="SKU: LEF-00347" title="SKU: LEF-00347" border="0" /> </div> <div> <span id="Span238" class="font12grey" style="{text-decoration:none;}">Folic Acid + B12, 200 Caps...</span> <br /> <span id="Span248" class="font12grey" style="{text-decoration:none;}">LEF-00347</span> <br /> <font class="font12" style="{font-weight:bold;color:#FF9900;text-decoration:none;}">[ Free Shipping* ]</font> <span id="span258" class="font12grey" style="{text-decoration:none;}"><b>$7.88</b></span> </div> </a> <div> <div style="{float:left;}"> <input type="text" name="Quantity" size="1,5" value="1" /> <input type="hidden" name="action" value="additem" /> <input type="hidden" name="idProduct" value="200" /> <input type="hidden" name="idCategory" value="581" /> <input type="hidden" name="idSuperCategory" value="" /> <input type="hidden" name="varTheme" value="2" /> </div> <div> <input type="image" name="add" src="../UserMods/butt_add.gif" /> </div> </div> </form> </div> </div> </div><style type="text/css">div.navsection {height:36px;width:574px;border:1px solid #CFE9F5;position:relative;top:20px;float:left;}div.navsection .range {border-top:1px solid #CFE9F5;border-bottom:1px solid #CFE9F5;width:178px;height:20px;float:left;padding-left:15px;padding-top:15px;vertical-align:middle;background-color:#CFE9F5;} div.navsection .navPaging {border-top:1px solid #CFE9F5;border-bottom:1px solid #CFE9F5;width:205px;height:25px;float:left;padding-top:10px;vertical-align:middle;background-color:#CFE9F5;}div.navsection .navPaging a:link {color:#333399;}div.navsection .pageSort {border-top:1px solid #CFE9F5;border-bottom:1px solid #CFE9F5;width:170px;height:22px;text-align:center;float:left;padding-top:13px;vertical-align:middle;background-color:#CFE9F5;}</style> <!--[if gte IE 4 ]><style type="text/css">div.navsection {position:relative;top:18px;background-color:#ffffff;height:30px;width:570px;border:0px solid #ffffff;}div.navsection div {float:left;}div.navsection .range {border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;float:left;background-color:#ffffff;height:100%;width:35%;vertical-align:middle;} div.navsection .navPaging {border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;text-align:center;float:left;background-color:#ffffff;height:100%;width:34%;}div.navsection .navPaging a:link {color:#333399;}div.navsection .pageSort {border-top:1px solid #ffffff;border-bottom:1px solid #ffffff;text-align:right;vertical-align:middle;float:none;background-color:#ffffff;padding-top:12px;height:100%;width:100%;position:relative;right:7px;padding-right:7px;}div.navsection div {background-image: url('usermods/images/pagingBackground.gif');background-repeat: repeat-x}</style><![endif]--> <div> <div class="navsection"> <div class="range"> <span style="{vertical-align:middle;text-align:center;}"><font class="font10">Showing 1 - 8 of 13 Results </font></span> </div> <div class="navPaging"> <span style="{vertical-align:middle;text-align:center;position:relative;top:5px;}"><font class="font10"> ? Previous | Page: 1 <a id="pageNav_link" href="prodList.asp?idCategory=581&amp;idsupercategory=2&amp;pageid=2&amp;sortby=default">2</a>&nbsp;</font></span> </div> <div class="pageSort"> <font class="font10"> <form name="sortForm"> Sort : <select onchange="location.href=this.options[selectedIndex].value" name="sortForm" style="FONT-SIZE: 10pt"> <option value="prodList.asp?idCategory=581&amp;&amp;sortField=default">Default</option> <option value="prodList.asp?idCategory=581&amp;&amp;sortField=description">Item Description</option> <option value="prodList.asp?idCategory=581&amp;&amp;sortField=sku">SKU</option> </select> </form> </font> </div> </div> <div> <br /> <script type="text/javascript"> if (navigator.appCodeName == "Mozilla") { document.write("<br><br><br><br>"); } </script> </div> </div></td> </tr> <!-- Footer --> <tr bgcolor="#FFFFFF"> <td colspan="4"> <!-- Footer--><br /> <div id="footer"> <table width="800" cellpadding="0" cellspacing="0" border="0" style="padding-bottom:5px;"> <tbody> <tr align="center"> <td width="260" class="footertopcol" valign="top"> <div class="linkarea"> <span class="head">YOUR ORDER</span> <table width="100%" cellpadding="0" cellspacing="0" border="0"> <tbody> <tr> <td valign="top"> <ul> <li><a href="https://www.healthmegamall.com/05_Gateway.asp?action=logon&amp;vartheme=2">Manage Your Order</a></li> <li><a href="support.asp?support=shipping">Shipping &amp; Delivery</a></li> </ul> </td> <td valign="top"> <ul> <li><a href="support.asp?support=returns">Returns &amp; Exchanges</a></li> <li><a href="support.asp?support=payment">Payment Options</a></li> </ul> </td> </tr> </tbody> </table> </div> </td> <td width="300" class="footertopcol" valign="top"> <div class="linkarea"> <span class="head">SHOPPING SERVICES</span> <table width="100%" cellpadding="0" cellspacing="0" border="0"> <tbody> <tr> <td valign="top"> <ul> <li><a href="http://www.healthmegamall.com/guarantee.asp">Big 8 Guarantee</a></li> <li><a href="support.asp?support=disc">Discounts &amp; Guarantees</a></li> </ul> </td> <td valign="top"> <ul> <li><a href="support.asp?support=disc#lowest_price_guarantee">Lowest Price Guarantee</a></li> </ul> </td> </tr> </tbody> </table> </div> </td> <td width="220" class="footertopcol" valign="top"> &nbsp; </td> </tr> </tbody> </table> </div> <div class="footer"> Copyright &copy; 2003-11 <a href="" class="link">HealthMegaMall LLC.</a> <br /> <a href="http://www.healthmegamall.com/legaldisc.asp" class="link"><u>Legal Disclaimer</u></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href="http://www.healthmegamall.com/privacy.asp" class="link"><u>Privacy Policy</u></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href="http://www.healthmegamall.com/termspage.asp" class="link"><u>Terms and Conditions</u></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href="http://www.healthmegamall.com/sitemap.asp" class="link"><u>Site Map</u></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href="http://www.healthmegamall.com/link.htm" class="link"><u>Featured Links</u></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href="http://www.healthmegamall.com/contactUs.asp" class="link"><u>Contact Us</u></a> <br /> <br /> The statements on this website have not been evaluated by the FDA or Health Canada. <br /> Content and products are not intended to diagnose, treat, cure or prevent any disease. Please consult your Doctor. <br /> <br /> HealthMegaMall.com was made possible by limited financial assistance from <a href="http://www.healthmegamall.com/coinfo.asp#HRDCFunding" class="link">the Government of Canada</a> and by limitless grace of God. &quot;From the fullness of His grace we have all received one blessing after another.&quot; <br /> <br /> <br /> </div> </td> </tr> </tbody> </table><script language="JavaScript" type="text/javascript">COT("https://www.healthmegamall.com/UserMods/Images/secure_site.gif", "SC2", "none");</script></td> </tr> </tbody> </table> </div> </body> </html>
254	faceted	barrett's esophagus	Find the causes and risk factors of Barrett's Esophagus.	clueweb12-0311wb-03-12671	3	<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"> <!--DVID=00000005--> <html> <head> <meta charset="ISO-8859-1" /> <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" /> <meta name="ROBOTS" content="NOODP" /> <meta name="pd" content="Monday, 14-Jun-2010 21:03:40 UTC" /> <link rel="icon" href="http://0.tqn.com/f/a08.ico" /> <link rel="search" type="application/opensearchdescription+xml" href="http://0.tqn.com/4/o/os.xml" title="About.com" /> <script>zGR='ca-about-health_js';var ziRfw=0;zobt=" Heartburn / GERD Ads";zOBT=" Ads";function zIpSS(u){zpu(0,u,280,375,"ssWin")}function zIlb(l,t,f){zT(l,'18/1Pp/wX')}function rsi(i,h,w){if(gEI(i)){if(h)gEI(i).height=h;if(w)gEI(i).width=w}}</script> <link rel="stylesheet" href="http://0.tqn.com/0/dc/s109.css" media="all" /> <!--[if lt IE 8]><link rel="stylesheet" href="http://0.tqn.com/8/dc/rdie.css" type="text/css" media="all"><![endif]--> <meta http-equiv="pics-Label" content="(pics-1.1 &quot;http://www.icra.org/pics/vocabularyv03/&quot; l gen true for &quot;http://heartburn.about.com&quot; r (n 0 s 0 v 0 l 0 oa 0 ob 0 oc 0 od 0 oe 0 of 0 og 0 oh 0 c 0) gen true for &quot;http://heartburn.about.com&quot; r (n 0 s 0 v 0 l 0 oa 0 ob 0 oc 0 od 0 oe 0 of 0 og 0 oh 0 c 0))" /> <meta property="og:title" content="What Are the Risk Factors of Developing Cancer if You Have Barrett's Esophagus?" /> <meta property="og:type" content="article" /> <meta property="og:url" content="http://heartburn.about.com/cs/barrettsesophagus/f/cancer_risk.htm" /> <meta property="og:site_name" content="About.com Heartburn / GERD" /> <meta property="fb:app_id" content="121030274606741" /> <script>zWASL=1;var zSBT='Ads';zGRH=1</script> <style>#abm #rnCt li{list-style-type:none;margin-bottom:0.5em;}#rnCt .rnDt .r,#rnCt .rnDt .b{color:#707070;font-weight:bold;}#rnCt .rnDt .b{margin-left:12px;}#tt26 #comments dt .date{margin:1px 10px 0 0;}</style> <title>Barrett's Esophagus - What Are the Risk Factors of Developing Cancer if You Have Barrett's Esophagus</title> <meta name="keywords" content="gastroesophageal reflux disease gerd Barrett's esophagus acid reflux Barrett's esophagus acid reflux barretts esophagus irritate lining of esophagus complications Barrett's esophagus" /> <meta name="description" content="Acid reflux that is severe or occurs frequently over a long period of time it can be harmful; the constant acid reflux will irritate the lining of the esophagus, and complications can occur. One of these complication is Barrett's esophagus. What are the risk factors for developing cancer if you have Barrett's esophagus?" /> </head> <body id="tt12" class="gt2 health nd"> <script language="JavaScript"><!--zGOW=0;xd=0;zap="";zAth='9143';zAthG='9143';zTt='12';zir='';zBTS=1;zBT=0;zCT=0;zSt='';zGz=''ch='health';gs='heartburn';xg="Heartburn / GERD";zcs=''zFDT='0'zFST='0'zOr='C2OFiK2620kA150y';zTbO=zRQO=1;zp0=zp1=zp2=zp3=zfs=0;zDc=1;zSm=zSu=zhc=zpb=zgs=zdn='';zFS='C2O10C20110C00101';zFD='C2O10C20110C00101'zDO=zis=1;zpid=zi=zRf=ztp=zpo=0;zdx=20;zfx=100;zJs=0;zi=1;zz=';336280=2-1-1299;72890=2-1-1299;336155=2-1-12-1;93048=2-1-12-1;30050=2-1-12-1';zx='100';zde=15;zdp=1440;zds=1440;zfp=0;zfs=66;zfd=100;zdd=20;zaX=new Array(11, new Array(100,1051,8192,5,'342,300'),7, new Array(100,284,8196,13,'342,400'));zDc=1;;zDO=1;;zhc='';;zGTH=1;zGo=0;zG=17;zTac=2;zDot=0;zObT="Heartburn";zRad=5;var tp=" primedia_"+(zBT?"":"non_")+"site_targeting";if(!this.zGCID)zGCID=tpelse zGCID+=tp;if(zBT>0){zOBR=1}if(!this.uy)uy='about.com';if(typeof document.domain!="undefined")document.domain=uy;//--></script> <script language="JavaScript" src="http://0.tqn.com/0/js/cj017x14t421p9.js?rdv=j25"></script> <script>function zob(p){if(!this.zOfs)return;var a=zOfs,t,i=0,l=a.length;if(l){w('<div id="oF"><b>'+(this.zobt?zobt:xg+' Ads')+'</b><ul>');while((i<l)&&i<zRad){t=a[i++].line1;w('<li><a href="/z/js/o'+(p?p:'')+'.htm?k='+zUriS(t.toLowerCase())+(this.zobr?zobr:'')+'&d='+zUriS(t)+'&r='+zUriS(zWl)+'" target="_'+(this.zOBNW?'new'+zr(9999):'top')+'">'+t+'</a></li>');}w('</ul></div>')}}function rb600(){if(gEI('bb'))gEI('bb').height=600}</script> <script language="JavaScript">zJs=10</script> <script language="JavaScript1.1">zJs=11</script> <script language="JavaScript1.2">zJs=12</script> <script language="JavaScript1.3">zJs=13</script> <script>zc(5,'jsc',zJs,9999999,'')</script> <script>zDO=0</script> <script language="JavaScript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script> <script>z930=zpreC(930,48);z160=zpreC(160,600);z336=zpreC(336,280);z728=zpreC(728,90);z155=zpreC(336,155);zItw=160</script> <div id="abw"> <div id="abh"> <ol class="ct"> <li class="h"><a href="http://www.about.com/" zt="18/1Yd/Zz">About.com</a></li> <li><a href="http://www.about.com/health/" zt="18/1Yd/Zz">Health</a></li> <li><a href="/" zt="18/1Yd/Zz">Heartburn / GERD</a></li> </ol> <div id="adL"> <script>if(z930==0 && z728>0){adunit('','',uy,ch,gs,728,90,'1','lb',1)}</script> <noscript> <a href="http://ad.doubleclick.net/jump/abt.health/health_heartburn;kw=;site=heartburn;chan=health;pos=lb;sz=728x90;ord=1C2OFiK2620kA150y" target="_new"><img src="http://ad.doubleclick.net/ad/abt.health/health_heartburn;kw=;site=heartburn;chan=health;pos=lb;sz=728x90;ord=1C2OFiK2620kA150y" /></a> </noscript> </div> <div class="ma"> <div class="lg"> <a href="http://www.about.com/" zt="18/1Yb/Zv"><img src="http://0.tqn.com/f/lg/a148.png" alt="About.com" /></a> </div> <div class="h2"> <a href="/" zt="18/1Yc/Zx" title="Heartburn / GERD">Heartburn / GERD</a> </div> </div> <form class="gs" method="get" action="http://heartburn.about.com/sitesearch.htm" target="_top"> <fieldset> <input id="sv" name="q" value="" validate="required" alert="Please enter something to search for!" /> <input type="hidden" name="SUName" value="heartburn" /> <button class="btn" type="submit">Search</button> </fieldset> </form> <ul id="up"> <li class="h"><a href="http://heartburn.about.com/" zt="18/1ZZ/aZ"><span>Heartburn / GERD</span></a></li> <li><a href="http://heartburn.about.com/od/symptomscauses/u/symptomsdiagnosis.htm" zt="18/1ZZ/11o">Symptoms / Diagnosis</a></li> <li><a href="http://heartburn.about.com/od/preventiontreatment/u/treatment.htm" zt="18/1ZZ/11q">Get Relief</a></li> <li><a href="http://heartburn.about.com/od/dailylife/u/coping.htm" zt="18/1ZZ/11r">Burn-Free Diet</a></li> <li class="last "></li> <script>if(typeof zp != 'undefined'){if(zp[8].d){if((zp[8].d==1089||zp[8].d==1090||zp[8].d==1091||zp[8].d==1092||zp[8].d==1097||zp[8].d==1099)&&(zp[8].u==3||zp[8].u==8)){zp[8].u=10;zp[8].w=147;zp[8].h=30}if((zp[8].d==1089||zp[8].d==1090||zp[8].d==1091||zp[8].d==1092||zp[8].d==1097||zp[8].d==1099)&&(zp[8].u==4||zp[8].u==9)){zp[8].u=11;zp[8].w=200;zp[8].h=30;if(zp[8].d==1097)zp[8].d=1099}if((zp[8].d==1093 && zp[8].u==1)){zp[8].u=3;zp[8].w=175;zp[8].h=30}if((zp[8].d==1101 && zp[8].u==1)){zp[8].u=2;zp[8].w=160;zp[8].h=30}w('<li id="st">');Dsp(zp[8],'ip');w('</li>')}}</script> </ul> <ul id="pa"> <li id="ea"><a href="/gi/pages/shareurl.htm?PG=http%3a%2f%2fheartburn%2eabout%2ecom%2fcs%2fbarrettsesophagus%2ff%2fcancer%5frisk%2ehtm&amp;zItl=Barrett%27s%20Esophagus%20and%20Cancer" zt="18/1Z0/[3">Share</a></li> <li id="pra"><script>w(x2+zWl+'?p=1" zT="18/1[N" rel="nofollow">Print</a>')</script></li> </ul> </div> <div id="abb"> <script type="text/javascript">if(z930>0){adunit('','',uy,ch,gs,930,48,'1','s',1)}</script> <div id="com"> <form class="nl" name="subscription" action="http://clk.about.com/" method="get" alert="Please enter a valid email address."> <label for="nTxt">Free <strong>Heartburn / GERD Newsletter!</strong></label> <input type="hidden" name="zi" value="18/1a9" /> <input type="hidden" name="surl" value="http://heartburn.about.com/gi/pages/mmail.htm" /> <input type="hidden" name="eurl" value="http://heartburn.about.com/gi/pages/mmail.htm" /> <input type="hidden" name="cmd_heartburn" value="+:gs::heartburn" /> <input type="hidden" name="gs" value="1" /> <input type="hidden" name="sdn" value="heartburn" /> <input type="hidden" name="tt" value="12" /> <input type="hidden" name="bts" value="1" /> <span><input id="nTxt" type="email" name="email" placeholder="Enter email address" validate="email" /></span> <button type="submit" name="newsub">Sign Up</button> </form> <p><a href="http://forums.about.com/n/pfx/forum.aspx?nav=messages&amp;webtag=ab-heartburn" zt="18/1Z1"><b>Discuss</b> in my forum</a></p> </div> <!--gc--> <div id="abt"> <h1><span class="fn">What Are the Risk Factors of Developing Cancer if You Have Barrett's Esophagus?</span></h1> <p id="by">By&nbsp;<a href="/bio/Sharon-Gillson-9143.htm" rel="author">Sharon Gillson</a>,&nbsp;About.com Guide</p> <p id="date">Updated September 18, 2008</p> <p id="hr">About.com Health's Disease and Condition content is reviewed by the <a href="http://www.about.com/health/review.htm">Medical Review Board</a></p> </div> <div class="tr"> <div class="h4"> See More About: </div> <ul> <li><a href="/lr/symptoms_of_barrett_s_esophagus/1245079/1/" zt="18/1Ys/[1" rel="nofollow">symptoms of barrett's esophagus</a></li> <li><a href="/lr/causes_of_barrett_s_esophagus/1245079/2/" zt="18/1Ys/[1" rel="nofollow">causes of barrett's esophagus</a></li> <li><a href="/lr/esophageal_cancer/1245079/3/" zt="18/1Ys/[1" rel="nofollow">esophageal cancer</a></li> <li><a href="/lr/symptoms_of_esophageal_cancer/1245079/4/" zt="18/1Ys/[1" rel="nofollow">symptoms of esophageal cancer</a></li> </ul> </div> <div id="abm" class="clear"> <div id="abc"> <div id="articlebody"> <div> <b>Question: </b>What Are the Risk Factors of Developing Cancer if You Have Barrett's Esophagus? </div> <div> <b>Answer: </b>GERD - Chronic heartburn (GERD) is the biggest risk factor. The cancer risk increases in proportion to the length of time you've suffered from chronic heartburn, and how often you get acid reflux. <p><b>Other factors that increase the risk of acid reflux:</b></p> <ul> <li>Obesity - This is a significant risk factor for esophageal adenocarcinoma. One study shwed that it isn't how overweight you are in general that increases the risk, but the amount of fat around the abdominal area, between the chest and the hips. <p></p></li> <li>Diet - A diet high in fatty foods and low in fruits and vegetables has been associated with the development of esophageal adenocarcinoma. <p></p></li> <li>Smoking - Cigarette smoking has been shown to significantly increase the risk for the development of esophageal adenocarcinoma.</li> </ul> </div> <!--/gc--> </div> <div id="coda"> <div id="resources"> <div class="lkbx"> <div class="n5"> Suggested Reading </div> <ul> <li><a href="http://heartburn.about.com/cs/barrettsesophagus/" zt="18/1Pp">Barrett's Esophagus Informational Links</a></li> <li><a href="http://heartburn.about.com/cs/gerdacidreflux/" zt="18/1Pp">Acid Reflux Disease Informational Links</a></li> </ul> </div> <div id="rel"> <div class="h5"> Related Articles </div> <ul> <li><a href="http://heartburn.about.com/od/acidrefluxcomplications/a/prevent_ecancer.htm" zt="18/1YL/Zn">Preventing Esophageal Cancer - Ways for Preventing Esophageal Cancer</a></li> <li><a href="http://heartburn.about.com/od/esophagealcance1/a/esophcancerrisk.htm" zt="18/1YL/Zn">Risk Factors for Esophageal Cancer - Lowering Your Risk Factors for Esophag...</a></li> <li><a href="http://cancer.about.com/od/esophagealcancer/a/preventionesoph.htm" zt="18/1YL/Zn">How to Prevent Esophageal Cancer</a></li> <li><a href="http://cancer.about.com/od/testicularcancer/a/testiccancrrisk.htm" zt="18/1YL/Zn">Testicular Cancer - Risk Factors for Testicular Cancer</a></li> <li><a href="http://cancer.about.com/od/penilecancer/a/penileriskfact.htm" zt="18/1YL/Zn">Penile Cancer Causes</a></li> </ul> </div> </div> <div id="gi"> <div class="cr"> <div class="img"> <a href="/bio/Sharon-Gillson-9143.htm" zt="18/1YK"><img src="http://0.tqn.com/d/g/9143.jpg" alt="Sharon Gillson" /></a> </div> <p><a href="/bio/Sharon-Gillson-9143.htm" zt="18/1YO">Sharon Gillson</a><br />Heartburn / GERD Guide</p> <ul> <li><a href="/gi/pages/stay.htm" zt="18/1YS"><b>Sign up</b> for My Newsletter</a></li> </ul> <ul class="so"> <li><a href="/b/" zt="18/1YM">Headlines</a></li> <li><a href="http://forums.about.com/n/pfx/forum.aspx?nav=messages&amp;webtag=ab-heartburn" zt="18/1YN">Forum</a></li> </ul> </div> </div> </div> </div> <div id="aba"> <script type="text/javascript">if(z336>0){w('<div id="adB"><p>Advertisement</p>');adunit('','','about.com',ch,gs,336,280,'1','bb',3);w('</div>')}if(z155>0){w('<div id="adP"><p>Advertisement</p>');adunit('','','about.com',ch,gs,336,155,'1','ps',4);w('</div>')}</script> <script>zob();</script> </div> <script>if(zSbL<1)zSbL=3;zSB(2);zSbL=0</script> </div> <div id="rs"> <span id="n5">Related Searches</span> <a href="http://search.about.com/r.htm?q=cancer risk increases" zt="18/1lu">cancer risk increases</a> <a href="http://search.about.com/r.htm?q=chronic heartburn" zt="18/1lu">chronic heartburn</a> <a href="http://search.about.com/r.htm?q=fruits and vegetables" zt="18/1lu">fruits and vegetables</a> <a href="http://search.about.com/r.htm?q=cigarette smoking" zt="18/1lu">cigarette smoking</a> <a href="http://search.about.com/r.htm?q=fatty foods" zt="18/1lu">fatty foods</a> <a href="http://search.about.com/r.htm?q=risk factor" zt="18/1lu">risk factor</a> </div> <div id="abf"> <div id="browse" class="pane clear"> <div class="h3"> Explore Heartburn / GERD </div> <div id="bc1"> <div class="h4"> Must Reads </div> <ul> <li><a href="/cs/notdiagnosedyet/a/050503.htm" zt="18/1fG/1">What is Heartburn?</a></li> <li><a href="/cs/heartburn101/a/hrtbrn_symptoms.htm" zt="18/1fG/2">Symptoms of Heartburn</a></li> <li><a href="/od/diagnosingheartburn/qt/diagnostictests.htm" zt="18/1fG/3">Diagnosis of Heartburn</a></li> <li><a href="/od/treatment/qt/treatinghrtburn.htm" zt="18/1fG/4">Treatment of Heartburn</a></li> <li><a href="http://heartburn.about.com/od/whatcausesheartburn/a/hrtburn_causes.htm" zt="18/1fG/5">What Causes Heartburn</a></li> </ul> <div class="h4"> Most Popular </div> <ul> <li><a href="http://heartburn.about.com/cs/dietfood/a/heartburnfoods1.htm" zt="18/yV/O3">Acid Reflux Diet - Safe Foods</a></li> <li><a href="http://heartburn.about.com/library/quizzes/bl_infantrefluxquiz.htm" zt="18/yV/O3">Infant Reflux Screening Quiz</a></li> <li><a href="http://heartburn.about.com/cs/dietfood/a/heartburnfoods3.htm" zt="18/yV/O3">Foods You Should Avoid</a></li> <li><a href="http://heartburn.about.com/cs/dietfood/a/heartburnfoods2.htm" zt="18/yV/O3">Foods to Eat With Discretion</a></li> <li><a href="http://heartburn.about.com/cs/causes/a/heartburncauses.htm" zt="18/yV/O3">Frequent Causes of Heartburn</a></li> </ul> </div> <div id="bc2"> <div class="tr"> <div class="h4"> See More About: </div> <ul> <li><a href="/lr/symptoms_of_barrett_s_esophagus/1245079/1/" zt="18/1gH" rel="nofollow">symptoms of barrett's esophagus</a></li> <li><a href="/lr/causes_of_barrett_s_esophagus/1245079/2/" zt="18/1gH" rel="nofollow">causes of barrett's esophagus</a></li> <li><a href="/lr/esophageal_cancer/1245079/3/" zt="18/1gH" rel="nofollow">esophageal cancer</a></li> <li><a href="/lr/symptoms_of_esophageal_cancer/1245079/4/" zt="18/1gH" rel="nofollow">symptoms of esophageal cancer</a></li> </ul> </div> <script>splitList(getElementsByClassName('tr',gEI('bc2'))[0].getElementsByTagName('ul')[0]);</script> <div class="h4"> By Category </div> <ul id="bcl"> <li><a href="/od/gerdacidrefluxdisease/Gastroesophageal_Reflux_Disease.htm" zt="18/1hZ/1">GERD</a></li> <li><a href="/od/understandingheartburn/Heartburn_Understanding_Heartburn_Acid_Reflux.htm" zt="18/1hZ/2">Heartburn</a></li> <li><a href="/od/hiatalhern2/Hiatal_Hernia.htm" zt="18/1hZ/3">Hiatal Hernia</a></li> <li><a href="/od/pepticulcers/Ulcers.htm" zt="18/1hZ/4">Ulcers</a></li> <li><a href="/od/complicationsofheartburn/Complications_of_Chronic_Heartburn.htm" zt="18/1hZ/5">Complications of Heartburn</a></li> <li><a href="/od/otherdigestivedisorder1/Other_Digestive_Disorders.htm" zt="18/1hZ/6">Other Digestive Disorders</a></li> <li><a href="/od/goodfoodsbadfoods/Good_Foods_Bad_Foods_For_Heartburn_Sufferers_Acid_Reflux_Diet.htm" zt="18/1hZ/7">Good Foods / Bad Foods</a></li> <li><a href="/od/symptomscauses/Symptoms_and_Causes_of_Chronic_Heartburn.htm" zt="18/1hZ/8">Symptoms / Causes</a></li> <li><a href="/od/preventiontreatment/Prevention_and_Treatment.htm" zt="18/1hZ/9">Prevention / Treatment</a></li> <li><a href="/od/medsremedies/Medications_and_Remedies.htm" zt="18/1hZ/10">Meds / Remedies</a></li> <li><a href="/od/dailylife/Daily_Life.htm" zt="18/1hZ/11">Daily Life</a></li> <li><a href="/od/cancer/Cancer_Digestive_System.htm" zt="18/1hZ/12">Cancer</a></li> <li><a href="/od/quizzesfaqs/Screening_Quizzes_Test_Your_Knowledge_FAQs.htm" zt="18/1hZ/13">Screening Quizzes / FAQs</a></li> <li><a href="/od/glossary/Glossary_of_HeartburnRelated_Terms.htm" zt="18/1hZ/14">Glossary</a></li> <li><a href="/od/personalstories/Personal_Stories.htm" zt="18/1hZ/15">Personal Stories</a></li> </ul> </div> </div> <script>splitList(gEI('bcl'));</script> <script>zau(256,'341px','230px','fp','http://z.about.com/6/ip/284/29.htm?s=heartburn','','');</script> <div class="ma"> <div class="lg"> <a href="http://www.about.com/" zt="18/1Yb/Zv"><img src="http://0.tqn.com/f/lg/a148.png" alt="About.com" /></a> </div> <div class="h2"> <a href="/" zt="18/1Yc/Zx" title="Heartburn / GERD">Heartburn / GERD</a> </div> </div> <ol class="ct"> <li class="h"><a href="http://www.about.com/" zt="18/1Yd/Zz">About.com</a></li> <li><a href="http://www.about.com/health/" zt="18/1Yd/Zz">Health</a></li> <li><a href="/" zt="18/1Yd/Zz">Heartburn / GERD</a></li> </ol> <div id="lks" class="hl"> <ul> <li class="f"><a href="/popular.htm" zt="18/1YY">Most Popular</a></li> <li><a href="/updated.htm" zt="18/1]c">Latest Articles</a></li> <li class="rss"><a href="/gi/pages/stay.htm#rs" zt="18/1YZ/Zt">RSS</a></li> </ul> </div> </div> </div> <div id="abi" class="hl"> <div id="lftr"> <div id="mf"> <div class="h6"> Also from About.com: </div> <ul> <li class="f"><a href="http://caloriecount.about.com/" zt="18/1]2/c[">Calorie Count - Nutrition Database</a></li> </ul> </div> <ul id="si"> <li class="f"><a href="http://www.advertiseonabout.com/" zt="18/1YX/Zr" rel="nofollow">Advertise on About.com</a></li> <li><a href="http://www.advertiseonabout.com/about-us/" zt="18/1YX/Zr" rel="nofollow">Our Story</a></li> <li><a href="http://www.advertiseonabout.com/category/press-releases/" zt="18/1YX/Zr" rel="nofollow">News &amp; Events</a></li> <li><a href="http://jobs.about.com/" zt="18/1YX/Zr" rel="nofollow">Work at About</a></li> <li><a href="http://spiderbites.about.com/sitemap.htm" zt="18/1YX/Zr">SiteMap</a></li> <li><a href="http://azlist.about.com/a.htm" zt="18/1]]">All Topics</a></li> <li><a href="http://www.about.com/gi/pages/printrequests.html" zt="18/1YX/Zr" rel="nofollow">Reprints</a></li> <li><a href="http://www.about.com/gi/pages/hc.htm" zt="18/1YX/Zr" rel="nofollow">Help</a></li> </ul> <ul id="li"> <li class="f"><a href="http://beaguide.about.com/" zt="18/1YX/Zr" rel="nofollow">Write for About</a></li> <li><a href="http://www.about.com/gi/pages/uagree.htm" zt="18/1YX/Zr" rel="nofollow">User Agreement</a></li> <li><a href="http://www.about.com/gi/pages/ethics.htm" zt="18/1YX/Zr" rel="nofollow">Ethics Policy</a></li> <li><a href="http://www.about.com/gi/pages/patent.htm" zt="18/1YX/Zr" rel="nofollow">Patent Info.</a></li> <li><a href="http://www.about.com/gi/pages/mprivacy.htm" zt="18/1YX/Zr" rel="nofollow">Privacy Policy</a></li> <li><a href="http://www.about.com/gi/pages/mprivacy.htm#adchoices" zt="18/1YX/Zr" rel="nofollow">Your Ad Choices</a></li> </ul> </div> <div id="di"> <p>&copy;2012 About.com. All rights reserved.&nbsp;</p> <p>A part of&nbsp;<a href="http://www.nytco.com/" zt="1/1JK">The New York Times Company</a>.</p> </div> <div id="zIhf"> <div id="zIHC"> <a href="http://www.hon.ch/HONcode/Conduct.html?HONConduct241149"><img src="http://0.tqn.com/f/p/650/ho2.gif" width="69" height="31" align="right" border="0" title="This website is accredited by Health On the Net Foundation. Click to verify." /></a>We comply with the <a href="http://www.hon.ch/HONcode/Conduct.html">HONcode standard<br /> for trustworthy health</a> information: <a href="http://www.hon.ch/HONcode/Conduct.html?HONConduct241149">verify here</a>. </div> </div> </div> <script>check_modal();zCi();validateForms();splitLists();</script> </div> <script>if(this.zKW&&gEI('sv'))gEI('sv').value=zE(zE(zKW,1),1).replace(new RegExp('\\+','g'),' ')</script> <script type="text/javascript"><!--zPxA[zPxC]=new Image();zPxA[zPxC++].src="http://b.scorecardresearch.com/p?c1=2&c2=6036459&c7=http%3a%2f%2fheartburn%2eabout%2ecom%2fcs%2fbarrettsesophagus%2ff%2fcancer%5frisk%2ehtm&c8=What%20Are%20the%20Risk%20Factors%20of%20Developing%20Cancer%20if%20You%20Have%20Barrett%27s%20Esophagus%3f&c9=http%3a%2f%2fergonomics%2eabout%2ecom%2fod%2fTrigger%2dFinger%2ftp%2fWho%2dIs%2dAt%2dRisk%2dFor%2dTrigger%2dFinger%2ehtm&cv=2.0&cj=1";adclose()//--></script> <noscript> <img src="http://b.scorecardresearch.com/p?c1=2&amp;c2=6036459&amp;c7=http%3a%2f%2fheartburn%2eabout%2ecom%2fcs%2fbarrettsesophagus%2ff%2fcancer%5frisk%2ehtm&amp;c8=What%20Are%20the%20Risk%20Factors%20of%20Developing%20Cancer%20if%20You%20Have%20Barrett%27s%20Esophagus%3f&amp;c9=http%3a%2f%2fergonomics%2eabout%2ecom%2fod%2fTrigger%2dFinger%2ftp%2fWho%2dIs%2dAt%2dRisk%2dFor%2dTrigger%2dFinger%2ehtm&amp;cv=2.0&amp;cj=1" class="hide" /> </noscript> </body> </html>
221	single	electoral college 2008 results	What were the results of the electoral college for the 2008 US presidential race?	clueweb12-0009wb-33-00709	2	<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml" id="typepad-standard" xmlns:fb="http://www.facebook.com/2008/fbml"> <head> <meta http-equiv="Content-Type" content="text/html; charset=utf-8" /> <meta name="generator" content="http://www.typepad.com/" /> <meta name="description" content="I used to visit this site just about every day leading up to the 2004 presidential race. While many news reports may give you national polls on potential presidential match-ups, we all know that only the electoral college matters. The..." /> <link rel="stylesheet" href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/styles.css?v=6" type="text/css" media="screen" /> <link rel="stylesheet" href="http://static.typepad.com/.shared:v20120209.02-0-ga1787ee:typepad:en_us/themes/common/print.css" type="text/css" media="print" /> <link rel="alternate" type="application/atom+xml" title="Posts on 'Montana Main Street Blog' (Atom)" href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/atom.xml" /> <link rel="alternate" type="application/rss+xml" title="Posts on 'Montana Main Street Blog' (RSS 1.0)" href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/index.rdf" /> <link rel="alternate" type="application/rss+xml" title="Posts on 'Montana Main Street Blog' (RSS 2.0)" href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/rss.xml" /> <script type="text/javascript"> var TPApp = {}; TPApp.app_uri = "http://www.typepad.com/"; </script> <script type="text/javascript" src="http://static.typepad.com/.shared:v20120209.02-0-ga1787ee:typepad:en_us/js/yui/yahoo-dom-event.js,/js/app/thumbnail-gallery-min.js,/js/app/flyouts-min.js"></script> <script type="text/javascript"> var _gaq = _gaq || []; _gaq.push(['t2._setAccount', 'UA-225723-36']); _gaq.push(['t2._setDomainName', 'none']); _gaq.push(['t2._setAllowLinker', true]); _gaq.push(['t2._setCustomVar', 1, 'Blog', '6a00d8341ca62a53ef00d8341d589053ef', 3]); _gaq.push(['t2._setCustomVar', 2, 'Page Type', 'Individual', 3]); _gaq.push(['t2._trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); </script> <title>Montana Main Street Blog: Electoral College Map for 2008</title> <link rel="start" href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/" title="Home" /> <link rel="prev" href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2008/04/bill-draft-requ.html?no_prefetch=1" title="Bill Draft Requests for the 2009 Legislature" /> <link rel="next" href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2008/04/state-governmen.html?no_prefetch=1" title="State Government Stimulus" /> <!--<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:trackback="http://madskills.com/public/xml/rss/module/trackback/" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2008/04/electoral-colle.html" trackback:ping="http://www.typepad.com/services/trackback/6a00d8341ca62a53ef00e551daa6718834" dc:title="Electoral College Map for 2008" dc:identifier="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2008/04/electoral-colle.html" dc:description="I used to visit this site just about every day leading up to the 2004 presidential race. While many news reports may give you national polls on potential presidential match-ups, we all know that only the electoral college matters. The..." dc:creator="Jon Bennion" dc:date="2008-04-10T14:41:50-06:00" /></rdf:RDF>--> </head> <body class="layout-two-column-right"> <div id="container"> <div id="container-inner" class="pkg"> <!-- banner --> <div id="banner"> <div id="banner-inner" class="pkg"> <h1 id="banner-header"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/" accesskey="1">Montana Main Street Blog</a></h1> <h2 id="banner-description"> </h2> </div> </div> <div id="pagebody"> <div id="pagebody-inner" class="pkg"> <div id="alpha"> <div id="alpha-inner" class="pkg"> <!-- content nav --> <p class="content-nav"> <a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2008/04/bill-draft-requ.html">&laquo; Bill Draft Requests for the 2009 Legislature</a> | <a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/">Main</a> | <a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2008/04/state-governmen.html">State Government Stimulus &raquo;</a></p> <!-- entry --> <h2 class="date-header">April 10, 2008</h2> <div class="entry-author-jon_bennion entry-type-post entry" id="entry-48276774"> <h3 class="entry-header">Electoral College Map for 2008</h3> <div class="entry-content"> <div class="entry-body"> <p>I used to visit <a href="http://www.electoral-vote.com/">this site</a> just about every day leading up to the 2004 presidential race. While many news reports may give you national polls on potential presidential match-ups, we all know that only the electoral college matters. The folks at the site post the latest polls in each state and put the results together to show who would win the election based on state victories. </p> <p>If you visit the <a href="http://www.electoral-vote.com/evp2008/Obama/Maps/Apr10.html">Obama v. McCain</a> and <a href="http://www.electoral-vote.com/evp2008/Clinton/Maps/Apr10.html">Clinton v. McCain</a> pages, you'll see that both races are close. McCain does better than both Democratic candidates in Montana with Obama being the stronger of the two. </p> </div> </div> <div class="entry-footer"> <p class="entry-footer-info"> <span class="post-footers">Posted at 02:41 PM </span> <span class="separator">|</span> <a class="permalink" href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2008/04/electoral-colle.html">Permalink</a> </p> <!-- technorati tags --> <!-- post footer links --> </div> </div> <div class="trackbacks"> <a id="trackback"></a> <h3 class="trackbacks-header">TrackBack</h3> <div class="trackbacks-info"> <p>TrackBack URL for this entry:<br /><span class="trackbacks-link">http://www.typepad.com/services/trackback/6a00d8341ca62a53ef00e551daa6718834</span></p> <p>Listed below are links to weblogs that reference <a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2008/04/electoral-colle.html">Electoral College Map for 2008</a>:</p> </div> <div class="trackbacks-content"> </div> </div> <a id="comments"></a> <div class="comments" id="all-comments"> <h3 class="comments-header">Comments</h3> <div class="comments-content" id="comments-content"> <!-- comment list --> <a id="c110237514"></a> <div class="comment comment-odd comment-has-avatar" id="comment-110237514"> <div class="comment-avatar"> <img id="comment-6a00d8341ca62a53ef00e551c5de1a8833-avatarimg" src="http://static.typepad.com/.shared:v20120209.02-0-ga1787ee:typepad:en_us/default-userpics/16-50si.gif" alt="Montana Headlines" width="50" height="50" /> </div> <div class="comment-content" id="comment-110237514-content"> <span id="comment-110237514-content"><p>It is interesting to look at the big 4 swing states -- Michigan, Ohio, Pennsylvania, and Florida.</p><p>Against Clinton, McCain at this point could amazingly lose 3 of the 4 and still win the election.</p><p>Of course, that's assuming that the other things are actually plausible -- like him winning Oregon and Washington.</p><p>Still, fascinating stuff for us political junkies.</p></span> </div> <p class="comment-footer"> Posted by: <a rel="nofollow" target="_blank" title="http://www.montanaheadlines.blogspot.com" href="http://www.montanaheadlines.blogspot.com">Montana Headlines</a> | <a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2008/04/electoral-colle.html?cid=110237514#comment-6a00d8341ca62a53ef00e551c5de1a8833">April 10, 2008 at 04:13 PM</a> </p> </div> <a id="c110238348"></a> <div class="comment comment-even comment-has-avatar" id="comment-110238348"> <div class="comment-avatar"> <img id="comment-6a00d8341ca62a53ef00e551daf2a88834-avatarimg" src="http://static.typepad.com/.shared:v20120209.02-0-ga1787ee:typepad:en_us/default-userpics/20-50si.gif" alt="montanamainstreetblog" width="50" height="50" /> </div> <div class="comment-content" id="comment-110238348-content"> <span id="comment-110238348-content"><p>I was a little thrown off by the Washington state and Oregon numbers myself. It's hard for me to image that McCain could pull things off there. </p><p>I think some numbers are a little too favorable for Obama at the moment as well(Texas, North Dakota, and even Colorado). I think when everything settles, these states will fall into the Republican column. </p><p>As things change in the coming months, I think we'll come to realize how much they've stayed the same since 2000 and 2004 in most states. </p></span> </div> <p class="comment-footer"> Posted by: montanamainstreetblog | <a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2008/04/electoral-colle.html?cid=110238348#comment-6a00d8341ca62a53ef00e551daf2a88834">April 10, 2008 at 04:23 PM</a> </p> </div> </div> </div> <!-- comment-form-atp --> <p class="comments-closed"> The comments to this entry are closed.</p> </div> </div> <div id="beta"> <div id="beta-inner" class="pkg"> <!-- sidebar --> <div class="module-typelist module"> <h2 class="module-header">Montana Elections 2010</h2> <div class="module-content"> <ul class="module-list"> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/montana-elections-2010.html">Click Here For 2010 Montana Elections Info</a><br /></li> </ul> </div> </div> <div class="module-typelist module"> <h2 class="module-header">2009 Legislative Session</h2> <div class="module-content"> <ul class="module-list"> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/contact-your-legislators.html">Contact Your Legislators</a><br /></li> <li class="module-list-item"><a href="http://www.rotundareport.com/">Rotunda Report</a><br /></li> <li class="module-list-item"><a href="http://www.mtcapitolreport.org/">Montana Capitol Report</a><br /></li> <li class="module-list-item"><a href="http://leg.mt.gov/css/sessions/61st/default.asp">Montana Legislature</a><br /></li> </ul> </div> </div> <!-- about page link --> <div class="module-about module"> <h2 class="module-header"><a href="http://montanamainstreetblog.typepad.com/about.html">About</a></h2> </div> <div class="module-typelist module"> <h2 class="module-header">Useful Links</h2> <div class="module-content"> <ul class="module-list"> <li class="module-list-item"><a title="" href="http://governor.mt.gov/">Montana Governor </a></li> <li class="module-list-item"><a title="" href="http://www.mtbusiness.com/">Montana Business</a></li> <li class="module-list-item"><a title="" href="http://www.montanachamber.com/">Montana Chamber of Commerce</a></li> <li class="module-list-item"><a title="" href="http://leg.mt.gov/css/default.asp">Montana Legislative Branch Website</a></li> <li class="module-list-item"><a title="" href="http://courts.mt.gov/supreme/">Montana Supreme Court</a></li> <li class="module-list-item"><a title="" href="http://www.politicalwire.com">Taegan Goddard's Political Wire</a></li> </ul> </div> </div> <div class="module-typelist module"> <h2 class="module-header">Montana Blogs</h2> <div class="module-content"> <ul class="module-list"> <li class="module-list-item"><a title="" href="http://2helenahandbaskets.com/">2 Helena Handbaskets</a></li> <li class="module-list-item"><a title="" href="http://2ndgradebikerack.blogspot.com/">2nd Grade Bike Rack</a></li> <li class="module-list-item"><a title="" href="http://4and20blackbirds.wordpress.com/">4&amp;20 blackbirds</a></li> <li class="module-list-item"><a title="" href="http://davebudge.com/">Dave Budge</a></li> <li class="module-list-item"><a title="" href="http://electriccityweblog.com/">Electric City Weblog</a></li> <li class="module-list-item"><a title="" href="http://intelligentdiscontent.com/">Intelligent Discontent</a></li> <li class="module-list-item"><a title="" href="http://blog.just-citizens.com/">Just Talk</a></li> <li class="module-list-item"><a title="" href="http://www.leftinthewest.com">Left in the West </a></li> <li class="module-list-item"><a title="" href="http://missoulapolis.com/">Missoulapolis</a></li> <li class="module-list-item"><a title="" href="http://mtstockgrower.blogspot.com/">Montana Stockgrower Blog</a></li> <li class="module-list-item"><a title="" href="http://MontanaWithKids.com">Montana With Kids</a></li> <li class="module-list-item"><a title="" href="http://rabidsanity.blogspot.com/">Rabid Sanity</a></li> <li class="module-list-item"><a title="" href="http://bigskyblog.com/">The Big Sky Blog</a></li> <li class="module-list-item"><a title="" href="http://www.mtmis.net/">The Montana Misanthrope</a></li> <li class="module-list-item"><a title="" href="http://takeitontherun.blogspot.com/">The Western Word</a></li> <li class="module-list-item"><a title="" href="http://sarpysam.com/">Thoughts From the Middle of Nowhere</a></li> </ul> </div> </div> <div class="module-archives module"> <h2 class="module-header"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/archives.html">Archives</a></h2> <div class="module-content"> <ul class="module-list"> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2010/04/index.html">April 2010</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2010/02/index.html">February 2010</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2010/01/index.html">January 2010</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2009/12/index.html">December 2009</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2009/11/index.html">November 2009</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2009/10/index.html">October 2009</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2009/09/index.html">September 2009</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2009/08/index.html">August 2009</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2009/07/index.html">July 2009</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/2009/06/index.html">June 2009</a></li> </ul> <p class="module-more"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/archives.html">More...</a></p> </div> </div> <div class="module-categories module"> <h2 class="module-header"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/archives.html">Categories</a></h2> <div class="module-content"> <ul class="module-list"> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/antibusiness/">Anti-Business</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/congress/">Congress</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/current_affairs/">Current Affairs</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/departments_and_agencies/">Departments and Agencies</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/economy/">Economy</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/elections/">Elections</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/governor/">Governor</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/health_care/">Health Care</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/human_resources/">Human Resources</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/legal_reform/">Legal Reform</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/manufacturing/">Manufacturing</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/montana_courts/">Montana Courts</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/montana_legislature/">Montana Legislature</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/natural_resources/">Natural Resources</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/science/">Science</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/taxes/">Taxes</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/test_your_knowledge/">Test Your Knowledge</a></li> <li class="module-list-item"><a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/work_comp/">Work Comp</a></li> </ul> </div> </div> <div class="module-subscribe module"> <div class="module-content"> <a onclick="window.open(this.href, 'blogroll', 'width=550,height=600,scrollbars=yes'); return false;" href="http://www.typepad.com/t/app/lists?__mode=quickpost&amp;is_qp=1&amp;type=1&amp;qp_href=http%3A%2F%2Fmontanamainstreetblog.typepad.com%2Fmontana_main_street_blog%2F">Add me to your TypePad People list</a> </div> </div> <div class="module-syndicate module"> <div class="module-content"> <a href="http://montanamainstreetblog.typepad.com/montana_main_street_blog/atom.xml">Subscribe to this blog's feed</a> </div> </div> <!-- powered by --> <div class="module-powered module"> <div class="module-content"> <a href="http://www.typepad.com/" title="Blog">Blog</a> powered by <a href="http://www.typepad.com/" title="TypePad">TypePad</a> </div> </div> <div class="module-widget module" id="widget-Site_Meter_s41mtmain"> <div class="module-content"> <!-- Site Meter --> <script type="text/javascript" src="http://s41.sitemeter.com/js/counter.js?site=s41mtmain"></script> <noscript> <a href="http://s41.sitemeter.com/stats.asp?site=s41mtmain" target="_top"><img src="http://s41.sitemeter.com/meter.asp?site=s41mtmain" alt="Site Meter" border="0" /></a> </noscript> <!-- Copyright (c)2006 Site Meter --> </div> </div> </div> </div> </div> </div> </div> </div> <script type="text/javascript"><!--var extra_happy = Math.floor(1000000000 * Math.random());document.write('<img src="http://www.typepad.com/t/stats?blog_id=528177&amp;user_id=1100469&amp;page=' + escape(location.href) + '&amp;referrer=' + escape(document.referrer) + '&amp;i=' + extra_happy + '" width="1" height="1" alt="" style="position: absolute; top: 0; left: 0;" />');// --></script> <!-- Start Quantcast tag --> <script type="text/javascript" src="http://edge.quantserve.com/quant.js"></script> <script type="text/javascript">_qoptions = { tags:"typepad.core" }; _qacct="p-fcYWUmj5YbYKM"; quantserve();</script> <noscript> <a href="http://www.quantcast.com/p-fcYWUmj5YbYKM" target="_blank"><img src="http://pixel.quantserve.com/pixel/p-fcYWUmj5YbYKM.gif?tags=typepad.core" style="display: none" border="0" height="1" width="1" alt="Quantcast" /></a> </noscript> <!-- End Quantcast tag --> <script type="text/javascript">var captchaImgAttempts = 0;var allowAnonComments = '0';var registrationRequired = 0;var registrationOptional = 1;var emailRequired = 1;var useAvatars = 1;var showSignInMessaging = 0;var jsonURL = "/.services/json-rpc";var captchaSrc = "/.services/captcha?code_encrypted=";var alertCommentCannotBeBlank = "You can not leave an empty comment. Please enter some text in the Comment field.";var alertEditingExpired = "Sorry, you're no longer allowed to edit this comment. You may have taken too much time before submitting your edit or someone may have already replied to it.";var alertAuthorCannotBeBlank = "Name must not be blank.";var alertEmailCannotBeBlank = "Email Address must not be blank.";var alertAuthorAndEmailCannotBeBlank = "Name and email address are both required!";var alertEmailIsInvalid = "The Email Address you entered is invalid. Please enter a valid email address.";var alertUnauthorizedAction = "The comments on this post are closed.";var msgPostReplyTo = "Reply to "; var msgInReplyTo = "In reply to ";var msgPostAComment = "Post a comment ";var atpCommentsPath = "/.shared/js/atpcomments_yui.js?v=5";var hasChanged = 0;var hostName = ".typepad.com";var tp_comment_token = "1328969001-cd97ec9d6b6431802c680d878f6f1b767ef9aba4:iGZVCbMGHlWjLlUg";var isPage = 0;var blog_xid = "6a00d8341ca62a53ef00d8341d589053ef";var xid = "";var injectCode = '<div id=\"comment-preview\" class=\"hiddenBox\">\n\t<h3 id=\"header-verify-comment\" class=\"comments-header hiddenBox\">Verify your Comment<\/h3>\n <h3 id=\"header-preview-comment\" class=\"comments-header hiddenBox\">Previewing your Comment<\/h3>\n\t<div class=\"comments-content\">\n\t\t<div class=\"comment comment-has-avatar\">\n\t\t\t<div id=\"comment-preview-content\" class=\"comment-content\">\n\t\t\t<\/div>\n\t\t\t<p class=\"comment-footer\">\n\t\t\t\tPosted by: \n\t\t\t\t<span id=\"comment-preview-author\"><\/span>&nbsp;|&nbsp;<span id=\"comment-preview-datetime\"><\/span>\n\t\t\t<\/p>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n<div id=\"comment-preview-confirmation\" class=\"hiddenBox yellowBox\">\n <p>This is only a preview. Your comment has not yet been posted.<\/p>\n \t<form id=\"comment-preview-form\"\n \t\tmethod=\"post\"\n \t\tonsubmit=\"atpComments.interceptPost(); return false;\">\n\t\t<input type=\"submit\" name=\"post\" id=\"comment-confirm-post\" value=\"&nbsp;Post&nbsp;\" onclick=\"atpComments.interceptPost(); return false;\"/>\t\t \n\t\t<input type=\"submit\" name=\"edit\" id=\"comment-edit\" value=\"&nbsp;&nbsp;Edit&nbsp;&nbsp;\" onclick=\"atpComments.previewOnly(2); return false;\"/>\n <span id=\"previewFormSpinner\" class=\"hiddenBox\"><img src=\"/.shared/images/spinner.gif\" alt=\"Working...\" /><\/span>\n\t<\/form>\n<\/div>\n<div id=\"comment-error\" class=\"hiddenBox redBox\">\t \n Your comment could not be posted. Error type: <span id=\"comment-error-msg\"><\/span> \n<\/div>\t\n<div id=\"comment-complete\" class=\"hiddenBox redBox\">\n Your comment has been saved. Comments are moderated and will not appear until approved by the author. <a href=\"javascript:void 0;\" onclick=\"window.location.hash=\'#comment-form\';window.location.reload(false)\">Post another comment<\/a>\n<\/div>\t\n<div id=\"comment-captcha\" class=\"hiddenBox yellowBox\">\t\n <div id=\"captchaText\">\n\t <p id=\"captchaFailMsg\" class=\"captchaErrorText hiddenBox\">The letters and numbers you entered did not match the image. Please try again.<\/p>\t \t \n\t <p>As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.<\/p>\n\t <p><span id=\"comment-captcha-viewalt\">Having trouble reading this image? <a href=\"#comment-captcha\" onClick=\"atpComments.generateCaptcha();\">View an alternate.<\/a><\/span><\/p>\n <\/div>\n <p class=\"\"><img id=\"captchaImg\" /><\/p>\t\t\n <form id=\"comment-captcha-form\" \n\t\t method=\"post\"\n\t\t onsubmit=\"atpComments.submitWithCaptcha(); return false;\">\n\t\t<input type=\"hidden\" name=\"captcha_chal\" id=\"comment-captcha-chal\" value=\"\" />\n <p>\n\t <input id=\"comment-captcha-text\" name=\"captcha_text\" size=\"10\" />\n <\/p>\n <p>\n <input type=\"submit\" name=\"continue\" id=\"captcha-continue\" value=\"&nbsp;Continue&nbsp;\" />\n <span id=\"captchaFormSpinner\" class=\"commentSpinner hiddenBox\"><img src=\"/.shared/images/spinner.gif\" alt=\"Working...\" /><\/span>\n <\/p>\n <\/form>\n<\/div>\n'; var entryPermalink = "http://montanamainstreetblog.typepad.com/montana_main_street_blog/2008/04/electoral-colle.html";var inlineReply = document.createElement("div");var commentFooterLinks;var commentHeader;var commentReplyXID;var commentReplyAuthor;var commentReplyComplete;var inlineReplyLoaded = 0;var commentFormNum = undefined; /* Deprecated but still exists in advanced template sets, so must be defined */function xidToCommentPermalink (entryUrl, xid) { return entryUrl + "?cid=" + xid + "#comment-" + xid;}/* Deprecated advanced template functions */function handleSubmit() { return true; };function handleChange() { return true; };</script> <script type="text/javascript" src="/.shared/js/yui/yuiloader-beta-min.js"></script> <script type="text/javascript" src="/.shared/js/atpcomments.js?v=5"></script> <!-- Blogside Toolbar --> <script type="text/javascript"> var TPToolbar = { src: "http://www.typepad.com/services/toolbar?blog_id=6a00d8341ca62a53ef00d8341d589053ef&asset_id=6a00d8341ca62a53ef00e551daa6718834&atype=Individual&to=http%3A%2F%2Fmontanamainstreetblog.typepad.com%2Fmontana_main_street_blog%2F2008%2F04%2Felectoral-colle.html&autofollowed=0", asset_xid: "6a00d8341ca62a53ef00e551daa6718834", bookmarklet_uri: "http://static.typepad.com/.shared/js/qp/loader-combined-min.js" }; var TYPEPAD___bookmarklet_domain = "http://www.typepad.com/";</script> <script type="text/javascript" src="/.shared/js/toolbar/blogside-toolbar-combined-min.js"></script> <!-- End Blogside Toolbar --> <!-- Begin comScore Tag --> <script>document.write(unescape("%3Cscript src='" + (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js'%3E%3C/script%3E"));</script> <script>COMSCORE.beacon({ c1: 2, c2: "6035669", c3: "", c4: "http://montanamainstreetblog.typepad.com/montana_main_street_blog/2008/04/electoral-colle.html", c5: "", c6: "", c15: ""});</script> <noscript> <img src="http://b.scorecardresearch.com/b?c1=2&amp;c2=6035669&amp;c3=&amp;c4=http%3A%2F%2Fmontanamainstreetblog.typepad.com%2Fmontana_main_street_blog%2F2008%2F04%2Felectoral-colle.html&amp;c5=&amp;c6=&amp;c15=&amp;cv=1.3&amp;cj=1" style="display:none" width="0" height="0" alt="" /> </noscript> <!-- End comScore Tag --> <!-- ph=1 --> </body> </html>
283	single	hayrides in pa	Where can I go on a hay ride in Pennsylvania?	clueweb12-1304wb-16-14400	3	<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> <html> <head> <title>Haunted house haunt blog detail</title> <meta name="keywords" content=" haunted house, halloween haunted house, haunted houses, halloween attractions, real haunted houses, virtual haunted house, haunted attractions, halloween, haunted hayrides, haunt, scary" /> <meta name="description" content="Haunted House directory to help you find haunted houses and halloween attractions across the United States." /> <meta name="robots" content="All" /> <meta name="robots" content="`index`" /> <meta name="revisit-after" content="14 days" /> <meta http-equiv="expires" content="0" /> <meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1" /> <link rel="SHORTCUT ICON" href="hho.ico" /> <link href="/css/style.css" rel="stylesheet" /> <script> function showdiv(id) { document.getElementById(id).style.display = '' } function Hidediv(id) { document.getElementById(id).style.display = 'none'; } function valid() { frm=window.document.frm_Viewblog; if(frm.AddGuestComment.value.length < 1) { alert('Please Add Your Comment'); frm.AddGuestComment.focus(); return false; } frm.Method.value="AddComment"; frm.submit(); } function textLimit(field, maxlen) { if (field.value.length > maxlen + 1) alert('Please enter no more than '+ maxlen +' characters!'); if (field.value.length > maxlen) field.value = field.value.substring(0, maxlen); } </script> </head> <body leftmargin="0" topmargin="0" marginwidth="0" marginheight="0"> <center> <div align="center" class="tableborder"> <script src="/js/imageRotator.js" type="text/javascript"></script> <script>function funImageHref(obj){ var myURL = new String(); myURL = obj.alt; if(myURL != "" && myURL != "undefined") { window.open(myURL,'',''); }}</script> <table cellpadding="0" cellspacing="0" border="0" width="1000"> <tbody> <tr> <td> <table width="1000" cellspacing="0" cellpadding="0" border="0"> <tbody> <tr> <td width="1000"><a href="/index.cfm"> <img width="1000" height="116" border="0" title="FIND HAUNTED HOUSES, HAYRIDES, CORN MAZES, &amp; PUMPKIN PATCHES" alt="FIND HAUNTED HOUSES, HAYRIDES, CORN MAZES, &amp; PUMPKIN PATCHES" src="http://cdn.hauntedhouseonline.com/images/new_header.jpg" /> </a></td> </tr> </tbody> </table> <table width="1000" cellspacing="0" cellpadding="0" border="0"> <tbody> <tr> <td align="center" class="linkbg_new"> <table cellspacing="0" cellpadding="2" border="0"> <tbody> <tr> <td class="toplink"><a href="/">Home</a></td> <td><img width="3" height="14" border="0" alt="" src="/images/new_line.jpg" /></td> <td class="toplink"><a target="_blank" href="http://www.hauntworld.com">Hauntworld.com</a></td> <td><img width="3" height="14" border="0" alt="" src="/images/new_line.jpg" /></td> <td class="toplink"><a href="/americas_scariest_best_haunted_houses">Find Haunted Houses</a></td> <td><img width="3" height="14" border="0" alt="" src="/images/new_line.jpg" /></td> <td class="toplink"><a href="/americas_best_haunted_houses_halloween.cfm">Featured Haunts Articles</a></td> <td><img width="3" height="14" border="0" alt="" src="/images/new_line.jpg" /></td> <td class="toplink"><a target="_blank" href="http://www.hauntedhousemagazine.com/">Hauntworld Magazine</a></td> <td><img width="3" height="14" border="0" alt="" src="/images/new_line.jpg" /></td> <td class="toplink"><a target="_blank" href="http://www.halloweenattractions.com/">Corn Mazes &amp; Pumpkin Patches</a></td> <td><img width="3" height="14" border="0" alt="" src="/images/new_line.jpg" /></td> <td class="toplink"><a target="_blank" href="http://www.hauntworld.com/haunted_house_forums/">Haunt Forums</a></td> </tr> </tbody> </table> <table width="100%" cellspacing="0" cellpadding="0" border="0"> <tbody> <tr> <td width="100%" style="text-align: center;" class="linkbg_new_small"> <table cellspacing="0" cellpadding="2" border="0"> <tbody> <tr> <td class="toplink_new_home"><a title="Haunted News" href="/news_blog.cfm?pageNo=1">Haunted News</a></td> <td><img width="3" height="14" border="0" alt="" src="/images/new_line.jpg" /></td> <td class="toplink_new_home"><a href="/ViewAllVideos.cfm">View Latest Videos</a></td> <td><img width="3" height="14" border="0" alt="" src="/images/new_line.jpg" /></td> <td class="toplink_new_home"><a href="/ViewAllPhotos.cfm">View Latest Photos</a></td> <td><img width="3" height="14" border="0" alt="" src="/images/new_line.jpg" /></td> <td class="toplink_new_home"><a target="_BLANK" href="http://www.hauntworld.com/free_pumpkin_patterns.cfm">Free Pumpkin Patterns</a></td> <td><img width="3" height="14" border="0" alt="" src="/images/new_line.jpg" /></td> <td class="toplink_new_home"><a href="/haunted_attraction_information.cfm">Haunted Facts</a></td> <td><img width="3" height="14" border="0" alt="" src="/images/new_line.jpg" /></td> <td class="toplink_new_home"><a href="/halloween_haunted_house_links.cfm">Haunted links</a></td> <td><img width="3" height="14" border="0" alt="" src="/images/new_line.jpg" /></td> <td class="toplink_new_home"><a target="_blank" href="http://www.hauntworld.com/haunted_house_marketing/index.html">Advertise With Us</a></td> <td><img width="3" height="14" border="0" alt="" src="/images/new_line.jpg" /></td> <td class="toplink_new_home"><a href="/haunted_house_association_contact_information.cfm">Contact Us</a></td> <td><img width="3" height="14" border="0" alt="" src="/images/new_line.jpg" /></td> <td class="toplink_new_home"><a href="http://www.hauntworld.com/myaccount/new_sign_up.cfm">Create An Account / Add Your Event</a></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table width="1000" border="0" cellpadding="5" cellspacing="5"> <tbody> <tr> <td width="1000" class="membg"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tbody> <tr> <td width="100%" class="memcap"><b>Haunt Profile</b>: <b><a href="/pennsylvania_haunted_houses">Pennsylvania</a> &gt;&gt;</b> <a href="/haunted_house_in_gradyville_Pennsylvania_the_bates_motel">The Bates Motel and Haunted Hayride</a> &gt;&gt; <a href="/haunted_house_in_gradyville_Pennsylvania_the_bates_motel/Blogs">Blogs</a> &gt;&gt; Bates Motel... </td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%">&nbsp;</td> </tr> </tbody> </table> <table cellpadding="0" cellspacing="0" border="0"> <tbody> <tr> <td> <form name="frm_Viewblog" action="/HauntSingleBlog_action.cfm" method="post"> <input type="HIDDEN" name="ReturnURL" value="/haunted_house_in_gradyville_Pennsylvania_the_bates_motel/blogs/138" /> <input type="HIDDEN" name="HauntID" value="322" /> <input type="HIDDEN" name="HauntBlogID" value="138" /> <input type="HIDDEN" name="Method" value="" /> </form></td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="78%" valign="top"> <b class="atop"> <b class="ab1"></b> <b class="ab2 color_a"></b> <b class="ab3 color_a"></b> <b class="ab4 color_a"></b> </b> <div class="aboxcontent"> <table width="100%" cellpadding="3" cellspacing="0" border="0"> <tbody> <tr> <td class="color_a" width="100%">Bates Motel</td> </tr> </tbody> </table> <div> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" class="memsub_bordera"> <table cellspacing="1" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" class="membg"> <table width="100%" cellpadding="3" cellspacing="0" border="0"> <tbody> <tr> <td colspan="2"> <table width="100%" cellpadding="3" cellspacing="0" border="0" style="border-top:1px solid #333333;border-bottom:1px solid #333333;"> <tbody> <tr> <td class="text4"> <table border="0" cellspacing="10" cellpadding="0" width="100%"> <tbody> <tr> <td> <p align="center"><font color="#ff6600"><a href="http://www.hauntworld.com/pennsylvania_haunted_houses"><img alt="" width="468" height="160" src="http://www.hauntedhouseonline.com/static_banners/Americas_best_header_final.jpg" /></a></font></p> <p class="pageheader" align="center"><font color="#ff6600" size="1"><font size="3"><span style="font-weight: bold">Philadelphia, Pennsylvania PA&nbsp;Haunted House - The Terrifying Bates Motel and Haunted Hayride!</span></font><br /> Ben Armstrong NETHERWORLD Haunted House</font></p> <p class="pageheader" align="center">To Find the best haunted houses in Pennsylvania PA click on this link <a href="http://www.hauntworld.com/pennsylvania_haunted_houses">http://www.hauntworld.com/pennsylvania_haunted_houses</a></p> <p class="pageheader" align="center">&nbsp;</p> <p class="pageheader" align="center">Haunted Houses in Philadelphia, Pennsylvania PA are some of the scariest haunted houses in America.&nbsp; Hauntworld.com tries to review only the best haunted houses in Philadelphia, Pennsylvania, PA.&nbsp; When you are looking for simply the best, scariest, haunted houses in Pennsylvania PA there is no other place to search than Hauntworld.com which offers our guests the best information to find Pennsylvania PA Haunted Houses including the best haunted attractions in Philadelphia, Pennsylvania PA.&nbsp; There are many haunted houses in Philadelphia that claim to the best haunted attraction but only one can truly lay claim to the being the scariest haunted house in Pennsylvania...&nbsp;Bates Motel and Haunted Hayride in Philadelphia, Pennsylvania, Pa.&nbsp;&nbsp;</p> <p class="pageheader" align="center">To learn more about Philadelphia, Pennsylvania PA Bates Motel &amp; Haunted Hayride visit their website below:</p> <p class="pageheader" align="center"><a href="http://www.thebatesmotel.com/">http://www.thebatesmotel.com/</a></p> <p class="pageheader" align="center">&nbsp;</p> </td> </tr> <tr> <td class="text"> <p>&nbsp;</p> <div align="center"> <a href="http://www.thebatesmotel.com/"><img alt="" width="800" height="1035" src="http://www.hauntedhouseonline.com/userfiles/Image/bates_1.jpg" /></a> </div> <p><font color="#ffcc00"><strong>The essence of what we do in this business is simple, SCARE PEOPLE, and that is what the Bates Motel and Haunted Hayride in Gradyville, Pennsylvania is all about! I first met the owner, Randy Bates about 8 or 9 years ago and he was already at the top of his game. With three events, a Hayride, Corn Maze and Haunted House he had all the bases covered, three different ways to reach deep into the minds of his guests and make ‘em scream! In a market packed with major events he always brings in massive hordes of scared patrons every year, and weather permitting, things just keep getting better.</strong></font></p> <p>I had the chance to visit the Bates Motel and Haunted Hayride in the off season this year and walk the shows with Randy. Although they were still half converted to a Christmas event, his approach to shocking his guests was very clear to me. Blow them away with pure unrelenting action. After checking out the set up I could see why this event is considered one of the scariest haunted attractions in America! Classically hayrides work in a stop and show format, with the wagon pulling up to a scene and some sort of skit unfolding. Not so at his haunted hayride! This event is operated like a high throughput haunted house…once the wagons load they never stop, continuously moving through high action, high startle scenes with relentless attacks from all sides of the trail. Barrels hurl down from overhead, enormous living trees grasp at the riders from above, walls collapse, actors fly over the wagon and monsters jump on with the guests bringing the action right into their faces! Another big factor for Randy is the use of fire, with a huge dragon, a flaming gas station and exploding dynamite shack just the beginning of the pyrotechnics. His approach almost plays out like a high action stunt show with trained employees pushing the guests’ fear quotient to the limit!<br /> <br /> <img hspace="10" alt="" vspace="10" align="right" width="500" height="405" src="http://www.hauntedhouseonline.com/userfiles/Image/bates_2.jpg" /> Big sets and detail are also part of the winning equation at the Bates Motel. Surrounded on all sides by massive trees, the wagon rolls through enclosed barns and compounds full of buildings. After entering the mouth of a dragon and going almost 100 feet though its smoky strobe filled guts (to the pounding,&nbsp;&nbsp;heartbeat sound of huge 1200 watt subwoofers), the wagon passes through a series of asylum style buildings. This puts the actors right on top of the wagon with inmates swarming out of every door and window! Not only were the elaborate building constructed from the ground up by Randy and his staff, all of the wood was milled right in the farm from trees on the property. Other big sets include a King Kong style village, a zombie strip mall, a haunted church with ghostly pallbearers, a toxic waste facility, and a 300 foot long cave and mine shaft filled with collapsing beams and giant monsters. And when I say monsters I mean monsters! Randy has amassed a huge collection of the biggest animatronic beasts the industry has to offer including such favorites as the Slayer, the Giant Spawn and the 17 foot tall Pumpkin King. One thing that sets this hayride apart from the others is the use of an onboard, digital soundtrack, that is choreographed to the&nbsp;scenes. Using 500 watt amps, MP-3 players,&nbsp;and full range cabinet speaker systems, the Bates Haunted Hayride adds an element found nowhere else. <br /> <br /> After surviving the hayride guests queue up for the famous Bates Motel itself. Already rattled, they are now REALLY up close and personal with the actors. This event is high action high startle as well, with monsters getting at the patrons from every possible angle of attack. Packed with tight set dressing and special effects, guests barely have time to catch their breath before the next scare hits! Many classic haunted mansion style scenes are found inside including libraries, kitchens, multi-doored hallways and my favorite, the Trophy Room. This scene has over 30 REAL exotic animal heads from an old big game hunter’s collection. When the actor shows up with his air powered shotgun you can guess what happens next! Another thing one notices in this haunted house is the density of special effects. Everywhere are moving props, slamming doors, overhead ghosts, unusual lighting effects and illusions, including a live action CGI style ghost greeter. After a brief dip outdoors to view a haunted playground with animated swing set and merry-go-round, it’s back inside for the conclusion of the haunt. After more cavern-like twists and turns including a body bag room, the final blow off occurs, a large room with a massive sweeping staircase. Hidden here are several intense scares designed to blast the guests out of the double doors screaming. I cannot tell you what they are (One is a custom effect found ONLY here), so you need to check them out in person!<br /> <br /> <img hspace="10" alt="" vspace="10" align="left" width="637" height="805" src="http://www.hauntedhouseonline.com/userfiles/Image/bates_3.jpg" /> The final element is the corn maze. Entering underneath a colossal cow skull that literally swallows them up, guests begin a harrowing journey through the tightly packed stalks. Although much of the path is through a cornfield there are many other structures hidden in the rows. First is a graveyard and crypt area loaded with another of Randy’s special collections…real tombstones! Apparently he got a deal on mis-carved and out of service monuments from a local dealer after offering him a super low price for the lot. Randy said ,“Hey don’t you go to conventions where you get together with your fellow stone carvers? Think what a great story this will make, how you sold the same tombstones TWICE!“ The guy loved the idea and made the deal! After the crypt with its automated doors comes a complete house totally hidden in the corn. The entire structure is a bloody murder scene loaded with props and animations. Another large structure near the end of the maze is a walk through mine shaft, complete with flickering lanterns and crazy miners! Scattered throughout the corn are many other sets, including a western area with a black lit forge that gives the appearance of red hot coals (and the guests are gonna get branded!) not to mention the ever present swaying corn. At any time actors can suddenly appear and disappear in the stalks, making the entire journey seemingly fraught with danger, although Randy is renowned for having one of the most expansive safety programs in the haunt industry. The maze also has a background digital soundtrack playing custom erie music, that sets each customer on edge, and makes it easier to scare them.<br /> <br /> The entire event is wildly successful, one of the consistently most heavily attended haunted attractions in the country, and ranks highly on top ten national haunt lists every year. The combination of a wooded farm location in a major market (Philadelphia), big effects, major sets, unique scares and pure adrenaline makes it an all time fan favorite. And you cannot forget the most important thing that ultimately makes a haunt likely to succeed - ask Randy why he haunts and he will lay it out plain and simple - “I love to scare people!”</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><img hspace="10" alt="" vspace="10" align="right" width="253" height="700" src="http://www.hauntedhouseonline.com/userfiles/Image/bates_6.jpg" /><br /> <font color="#ffcc00"><strong><img hspace="10" alt="" vspace="10" align="left" width="326" height="441" src="http://www.hauntedhouseonline.com/userfiles/Image/bates_5.jpg" /></strong></font></p> <p>&nbsp;</p> <p><font color="#ffcc00">&nbsp;</font></p> <p><font color="#ffcc00">&nbsp;</font></p> <p><font color="#ffcc00">&nbsp;</font></p> <p><font color="#ffcc00"><font color="#ffffff"><strong>1) How long has your event been operating? How did it begin?</strong></font><br /> <br /> We opened our first event, the Haunted Hayride, in October of 1991. We had been running hayrides on our farm for 15 years, with a 45 minute trip around the fields and forests, and ending up at a secluded bonfire pit. Since we already had the infrastructure, tractors and wagons, in place, we decided to make the jump to the haunted attraction industry. I was not aware of other attractions doing this type of ride until several years later. The first season saw us open for 6 nights, and using 4 tractors and wagons, we ran a few thousand screaming customers through the show. Even with a slow start, I could see the potential in this industry, and decided to put all my efforts into my business. 18 years later, I look back and laugh at the corny costumes, masks and scares, but I still remember the screaming, satisfied customers climbing from the wagons. In 1996, after attending the Transworld Halloween and Party Show, we made plans for a new building to house a permanent attraction, and called it the Bates Motel. That year we also incorporated under the name Agritainment, Inc. The Bates motel became an instant success, with customers dashing from the exit, screaming and laughing. In 2000, we opened our haunted Corn Maze. It isn't really a maze, but a large, haunted trail, that is set up like our haunted house, located in a corn field. Room areas with animatronics, structures, actors and lighting are connected by long dark corridors, cut through the 12' tall corn stalks. We don't want you to get lost, as that reduces our throughput. We even light the trails in some places so you can see where you are running.</font></p> <p><font color="#ffcc00"><font color="#ffffff"><strong>2) You have always been at the forefront when it comes to helping out the industry as a whole. Why is this important to you?</strong></font><br /> <br /> I love my job, and truly like this industry as a whole. I feel it is important to the industry to help each other, especially when it comes to safety. A negligent accident, such as the fire in the Rhode Island nightclub, can have lasting ramifications on the entire industry. Look what happened to the haunted attractions in New Jersey after that fire. Many were shut down until they could comply with new fire and safety codes that were enacted because of that tragedy. I believe that by teaching safety in Haunted Houses will be positive for all of us in this business. Pennsylvania attractions are regulated and inspected by the PA Department of Agriculture, division of Ride Safety. They hold safety seminars each spring, with a major portion dedicated to fire safety. Even after being in this business for as long as I have, I learned a ton of usable, good information from this program. Another reason that I tend to help others in our industry is that I have met and made friends with people all over the world. I love networking and sharing ideas with them. Some of these have become great friends who like to get together in the off season.&nbsp; <br /> <font color="#ffcc00"><br /> <font color="#ffffff"><strong>3) You have three elements, The Bates Motel, The Hayride and the Corn Maze. What is the most popular?</strong></font></font><font color="#ffffff"> </font><br /> <br /> Our most popular event is our Haunted Hayride. I think this is true because it can accommodate families with young children. Our scariest event is the Bates Motel, with an age recommendation of over 8 years old. The Hayride is our oldest event, and is also our largest spectacle. The sets are huge, and many of them are drive through scares. These are large structures that the wagon is pulled through. They have animatronics, actors, digital sound and lighting, and are controlled by computers. All the monsters are big, and most of the sets and props are located very close to the trail. My customers tell me that it is one of a very few Haunted Hayrides that invoke screams at every spot in the trail. My theory for this is simple; attack the customers from all angles, every chance you get. You could go through this ride 10 times and it will never appear the same. There is just too much to look at on both sides of the trail. This format allows my customers to return several times a season and still have a great time. Most of my customers that come here go through the Haunted Hayride. <br /> <br /> <font color="#ffffff" style="background-color: rgb(0,0,0)"><strong>4) Your event is known for being very intense. What are some of your top scares?</strong></font><br /> <br /> We like to categorize our attraction as &quot;a high action, high startle, haunted attraction&quot;. We design all three attractions to be filled with good scares, mixed with automation, sound and lighting. Our hayride begins in front of a 60' tall castle, with a drive through Dragon head, completely lit with real fire. The soundtrack begins with wind and rain, then, as the music crescendos, the tractor starts, and into the mouth you go. It is like riding a coaster, and you just went over the top. With a combination of lighting, great audio, and atmosphere, we create and environment that makes it easy to scare our customers. One of our best scares on the Hayride is our Darkwood Home for the Criminally Insane, a huge Victorian asylum, with two story structures on both sides of the trail. Lit with search lights, and low voltage spots, it is full of animatronics, one of a kind sets and five actors in straight jackets. Another of my favorite sets is the mine shaft. As the wagon enters the mine, overhead beams begin to collapse towards the customers. Using computer show controls, digital sound and DMX lighting, the entire set appears to fall on the wagon. Other scares at the Bates Motel include a custom elevator simulator, flying ghosts, a split china closet and many more. In the Corn Maze, we built a new, full size Mausoleum, with an actor flying rig, real tombstones and slamming doors. <br /> <br /> <font color="#ffffff"><strong>5) You make many of your automated effects in house. How long have you been making animations, and what are a few examples?</strong></font><br /> <br /> We have a complete workshop on the premises. A full woodworking shop, metal shop, and all the parts for pneumatics, electrical, and show controls. Over the years, we have made a lot of custom effects used in all three of our attractions. One thing that sets us apart is the professional staff that works here. Our lighting and sound guy toured with Bon Jovi and did his sound board. We have professional carpenters, commercial artists, and manufacturing automation technicians. We began building props our first year. Each year they got bigger, more complicated and more interactive. A couple of props we built include a table that splits open and an actor jumps out. There is a pumpkin on the middle of the table, with the actor's head in it. I built a flying ghost that runs on a track down a hallway. We used a pneumatic motor and timed control system with an audio card. Works great every time. Another prop we built is a saw mill illusion that has an actor being cut in half. It is completely automated and quite realistic. It’s funny when you look at something like this in the shop, and wonder if you can pull off the illusion, but when the lighting and sound are just right, you can't tell it's not real. <br /> <br /> <font color="#ffffff"><strong>6) I understand you have a professional foam and hard coating machine. What sorts of props and sets have you built with it? Do you make big sets for other haunters?</strong></font><br /> <br /> We bought a Gussemier Foam machine about 6 years ago. It uses 2 55 gallon drums of &quot;product&quot;. It heats the lines and mixes part A and part B, and shoots it onto any surface you choose. We usually frame a piece with metal studs, and then cover it with stucco wire and burlap cloth. When you apply the foam, it locks this together and makes an extremely strong bond. We built several static pieces over the years, including a 15' tall skull, our 25' tall cow skull that resides in our corn maze, and catacombs in the Bates Motel. By far the biggest project we have done was to make a 200' long cave for the hayride. It is about 9' tall and 12' wide, then opens up to a big cavern at the end, where we have placed several different giant monsters. It took 5 of us 4 days to complete. It is framed with rebar and concrete wire, than covered with burlap and shot with the foam gun. Occasionally, we have been asked to make props for other attractions around the country, however that usually happens in August or September and we are too busy at that point. We have sold several pieces to other haunts. <br /> <br /> <font color="#ffffff"><strong>7) Your use of fire is famous - Any dos and don’t for those interested in using fire at events?</strong></font><br /> <br /> The most important thing to remember is to be safe. Find an experienced HVAC person who knows propane, and have them build your pyrotechnics. You will also need to check with your local authority about any restrictions, and I would recommend checking with your insurance company. If possible, hire a professional pyro technician and have him make your devices. Last year, I met a pyro guy who later came over and built our exploding gas station. The idea I had was to have a car smashed into a tree (since we are in the woods) with smoke pouring out of the engine compartment. Suddenly, a fire starts at the car, and then trails along the ground to the gas pumps. We bought two real pumps that were out of service. When the flames reached the pump, it explodes, sending a huge ball of fire into the air. The video can be seen on our website. The cool thing about this set is that it is completely automated, using Prop-1 controls. The actor hits the start button, and activates the sequence. The main thing to remember is to be safe when using pyro stunts. ALWAYS have an extinguisher close by, with someone who knows how to use it. <br /> <br /> <font color="#ffffff"><strong>8) There are many well known haunted events in your area. Any particular reason they are so popular there?</strong></font><br /> <br /> We were one of the first to open in the Philly area. Jason's Woods was open in Lancaster, and another hayride was running about an hour north of us. As our business took off, others began entering the scene. Now, there are over 12 major attractions located within 100 miles of our place. There are also hundreds of small, charity haunts that are open for a few nights each year. I think one of the reasons that haunted attractions have become so popular here is the massive amount of advertising that goes on. Each large attraction dumps hundreds of thousands of dollars into marketing, and our customers are bombarded all October. This has raised the awareness of such attractions, and made them popular. A group of us have banded together to for 13 Haunts. This group makes bulk purchases and does a lot of cooperative marketing, thus lowering the amount we need to do on an individual basis. <br /> <strong><br /> <font color="#ffffff">9) What sort of staff does it take to pull off your event every night?</font></strong><br /> <br /> Most of our staff returns each year because we have learned to treat them well. We provide costumes, makeup, jackets, flashlights, flares, parking lot pinnies, and anything they need to perform their job. They are also put on a payroll system and get a regular paycheck each week. We hire about 180 staff members each year. 100 are actors and entertainers, with the remainder being support staff. With a production like this, we need a pretty big security staff, so we hire off duty police officers. We have full time EMTs on site as well. Other support staff includes parking lot attendants, traffic control, ticket sales, and ticket takers, loading and unloading for the hayride, tractor drivers and concession staff. We operate with s system of managers for each part of our event. Managers include parking, security, concessions, maintenance for each event, mechanical for the tractors and wagons; make up, costumes and acting. This really takes the burden off of my wife and me. I am very proud of the employees we have as they are dedicated, team players. <br /> <font color="#ffcc00"><br /> <font color="#ffffff"><strong>10) Who are some of the key staff at your event?</strong></font></font><font color="#ffffff"> </font><br /> <br /> We have a HVAC manager named Mike Hearn, who has been with me since 1992. He can build just about anything out of steel, and makes most of our pyro props. John Brady did the sound for Jon Bon Jovi and John Melanchamp, and now handles the audio, sound and automation controls here. John also is a main player in our Christmas hayride. His wife, Kelly runs our concession stand and gift shop. Casey Grant has been building sets here since 2000. He has vast experience in carpentry. Todd Beringer is the operations manager for Amoroso Bakery, in Philadelphia, and brings a huge knowledge of automation to our show. Sam Bonsall is a commercial artist who works in a downtown office during the day. Harley Newton is the chief pathologist for the Bronx Zoo. She helps design and paint sets and props. Chris Polito and Marissa Giametteo are professional makeup artists. Jo Anna Van Thyne is the actor manager, and has a background in theatre. Jon Walsh and Charlie Conrad run the corn maze. A couple of brothers started last year. Shawn and Bob Sieger help with set design, painting and molding props. My sons, Ben and Drew, help during the summer, and my wife, Anne handles payroll and financials.&nbsp; Many other people come out each year to help set up and run the show. <br /> <font color="#ffcc00"><strong><br /> <font color="#ffffff">11) I understand your event is held on a working farm…what sorts of farming are you involved in?</font></strong></font><br /> <br /> The farming is really small time compared to the entertainment part of our business; however, we still raise game birds, sheep and chickens. We harvest hay and straw, and other crops, in order to keep our agricultural status. Other events include farm tours and pumpkin patches, as well as regular hayrides to a bonfire. Even though we are located just a few minutes from downtown Philadelphia, we still have that rural feeling. My wife and kids all help on the farm, and work the events too. </font><br /> <font color="#ffcc00"><br /> <font color="#ffffff"><strong>12) You have a large well known Christmas show now. Is that a popular event?</strong></font><br /> <br /> We started our Holiday Hayride two years ago. It includes a hayride through the rolling hills of the farm, with giant light displays, snow machines and live reindeer. A Santa's workshop includes 20 animatronic elves building toys, a real beard Santa, and several other Christmas displays. It's pretty funny as many of our Christmas customers have been to the Bates Motel. They are very tentative when entering Santa's workshop, as it is located in a section of our haunt! We also sell Christmas trees, wreaths and decorations. It really funny when my boys crank up the chain saw (with the blade on) to trim the trees. The Holiday Hayride is growing in popularity and we hope to grow it into a much larger event.<br /> <br /> <font color="#ffffff"><strong>13) Where do you see the haunt industry headed in the next few years?</strong></font><br /> <br /> I think the haunted attraction industry will have some ups and downs in the next few years. Everything is getting very high tech, and customers are looking for more &quot;wow&quot;. I believe we will need to add bigger and better props and scares, and move towards newer high tech advertising, and other types of promotions. Those who do not grow with the industry, and make changes, will be left in the dust. I also see a big jump in cooperative marketing. If you are in an area where there are other haunted attractions, try to team up with them to make the public aware of this industry.</font></p> <p align="center"><font color="#ffcc00"><img hspace="10" alt="" align="middle" width="602" height="387" src="http://www.hauntedhouseonline.com/userfiles/Image/bates_4.jpg" /></font></p> <p>&nbsp;</p> <p>&nbsp;</p> <p class="pageheader" align="center">To Find the best haunted houses in Pennsylvania PA click on this link <a href="http://www.hauntworld.com/pennsylvania_haunted_houses">http://www.hauntworld.com/pennsylvania_haunted_houses</a></p> <p class="pageheader" align="center">On that page you will find over 100 PA Haunted Houses.</p> </td> </tr> </tbody> </table> <p></p></td> </tr> <tr> <td class="text4">Posted On Tuesday, Jan 17,2012</td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="3" border="0" width="100%"> <tbody> <tr> <td> <table cellpadding="0" cellspacing="1" width="100%" align="center" border="0"> <tbody> <tr> <td class="text4"> <font color="#006633"><strong>To add comments login as user.</strong></font> <a href="/guestlogin.cfm?returnURL=/haunted_house_in_gradyville_Pennsylvania_the_bates_motel/blogs/138">Login here</a> </td> </tr> </tbody> </table> <div id="divAddcomment" style="display:none;"> <table cellpadding="5" cellspacing="1" width="100%" align="center" border="0"> <tbody> <tr> <td class="memsub_bordera"> <table cellpadding="0" cellspacing="1" width="100%" align="center" border="0"> <tbody> <tr> <td width="100%"> <table cellpadding="0" cellspacing="1" width="100%" border="0"> <tbody> <tr> <td><textarea name="AddGuestComment" class="txtfielda" rows="5" cols="50" onkeyup="textLimit(frm_Viewblog.AddGuestComment,500)"></textarea></td> </tr> <tr> <td> <input type="button" name="AddComment" value="Add your Comment" class="but" onclick="valid();" />&nbsp; <input type="button" name="AclodeComment" value="close" class="but" onclick="Hidediv('divAddcomment')" /> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </div> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </div> </div> <b class="abottom"> <b class="ab4"></b> <b class="ab3"></b> <b class="ab2"></b> <b class="ab1"></b> </b> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%">&nbsp;</td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%">&nbsp;</td> </tr> </tbody> </table> <table cellpadding="0" cellspacing="0" border="0"> <tbody> <tr> <td></td> </tr> </tbody> </table> </td> <td width="2%">&nbsp;</td> <td width="20%" valign="top"> <script src="http://connect.facebook.net/en_US/all.js"></script> <script> function funlogin() { var frm=document.frm_guestlogin; frm.loginmethod.value='GuestLogin'; frm.submit(); } function funlogout() { FB.init({ appId:'157814444240305', cookie:true, status:true, xfbml:true }); FB.logout(function(response) { // user is now logged out // window.location.href=window.location.href; funlogout1(); }); } function funlogout1() { frm=window.document.frm_guestlogin; frm.loginmethod.value='GuestLogOut'; frm.submit(); } function funchangepassword() { frm=window.document.frm_guestlogin; frm.showdiv.value="ChangePassword"; frm.action='/guestlogin.cfm'; frm.submit(); } function funsignup() { frm=window.document.frm_guestlogin; frm.showdiv.value="divRegister"; frm.action='/guestlogin.cfm'; frm.submit(); } function funEditProfile() { frm=window.document.frm_guestlogin; frm.showdiv.value="divEdit"; frm.action='/myaccount/Owner_profile.cfm'; frm.submit(); } </script> <div id="fb-root"></div> <b class="atop"> <b class="ab1"></b> <b class="ab2 color_a"></b> <b class="ab3 color_a"></b> <b class="ab4 color_a"></b> </b> <div class="aboxcontent"> <table cellspacing="0" cellpadding="3" border="0" width="100%"> <tbody> <tr> <td width="100%" class="color_a">Login here</td> </tr> </tbody> </table> <div> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%"> <form name="frm_guestlogin" action="/guestlogin_action.cfm" method="post"> <input type="hidden" name="loginmethod" value="" /> <input type="HIDDEN" name="returnURL" value="/haunted_house_in_gradyville_Pennsylvania_the_bates_motel/blogs/138" /> <input type="HIDDEN" name="showdiv" value="" /> </form></td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="1%">&nbsp;</td> <td width="98%" align="center"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tbody> <tr> <td width="30%" class="text4">User Name</td> <td width="70%" height="25"><input type="text" name="guestuserid" size="15" maxlength="50" class="txtfield" /></td> </tr> <tr> <td class="text4">Password</td> <td height="25"><input type="password" name="pass" size="15" maxlength="25" height="20" class="txtfield" /></td> </tr> <tr> <td colspan="2" align="center" class="text4"> <a href="javascript:funlogin();">Login</a> </td> </tr> <tr> <td colspan="2" align="center" class="text4"> <a href="javascript:funsignup()">Guest Sign Up</a>&nbsp;&nbsp;|&nbsp;&nbsp;<a href="http://www.hauntworld.com/myaccount/new_sign_up.cfm">Owner Sign Up</a> </td> </tr> </tbody> </table> </td> <td width="1%">&nbsp;</td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%"></td> </tr> </tbody> </table> </div> </div> <b class="abottom"> <b class="ab4"></b> <b class="ab3"></b> <b class="ab2"></b> <b class="ab1"></b> </b> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" height="10"></td> </tr> </tbody> </table> <div style="display:none;"> <table class="copy" height="450" cellspacing="0" cellpadding="5" width="100" border="0"> <tbody> <tr> <td valign="top" align="left" height="450"> <div id="hold4"> <div id="wn4"> <div class="content" id="lyr14"> </div> </div> </div> </td> <td id="scrollLinks4" width="20" height="450"> <div id="scrollbar4"> <div id="up"> <a onmouseup="dw_scrollObj.resetSpeed('wn4')" onmousedown="dw_scrollObj.doubleSpeed('wn4')" onmouseover="dw_scrollObj.initScroll('wn4','up')" onclick="return false" onmouseout="dw_scrollObj.stopScroll('wn4')" href="javascript:;"><img height="13" alt="Up Scroll" src="http://cdn.hauntedhouseonline.com/images/scroll_btn_up.jpg" width="15" border="0" title="Up Scroll" /></a> </div> <div id="track4"> <div id="dragBar4"></div> </div> <div id="down"> <a onmouseup="dw_scrollObj.resetSpeed('wn4')" onmousedown="dw_scrollObj.doubleSpeed('wn4')" onmouseover="dw_scrollObj.initScroll('wn4','down')" onclick="return false" onmouseout="dw_scrollObj.stopScroll('wn4')" href="javascript:;"><img height="13" src="http://cdn.hauntedhouseonline.com/images/scroll_btn_down.jpg" width="15" border="0" alt="Down Scroll" title="Down Scroll" /></a> </div> </div> </td> </tr> </tbody> </table> </div> <table cellspacing="0" cellpadding="0" width="200" border="0"> <tbody> <tr> <td> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" height="5"></td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" class="he_border"> <table cellspacing="1" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" class="mosthe"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" align="center" class="mosthelink">Members' latest activity on haunt</td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" height="5"></td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_border"> <table cellspacing="1" cellpadding="2" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_bg"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="15%" valign="top"> <img src="http://cdn.hauntedhouseonline.com/images/noimgavailable.gif" width="35" height="34" border="0" alt="" /> </td> <td width="10%" valign="top" align="center" class="mostviewlink"></td> <td width="75%" valign="top"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td class="mostviewlink"><a href="/viewprofile.cfm?FromURL=%2Fprofile%2F&amp;ID=16314">Patrick Matthews...</a></td> </tr> <tr> <td class="text5">New video added </td> </tr> <tr> <td class="text4"> ( 1 hour ago ) - <a href="/viewhauntvideo.cfm?FromURL=%2Fhttp%5Fnightmarestudios%5Ftripod%5Fcom%5Fzombieapocalypse%5Fhtml%2Fvideos%2F2223&amp;HauntvideoID=2223">View</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" height="3"></td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_border"> <table cellspacing="1" cellpadding="2" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_bg"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="15%" valign="top"> <img src="http://cdn.hauntedhouseonline.com/images/noimgavailable.gif" width="35" height="34" border="0" alt="" /> </td> <td width="10%" valign="top" align="center" class="mostviewlink"></td> <td width="75%" valign="top"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td class="mostviewlink"><a href="/viewprofile.cfm?FromURL=%2Fprofile%2F&amp;ID=16313">Gary Berger...</a></td> </tr> <tr> <td class="text5">New video added </td> </tr> <tr> <td class="text4"> ( 2 hours ago ) - <a href="/viewhauntvideo.cfm?FromURL=%2Fhaunted%5Fhouse%5Fin%5Fguthrie%5FOklahoma%5Fguthrie%5Fhaunts%5Fscaregrounds%2Fvideos%2F2222&amp;HauntvideoID=2222">View</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" height="3"></td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_border"> <table cellspacing="1" cellpadding="2" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_bg"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="15%" valign="top"> <img src="http://cdn.hauntedhouseonline.com/images/noimgavailable.gif" width="35" height="34" border="0" alt="" /> </td> <td width="10%" valign="top" align="center" class="mostviewlink"></td> <td width="75%" valign="top"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td class="mostviewlink"><a href="/viewprofile.cfm?FromURL=%2Fprofile%2Fgashfx&amp;ID=16310">Brecky</a></td> </tr> <tr> <td class="text5">New photo added </td> </tr> <tr> <td class="text4"> ( 3 days ago ) - <a href="/viewhauntphoto.cfm?FromURL=%2Fhaunted%5Fhouse%5Fin%5Fmount%5Fvernon%5FWashington%5Fhaunted%5Fnightmare%5Fat%2Fphotos%2F5663&amp;HauntphotoID=5663">View</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" height="3"></td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_border"> <table cellspacing="1" cellpadding="2" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_bg"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="15%" valign="top"> <img src="http://cdn.hauntedhouseonline.com/images/noimgavailable.gif" width="35" height="34" border="0" alt="" /> </td> <td width="10%" valign="top" align="center" class="mostviewlink"></td> <td width="75%" valign="top"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td class="mostviewlink"><a href="/viewprofile.cfm?FromURL=%2Fprofile%2Fgashfx&amp;ID=16310">Brecky</a></td> </tr> <tr> <td class="text5">New photo added </td> </tr> <tr> <td class="text4"> ( 3 days ago ) - <a href="/viewhauntphoto.cfm?FromURL=%2Fhaunted%5Fhouse%5Fin%5Fmount%5Fvernon%5FWashington%5Fhaunted%5Fnightmare%5Fat%2Fphotos%2F5662&amp;HauntphotoID=5662">View</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" height="3"></td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_border"> <table cellspacing="1" cellpadding="2" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_bg"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="15%" valign="top"> <img src="http://cdn.hauntedhouseonline.com/images/noimgavailable.gif" width="35" height="34" border="0" alt="" /> </td> <td width="10%" valign="top" align="center" class="mostviewlink"></td> <td width="75%" valign="top"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td class="mostviewlink"><a href="/viewprofile.cfm?FromURL=%2Fprofile%2Fgashfx&amp;ID=16310">Brecky</a></td> </tr> <tr> <td class="text5">New photo added </td> </tr> <tr> <td class="text4"> ( 3 days ago ) - <a href="/viewhauntphoto.cfm?FromURL=%2Fhaunted%5Fhouse%5Fin%5Fmount%5Fvernon%5FWashington%5Fhaunted%5Fnightmare%5Fat%2Fphotos%2F5661&amp;HauntphotoID=5661">View</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" height="3"></td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_border"> <table cellspacing="1" cellpadding="2" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_bg"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="15%" valign="top"> <img src="http://cdn.hauntedhouseonline.com/images/noimgavailable.gif" width="35" height="34" border="0" alt="" /> </td> <td width="10%" valign="top" align="center" class="mostviewlink"></td> <td width="75%" valign="top"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td class="mostviewlink"><a href="/viewprofile.cfm?FromURL=%2Fprofile%2Fgashfx&amp;ID=16310">Brecky</a></td> </tr> <tr> <td class="text5">New photo added </td> </tr> <tr> <td class="text4"> ( 3 days ago ) - <a href="/viewhauntphoto.cfm?FromURL=%2Fhaunted%5Fhouse%5Fin%5Fmount%5Fvernon%5FWashington%5Fhaunted%5Fnightmare%5Fat%2Fphotos%2F5660&amp;HauntphotoID=5660">View</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" height="3"></td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_border"> <table cellspacing="1" cellpadding="2" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_bg"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="15%" valign="top"> <img src="http://cdn.hauntedhouseonline.com/images/noimgavailable.gif" width="35" height="34" border="0" alt="" /> </td> <td width="10%" valign="top" align="center" class="mostviewlink"></td> <td width="75%" valign="top"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td class="mostviewlink"><a href="/viewprofile.cfm?FromURL=%2Fprofile%2Fgashfx&amp;ID=16310">Brecky</a></td> </tr> <tr> <td class="text5">New photo added </td> </tr> <tr> <td class="text4"> ( 3 days ago ) - <a href="/viewhauntphoto.cfm?FromURL=%2Fhaunted%5Fhouse%5Fin%5Fmount%5Fvernon%5FWashington%5Fhaunted%5Fnightmare%5Fat%2Fphotos%2F5659&amp;HauntphotoID=5659">View</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" height="3"></td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_border"> <table cellspacing="1" cellpadding="2" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_bg"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="15%" valign="top"> <img src="http://cdn.hauntedhouseonline.com/images/noimgavailable.gif" width="35" height="34" border="0" alt="" /> </td> <td width="10%" valign="top" align="center" class="mostviewlink"></td> <td width="75%" valign="top"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td class="mostviewlink"><a href="/viewprofile.cfm?FromURL=%2Fprofile%2Fgashfx&amp;ID=16310">Brecky</a></td> </tr> <tr> <td class="text5">New photo added </td> </tr> <tr> <td class="text4"> ( 3 days ago ) - <a href="/viewhauntphoto.cfm?FromURL=%2Fhaunted%5Fhouse%5Fin%5Fmount%5Fvernon%5FWashington%5Fhaunted%5Fnightmare%5Fat%2Fphotos%2F5658&amp;HauntphotoID=5658">View</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" height="3"></td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_border"> <table cellspacing="1" cellpadding="2" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_bg"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="15%" valign="top"> <img src="http://cdn.hauntedhouseonline.com/images/noimgavailable.gif" width="35" height="34" border="0" alt="" /> </td> <td width="10%" valign="top" align="center" class="mostviewlink"></td> <td width="75%" valign="top"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td class="mostviewlink"><a href="/viewprofile.cfm?FromURL=%2Fprofile%2Fjim%5Fghoulmansion%5Fcom&amp;ID=1397">Jim Bugos</a></td> </tr> <tr> <td class="text5">New photo added </td> </tr> <tr> <td class="text4"> ( 4 days ago ) - <a href="/viewhauntphoto.cfm?FromURL=%2Fhaunted%5Fhouse%5Fin%5Fsharon%5FPennsylvania%5Fghoul%5Fmansion%2Fphotos%2F5657&amp;HauntphotoID=5657">View</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" height="3"></td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_border"> <table cellspacing="1" cellpadding="2" border="0" width="100%"> <tbody> <tr> <td width="100%" class="viewed_attractions_bg"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="15%" valign="top"> <img src="http://cdn.hauntedhouseonline.com/images/noimgavailable.gif" width="35" height="34" border="0" alt="" /> </td> <td width="10%" valign="top" align="center" class="mostviewlink"></td> <td width="75%" valign="top"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td class="mostviewlink"><a href="/viewprofile.cfm?FromURL=%2Fprofile%2Fjim%5Fghoulmansion%5Fcom&amp;ID=1397">Jim Bugos</a></td> </tr> <tr> <td class="text5">New photo added </td> </tr> <tr> <td class="text4"> ( 4 days ago ) - <a href="/viewhauntphoto.cfm?FromURL=%2Fhaunted%5Fhouse%5Fin%5Fsharon%5FPennsylvania%5Fghoul%5Fmansion%2Fphotos%2F5656&amp;HauntphotoID=5656">View</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" height="3"></td> </tr> </tbody> </table> <!-- Section one start --> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" height="3"></td> </tr> </tbody> </table> <!-- Section one end --> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <script> var FB1 = new Array(); var count =0 FB1[count] = 'http://cdn.hauntedhouseonline.com/banners/topbanner_3_hunt.jpg'; </script> <script> var FB2 = new Array(); var count =0 FB2[count] = 'http://cdn.hauntedhouseonline.com/banners/topbanner_4_hunt.jpg'; </script> <table cellspacing="0" cellpadding="0" border="0" width="1000"> <tbody> <tr> <td width="100%" class="linkbgb" align="center"> <table cellspacing="0" cellpadding="2" border="0" width="100%"> <tbody> <tr> <td class="folink" align="center"> <a href="/profile_list">Members</a>&nbsp; <img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" />&nbsp; <a href="/">Featured Haunts</a>&nbsp; <img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" />&nbsp; <a href="/haunted_attraction_information.cfm">Haunted Facts</a>&nbsp; <img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" />&nbsp; <a href="/MostViewdHaunt.cfm">Find Most Popular Viewed Haunts</a>&nbsp; <img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" />&nbsp; <a href="/ViewAllPhotos.cfm">Latest Photo Uploads</a>&nbsp; <img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" />&nbsp; <a href="/ViewAllVideos.cfm">Watch Latest Videos</a>&nbsp; <img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" />&nbsp; <a href="/ViewAllBlogs.cfm">Read Latest Blogs</a> <br /> Rate a Haunt and Write Reviews Today&nbsp; <img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" />&nbsp; <a href="http://www.hauntworld.com/myaccount/new_sign_up.cfm">Sign Up Now</a>&nbsp; <img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" />&nbsp; <a href="http://www.hauntworld.com/" target="_blank">Haunt World</a>&nbsp; <img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" />&nbsp; <a href="#" title="Coming soon...">Free Pumpkin Patterns, Templates &amp; Tips</a> <img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" />&nbsp; <a href="/guestlogin.cfm">Guest Login</a>&nbsp; <img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" />&nbsp; <a href="http://www.hauntworld.com/haunted_house_forums/" target="_blank">Haunted Forums</a> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="1000"> <tbody> <tr> <td width="1000" class="linkbga" align="center"> <table cellspacing="0" cellpadding="2" border="0"> <tbody> <tr> <td class="folink"><a href="/halloween_haunted_house_links.cfm">Haunted links</a></td> <td><img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" /></td> <td class="folink"><a href="http://hauntworld.com/horror_games_halloween.php" target="_blank">Haunted Games</a></td> <td><img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" /></td> <td class="folink"><a href="http://groups.yahoo.com/group/hauntworld/" target="_blank">Join Yahoo Clubs</a></td> <td><img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" /></td> <td class="folink"><a href="#" title="Coming soon...">Find Haunted Vendors</a></td> <td><img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" /></td> <td class="folink"><a href="http://hauntworld.com/halloween_screensavers_haunted_house.php" target="_blank">Download Hauntworld Banners &amp; Screensavers</a></td> <td><img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" /></td> <td class="folink"><a href="http://www.hauntworld.com/haunted_house_marketing/index.html" target="_blank">Advertise With Us</a></td> <td><img src="http://cdn.hauntedhouseonline.com/images/line.jpg" width="2" height="12" border="0" alt="" /></td> <td class="folink"><a href="/haunted_house_association_contact_information.cfm">Contact Us</a></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="1000"> <tbody> <tr> <td width="1000"><img src="http://cdn.hauntedhouseonline.com/images/footer_strip.jpg" width="1000" height="23" border="0" alt="" /></td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="1000"> <tbody> <tr> <td width="1000" class="topbannerbg"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="50%"> <script type="text/javascript"><!-- google_ad_client = "ca-pub-7070187019671677"; /* TOP BANNER */ google_ad_slot = "7982422700"; google_ad_width = 468; google_ad_height = 60; //--> </script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"> </script> </td> <td width="50%" align="right"> <script type="text/javascript"><!-- google_ad_client = "ca-pub-7070187019671677"; /* TOP BANNER */ google_ad_slot = "7982422700"; google_ad_width = 468; google_ad_height = 60; //--> </script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"> </script> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr> <td width="100%" bgcolor="##000000" align="center" class="text4"> <a href="/halloween_haunted_house_Conditon.cfm">Condition of use</a> | <a href="/halloween_haunted_house_privacy.cfm">Privacy notice</a> &copy; 2008 Halloween Production Inc. | All Rights Reserved </td> </tr> </tbody> </table> <table> <tbody> <tr> <td> <script src="http://www.google-analytics.com/urchin.js" type="text/javascript"> </script> <script type="text/javascript"> _uacct = "UA-4130632-1"; urchinTracker(); </script> </td> </tr> </tbody> </table> </div> </center> </body> </html>
182	faceted	quit smoking	What are the ways you can quit smoking?	clueweb09-en0003-56-06359	2	<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <head profile="http://gmpg.org/xfn/11"> <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /> <meta name="generator" content="WordPress 1.5.2" /> <!-- leave this for stats --> <title>Quit Smoking</title> <link rel="stylesheet" href="http://self-help.vocaboly.com/wp-content/themes/thirteen/style.css" type="text/css" media="screen" /> <link rel="alternate" type="application/rss+xml" title="RSS 2.0" href="http://self-help.vocaboly.com/feed/" /> <link rel="alternate" type="text/xml" title="RSS .92" href="http://self-help.vocaboly.com/feed/rss/" /> <link rel="alternate" type="application/atom+xml" title="Atom 0.3" href="http://self-help.vocaboly.com/feed/atom/" /> <link rel="pingback" href="http://self-help.vocaboly.com/xmlrpc.php" /> <style type="text/css"> /* For medium length blog names, uncomment this CSS (remove these two lines, and the next * / one) #title { font-size: 2em; } #title a { padding-top: 15px !important; voice-family: "\"}\""; voice-family: inherit; height: 40px !important; } html>body #title a { height: 40px !important; } */ /* For long blog names, uncomment this CSS (remove these two lines, and the next * / one) #title { font-size: 1.8em; } #title a { padding-top: 18px !important; voice-family: "\"}\""; voice-family: inherit; height: 37px !important; } html>body #title a { height: 37px !important; } */ </style> <link rel="archives" title="September 2007" href="http://self-help.vocaboly.com/archives/date/2007/09/" /> <link rel="archives" title="May 2007" href="http://self-help.vocaboly.com/archives/date/2007/05/" /> <link rel="archives" title="March 2007" href="http://self-help.vocaboly.com/archives/date/2007/03/" /> <link rel="archives" title="February 2007" href="http://self-help.vocaboly.com/archives/date/2007/02/" /> <link rel="archives" title="January 2007" href="http://self-help.vocaboly.com/archives/date/2007/01/" /> <link rel="archives" title="December 2006" href="http://self-help.vocaboly.com/archives/date/2006/12/" /> <link rel="archives" title="November 2006" href="http://self-help.vocaboly.com/archives/date/2006/11/" /> <link rel="archives" title="October 2006" href="http://self-help.vocaboly.com/archives/date/2006/10/" /> <link rel="archives" title="September 2006" href="http://self-help.vocaboly.com/archives/date/2006/09/" /> <link rel="archives" title="August 2006" href="http://self-help.vocaboly.com/archives/date/2006/08/" /> <link rel="archives" title="July 2006" href="http://self-help.vocaboly.com/archives/date/2006/07/" /> <link rel="archives" title="June 2006" href="http://self-help.vocaboly.com/archives/date/2006/06/" /> <link rel="archives" title="May 2006" href="http://self-help.vocaboly.com/archives/date/2006/05/" /> <link rel="archives" title="April 2006" href="http://self-help.vocaboly.com/archives/date/2006/04/" /> <link rel="archives" title="March 2006" href="http://self-help.vocaboly.com/archives/date/2006/03/" /> <link rel="archives" title="February 2006" href="http://self-help.vocaboly.com/archives/date/2006/02/" /> <link rel="archives" title="January 2006" href="http://self-help.vocaboly.com/archives/date/2006/01/" /> <link rel="archives" title="December 2005" href="http://self-help.vocaboly.com/archives/date/2005/12/" /> </head> <body> <div id="headwrapper"> <div id="header"> <h1 id="title"><a href="http://self-help.vocaboly.com">Self Help</a></h1> </div> </div> <div id="wrapper"> <div id="content" class="narrowcolumn"> <h2 class="pagetitle">Quit Smoking</h2> <script type="text/javascript"><!--google_ad_client = "pub-8768391963079401";google_ad_width = 336;google_ad_height = 280;google_ad_format = "336x280_as";google_ad_type = "text_image";google_ad_channel ="";google_color_border = "FFFFE3";google_color_bg = "FFFFE3";google_color_link = "C86C00";google_color_text = "000000";google_color_url = "008000";//--></script> <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script> <div class="post"> <h3 id="post-1228"><a href="http://self-help.vocaboly.com/archives/1228/the-dangers-of-false-%e2%80%9csmoke-safe%e2%80%9d-solutions/" rel="bookmark" title="Permanent Link to The Dangers of False Smoke-Safe Solutions">The Dangers of False Smoke-Safe Solutions</a></h3> <small>Sunday, September 17th, 2006</small> <div class="entry"> <p>The tobacco companies have brought out several cigarettes they’d like us to believe are safer than regular cigarettes. A product called Eclipse burns a piece of charcoal. The smoke from the charcoal passes over beads with nicotine extract on them.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1228/the-dangers-of-false-%e2%80%9csmoke-safe%e2%80%9d-solutions/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1227"><a href="http://self-help.vocaboly.com/archives/1227/talk-with-your-doctor-before-you-officially-quit-smoking/" rel="bookmark" title="Permanent Link to Talk with Your Doctor Before You Officially Quit Smoking">Talk with Your Doctor Before You Officially Quit Smoking</a></h3> <small>Saturday, September 16th, 2006</small> <div class="entry"> <p>Before you start your countdown to quit-smoking day, do consider making an appointment with your doctor to discuss your plans.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1227/talk-with-your-doctor-before-you-officially-quit-smoking/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1226"><a href="http://self-help.vocaboly.com/archives/1226/why-having-a-relapse-after-you-quit-smoking-is-a-good-thing/" rel="bookmark" title="Permanent Link to Why Having a Relapse After You Quit Smoking Is a Good Thing!">Why Having a Relapse After You Quit Smoking Is a Good Thing!</a></h3> <small>Friday, September 15th, 2006</small> <div class="entry"> <p>It may seem too soon to discuss the concept of relapse since you may not have even begun your quit attempt as yet. But it’s important to discuss relapse now because, chances are, you’ve experienced a return to smoking after a quit attempt in the past. Before you go forward now, you need to deal with the feelings of frustration and failure you felt the last time you relapsed.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1226/why-having-a-relapse-after-you-quit-smoking-is-a-good-thing/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1225"><a href="http://self-help.vocaboly.com/archives/1225/turning-to-family-friends-after-having-a-smoking-relapse/" rel="bookmark" title="Permanent Link to Turning to Family &amp; Friends After Having a Smoking Relapse">Turning to Family &amp; Friends After Having a Smoking Relapse</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>Just as athletes rely on their team members and encourage each other, don’t forget that you have a team, too. Now that the going’s gotten rough with your decision to quit smoking, it’s time to call on your team - the family and friends who will cooperate and encourage you in your “big game.”</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1225/turning-to-family-friends-after-having-a-smoking-relapse/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1224"><a href="http://self-help.vocaboly.com/archives/1224/safeguarding-against-temptations-to-smoke/" rel="bookmark" title="Permanent Link to Safeguarding Against Temptations to Smoke">Safeguarding Against Temptations to Smoke</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>In order to stay on your course of becoming a nonsmoker, you’ll have to keep vigilant and guard against the temptations that could cause you to slip up.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1224/safeguarding-against-temptations-to-smoke/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1223"><a href="http://self-help.vocaboly.com/archives/1223/helping-your-child-overcome-the-peer-pressure-to-smoke/" rel="bookmark" title="Permanent Link to Helping Your Child Overcome the Peer Pressure to Smoke">Helping Your Child Overcome the Peer Pressure to Smoke</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>One of the most common reasons kids smoke is to fit in with their friends. If the group they hang out with smokes, they’ll probably feel pressured to try a few cigarettes.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1223/helping-your-child-overcome-the-peer-pressure-to-smoke/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1222"><a href="http://self-help.vocaboly.com/archives/1222/cigars-are-they-just-as-dangerous-as-cigarettes/" rel="bookmark" title="Permanent Link to Cigars: Are They Just as Dangerous as Cigarettes?">Cigars: Are They Just as Dangerous as Cigarettes?</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>Many people who smoke cigars are surprised to find out that they are addictive. But when you consider the fact that a typical cigar contains as much nicotine as at least three or four cigarettes, it’s not a surprise any longer.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1222/cigars-are-they-just-as-dangerous-as-cigarettes/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1221"><a href="http://self-help.vocaboly.com/archives/1221/smoking-breaking-the-habit/" rel="bookmark" title="Permanent Link to Smoking: Breaking the Habit">Smoking: Breaking the Habit</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>It is often said that cigarette smoking is the single most important modifiable risk factor for illness and the greatest single cause of preventable premature deaths in the United States. What exactly can be expected when smokers “modify” their behavior?</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1221/smoking-breaking-the-habit/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1220"><a href="http://self-help.vocaboly.com/archives/1220/are-you-smoking-for-mental-needs/" rel="bookmark" title="Permanent Link to Are You Smoking for Mental Needs?">Are You Smoking for Mental Needs?</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>About 20 to 50 percent of cigarettes are smoked for an explicit, expressed need. Smokers come to rely on cigarettes to hone their performance.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1220/are-you-smoking-for-mental-needs/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1219"><a href="http://self-help.vocaboly.com/archives/1219/nicotine-replacement-therapies-nasal-sprays-inhalers/" rel="bookmark" title="Permanent Link to Nicotine Replacement Therapies: Nasal Sprays &amp; Inhalers">Nicotine Replacement Therapies: Nasal Sprays &amp; Inhalers</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p> Nicotine Nasal Spray<br /> Nicotine nasal spray became available by prescription in March 1996. It comes in a pump bottle and is sprayed into the nose, one time in each nostril. If you decide to use the spray, it’s important not to inhale while spraying because you want the nicotine to attach to the nasal lining. Once […]</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1219/nicotine-replacement-therapies-nasal-sprays-inhalers/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1218"><a href="http://self-help.vocaboly.com/archives/1218/nicotine-replacement-therapies/" rel="bookmark" title="Permanent Link to Nicotine Replacement Therapies">Nicotine Replacement Therapies</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>Although it may seem unbelievable, the first pharmacological agent approved by the Food and Drug Administration (FDA) for use in smoking cessation therapy was nicotine.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1218/nicotine-replacement-therapies/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1217"><a href="http://self-help.vocaboly.com/archives/1217/nicotine-anonymous-the-pros-cons-of-the-12-step-program/" rel="bookmark" title="Permanent Link to Nicotine Anonymous: The Pros &amp; Cons of the 12-Step Program">Nicotine Anonymous: The Pros &amp; Cons of the 12-Step Program</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p> The following Are the Twelve Steps of Nicotine Anonymous:<br /> 1. We admitted that we were powerless over nicotine - that our lives had become unmanageable.<br />2. Came to believe that a Power greater than ourselves could restore us to sanity.<br />3. Made a decision to turn our will and our lives over to the care of God as […]</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1217/nicotine-anonymous-the-pros-cons-of-the-12-step-program/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1216"><a href="http://self-help.vocaboly.com/archives/1216/nicotine-anonymous-a-free-program-for-people-addicted-to-nicotine/" rel="bookmark" title="Permanent Link to Nicotine Anonymous: A Free Program for People Addicted to Nicotine">Nicotine Anonymous: A Free Program for People Addicted to Nicotine</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>Nicotine Anonymous is sort of a cousin program of Alcoholics Anonymous. Many people who have become addicted to alcohol have successfully quit by using the 12-step program that’s part of Alcoholics Anonymous.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1216/nicotine-anonymous-a-free-program-for-people-addicted-to-nicotine/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1215"><a href="http://self-help.vocaboly.com/archives/1215/basic-information-about-nicotine-patches/" rel="bookmark" title="Permanent Link to Basic Information About Nicotine Patches">Basic Information About Nicotine Patches</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>The nicotine patch is applied to your skin. Over a prolonged period of time, the nicotine dissolves right through the skin and enters the body. Nicotine from the patch replaces some of the nicotine you were getting from cigarettes.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1215/basic-information-about-nicotine-patches/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1214"><a href="http://self-help.vocaboly.com/archives/1214/substituting-caffeine-for-nicotine/" rel="bookmark" title="Permanent Link to Substituting Caffeine for Nicotine?">Substituting Caffeine for Nicotine?</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>Since nicotine is a central nervous system stimulant, you may be wondering if you could substitute caffeine for nicotine.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1214/substituting-caffeine-for-nicotine/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1213"><a href="http://self-help.vocaboly.com/archives/1213/your-first-day-of-quitting-smoking/" rel="bookmark" title="Permanent Link to Your First Day of Quitting Smoking">Your First Day of Quitting Smoking</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>Here are 3 strategies to help you on your first day of quitting smoking.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1213/your-first-day-of-quitting-smoking/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1212"><a href="http://self-help.vocaboly.com/archives/1212/using-meditation-to-help-keep-you-in-%e2%80%9cnon-smoker-status%e2%80%9d/" rel="bookmark" title="Permanent Link to Using Meditation to Help Keep You in Non-Smoker Status">Using Meditation to Help Keep You in Non-Smoker Status</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>Keeping your mind strong and supple will help you maintain a nonsmoker status and reduce your stress during the battle to quit. Meditation can help you summon your mind’s healing energy, and retrieve your mind from a war zone and place it in a neutral zone.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1212/using-meditation-to-help-keep-you-in-%e2%80%9cnon-smoker-status%e2%80%9d/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1211"><a href="http://self-help.vocaboly.com/archives/1211/how-to-deal-with-the-psychological-dependency-of-smoking/" rel="bookmark" title="Permanent Link to How to Deal with the Psychological Dependency of Smoking">How to Deal with the Psychological Dependency of Smoking</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>Although all forms of dependency on cigarettes have a certain chemical basis, unless you are a heavy smoker (pack a day or more) the chemical basis is not likely to be particularly strong.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1211/how-to-deal-with-the-psychological-dependency-of-smoking/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1210"><a href="http://self-help.vocaboly.com/archives/1210/how-smoking-affects-your-emotions/" rel="bookmark" title="Permanent Link to How Smoking Affects Your Emotions">How Smoking Affects Your Emotions</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>Nicotine is one of the fastest-acting drugs known to man. When a smoker inhales tobacco smoke, the nicotine is absorbed into the bloodstream and the effects are felt almost immediately.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1210/how-smoking-affects-your-emotions/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1209"><a href="http://self-help.vocaboly.com/archives/1209/common-frustrations-felt-when-it-comes-to-quitting-smoking-part-2/" rel="bookmark" title="Permanent Link to Common Frustrations Felt When It Comes to Quitting Smoking (Part 2)">Common Frustrations Felt When It Comes to Quitting Smoking (Part 2)</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>The tiny, hair-like structures in your lungs, called cilia, finally get a chance to begin sweeping out the tobacco debris that has accumulated over the years. Until now, the tar in your cigarettes had immobilized them, but now that they are free again, they sweep out the tar causing you to cough more than usual.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1209/common-frustrations-felt-when-it-comes-to-quitting-smoking-part-2/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1208"><a href="http://self-help.vocaboly.com/archives/1208/common-frustrations-felt-when-it-comes-to-quitting-smoking-part-1/" rel="bookmark" title="Permanent Link to Common Frustrations Felt When It Comes to Quitting Smoking (Part 1)">Common Frustrations Felt When It Comes to Quitting Smoking (Part 1)</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>If you used to take a break to smoke, you probably felt justified in doing so because you were actually “doing something” when you left your post for that 5 or 10 minutes.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1208/common-frustrations-felt-when-it-comes-to-quitting-smoking-part-1/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1207"><a href="http://self-help.vocaboly.com/archives/1207/tapering-off-your-cigarettes/" rel="bookmark" title="Permanent Link to Tapering off Your Cigarettes">Tapering off Your Cigarettes</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>After you have tapered off of your cigarette smoking for at least a week, the thought that you are about to break free and can never have another cigarette can be daunting.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1207/tapering-off-your-cigarettes/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1206"><a href="http://self-help.vocaboly.com/archives/1206/dont-let-your-guard-down-just-because-youve-stopped-smoking-for-a-while/" rel="bookmark" title="Permanent Link to Don’t Let Your Guard down Just Because You’ve Stopped Smoking for a While">Don’t Let Your Guard down Just Because You’ve Stopped Smoking for a While</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>After you have successfully stopped smoking for a while, you may feel quitting has been easier than you expected. Not that it’s been easy altogether, but it still has not been as hard as you feared.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1206/dont-let-your-guard-down-just-because-youve-stopped-smoking-for-a-while/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1205"><a href="http://self-help.vocaboly.com/archives/1205/psychological-recovery-stages-of-quitting-smoking-part-3-bargaining-acceptance/" rel="bookmark" title="Permanent Link to Psychological Recovery Stages of Quitting Smoking: Part 3 (Bargaining, Acceptance)">Psychological Recovery Stages of Quitting Smoking: Part 3 (Bargaining, Acceptance)</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>Many smokers are only slightly bothered by physical symptoms of nicotine withdrawal, but experience a lot more trouble with the psychological symptoms of recovery. Getting over the psychological loss can be very complex.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1205/psychological-recovery-stages-of-quitting-smoking-part-3-bargaining-acceptance/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1204"><a href="http://self-help.vocaboly.com/archives/1204/psychological-recovery-stages-of-quitting-smoking-part-2-anger-depression/" rel="bookmark" title="Permanent Link to Psychological Recovery Stages of Quitting Smoking: Part 2 (Anger, Depression)">Psychological Recovery Stages of Quitting Smoking: Part 2 (Anger, Depression)</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>Many smokers are only slightly bothered by physical symptoms of nicotine withdrawal, but experience a lot more trouble with the psychological symptoms of recovery. Getting over the psychological loss can be very complex.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1204/psychological-recovery-stages-of-quitting-smoking-part-2-anger-depression/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1203"><a href="http://self-help.vocaboly.com/archives/1203/psychological-recovery-stages-of-quitting-smoking-part-1-denial/" rel="bookmark" title="Permanent Link to Psychological Recovery Stages of Quitting Smoking: Part 1 (Denial)">Psychological Recovery Stages of Quitting Smoking: Part 1 (Denial)</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>Many smokers are only slightly bothered by physical symptoms of nicotine withdrawal, but experience a lot more trouble with the psychological symptoms of recovery. Getting over the psychological loss can be very complex.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1203/psychological-recovery-stages-of-quitting-smoking-part-1-denial/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1202"><a href="http://self-help.vocaboly.com/archives/1202/tips-to-help-you-cope-when-quitting-the-smoking-habit/" rel="bookmark" title="Permanent Link to Tips to Help You Cope When Quitting the Smoking Habit">Tips to Help You Cope When Quitting the Smoking Habit</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>Unless you are completely confident that the presence and sight of a cigarette will not provide a stimulus to smoke, you should get rid of all smoking paraphernalia, at least temporarily. Throw away or give away all cigarettes, ashtrays, cigarette lighters, and matches in your home and workplace.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1202/tips-to-help-you-cope-when-quitting-the-smoking-habit/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1201"><a href="http://self-help.vocaboly.com/archives/1201/5-steps-to-managing-weight-gain-for-the-ex-smoker/" rel="bookmark" title="Permanent Link to 5 Steps to Managing Weight-Gain for the Ex-Smoker">5 Steps to Managing Weight-Gain for the Ex-Smoker</a></h3> <small>Thursday, September 14th, 2006</small> <div class="entry"> <p>What if you have just recently quit smoking, still crave cigarettes, and to top it off, find that you are gaining weight? If you have just recently quit and are still fighting the urge to resume smoking, it’s best to move gradually into a weight-management program.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1201/5-steps-to-managing-weight-gain-for-the-ex-smoker/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1200"><a href="http://self-help.vocaboly.com/archives/1200/using-rewards-as-a-smoke-free-motivator/" rel="bookmark" title="Permanent Link to Using Rewards as a Smoke-Free Motivator">Using Rewards as a Smoke-Free Motivator</a></h3> <small>Monday, September 11th, 2006</small> <div class="entry"> <p>As human beings, many of our decisions in life are guided by what is known as the pleasure principle. In other words, if it feels good, we are likely to continue doing it; if it feels bad (physically or mentally), we are less likely to keep doing it or to try it again. So in order to quit smoking successfully, it’s important to make the process of quitting, and life thereafter, as positive and pleasurable as possible.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1200/using-rewards-as-a-smoke-free-motivator/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1199"><a href="http://self-help.vocaboly.com/archives/1199/the-nasty-truth-about-cigarettes/" rel="bookmark" title="Permanent Link to The Nasty Truth About Cigarettes">The Nasty Truth About Cigarettes</a></h3> <small>Monday, September 11th, 2006</small> <div class="entry"> <p>More than 700 chemical additives are found in cigarettes. Some of them are classified as toxic and are not allowed in food. Once lit, a cigarette reaches a temperature of nearly 2,000 degrees Fahrenheit.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1199/the-nasty-truth-about-cigarettes/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1198"><a href="http://self-help.vocaboly.com/archives/1198/how-to-use-nicotine-gum/" rel="bookmark" title="Permanent Link to How to Use Nicotine Gum">How to Use Nicotine Gum</a></h3> <small>Monday, September 11th, 2006</small> <div class="entry"> <p>When you use nicotine gum, chewing a piece every hour or whenever you have the urge to smoke, you tend to mimic the cyclic rise and fall of nicotine in your system that occurs when you smoke cigarettes.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1198/how-to-use-nicotine-gum/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1197"><a href="http://self-help.vocaboly.com/archives/1197/exercising-can-help-keep-you-smoke-free/" rel="bookmark" title="Permanent Link to Exercising Can Help Keep You Smoke-Free">Exercising Can Help Keep You Smoke-Free</a></h3> <small>Monday, September 11th, 2006</small> <div class="entry"> <p>The most important strategy in remaining free from smoking is to put an exercise component into your life.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1197/exercising-can-help-keep-you-smoke-free/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1196"><a href="http://self-help.vocaboly.com/archives/1196/smokeless-tobacco-is-just-as-dangerous-as-smoking-cigarettes/" rel="bookmark" title="Permanent Link to Smokeless Tobacco Is Just as Dangerous as Smoking Cigarettes">Smokeless Tobacco Is Just as Dangerous as Smoking Cigarettes</a></h3> <small>Monday, September 11th, 2006</small> <div class="entry"> <p>Many people seem to think that chewing tobacco and snuff are safe substitutes for cigarettes. But the truth is that they are not safe.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1196/smokeless-tobacco-is-just-as-dangerous-as-smoking-cigarettes/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1195"><a href="http://self-help.vocaboly.com/archives/1195/how-smoking-directly-destroys-vitamin-a-c-in-your-body/" rel="bookmark" title="Permanent Link to How Smoking Directly Destroys Vitamin A &amp; C in Your Body">How Smoking Directly Destroys Vitamin A &amp; C in Your Body</a></h3> <small>Monday, September 11th, 2006</small> <div class="entry"> <p>When it comes to the dangers of smoking and applying the will to quit, you can’t leave out a discussion of vitamin and mineral supplements. Vitamins are essential to life, and they can make or break a person’s health. Unfortunately, a cigarette is not a vitamin’s best friend.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1195/how-smoking-directly-destroys-vitamin-a-c-in-your-body/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1194"><a href="http://self-help.vocaboly.com/archives/1194/congratulations-on-your-final-%e2%80%9cquit-smoking%e2%80%9d-day/" rel="bookmark" title="Permanent Link to Congratulations on Your Final Quit Smoking Day!">Congratulations on Your Final Quit Smoking Day!</a></h3> <small>Monday, September 11th, 2006</small> <div class="entry"> <p>Your Quit Day is one of the most important days of your life, youve gotten ready to quit.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1194/congratulations-on-your-final-%e2%80%9cquit-smoking%e2%80%9d-day/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1193"><a href="http://self-help.vocaboly.com/archives/1193/a-question-for-smokers-would-you-drink-ammonia/" rel="bookmark" title="Permanent Link to A Question for Smokers: Would You Drink Ammonia?">A Question for Smokers: Would You Drink Ammonia?</a></h3> <small>Monday, September 11th, 2006</small> <div class="entry"> <p>This is scary: Did you know that there are chemicals added to cigarettes which increase the speed at which nicotine reaches your brain?</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1193/a-question-for-smokers-would-you-drink-ammonia/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1192"><a href="http://self-help.vocaboly.com/archives/1192/young-women-smoking-for-all-the-wrong-reasons/" rel="bookmark" title="Permanent Link to Young Women Smoking for All the Wrong Reasons">Young Women Smoking for All the Wrong Reasons</a></h3> <small>Monday, September 11th, 2006</small> <div class="entry"> <p>Nicotine dependency is the most common form of drug addiction and causes more deaths and disease than all other addictions combined.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1192/young-women-smoking-for-all-the-wrong-reasons/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1191"><a href="http://self-help.vocaboly.com/archives/1191/the-truth-about-cigarette-filters-they-dont-really-work/" rel="bookmark" title="Permanent Link to The Truth About Cigarette Filters: They Don’t Really Work!">The Truth About Cigarette Filters: They Don’t Really Work!</a></h3> <small>Monday, September 11th, 2006</small> <div class="entry"> <p>The filter of a cigarette is actually a very complicated structure that is made up of four parts. Basically, it consists of fibers bound together by glue, but there are also chemical additives that enhance the taste and speed up the rate at which nicotine is delivered to your brain.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1191/the-truth-about-cigarette-filters-they-dont-really-work/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1190"><a href="http://self-help.vocaboly.com/archives/1190/smoking-and-depression/" rel="bookmark" title="Permanent Link to Smoking and Depression">Smoking and Depression</a></h3> <small>Monday, September 11th, 2006</small> <div class="entry"> <p>Today little information suggests that nicotine use directly causes depression. Most evidence indicates that it is nicotine withdrawal that provokes depression.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1190/smoking-and-depression/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1189"><a href="http://self-help.vocaboly.com/archives/1189/a-scary-look-inside-the-body-of-a-smoker-part-2/" rel="bookmark" title="Permanent Link to A Scary Look Inside the Body of a Smoker (Part 2)">A Scary Look Inside the Body of a Smoker (Part 2)</a></h3> <small>Monday, September 11th, 2006</small> <div class="entry"> <p>Lets take a look at what happens inside your body each time you light up. Think about how quickly tobacco smoke can produce harmful effects.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1189/a-scary-look-inside-the-body-of-a-smoker-part-2/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1188"><a href="http://self-help.vocaboly.com/archives/1188/a-scary-look-inside-the-body-of-a-smoker-part-1/" rel="bookmark" title="Permanent Link to A Scary Look Inside the Body of a Smoker (Part 1)">A Scary Look Inside the Body of a Smoker (Part 1)</a></h3> <small>Monday, September 11th, 2006</small> <div class="entry"> <p>Let’s take a look at what happens inside your body each time you light up. Think about how quickly tobacco smoke can produce harmful effects.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1188/a-scary-look-inside-the-body-of-a-smoker-part-1/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1187"><a href="http://self-help.vocaboly.com/archives/1187/a-non-nicotine-pill-designed-to-help-you-quit-smoking/" rel="bookmark" title="Permanent Link to A Non-Nicotine Pill Designed to Help You Quit Smoking">A Non-Nicotine Pill Designed to Help You Quit Smoking</a></h3> <small>Monday, September 11th, 2006</small> <div class="entry"> <p>Even as you are reading this article, new medications are emerging to help smokers quit. In fact, there is a new prescription pill that’s designed to do just that.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1187/a-non-nicotine-pill-designed-to-help-you-quit-smoking/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1154"><a href="http://self-help.vocaboly.com/archives/1154/hypnosis-common-questions-people-have-when-using-hypnosis-to-quit-smoking/" rel="bookmark" title="Permanent Link to Hypnosis: Common Questions People Have When Using Hypnosis to Quit Smoking">Hypnosis: Common Questions People Have When Using Hypnosis to Quit Smoking</a></h3> <small>Saturday, September 9th, 2006</small> <div class="entry"> <p>How Does Hypnosis Work? Agreed suggestions are placed into your subconscious mind to help you to overcome problems.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1154/hypnosis-common-questions-people-have-when-using-hypnosis-to-quit-smoking/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1153"><a href="http://self-help.vocaboly.com/archives/1153/pay-attention-to-the-dangers-of-second-hand-smoke/" rel="bookmark" title="Permanent Link to Pay Attention to the Dangers of Second-Hand Smoke!">Pay Attention to the Dangers of Second-Hand Smoke!</a></h3> <small>Saturday, September 9th, 2006</small> <div class="entry"> <p>Even people who don’t smoke are often exposed to other people who smoke. Inhaling someone else’s cigarette smoke is called passive smoking or involuntary smoking. It is a proven health hazard to nonsmokers, and it’s not easy to avoid, because about one in four people smoke.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1153/pay-attention-to-the-dangers-of-second-hand-smoke/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1152"><a href="http://self-help.vocaboly.com/archives/1152/the-connection-between-smoking-stress/" rel="bookmark" title="Permanent Link to The Connection Between Smoking &amp; Stress">The Connection Between Smoking &amp; Stress</a></h3> <small>Saturday, September 9th, 2006</small> <div class="entry"> <p>Smoking often seems like one of the best ways of handling stressful situations. For example, when you smoke, you may physically remove yourself from a stressful situation by going into another room or even outside the home or office.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1152/the-connection-between-smoking-stress/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1151"><a href="http://self-help.vocaboly.com/archives/1151/hypnosis-the-pros-cons-of-using-hypnosis-to-help-quit-smoking/" rel="bookmark" title="Permanent Link to Hypnosis: The Pros &amp; Cons of Using Hypnosis to Help Quit Smoking">Hypnosis: The Pros &amp; Cons of Using Hypnosis to Help Quit Smoking</a></h3> <small>Saturday, September 9th, 2006</small> <div class="entry"> <p>When people talk about quitting smoking, they frequently mention hypnosis. In fact, hypnosis is one of the methods most frequently used by individuals wanting to quit smoking. Some people who have quit swear by this method, while many others feel as though they wasted their time and money.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1151/hypnosis-the-pros-cons-of-using-hypnosis-to-help-quit-smoking/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1150"><a href="http://self-help.vocaboly.com/archives/1150/true-benefits-of-quitting-smoking/" rel="bookmark" title="Permanent Link to True Benefits of Quitting Smoking">True Benefits of Quitting Smoking</a></h3> <small>Saturday, September 9th, 2006</small> <div class="entry"> <p>When you take that last puff of a cigarette and are on your way to total freedom, there are many benefits that you will enjoy.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1150/true-benefits-of-quitting-smoking/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1149"><a href="http://self-help.vocaboly.com/archives/1149/why-people-who-quit-smoking-eat-more-food/" rel="bookmark" title="Permanent Link to Why People Who Quit Smoking Eat More Food">Why People Who Quit Smoking Eat More Food</a></h3> <small>Saturday, September 9th, 2006</small> <div class="entry"> <p>There are at least three reasons why quitters report an increase in appetite after quitting, with a particular increase in their desire for sweets.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1149/why-people-who-quit-smoking-eat-more-food/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1148"><a href="http://self-help.vocaboly.com/archives/1148/have-you-ever-wondered-why-you-gain-weight-after-quitting-smoking/" rel="bookmark" title="Permanent Link to Have You Ever Wondered Why You Gain Weight After Quitting Smoking?">Have You Ever Wondered Why You Gain Weight After Quitting Smoking?</a></h3> <small>Saturday, September 9th, 2006</small> <div class="entry"> <p>Unfortunately, cigarette smoking really is an aid to weight management. Here is how it works and why it is so effective: Nicotine can reduce your desire to eat by directly affecting the activity of serotonin and dopamine, which are substances that control neural transmission in areas of your brain that turn your appetite on and off.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1148/have-you-ever-wondered-why-you-gain-weight-after-quitting-smoking/#comments">No Comments &raquo;</a></p> </div> <div class="post"> <h3 id="post-1147"><a href="http://self-help.vocaboly.com/archives/1147/scary-statistics-of-smokers/" rel="bookmark" title="Permanent Link to Scary Statistics of Smokers">Scary Statistics of Smokers</a></h3> <small>Saturday, September 9th, 2006</small> <div class="entry"> <p>A growing number of studies have linked smoking with poor mental health. Several of these have shown that patients with major depression are more likely to smoke than are members of the general population. These studies also reveal the influence of major depression on smoking cessation.</p> </div> <p class="postmetadata">Posted in <a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts in Quit Smoking" rel="category tag">Quit Smoking</a> <strong>|</strong> <a href="http://self-help.vocaboly.com/archives/1147/scary-statistics-of-smokers/#comments">No Comments &raquo;</a></p> </div> <div class="navigation"> <div class="alignleft"> <a href="http://self-help.vocaboly.com/category/quit-smoking/page/2/">&laquo; Previous Entries</a> </div> <div class="alignright"></div> </div> </div> <div id="sidebar"> <ul> <li> <h3>Topics</h3> <ul> <li><a href="http://self-help.vocaboly.com/category/financial-success/" title="View all posts filed under Financial Success">Financial Success</a> <ul class="children"> <li><a href="http://self-help.vocaboly.com/category/financial-success/investing/" title="View all posts filed under Investing">Investing</a></li> <li><a href="http://self-help.vocaboly.com/category/financial-success/real-estate/" title="View all posts filed under Real Estate">Real Estate</a></li> <li><a href="http://self-help.vocaboly.com/category/financial-success/millionaire-mindset/" title="View all posts filed under Millionaire Mindset">Millionaire Mindset</a></li> </ul></li> <li><a href="http://self-help.vocaboly.com/category/loving-relationships/" title="View all posts filed under Loving Relationships">Loving Relationships</a></li> <li><a href="http://self-help.vocaboly.com/category/business-management/" title="View all posts filed under Business Management">Business Management</a> <ul class="children"> <li><a href="http://self-help.vocaboly.com/category/business-management/start-a-business/" title="View all posts filed under Start a Business">Start a Business</a></li> </ul></li> <li><a href="http://self-help.vocaboly.com/category/parenting/" title="View all posts filed under Parenting">Parenting</a></li> <li><a href="http://self-help.vocaboly.com/category/goal-setting/" title="View all posts filed under Goal Setting">Goal Setting</a></li> <li><a href="http://self-help.vocaboly.com/category/positive-thinking/" title="View all posts filed under Positive Thinking">Positive Thinking</a></li> <li><a href="http://self-help.vocaboly.com/category/brain-power/" title="View all posts filed under Brain Power">Brain Power</a></li> <li><a href="http://self-help.vocaboly.com/category/self-confidence/" title="View all posts filed under Self Confidence">Self Confidence</a></li> <li><a href="http://self-help.vocaboly.com/category/stress-relief/" title="View all posts filed under Stress Relief">Stress Relief</a></li> <li><a href="http://self-help.vocaboly.com/category/anger-management/" title="View all posts filed under Anger Management">Anger Management</a></li> <li><a href="http://self-help.vocaboly.com/category/leadership/" title="View all posts filed under Leadership">Leadership</a></li> <li><a href="http://self-help.vocaboly.com/category/professional-appearance/" title="View all posts filed under Professional Appearance">Professional Appearance</a></li> <li><a href="http://self-help.vocaboly.com/category/overcoming-fear/" title="View all posts filed under Overcoming Fear">Overcoming Fear</a></li> <li><a href="http://self-help.vocaboly.com/category/dating-tips/" title="View all posts filed under Dating Tips">Dating Tips</a> <ul class="children"> <li><a href="http://self-help.vocaboly.com/category/dating-tips/online-dating/" title="View all posts filed under Online Dating">Online Dating</a></li> </ul></li> <li><a href="http://self-help.vocaboly.com/category/communication/" title="View all posts filed under Communication">Communication</a></li> <li><a href="http://self-help.vocaboly.com/category/time-management/" title="View all posts filed under Time Management">Time Management</a></li> <li><a href="http://self-help.vocaboly.com/category/organization/" title="View all posts filed under Organization">Organization</a></li> <li><a href="http://self-help.vocaboly.com/category/health-fitness/" title="View all posts filed under Health &amp; Fitness">Health &amp; Fitness</a> <ul class="children"> <li><a href="http://self-help.vocaboly.com/category/health-fitness/high-blood-pressure/" title="View all posts filed under High Blood Pressure">High Blood Pressure</a></li> <li><a href="http://self-help.vocaboly.com/category/health-fitness/weight-loss/" title="View all posts filed under Weight Loss &amp; Dieting">Weight Loss &amp; Dieting</a></li> <li><a href="http://self-help.vocaboly.com/category/health-fitness/natural-health-food/" title="View all posts filed under Natural Health Food">Natural Health Food</a></li> <li><a href="http://self-help.vocaboly.com/category/health-fitness/headache/" title="View all posts filed under Headache">Headache</a></li> </ul></li> <li><a href="http://self-help.vocaboly.com/category/overcome-shyness/" title="View all posts filed under Overcome Shyness">Overcome Shyness</a></li> <li><a href="http://self-help.vocaboly.com/category/career/" title="View all posts filed under Career">Career</a></li> <li><a href="http://self-help.vocaboly.com/category/happiness/" title="View all posts filed under Happiness">Happiness</a></li> <li><a href="http://self-help.vocaboly.com/category/marriage/" title="View all posts filed under Marriage">Marriage</a></li> <li><a href="http://self-help.vocaboly.com/category/meditation/" title="View all posts filed under Meditation">Meditation</a></li> <li><a href="http://self-help.vocaboly.com/category/self-esteem/" title="View all posts filed under Self Esteem">Self Esteem</a></li> <li><a href="http://self-help.vocaboly.com/category/management/" title="View all posts filed under Management">Management</a></li> <li><a href="http://self-help.vocaboly.com/category/success/" title="View all posts filed under Success">Success</a></li> <li><a href="http://self-help.vocaboly.com/category/divorce/" title="View all posts filed under Divorce">Divorce</a></li> <li><a href="http://self-help.vocaboly.com/category/negotiation/" title="View all posts filed under Negotiation">Negotiation</a></li> <li><a href="http://self-help.vocaboly.com/category/retirement/" title="View all posts filed under Retirement">Retirement</a></li> <li><a href="http://self-help.vocaboly.com/category/genealogy/" title="View all posts filed under Genealogy">Genealogy</a></li> <li><a href="http://self-help.vocaboly.com/category/depression/" title="View all posts filed under Depression">Depression</a></li> <li><a href="http://self-help.vocaboly.com/category/credit-debt/" title="View all posts filed under Credit &amp; Debt">Credit &amp; Debt</a></li> <li><a href="http://self-help.vocaboly.com/category/quit-smoking/" title="View all posts filed under Quit Smoking">Quit Smoking</a></li> <li><a href="http://self-help.vocaboly.com/category/sleep/" title="View all posts filed under Sleep">Sleep</a></li> <li><a href="http://self-help.vocaboly.com/category/cleaning/" title="View all posts filed under Cleaning">Cleaning</a></li> <li><a href="http://self-help.vocaboly.com/category/forgive/" title="View all posts filed under Forgive">Forgive</a></li> </ul> </li> <li> <h2>Archives</h2> <ul> <li><a href="http://self-help.vocaboly.com/archives/date/2007/09/" title="September 2007">September 2007</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2007/05/" title="May 2007">May 2007</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2007/03/" title="March 2007">March 2007</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2007/02/" title="February 2007">February 2007</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2007/01/" title="January 2007">January 2007</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2006/12/" title="December 2006">December 2006</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2006/11/" title="November 2006">November 2006</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2006/10/" title="October 2006">October 2006</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2006/09/" title="September 2006">September 2006</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2006/08/" title="August 2006">August 2006</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2006/07/" title="July 2006">July 2006</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2006/06/" title="June 2006">June 2006</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2006/05/" title="May 2006">May 2006</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2006/04/" title="April 2006">April 2006</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2006/03/" title="March 2006">March 2006</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2006/02/" title="February 2006">February 2006</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2006/01/" title="January 2006">January 2006</a></li> <li><a href="http://self-help.vocaboly.com/archives/date/2005/12/" title="December 2005">December 2005</a></li> </ul> </li> <li><h2>Meta</h2> <ul> <li><a href="http://self-help.vocaboly.com/wp-register.php">Register</a></li> <li><a href="http://self-help.vocaboly.com/wp-login.php">Login</a></li> <li><a href="http://wordpress.org">WordPress</a></li> </ul> </li> </ul> </div> <div id="footer"> <p><a href="http://www.vocaboly.com/">Vocaboly.com</a><font color="#C0996C"> @ 2005-2008. All rights reserved.</font></p> </div> </div> </body> </html>
